accession,entry_name,protein_name,gene_name,organism,sequence_length,review_status,gene_synonyms,sequence,sequence_mass,go_biological_process,go_molecular_function,go_cellular_component,domains_motifs,ptms,diseases,disease_types,ppi_data,pathways,isoforms,xref_PDB,xref_AlphaFoldDB,xref_Pfam,xref_InterPro,xref_KEGG,xref_Reactome,xref_GeneID,xref_OMIM,other_xrefs,annotation_score
P21554,,Cannabinoid receptor 1,CNR1,Homo sapiens,472,False,CNR,MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLLVLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASFTASVGSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPLLGWNCEKLQSVCSDIFPHIDETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIRLAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL,0,,,,,,"Obesity:A condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.|:",Obesity,P29274(ADORA2A)|P21554(CNR1),,1:P21554-1:|2:P21554-2:|3:P21554-3:,,,,,,,,,,5.0
O60260,,E3 ubiquitin-protein ligase parkin,PRKN,Homo sapiens,465,False,PARK2,MIVFVRFNSSHGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQEMNATGGDDPRNAAGGCEREPQSLTRVDLSSSVLPGDSVGLAVILHTDSRKDSPPAGSPAGRSIYNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHCPGTSAEFFFKCGAHPTSDKETSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDRQFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEGECSAVFEASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV,0,,,,,,"Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.|Parkinson disease 2:A neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually before 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.|:",Parkinson disease|Parkinson disease 2,P54252-2(ATXN3)|Q8IZ52-2(CHPF)|Q9Y3I1(FBXO7)|Q9Y3I1-1(FBXO7)|Q9UBN7(HDAC6)|P08238(HSP90AB1)|Q5S007(LRRK2)|O95140(MFN2)|Q16342(PDCD2)|Q9BXM7(PINK1)|Q9BXM7-1(PINK1)|O60260(PRKN)|P49792(RANBP2)|Q8IXI2(RHOT1)|Q15645(TRIP13)|Q6NUN9(ZNF746)|Q9Z2Q6(Septin5)|P68510(Ywhah)|Q99IB8()|Q6ZTN6-2(ANKRD13D)|Q86WR3(ANUBL1)|P63010-2(AP2B1)|P05067(APP)|Q0P5N6(ARL16)|Q86TN1(ARNT2)|Q8WXK3(ASB13)|Q8WXK3-2(ASB13)|Q9Y575-3(ASB3)|Q9H672-2(ASB7)|Q96DX5(ASB9)|Q96DX5-3(ASB9)|Q9H0Y0(ATG10)|P54253(ATXN1)|O14867(BACH1)|P46379-2(BAG6)|A8KA13(BCL6B)|Q8WUW1(BRK1)|P29466-3(CASP1)|Q13939(CCIN)|P78396-2(CCNA1)|Q00535(CDK5)|Q9UNS2(COPS3)|Q9UBU7(DBF4)|Q5QP82-2(DCAF10)|P61962(DCAF7)|Q5TAQ9-2(DCAF8)|Q9BW61(DDA1)|Q8NDP9(DKFZp547K2416)|P78352-2(DLG4)|P31689(DNAJA1)|O77932(DXO)|O75530-2(EED)|Q8TC29(ENKUR)|Q6P1L5(FAM117B)|O00757(FBP2)|P57775(FBXW4)|Q9UHY8(FEZ2)|P22607(FGFR3)|Q9H2C0(GAN)|Q9NXC2(GFOD1)|Q96IK5(GMCL1)|P62879(GNB2)|Q7Z602(GPR141)|P06396(GSN)|P68431(H3C12)|Q86YM7(HOMER1)|P0DMV8(HSPA1A)|P11142(HSPA8)|Q6DN90-2(IQSEC1)|Q8NA54(IQUB)|P05161(ISG15)|Q9UKP3-2(ITGB1BP2)|Q9NVX7-2(KBTBD4)|Q9UIH9(KLF15)|Q6TDP4(KLHL17)|O94889(KLHL18)|Q9Y2M5(KLHL20)|Q8WZ60(KLHL6)|Q3SY46(KRTAP13-3)|Q9BYQ4(KRTAP9-2)|Q9BYZ2(LDHAL6B)|Q8TBB1(LNX1)|O95777(LSM8)|Q9GZQ8(MAP1LC3B)|P10636-6(MAPT)|P61244-4(MAX)|Q8TDB4(MGARP)|A4FUJ8(MKL1)|P51948(MNAT1)|Q8N594(MPND)|Q9Y483-4(MTF2)|Q9NPC7(MYNN)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|P68402(PAFAH1B2)|Q9NR21-5(PARP11)|Q9HBE1-4(PATZ1)|Q96MG8(PCMTD1)|Q9NV79(PCMTD2)|Q13113(PDZK1IP1)|Q96LB9(PGLYRP3)|Q6ZR37(PLEKHG7)|P25786(PSMA1)|P40306(PSMB10)|P28070(PSMB4)|O60671(RAD1)|Q8NDN9-2(RCBTB1)|P41220(RGS2)|A0A087WUY2(RGS3)|O94844(RHOBTB1)|Q8N5U6(RNF10)|Q9Y3C5(RNF11)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q8WVD3(RNF138)|Q9UBS8(RNF14)|Q96A37(RNF166)|Q96D59(RNF183)|Q96BH1(RNF25)|P08865(RPSA)|Q8N488(RYBP)|Q15393(SF3B3)|Q2NKQ1-4(SGSM1)|Q14190-2(SIM2)|Q9GZS3(SKIC8)|Q9HCE7-2(SMURF1)|P37840(SNCA)|Q9Y6H5-5(SNCAIP)|Q96DI7(SNRNP40)|O14544(SOCS6)|Q99932-2(SPAG8)|Q8IUW3(SPATA2L)|Q8TCT7-2(SPPL2B)|Q7Z699(SPRED1)|Q9C004(SPRY4)|Q96BD6(SPSB1)|Q99619(SPSB2)|O75886(STAM2)|O95630(STAMBP)|Q9UNE7(STUB1)|Q9BT88(SYT11)|Q13148(TARDBP)|Q16650(TBR1)|Q15554-4(TERF2)|Q04724(TLE1)|Q71RG4-4(TMUB2)|Q9H0E2(TOLLIP)|P19474(TRIM21)|Q9UPQ4-2(TRIM35)|Q8NBM4-4(UBAC2)|P57075-2(UBASH3A)|P0CG47(UBB)|O15205(UBD)|Q9Y385(UBE2J1)|P68036(UBE2L3)|P61081(UBE2M)|Q9C0C9(UBE2O)|Q13404(UBE2V1)|Q04323-2(UBXN1)|Q9Y3C8(UFC1)|Q96RL1-2(UIMC1)|O75604-3(USP2)|P18206-2(VCL)|P45880(VDAC2)|P40337-2(VHL)|Q9UBQ0-2(VPS29)|O00308(WWP2)|Q04917(YWHAH)|O43167-2(ZBTB24)|Q15916(ZBTB6)|Q9Y649(),,1:O60260-1:|2:O60260-2:|3:O60260-3:|4:O60260-4:|5:O60260-5:|6:O60260-6:|7:O60260-7:|8:O60260-8:,,,,,,,,,,5.0
P37840,,Alpha-synuclein,SNCA,Homo sapiens,140,False,NACP|PARK1,MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA,0,,,,,,":|Parkinson disease 1, autosomal dominant:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.|Parkinson disease 4, autosomal dominant:A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.|Dementia, Lewy body:A neurodegenerative disorder characterized by mental impairment leading to dementia, parkinsonism, fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Brainstem or cortical intraneuronal accumulations of aggregated proteins (Lewy bodies) are the only essential pathologic features. Patients may also have hippocampal and neocortical senile plaques, sometimes in sufficient number to fulfill the diagnostic criteria for Alzheimer disease.","Parkinson disease 1, autosomal dominant|Parkinson disease 4, autosomal dominant|Dementia, Lewy body",Q6PCB6(ABHD17C)|P00519(ABL1)|P00519-1(ABL1)|P00519-2(ABL1)|Q6ZTN6-2(ANKRD13D)|P63010-2(AP2B1)|O00203(AP3B1)|P02647(APOA1)|P02649(APOE)|P05067(APP)|Q8N6T3-3(ARFGAP1)|Q9NP61(ARFGAP3)|Q0P5N6(ARL16)|Q8WXK3(ASB13)|P18847(ATF3)|Q9H0Y0(ATG10)|P46379-2(BAG6)|Q07812(BAX)|Q07817(BCL2L1)|O15392(BIRC5)|Q8WUW1(BRK1)|Q5SZD1(C6orf141)|P62158(CALM3)|Q8N5S9-2(CAMKK1)|P55212(CASP6)|Q7Z7K6(CENPV)|Q9HD42(CHMP1A)|Q16740(CLPP)|P10909(CLU)|Q9UNS2(COPS3)|Q8IUI8(CRLF3)|P48730-2(CSNK1D)|P99999(CYCS)|O75398(DEAF1)|Q8NDP9(DKFZp547K2416)|O60479(DLX3)|A0AVK6(E2F8)|O75530-2(EED)|O00472(ELL2)|Q8TC29(ENKUR)|O00471(EXOC5)|Q9UHY8(FEZ2)|Q0VDC6(FKBP1A)|Q6PIV2(FOXR1)|P02792(FTL)|P06241(FYN)|P06241-3(FYN)|P62879(GNB2)|P49841(GSK3B)|P68431(H3C12)|Q71DI3(H3C15)|Q969S8(HDAC10)|Q9HCC6(HES4)|Q8WVV9-3(HNRNPLL)|P09017(HOXC4)|P08107(HSPA1B)|P42858(HTT)|P80217-2(IFI35)|Q16352(INA)|Q6DN90-2(IQSEC1)|O14713(ITGB1BP1)|Q9UIH9(KLF15)|Q9Y2M5(KLHL20)|Q92876(KLK6)|Q9BYQ4(KRTAP9-2)|Q96JM7-2(L3MBTL3)|P13473-2(LAMP2)|Q9BYZ2(LDHAL6B)|Q9H2C1(LHX5)|Q9UPM6(LHX6)|Q8TBB1(LNX1)|Q8N448(LNX2)|A2RU56(LOC401296)|Q5S007(LRRK2)|O95777(LSM8)|P07948(LYN)|Q8TD91-2(MAGEC3)|P10636-6(MAPT)|P10636-8(MAPT)|Q8N6F8(METTL27)|Q8TDB4(MGARP)|A4FUJ8(MKL1)|Q8N594(MPND)|Q9Y3D2(MSRB2)|P00414(MT-CO3)|P02795(MT2A)|Q9Y483-4(MTF2)|O00746(NME4)|O15381-5(NVL)|Q86WS3(OOSP2)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|Q6VY07(PACS1)|O96013-2(PAK4)|Q9NR21-5(PARP11)|Q9NV79(PCMTD2)|Q13113(PDZK1IP1)|O75925(PIAS1)|Q6ZR37(PLEKHG7)|P17252(PRKCA)|Q02156(PRKCE)|O60260-5(PRKN)|O75400-2(PRPF40A)|P62191(PSMC1)|P17980(PSMC3)|Q9UI14(RABAC1)|Q9UJ41-4(RABGEF1)|P62826(RAN)|Q13702-2(RAPSN)|P57052(RBM11)|Q8N5U6(RNF10)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q8WVD3(RNF138)|Q8IYW5(RNF168)|Q96D59(RNF183)|Q8N488(RYBP)|O75446(SAP30)|O00560(SDCBP)|O43236(SEPTIN4)|O75920-2(SERF1B)|Q2NKQ1-4(SGSM1)|Q9GZS3(SKIC8)|Q01959(SLC6A3)|Q9HCE7-2(SMURF1)|P37840(SNCA)|Q9Y6H5(SNCAIP)|Q9Y6H5-2(SNCAIP)|Q16143(SNCB)|P00441(SOD1)|P23497-2(SP100)|Q99932-2(SPAG8)|Q8NHS9(SPATA22)|Q8TCT7-2(SPPL2B)|Q13501(SQSTM1)|O75886(STAM2)|Q16623(STX1A)|Q9BR01-2(SULT4A1)|Q92797-2(SYMPK)|Q16650(TBR1)|Q13569(TDG)|P28347-2(TEAD1)|Q15554-4(TERF2)|Q9H0E2(TOLLIP)|O94811(TPPP)|P19474(TRIM21)|P68363(TUBA1B)|P07437(TUBB)|Q8WVJ9(TWIST2)|P62987(UBA52)|Q9BSL1(UBAC1)|O15205(UBD)|Q04323-2(UBXN1)|Q96RL1-2(UIMC1)|O75604-3(USP2)|P63027(VAMP2)|P40337-2(VHL)|Q9UBQ0-2(VPS29)|O00308(WWP2)|Q04917(YWHAH)|O43167-2(ZBTB24)|Q96NC0(ZMAT2)|Q8WUU4(ZNF296)|Q8N895(ZNF366)|Q8N988-2(ZNF557)|Q68EA5(ZNF57)|Q8NBB4-2(ZSCAN1)|A8K878()|P0DTC9(N)|Q61327(Slc6a3)|P37840-1(SNCA)|Q04917(YWHAH),,1:P37840-1:|2-4:P37840-2:|2-5:P37840-3:,,,,,,,,,,5.0
Q9BXS0,,Collagen alpha-1(XXV) chain,COL25A1,Homo sapiens,654,False,,MLLKKHAGKGGGREPRSEDPTPAEQHCARTMPPCAVLAALLSVVAVVSCLYLGVKTNDLQARIAALESAKGAPSIHLLPDTLDHLKTMVQEKVERLLAQKSYEHMAKIRIAREAPSECNCPAGPPGKRGKRGRRGESGPPGQPGPQGPPGPKGDKGEQGDQGPRMVFPKINHGFLSADQQLIKRRLIKGDQGQAGPPGPPGPPGPRGPPGDTGKDGPRGMPGVPGEPGKPGEQGLMGPLGPPGQKGSIGAPGIPGMNGQKGEPGLPGAVGQNGIPGPKGEPGEQGEKGDAGENGPKGDTGEKGDPGSSAAGIKGEPGESGRPGQKGEPGLPGLPGLPGIKGEPGFIGPQGEPGLPGLPGTKGERGEAGPPGRGERGEPGAPGPKGKQGESGTRGPKGSKGDRGEKGDSGAQGPRGPPGQKGDQGATEIIDYNGNLHEALQRITTLTVTGPPGPPGPQGLQGPKGEQGSPGIPGMDGEQGLKGSKGDMGDPGMTGEKGGIGLPGLPGANGMKGEKGDSGMPGPQGPSIIGPPGPPGPHGPPGPMGPHGLPGPKGTDGPMGPHGPAGPKGERGEKGAMGEPGPRGPYGLPGKDGEPGLDGFPGPRGEKGDLGEKGEKGFRGVKGEKGEPGQPGLDGLDAPCQLGPDGLPMPGCWQK,0,,,,,,"Fibrosis of extraocular muscles, congenital, 5:An ocular motility disorder characterized by congenital dysinnervation of various cranial nerves to ocular muscles. Clinical features are ophthalmoplegia, anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head.","Fibrosis of extraocular muscles, congenital, 5",Q9BXS0-3(COL25A1),,1:Q9BXS0-1:|2:Q9BXS0-2:|3:Q9BXS0-3:,,,,,,,,,,5.0
Q99497,,Parkinson disease protein 7,PARK7,Homo sapiens,189,False,,MASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFGSKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD,0,,,,,,"Parkinson disease 7:A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).",Parkinson disease 7,P01023(A2M)|P63010-2(AP2B1)|P05067(APP)|P10275(AR)|Q8NFJ9(BBS1)|Q8N5S9-2(CAMKK1)|Q9UER7(DAXX)|P50570-2(DNM2)|Q13158(FADD)|P06241-3(FYN)|Q9HD26(GOPC)|P42858(HTT)|Q6DN90-2(IQSEC1)|Q9BYQ4(KRTAP9-2)|Q9BYZ2(LDHAL6B)|O94776(MTA2)|Q8NFH3(NUP43)|Q96FW1(OTUB1)|Q6GQQ9(OTUD7B)|Q99497(PARK7)|P32322(PYCR1)|P63244(RACK1)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q9GZS3(SKIC8)|Q8IUW3(SPATA2L)|O14656-2(TOR1A)|Q9UBQ0-2(VPS29),,,,,,,,,,,,5.0
P42858,,Huntingtin,HTT,Homo sapiens,3142,False,HD|IT15,MATLEKLMKAFESLKSFQQQQQQQQQQQQQQQQQQQQQPPPPPPPPPPPQLPQPPPQAQPLLPQPQPPPPPPPPPPGPAVAEEPLHRPKKELSATKKDRVNHCLTICENIVAQSVRNSPEFQKLLGIAMELFLLCSDDAESDVRMVADECLNKVIKALMDSNLPRLQLELYKEIKKNGAPRSLRAALWRFAELAHLVRPQKCRPYLVNLLPCLTRTSKRPEESVQETLAAAVPKIMASFGNFANDNEIKVLLKAFIANLKSSSPTIRRTAAGSAVSICQHSRRTQYFYSWLLNVLLGLLVPVEDEHSTLLILGVLLTLRYLVPLLQQQVKDTSLKGSFGVTRKEMEVSPSAEQLVQVYELTLHHTQHQDHNVVTGALELLQQLFRTPPPELLQTLTAVGGIGQLTAAKEESGGRSRSGSIVELIAGGGSSCSPVLSRKQKGKVLLGEEEALEDDSESRSDVSSSALTASVKDEISGELAASSGVSTPGSAGHDIITEQPRSQHTLQADSVDLASCDLTSSATDGDEEDILSHSSSQVSAVPSDPAMDLNDGTQASSPISDSSQTTTEGPDSAVTPSDSSEIVLDGTDNQYLGLQIGQPQDEDEEATGILPDEASEAFRNSSMALQQAHLLKNMSHCRQPSDSSVDKFVLRDEATEPGDQENKPCRIKGDIGQSTDDDSAPLVHCVRLLSASFLLTGGKNVLVPDRDVRVSVKALALSCVGAAVALHPESFFSKLYKVPLDTTEYPEEQYVSDILNYIDHGDPQVRGATAILCGTLICSILSRSRFHVGDWMGTIRTLTGNTFSLADCIPLLRKTLKDESSVTCKLACTAVRNCVMSLCSSSYSELGLQLIIDVLTLRNSSYWLVRTELLETLAEIDFRLVSFLEAKAENLHRGAHHYTGLLKLQERVLNNVVIHLLGDEDPRVRHVAAASLIRLVPKLFYKCDQGQADPVVAVARDQSSVYLKLLMHETQPPSHFSVSTITRIYRGYNLLPSITDVTMENNLSRVIAAVSHELITSTTRALTFGCCEALCLLSTAFPVCIWSLGWHCGVPPLSASDESRKSCTVGMATMILTLLSSAWFPLDLSAHQDALILAGNLLAASAPKSLRSSWASEEEANPAATKQEEVWPALGDRALVPMVEQLFSHLLKVINICAHVLDDVAPGPAIKAALPSLTNPPSLSPIRRKGKEKEPGEQASVPLSPKKGSEASAASRQSDTSGPVTTSKSSSLGSFYHLPSYLKLHDVLKATHANYKVTLDLQNSTEKFGGFLRSALDVLSQILELATLQDIGKCVEEILGYLKSCFSREPMMATVCVQQLLKTLFGTNLASQFDGLSSNPSKSQGRAQRLGSSSVRPGLYHYCFMAPYTHFTQALADASLRNMVQAEQENDTSGWFDVLQKVSTQLKTNLTSVTKNRADKNAIHNHIRLFEPLVIKALKQYTTTTCVQLQKQVLDLLAQLVQLRVNYCLLDSDQVFIGFVLKQFEYIEVGQFRESEAIIPNIFFFLVLLSYERYHSKQIIGIPKIIQLCDGIMASGRKAVTHAIPALQPIVHDLFVLRGTNKADAGKELETQKEVVVSMLLRLIQYHQVLEMFILVLQQCHKENEDKWKRLSRQIADIILPMLAKQQMHIDSHEALGVLNTLFEILAPSSLRPVDMLLRSMFVTPNTMASVSTVQLWISGILAILRVLISQSTEDIVLSRIQELSFSPYLISCTVINRLRDGDSTSTLEEHSEGKQIKNLPEETFSRFLLQLVGILLEDIVTKQLKVEMSEQQHTFYCQELGTLLMCLIHIFKSGMFRRITAAATRLFRSDGCGGSFYTLDSLNLRARSMITTHPALVLLWCQILLLVNHTDYRWWAEVQQTPKRHSLSSTKLLSPQMSGEEEDSDLAAKLGMCNREIVRRGALILFCDYVCQNLHDSEHLTWLIVNHIQDLISLSHEPPVQDFISAVHRNSAASGLFIQAIQSRCENLSTPTMLKKTLQCLEGIHLSQSGAVLTLYVDRLLCTPFRVLARMVDILACRRVEMLLAANLQSSMAQLPMEELNRIQEYLQSSGLAQRHQRLYSLLDRFRLSTMQDSLSPSPPVSSHPLDGDGHVSLETVSPDKDWYVHLVKSQCWTRSDSALLEGAELVNRIPAEDMNAFMMNSEFNLSLLAPCLSLGMSEISGGQKSALFEAAREVTLARVSGTVQQLPAVHHVFQPELPAEPAAYWSKLNDLFGDAALYQSLPTLARALAQYLVVVSKLPSHLHLPPEKEKDIVKFVVATLEALSWHLIHEQIPLSLDLQAGLDCCCLALQLPGLWSVVSSTEFVTHACSLIYCVHFILEAVAVQPGEQLLSPERRTNTPKAISEEEEEVDPNTQNPKYITAACEMVAEMVESLQSVLALGHKRNSGVPAFLTPLLRNIIISLARLPLVNSYTRVPPLVWKLGWSPKPGGDFGTAFPEIPVEFLQEKEVFKEFIYRINTLGWTSRTQFEETWATLLGVLVTQPLVMEQEESPPEEDTERTQINVLAVQAITSLVLSAMTVPVAGNPAVSCLEQQPRNKPLKALDTRFGRKLSIIRGIVEQEIQAMVSKRENIATHHLYQAWDPVPSLSPATTGALISHEKLLLQINPERELGSMSYKLGQVSIHSVWLGNSITPLREEEWDEEEEEEADAPAPSSPPTSPVNSRKHRAGVDIHSCSQFLLELYSRWILPSSSARRTPAILISEVVRSLLVVSDLFTERNQFELMYVTLTELRRVHPSEDEILAQYLVPATCKAAAVLGMDKAVAEPVSRLLESTLRSSHLPSRVGALHGVLYVLECDLLDDTAKQLIPVISDYLLSNLKGIAHCVNIHSQQHVLVMCATAFYLIENYPLDVGPEFSASIIQMCGVMLSGSEESTPSIIYHCALRGLERLLLSEQLSRLDAESLVKLSVDRVNVHSPHRAMAALGLMLTCMYTGKEKVSPGRTSDPNPAAPDSESVIVAMERVSVLFDRIRKGFPCEARVVARILPQFLDDFFPPQDIMNKVIGEFLSNQQPYPQFMATVVYKVFQTLHSTGQSSMVRDWVMLSLSNFTQRAPVAMATWSLSCFFVSASTSPWVAAILPHVISRMGKLEQVDVNLFCLVATDFYRHQIEEELDRRAFQSVLEVVAAPGSPYHRLLTCLRNVHKVTTC,0,,,,,,"Huntington disease:A neurodegenerative disorder characterized by involuntary movements (chorea), general motor impairment, psychiatric disorders and dementia. Onset of the disease occurs usually in the third or fourth decade of life. Onset and clinical course depend on the degree of poly-Gln repeat expansion, longer expansions resulting in earlier onset and more severe clinical manifestations. Neuropathology of Huntington disease displays a distinctive pattern with loss of neurons, especially in the caudate and putamen.|Lopes-Maciel-Rodan syndrome:An autosomal recessive neurodevelopmental disorder characterized by developmental regression in infancy, delayed psychomotor development, severe intellectual disability, and cerebral and cerebellar atrophy. Additional features include swallowing problems, dystonia, bradykinesia, and continuous manual stereotypies without chorea. Some patients manifest seizures.",Huntington disease|Lopes-Maciel-Rodan syndrome,Q9H7C9(AAMDC)|Q6PCB6(ABHD17C)|Q9ULW3(ABT1)|P60709(ACTB)|P63261(ACTG1)|P42025(ACTR1B)|Q15848(ADIPOQ)|Q9Y4W6(AFG3L2)|Q53H12(AGK)|Q53H12-2(AGK)|Q5TGY3(AHDC1)|Q9UIJ7(AK3)|P14550(AKR1A1)|P31749(AKT1)|Q3SY69(ALDH1L2)|P04075-2(ALDOA)|Q9H553(ALG2)|Q8IWZ3-3(ANKHD1)|Q6ZTN6-2(ANKRD13D)|Q5TZF3-1(ANKRD45)|Q16853(AOC3)|P63010-2(AP2B1)|O00203(AP3B1)|Q9Y2T2(AP3M1)|P05067(APP)|P48444(ARCN1)|Q9NP61(ARFGAP3)|P53365(ARFIP2)|Q8N264(ARHGAP24)|Q52LW3-2(ARHGAP29)|Q0P5N6(ARL16)|Q6P1M9(ARMCX5)|Q86TN1(ARNT2)|Q9Y575-3(ASB3)|Q6XD76(ASCL4)|Q96FT7-4(ASIC4)|Q12797-6(ASPH)|Q12797-7(ASPH)|Q96DT6(ATG4C)|Q8WXF7(ATL1)|P25705(ATP5F1A)|P24539(ATP5PB)|P48047(ATP5PO)|Q15904(ATP6AP1)|P61421(ATP6V0D1)|P21281(ATP6V1B2)|Q9UI12(ATP6V1H)|Q9UQB8-3(BAIAP2)|Q9UQB8-6(BAIAP2)|Q16520(BATF)|Q9NRL2(BAZ1A)|Q9BUW7(BBLN)|Q8WY36-3(BBX)|P51572(BCAP31)|Q14457(BECN1)|Q00994(BEX3)|O15392(BIRC5)|Q9GZL8(BPESC1)|P38398-6(BRCA1)|Q8WUW1(BRK1)|Q13901(C1D)|Q6P1W5(C1orf94)|Q9BXJ4(C1QTNF3)|Q9NUB4(C20orf141)|Q6P5X5-2(C22orf39)|Q9BRJ6(C7orf50)|Q8IVU9(CABCOCO1)|P62158(CALM3)|Q14012(CAMK1)|Q8N5S9-2(CAMKK1)|Q9HC96(CAPN10)|P29466-3(CASP1)|P42574(CASP3)|P55212(CASP6)|P55210(CASP7)|P22681(CBL)|P35520(CBS)|P83916(CBX1)|Q96HB5(CCDC120)|Q96M83-3(CCDC7)|Q9Y3X0(CCDC9)|Q13939(CCIN)|Q9NPC3(CCNB1IP1)|P24863(CCNC)|O96020(CCNE2)|P51959(CCNG1)|P78371(CCT2)|P48643(CCT5)|P40227(CCT6A)|P50990(CCT8)|P13987(CD59)|Q9H3Q1(CDC42EP4)|Q99459(CDC5L)|O00311(CDC7)|Q9BWT1(CDCA7)|P55290(CDH13)|O95674(CDS2)|Q8N2Z9(CENPS)|Q7Z7K6(CENPV)|Q9P2H0(CEP126)|Q53EZ4(CEP55)|Q96MT8-3(CEP63)|Q8NHQ1-3(CEP70)|P41208(CETN2)|Q9Y6H1(CHCHD2)|Q9NX63(CHCHD3)|Q12873(CHD3)|Q9HD42(CHMP1A)|O43633(CHMP2A)|Q9H444(CHMP4B)|Q9UHD4(CIDEB)|P06732(CKM)|Q9Y240(CLEC11A)|Q92478(CLEC2B)|Q16740(CLPP)|Q8NCR9(CLRN3)|Q9H9A5(CNOT10)|Q9H9A5-3(CNOT10)|Q9UIV1(CNOT7)|P09543(CNP)|Q96MW5(COG8)|P53618(COPB1)|Q9UNS2(COPS3)|Q86WV2(COX4I1)|P10606(COX5B)|P12074(COX6A1)|P09669(COX6C)|Q9UKF6(CPSF3)|A2RRE8(CPT1B)|Q9BSW2(CRACR2A)|P16220(CREB1)|Q92793(CREBBP)|Q6UXH1-2(CRELD2)|P46108(CRK)|Q14194(CRMP1)|P02489(CRYAA)|P53672(CRYBA2)|P04141(CSF2)|P48730-2(CSNK1D)|P50461(CSRP3)|Q9H6J7-2(CSTPP1)|P56545-3(CTBP2)|P35222(CTNNB1)|Q13618(CUL3)|Q93034(CUL5)|Q8TB03(CXorf38)|P08574(CYC1)|P20815(CYP3A5)|Q5D0E6-2(DALRD3)|Q9UN19(DAPP1)|Q9UER7(DAXX)|Q15038(DAZAP2)|Q9UJU6(DBNL)|P61962(DCAF7)|Q9H816(DCLRE1B)|Q13561(DCTN2)|Q9UJW0(DCTN4)|Q9UHI6(DDX20)|Q9NR30(DDX21)|O00148(DDX39A)|Q9UJV9(DDX41)|Q14154(DELE1)|P78524(DENND2B)|P17661(DES)|Q05D60(DEUP1)|Q5T7M9-2(DIPK1A)|P09622(DLD)|P36957(DLST)|O60479(DLX3)|P31689(DNAJA1)|Q96EY1(DNAJA3)|Q9UDY4(DNAJB4)|O75190-2(DNAJB6)|Q9NVH1(DNAJC11)|Q5F1R6(DNAJC21)|Q9NNZ3(DNAJC4)|O14645(DNALI1)|Q05193(DNM1)|P50570-2(DNM2)|Q9H147(DNTTIP1)|Q9H3H5(DPAGT1)|Q16555(DPYSL2)|Q9BPU6(DPYSL5)|Q14204(DYNC1H1)|P63167(DYNLL1)|A0AVK6(E2F8)|Q13011(ECH1)|O60869(EDF1)|Q3B7T1(EDRF1)|Q05639(EEF1A2)|P24534(EEF1B2)|P29692(EEF1D)|P13639(EEF2)|Q12805(EFEMP1)|O14602(EIF1AY)|P20042(EIF2S2)|P41091(EIF2S3)|O75821(EIF3G)|Q13347(EIF3I)|Q14240-2(EIF4A2)|O60573(EIF4E2)|P55010(EIF5)|O95163(ELP1)|Q9Y6C2-2(EMILIN1)|O14682(ENC1)|Q8TC29(ENKUR)|P06733(ENO1)|Q9Y5L3(ENTPD2)|O75356(ENTPD5)|A0A0C4DH22(EPB41L1)|Q8TE68-3(EPS8L1)|Q2NKX8(ERCC6L)|A1L162(ERICH2)|Q96DN0(ERP27)|Q6NXG1-3(ESRP1)|Q9UI08-2(EVL)|Q01844-4(EWSR1)|O00471(EXOC5)|Q99504(EYA3)|P15311(EZR)|P23610(F8A3)|Q6SJ93(FAM111B)|Q96GL9(FAM163A)|Q96KS9(FAM167A)|Q5HYJ3-3(FAM76B)|Q5JUQ0(FAM78A)|Q8IZU1(FAM9A)|Q9NPI8(FANCF)|Q8TC84(FANK1)|Q9NSD9(FARSB)|P49327(FASN)|Q53R41(FASTKD1)|Q8NFZ0(FBH1)|P09467(FBP1)|Q99689(FEZ1)|Q9UHY8(FEZ2)|Q13643(FHL3)|Q9BVA6(FICD)|P26885(FKBP2)|O75955(FLOT1)|Q8N3X1(FNBP4)|Q3SYB3(FOXD4L6)|Q6PIV2(FOXR1)|O95073-2(FSBP)|P02792(FTL)|P06241-3(FYN)|Q9ULV1(FZD4)|Q7L622(G2E3)|Q13283(G3BP1)|Q9UQC2(GAB2)|Q8N4A0(GALNT4)|P04406(GAPDH)|P28676(GCA)|P14136(GFAP)|Q9NXC2(GFOD1)|Q9UG22(GIMAP2)|Q9Y2X7(GIT1)|P48060(GLIPR1)|P09471(GNAO1)|P62873(GNB1)|P62879(GNB2)|Q08379(GOLGA2)|Q9H4A5(GOLPH3L)|Q8IYG2(GPC3)|Q8IV16(GPIHBP1)|P51674(GPM6A)|Q86YB0(GPM6A)|Q7Z602(GPR141)|Q96D09(GPRASP2)|Q96SL4(GPX7)|Q13588(GRAP)|Q8IY40(GRIK2)|P49840(GSK3A)|Q9Y5Q9(GTF3C3)|Q9BZE4(GTPBP4)|O75409(H2AP)|Q93079(H2BC9)|Q6NXT2(H3-5)|P68431(H3C12)|Q71DI3(H3C15)|P62805(H4C9)|P40939(HADHA)|P54257-2(HAP1)|Q99871(HAUS7)|O00165(HAX1)|Q8N779(hCG_1998195)|Q969S8(HDAC10)|Q9UBN7(HDAC6)|Q9HCC6(HES4)|Q9UBP5(HEY2)|O00291(HIP1)|Q9BW71(HIRIP3)|P52790(HK3)|P08397(HMBS)|Q9NP66(HMG20A)|Q9P0W2(HMG20B)|P09429(HMGB1)|P07910(HNRNPC)|P07910-2(HNRNPC)|P61978(HNRNPK)|P20719(HOXA5)|O43248(HOXC11)|P09017(HOXC4)|P00492(HPRT1)|P0DMV8(HSPA1A)|P54652(HSPA2)|P11142(HSPA8)|P42858(HTT)|Q12891(HYAL2)|Q9NX55(HYPK)|Q02363(ID2)|Q8IY31-2(IFT20)|Q8IY31-3(IFT20)|Q9NWB7(IFT57)|P22692(IGFBP4)|Q14005-2(IL16)|Q16891(IMMT)|P29218-3(IMPA1)|Q9UNL4(ING4)|Q8WYH8-2(ING5)|Q8NBZ0(INO80E)|Q8TEX9(IPO4)|O00410-3(IPO5)|Q6DN90-2(IQSEC1)|Q96N16(JAKMIP1)|Q92993(KAT5)|Q13303(KCNAB2)|Q9Y691(KCNMB2)|Q96SI1-2(KCTD15)|Q8N5Z5(KCTD17)|A0A384DVV8(KIAA0040)|Q6ZU52(KIAA0408)|Q5T5P2-6(KIAA1217)|O14901(KLF11)|Q9Y4X4(KLF12)|P57682(KLF3)|Q53G59(KLHL12)|Q9Y2M5(KLHL20)|O60259(KLK8)|O15229-2(KMO)|Q9Y448(KNSTRN)|O00505(KPNA3)|P05783(KRT18)|P08727(KRT19)|P35900(KRT20)|Q14525(KRT33B)|P60409(KRTAP10-7)|Q8IUC1(KRTAP11-1)|Q8IUC2(KRTAP8-1)|Q9BYQ4(KRTAP9-2)|Q96JM7-2(L3MBTL3)|O43813(LANCL1)|Q92615(LARP4B)|O95447(LCA5L)|Q5T7P3(LCE1B)|Q86U70-2(LDB1)|Q9BYZ2(LDHAL6B)|P07195(LDHB)|O95751(LDOC1)|Q8TCE9(LGALS14)|Q9H2C1(LHX5)|Q9UPM6(LHX6)|Q68G74(LHX8)|Q9H9Z2(LIN28A)|Q8N0U6(LINC00518)|Q9H0V9(LMAN2L)|Q8TBB1(LNX1)|Q8N448(LNX2)|A2RU56(LOC401296)|Q1L5Z9(LONRF2)|Q14693(LPIN1)|Q96CN5(LRRC45)|Q32MZ4(LRRFIP1)|O95777(LSM8)|Q9Y383(LUC7L2)|Q8N1E2(LYG1)|Q9H063(MAF1)|P43357(MAGEA3)|Q96M61(MAGEB18)|Q8N7X4(MAGEB6)|Q96EH3(MALSU1)|Q99683(MAP3K5)|Q00266(MAT1A)|P43243(MATR3)|P56270-2(MAZ)|Q9UIS9(MBD1)|O95243-2(MBD4)|Q96EZ8(MCRS1)|Q9HAF1(MEAF6)|P51608(MECP2)|Q96RN5(MED15)|Q96RN5-2(MED15)|Q15528-2(MED22)|Q9H204(MED28)|Q96HR3(MED30)|Q9Y3C7(MED31)|P50221(MEOX1)|Q8N6F8(METTL27)|Q8TDB4(MGARP)|O94851(MICAL2)|A4FUJ8(MKL1)|Q9BUB5(MKNK1)|Q9H000(MKRN2)|P22033(MMUT)|P51948(MNAT1)|P41218(MNDA)|Q16653-13(MOG)|Q15014(MORF4L2)|Q8N594(MPND)|P49959(MRE11)|Q9Y605(MRFAP1)|Q96HT8(MRFAP1L1)|Q9BYD1(MRPL13)|O43196-4(MSH5)|Q9Y3D2(MSRB2)|P35548(MSX2)|P02795(MT2A)|O43312(MTSS1)|Q9ULD2-3(MTUS1)|Q9ULD2-4(MTUS1)|O15069(NACAD)|Q9ULW6(NAP1L2)|P54920(NAPA)|Q14596(NBR1)|P14598(NCF1)|Q969V3(NCLN)|O75376(NCOR1)|Q99608(NDN)|Q9P0J0(NDUFA13)|Q16795(NDUFA9)|O96000(NDUFB10)|O96000-2(NDUFB10)|Q9Y6M9(NDUFB9)|P28331-5(NDUFS1)|O43920(NDUFS5)|O76041(NEBL)|I6L9F6(NEFL)|Q86SG6(NEK8)|Q13562(NEUROD1)|P19838-2(NFKB1)|Q8N5V2(NGEF)|Q9NX24(NHP2)|Q9UBE8(NLK)|Q96AM0(NLRP1)|O00746(NME4)|P56597(NME5)|Q9C002(NMES1)|Q9Y239(NOD1)|O15130-2(NPFF)|Q9Y639-1(NPTN)|Q13133-2(NR1H3)|Q86WQ0(NR2C2AP)|Q6X4W1-6(NSMF)|P36639-4(NUDT1)|Q9NZJ9(NUDT4)|Q7Z417(NUFIP2)|Q9BVL2(NUP58)|Q9NPJ8-3(NXT2)|Q96GC1(ODF2L)|Q02218(OGDH)|Q86WS3(OOSP2)|Q6B0I4(OPCML)|Q96CV9(OPTN)|Q96CV9-2(OPTN)|Q92882(OSTF1)|Q3ZCN5(OTOGL)|Q8IVL6-2(P3H3)|P13674(P4HA1)|Q6VY07(PACS1)|Q9BY11(PACSIN1)|Q13177(PAK2)|Q9P286(PAK5)|Q9NP74(PALMD)|Q8N3R9(PALS1)|Q86WK9(PAQR7)|Q99497(PARK7)|Q9HBE1-4(PATZ1)|Q9BYU1(PBX4)|Q9Y5G3-2(PCDHGB1)|Q6UW60-2(PCSK4)|P54750-4(PDE1A)|Q15119(PDK2)|Q96HC4(PDLIM5)|O15530-4(PDPK1)|Q13113(PDZK1IP1)|Q96FA3(PELI1)|Q9BRX2(PELO)|O00541(PES1)|Q99471(PFDN5)|P35080(PFN2)|O75925(PIAS1)|Q8N2W9(PIAS4)|Q8WXW3(PIBF1)|Q9NRD5(PICK1)|Q8WWB5(PIH1D2)|P42336(PIK3CA)|P27986(PIK3R1)|P27986-2(PIK3R1)|O00459(PIK3R2)|Q92569(PIK3R3)|Q9BXM7(PINK1)|Q96J94(PIWIL1)|P14618(PKM)|Q9BS22(PLA2G1B)|Q9UP65(PLA2G4C)|Q15149(PLEC)|Q6ZR37(PLEKHG7)|Q9HCM2-3(PLXNA4)|Q6P1K2-3(PMF1)|Q8NBT0(POC1A)|Q9H2U2-3(PPA2)|Q9H2U2-6(PPA2)|Q07869(PPARA)|Q03181-2(PPARD)|P37231(PPARG)|Q59EV6(PPGB)|O43447(PPIH)|O60437(PPL)|P62136(PPP1CA)|Q96T49(PPP1R16B)|Q6ZMI0-5(PPP1R21)|Q16537(PPP2R5E)|O75170-4(PPP6R2)|O60828(PQBP1)|P49642(PRIM1)|P17612(PRKACA)|P55345(PRMT2)|P04156(PRNP)|Q53TL4(PRO0132)|Q8WWY3(PRPF31)|O75400(PRPF40A)|O75400-2(PRPF40A)|Q96M27(PRRC1)|Q8WUY3(PRUNE2)|P25786(PSMA1)|P25789(PSMA4)|P60900(PSMA6)|O14818(PSMA7)|P20618(PSMB1)|P49721(PSMB2)|P49720(PSMB3)|P28072(PSMB6)|P28062-2(PSMB8)|P17980(PSMC3)|O00487(PSMD14)|O43242(PSMD3)|P55036(PSMD4)|P51665(PSMD7)|Q13635-3(PTCH1)|P41222(PTGDS)|Q13882(PTK6)|Q9UHX1-2(PUF60)|Q9UHX1-6(PUF60)|P47897(QARS1)|Q15286(RAB35)|P61020(RAB5B)|P54725(RAD23A)|P78406(RAE1)|P62826(RAN)|P46060(RANGAP1)|Q8WZA2(RAPGEF4)|Q13702-2(RAPSN)|P20936(RASA1)|Q6T310(RASL11A)|Q9NS23-4(RASSF1)|P50749(RASSF2)|Q8WWW0-2(RASSF5)|O43251-3(RBFOX2)|P57052(RBM11)|P52756(RBM5)|Q93062-3(RBPMS)|Q9UKA8(RCAN3)|Q15293(RCN1)|Q9GZR2(REXO4)|Q8IXN7(RIMKLA)|Q6NUQ1(RINT1)|Q5TAB7(RIPPLY2)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q96D59(RNF183)|Q5VTR2(RNF20)|Q9H0F5-2(RNF38)|O75150(RNF40)|P26373(RPL13)|Q6NZ55(RPL13)|P61313(RPL15)|Q07020(RPL18)|P84098(RPL19)|P35268(RPL22)|Q9UNX3(RPL26L1)|P61353(RPL27)|P62899(RPL31)|P36578(RPL4)|P25398(RPS12)|P62244(RPS15A)|P39019(RPS19)|P62979(RPS27A)|P23396(RPS3)|P46782(RPS5)|Q16799-3(RTN1)|Q6ZNE9(RUFY4)|Q66K80(RUSC1-AS1)|Q96GQ5(RUSF1)|P48443(RXRG)|Q8N488(RYBP)|P25815(S100P)|Q8N6K7-2(SAMD3)|G3V2R1(SAMD4A)|O75446(SAP30)|Q6UVJ0(SASS6)|Q9BY12-3(SCAPER)|Q8WVM8(SCFD1)|Q96NL6-3(SCLT1)|Q12765-2(SCRN1)|O00560(SDCBP)|P55735-3(SEC13)|Q15437(SEC23B)|Q96T21(SECISBP2)|O43236(SEPTIN4)|Q14141(SEPTIN6)|Q16181-2(SEPTIN7)|Q9UHV2(SERTAD1)|Q9BYW2(SETD2)|Q15047-2(SETDB1)|Q12874(SF3A3)|Q15393(SF3B3)|Q9BWM7(SFXN3)|Q2NKQ1-4(SGSM1)|Q99961(SH3GL1)|Q99963(SH3GL3)|Q9NR46(SH3GLB2)|Q8IYI0(SHLD1)|Q9Y2K2-7(SIK3)|Q96ST3(SIN3A)|Q9GZS3(SKIC8)|P43004(SLC1A2)|Q02978(SLC25A11)|Q00325-2(SLC25A3)|Q8NCS7(SLC44A5)|Q12824(SMARCB1)|Q8TAQ2-2(SMARCC2)|Q96GM5(SMARCD1)|Q16637-3(SMN2)|Q9HCE7-2(SMURF1)|P60880-2(SNAP25)|O95721(SNAP29)|P37840(SNCA)|P62316(SNRPD2)|P62306(SNRPF)|Q13573(SNW1)|Q9UMY4(SNX12)|O60749(SNX2)|Q8WV41(SNX33)|Q8WXH5(SOCS4)|Q9BX66(SORBS1)|O95416(SOX14)|Q9BT81(SOX7)|Q02447(SP3)|Q3SY56(SP6)|Q99932-2(SPAG8)|Q9NY87(SPANXC)|Q7Z6I5(SPATA12)|Q8NHS9(SPATA22)|Q8IUW3(SPATA2L)|P61009(SPCS3)|Q01892(SPIB)|Q1W4C9(SPINK13)|Q8N865(SPMIP4)|Q7Z698(SPRED2)|Q13501(SQSTM1)|P36956(SREBF1)|Q7Z6B7(SRGAP1)|O75044(SRGAP2)|O43295(SRGAP3)|Q8IXS7(SRGAP3)|Q9BXP5(SRRT)|Q9BXP5-3(SRRT)|Q9BXP5-4(SRRT)|P05455(SSB)|Q9NP77(SSU72)|P50502(ST13)|O75886(STAM2)|P49675(STAR)|Q9H668(STN1)|Q9Y3F4(STRAP)|A1L378(STRC)|Q9UNE7(STUB1)|O14662-5(STX16)|P61764(STXBP1)|Q9BR01-2(SULT4A1)|Q8NBJ7(SUMF2)|P63165(SUMO1)|P55854(SUMO3)|A1L190(SYCE3)|Q92797(SYMPK)|Q92797-2(SYMPK)|P08247(SYP)|Q9BQS2-2(SYT15)|Q8N9I0(SYT2)|Q9BQG1(SYT3)|Q5T7P8-2(SYT6)|O75410(TACC1)|O75410-7(TACC1)|Q86TJ2-3(TADA2B)|P37802(TAGLN2)|P37837(TALDO1)|Q6NW12(TANK)|Q92844(TANK)|Q92844-3(TANK)|Q9H2K8(TAOK3)|Q5VWN6(TASOR2)|Q92609(TBC1D5)|Q32MN6(TBP)|Q16650(TBR1)|Q9Y458(TBX22)|O14776(TCERG1)|P17987(TCP1)|Q8TDR4(TCP10L)|P28347-2(TEAD1)|Q86WV5(TEN1)|Q96A09(TENT5B)|Q15554-4(TERF2)|Q96M34(TEX55)|Q03403(TFF2)|Q92734(TFG)|O95455(TGDS)|P37173(TGFBR2)|P21980-2(TGM2)|Q96MW7(TIGD1)|O60220(TIMM8A)|Q08117(TLE5)|Q9BZW5-2(TM6SF1)|Q96EY4(TMA16)|Q9NUM4(TMEM106B)|Q12893(TMEM115)|Q6UW68(TMEM205)|Q8WW34-2(TMEM239)|Q9NV96-2(TMEM30A)|Q9BTV4(TMEM43)|Q9BQJ4(TMEM47)|Q8IUR5-4(TMTC1)|Q71RG4-4(TMUB2)|Q13829(TNFAIP1)|O00300(TNFRSF11B)|O95150(TNFSF15)|Q96KP6(TNIP3)|P22105-1(TNXB)|Q9NS69(TOMM22)|P04637(TP53)|P60174(TPI1)|Q12933(TRAF2)|O14545(TRAFD1)|P19474(TRIM21)|Q9UPQ4-2(TRIM35)|P0CI25(TRIM49)|Q15642-2(TRIP10)|Q15654(TRIP6)|Q99614(TTC1)|Q6DKK2(TTC19)|Q5W5X9-3(TTC23)|Q71U36(TUBA1A)|P07437(TUBB)|Q9BUF5(TUBB6)|Q9UGJ1-2(TUBGCP4)|Q15672(TWIST1)|Q8WVJ9(TWIST2)|Q99757(TXN2)|Q6PKC3(TXNDC11)|Q01081(U2AF1)|P22314(UBA1)|Q9BSL1(UBAC1)|P0CG48(UBC)|Q9Y2X8(UBE2D4)|P62256(UBE2H)|P63279(UBE2I)|P61086(UBE2K)|Q9UHD9(UBQLN2)|Q92890(UFD1)|O75385(ULK1)|Q495M9(USH1G)|Q9UMW8(USP18)|O75604-3(USP2)|Q9UPU5(USP24)|Q8NFA0-2(USP32)|Q93008(USP9X)|Q9BVJ6(UTP14A)|Q9NYH9(UTP6)|Q08AM6(VAC14)|Q9HCJ6(VAT1L)|P55072(VCP)|P45880(VDAC2)|P40337-2(VHL)|P09327-2(VIL1)|P08670(VIM)|Q9UK41(VPS28)|Q8NEZ2(VPS37A)|O75351(VPS4B)|Q9BTA9(WAC)|Q9BTA9-5(WAC)|O75554(WBP4)|Q8IZQ1(WDFY3)|A4D1P6(WDR91)|Q15007-2(WTAP)|O00308(WWP2)|Q9HCS7(XAB2)|Q8WTP9(XAGE3)|P12956(XRCC6)|O95070(YIF1A)|P31946(YWHAB)|Q9H869-2(YY1AP1)|Q9H171(ZBP1)|Q05516(ZBTB16)|O43167-2(ZBTB24)|Q53FD0-2(ZC2HC1C)|Q6PEW1(ZCCHC12)|Q8IUH5(ZDHHC17)|Q8WVZ1-3(ZDHHC19)|G3V1X1(ZFC3H1)|Q6ZN57(ZFP2)|Q96K21(ZFYVE19)|Q9UKY1(ZHX1)|Q96EF9(ZHX1-C8orf76)|Q9BRR0(ZKSCAN3)|Q15776(ZKSCAN8)|Q96NC0(ZMAT2)|O95789-4(ZMYM6)|P52744(ZNF138)|Q9UJW8-4(ZNF180)|P17023(ZNF19)|Q9BSG1(ZNF2)|Q9Y2X9(ZNF281)|Q9HBT8(ZNF286A)|Q9NR11-2(ZNF302)|Q8N895(ZNF366)|Q9C0F3(ZNF436)|Q8N0Y2-2(ZNF444)|Q6ZNH5(ZNF497)|O60304(ZNF500)|Q8N988-2(ZNF557)|Q68EA5(ZNF57)|Q7Z3I7(ZNF572)|Q96N77-2(ZNF641)|Q8N720(ZNF655)|Q5TEC3(ZNF697)|Q3KNS6-3(ZNF829)|Q5JTY5(ZNG1C)|O15535(ZSCAN9)|Q2QGD7(ZXDC)|A8K3Q9()|A8K878()|B7Z3E8()|Q0VG73()|Q7L8T7()|Q86V28()|Q96IQ6()|O88485(Dync1i1)|P54256(Hap1)|P51660(Hsd17b4)|P29994(Itpr1)|Q99KR7(Ppif),,,,,,,,,,,,5.0
Q9NR83,,SLC2A4 regulator,SLC2A4RG,Homo sapiens,387,False,HDBP1,MERPPPRAAGRDPSALRAEAPWLRAEGPGPRAAPVTVPTPPQGSSVGGGFAGLEFARPQESEPRASDLGAPRTWTGAAAGPRTPSAHIPVPAQRATPGKARLDEVMAAAALTSLSTSPLLLGAPVAAFSPEPGLEPWKEALVRPPGSYSSSSNSGDWGWDLASDQSSPSTPSPPLPPEAAHFLFGEPTLRKRKSPAQVMFQCLWKSCGKVLSTASAMQRHIRLVHLGRQAEPEQSDGEEDFYYTELDVGVDTLTDGLSSLTPVSPTASMPPAFPRLELPELLEPPALPSPLRPPAPPLPPPPVLSTVANPQSCHSDRVYQGCLTPARLEPQPTEVGACPPALSSRIGVTLRKPRGDAKKCRKVYGMERRDLWCTACRWKKACQRFLD,0,,,,,,,,,,1:Q9NR83-1:|2:Q9NR83-4:|3:Q9NR83-3:,,,,,,,,,,5.0
P05067,,Amyloid-beta precursor protein,APP,Homo sapiens,770,False,A4|AD1,MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN,0,,,,,,"Alzheimer disease 1:A form of Alzheimer disease, a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death. It can be associated with cerebral amyloid angiopathy. Alzheimer disease can be associated with cerebral amyloid angiopathy.|Cerebral amyloid angiopathy, APP-related:A hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease. Some affected individuals manifest progressive aphasic dementia, leukoencephalopathy, and occipital calcifications.","Alzheimer disease 1|Cerebral amyloid angiopathy, APP-related",Q9NY61(AATF)|P16112(ACAN)|P60709(ACTB)|P61158(ACTR3)|O14672(ADAM10)|A0AVL1(ADAM9)|P18509(ADCYAP1)|P41586-2(ADCYAP1R1)|Q15109(AGER)|Q13155(AIMP2)|P63010-2(AP2B1)|Q02410(APBA1)|Q99767(APBA2)|O96018(APBA3)|O00213(APBB1)|O00213-2(APBB1)|Q92870(APBB2)|Q92870-2(APBB2)|O95704(APBB3)|P02743(APCS)|Q96BI3(APH1A)|Q8WW43(APH1B)|Q06481-5(APLP2)|P02647(APOA1)|P05067(APP)|Q92624(APPBP2)|Q6P4J0(ARD1A)|P61204(ARF3)|Q0P5N6(ARL16)|P56211(ARPP19)|P05026(ATP1B1)|P54253(ATXN1)|P56817(BACE1)|Q9Y5Z0(BACE2)|Q92934(BAD)|P46379-2(BAG6)|Q96GW7(BCAN)|P51572(BCAP31)|P10415(BCL2)|P23560-2(BDNF)|O15392(BIRC5)|Q13867(BLMH)|P35613(BSG)|Q8IU99(CALHM1)|P62158(CALM3)|P27797(CALR)|O43852-3(CALU)|Q9UQM7(CAMK2A)|P27824-2(CANX)|P07384(CAPN1)|P29466-3(CASP1)|P42574(CASP3)|Q14790(CASP8)|Q03135(CAV1)|P83916(CBX1)|P40227(CCT6A)|P16671(CD36)|Q08722-3(CD47)|P06493(CDK1)|Q00535(CDK5)|P42773(CDKN2C)|P43681(CHRNA4)|P36544(CHRNA7)|Q16740(CLPP)|O94985-2(CLSTN1)|Q8IUW6(CLSTN3)|P10909(CLU)|P26441(CNTF)|Q02246(CNTN2)|Q8NE08(COL25A1)|Q96A83-2(COL26A1)|P29400-2(COL4A5)|Q14031(COL4A6)|P31146(CORO1A)|P20674(COX5A)|P15086(CPB1)|P02511(CRYAB)|P48730(CSNK1D)|P48730-2(CSNK1D)|P68400(CSNK2A1)|P01034(CST3)|P49711(CTCF)|P07339(CTSD)|P99999(CYCS)|O75553-4(DAB1)|P98082(DAB2)|Q14203-5(DCTN1)|Q13561(DCTN2)|Q6I9W9(DKFZP586N0721)|O14645(DNALI1)|Q01658(DR1)|P21917(DRD4)|Q16828(DUSP6)|Q92997(DVL3)|O14576-2(DYNC1I1)|O14576-5(DYNC1I1)|Q01094(E2F1)|Q3B7T1(EDRF1)|P20042(EIF2S2)|P19419(ELK1)|P11171-2(EPB41)|P11171-7(EPB41)|Q9BS26(ERP44)|P00748(F12)|P00734(F2)|P23142-4(FBLN1)|Q92915(FGF14)|P62942(FKBP1A)|P21333-2(FLNA)|O75955(FLOT1)|Q9BTI6(FLOT2)|P01100(FOS)|P25090(FPR2)|P09958(FURIN)|P06241(FYN)|P04406(GAPDH)|Q9UJY5-4(GGA1)|Q05586(GRIN1)|P25098(GRK2)|P43250(GRK6)|P43250-2(GRK6)|A4D1B5(GSAP)|P49841-2(GSK3B)|Q03013(GSTM4)|Q00403(GTF2B)|Q9Y5Q9(GTF3C3)|P09429(HMGB1)|P30519(HMOX2)|Q9UJC3(HOOK1)|Q99714(HSD17B10)|Q99714-2(HSD17B10)|P07900(HSP90AA1)|P14625(HSP90B1)|P11021(HSPA5)|P11142(HSPA8)|P04792(HSPB1)|Q16082(HSPB2)|P10809(HSPD1)|P42858(HTT)|Q9UMF0(ICAM5)|P14735(IDE)|Q16352(INA)|Q6DN90-2(IQSEC1)|P05556(ITGB1)|Q9Y287(ITM2B)|P05412(JUN)|P17535(JUND)|Q92993(KAT5)|Q92993-2(KAT5)|Q13303(KCNAB2)|Q9Y2W7(KCNIP3)|O60333-2(KIF1B)|Q07866-2(KLC1)|O14901(KLF11)|Q92876(KLK6)|P01116-2(KRAS)|Q16363-3(LAMA4)|Q9BYZ2(LDHAL6B)|Q96FE5(LINGO1)|Q07954-2(LRP1)|Q9NZR2(LRP1B)|P30533(LRPAP1)|P42704(LRPPRC)|P07948(LYN)|Q9GZQ8(MAP1LC3B)|P36507(MAP2K2)|P28482(MAPK1)|P53778(MAPK12)|Q9UQF2(MAPK8IP1)|P10636(MAPT)|P10636-8(MAPT)|Q9P0L2(MARK1)|Q6IPE9(MARK4)|Q96L34(MARK4)|Q00266(MAT1A)|P02686-2(MBP)|Q93074(MED12)|Q8TDB4(MGARP)|O94851(MICAL2)|A4FUJ8(MKL1)|P08473(MME)|P08253(MMP2)|Q99547(MPHOSPH6)|Q8N594(MPND)|P41227(NAA10)|Q13765(NACA)|Q13564(NAE1)|P41271-2(NBL1)|P19404(NDUFV2)|O76041(NEBL)|P12036(NEFH)|I6L9F6(NEFL)|P21359(NF1)|P01138(NGF)|P08138(NGFR)|Q6IAD4(NOTCH1)|Q99466(NOTCH4)|P43354(NR4A2)|Q6PK61(NRG1)|Q02818(NUCB1)|P49757-8(NUMB)|P04181(OAT)|Q96FW1(OTUB1)|P11940(PABPC1)|O96013-2(PAK4)|Q99497(PARK7)|Q6ZW49(PAXIP1)|P61457(PCBD1)|P16234-2(PDGFRA)|P09619(PDGFRB)|P30101(PDIA3)|Q15084(PDIA6)|Q15118(PDK1)|Q13113(PDZK1IP1)|P18669(PGAM1)|Q8WUB8-2(PHF10)|Q8N2W9(PIAS4)|P42338(PIK3CB)|P48736(PIK3CG)|P27986-2(PIK3R1)|Q13526(PIN1)|Q9BXM7(PINK1)|Q16512(PKN1)|P00749(PLAU)|Q13393(PLD1)|O14939(PLD2)|P53350(PLK1)|O14494(PLPP1)|O15162(PLSCR1)|Q8WVK1(PLSCR1)|A0A6Q8PF08(PMP22)|P00491(PNP)|P62937(PPIA)|P62136(PPP1CA)|P41236(PPP1R2)|P67775(PPP2CA)|P63151(PPP2R2A)|Q00005(PPP2R2B)|Q15172(PPP2R5A)|P48454(PPP3CC)|P17612(PRKACA)|P22694(PRKACB)|P22694-8(PRKACB)|P22612(PRKACG)|Q9UGJ0-3(PRKAG2)|Q05655(PRKCD)|Q02156(PRKCE)|O60260-5(PRKN)|P04156(PRNP)|P60891(PRPS1)|P07602(PSAP)|P49768(PSEN1)|P49768-2(PSEN1)|P49810(PSEN2)|Q9NZ42(PSENEN)|P28062-2(PSMB8)|P17980(PSMC3)|Q14289(PTK2B)|P20340-2(RAB6A)|P63000(RAC1)|P04049(RAF1)|Q96S59(RANBP9)|Q9Y272(RASD1)|P61586(RHOA)|Q9Y3C5(RNF11)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|O75116(ROCK2)|P46779(RPL28)|Q15349(RPS6KA2)|P23443-4(RPS6KB1)|P04271(S100B)|P21673(SAT1)|Q6AZY7-2(SCARA3)|Q8WTV0(SCARB1)|P18827(SDC1)|Q15019-3(SEPTIN2)|O43236(SEPTIN4)|Q99719(SEPTIN5)|Q92599-3(SEPTIN8)|P01011(SERPINA3)|P29353(SHC1)|Q92529(SHC3)|Q8IUQ4-2(SIAH1)|Q9GZS3(SKIC8)|Q7Z2H8(SLC36A1)|Q9NP59(SLC40A1)|P84022(SMAD3)|Q13485(SMAD4)|P37840(SNCA)|Q16143(SNCB)|Q15036(SNX17)|O60749(SNX2)|Q8WV41(SNX33)|Q9UNH7(SNX6)|Q92673(SORL1)|Q99932-2(SPAG8)|P11277(SPTB)|Q13501(SQSTM1)|P61278(SST)|P32745(SSTR3)|P40763-2(STAT3)|Q8IWL8(STH)|O14662-5(STX16)|Q13190-4(STX5)|O43752(STX6)|P61764(STXBP1)|Q9Y5B9(SUPT16H)|P43405(SYK)|P43405-2(SYK)|P08247(SYP)|Q13148(TARDBP)|P20226(TBP)|Q16650(TBR1)|O43680(TCF21)|P01137(TGFB1)|P61812(TGFB2)|Q15583(TGIF1)|Q15583-2(TGIF1)|P04216(THY1)|P04183(TK1)|Q9BX74(TM2D1)|P49755(TMED10)|Q9BTD3(TMEM121)|Q9NV96(TMEM30A)|P62328(TMSB4X)|P01375(TNF)|O43508(TNFSF12)|O75888-3(TNFSF13)|Q96GM8(TOE1)|O14656(TOR1A)|O14656-2(TOR1A)|Q05BL1(TP53BP2)|Q13625(TP53BP2)|Q9C026(TRIM9)|Q15714-2(TSC22D1)|P02766(TTR)|Q71U36(TUBA1A)|P68363(TUBA1B)|P68366(TUBA4A)|P07437(TUBB)|Q8TBC4(UBA3)|P0CG47(UBB)|P62837(UBE2D2)|Q9UMX0(UBQLN1)|P09936(UCHL1)|P13051-2(UNG)|O75604-3(USP2)|Q9BVJ6(UTP14A)|Q9H270(VPS11)|Q8N0S8(VPS29)|Q96AX1(VPS33A)|Q96QK1(VPS35)|O76024(WFS1)|O00744(WNT10B)|P19544-6(WT1)|P31946(YWHAB)|O60293(ZFC3H1)|P17028(ZNF24)|Q8N895(ZNF366)|Q03936(ZNF92)|Q8NHT4()|O35431(Apba2)|P15253(CALR)|Q8BGY9(Slc5a7)|Q306T3()|Q9H7C9(AAMDC)|P63010-2(AP2B1)|Q0P5N6(ARL16)|O15392(BIRC5)|Q9UHY8(FEZ2)|P06241-3(FYN)|Q12891(HYAL2)|Q6DN90-2(IQSEC1)|Q9BYQ4(KRTAP9-2)|O95447(LCA5L)|Q9BYZ2(LDHAL6B)|Q8TDB4(MGARP)|A4FUJ8(MKL1)|P15941-11(MUC1)|Q13113(PDZK1IP1)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q2NKQ1-4(SGSM1)|Q8IUQ4-2(SIAH1)|Q9GZS3(SKIC8)|Q99932-2(SPAG8)|Q8IUW3(SPATA2L)|Q13148(TARDBP)|Q16650(TBR1)|Q5HYA8(TMEM67)|P09936(UCHL1)|O00213(APBB1)|P51693(APLP1)|Q06481(APLP2)|P05067-4(APP)|Q13867(BLMH)|Q9NZU0(FLRT3)|P46089(GPR3)|O43736(ITM2A)|Q68DU8(KCTD16)|Q96FE5(LINGO1)|P04629(NTRK1)|Q13526(PIN1)|P60201(PLP1)|P04156(PRNP)|P49768(PSEN1)|Q92673(SORL1)|Q99523(SORT1)|Q9HCB6(SPON1)|O95793(STAU1)|Q8VEK0(Tmem30a)|P17677(GAP43)|Q9NSC5(HOMER3)|Q9Y287(ITM2B)|O95631(NTN1)|Q9UIK5(TMEFF2)|Q92673(SORL1)|Q8K3H7(CALR)|Q8VEK0(Tmem30a)|Q9BYF1(ACE2)|P05067(APP)|P48047(ATP5PO)|P36544(CHRNA7)|P10909-5(CLU)|P39060(COL18A1)|O00230(CORT)|Q99714(HSD17B10)|Q8N423(LILRB2)|P10636(MAPT)|P08253(MMP2)|Q9NZV6(MSRB1)|P03897(MT-ND3)|Q8IVG9(MT-RNR2)|O95411(MYO18A)|O95631(NTN1)|Q15113(PCOLCE)|Q08752(PPID)|P30405(PPIF)|P04156(PRNP)|P11686-1(SFTPC)|P61278(SST)|P21980(TGM2)|O60602(TLR5)|Q9NZC2(TREM2)|P02766(TTR)|P15253(CALR)|Q05941(Chrna7)|P03452(HA)|P97484(Lilrb3)|K9N5Q8(S)|P0DTC2(S)|Q99NH8(Trem2)|P02649(APOE)|P05067(APP)|P10909(CLU)|P49840(GSK3A)|P49841(GSK3B)|P14735-1(IDE)|P08253(MMP2)|P08138(NGFR)|Q5JRX3-1(PITRM1)|Q08752(PPID)|Q92673(SORL1)|O60602(TLR5)|P31696(AGRN)|P15253(CALR)|P07174(Ngfr),,APP770:P05067-1:|APP305:P05067-2:|L-APP677:P05067-3:|APP695:P05067-4:|L-APP696:P05067-5:|APP714:P05067-6:|L-APP733:P05067-7:|APP751:P05067-8:|L-APP752:P05067-9:|APP639:P05067-10:|11:P05067-11:,,,,,,,,,,5.0
P10636,,Microtubule-associated protein tau,MAPT,Homo sapiens,758,False,MAPTL|MTBT1|TAU,MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL,0,,,,,,":|Frontotemporal dementia 1:A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.|Pick disease of the brain:A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.|:|Progressive supranuclear palsy 1:Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.|Parkinson-dementia syndrome:A syndrome characterized by parkinsonism, tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.",Frontotemporal dementia 1|Pick disease of the brain|Progressive supranuclear palsy 1|Parkinson-dementia syndrome,P31749(AKT1)|P02649(APOE)|P05067(APP)|P05067(APP)|Q9HC96(CAPN10)|Q9NR30(DDX21)|O43583(DENR)|Q92608-2(DOCK2)|P06241(FYN)|P49841(GSK3B)|P11142(HSPA8)|Q8TCE9(LGALS14)|Q9UPY8(MAPRE3)|P10636(MAPT)|P04156(PRNP)|P46779(RPL28)|P43004(SLC1A2)|Q9UNE7(STUB1)|Q9UNE7-1(STUB1)|O15195-2(VILL)|P63104(YWHAZ)|Q9C0A1(ZFHX2)|P06241(FYN)|Q5S007(LRRK2)|P31947(SFN)|P63104(YWHAZ)|P63104(YWHAZ)|P06241(FYN)|P02649(APOE)|Q14203-5(DCTN1)|Q92608-2(DOCK2)|P06241(FYN)|P11142(HSPA8)|O60260-5(PRKN)|P37840(SNCA)|Q9C0A1(ZFHX2)|O00499-1(BIN1)|P07355(ANXA2)|P08133(ANXA6)|P05067(APP)|O00499-1(BIN1)|Q14203(DCTN1)|P26196(DDX6)|Q02790(FKBP4)|Q13451(FKBP5)|P06241(FYN)|P49840(GSK3A)|P49841(GSK3B)|P08238(HSP90AB1)|P14625(HSP90B1)|Q92743(HTRA1)|Q5S007(LRRK2)|P10636-8(MAPT)|O43347(MSI1)|Q96DH6(MSI2)|P07237(P4HB)|Q12765(SCRN1)|P37840(SNCA)|Q71U36(TUBA1A)|P07437(TUBB),,PNS-tau:P10636-1:|Fetal-tau:P10636-2:|Tau-A:P10636-3:|Tau-B:P10636-4:|Tau-C:P10636-5:|Tau-D:P10636-6:|Tau-E:P10636-7:|Tau-F:P10636-8:|Tau-G:P10636-9:,,,,,,,,,,5.0
P09936,,Ubiquitin carboxyl-terminal hydrolase isozyme L1,UCHL1,Homo sapiens,223,False,,MQLKPMEINPEMLNKVLSRLGVAGQWRFVDVLGLEEESLGSVPAPACALLLLFPLTAQHENFRKKQIEELKGQEVSPKVYFMKQTIGNSCGTIGLIHAVANNQDKLGFEDGSVLKQFLSETEKMSPEDRAKCFEKNEAIQAAHDAVAQEGQCRVDDKVNFHFILFNNVDGHLYELDGRMPFPVNHGASSEDTLLKDAAKVCREFTEREQGEVRFSAVALCKAA,0,,,,,,"Parkinson disease 5:A complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.|Spastic paraplegia 79A, autosomal dominant, with ataxia:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG79A is a slowly progressive form characterized by late-onset spastic ataxia, neuropathy, and often optic atrophy.|Spastic paraplegia 79B, autosomal recessive:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG79B is characterized by childhood onset blindness, cerebellar ataxia, nystagmus, dorsal column dysfunction, and spasticity with upper motor neuron dysfunction.","Parkinson disease 5|Spastic paraplegia 79A, autosomal dominant, with ataxia|Spastic paraplegia 79B, autosomal recessive",P63010-2(AP2B1)|P05067(APP)|P05067-2(APP)|Q8N6T3-3(ARFGAP1)|P18847(ATF3)|Q9H1Y0(ATG5)|O15392(BIRC5)|Q8WUW1(BRK1)|P83916(CBX1)|P11802(CDK4)|Q00535(CDK5)|Q9UNS2(COPS3)|Q92905(COPS5)|P00533(EGFR)|O60739(EIF1B)|Q8TC29(ENKUR)|Q9UI08-2(EVL)|Q8WVV9-3(HNRNPLL)|Q14164(IKBKE)|Q6DN90-2(IQSEC1)|Q96JM7-2(L3MBTL3)|P13473-2(LAMP2)|Q9BYZ2(LDHAL6B)|O95777(LSM8)|A4FUJ8(MKL1)|Q15843(NEDD8)|O15381-5(NVL)|Q9BR81(PCDHGC3)|Q13113(PDZK1IP1)|P62826(RAN)|Q8TAI7(RHEBL1)|Q9ULX5(RNF112)|Q15554-4(TERF2)|Q9NYB0(TERF2IP)|P04637(TP53)|Q9Y4K3(TRAF6)|P19474(TRIM21)|Q9BSL1(UBAC1)|Q7KZS0(UBE2I)|P61086(UBE2K)|Q9UK80(USP21)|Q86WB0-2(ZC3HC1),,,,,,,,,,,,5.0
Q9Y6H5,,Synphilin-1,SNCAIP,Homo sapiens,919,False,,MEAPEYLDLDEIDFSDDISYSVTSLKTIPELCRRCDTQNEDRSVSSSSWNCGISTLITNTQKPTGIADVYSKFRPVKRVSPLKHQPETLENNESDDQKNQKVVEYQKGGESDLGPQPQELGPGDGVGGPPGKSSEPSTSLGELEHYDLDMDEILDVPYIKSSQQLASFTKVTSEKRILGLCTTINGLSGKACSTGSSESSSSNMAPFCVLSPVKSPHLRKASAVIHDQHKLSTEETEISPPLVKCGSAYEPENQSKDFLNKTFSDPHGRKVEKTTPDCQLRAFHLQSSAAESKPEEQVSGLNRTSSQGPEERSEYLKKVKSILNIVKEGQISLLPHLAADNLDKIHDENGNNLLHIAASQGHAECLQHLTSLMGEDCLNERNTEKLTPAGLAIKNGQLECVRWMVSETEAIAELSCSKDFPSLIHYAGCYGQEKILLWLLQFMQEQGISLDEVDQDGNSAVHVASQHGYLGCIQTLVEYGANVTMQNHAGEKPSQSAERQGHTLCSRYLVVVETCMSLASQVVKLTKQLKEQTVERVTLQNQLQQFLEAQKSEGKSLPSSPSSPSSPASRKSQWKSPDADDDSVAKSKPGVQEGIQVLGSLSASSRARPKAKDEDSDKILRQLLGKEISENVCTQEKLSLEFQDAQASSRNSKKIPLEKRELKLARLRQLMQRSLSESDTDSNNSEDPKTTPVRKADRPRPQPIVESVESMDSAESLHLMIKKHTLASGGRRFPFSIKASKSLDGHSPSPTSESSEPDLESQYPGSGSIPPNQPSGDPQQPSPDSTAAQKVATSPKSALKSPSSKRRTSQNLKLRVTFEEPVVQMEQPSLELNGEKDKDKGRTLQRTSTSNESGDQLKRPFGAFRSIMETLSGNQNNNNNYQAANQLKTSTLPLTSLGRKTDAKGNPASSASKGKNKAA,0,,,,,,"Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.",Parkinson disease,P37840(SNCA)|Q9Y6H5(SNCAIP)|O60229-2(KALRN)|P37840(SNCA)|O60260-5(PRKN),,1:Q9Y6H5-1:|2:Q9Y6H5-2:|3:Q9Y6H5-3:|4:Q9Y6H5-4:|5:Q9Y6H5-5:|6:Q9Y6H5-6:,,,,,,,,,,5.0
Q9NZC2,,Triggering receptor expressed on myeloid cells 2,TREM2,Homo sapiens,230,False,,MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDCGHDPGYQLQTLPGLRDT,0,,,,,,"Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2:An autosomal recessive disease characterized by presenile frontal dementia with leukoencephalopathy and basal ganglia calcification. In most cases the disorder first manifests in early adulthood as pain and swelling in ankles and feet, followed by bone fractures. Neurologic symptoms manifest in the fourth decade of life as a frontal lobe syndrome with loss of judgment, euphoria, and disinhibition. Progressive decline in other cognitive domains begins to develop at about the same time. The disorder culminates in a profound dementia and death by age 50 years.|Alzheimer disease 17:A late-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 2|Alzheimer disease 17,P02649(APOE)|P05067(APP)|P49768(PSEN1)|O43914(TYROBP),,1:Q9NZC2-1:|2:Q9NZC2-2:|3:Q9NZC2-3:,,,,,,,,,,5.0
Q12830,,Nucleosome-remodeling factor subunit BPTF,BPTF,Homo sapiens,3046,False,FAC1|FALZ,MRGRRGRPPKQPAAPAAERCAPAPPPPPPPPTSGPIGGLRSRHRGSSRGRWAAAQAEVAPKTRLSSPRGGSSSRRKPPPPPPAPPSTSAPGRGGRGGGGGRTGGGGGGGHLARTTAARRAVNKVVYDDHESEEEEEEEDMVSEEEEEEDGDAEETQDSEDDEEDEMEEDDDDSDYPEEMEDDDDDASYCTESSFRSHSTYSSTPGRRKPRVHRPRSPILEEKDIPPLEFPKSSEDLMVPNEHIMNVIAIYEVLRNFGTVLRLSPFRFEDFCAALVSQEQCTLMAEMHVVLLKAVLREEDTSNTTFGPADLKDSVNSTLYFIDGMTWPEVLRVYCESDKEYHHVLPYQEAEDYPYGPVENKIKVLQFLVDQFLTTNIAREELMSEGVIQYDDHCRVCHKLGDLLCCETCSAVYHLECVKPPLEEVPEDEWQCEVCVAHKVPGVTDCVAEIQKNKPYIRHEPIGYDRSRRKYWFLNRRLIIEEDTENENEKKIWYYSTKVQLAELIDCLDKDYWEAELCKILEEMREEIHRHMDITEDLTNKARGSNKSFLAAANEEILESIRAKKGDIDNVKSPEETEKDKNETENDSKDAEKNREEFEDQSLEKDSDDKTPDDDPEQGKSEEPTEVGDKGNSVSANLGDNTTNATSEETSPSEGRSPVGCLSETPDSSNMAEKKVASELPQDVPEEPNKTCESSNTSATTTSIQPNLENSNSSSELNSSQSESAKAADDPENGERESHTPVSIQEEIVGDFKSEKSNGELSESPGAGKGASGSTRIITRLRNPDSKLSQLKSQQVAAAAHEANKLFKEGKEVLVVNSQGEISRLSTKKEVIMKGNINNYFKLGQEGKYRVYHNQYSTNSFALNKHQHREDHDKRRHLAHKFCLTPAGEFKWNGSVHGSKVLTISTLRLTITQLENNIPSSFLHPNWASHRANWIKAVQMCSKPREFALALAILECAVKPVVMLPIWRESLGHTRLHRMTSIEREEKEKVKKKEKKQEEEETMQQATWVKYTFPVKHQVWKQKGEEYRVTGYGGWSWISKTHVYRFVPKLPGNTNVNYRKSLEGTKNNMDENMDESDKRKCSRSPKKIKIEPDSEKDEVKGSDAAKGADQNEMDISKITEKKDQDVKELLDSDSDKPCKEEPMEVDDDMKTESHVNCQESSQVDVVNVSEGFHLRTSYKKKTKSSKLDGLLERRIKQFTLEEKQRLEKIKLEGGIKGIGKTSTNSSKNLSESPVITKAKEGCQSDSMRQEQSPNANNDQPEDLIQGCSESDSSVLRMSDPSHTTNKLYPKDRVLDDVSIRSPETKCPKQNSIENDIEEKVSDLASRGQEPSKSKTKGNDFFIDDSKLASADDIGTLICKNKKPLIQEESDTIVSSSKSALHSSVPKSTNDRDATPLSRAMDFEGKLGCDSESNSTLENSSDTVSIQDSSEEDMIVQNSNESISEQFRTREQDVEVLEPLKCELVSGESTGNCEDRLPVKGTEANGKKPSQQKKLEERPVNKCSDQIKLKNTTDKKNNENRESEKKGQRTSTFQINGKDNKPKIYLKGECLKEISESRVVSGNVEPKVNNINKIIPENDIKSLTVKESAIRPFINGDVIMEDFNERNSSETKSHLLSSSDAEGNYRDSLETLPSTKESDSTQTTTPSASCPESNSVNQVEDMEIETSEVKKVTSSPITSEEESNLSNDFIDENGLPINKNENVNGESKRKTVITEVTTMTSTVATESKTVIKVEKGDKQTVVSSTENCAKSTVTTTTTTVTKLSTPSTGGSVDIISVKEQSKTVVTTTVTDSLTTTGGTLVTSMTVSKEYSTRDKVKLMKFSRPKKTRSGTALPSYRKFVTKSSKKSIFVLPNDDLKKLARKGGIREVPYFNYNAKPALDIWPYPSPRPTFGITWRYRLQTVKSLAGVSLMLRLLWASLRWDDMAAKAPPGGGTTRTETSETEITTTEIIKRRDVGPYGIRSEYCIRKIICPIGVPETPKETPTPQRKGLRSSALRPKRPETPKQTGPVIIETWVAEEELELWEIRAFAERVEKEKAQAVEQQAKKRLEQQKPTVIATSTTSPTSSTTSTISPAQKVMVAPISGSVTTGTKMVLTTKVGSPATVTFQQNKNFHQTFATWVKQGQSNSGVVQVQQKVLGIIPSSTGTSQQTFTSFQPRTATVTIRPNTSGSGGTTSNSQVITGPQIRPGMTVIRTPLQQSTLGKAIIRTPVMVQPGAPQQVMTQIIRGQPVSTAVSAPNTVSSTPGQKSLTSATSTSNIQSSASQPPRPQQGQVKLTMAQLTQLTQGHGGNQGLTVVIQGQGQTTGQLQLIPQGVTVLPGPGQQLMQAAMPNGTVQRFLFTPLATTATTASTTTTTVSTTAAGTGEQRQSKLSPQMQVHQDKTLPPAQSSSVGPAEAQPQTAQPSAQPQPQTQPQSPAQPEVQTQPEVQTQTTVSSHVPSEAQPTHAQSSKPQVAAQSQPQSNVQGQSPVRVQSPSQTRIRPSTPSQLSPGQQSQVQTTTSQPIPIQPHTSLQIPSQGQPQSQPQVQSSTQTLSSGQTLNQVTVSSPSRPQLQIQQPQPQVIAVPQLQQQVQVLSQIQSQVVAQIQAQQSGVPQQIKLQLPIQIQQSSAVQTHQIQNVVTVQAASVQEQLQRVQQLRDQQQKKKQQQIEIKREHTLQASNQSEIIQKQVVMKHNAVIEHLKQKKSMTPAEREENQRMIVCNQVMKYILDKIDKEEKQAAKKRKREESVEQKRSKQNATKLSALLFKHKEQLRAEILKKRALLDKDLQIEVQEELKRDLKIKKEKDLMQLAQATAVAAPCPPVTPAPPAPPAPPPSPPPPPAVQHTGLLSTPTLPAASQKRKREEEKDSSSKSKKKKMISTTSKETKKDTKLYCICKTPYDESKFYIGCDRCQNWYHGRCVGILQSEAELIDEYVCPQCQSTEDAMTVLTPLTEKDYEGLKRVLRSLQAHKMAWPFLEPVDPNDAPDYYGVIKEPMDLATMEERVQRRYYEKLTEFVADMTKIFDNCRYYNPSDSPFYQCAEVLESFFVQKLKGFKASRSHNNKLQSTAS,0,,,,,,"Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies:An autosomal dominant neurodevelopmental disorder characterized by variable degrees of developmental delay, intellectual disability, speech delay, postnatal microcephaly, dysmorphic features, and mild abnormalities of the hands and feet.",Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies,P62805(H4C9)|P28370(SMARCA1)|O60264(SMARCA5)|Q71DI3(H3C15)|P62805(H4C9),,1:Q12830-1:|2:Q12830-2:|4:Q12830-4:,,,,,,,,,,5.0
Q96A57,,Transmembrane protein 230,TMEM230,Homo sapiens,120,False,C20orf30,MMPSRTNLATGIPSSKVKYSRLSSTDDGYIDLQFKKTPPKIPYKAIALATVLFLIGAFLIIIGSLLLSGYISKGGADRAVPVLIIGILVFLPGFYHLRIAYYASKGYRGYSYDDIPDFDD,0,,,,,,"Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.",Parkinson disease,O43765(SGTA),,2:Q96A57-1:|1:Q96A57-2:,,,,,,,,,,5.0
P49768,,Presenilin-1,PSEN1,Homo sapiens,467,False,AD3|PS1|PSNL1,MTELPAPLSYFQNAQMSEDNHLSNTVRSQNDNRERQEHNDRRSLGHPEPLSNGRPQGNSRQVVEQDEEEDEELTLKYGAKHVIMLFVPVTLCMVVVVATIKSVSFYTRKDGQLIYTPFTEDTETVGQRALHSILNAAIMISVIVVMTILLVVLYKYRCYKVIHAWLIISSLLLLFFFSFIYLGEVFKTYNVAVDYITVALLIWNFGVVGMISIHWKGPLRLQQAYLIMISALMALVFIKYLPEWTAWLILAVISVYDLVAVLCPKGPLRMLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAESTERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSILAGEDPEERGVKLGLGDFIFYSVLVGKASATASGDWNTTIACFVAILIGLCLTLLLLAIFKKALPALPISITFGLVFYFATDYLVQPFMDQLAFHQFYI,0,,,,,,"Alzheimer disease 3:A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.|Frontotemporal dementia 1:A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.|Cardiomyopathy, dilated, 1U:A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.|Acne inversa, familial, 3:A chronic relapsing inflammatory disease of the hair follicles characterized by recurrent draining sinuses, painful skin abscesses, and disfiguring scars. Manifestations typically appear after puberty.|Pick disease of the brain:A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.","Alzheimer disease 3|Frontotemporal dementia 1|Cardiomyopathy, dilated, 1U|Acne inversa, familial, 3|Pick disease of the brain",Q02410(APBA1)|Q96BI3(APH1A)|P05067(APP)|P05067-4(APP)|P56817(BACE1)|Q16543(CDC37)|Q9BQ95(ECSIT)|Q92542(NCSTN)|Q9NZ42(PSENEN)|P50502(ST13)|P55061(TMBIM6)|P49755(TMED10)|Q9NZC2(TREM2)|P98084(Apba2)|P63010-2(AP2B1)|P05067(APP)|P16870(CPE)|Q5D0E6-2(DALRD3)|Q9H816(DCLRE1B)|Q9UHY8(FEZ2)|Q06787-7(FMR1)|P02792(FTL)|P68431(H3C12)|Q12891(HYAL2)|Q6DN90-2(IQSEC1)|Q9NVX7-2(KBTBD4)|Q9BYQ4(KRTAP9-2)|Q9BYZ2(LDHAL6B)|Q8TDB4(MGARP)|A4FUJ8(MKL1)|Q9Y605(MRFAP1)|Q86WS3(OOSP2)|Q96FW1(OTUB1)|Q13113(PDZK1IP1)|P53350(PLK1)|O14494(PLPP1)|Q9NZ42(PSENEN)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q8N488(RYBP)|Q2NKQ1-4(SGSM1)|Q9GZS3(SKIC8)|Q3KNW5(SLC10A6)|Q99932-2(SPAG8)|O00300(TNFRSF11B)|Q96NC0(ZMAT2)|Q63053(Arc)|P35613(BSG)|Q92542(NCSTN),,1:P49768-1:|2:P49768-2:|3:P49768-3:|4:P49768-4:|5:P49768-5:|6:P49768-6:|7:P49768-7:,,,,,,,,,,5.0
P04062,,Lysosomal acid glucosylceramidase,GBA1,Homo sapiens,536,False,GBA|GC|GLUC,MEFSSPSREECPKPLSRVSIMAGSLTGLLLLQAVSWASGARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEHQRDFIARDLGPTLANSTHHNVRLLMLDDQRLLLPHWAKVVLTDPEAAKYVHGIAVHWYLDFLAPAKATLGETHRLFPNTMLFASEACVGSKFWEQSVRLGSWDRGMQYSHSIITNLLYHVVGWTDWNLALNPEGGPNWVRNFVDSPIIVDITKDTFYKQPMFYHLGHFSKFIPEGSQRVGLVASQKNDLDAVALMHPDGSAVVVVLNRSSKDVPLTIKDPAVGFLETISPGYSIHTYLWRRQ,0,,,,,,"Gaucher disease:An autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD is a multisystem disease historically divided into three main subtypes on the basis of the presence of neurologic involvement, age at onset and progression rate: type 1 is the non-neuropathic form, type 2 is the acute neuropathic form with early onset and rapid neurologic deterioration, type 3 is the chronic neuropathic form with slow progression of neurologic features. GD shows a marked phenotypic diversity ranging from adult asymptomatic forms, at the mild end, to perinatal lethal forms at the severe end of the disease spectrum. Formal diagnosis of Gaucher disease is based on the measurement of glucocerebrosidase levels in circulating leukocytes and molecular genetic analysis.|Gaucher disease 1:A form of Gaucher disease, an autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD1 is characterized by hepatosplenomegaly with consequent anemia and thrombopenia, and bone involvement. The central nervous system is not involved.|Gaucher disease 2:The most severe form of Gaucher disease, an autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD2 is an acute neuronopathic form that manifests soon after birth, with death generally occurring before patients reach two years of age. Clinical features include hepatosplenomegaly, developmental regression, growth arrest, and rapidly progressing neurologic deterioration.|Gaucher disease 3:A form of Gaucher disease, an autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD3 is a subacute neuronopathic form characterized by later onset and slower progression compared to Gaucher disease 2.|Gaucher disease 3C:A variant of subacute neuronopathic Gaucher disease 3 associated with cardiovascular calcifications.|Gaucher disease perinatal lethal:Distinct form of Gaucher disease type 2, characterized by fetal onset. Hydrops fetalis, in utero fetal death and neonatal distress are prominent features. When hydrops is absent, neurologic involvement begins in the first week and leads to death within 3 months. Hepatosplenomegaly is a major sign, and is associated with ichthyosis, arthrogryposis, and facial dysmorphism.|Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.",Gaucher disease|Gaucher disease 1|Gaucher disease 2|Gaucher disease 3|Gaucher disease 3C|Gaucher disease perinatal lethal|Parkinson disease,P17987(TCP1),,Long:P04062-1:|Short:P04062-2:|3:P04062-3:|4:P04062-4:|5:P04062-5:,,,,,,,,,,5.0
P03891,,NADH-ubiquinone oxidoreductase chain 2,MT-ND2,Homo sapiens,347,False,MTND2|NADH2|ND2,MNPLAQPVIYSTIFAGTLITALSSHWFFTWVGLEMNMLAFIPVLTKKMNPRSTEAAIKYFLTQATASMILLMAILFNNMLSGQWTMTNTTNQYSSLMIMMAMAMKLGMAPFHFWVPEVTQGTPLTSGLLLLTWQKLAPISIMYQISPSLNVSLLLTLSILSIMAGSWGGLNQTQLRKILAYSSITHMGWMMAVLPYNPNMTILNLTIYIILTTTAFLLLNLNSSTTTLLLSRTWNKLTWLTPLIPSTLLSLGGLPPLTGFLPKWAIIEEFTKNNSLIIPTIMATITLLNLYFYLRLIYSTSITLLPMSNNVKMKWQFEHTKPTPFLPTLIALTTLLLPISPFMLMIL,0,,,,,,"Leber hereditary optic neuropathy:A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.|Alzheimer disease mitochondrial:Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.|Leigh syndrome:An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.",Leber hereditary optic neuropathy|Alzheimer disease mitochondrial|Leigh syndrome,,,,,,,,,,,,,5.0
O95185,,Netrin receptor UNC5C,UNC5C,Homo sapiens,931,False,UNC5H3,MRKGLRATAARCGLGLGYLLQMLVLPALALLSASGTGSAAQDDDFFHELPETFPSDPPEPLPHFLIEPEEAYIVKNKPVNLYCKASPATQIYFKCNSEWVHQKDHIVDERVDETSGLIVREVSIEISRQQVEELFGPEDYWCQCVAWSSAGTTKSRKAYVRIAYLRKTFEQEPLGKEVSLEQEVLLQCRPPEGIPVAEVEWLKNEDIIDPVEDRNFYITIDHNLIIKQARLSDTANYTCVAKNIVAKRKSTTATVIVYVNGGWSTWTEWSVCNSRCGRGYQKRTRTCTNPAPLNGGAFCEGQSVQKIACTTLCPVDGRWTPWSKWSTCGTECTHWRRRECTAPAPKNGGKDCDGLVLQSKNCTDGLCMQTAPDSDDVALYVGIVIAVIVCLAISVVVALFVYRKNHRDFESDIIDSSALNGGFQPVNIKAARQDLLAVPPDLTSAAAMYRGPVYALHDVSDKIPMTNSPILDPLPNLKIKVYNTSGAVTPQDDLSEFTSKLSPQMTQSLLENEALSLKNQSLARQTDPSCTAFGSFNSLGGHLIVPNSGVSLLIPAGAIPQGRVYEMYVTVHRKETMRPPMDDSQTLLTPVVSCGPPGALLTRPVVLTMHHCADPNTEDWKILLKNQAAQGQWEDVVVVGEENFTTPCYIQLDAEACHILTENLSTYALVGHSTTKAAAKRLKLAIFGPLCCSSLEYSIRVYCLDDTQDALKEILHLERQMGGQLLEEPKALHFKGSTHNLRLSIHDIAHSLWKSKLLAKYQEIPFYHVWSGSQRNLHCTFTLERFSLNTVELVCKLCVRQVEGEGQIFQLNCTVSEEPTGIDLPLLDPANTITTVTGPSAFSIPLPIRQKLCSSLDAPQTRGHDWRMLAHKLNLDRYLNYFATKSSPTGVILDLWEAQNFPDGNLSMLAAVLEEMGRHETVVSLAAEGQY,0,,,,,,"Alzheimer disease:Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Alzheimer disease,Q13509(TUBB3),,1:O95185-1:|2:O95185-2:,,,,,,,,,,5.0
P03886,,NADH-ubiquinone oxidoreductase chain 1,MT-ND1,Homo sapiens,318,False,MTND1|NADH1|ND1,MPMANLLLLIVPILIAMAFLMLTERKILGYMQLRKGPNVVGPYGLLQPFADAMKLFTKEPLKPATSTITLYITAPTLALTIALLLWTPLPMPNPLVNLNLGLLFILATSSLAVYSILWSGWASNSNYALIGALRAVAQTISYEVTLAIILLSTLLMSGSFNLSTLITTQEHLWLLLPSWPLAMMWFISTLAETNRTPFDLAEGESELVSGFNIEYAAGPFALFFMAEYTNIIMMNTLTTTIFLGTTYDALSPELYTTYFVTKTLLLTSLFLWIRTAYPRFRYDQLMHLLWKNFLPLTLALLMWYVSMPITISSIPPQT,0,,,,,,"Leber hereditary optic neuropathy:A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.|Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome:Genetically heterogeneous disorder, characterized by episodic vomiting, seizures, and recurrent cerebral insults resembling strokes and causing hemiparesis, hemianopsia, or cortical blindness.|Alzheimer disease mitochondrial:Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.|Type 2 diabetes mellitus:A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.",Leber hereditary optic neuropathy|Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome|Alzheimer disease mitochondrial|Type 2 diabetes mellitus,P43490(NAMPT),,,,,,,,,,,,5.0
P07339,,Cathepsin D,CTSD,Homo sapiens,412,False,CPSD,MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL,0,,,,,,"Ceroid lipofuscinosis, neuronal, 10:A form of neuronal ceroid lipofuscinosis with onset at birth or early childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy.","Ceroid lipofuscinosis, neuronal, 10",P05067(APP)|Q9P1A6-3(DLGAP2)|I6L9I8(EPN3)|Q9H6S3(EPS8L2)|Q7Z602(GPR141)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P28799(GRN)|P68431(H3C12)|Q9Y6F6-3(IRAG1)|Q12756(KIF1A)|Q5TA79(LCE2A)|Q86VF5-3(MOGAT3)|O15130-2(NPFF)|Q96LB9(PGLYRP3)|P09565(PP9974)|Q9C004(SPRY4)|Q8NBJ7(SUMF2)|Q9BQG1(SYT3)|P28347-2(TEAD1)|P45880(VDAC2)|Q15007-2(WTAP)|O00308(WWP2)|Q5W0Z9-4(ZDHHC20)|Q6ZNH5(ZNF497),,,,,,,,,,,,5.0
Q92673,,Sortilin-related receptor,SORL1,Homo sapiens,2214,False,C11orf32,MATRSSRRESRLPFLFTLVALLPPGALCEVWTQRLHGGSAPLPQDRGFLVVQGDPRELRLWARGDARGASRADEKPLRRKRSAALQPEPIKVYGQVSLNDSHNQMVVHWAGEKSNVIVALARDSLALARPKSSDVYVSYDYGKSFKKISDKLNFGLGNRSEAVIAQFYHSPADNKRYIFADAYAQYLWITFDFCNTLQGFSIPFRAADLLLHSKASNLLLGFDRSHPNKQLWKSDDFGQTWIMIQEHVKSFSWGIDPYDKPNTIYIERHEPSGYSTVFRSTDFFQSRENQEVILEEVRDFQLRDKYMFATKVVHLLGSEQQSSVQLWVSFGRKPMRAAQFVTRHPINEYYIADASEDQVFVCVSHSNNRTNLYISEAEGLKFSLSLENVLYYSPGGAGSDTLVRYFANEPFADFHRVEGLQGVYIATLINGSMNEENMRSVITFDKGGTWEFLQAPAFTGYGEKINCELSQGCSLHLAQRLSQLLNLQLRRMPILSKESAPGLIIATGSVGKNLASKTNVYISSSAGARWREALPGPHYYTWGDHGGIITAIAQGMETNELKYSTNEGETWKTFIFSEKPVFVYGLLTEPGEKSTVFTIFGSNKENVHSWLILQVNATDALGVPCTENDYKLWSPSDERGNECLLGHKTVFKRRTPHATCFNGEDFDRPVVVSNCSCTREDYECDFGFKMSEDLSLEVCVPDPEFSGKSYSPPVPCPVGSTYRRTRGYRKISGDTCSGGDVEARLEGELVPCPLAEENEFILYAVRKSIYRYDLASGATEQLPLTGLRAAVALDFDYEHNCLYWSDLALDVIQRLCLNGSTGQEVIINSGLETVEALAFEPLSQLLYWVDAGFKKIEVANPDGDFRLTIVNSSVLDRPRALVLVPQEGVMFWTDWGDLKPGIYRSNMDGSAAYHLVSEDVKWPNGISVDDQWIYWTDAYLECIERITFSGQQRSVILDNLPHPYAIAVFKNEIYWDDWSQLSIFRASKYSGSQMEILANQLTGLMDMKIFYKGKNTGSNACVPRPCSLLCLPKANNSRSCRCPEDVSSSVLPSGDLMCDCPQGYQLKNNTCVKQENTCLRNQYRCSNGNCINSIWWCDFDNDCGDMSDERNCPTTICDLDTQFRCQESGTCIPLSYKCDLEDDCGDNSDESHCEMHQCRSDEYNCSSGMCIRSSWVCDGDNDCRDWSDEANCTAIYHTCEASNFQCRNGHCIPQRWACDGDTDCQDGSDEDPVNCEKKCNGFRCPNGTCIPSSKHCDGLRDCSDGSDEQHCEPLCTHFMDFVCKNRQQCLFHSMVCDGIIQCRDGSDEDAAFAGCSQDPEFHKVCDEFGFQCQNGVCISLIWKCDGMDDCGDYSDEANCENPTEAPNCSRYFQFRCENGHCIPNRWKCDRENDCGDWSDEKDCGDSHILPFSTPGPSTCLPNYYRCSSGTCVMDTWVCDGYRDCADGSDEEACPLLANVTAASTPTQLGRCDRFEFECHQPKTCIPNWKRCDGHQDCQDGRDEANCPTHSTLTCMSREFQCEDGEACIVLSERCDGFLDCSDESDEKACSDELTVYKVQNLQWTADFSGDVTLTWMRPKKMPSASCVYNVYYRVVGESIWKTLETHSNKTNTVLKVLKPDTTYQVKVQVQCLSKAHNTNDFVTLRTPEGLPDAPRNLQLSLPREAEGVIVGHWAPPIHTHGLIREYIVEYSRSGSKMWASQRAASNFTEIKNLLVNTLYTVRVAAVTSRGIGNWSDSKSITTIKGKVIPPPDIHIDSYGENYLSFTLTMESDIKVNGYVVNLFWAFDTHKQERRTLNFRGSILSHKVGNLTAHTSYEISAWAKTDLGDSPLAFEHVMTRGVRPPAPSLKAKAINQTAVECTWTGPRNVVYGIFYATSFLDLYRNPKSLTTSLHNKTVIVSKDEQYLFLVRVVVPYQGPSSDYVVVKMIPDSRLPPRHLHVVHTGKTSVVIKWESPYDSPDQDLLYAVAVKDLIRKTDRSYKVKSRNSTVEYTLNKLEPGGKYHIIVQLGNMSKDSSIKITTVSLSAPDALKIITENDHVLLFWKSLALKEKHFNESRGYEIHMFDSAMNITAYLGNTTDNFFKISNLKMGHNYTFTVQARCLFGNQICGEPAILLYDELGSGADASATQAARSTDVAAVVVPILFLILLSLGVGFAILYTKHRRLQSSFTAFANSHYSSRLGSAIFSSGDDLGEDDEDAPMITGFSDDVPMVIA,0,,,,,,"Alzheimer disease:Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Alzheimer disease,P05067(APP)|P05067-4(APP)|P05067(APP)|P05067(APP)|P83916(CBX1)|P43681(CHRNA4)|P26992(CNTFR)|O75462(CRLF1)|Q96D03(DDIT4L)|P20042(EIF2S2)|P39905(GDNF)|P56159-2(GFRA1)|Q9UJY5(GGA1)|Q9UJY4(GGA2)|O43301(HSPA12A)|P05231(IL6)|P08887(IL6R)|Q92993(KAT5)|P30533(LRPAP1)|P19404(NDUFV2)|P00491(PNP)|P78424(POU6F2)|Q15669(RHOH)|Q92673(SORL1)|Q8N0S8(VPS29)|Q62997(Gfra1),,,,,,,,,,,,5.0
P49810,,Presenilin-2,PSEN2,Homo sapiens,448,False,AD4|PS2|PSNL2|STM2,MLTFMASDSEEEVCDERTSLMSAESPTPRSCQEGRQGPEDGENTAQWRSQENEEDGEEDPDRYVCSGVPGRPPGLEEELTLKYGAKHVIMLFVPVTLCMIVVVATIKSVRFYTEKNGQLIYTPFTEDTPSVGQRLLNSVLNTLIMISVIVVMTIFLVVLYKYRCYKFIHGWLIMSSLMLLFLFTYIYLGEVLKTYNVAMDYPTLLLTVWNFGAVGMVCIHWKGPLVLQQAYLIMISALMALVFIKYLPEWSAWVILGAISVYDLVAVLCPKGPLRMLVETAQERNEPIFPALIYSSAMVWTVGMAKLDPSSQGALQLPYDPEMEEDSYDSFGEPSYPEVFEPPLTGYPGEELEEEEERGVKLGLGDFIFYSVLVGKAAATGSGDWNTTLACFVAILIGLCLTLLLLAVFKKALPALPISITFGLIFYFSTDNLVRPFMDTLASHQLYI,0,,,,,,"Alzheimer disease 4:A familial early-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.|Cardiomyopathy, dilated, 1V:A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.","Alzheimer disease 4|Cardiomyopathy, dilated, 1V",P54819(AK2)|P05067(APP)|Q0P5N6(ARL16)|Q16611(BAK1)|P29466-3(CASP1)|Q86WV2(COX4I1)|Q14204(DYNC1H1)|Q9BQ95(ECSIT)|O00472(ELL2)|Q3SYB3(FOXD4L6)|P02792(FTL)|P68431(H3C12)|Q8WVV9-3(HNRNPLL)|Q8TDB4(MGARP)|O94851(MICAL2)|A4FUJ8(MKL1)|P41218(MNDA)|Q96HT8(MRFAP1L1)|O76041(NEBL)|Q53EL6(PDCD4)|Q13113(PDZK1IP1)|P27986-2(PIK3R1)|Q99496(RNF2)|Q8N488(RYBP)|Q2NKQ1-4(SGSM1)|Q9GZS3(SKIC8)|Q9NSD5-3(SLC6A13)|O95416(SOX14)|Q3SY56(SP6)|Q9BSL1(UBAC1)|Q96NC0(ZMAT2)|Q8N895(ZNF366)|Q8NBB4-2(ZSCAN1)|Q2QGD7(ZXDC),,1:P49810-1:|2:P49810-2:|3:P49810-3:,,,,,,,,,,5.0
Q16643,,Drebrin,DBN1,Homo sapiens,649,False,D0S117E,MAGVSFSGHRLELLAAYEEVIREESAADWALYTYEDGSDDLKLAASGEGGLQELSGHFENQKVMYGFCSVKDSQAALPKYVLINWVGEDVPDARKCACASHVAKVAEFFQGVDVIVNASSVEDIDAGAIGQRLSNGLARLSSPVLHRLRLREDENAEPVGTTYQKTDAAVEMKRINREQFWEQAKKEEELRKEEERKKALDERLRFEQERMEQERQEQEERERRYREREQQIEEHRRKQQTLEAEEAKRRLKEQSIFGDHRDEEEETHMKKSESEVEEAAAIIAQRPDNPREFFKQQERVASASAGSCDVPSPFNHRPGSHLDSHRRMAPTPIPTRSPSDSSTASTPVAEQIERALDEVTSSQPPPLPPPPPPAQETQEPSPILDSEETRAAAPQAWAGPMEEPPQAQAPPRGPGSPAEDLMFMESAEQAVLAAPVEPATADATEIHDAADTIETDTATADTTVANNVPPAATSLIDLWPGNGEGASTLQGEPRAPTPPSGTEVTLAEVPLLDEVAPEPLLPAGEGCATLLNFDELPEPPATFCDPEEVEGESLAAPQTPTLPSALEELEQEQEPEPHLLTNGETTQKEGTQASEGYFSQSQEEEFAQSEELCAKAPPPVFYNKPPEIDITCWDADPVPEEEEGFEGGD,0,,,,,,"Alzheimer disease:Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Alzheimer disease,P55196(AFDN)|P61073(CXCR4)|Q16643-1(DBN1)|P62993(GRB2)|P28799(GRN)|P60484(PTEN)|Q9BSI4(TINF2)|Q9ULU4(ZMYND8)|O35889(Afdn),,1:Q16643-1:|2:Q16643-2:|3:Q16643-3:,,,,,,,,,,5.0
O75165,,DnaJ homolog subfamily C member 13,DNAJC13,Homo sapiens,2243,False,KIAA0678|RME8,MNIIRENKDLACFYTTKHSWRGKYKRVFSVGTHAITTYNPNTLEVTNQWPYGDICSISPVGKGQGTEFNLTFRKGSGKKSETLKFSTEHRTELLTEALRFRTDFSEGKITGRRYNCYKHHWSDSRKPVILEVTPGGFDQINPATNRVLCSYDYRNIEGFVDLSDYQGGFCILYGGFSRLHLFASEQREEIIKSAIDHAGNYIGISLRIRKEPLEFEQYLNLRFGKYSTDESITSLAEFVVQKISPRHSEPVKRVLALTETCLVERDPATYNIATLKPLGEVFALVCDSENPQLFTIEFIKGQVRKYSSTERDSLLASLLDGVRASGNRDVCVKMTPTHKGQRWGLLSMPVDEEVESLHLRFLATPPNGNFADAVFRFNANISYSGVLHAVTQDGLFSENKEKLINNAITALLSQEGDVVASNAELESQFQAVRRLVASKAGFLAFTQLPKFRERLGVKVVKALKRSNNGIIHAAVDMLCALMCPMHDDYDLRQEQLNKASLLSSKKFLENLLEKFNSHVDHGTGALVISSLLDFLTFALCAPYSETTEGQQFDMLLEMVASNGRTLFKLFQHPSMAIIKGAGLVMKAIIEEGDKEIATKMQELALSEGALPRHLHTAMFTISSDQRMLTNRQLSRHLVGLWTADNATATNLLKRILPPGLLAYLESSDLVPEKDADRMHVRDNVKIAMDQYGKFNKVPEWQRLAGKAAKEVEKFAKEKVDLVLMHWRDRMGIAQKENINQKPVVLRKRRQRIKIEANWDLFYYRFGQDHARSNLIWNFKTREELKDTLESEMRAFNIDRELGSANVISWNHHEFEVKYECLAEEIKIGDYYLRLLLEEDENEESGSIKRSYEFFNELYHRFLLTPKVNMKCLCLQALAIVYGRCHEEIGPFTDTRYIIGMLERCTDKLERDRLILFLNKLILNKKNVKDLMDSNGIRILVDLLTLAHLHVSRATVPLQSNVIEAAPDMKRESEKEWYFGNADKERSGPYGFHEMQELWTKGMLNAKTRCWAQGMDGWRPLQSIPQLKWCLLASGQAVLNETDLATLILNMLITMCGYFPSRDQDNAIIRPLPKVKRLLSDSTCLPHIIQLLLTFDPILVEKVAILLYHIMQDNPQLPRLYLSGVFFFIMMYTGSNVLPVARFLKYTHTKQAFKSEETKGQDIFQRSILGHILPEAMVCYLENYEPEKFSEIFLGEFDTPEAIWSSEMRRLMIEKIAAHLADFTPRLQSNTRALYQYCPIPIINYPQLENELFCNIYYLKQLCDTLRFPDWPIKDPVKLLKDTLDAWKKEVEKKPPMMSIDDAYEVLNLPQGQGPHDESKIRKAYFRLAQKYHPDKNPEGRDMFEKVNKAYEFLCTKSAKIVDGPDPENIILILKTQSILFNRHKEDLQPYKYAGYPMLIRTITMETSDDLLFSKESPLLPAATELAFHTVNCSALNAEELRRENGLEVLQEAFSRCVAVLTRASKPSDMSVQVCGYISKCYSVAAQFEECREKITEMPSIIKDLCRVLYFGKSIPRVAALGVECVSSFAVDFWLQTHLFQAGILWYLLGFLFNYDYTLEESGIQKSEETNQQEVANSLAKLSVHALSRLGGYLAEEQATPENPTIRKSLAGMLTPYVARKLAVASVTEILKMLNSNTESPYLIWNNSTRAELLEFLESQQENMIKKGDCDKTYGSEFVYSDHAKELIVGEIFVRVYNEVPTFQLEVPKAFAASLLDYIGSQAQYLHTFMAITHAAKVESEQHGDRLPRVEMALEALRNVIKYNPGSESECIGHFKLIFSLLRVHGAGQVQQLALEVVNIVTSNQDCVNNIAESMVLSSLLALLHSLPSSRQLVLETLYALTSSTKIIKEAMAKGALIYLLDMFCNSTHPQVRAQTAELFAKMTADKLIGPKVRITLMKFLPSVFMDAMRDNPEAAVHIFEGTHENPELIWNDNSRDKVSTTVREMMLEHFKNQQDNPEANWKLPEDFAVVFGEAEGELAVGGVFLRIFIAQPAWVLRKPREFLIALLEKLTELLEKNNPHGETLETLTMATVCLFSAQPQLADQVPPLGHLPKVIQAMNHRNNAIPKSAIRVIHALSENELCVRAMASLETIGPLMNGMKKRADTVGLACEAINRMFQKEQSELVAQALKADLVPYLLKLLEGIGLENLDSPAATKAQIVKALKAMTRSLQYGEQVNEILCRSSVWSAFKDQKHDLFISESQTAGYLTGPGVAGYLTAGTSTSVMSNLPPPVDHEAGDLGYQT,0,,,,,,"Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.",Parkinson disease,O15126(SCAMP1),,,,,,,,,,,,5.0
Q8IZY2,,Phospholipid-transporting ATPase ABCA7,ABCA7,Homo sapiens,2146,False,,MAFWTQLMLLLWKNFMYRRRQPVQLLVELLWPLFLFFILVAVRHSHPPLEHHECHFPNKPLPSAGTVPWLQGLICNVNNTCFPQLTPGEEPGRLSNFNDSLVSRLLADARTVLGGASAHRTLAGLGKLIATLRAARSTAQPQPTKQSPLEPPMLDVAELLTSLLRTESLGLALGQAQEPLHSLLEAAEDLAQELLALRSLVELRALLQRPRGTSGPLELLSEALCSVRGPSSTVGPSLNWYEASDLMELVGQEPESALPDSSLSPACSELIGALDSHPLSRLLWRRLKPLILGKLLFAPDTPFTRKLMAQVNRTFEELTLLRDVREVWEMLGPRIFTFMNDSSNVAMLQRLLQMQDEGRRQPRPGGRDHMEALRSFLDPGSGGYSWQDAHADVGHLVGTLGRVTECLSLDKLEAAPSEAALVSRALQLLAEHRFWAGVVFLGPEDSSDPTEHPTPDLGPGHVRIKIRMDIDVVTRTNKIRDRFWDPGPAADPLTDLRYVWGGFVYLQDLVERAAVRVLSGANPRAGLYLQQMPYPCYVDDVFLRVLSRSLPLFLTLAWIYSVTLTVKAVVREKETRLRDTMRAMGLSRAVLWLGWFLSCLGPFLLSAALLVLVLKLGDILPYSHPGVVFLFLAAFAVATVTQSFLLSAFFSRANLAAACGGLAYFSLYLPYVLCVAWRDRLPAGGRVAASLLSPVAFGFGCESLALLEEQGEGAQWHNVGTRPTADVFSLAQVSGLLLLDAALYGLATWYLEAVCPGQYGIPEPWNFPFRRSYWCGPRPPKSPAPCPTPLDPKVLVEEAPPGLSPGVSVRSLEKRFPGSPQPALRGLSLDFYQGHITAFLGHNGAGKTTTLSILSGLFPPSGGSAFILGHDVRSSMAAIRPHLGVCPQYNVLFDMLTVDEHVWFYGRLKGLSAAVVGPEQDRLLQDVGLVSKQSVQTRHLSGGMQRKLSVAIAFVGGSQVVILDEPTAGVDPASRRGIWELLLKYREGRTLILSTHHLDEAELLGDRVAVVAGGRLCCCGSPLFLRRHLGSGYYLTLVKARLPLTTNEKADTDMEGSVDTRQEKKNGSQGSRVGTPQLLALVQHWVPGARLVEELPHELVLVLPYTGAHDGSFATLFRELDTRLAELRLTGYGISDTSLEEIFLKVVEECAADTDMEDGSCGQHLCTGIAGLDVTLRLKMPPQETALENGEPAGSAPETDQGSGPDAVGRVQGWALTRQQLQALLLKRFLLARRSRRGLFAQIVLPALFVGLALVFSLIVPPFGHYPALRLSPTMYGAQVSFFSEDAPGDPGRARLLEALLQEAGLEEPPVQHSSHRFSAPEVPAEVAKVLASGNWTPESPSPACQCSRPGARRLLPDCPAAAGGPPPPQAVTGSGEVVQNLTGRNLSDFLVKTYPRLVRQGLKTKKWVNEVRYGGFSLGGRDPGLPSGQELGRSVEELWALLSPLPGGALDRVLKNLTAWAHSLDAQDSLKIWFNNKGWHSMVAFVNRASNAILRAHLPPGPARHAHSITTLNHPLNLTKEQLSEGALMASSVDVLVSICVVFAMSFVPASFTLVLIEERVTRAKHLQLMGGLSPTLYWLGNFLWDMCNYLVPACIVVLIFLAFQQRAYVAPANLPALLLLLLLYGWSITPLMYPASFFFSVPSTAYVVLTCINLFIGINGSMATFVLELFSDQKLQEVSRILKQVFLIFPHFCLGRGLIDMVRNQAMADAFERLGDRQFQSPLRWEVVGKNLLAMVIQGPLFLLFTLLLQHRSQLLPQPRVRSLPLLGEEDEDVARERERVVQGATQGDVLVLRNLTKVYRGQRMPAVDRLCLGIPPGECFGLLGVNGAGKTSTFRMVTGDTLASRGEAVLAGHSVAREPSAAHLSMGYCPQSDAIFELLTGREHLELLARLRGVPEAQVAQTAGSGLARLGLSWYADRPAGTYSGGNKRKLATALALVGDPAVVFLDEPTTGMDPSARRFLWNSLLAVVREGRSVMLTSHSMEECEALCSRLAIMVNGRFRCLGSPQHLKGRFAAGHTLTLRVPAARSQPAAAFVAAEFPGAELREAHGGRLRFQLPPGGRCALARVFGELAVHGAEHGVEDFSVSQTMLEEVFLYFSKDQGKDEDTEEQKEAGVGVDPAPGLQHPKRVSQFLDDPSTAETVL,0,,,,,,"Alzheimer disease 9:A familial, late-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Alzheimer disease 9,,,1:Q8IZY2-1:|2:Q8IZY2-2:,,,,,,,,,,5.0
Q9BSA9,,Endosomal/lysosomal proton channel TMEM175,TMEM175,Homo sapiens,504,False,,MSQPRTPEQALDTPGDCPPGRRDEDAGEGIQCSQRMLSFSDALLSIIATVMILPVTHTEISPEQQFDRSVQRLLATRIAVYLMTFLIVTVAWAAHTRLFQVVGKTDDTLALLNLACMMTITFLPYTFSLMVTFPDVPLGIFLFCVCVIAIGVVQALIVGYAFHFPHLLSPQIQRSAHRALYRRHVLGIVLQGPALCFAAAIFSLFFVPLSYLLMVTVILLPYVSKVTGWCRDRLLGHREPSAHPVEVFSFDLHEPLSKERVEAFSDGVYAIVATLLILDICEDNVPDPKDVKERFSGSLVAALSATGPRFLAYFGSFATVGLLWFAHHSLFLHVRKATRAMGLLNTLSLAFVGGLPLAYQQTSAFARQPRDELERVRVSCTIIFLASIFQLAMWTTALLHQAETLQPSVWFGGREHVLMFAKLALYPCASLLAFASTCLLSRFSVGIFHLMQIAVPCAFLLLRLLVGLALATLRVLRGLARPEHPPPAPTGQDDPQSQLLPAPC,0,,,,,,"Parkinson disease:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.",Parkinson disease,,,1:Q9BSA9-1:|2:Q9BSA9-2:,,,,,,,,,,5.0
P04156,,Major prion protein,PRNP,Homo sapiens,253,False,ALTPRP|PRIP|PRP,MANLGCWMLVLFVATWSDLGLCKKRPKPGGWNTGGSRYPGQGSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQGGGTHSQWNKPSKPKTNMKHMAGAAAAGAVVGGLGGYMLGSAMSRPIIHFGSDYEDRYYRENMHRYPNQVYYRPMDEYSNQNNFVHDCVNITIKQHTVTTTTKGENFTETDVKMMERVVEQMCITQYERESQAYYQRGSSMVLFSSPPVILLISFLIFLIVG,0,,,,,,":|Creutzfeldt-Jakob disease:Occurs primarily as a sporadic disorder (1 per million), while 10-15% are familial. Accidental transmission of CJD to humans appears to be iatrogenic (contaminated human growth hormone (HGH), corneal transplantation, electroencephalographic electrode implantation, etc.). Epidemiologic studies have failed to implicate the ingestion of infected animal meat in the pathogenesis of CJD in human. The triad of microscopic features that characterize the prion diseases consists of (1) spongiform degeneration of neurons, (2) severe astrocytic gliosis that often appears to be out of proportion to the degree of nerve cell loss, and (3) amyloid plaque formation. CJD is characterized by progressive dementia and myoclonic seizures, affecting adults in mid-life. Some patients present sleep disorders, abnormalities of high cortical function, cerebellar and corticospinal disturbances. The disease ends in death after a 3-12 months illness.|Fatal familial insomnia:Autosomal dominant disorder and is characterized by neuronal degeneration limited to selected thalamic nuclei and progressive insomnia.|Gerstmann-Straussler disease:A rare inherited prion disease characterized by adult onset of memory loss, dementia, ataxia, and pathologic deposition of amyloid-like plaques in the brain. GSD presents with progressive limb and truncal ataxia, dysarthria, and cognitive decline in the thirties and forties, and the average disease duration is 7 years.|Huntington disease-like 1:Autosomal dominant, early-onset neurodegenerative disorder with prominent psychiatric features.|Kuru:Kuru is transmitted during ritualistic cannibalism, among natives of the New Guinea highlands. Patients exhibit various movement disorders like cerebellar abnormalities, rigidity of the limbs, and clonus. Emotional lability is present, and dementia is conspicuously absent. Death usually occurs from 3 to 12 month after onset.|Spongiform encephalopathy with neuropsychiatric features:Autosomal dominant presenile dementia with a rapidly progressive and protracted clinical course. The dementia was characterized clinically by frontotemporal features, including early personality changes. Some patients had memory loss, several showed aggressiveness, hyperorality and verbal stereotypy, others had parkinsonian symptoms.",Creutzfeldt-Jakob disease|Fatal familial insomnia|Gerstmann-Straussler disease|Huntington disease-like 1|Kuru|Spongiform encephalopathy with neuropsychiatric features,Q9UL18(AGO1)|Q9UKV8(AGO2)|P05067(APP)|P05067-4(APP)|P05067(APP)|Q8WXF7(ATL1)|P25311(AZGP1)|P55085(F2RL1)|Q13642(FHL1)|O75084(FZD7)|P49639(HOXA1)|P42858(HTT)|P10636(MAPT)|P29372(MPG)|Q9BSJ6(PIMREG)|Q9H4B4(PLK3)|Q06830(PRDX1)|P04156(PRNP)|Q8N6K7-2(SAMD3)|Q8CJG0(Ago2)|P04925(Prnp)|P10279(PRNP)|P23907(PRNP)|P31424-2(Grm5)|P52480(Pkm),,1:P04156-1:|3:F7VJQ1-1:,,,,,,,,,,5.0
P02649,,Apolipoprotein E,APOE,Homo sapiens,317,False,,MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH,0,,,,,,"Hyperlipoproteinemia 3:A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.|Alzheimer disease 2:A late-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.|Sea-blue histiocyte disease:Characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.|Lipoprotein glomerulopathy:Uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries.",Hyperlipoproteinemia 3|Alzheimer disease 2|Sea-blue histiocyte disease|Lipoprotein glomerulopathy,Q9UIJ7(AK3)|Q06481-5(APLP2)|P05067(APP)|Q9HBG4(ATP6V0A4)|Q9NUB4(C20orf141)|P02748(C9)|Q16543(CDC37)|P08603(CFH)|Q9UBD9(CLCF1)|Q8IUW6(CLSTN3)|P26441(CNTF)|Q9H6J7-2(CSTPP1)|Q9H816(DCLRE1B)|Q9BQ95(ECSIT)|Q9Y6C2-2(EMILIN1)|Q3SYB3(FOXD4L6)|Q8IY40(GRIK2)|O75409(H2AP)|P00738(HP)|Q9BYZ2(LDHAL6B)|P01130(LDLR)|P09382(LGALS1)|Q07954(LRP1)|Q14114(LRP8)|Q14114-3(LRP8)|P11137-4(MAP2)|P10636-6(MAPT)|Q9Y3D2(MSRB2)|P02795(MT2A)|Q53EL6(PDCD4)|Q9NS23-4(RASSF1)|P52756(RBM5)|Q6ZNA4-2(RNF111)|Q8WTV0-2(SCARB1)|P37840(SNCA)|Q8IUW3(SPATA2L)|P50502(ST13)|O75069(TMCC2)|Q13829(TNFAIP1)|Q9NZC2(TREM2)|Q6PID6(TTC33)|Q8TBC4(UBA3)|Q9NYH9(UTP6)|P21796(VDAC1)|P17028(ZNF24)|P27958()|P10636(MAPT),,,,,,,,,,,,5.0
Q9NP95,,Fibroblast growth factor 20,FGF20,Homo sapiens,211,False,,MAPLAEVGGFLGGLEGLGQQVGSHFLLPPAGERPPLLGERRSAAERSARGGPGAAQLAHLHGILRRRQLYCRTGFHLQILPDGSVQGTRQDHSLFGILEFISVAVGLVSIRGVDSGLYLGMNDKGELYGSEKLTSECIFREQFEENWYNTYSSNIYKHGDTGRRYFVALNKDGTPRDGARSKRHQKFTHFLPRPVDPERVPELYKDLLMYT,0,,,,,,"Renal hypodysplasia/aplasia 2:A perinatally lethal renal disease encompassing a spectrum of kidney development defects, including renal agenesis, bilateral renal aplasia, hypoplasia, (cystic) dysplasia, and severe obstructive uropathy.",Renal hypodysplasia/aplasia 2,,,,,,,,,,,,,5.0
Q8IV08,,5'-3' exonuclease PLD3,PLD3,Homo sapiens,490,False,,MKPKLMYQELKVPAEEPANELPMNEIEAWKAAEKKARWVLLVLILAVVGFGALMTQLFLWEYGDLHLFGPNQRPAPCYDPCEAVLVESIPEGLDFPNASTGNPSTSQAWLGLLAGAHSSLDIASFYWTLTNNDTHTQEPSAQQGEEVLRQLQTLAPKGVNVRIAVSKPSGPQPQADLQALLQSGAQVRMVDMQKLTHGVLHTKFWVVDQTHFYLGSANMDWRSLTQVKELGVVMYNCSCLARDLTKIFEAYWFLGQAGSSIPSTWPRFYDTRYNQETPMEICLNGTPALAYLASAPPPLCPSGRTPDLKALLNVVDNARSFIYVAVMNYLPTLEFSHPHRFWPAIDDGLRRATYERGVKVRLLISCWGHSEPSMRAFLLSLAALRDNHTHSDIQVKLFVVPADEAQARIPYARVNHNKYMVTERATYIGTSNWSGNYFTETAGTSLLVTQNGRGGLRSQLEAIFLRDWDSPYSHDLDTSADSVGNACRLL,0,,,,,,"Spinocerebellar ataxia 46:A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA46 is a slowly progressive, autosomal dominant form with onset in adulthood.|:",Spinocerebellar ataxia 46,Q8TBE1(CNIH3)|P19838(NFKB1)|P35372-10(OPRM1)|Q9NRQ5(SMCO4),,,,,,,,,,,,5.0
Q96DA2,,Ras-related protein Rab-39B,RAB39B,Homo sapiens,213,False,,MEAIWLYQFRLIVIGDSTVGKSCLIRRFTEGRFAQVSDPTVGVDFFSRLVEIEPGKRIKLQIWDTAGQERFRSITRAYYRNSVGGLLLFDITNRRSFQNVHEWLEETKVHVQPYQIVFVLVGHKCDLDTQRQVTRHEAEKLAAAYGMKYIETSARDAINVEKAFTDLTRDIYELVKRGEITIQEGWEGVKSGFVPNVVHSSEEVVKSERRCLC,0,,,,,,"Intellectual developmental disorder, X-linked 72:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked forms, while syndromic forms present with associated physical, neurological and/or psychiatric manifestations. XLID72 patients can manifest autism spectrum disorder, seizures and macrocephaly as additional features.|Waisman syndrome:A neurologic disorder characterized by delayed psychomotor development, intellectual disability, and early-onset Parkinson disease.","Intellectual developmental disorder, X-linked 72|Waisman syndrome",Q08379(GOLGA2)|Q96T51(RUFY1)|O14972(VPS26C)|Q8IUH5(ZDHHC17),,,,,,,,,,,,5.0
O94985,,Calsyntenin-1,CLSTN1,Homo sapiens,981,False,CS1|KIAA0911,MLRRPAPALAPAARLLLAGLLCGGGVWAARVNKHKPWLEPTYHGIVTENDNTVLLDPPLIALDKDAPLRFAESFEVTVTKEGEICGFKIHGQNVPFDAVVVDKSTGEGVIRSKEKLDCELQKDYSFTIQAYDCGKGPDGTNVKKSHKATVHIQVNDVNEYAPVFKEKSYKATVIEGKQYDSILRVEAVDADCSPQFSQICSYEIITPDVPFTVDKDGYIKNTEKLNYGKEHQYKLTVTAYDCGKKRATEDVLVKISIKPTCTPGWQGWNNRIEYEPGTGALAVFPNIHLETCDEPVASVQATVELETSHIGKGCDRDTYSEKSLHRLCGAAAGTAELLPSPSGSLNWTMGLPTDNGHDSDQVFEFNGTQAVRIPDGVVSVSPKEPFTISVWMRHGPFGRKKETILCSSDKTDMNRHHYSLYVHGCRLIFLFRQDPSEEKKYRPAEFHWKLNQVCDEEWHHYVLNVEFPSVTLYVDGTSHEPFSVTEDYPLHPSKIETQLVVGACWQEFSGVENDNETEPVTVASAGGDLHMTQFFRGNLAGLTLRSGKLADKKVIDCLYTCKEGLDLQVLEDSGRGVQIQAHPSQLVLTLEGEDLGELDKAMQHISYLNSRQFPTPGIRRLKITSTIKCFNEATCISVPPVDGYVMVLQPEEPKISLSGVHHFARAASEFESSEGVFLFPELRIISTITREVEPEGDGAEDPTVQESLVSEEIVHDLDTCEVTVEGEELNHEQESLEVDMARLQQKGIEVSSSELGMTFTGVDTMASYEEVLHLLRYRNWHARSLLDRKFKLICSELNGRYISNEFKVEVNVIHTANPMEHANHMAAQPQFVHPEHRSFVDLSGHNLANPHPFAVVPSTATVVIVVCVSFLVFMIILGVFRIRAAHRRTMRDQDTGKENEMDWDDSALTITVNPMETYEDQHSSEEEEEEEEEEESEDGEEEDDITSAESESSEEEEGEQGDPQNATRQQQLEWDDSTLSY,0,,,,,,,,Q99767(APBA2)|Q8CD76(Klc1)|P05067(APP)|Q9UK58-5(CCNL1)|P09496-2(CLTA)|Q8N5Z5(KCTD17)|Q16609(LPAL2)|Q9Y6R0(NUMBL)|O60927(PPP1R11)|Q09028(RBBP4)|Q8N5U6(RNF10)|Q13573(SNW1)|Q91YS4(Klc2),,1:O94985-1:|2:O94985-2:,,,,,,,,,,5.0
P78380,,Oxidized low-density lipoprotein receptor 1,OLR1,Homo sapiens,273,False,CLEC8A|LOX1,MTFDDLKIQTVKDQPDEKSNGKKAKGLQFLYSPWWCLAAATLGVLCLGLVVTIMVLGMQLSQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLARKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAAFSICQKKANLRAQ,0,,,,,,:|:,,P50991(CCT4)|P12259(F5)|P78380(OLR1)|P17987(TCP1),,1:P78380-1:|2:P78380-2:|3:P78380-3:,,,,,,,,,,5.0
O14672,,Disintegrin and metalloproteinase domain-containing protein 10,ADAM10,Homo sapiens,748,False,KUZ|MADM,MVLLRVLILLLSWAAGMGGQYGNPLNKYIRHYEGLSYNVDSLHQKHQRAKRAVSHEDQFLRLDFHAHGRHFNLRMKRDTSLFSDEFKVETSNKVLDYDTSHIYTGHIYGEEGSFSHGSVIDGRFEGFIQTRGGTFYVEPAERYIKDRTLPFHSVIYHEDDINYPHKYGPQGGCADHSVFERMRKYQMTGVEEVTQIPQEEHAANGPELLRKKRTTSAEKNTCQLYIQTDHLFFKYYGTREAVIAQISSHVKAIDTIYQTTDFSGIRNISFMVKRIRINTTADEKDPTNPFRFPNIGVEKFLELNSEQNHDDYCLAYVFTDRDFDDGVLGLAWVGAPSGSSGGICEKSKLYSDGKKKSLNTGIITVQNYGSHVPPKVSHITFAHEVGHNFGSPHDSGTECTPGESKNLGQKENGNYIMYARATSGDKLNNNKFSLCSIRNISQVLEKKRNNCFVESGQPICGNGMVEQGEECDCGYSDQCKDECCFDANQPEGRKCKLKPGKQCSPSQGPCCTAQCAFKSKSEKCRDDSDCAREGICNGFTALCPASDPKPNFTDCNRHTQVCINGQCAGSICEKYGLEECTCASSDGKDDKELCHVCCMKKMDPSTCASTGSVQWSRHFSGRTITLQPGSPCNDFRGYCDVFMRCRLVDADGPLARLKKAIFSPELYENIAEWIVAHWWAVLLMGIALIMLMAGFIKICSVHTPSSNPKLPPPKPLPGTLKRRRPPQPIQQPQRQRPRESYQMGHMRR,0,,,,,,"Reticulate acropigmentation of Kitamura:A rare cutaneous pigmentation disorder characterized by reticulate, slightly depressed, sharply demarcated brown macules without hypopigmentation, affecting the dorsa of the hands and feet and appearing in the first or second decade of life. The macules gradually darken and extend to the proximal regions of the extremities. The manifestations tend to progress until middle age, after which progression of the eruptions stops. The pigmentary augmentation is found on the flexor aspects of the wrists, neck, patella and olecranon. Other features include breaks in the epidermal ridges on the palms and fingers, palmoplantar pits, occasionally plantar keratoderma, and partial alopecia.|Alzheimer disease 18:A late-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.",Reticulate acropigmentation of Kitamura|Alzheimer disease 18,P00519(ABL1)|P05067(APP)|P56817(BACE1)|P60033(CD81)|P21926(CD9)|P06241(FYN)|Q13588(GRAP)|O75791(GRAP2)|P62993(GRB2)|P08631(HCK)|P06239(LCK)|Q9BY11(PACSIN1)|Q9UNF0(PACSIN2)|Q9UKS6(PACSIN3)|Q99961(SH3GL1)|Q96RF0(SNX18)|P12931(SRC)|O95859(TSPAN12)|Q8NG11(TSPAN14)|O95858(TSPAN15)|Q86UF1(TSPAN33)|P62079(TSPAN5)|P07947(YES1)|P60033(CD81)|O95859(TSPAN12),,1:O14672-1:|2:O14672-2:,,,,,,,,,,5.0
Q13637,,Ras-related protein Rab-32,RAB32,Homo sapiens,225,False,,MAGGGAGDPGLGAAAAPAPETREHLFKVLVIGELGVGKTSIIKRYVHQLFSQHYRATIGVDFALKVLNWDSRTLVRLQLWDIAGQERFGNMTRVYYKEAVGAFVVFDISRSSTFEAVLKWKSDLDSKVHLPNGSPIPAVLLANKCDQNKDSSQSPSQVDQFCKEHGFAGWFETSAKDNINIEEAARFLVEKILVNHQSFPNEENDVDKIKLDQETLRAENKSQCC,0,,,,,,"Parkinson disease 26, autosomal dominant:An autosomal dominant form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK26 shows incomplete penetrance.","Parkinson disease 26, autosomal dominant",Q96D03(DDIT4L)|A0A087WWI0(LRMDA)|Q5S007(LRRK2),,,,,,,,,,,,5.0
Q9Y3I1,,F-box only protein 7,FBXO7,Homo sapiens,522,False,FBX7,MRLRVRLLKRTWPLEVPETEPTLGHLRSHLRQSLLCTWGYSSNTRFTITLNYKDPLTGDEETLASYGIVSGDLICLILQDDIPAPNIPSSTDSEHSSLQNNEQPSLATSSNQTSMQDEQPSDSFQGQAAQSGVWNDDSMLGPSQNFEAESIQDNAHMAEGTGFYPSEPMLCSESVEGQVPHSLETLYQSADCSDANDALIVLIHLLMLESGYIPQGTEAKALSMPEKWKLSGVYKLQYMHPLCEGSSATLTCVPLGNLIVVNATLKINNEIRSVKRLQLLPESFICKEKLGENVANIYKDLQKLSRLFKDQLVYPLLAFTRQALNLPDVFGLVVLPLELKLRIFRLLDVRSVLSLSAVCRDLFTASNDPLLWRFLYLRDFRDNTVRVQDTDWKELYRKRHIQRKESPKGRFVMLLPSSTHTIPFYPNPLHPRPFPSSRLPPGIIGGEYDQRPTLPYVGDPISSLIPGPGETPSQFPPLRPRFDPVGPLPGPNPILPGRGGPNDRFPFRPSRGRPTDGRLSFM,0,,,,,,"Parkinson disease 15:A neurodegenerative disorder characterized by parkinsonian and pyramidal signs. Clinical manifestations include tremor, bradykinesia, rigidity, postural instability, spasticity, mainly in the lower limbs, and hyperreflexia.",Parkinson disease 15,P22607(FGFR3)|Q9BXM7(PINK1)|O60260(PRKN)|P25788(PSMA3)|P61289(PSME3)|Q92530(PSMF1)|P63208(SKP1)|Q9Y649()|Q9BXM7(PINK1)|O60260(PRKN),,1:Q9Y3I1-1:|2:Q9Y3I1-2:|3:Q9Y3I1-3:,,,,,,,,,,5.0
Q9BXM7,,"Serine/threonine-protein kinase PINK1, mitochondrial",PINK1,Homo sapiens,581,False,,MAVRQALGRGLQLGRALLLRFTGKPGRAYGLGRPGPAAGCVRGERPGWAAGPGAEPRRVGLGLPNRLRFFRQSVAGLAARLQRQFVVRAWGCAGPCGRAVFLAFGLGLGLIEEKQAESRRAVSACQEIQAIFTQKSKPGPDPLDTRRLQGFRLEEYLIGQSIGKGCSAAVYEATMPTLPQNLEVTKSTGLLPGRGPGTSAPGEGQERAPGAPAFPLAIKMMWNISAGSSSEAILNTMSQELVPASRVALAGEYGAVTYRKSKRGPKQLAPHPNIIRVLRAFTSSVPLLPGALVDYPDVLPSRLHPEGLGHGRTLFLVMKNYPCTLRQYLCVNTPSPRLAAMMLLQLLEGVDHLVQQGIAHRDLKSDNILVELDPDGCPWLVIADFGCCLADESIGLQLPFSSWYVDRGGNGCLMAPEVSTARPGPRAVIDYSKADAWAVGAIAYEIFGLVNPFYGQGKAHLESRSYQEAQLPALPESVPPDVRQLVRALLQREASKRPSARVAANVLHLSLWGEHILALKNLKLDKMVGWLLQQSAATLLANRLTEKCCVETKMKMLFLANLECETLCQAALLLCSWRAAL,0,,,,,,"Parkinson disease 6:An early-onset form of Parkinson disease, a neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep. PARK6 pathogenesis involves respiratory complex I deficiency causing mitochondrial depolarization and dysfunction. Inheritance is autosomal recessive.",Parkinson disease 6,P63010-2(AP2B1)|P05067(APP)|O15392(BIRC5)|Q9Y3I1(FBXO7)|Q9Y3I1-1(FBXO7)|Q9UHY8(FEZ2)|P08238(HSP90AB1)|P42858(HTT)|Q6DN90-2(IQSEC1)|Q9BYZ2(LDHAL6B)|Q9GZQ8(MAP1LC3B)|Q13113(PDZK1IP1)|P00491(PNP)|O60260(PRKN)|Q8IXI2(RHOT1)|Q8WXH5(SOCS4)|Q99932-2(SPAG8)|P28347-2(TEAD1)|Q9UBQ0-2(VPS29)|Q8N895(ZNF366)|O60260(PRKN)|Q12931(TRAP1),,1:Q9BXM7-1:|2:Q9BXM7-2:,,,,,,,,,,5.0
O43426,,Synaptojanin-1,SYNJ1,Homo sapiens,1573,False,KIAA0910,MAFSKGFRIYHKLDPPPFSLIVETRHKEECLMFESGAVAVLSSAEKEAIKGTYSKVLDAYGLLGVLRLNLGDTMLHYLVLVTGCMSVGKIQESEVFRVTSTEFISLRIDSSDEDRISEVRKVLNSGNFYFAWSASGISLDLSLNAHRSMQEQTTDNRFFWNQSLHLHLKHYGVNCDDWLLRLMCGGVEIRTIYAAHKQAKACLISRLSCERAGTRFNVRGTNDDGHVANFVETEQVVYLDDSVSSFIQIRGSVPLFWEQPGLQVGSHRVRMSRGFEANAPAFDRHFRTLKNLYGKQIIVNLLGSKEGEHMLSKAFQSHLKASEHAADIQMVNFDYHQMVKGGKAEKLHSVLKPQVQKFLDYGFFYFNGSEVQRCQSGTVRTNCLDCLDRTNSVQAFLGLEMLAKQLEALGLAEKPQLVTRFQEVFRSMWSVNGDSISKIYAGTGALEGKAKLKDGARSVTRTIQNNFFDSSKQEAIDVLLLGNTLNSDLADKARALLTTGSLRVSEQTLQSASSKVLKSMCENFYKYSKPKKIRVCVGTWNVNGGKQFRSIAFKNQTLTDWLLDAPKLAGIQEFQDKRSKPTDIFAIGFEEMVELNAGNIVSASTTNQKLWAVELQKTISRDNKYVLLASEQLVGVCLFVFIRPQHAPFIRDVAVDTVKTGMGGATGNKGAVAIRMLFHTTSLCFVCSHFAAGQSQVKERNEDFIEIARKLSFPMGRMLFSHDYVFWCGDFNYRIDLPNEEVKELIRQQNWDSLIAGDQLINQKNAGQVFRGFLEGKVTFAPTYKYDLFSDDYDTSEKCRTPAWTDRVLWRRRKWPFDRSAEDLDLLNASFQDESKILYTWTPGTLLHYGRAELKTSDHRPVVALIDIDIFEVEAEERQNIYKEVIAVQGPPDGTVLVSIKSSLPENNFFDDALIDELLQQFASFGEVILIRFVEDKMWVTFLEGSSALNVLSLNGKELLNRTITIALKSPDWIKNLEEEMSLEKISIALPSSTSSTLLGEDAEVAADFDMEGDVDDYSAEVEELLPQHLQPSSSSGLGTSPSSSPRTSPCQSPTISEGPVPSLPIRPSRAPSRTPGPPSAQSSPIDAQPATPLPQKDPAQPLEPKRPPPPRPVAPPTRPAPPQRPPPPSGARSPAPTRKEFGGIGAPPSPGVARREMEAPKSPGTTRKDNIGRSQPSPQAGLAGPGPAGYSTARPTIPPRAGVISAPQSHARASAGRLTPESQSKTSETSKGSTFLPEPLKPQAAFPPQSSLPPPAQRLQEPLVPVAAPMPQSGPQPNLETPPQPPPRSRSSHSLPSEASSQPQVKTNGISDGKRESPLKIDPFEDLSFNLLAVSKAQLSVQTSPVPTPDPKRLIQLPSATQSNVLSSVSCMPTMPPIPARSQSQENMRSSPNPFITGLTRTNPFSDRTAAPGNPFRAKSEESEATSWFSKEEPVTISPFPSLQPLGHNKSRASSSLDGFKDSFDLQGQSTLKISNPKGWVTFEEEEDFGVKGKSKSACSDLLGNQPSSFSGSNLTLNDDWNKGTNVSFCVLPSRRPPPPPVPLLPPGTSPPVDPFTTLASKASPTLDFTER,0,,,,,,"Parkinson disease 20, early-onset:An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK20 is characterized by young adult-onset of parkinsonism. Additional features may include seizures, cognitive decline, abnormal eye movements, and dystonia.|Developmental and epileptic encephalopathy 53:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE53 inheritance is autosomal recessive.","Parkinson disease 20, early-onset|Developmental and epileptic encephalopathy 53",Q15811(ITSN1),,1:O43426-1:|2:O43426-2:|3:O43426-4:|4:O43426-5:,,,,,,,,,,5.0
O75061,,Auxilin,DNAJC6,Homo sapiens,913,False,KIAA0473,MKDSENKGASSPDMEPSYGGGLFDMVKGGAGRLFSNLKDNLKDTLKDTSSRVIQSVTSYTKGDLDFTYVTSRIIVMSFPLDNVDIGFRNQVDDIRSFLDSRHLDHYTVYNLSPKSYRTAKFHSRVSECSWPIRQAPSLHNLFAVCRNMYNWLLQNPKNVCVVHCLDGRAASSILVGAMFIFCNLYSTPGPAIRLLYAKRPGIGLSPSHRRYLGYMCDLLADKPYRPHFKPLTIKSITVSPIPFFNKQRNGCRPYCDVLIGETKIYSTCTDFERMKEYRVQDGKIFIPLNITVQGDVVVSMYHLRSTIGSRLQAKVTNTQIFQLQFHTGFIPLDTTVLKFTKPELDACDVPEKYPQLFQVTLDVELQPHDKVIDLTPPWEHYCTKDVNPSILFSSHQEHQDTLALGGQAPIDIPPDNPRHYGQSGFFASLCWQDQKSEKSFCEEDHAALVNQESEQSDDELLTLSSPHGNANGDKPHGVKKPSKKQQEPAAPPPPEDVDLLGLEGSAMSNSFSPPAAPPTNSELLSDLFGGGGAAGPTQAGQSGVEDVFHPSGPASTQSTPRRSATSTSASPTLRVGEGATFDPFGAPSKPSGQDLLGSFLNTSSASSDPFLQPTRSPSPTVHASSTPAVNIQPDVSGGWDWHAKPGGFGMGSKSAATSPTGSSHGTPTHQSKPQTLDPFADLGTLGSSSFASKPTTPTGLGGGFPPLSSPQKASPQPMGGGWQQGGAYNWQQPQPKPQPSMPHSSPQNRPNYNVSFSAMPGGQNERGKGSSNLEGKQKAADFEDLLSGQGFNAHKDKKGPRTIAEMRKEEMAKEMDPEKLKILEWIEGKERNIRALLSTMHTVLWAGETKWKPVGMADLVTPEQVKKVYRKAVLVVHPDKATGQPYEQYAKMIFMELNDAWSEFENQGQKPLY,0,,,,,,"Parkinson disease 19A, juvenile-onset:A juvenile form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK19A is characterized by onset of parkinsonian symptoms in the first or second decade of life. Some patients may have additional neurologic features, including intellectual disability and seizures.|Parkinson disease 19B, early-onset:An early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK19B is characterized by symptoms onset in the third-to-fifth decade, slow disease progression, and prominent. response to dopaminergic therapies. Inheritance is autosomal recessive.","Parkinson disease 19A, juvenile-onset|Parkinson disease 19B, early-onset",,,1:O75061-1:|2:O75061-2:|3:O75061-3:|4:O75061-4:,,,,,,,,,,5.0
Q9Y6H1,,Coiled-coil-helix-coiled-coil-helix domain-containing protein 2,CHCHD2,Homo sapiens,151,False,C7orf17,MPRGSRSRTSRMAPPASRAPQMRAAPRPAPVAQPPAAAPPSAVGSSAAAPRQPGLMAQMATTAAGVAVGSAVGHTLGHAITGGFSGGSNAEPARPDITYQEPQGTQPAQQQQPCLYEIKQFLECAQNQGDIKLCEGFNEVLKQCRLANGLA,0,,,,,,"Parkinson disease 22:An autosomal dominant form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.",Parkinson disease 22,Q6UY14-3(ADAMTSL4)|P18825(ADRA2C)|Q8WYQ3(CHCHD10)|P05813(CRYBA1)|P78358(CTAG1B)|A8MQ03(CYSRT1)|A2ABF9(EHMT2)|Q08379(GOLGA2)|P42858(HTT)|Q9UKT9(IKZF3)|Q0VD86(INCA1)|Q15323(KRT31)|Q6A162(KRT40)|Q969G2(LHX4)|A9UHW6-2(MIF4GD)|O43482(OIP5)|P07237(P4HB)|Q9BYU1(PBX4)|Q9H8W4(PLEKHF2)|Q9Y2S7(POLDIP2)|Q04864(REL)|P15884(TCF4)|Q12933(TRAF2)|Q8IWZ5(TRIM42)|Q9BYV2(TRIM54)|Q86WV8(TSC1)|Q70EL1-9(USP54)|Q9H0C1(ZMYND12)|P08563(),,,,,,,,,,,,5.0
P53041,,Serine/threonine-protein phosphatase 5,PPP5C,Homo sapiens,499,False,PPP5,MAMAEGERTECAEPPRDEPPADGALKRAEELKTQANDYFKAKDYENAIKFYSQAIELNPSNAIYYGNRSLAYLRTECYGYALGDATRAIELDKKYIKGYYRRAASNMALGKFRAALRDYETVVKVKPHDKDAKMKYQECNKIVKQKAFERAIAGDEHKRSVVDSLDIESMTIEDEYSGPKLEDGKVTISFMKELMQWYKDQKKLHRKCAYQILVQVKEVLSKLSTLVETTLKETEKITVCGDTHGQFYDLLNIFELNGLPSETNPYIFNGDFVDRGSFSVEVILTLFGFKLLYPDHFHLLRGNHETDNMNQIYGFEGEVKAKYTAQMYELFSEVFEWLPLAQCINGKVLIMHGGLFSEDGVTLDDIRKIERNRQPPDSGPMCDLLWSDPQPQNGRSISKRGVSCQFGPDVTKAFLEENNLDYIIRSHEVKAEGYEVAHGGRCVTVFSAPNYCDQMGNKASYIHLQGSDLRPQFHQFTAVPHPNVKPMAYANTLLQLGMM,0,,,,,,,,Q9UL18(AGO1)|Q9H9G7(AGO3)|Q16543(CDC37)|P50750(CDK9)|Q49AN0(CRY2)|P03372(ESR1)|Q92731(ESR2)|P07900(HSP90AA1)|P08238(HSP90AB1)|Q5SY16(NOL9)|P30153(PPP2R1A)|P53041(PPP5C)|Q5JT25(RAB41)|P31948(STIP1),,,,,,,,,,,,5.0
O43464,,"Serine protease HTRA2, mitochondrial",HTRA2,Homo sapiens,458,False,OMI|PRSS25,MAAPRAGRGAGWSLRAWRALGGIRWGRRPRLTPDLRALLTSGTSDPRARVTYGTPSLWARLSVGVTEPRACLTSGTPGPRAQLTAVTPDTRTREASENSGTRSRAWLAVALGAGGAVLLLLWGGGRGPPAVLAAVPSPPPASPRSQYNFIADVVEKTAPAVVYIEILDRHPFLGREVPISNGSGFVVAADGLIVTNAHVVADRRRVRVRLLSGDTYEAVVTAVDPVADIATLRIQTKEPLPTLPLGRSADVRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGLPQTNVEYIQTDAAIDFGNSGGPLVNLDGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVMMLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNAEDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTE,0,,,,,,"3-methylglutaconic aciduria 8:An autosomal recessive inborn error of metabolism resulting in early death. Clinical features include extreme hypertonia observed at birth, alternating with hypotonia, subsequent appearance of extrapyramidal symptoms, lack of psychomotor development, microcephaly, and intractable seizures. Patients show lactic acidemia, 3-methylglutaconic aciduria, intermittent neutropenia, and progressive brain atrophy.|Parkinson disease 13:A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.",3-methylglutaconic aciduria 8|Parkinson disease 13,Q6ZTN6-2(ANKRD13D)|Q86TN1(ARNT2)|Q9Y575-3(ASB3)|Q96DX5-3(ASB9)|Q96FT7-4(ASIC4)|Q13490(BIRC2)|Q96CA5(BIRC7)|Q7Z7K6(CENPV)|P02489(CRYAA)|Q5TAQ9-2(DCAF8)|O00303(EIF3F)|Q8TC29(ENKUR)|Q13216-2(ERCC8)|Q99871(HAUS7)|Q02363(ID2)|Q8IY31-2(IFT20)|Q8N5Z5(KCTD17)|Q6P597(KLC3)|P57682(KLF3)|Q9Y2M5(KLHL20)|P08727(KRT19)|Q14525(KRT33B)|Q1L5Z9(LONRF2)|Q99683(MAP3K5)|Q8NA82(MARCHF10)|Q8N594(MPND)|Q8WY64(MYLIP)|Q9P0J0(NDUFA13)|Q13562(NEUROD1)|O15381-5(NVL)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|Q9NUU6(OTULINL)|Q9HBE1-4(PATZ1)|Q9NV79(PCMTD2)|O14813(PHOX2A)|O75925(PIAS1)|Q8WWB5(PIH1D2)|Q96T49(PPP1R16B)|Q6ZMI0-5(PPP1R21)|P17980(PSMC3)|P57052(RBM11)|Q8WVD3(RNF138)|Q96D59(RNF183)|Q96GQ5(RUSF1)|Q8N488(RYBP)|Q8N6K7-2(SAMD3)|Q9NR46(SH3GLB2)|Q96GM5(SMARCD1)|Q16637-3(SMN2)|Q8WXH5(SOCS4)|Q5VWN6(TASOR2)|Q86WV5(TEN1)|O95150(TNFSF15)|Q6DKK2(TTC19)|Q495M9(USH1G)|O75604-3(USP2)|Q8NEZ2(VPS37A)|Q15007-2(WTAP)|O00308(WWP2)|P98170(XIAP)|P24278(ZBTB25)|Q9UNY5(ZNF232)|Q8N0Y2-2(ZNF444)|O60304(ZNF500)|O15535(ZSCAN9)|Q86V28()|P02666(CSN2)|Q60855(Ripk1)|P02666(CSN2),,1:O43464-1:|2:O43464-2:|3:O43464-3:|4:O43464-4:,,,,,,,,,,5.0
P07602,,Prosaposin,PSAP,Homo sapiens,524,False,GLBA|SAP1,MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASDCGAVKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDNATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDIIKGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIPELDMTEVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDCIQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADICKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQTLVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCEFLVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVVDTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHVTQPKDGGFCEVCKKLVGYLDRNLEKNSTKQEILAALEKGCSFLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIGACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRHVWN,0,,,,,,"Combined saposin deficiency:An autosomal recessive storage disorder characterized by hepatosplenomegaly and severe neurologic disease, due to absence of all saposins. PSAPD has a fatal outcome in infancy.|Metachromatic leukodystrophy due to saposin B deficiency:A form of metachromatic leukodystrophy biochemically characterized by tissue accumulation of cerebroside-3-sulfate, saposin B deficiency, and normal arylsulfatase A activity. Clinical manifestations include periventricular white matter abnormalities, demyelination, and peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotor regression, seizures, cognitive decline and spastic quadriparesis.|Gaucher disease, atypical, due to saposin C deficiency:A disease characterized by marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease. Gaucher disease is a lysosomal storage disorder characterized by skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.|Krabbe disease, atypical, due to saposin A deficiency:An autosomal recessive disorder of galactosylceramide metabolism. Clinical features include neurologic regression around age 3 months, loss of spontaneous movements, hyporeflexia, generalized brain atrophy, and diffuse white matter dysmyelination.|:|Parkinson disease 24, autosomal dominant:An autosomal dominant form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK24 shows incomplete penetrance.","Combined saposin deficiency|Metachromatic leukodystrophy due to saposin B deficiency|Gaucher disease, atypical, due to saposin C deficiency|Krabbe disease, atypical, due to saposin A deficiency|Parkinson disease 24, autosomal dominant",P05067(APP)|Q92624(APPBP2)|P31944(CASP14)|P48730-2(CSNK1D)|P28799(GRN)|P07948(LYN)|P50542-3(PEX5)|O96006(ZBED1)|P07602-1(PSAP)|P55072(VCP),,Sap-mu-0:P07602-1:|Sap-mu-6:P07602-2:|Sap-mu-9:P07602-3:,,,,,,,,,,5.0
Q04637,,Eukaryotic translation initiation factor 4 gamma 1,EIF4G1,Homo sapiens,1599,False,EIF4F|EIF4G|EIF4GI,MNKAPQSTGPPPAPSPGLPQPAFPPGQTAPVVFSTPQATQMNTPSQPRQHFYPSRAQPPSSAASRVQSAAPARPGPAAHVYPAGSQVMMIPSQISYPASQGAYYIPGQGRSTYVVPTQQYPVQPGAPGFYPGASPTEFGTYAGAYYPAQGVQQFPTGVAPTPVLMNQPPQIAPKRERKTIRIRDPNQGGKDITEEIMSGARTASTPTPPQTGGGLEPQANGETPQVAVIVRPDDRSQGAIIADRPGLPGPEHSPSESQPSSPSPTPSPSPVLEPGSEPNLAVLSIPGDTMTTIQMSVEESTPISRETGEPYRLSPEPTPLAEPILEVEVTLSKPVPESEFSSSPLQAPTPLASHTVEIHEPNGMVPSEDLEPEVESSPELAPPPACPSESPVPIAPTAQPEELLNGAPSPPAVDLSPVSEPEEQAKEVTASMAPPTIPSATPATAPSATSPAQEEEMEEEEEEEEGEAGEAGEAESEKGGEELLPPESTPIPANLSQNLEAAAATQVAVSVPKRRRKIKELNKKEAVGDLLDAFKEANPAVPEVENQPPAGSNPGPESEGSGVPPRPEEADETWDSKEDKIHNAENIQPGEQKYEYKSDQWKPLNLEEKKRYDREFLLGFQFIFASMQKPEGLPHISDVVLDKANKTPLRPLDPTRLQGINCGPDFTPSFANLGRTTLSTRGPPRGGPGGELPRGPAGLGPRRSQQGPRKEPRKIIATVLMTEDIKLNKAEKAWKPSSKRTAADKDRGEEDADGSKTQDLFRRVRSILNKLTPQMFQQLMKQVTQLAIDTEERLKGVIDLIFEKAISEPNFSVAYANMCRCLMALKVPTTEKPTVTVNFRKLLLNRCQKEFEKDKDDDEVFEKKQKEMDEAATAEERGRLKEELEEARDIARRRSLGNIKFIGELFKLKMLTEAIMHDCVVKLLKNHDEESLECLCRLLTTIGKDLDFEKAKPRMDQYFNQMEKIIKEKKTSSRIRFMLQDVLDLRGSNWVPRRGDQGPKTIDQIHKEAEMEEHREHIKVQQLMAKGSDKRRGGPPGPPISRGLPLVDDGGWNTVPISKGSRPIDTSRLTKITKPGSIDSNNQLFAPGGRLSWGKGSSGGSGAKPSDAASEAARPATSTLNRFSALQQAVPTESTDNRRVVQRSSLSRERGEKAGDRGDRLERSERGGDRGDRLDRARTPATKRSFSKEVEERSRERPSQPEGLRKAASLTEDRDRGRDAVKREAALPPVSPLKAALSEEELEKKSKAIIEEYLHLNDMKEAVQCVQELASPSLLFIFVRHGVESTLERSAIAREHMGQLLHQLLCAGHLSTAQYYQGLYEILELAEDMEIDIPHVWLYLAELVTPILQEGGVPMGELFREITKPLRPLGKAASLLLEILGLLCKSMGPKKVGTLWREAGLSWKEFLPEGQDIGAFVAEQKVEYTLGEESEAPGQRALPSEELNRQLEKLLKEGSSNQRVFDWIEANLSEQQIVSNTLVRALMTAVCYSAIIFETPLRVDVAVLKARAKLLQKYLCDEQKELQALYALQALVVTLEQPPNLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFKWLREAEEESDHN,0,,,,,,"Parkinson disease 18:An autosomal dominant, late-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.",Parkinson disease 18,O00571(DDX3X)|P55884(EIF3B)|O75822(EIF3J)|P60842(EIF4A1)|P06730(EIF4E)|Q14103-4(HNRNPD)|P11940(PABPC1)|Q9BWF3-1(RBM4)|Q9J0X9(UL54)|P60842(EIF4A1)|Q9NQ94(A1CF)|Q8N5M1(ATPAF2)|Q2TAC2-2(CCDC57)|P55273(CDKN2D)|Q99828(CIB1)|P56545-3(CTBP2)|Q86UW9(DTX2)|Q9H0I2(ENKD1)|P51116(FXR2)|Q15323(KRT31)|O76011(KRT34)|Q96HA8(NTAQ1)|Q9UBV8(PEF1)|Q96GM5(SMARCD1),,A:Q04637-1:|B:Q04637-3:|C:Q04637-4:|D:Q04637-5:|E:Q04637-6:|7:Q04637-7:|8:Q04637-8:|9:Q04637-9:,,,,,,,,,,5.0
Q709C8,,Intermembrane lipid transfer protein VPS13C,VPS13C,Homo sapiens,3753,False,KIAA1421,MVLESVVADLLNRFLGDYVENLNKSQLKLGIWGGNVALDNLQIKENALSELDVPFKVKAGQIDKLTLKIPWKNLYGEAVVATLEGLYLLVVPGASIKYDAVKEEKSLQDVKQKELSRIEEALQKAAEKGTHSGEFIYGLENFVYKDIKPGRKRKKHKKHFKKPFKGLDRSKDKPKEAKKDTFVEKLATQVIKNVQVKITDIHIKYEDDVTDPKRPLSFGVTLGELSLLTANEHWTPCILNEADKIIYKLIRLDSLSAYWNVNCSMSYQRSREQILDQLKNEILTSGNIPPNYQYIFQPISASAKLYMNPYAESELKTPKLDCNIEIQNIAIELTKPQYLSMIDLLESVDYMVRNAPYRKYKPYLPLHTNGRRWWKYAIDSVLEVHIRRYTQMWSWSNIKKHRQLLKSYKIAYKNKLTQSKVSEEIQKEIQDLEKTLDVFNIILARQQAQVEVIRSGQKLRKKSADTGEKRGGWFSGLWGKKESKKKDEESLIPETIDDLMTPEEKDKLFTAIGYSESTHNLTLPKQYVAHIMTLKLVSTSVTIRENKNIPEILKIQIIGLGTQVSQRPGAQALKVEAKLEHWYITGLRQQDIVPSLVASIGDTTSSLLKIKFETNPEDSPADQTLIVQSQPVEVIYDAKTVNAVVEFFQSNKGLDLEQITSATLMKLEEIKERTATGLTHIIETRKVLDLRINLKPSYLVVPQTGFHHEKSDLLILDFGTFQLNSKDQGLQKTTNSSLEEIMDKAYDKFDVEIKNVQLLFARAEETWKKCRFQHPSTMHILQPMDIHVELAKAMVEKDIRMARFKVSGGLPLMHVRISDQKMKDVLYLMNSIPLPQKSSAQSPERQVSSIPIISGGTKGLLGTSLLLDTVESESDDEYFDAEDGEPQTCKSMKGSELKKAAEVPNEELINLLLKFEIKEVILEFTKQQKEEDTILVFNVTQLGTEATMRTFDLTVVSYLKKISLDYHEIEGSKRKPLHLISSSDKPGLDLLKVEYIKADKNGPSFQTAFGKTEQTVKVAFSSLNLLLQTQALVASINYLTTIIPSDDQSISVAKEVQISTEKQQKNSTLPKAIVSSRDSDIIDFRLFAKLNAFCVIVCNEKNNIAEIKIQGLDSSLSLQSRKQSLFARLENIIVTDVDPKTVHKKAVSIMGNEVFRFNLDLYPDATEGDLYTDMSKVDGVLSLNVGCIQIVYLHKFLMSLLNFLNNFQTAKESLSAATAQAAERAATSVKDLAQRSFRVSINIDLKAPVIVIPQSSISTNAVVVDLGLIRVHNQFSLVSDEDYLNPPVIDRMDVQLTKLTLYRTVIQPGIYHPDIQLLHPINLEFLVNRNLAASWYHKVPVVEIKGHLDSMNVSLNQEDLNLLFRILTENLCEGTEDLDKVKPRVQETGEIKEPLEISISQDVHDSKNTLTTGVEEIRSVDIINMLLNFEIKEVVVTLMKKSEKKGRPLHELNVLQLGMEAKVKTYDMTAKAYLKKISMQCFDFTDSKGEPLHIINSSNVTDEPLLKMLLTKADSDGPEFKTIHDSTKQRLKVSFASLDLVLHLEALLSFMDFLSSAAPFSEPSSSEKESELKPLVGESRSIAVKAVSSNISQKDVFDLKITAELNAFNVFVCDQKCNIADIKIHGMDASISVKPKQTDVFARLKDIIVMNVDLQSIHKKAVSILGDEVFRFQLTLYPDATEGEAYADMSKVDGKLSFKVGCIQIVYVHKFFMSLLNFLNNFQTAKEALSTATVQAAERAASSMKDLAQKSFRLLMDINLKAPVIIIPQSSVSPNAVIADLGLIRVENKFSLVPMEHYSLPPVIDKMNIELTQLKLSRTILQASLPQNDIEILKPVNMLLSIQRNLAAAWYVQIPGMEIKGKLKPMQVALSEDDLTVLMKILLENLGEASSQPSPTQSVQETVRVRKVDVSSVPDHLKEQEDWTDSKLSMNQIVSLQFDFHFESLSIILYNNDINQESGVAFHNDSFQLGELRLHLMASSGKMFKDGSMNVSVKLKTCTLDDLREGIERATSRMIDRKNDQDNNSSMIDISYKQDKNGSQIDAVLDKLYVCASVEFLMTVADFFIKAVPQSPENVAKETQILPRQTATGKVKIEKDDSVRPNMTLKAMITDPEVVFVASLTKADAPALTASFQCNLSLSTSKLEQMMEASVRDLKVLACPFLREKRGKNITTVLQPCSLFMEKCTWASGKQNINIMVKEFIIKISPIILNTVLTIMAALSPKTKEDGSKDTSKEMENLWGIKSINDYNTWFLGVDTATEITESFKGIEHSLIEENCGVVVESIQVTLECGLGHRTVPLLLAESKFSGNIKNWTSLMAAVADVTLQVHYYNEIHAVWEPLIERVEGKRQWNLRLDVKKNPVQDKSLLPGDDFIPEPQMAIHISSGNTMNITISKSCLNVFNNLAKGFSEGTASTFDYSLKDRAPFTVKNAVGVPIKVKPNCNLRVMGFPEKSDIFDVDAGQNLELEYASMVPSSQGNLSILSRQESSFFTLTIVPHGYTEVANIPVARPGRRLYNVRNPNASHSDSVLVQIDATEGNKVITLRSPLQIKNHFSIAFIIYKFVKNVKLLERIGIARPEEEFHVPLDSYRCQLFIQPAGILEHQYKESTTYISWKEELHRSREVRCMLQCPSVEVSFLPLIVNTVALPDELSYICTHGEDWDVAYIIHLYPSLTLRNLLPYSLRYLLEGTAETHELAEGSTADVLHSRISGEIMELVLVKYQGKNWNGHFRIRDTLPEFFPVCFSSDSTEVTTVDLSVHVRRIGSRMVLSVFSPYWLINKTTRVLQYRSEDIHVKHPADFRDIILFSFKKKNIFTKNKVQLKISTSAWSSSFSLDTVGSYGCVKCPANNMEYLVGVSIKMSSFNLSRIVTLTPFCTIANKSSLELEVGEIASDGSMPTNKWNYIASSECLPFWPESLSGKLCVRVVGCEGSSKPFFYNRQDNGTLLSLEDLNGGILVDVNTAEHSTVITFSDYHEGSAPALIMNHTPWDILTYKQSGSPEEMVLLPRQARLFAWADPTGTRKLTWTYAANVGEHDLLKDGCGQFPYDANIQIHWVSFLDGRQRVLLFTDDVALVSKALQAEEMEQADYEITLSLHSLGLSLVNNESKQEVSYIGITSSGVVWEVKPKQKWKPFSQKQIILLEQSYQKHQISRDHGWIKLDNNFEVNFDKDPMEMRLPIRSPIKRDFLSGIQIEFKQSSHQRSLRARLYWLQVDNQLPGAMFPVVFHPVAPPKSIALDSEPKPFIDVSVITRFNEYSKVLQFKYFMVLIQEMALKIDQGFLGAIIALFTPTTDPEAERRRTKLIQQDIDALNAELMETSMTDMSILSFFEHFHISPVKLHLSLSLGSGGEESDKEKQEMFAVHSVNLLLKSIGATLTDVDDLIFKLAYYEIRYQFYKRDQLIWSVVRHYSEQFLKQMYVLVLGLDVLGNPFGLIRGLSEGVEALFYEPFQGAVQGPEEFAEGLVIGVRSLFGHTVGGAAGVVSRITGSVGKGLAAITMDKEYQQKRREELSRQPRDFGDSLARGGKGFLRGVVGGVTGIITKPVEGAKKEGAAGFFKGIGKGLVGAVARPTGGIVDMASSTFQGIQRAAESTEEVSSLRPPRLIHEDGIIRPYDRQESEGSDLLENHIKKLEGETYRYHCAIPGSKKTILMVTNRRVLCIKEVEILGLMCVDWQCPFEDFVFPPSVSENVLKISVKEQGLFHKKDSANQGCVRKVYLKDTATAERACNAIEDAQSTRQQQKLMKQSSVRLLRPQLPS,0,,,,,,"Parkinson disease 23, autosomal recessive, early onset:An autosomal recessive, early-onset form of Parkinson disease, a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.","Parkinson disease 23, autosomal recessive, early onset",,,1:Q709C8-1:|2:Q709C8-2:|3:Q709C8-3:|4:Q709C8-4:,,,,,,,,,,5.0
Q96QK1,,Vacuolar protein sorting-associated protein 35,VPS35,Homo sapiens,796,False,MEM3,MPTTQQSPQDEQEKLLDEAIQAVKVQSFQMKRCLDKNKLMDALKHASNMLGELRTSMLSPKSYYELYMAISDELHYLEVYLTDEFAKGRKVADLYELVQYAGNIIPRLYLLITVGVVYVKSFPQSRKDILKDLVEMCRGVQHPLRGLFLRNYLLQCTRNILPDEGEPTDEETTGDISDSMDFVLLNFAEMNKLWVRMQHQGHSRDREKRERERQELRILVGTNLVRLSQLEGVNVERYKQIVLTGILEQVVNCRDALAQEYLMECIIQVFPDEFHLQTLNPFLRACAELHQNVNVKNIIIALIDRLALFAHREDGPGIPADIKLFDIFSQQVATVIQSRQDMPSEDVVSLQVSLINLAMKCYPDRVDYVDKVLETTVEIFNKLNLEHIATSSAVSKELTRLLKIPVDTYNNILTVLKLKHFHPLFEYFDYESRKSMSCYVLSNVLDYNTEIVSQDQVDSIMNLVSTLIQDQPDQPVEDPDPEDFADEQSLVGRFIHLLRSEDPDQQYLILNTARKHFGAGGNQRIRFTLPPLVFAAYQLAFRYKENSKVDDKWEKKCQKIFSFAHQTISALIKAELAELPLRLFLQGALAAGEIGFENHETVAYEFMSQAFSLYEDEISDSKAQLAAITLIIGTFERMKCFSEENHEPLRTQCALAASKLLKKPDQGRAVSTCAHLFWSGRNTDKNGEELHGGKRVMECLKKALKIANQCMDPSLQVQLFIEILNRYIYFYEKENDAVTIQVLNQLIQKIREDLPNLESSEETEQINKHFHNTLEHLRLRRESPESEGPIYEGLIL,0,,,,,,"Parkinson disease 17:An autosomal dominant, adult-onset form of Parkinson disease. Parkinson disease is a complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.",Parkinson disease 17,P05067(APP)|Q13596(SNX1)|Q92609(TBC1D5)|O75436(VPS26A)|Q4G0F5(VPS26B)|Q9UBQ0(VPS29)|Q9UBQ0-2(VPS29)|Q9Y4E1(WASHC2C)|Q9QZ88(Vps29),,,,,,,,,,,,5.0
Q5S007,,Leucine-rich repeat serine/threonine-protein kinase 2,LRRK2,Homo sapiens,2527,False,PARK8,MASGSCQGCEEDEETLKKLIVRLNNVQEGKQIETLVQILEDLLVFTYSERASKLFQGKNIHVPLLIVLDSYMRVASVQQVGWSLLCKLIEVCPGTMQSLMGPQDVGNDWEVLGVHQLILKMLTVHNASVNLSVIGLKTLDLLLTSGKITLLILDEESDIFMLIFDAMHSFPANDEVQKLGCKALHVLFERVSEEQLTEFVENKDYMILLSALTNFKDEEEIVLHVLHCLHSLAIPCNNVEVLMSGNVRCYNIVVEAMKAFPMSERIQEVSCCLLHRLTLGNFFNILVLNEVHEFVVKAVQQYPENAALQISALSCLALLTETIFLNQDLEEKNENQENDDEGEEDKLFWLEACYKALTWHRKNKHVQEAACWALNNLLMYQNSLHEKIGDEDGHFPAHREVMLSMLMHSSSKEVFQASANALSTLLEQNVNFRKILLSKGIHLNVLELMQKHIHSPEVAESGCKMLNHLFEGSNTSLDIMAAVVPKILTVMKRHETSLPVQLEALRAILHFIVPGMPEESREDTEFHHKLNMVKKQCFKNDIHKLVLAALNRFIGNPGIQKCGLKVISSIVHFPDALEMLSLEGAMDSVLHTLQMYPDDQEIQCLGLSLIGYLITKKNVFIGTGHLLAKILVSSLYRFKDVAEIQTKGFQTILAILKLSASFSKLLVHHSFDLVIFHQMSSNIMEQKDQQFLNLCCKCFAKVAMDDYLKNVMLERACDQNNSIMVECLLLLGADANQAKEGSSLICQVCEKESSPKLVELLLNSGSREQDVRKALTISIGKGDSQIISLLLRRLALDVANNSICLGGFCIGKVEPSWLGPLFPDKTSNLRKQTNIASTLARMVIRYQMKSAVEEGTASGSDGNFSEDVLSKFDEWTFIPDSSMDSVFAQSDDLDSEGSEGSFLVKKKSNSISVGEFYRDAVLQRCSPNLQRHSNSLGPIFDHEDLLKRKRKILSSDDSLRSSKLQSHMRHSDSISSLASEREYITSLDLSANELRDIDALSQKCCISVHLEHLEKLELHQNALTSFPQQLCETLKSLTHLDLHSNKFTSFPSYLLKMSCIANLDVSRNDIGPSVVLDPTVKCPTLKQFNLSYNQLSFVPENLTDVVEKLEQLILEGNKISGICSPLRLKELKILNLSKNHISSLSENFLEACPKVESFSARMNFLAAMPFLPPSMTILKLSQNKFSCIPEAILNLPHLRSLDMSSNDIQYLPGPAHWKSLNLRELLFSHNQISILDLSEKAYLWSRVEKLHLSHNKLKEIPPEIGCLENLTSLDVSYNLELRSFPNEMGKLSKIWDLPLDELHLNFDFKHIGCKAKDIIRFLQQRLKKAVPYNRMKLMIVGNTGSGKTTLLQQLMKTKKSDLGMQSATVGIDVKDWPIQIRDKRKRDLVLNVWDFAGREEFYSTHPHFMTQRALYLAVYDLSKGQAEVDAMKPWLFNIKARASSSPVILVGTHLDVSDEKQRKACMSKITKELLNKRGFPAIRDYHFVNATEESDALAKLRKTIINESLNFKIRDQLVVGQLIPDCYVELEKIILSERKNVPIEFPVIDRKRLLQLVRENQLQLDENELPHAVHFLNESGVLLHFQDPALQLSDLYFVEPKWLCKIMAQILTVKVEGCPKHPKGIISRRDVEKFLSKKRKFPKNYMSQYFKLLEKFQIALPIGEEYLLVPSSLSDHRPVIELPHCENSEIIIRLYEMPYFPMGFWSRLINRLLEISPYMLSGRERALRPNRMYWRQGIYLNWSPEAYCLVGSEVLDNHPESFLKITVPSCRKGCILLGQVVDHIDSLMEEWFPGLLEIDICGEGETLLKKWALYSFNDGEEHQKILLDDLMKKAEEGDLLVNPDQPRLTIPISQIAPDLILADLPRNIMLNNDELEFEQAPEFLLGDGSFGSVYRAAYEGEEVAVKIFNKHTSLRLLRQELVVLCHLHHPSLISLLAAGIRPRMLVMELASKGSLDRLLQQDKASLTRTLQHRIALHVADGLRYLHSAMIIYRDLKPHNVLLFTLYPNAAIIAKIADYGIAQYCCRMGIKTSEGTPGFRAPEVARGNVIYNQQADVYSFGLLLYDILTTGGRIVEGLKFPNEFDELEIQGKLPDPVKEYGCAPWPMVEKLIKQCLKENPQERPTSAQVFDILNSAELVCLTRRILLPKNVIVECMVATHHNSRNASIWLGCGHTDRGQLSFLDLNTEGYTSEEVADSRILCLALVHLPVEKESWIVSGTQSGTLLVINTEDGKKRHTLEKMTDSVTCLYCNSFSKQSKQKNFLLVGTADGKLAIFEDKTVKLKGAAPLKILNIGNVSTPLMCLSESTNSTERNVMWGGCGTKIFSFSNDFTIQKLIETRTSQLFSYAAFSDSNIITVVVDTALYIAKQNSPVVEVWDKKTEKLCGLIDCVHFLREVMVKENKESKHKMSYSGRVKTLCLQKNTALWIGTGGGHILLLDLSTRRLIRVIYNFCNSVRVMMTAQLGSLKNVMLVLGYNRKNTEGTQKQKEIQSCLTVWDINLPHEVQNLEKHIEVRKELAEKMRRTSVE,0,,,,,,"Parkinson disease 8:A slowly progressive neurodegenerative disorder characterized by bradykinesia, rigidity, resting tremor, postural instability, neuronal loss in the substantia nigra, and the presence of neurofibrillary MAPT (tau)-positive and Lewy bodies in some patients.",Parkinson disease 8,Q9UKV8(AGO2)|O43865(AHCYL1)|P31749(AKT1)|Q8N8V4(ANKS4B)|O00203(AP3B1)|Q8N6T3-2(ARFGAP1)|Q14155(ARHGEF7)|O95816(BAG2)|O95817(BAG3)|Q9UL15(BAG5)|P10415-1(BCL2)|Q13191(CBLB)|Q16543(CDC37)|P60953(CDC42)|Q9UKI2(CDC42EP3)|Q9Y6A4(CFAP20)|P05060(CHGB)|Q9ULV4(CORO1C)|P48729-1(CSNK1A1)|P48730-2(CSNK1D)|Q9NWM3(CUEDC1)|P53355(DAPK1)|Q05193(DNM1)|O00429(DNM1L)|O00429-3(DNM1L)|O14640-2(DVL1)|O14641(DVL2)|Q92997(DVL3)|P30084(ECHS1)|Q05639(EEF1A2)|Q13158(FADD)|O14976(GAK)|P49841(GSK3B)|P11142(HSPA8)|Q71RC2(LARP4)|Q4G0J3(LARP7)|P07195(LDHB)|O75581(LRP6)|Q38SD2(LRRK1)|Q5S007(LRRK2)|P46821(MAP1B)|P46734(MAP2K3)|P52564(MAP2K6)|O14733(MAP2K7)|P10636-2(MAPT)|P10636-8(MAPT)|P42679(MATK)|O95140(MFN2)|P49406(MRPL19)|P26038(MSN)|Q7L592(NDUFAF7)|Q96PY6(NEK1)|Q13469(NFATC2)|Q8WUM0(NUP133)|O60313(OPA1)|Q9NQU5(PAK6)|P62136(PPP1CA)|Q12972(PPP1R8)|P63151(PPP2R2A)|P30048(PRDX3)|P17612(PRKACA)|O60260(PRKN)|P61026(RAB10)|Q6IQ22(RAB12)|Q9H0U4(RAB1B)|O14966(RAB29)|Q13637(RAB32)|P57729(RAB38)|P61020(RAB5B)|P61006(RAB8A)|P63000(RAC1)|P41220(RGS2)|P62906(RPL10A)|P26373(RPL13)|P50914(RPL14)|P62750(RPL23A)|P62888(RPL30)|P49207(RPL34)|Q9BUL9(RPP25)|P62280(RPS11)|P62277(RPS13)|P62841(RPS15)|P62249(RPS16)|P62269(RPS18)|P15880(RPS2)|P60866(RPS20)|P62266(RPS23)|P42677(RPS27)|P23396(RPS3)|O15027(SEC16A)|P60896(SEM1)|P31947(SFN)|Q99961(SH3GL1)|Q99962(SH3GL2)|P12235(SLC25A4)|P05141(SLC25A5)|P12236(SLC25A6)|O95295(SNAPIN)|P37840(SNCA)|Q8NHS9(SPATA22)|Q13501(SQSTM1)|Q9UNE7(STUB1)|Q9UNE7-1(STUB1)|Q9BQ70(TCF25)|Q6P3X3(TTC27)|P07437(TUBB)|Q13885(TUBB2A)|P04350(TUBB4A)|P68371(TUBB4B)|Q9BUF5(TUBB6)|Q53GS9(USP39)|P21796(VDAC1)|Q9Y6I7(WSB1)|P31946(YWHAB)|P62258(YWHAE)|P61981(YWHAG)|Q04917(YWHAH)|P27348(YWHAQ)|P63104(YWHAZ)|O95218(ZRANB2)|Q62848(Arfgap1)|O55143(Atp2a2)|P30275(Ckmt1)|P39053(Dnm1)|P02687(MBP)|Q811U4(Mfn1)|P00634(phoA)|P12369(Prkar2b)|Q63481(Rab29)|P61021(Rab5b)|Q58A65(Spag9)|Q9WUD1(Stub1)|P61983(Ywhag),,,,,,,,,,,,5.0
P49840,,Glycogen synthase kinase-3 alpha,GSK3A,Homo sapiens,483,False,,MSGGGPSGGGPGGSGRARTSSFAEPGGGGGGGGGGPGGSASGPGGTGGGKASVGAMGGGVGASSSGGGPGGSGGGGSGGPGAGTSFPPPGVKLGRDSGKVTTVVATLGQGPERSQEVAYTDIKVIGNGSFGVVYQARLAETRELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDELYLNLVLEYVPETVYRVARHFTKAKLTIPILYVKVYMYQLFRSLAYIHSQGVCHRDIKPQNLLVDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFKSRTPPEAIALCSSLLEYTPSSRLSPLEACAHSFFDELRCLGTQLPNNRPLPPLFNFSAGELSIQPSLNAILIPPHLRSPAGTTTLTPSSQALTETPTSSDWQSTDATPTLTNSS,0,,,,,,,,P05067(APP)|O15169(AXIN1)|Q9Y2T1(AXIN2)|O75398(DEAF1)|Q6P3S6(FBXO42)|Q92837(FRAT1)|Q9P0R6(GSKIP)|P08238(HSP90AB1)|P42858(HTT)|O75581(LRP6)|P10636-8(MAPT)|Q14596(NBR1)|P62258(YWHAE)|Q8IUH5(ZDHHC17),,,,,,,,,,,,5.0
P49841,,Glycogen synthase kinase-3 beta,GSK3B,Homo sapiens,420,False,,MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST,0,,,,,,,,P31749(AKT1)|P31751(AKT2)|P05067(APP)|O15169(AXIN1)|Q9Y2T1(AXIN2)|Q96G01(BICD1)|O75952-3(CABYR)|O75952-5(CABYR)|P35222(CTNNB1)|Q5VWQ8(DAB2IP)|Q5VWQ8-2(DAB2IP)|Q9NYF0(DACT1)|O75398(DEAF1)|Q13144(EIF2B5)|Q92837(FRAT1)|P13807(GYS1)|O75581(LRP6)|Q5S007(LRRK2)|P10636(MAPT)|P10636-8(MAPT)|Q14596(NBR1)|Q8N4C6(NIN)|P17612(PRKACA)|Q01201(RELB)|O95863(SNAI1)|P37840(SNCA)|Q6J9G0(STYK1)|P04637(TP53)|Q14134(TRIM29)|O95071(UBR5)|P63104(YWHAZ)|Q8IX07(ZFPM1)|O35625(Axin1)|Q14DJ8(Axin1)|Q02248(Ctnnb1)|Q811T9(Disc1)|P63085(Mapk1)|P0DTC9(N)|P05067(APP)|P35637(FUS)|P01106(MYC)|Q8BMD2-1(Dzip1),,1:P49841-1:|2:P49841-2:,,,,,,,,,,5.0
Q15047,,Histone-lysine N-methyltransferase SETDB1,SETDB1,Homo sapiens,1291,False,ESET|KIAA0067|KMT1E,MSSLPGCIGLDAATATVESEEIAELQQAVVEELGISMEELRHFIDEELEKMDCVQQRKKQLAELETWVIQKESEVAHVDQLFDDASRAVTNCESLVKDFYSKLGLQYRDSSSEDESSRPTEIIEIPDEDDDVLSIDSGDAGSRTPKDQKLREAMAALRKSAQDVQKFMDAVNKKSSSQDLHKGTLSQMSGELSKDGDLIVSMRILGKKRTKTWHKGTLIAIQTVGPGKKYKVKFDNKGKSLLSGNHIAYDYHPPADKLYVGSRVVAKYKDGNQVWLYAGIVAETPNVKNKLRFLIFFDDGYASYVTQSELYPICRPLKKTWEDIEDISCRDFIEEYVTAYPNRPMVLLKSGQLIKTEWEGTWWKSRVEEVDGSLVRILFLDDKRCEWIYRGSTRLEPMFSMKTSSASALEKKQGQLRTRPNMGAVRSKGPVVQYTQDLTGTGTQFKPVEPPQPTAPPAPPFPPAPPLSPQAGDSDLESQLAQSRKQVAKKSTSFRPGSVGSGHSSPTSPALSENVSGGKPGINQTYRSPLGSTASAPAPSALPAPPAPPVFHGMLERAPAEPSYRAPMEKLFYLPHVCSYTCLSRVRPMRNEQYRGKNPLLVPLLYDFRRMTARRRVNRKMGFHVIYKTPCGLCLRTMQEIERYLFETGCDFLFLEMFCLDPYVLVDRKFQPYKPFYYILDITYGKEDVPLSCVNEIDTTPPPQVAYSKERIPGKGVFINTGPEFLVGCDCKDGCRDKSKCACHQLTIQATACTPGGQINPNSGYQYKRLEECLPTGVYECNKRCKCDPNMCTNRLVQHGLQVRLQLFKTQNKGWGIRCLDDIAKGSFVCIYAGKILTDDFADKEGLEMGDEYFANLDHIESVENFKEGYESDAPCSSDSSGVDLKDQEDGNSGTEDPEESNDDSSDDNFCKDEDFSTSSVWRSYATRRQTRGQKENGLSETTSKDSHPPDLGPPHIPVPPSIPVGGCNPPSSEETPKNKVASWLSCNSVSEGGFADSDSHSSFKTNEGGEGRAGGSRMEAEKASTSGLGIKDEGDIKQAKKEDTDDRNKMSVVTESSRNYGYNPSPVKPEGLRRPPSKTSMHQSRRLMASAQSNPDDVLTLSSSTESEGESGTSRKPTAGQTSATAVDSDDIQTISSGSEGDDFEDKKNMTGPMKRQVAVKSTRGFALKSTHGIAIKSTNMASVDKGESAPVRKNTRQFYDGEESCYIIDAKLEGNLGRYLNHSCSPNLFVQNVFVDTHDLRFPWVAFFASKRIRAGTELTWDYNYEVGSVEGKELLCCCGAIECRGRLL,0,,,,,,,,P31749(AKT1)|Q6P1J9(CDC73)|Q9Y6K1(DNMT3A)|Q9UIS9(MBD1)|Q9NWR8(MCUB)|Q99549(MPHOSPH8)|Q15027(ACAP1)|Q9NPJ3(ACOT13)|Q8IWZ3-3(ANKHD1)|O43307(ARHGEF9)|Q66PJ3-4(ARL6IP4)|Q9Y576(ASB1)|Q14032(BAAT)|Q13072(BAGE)|Q8N9N5-2(BANP)|Q6PH81(C16orf87)|Q96HJ3-2(CCDC34)|Q96A33(CCDC47)|Q96LY2-2(CCDC74B)|Q9GZT6(CCDC90B)|Q7Z7K6(CENPV)|Q8TAP6(CEP76)|Q9NX63(CHCHD3)|Q99828(CIB1)|P15169(CPN1)|P43234(CTSO)|O95424(DEXI)|O43598(DNPH1)|P21728(DRD1)|P60228(EIF3E)|Q96J88-3(EPSTI1)|Q8IVH2-2(FOXP4)|Q96NE9-2(FRMD6)|O14926(FSCN2)|Q06547-2(GABPB1)|Q06547-3(GABPB1)|P19440-3(GGT1)|O95837(GNA14)|Q96F32(GNB5)|O43292-2(GPAA1)|Q9NWQ4-1(GPATCH2L)|Q9UJ42(GPR160)|Q96D09(GPRASP2)|Q13322-4(GRB10)|P62805(H4C9)|O00165(HAX1)|Q8N7T0(hCG_1820408)|P52597(HNRNPF)|Q92826(HOXB13)|P09017(HOXC4)|Q03933-2(HSF2)|P42858(HTT)|Q02363(ID2)|Q96FT9-2(IFT43)|P78318(IGBP1)|P17936(IGFBP3)|P26951(IL3RA)|Q8N5Z5(KCTD17)|Q9Y4X4(KLF12)|Q5JUW0-3(KRBOX4)|Q9BYR8(KRTAP3-1)|Q9H2C1(LHX5)|Q9Y234(LIPT1)|P51884(LUM)|Q96GV9(MACIR)|Q9H213(MAGEH1)|P80192(MAP3K9)|Q15759(MAPK11)|A0JLT2-2(MED19)|P41218(MNDA)|Q8N983-3(MRPL43)|Q16718(NDUFA5)|P49821(NDUFV1)|Q2M1J6(OXA1L)|Q16342(PDCD2)|Q9BRX2(PELO)|Q9Y6X2(PIAS3)|Q86T03(PIP4P1)|Q6P1J6-2(PLB1)|Q9UNA4(POLI)|P07225(PROS1)|Q3YEC7-3(RABL6)|Q96I51(RCC1L)|O94844(RHOBTB1)|Q9UJD0(RIMS3)|Q9NWS8-3(RMND1)|Q9Y508(RNF114)|Q9ULK6-3(RNF150)|P62913-2(RPL11)|P18077(RPL35A)|Q99643(SDHC)|Q14141(SEPTIN6)|Q01105-2(SET)|Q13573(SNW1)|Q9Y5X0(SNX10)|Q8WV41(SNX33)|P56693(SOX10)|Q9BRW5(SP2)|Q13586(STIM1)|Q13033-2(STRN3)|O43761(SYNGR3)|P15884(TCF4)|Q92481(TFAP2B)|Q3YBM2(TMEM176B)|Q969K7(TMEM54)|Q9H8H3(TMT1A)|P51580(TPMT)|Q9UJA5(TRMT6)|Q99598(TSNAX)|Q8NB14(USP38)|Q15836(VAMP3)|O95498(VNN2)|Q9NZC7-5(WWOX)|Q53FD0-2(ZC2HC1C)|Q8IUH5(ZDHHC17)|Q9BQ24(ZFYVE21)|Q15776(ZKSCAN8)|Q14202(ZMYM3)|Q05CR2(ZNF248)|Q9UL40(ZNF346)|Q8N0Y2-2(ZNF444)|O15535(ZSCAN9)|Q9HBH6()|O75031(HSF2BP)|Q15654(TRIP6),,1:Q15047-1:|2:Q15047-2:|3:Q15047-3:,,,,,,,,,,5.0
Q9NRI5,,Disrupted in schizophrenia 1 protein,DISC1,Homo sapiens,854,False,KIAA0457,MPGGGPQGAPAAAGGGGVSHRAGSRDCLPPAACFRRRRLARRPGYMRSSTGPGIGFLSPAVGTLFRFPGGVSGEESHHSESRARQCGLDSRGLLVRSPVSKSAAAPTVTSVRGTSAHFGIQLRGGTRLPDRLSWPCGPGSAGWQQEFAAMDSSETLDASWEAACSDGARRVRAAGSLPSAELSSNSCSPGCGPEVPPTPPGSHSAFTSSFSFIRLSLGSAGERGEAEGCPPSREAESHCQSPQEMGAKAASLDGPHEDPRCLSRPFSLLATRVSADLAQAARNSSRPERDMHSLPDMDPGSSSSLDPSLAGCGGDGSSGSGDAHSWDTLLRKWEPVLRDCLLRNRRQMEVISLRLKLQKLQEDAVENDDYDKAETLQQRLEDLEQEKISLHFQLPSRQPALSSFLGHLAAQVQAALRRGATQQASGDDTHTPLRMEPRLLEPTAQDSLHVSITRRDWLLQEKQQLQKEIEALQARMFVLEAKDQQLRREIEEQEQQLQWQGCDLTPLVGQLSLGQLQEVSKALQDTLASAGQIPFHAEPPETIRSLQERIKSLNLSLKEITTKVCMSEKFCSTLRKKVNDIETQLPALLEAKMHAISGNHFWTAKDLTEEIRSLTSEREGLEGLLSKLLVLSSRNVKKLGSVKEDYNRLRREVEHQETAYETSVKENTMKYMETLKNKLCSCKCPLLGKVWEADLEACRLLIQSLQLQEARGSLSVEDERQMDDLEGAAPPIPPRLHSEDKRKTPLKVLEEWKTHLIPSLHCAGGEQKEESYILSAELGEKCEDIGKKLLYLEDQLHTAIHSHDEDLIQSLRRELQMVKETLQAMILQLQPAKEAGEREAAASCMTAGVHEAQA,0,,,,,,":|Schizophrenia 9:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia 9,P35609(ACTN2)|Q99996(AKAP9)|Q8TCU4(ALMS1)|Q9UNK9(ANGEL1)|Q8IWZ3-1(ANKHD1)|P18848(ATF4)|Q9Y2D1(ATF5)|Q6VMQ6(ATF7IP)|Q6ZP82(CCDC141)|Q5SW79(CEP170)|Q96MT8(CEP63)|P10909(CLU)|P12110(COL6A2)|Q9NRI5(DISC1)|Q99615(DNAJC7)|P14416(DRD2)|Q03001(DST)|Q14204(DYNC1H1)|O15372(EIF3H)|Q8WXI9(GATAD2B)|Q4V328(GRIPAP1)|P06396(GSN)|O95714(HERC2)|Q16891(IMMT)|Q15811(ITSN1)|Q9Y496(KIF3A)|O14782(KIF3C)|Q9UPN3(MACF1)|P78559(MAP1A)|O95819(MAP4K4)|P43243(MATR3)|Q8NEY1(NAV1)|Q9NXR1(NDE1)|Q9GZM8(NDEL1)|Q12769(NUP160)|Q8TEM1(NUP210)|P43034(PAFAH1B1)|O95613(PCNT)|Q5VU43(PDE4DIP)|Q96S59(RANBP9)|Q99666(RGPD6)|O75150(RNF40)|Q96R06(SPAG5)|Q13813(SPTAN1)|Q01082(SPTBN1)|Q9H254(SPTBN4)|Q8NF91(SYNE1)|Q9UBB9(TFIP11)|Q9UKE5(TNIK)|O95271(TNKS)|Q9H2K2(TNKS2)|Q8TDR0(TRAF3IP1)|P14373(TRIM27)|O94972(TRIM37)|O75962(TRIO)|Q9H0D6(XRN2)|P62258(YWHAE)|P63104(YWHAZ)|Q6A065(Cep170)|Q8VD04(Gripap1)|Q9Z1B5(Mad2l1)|Q9CZA6(Nde1)|Q9ERR1(Ndel1)|O15372(EIF3H)|Q16891-1(IMMT)|Q9UPN3(MACF1)|Q9GZM8(NDEL1)|Q99784(OLFM1)|Q9NYB9-2(ABI2)|Q96SZ5(ADO)|Q13155(AIMP2)|Q9NX04(AIRIM)|A2BDD9(AMOT)|Q9BXS5(AP1M1)|Q9H6L4(ARMC7)|O95816(BAG2)|Q13515(BFSP2)|Q96GS4(BORCS6)|O95696(BRD1)|Q53TS8(C2CD6)|Q9H7E9(C8orf33)|Q9H257-2(CARD9)|Q68D86(CCDC102B)|Q8IYE1(CCDC13)|Q8NCU1(CCDC197)|Q2TAC2-2(CCDC57)|Q53HC0(CCDC92)|Q8TD31-3(CCHCR1)|Q9UJX2(CDC23)|Q16543(CDC37)|Q8IVW4(CDKL3)|Q86XR8-3(CEP57)|Q8IYR0(CFAP206)|Q9UI47-2(CTNNA3)|Q2TBE0(CWF19L2)|P26196(DDX6)|P38919(EIF4A3)|Q7Z589-5(EMSY)|Q9NWN3(FBXO34)|Q96Q35-2(FLACC1)|Q9H0R8(GABARAPL1)|Q8NHY3(GAS2L2)|O95995(GAS8)|Q96CN9(GCC1)|P55040(GEM)|Q9P2W3(GNG13)|O95872(GPANK1)|Q4V328(GRIPAP1)|P07910(HNRNPC)|Q8IY31-3(IFT20)|Q96LB3-2(IFT74)|Q9HAQ2(KIF9)|Q9BVG8-5(KIFC3)|Q96BZ8(LENG1)|Q8NEH6(MNS1)|Q15014(MORF4L2)|O43639(NCK2)|Q9GZM8(NDEL1)|Q8N987(NECAB1)|Q9Y5B8(NME7)|O43189(PHF1)|Q4G0R1(PIBF1)|Q92569(PIK3R3)|Q16512(PKN1)|Q9BUI4(POLR3C)|O75145(PPFIA3)|Q8WXF1-2(PSPC1)|P47897(QARS1)|Q96IZ5(RBM41)|Q6P9E2(RECK)|O75150(RNF40)|Q96GM5(SMARCD1)|Q969G3(SMARCE1)|Q8IY18(SMC5)|Q8NB12(SMYD1)|Q9H0A9-2(SPATC1L)|O75558(STX11)|Q9UMX1(SUFU)|Q9Y4C2-2(TCAF1)|Q8N8B7-2(TCEANC)|Q9BUZ4(TRAF4)|Q14134(TRIM29)|Q6AZZ1(TRIM68)|Q9BZW7(TSGA10)|Q969E8(TSR2)|Q5W5X9-3(TTC23)|P57075-2(UBASH3A)|Q8TF42(UBASH3B)|O75604(USP2)|Q15973(ZNF124)|P36508(ZNF76)|E9Q8Q6(Ccdc141),,1:Q9NRI5-1:|2:Q9NRI5-2:|3:Q9NRI5-3:|4:Q9NRI5-4:|5:Q9NRI5-5:|6:Q9NRI5-6:|7:Q9NRI5-7:|8:Q9NRI5-8:|9:Q9NRI5-9:|10:Q9NRI5-10:|11:Q9NRI5-11:,,,,,,,,,,5.0
Q12879,,"Glutamate receptor ionotropic, NMDA 2A",GRIN2A,Homo sapiens,1464,False,NMDAR2A,MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQAAGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHTFVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILTTAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPRLVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVEDIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLVTNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRSNGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVDQVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALLQFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHLFYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRSAKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNMNELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDSIRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVTLPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPHSETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNPATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLLEGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIGRCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYSTPRVLNSCSNRRVYKKMPSIESDV,0,,,,,,"Epilepsy, focal, with speech disorder and with or without impaired intellectual development:An autosomal dominant, highly variable neurologic disorder. Features range from severe early-onset seizures associated with delayed psychomotor development, persistent speech difficulties, and intellectual disability to a more benign entity characterized by childhood onset of mild or asymptomatic seizures associated with transient speech difficulties followed by remission of seizures in adolescence and normal psychomotor development. The disorder encompasses several clinical entities, including Landau-Kleffner syndrome, epileptic encephalopathy with continuous spike and wave during slow-wave sleep, autosomal dominant rolandic epilepsy, intellectual disability and speech dyspraxia, and benign epilepsy with centrotemporal spikes.|:|:|:","Epilepsy, focal, with speech disorder and with or without impaired intellectual development",P78352(DLG4)|Q07954(LRP1)|Q62936(Dlg3)|P31016(Dlg4)|Q05586-1(GRIN1),,1:Q12879-1:|2:Q12879-2:,,,,,,,,,,5.0
P48553,,Trafficking protein particle complex subunit 10,TRAPPC10,Homo sapiens,1259,False,EHOC1|TMEM1,MDASEEPLPPVIYTMENKPIVTCAGDQNLFTSVYPTLSQQLPREPMEWRRSYGRAPKMIHLESNFVQFKEELLPKEGNKALLTFPFLHIYWTECCDTEVYKATVKDDLTKWQNVLKAHSSVDWLIVIVENDAKKKNKTNILPRTSIVDKIRNDFCNKQSDRCVVLSDPLKDSSRTQESWNAFLTKLRTLLLMSFTKNLGKFEDDMRTLREKRTEPGWSFCEYFMVQEELAFVFEMLQQFEDALVQYDELDALFSQYVVNFGAGDGANWLTFFCQPVKSWNGLILRKPIDMEKRESIQRREATLLDLRSYLFSRQCTLLLFLQRPWEVAQRALELLHNCVQELKLLEVSVPPGALDCWVFLSCLEVLQRIEGCCDRAQIDSNIAHTVGLWSYATEKLKSLGYLCGLVSEKGPNSEDLNRTVDLLAGLGAERPETANTAQSPYKKLKEALSSVEAFEKHYLDLSHATIEMYTSIGRIRSAKFVGKDLAEFYMRKKAPQKAEIYLQGALKNYLAEGWALPITHTRKQLAECQKHLGQIENYLQTSSLLASDHHLTEEERKHFCQEILDFASQPSDSPGHKIVLPMHSFAQLRDLHFDPSNAVVHVGGVLCVEITMYSQMPVPVHVEQIVVNVHFSIEKNSYRKTAEWLTKHKTSNGIINFPPETAPFPVSQNSLPALELYEMFERSPSDNSLNTTGIICRNVHMLLRRQESSSSLEMPSGVALEEGAHVLRCSHVTLEPGANQITFRTQAKEPGTYTLRQLCASVGSVWFVLPHIYPIVQYDVYSQEPQLHVEPLADSLLAGIPQRVKFTVTTGHYTIKNGDSLQLSNAEAMLILCQAESRAVVYSNTREQSSEAALRIQSSDKVTSISLPVAPAYHVIEFELEVLSLPSAPALGGESDMLGMAEPHRKHKDKQRTGRCMVTTDHKVSIDCPWSIYSTVIALTFSVPFRTTHSLLSSGTRKYVQVCVQNLSELDFQLSDSYLVDTGDSTDLQLVPLNTQSQQPIYSKQSVFFVWELKWTEEPPPSLHCRFSVGFSPASEEQLSISLKPYTYEFKVENFFTLYNVKAEIFPPSGMEYCRTGSLCSLEVLITRLSDLLEVDKDEALTESDEHFSTKLMYEVVDNSSNWAVCGKSCGVISMPVAARATHRVHMEVMPLFAGYLPLPDVRLFKYLPHHSAHSSQLDADSWIENDSLSVDKHGDDQPDSSSLKSRGSVHSACSSEHKGLPMPRLQALPAGQVFNSSSGTQVLVIPSQDDHVLEVSVT,0,,,,,,"Neurodevelopmental disorder with microcephaly, short stature, and speech delay:An autosomal recessive disorder characterized by global developmental delay, short stature, severely impaired intellectual development, microcephaly, poor or absent speech, and behavioral abnormalities including autistic features and aggressive behavior.","Neurodevelopmental disorder with microcephaly, short stature, and speech delay",Q96QF0(RAB3IP),,1:P48553-1:|2:P48553-2:,,,,,,,,,,5.0
Q9H6U8,,"Alpha-1,2-mannosyltransferase ALG9",ALG9,Homo sapiens,611,False,DIBD1,MASRGARQRLKGSGASSGDTAPAADKLRELLGSREAGGAEHRTELSGNKAGQVWAPEGSTAFKCLLSARLCAALLSNISDCDETFNYWEPTHYLIYGEGFQTWEYSPAYAIRSYAYLLLHAWPAAFHARILQTNKILVFYFLRCLLAFVSCICELYFYKAVCKKFGLHVSRMMLAFLVLSTGMFCSSSAFLPSSFCMYTTLIAMTGWYMDKTSIAVLGVAAGAILGWPFSAALGLPIAFDLLVMKHRWKSFFHWSLMALILFLVPVVVIDSYYYGKLVIAPLNIVLYNVFTPHGPDLYGTEPWYFYLINGFLNFNVAFALALLVLPLTSLMEYLLQRFHVQNLGHPYWLTLAPMYIWFIIFFIQPHKEERFLFPVYPLICLCGAVALSALQKCYHFVFQRYRLEHYTVTSNWLALGTVFLFGLLSFSRSVALFRGYHGPLDLYPEFYRIATDPTIHTVPEGRPVNVCVGKEWYRFPSSFLLPDNWQLQFIPSEFRGQLPKPFAEGPLATRIVPTDMNDQNLEEPSRYIDISKCHYLVDLDTMRETPREPKYSSNKEEWISLAYRPFLDASRSSKLLRAFYVPFLSDQYTVYVNYTILKPRKAKQIRKKSGG,0,,,,,,":|Congenital disorder of glycosylation 1L:A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.|Gillessen-Kaesbach-Nishimura syndrome:A rare autosomal recessive syndrome characterized by severe skeletal dysplasia, facial dysmorphic features, polycystic kidney disease and other visceral malformations. It may be lethal in utero or early in life. The skeletal features uniformly comprise a round pelvis, mesomelic shortening of the upper limbs and defective ossification of the cervical spine.",Congenital disorder of glycosylation 1L|Gillessen-Kaesbach-Nishimura syndrome,,,1:Q9H6U8-1:|2:Q9H6U8-2:|3:Q9H6U8-3:|4:Q9H6U8-4:,,,,,,,,,,5.0
Q9BYB0,,SH3 and multiple ankyrin repeat domains protein 3,SHANK3,Homo sapiens,1731,False,KIAA1650|PROSAP2|PSAP2,MDGPGASAVVVRVGIPDLQQTKCLRLDPAAPVWAAKQRVLCALNHSLQDALNYGLFQPPSRGRAGKFLDEERLLQEYPPNLDTPLPYLEFRYKRRVYAQNLIDDKQFAKLHTKANLKKFMDYVQLHSTDKVARLLDKGLDPNFHDPDSGECPLSLAAQLDNATDLLKVLKNGGAHLDFRTRDGLTAVHCATRQRNAAALTTLLDLGASPDYKDSRGLTPLYHSALGGGDALCCELLLHDHAQLGITDENGWQEIHQACRFGHVQHLEHLLFYGADMGAQNASGNTALHICALYNQESCARVLLFRGANRDVRNYNSQTAFQVAIIAGNFELAEVIKTHKDSDVVPFRETPSYAKRRRLAGPSGLASPRPLQRSASDINLKGEAQPAASPGPSLRSLPHQLLLQRLQEEKDRDRDADQESNISGPLAGRAGQSKISPSGPGGPGPAPGPGPAPPAPPAPPPRGPKRKLYSAVPGRKFIAVKAHSPQGEGEIPLHRGEAVKVLSIGEGGFWEGTVKGRTGWFPADCVEEVQMRQHDTRPETREDRTKRLFRHYTVGSYDSLTSHSDYVIDDKVAVLQKRDHEGFGFVLRGAKAETPIEEFTPTPAFPALQYLESVDVEGVAWRAGLRTGDFLIEVNGVNVVKVGHKQVVALIRQGGNRLVMKVVSVTRKPEEDGARRRAPPPPKRAPSTTLTLRSKSMTAELEELASIRRRKGEKLDEMLAAAAEPTLRPDIADADSRAATVKQRPTSRRITPAEISSLFERQGLPGPEKLPGSLRKGIPRTKSVGEDEKLASLLEGRFPRSTSMQDPVREGRGIPPPPQTAPPPPPAPYYFDSGPPPAFSPPPPPGRAYDTVRSSFKPGLEARLGAGAAGLYEPGAALGPLPYPERQKRARSMIILQDSAPESGDAPRPPPAATPPERPKRRPRPPGPDSPYANLGAFSASLFAPSKPQRRKSPLVKQLQVEDAQERAALAVGSPGPGGGSFAREPSPTHRGPRPGGLDYGAGDGPGLAFGGPGPAKDRRLEERRRSTVFLSVGAIEGSAPGADLPSLQPSRSIDERLLGTGPTAGRDLLLPSPVSALKPLVSGPSLGPSGSTFIHPLTGKPLDPSSPLALALAARERALASQAPSRSPTPVHSPDADRPGPLFVDVQARDPERGSLASPAFSPRSPAWIPVPARREAEKVPREERKSPEDKKSMILSVLDTSLQRPAGLIVVHATSNGQEPSRLGGAEEERPGTPELAPAPMQSAAVAEPLPSPRAQPPGGTPADAGPGQGSSEEEPELVFAVNLPPAQLSSSDEETREELARIGLVPPPEEFANGVLLATPLAGPGPSPTTVPSPASGKPSSEPPPAPESAADSGVEEADTRSSSDPHLETTSTISTVSSMSTLSSESGELTDTHTSFADGHTFLLEKPPVPPKPKLKSPLGKGPVTFRDPLLKQSSDSELMAQQHHAASAGLASAAGPARPRYLFQRRSKLWGDPVESRGLPGPEDDKPTVISELSSRLQQLNKDTRSLGEEPVGGLGSLLDPAKKSPIAAARLFSSLGELSSISAQRSPGGPGGGASYSVRPSGRYPVARRAPSPVKPASLERVEGLGAGAGGAGRPFGLTPPTILKSSSLSIPHEPKEVRFVVRSVSARSRSPSPSPLPSPASGPGPGAPGPRRPFQQKPLQLWSKFDVGDWLESIHLGEHRDRFEDHEIEGAHLPALTKDDFVELGVTRVGHRMNIERALRQLDGS,0,,,,,,":|:|Phelan-McDermid syndrome:A developmental disorder with variable features. Common features include neonatal hypotonia, global developmental delay, normal to accelerated growth, absent to severely delayed speech, autistic behavior, and minor dysmorphic features.|Schizophrenia 15:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Phelan-McDermid syndrome|Schizophrenia 15,P12814(ACTN1)|Q14155(ARHGEF7)|Q9NX63(CHCHD3)|Q16555(DPYSL2)|O75821(EIF3G)|P21333(FLNA)|P62993(GRB2)|P07910(HNRNPC)|O75525(KHDRBS3)|P78559(MAP1A)|P16333(NCK1)|Q99435(NELL2)|Q9NRD5(PICK1)|P19174(PLCG1)|P55345(PRMT2)|P55036(PSMD4)|Q8IXJ6(SIRT2)|Q01668(CACNA1D),,1:Q9BYB0-1:|2:Q9BYB0-3:,,,,,,,,,,5.0
P59103,,D-amino acid oxidase regulator,DAOA,Homo sapiens,153,False,G72,MLEKLMGADSLQLFRSRYTLGKIYFIGFQRSILLSKSENSLNSIAKETEEGRETVTRKEGWKRRHEDGYLEMAQRHLQRSLCPWVSYLPQPYAELEEVSSHVGKVFMARNYEFLAYEASKDRRQPLERMWTCNYNQQKDQSCNHKEITSTKAE,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia,,,1:P59103-1:|2:P59103-2:|3:P59103-3:|4:P59103-4:,,,,,,,,,,5.0
O43272,,"Proline dehydrogenase 1, mitochondrial",PRODH,Homo sapiens,600,False,PIG6|POX2|PRODH2,MALRRALPALRPCIPRFVPLSTAPASREQPAAGPAAVPGGGSATAVRPPVPAVDFGNAQEAYRSRRTWELARSLLVLRLCAWPALLARHEQLLYVSRKLLGQRLFNKLMKMTFYGHFVAGEDQESIQPLLRHYRAFGVSAILDYGVEEDLSPEEAEHKEMESCTSAAERDGSGTNKRDKQYQAHWAFGDRRNGVISARTYFYANEAKCDSHMETFLRCIEASGRVSDDGFIAIKLTALGRPQFLLQFSEVLAKWRCFFHQMAVEQGQAGLAAMDTKLEVAVLQESVAKLGIASRAEIEDWFTAETLGVSGTMDLLDWSSLIDSRTKLSKHLVVPNAQTGQLEPLLSRFTEEEELQMTRMLQRMDVLAKKATEMGVRLMVDAEQTYFQPAISRLTLEMQRKFNVEKPLIFNTYQCYLKDAYDNVTLDVELARREGWCFGAKLVRGAYLAQERARAAEIGYEDPINPTYEATNAMYHRCLDYVLEELKHNAKAKVMVASHNEDTVRFALRRMEELGLHPADHRVYFGQLLGMCDQISFPLGQAGYPVYKYVPYGPVMEVLPYLSRRALENSSLMKGTHRERQLLWLELLRRLRTGNLFHRPA,0,,,,,,"Hyperprolinemia 1:An inborn error of proline metabolism resulting in elevated levels of proline in the plasma and urine. The disorder is generally benign and most affected individuals are clinically asymptomatic. Some patients, however, have neurologic manifestations, including epilepsy and intellectual disability. Association with certain forms of schizophrenia have been reported.|Schizophrenia 4:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Hyperprolinemia 1|Schizophrenia 4,,,1:O43272-4:|2:O43272-2:|3:O43272-1:,,,,,,,,,,5.0
P49798,,Regulator of G-protein signaling 4,RGS4,Homo sapiens,205,False,,MCKGLAGLPASCLRSAKDMKHRLGFLLQKSDSCEHNSSHNKKDKVVICQRVSQEEVKKWAESLENLISHECGLAAFKAFLKSEYSEENIDFWISCEEYKKIKSPSKLSPKAKKIYNEFISVQATKEVNLDSCTREETSRNMLEPTITCFDEAQKKIFNLMEKDSYRRFLKSRFYLDLVNPSSCGAEKQKGAKSSADCASLVPQCA,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia,,,1:P49798-1:|2:P49798-2:|3:P49798-3:|4:P49798-4:|5:P49798-5:,,,,,,,,,,5.0
Q92777,,Synapsin-2,SYN2,Homo sapiens,582,False,,MMNFLRRRLSDSSFIANLPNGYMTDLQRPEPQQPPPPPPPGPGAASASAAPPTASPGPERRPPPASAPAPQPAPTPSVGSSFFSSLSQAVKQTAASAGLVDAPAPAPAAARKAKVLLVVDEPHADWAKCFRGKKVLGDYDIKVEQAEFSELNLVAHADGTYAVDMQVLRNGTKVVRSFRPDFVLIRQHAFGMAENEDFRHLIIGMQYAGLPSINSLESIYNFCDKPWVFAQLVAIYKTLGGEKFPLIEQTYYPNHKEMLTLPTFPVVVKIGHAHSGMGKVKVENHYDFQDIASVVALTQTYATAEPFIDSKYDIRVQKIGNNYKAYMRTSISGNWKTNTGSAMLEQIAMSDRYKLWVDTCSEMFGGLDICAVKAVHGKDGKDYIFEVMDCSMPLIGEHQVEDRQLITELVISKMNQLLSRTPALSPQRPLTTQQPQSGTLKDPDSSKTPPQRPPPQGGPGQPQGMQPPGKVLPPRRLPPGPSLPPSSSSSSSSSSSAPQRPGGPTTHGDAPSSSSSLAEAQPPLAAPPQKPQPHPQLNKSQSLTNAFSFSESSFFRSSANEDEAKAETIRSLRKSFASLFSD,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia,,,IIa:Q92777-1:|IIb:Q92777-2:,,,,,,,,,,5.0
Q9NQV8,,PR domain zinc finger protein 8,PRDM8,Homo sapiens,689,False,PFM5,MEDTGIQRGIWDGDAKAVQQCLTDIFTSVYTTCDIPENAIFGPCVLSHTSLYDSIAFIALKSTDKRTVPYIFRVDTSAANGSSEGLMWLRLVQSARDKEEQNLEAYIKNGQLFYRSLRRIAKDEELLVWYGKELTELLLLCPSRSHNKMNGSSPYTCLECSQRFQFEFPYVAHLRFRCPKRLHSADISPQDEQGGGVGTKDHGGGGGGGKDQQQQQQEAPLGPGPKFCKAGPLHHYPSPSPESSNPSAAAGGSSAKPSTDFHNLARELENSRGGSSCSPAQSLSSGSGSGGGGGHQEAELSPDGIATGGGKGKRKFPEEAAEGGGGAGLVGGRGRFVERPLPASKEDLVCTPQQYRASGSYFGLEENGRLFAPPSPETGEAKRSAFVEVKKAARAASLQEEGTADGAGVASEDQDAGGGGGSSTPAAASPVGAEKLLAPRPGGPLPSRLEGGSPARGSAFTSVPQLGSAGSTSGGGGTGAGAAGGAGGGQGAASDERKSAFSQPARSFSQLSPLVLGQKLGALEPCHPADGVGPTRLYPAAADPLAVKLQGAADLNGGCGSLPSGGGGLPKQSPFLYATAFWPKSSAAAAAAAAAAAAGPLQLQLPSALTLLPPSFTSLCLPAQNWCAKCNASFRMTSDLVYHMRSHHKKEYAMEPLVKRRREEKLKCPICNESFRERHHLSRHMTSHN,0,,,,,,"Epilepsy, progressive myoclonic 10:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM10 is an autosomal recessive form characterized by progressive dysarthria, myoclonus, ataxia, cognitive decline, psychosis, dementia and spasticity, with onset in childhood. There is variability between patients.","Epilepsy, progressive myoclonic 10",,,1:Q9NQV8-1:|2:Q9NQV8-2:,,,,,,,,,,5.0
P43005,,Excitatory amino acid transporter 3,SLC1A1,Homo sapiens,524,False,EAAC1|EAAT3|HEAAC1,MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITTGVLVREHSNLSTLEKFYFAFPGEILMRMLKLIILPLIISSMITGVAALDSNVSGKIGLRAVVYYFCTTLIAVILGIVLVVSIKPGVTQKVGEIARTGSTPEVSTVDAMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNMTEESFTAVMTTAISKNKTKEYKIVGMYSDGINVLGLIVFCLVFGLVIGKMGEKGQILVDFFNALSDATMKIVQIIMCYMPLGILFLIAGKIIEVEDWEIFRKLGLYMATVLTGLAIHSIVILPLIYFIVVRKNPFRFAMGMAQALLTALMISSSSATLPVTFRCAEENNQVDKRITRFVLPVGATINMDGTALYEAVAAVFIAQLNDLDLGIGQIITISITATSASIGAAGVPQAGLVTMVIVLSAVGLPAEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVNIVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF,0,,,,,,"Dicarboxylic aminoaciduria:An autosomal recessive disorder characterized by abnormal excretion of urinary glutamate and aspartate, resulting from the incomplete reabsorption of anionic amino acids from the glomerular filtrate in the kidney. It can be associated with intellectual disability.|Schizophrenia 18:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Dicarboxylic aminoaciduria|Schizophrenia 18,Q9Y282(ERGIC3)|Q5JX71(FAM209A)|Q14802-3(FXYD3)|Q5T700(LDLRAD1)|O75459(PAGE1)|Q99942(RNF5)|P78382(SLC35A1)|Q8TBG9(SYNPR)|Q7Z7N9(TMEM179B),,,,,,,,,,,,5.0
Q9ULB1,,Neurexin-1,NRXN1,Homo sapiens,1477,False,KIAA0578,MGTALLQRGGCFLLCLSLLLLGCWAELGSGLEFPGAEGQWTRFPKWNACCESEMSFQLKTRSARGLVLYFDDEGFCDFLELILTRGGRLQLSFSIFCAEPATLLADTPVNDGAWHSVRIRRQFRNTTLFIDQVEAKWVEVKSKRRDMTVFSGLFVGGLPPELRAAALKLTLASVREREPFKGWIRDVRVNSSQVLPVDSGEVKLDDEPPNSGGGSPCEAGEEGEGGVCLNGGVCSVVDDQAVCDCSRTGFRGKDCSQEDNNVEGLAHLMMGDQGKSKGKEEYIATFKGSEYFCYDLSQNPIQSSSDEITLSFKTLQRNGLMLHTGKSADYVNLALKNGAVSLVINLGSGAFEALVEPVNGKFNDNAWHDVKVTRNLRQHSGIGHAMVTISVDGILTTTGYTQEDYTMLGSDDFFYVGGSPSTADLPGSPVSNNFMGCLKEVVYKNNDVRLELSRLAKQGDPKMKIHGVVAFKCENVATLDPITFETPESFISLPKWNAKKTGSISFDFRTTEPNGLILFSHGKPRHQKDAKHPQMIKVDFFAIEMLDGHLYLLLDMGSGTIKIKALLKKVNDGEWYHVDFQRDGRSGTISVNTLRTPYTAPGESEILDLDDELYLGGLPENKAGLVFPTEVWTALLNYGYVGCIRDLFIDGQSKDIRQMAEVQSTAGVKPSCSKETAKPCLSNPCKNNGMCRDGWNRYVCDCSGTGYLGRSCEREATVLSYDGSMFMKIQLPVVMHTEAEDVSLRFRSQRAYGILMATTSRDSADTLRLELDAGRVKLTVNLDCIRINCNSSKGPETLFAGYNLNDNEWHTVRVVRRGKSLKLTVDDQQAMTGQMAGDHTRLEFHNIETGIITERRYLSSVPSNFIGHLQSLTFNGMAYIDLCKNGDIDYCELNARFGFRNIIADPVTFKTKSSYVALATLQAYTSMHLFFQFKTTSLDGLILYNSGDGNDFIVVELVKGYLHYVFDLGNGANLIKGSSNKPLNDNQWHNVMISRDTSNLHTVKIDTKITTQITAGARNLDLKSDLYIGGVAKETYKSLPKLVHAKEGFQGCLASVDLNGRLPDLISDALFCNGQIERGCEGPSTTCQEDSCSNQGVCLQQWDGFSCDCSMTSFSGPLCNDPGTTYIFSKGGGQITYKWPPNDRPSTRADRLAIGFSTVQKEAVLVRVDSSSGLGDYLELHIHQGKIGVKFNVGTDDIAIEESNAIINDGKYHVVRFTRSGGNATLQVDSWPVIERYPAGRQLTIFNSQATIIIGGKEQGQPFQGQLSGLYYNGLKVLNMAAENDANIAIVGNVRLVGEVPSSMTTESTATAMQSEMSTSIMETTTTLATSTARRGKPPTKEPISQTTDDILVASAECPSDDEDIDPCEPSSGGLANPTRAGGREPYPGSAEVIRESSSTTGMVVGIVAAAALCILILLYAMYKYRNRDEGSYHVDESRNYISNSAQSNGAVVKEKQPSSAKSSNKNKKNKDKEYYV,0,,,,,,"Pitt-Hopkins-like syndrome 2:A syndrome characterized by severe intellectual disability and variable additional symptoms, such as impaired speech development, autistic behavior, breathing anomalies and a broad mouth, resembling Pitt-Hopkins syndrome. Other features include decreased reflexes in the upper extremities, constipation, strabismus, and protruding tongue with drooling. In contrast to patients with Pitt-Hopkins syndrome, PTHSL2 patients present with normal or only mildly to moderately delayed motor milestones.|Schizophrenia 17:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Pitt-Hopkins-like syndrome 2|Schizophrenia 17,,,1a:Q9ULB1-1:|2a:Q9ULB1-2:|3a:Q9ULB1-3:|3b:P58400-1:|4:Q9ULB1-4:|1b:P58400-2:|5:Q9ULB1-5:,,,,,,,,,,5.0
O15399,,"Glutamate receptor ionotropic, NMDA 2D",GRIN2D,Homo sapiens,1336,False,GluN2D|NMDAR2D,MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGPAYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDDSRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLEEYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVSAQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPLPAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESLHRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYGRFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPEKRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVTVFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEKNIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGSGKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKLDIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAEAAPPPAKPPPPPQPLPSPAYPAPRPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADGFHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPPSYFAIVRDKEPAEPPAGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAGGTGGAGGGAPAAPPPCRAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLEPWWFADFPYPYAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHDGLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGWDLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDLGTRRGSAHFSSLESEV,0,,,,,,"Developmental and epileptic encephalopathy 46:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.",Developmental and epileptic encephalopathy 46,Q62936(Dlg3),,,,,,,,,,,,5.0
Q9ULC8,,Palmitoyltransferase ZDHHC8,ZDHHC8,Homo sapiens,765,False,KIAA1292|ZDHHCL1|ZNF378,MPRSPGTRLKPAKYIPVATAAALLVGSSTLFFVFTCPWLTRAVSPAVPVYNGIIFLFVLANFSMATFMDPGVFPRADEDEDKEDDFRAPLYKNVDVRGIQVRMKWCATCHFYRPPRCSHCSVCDNCVEDFDHHCPWVNNCIGRRNYRYFFLFLLSLSAHMVGVVAFGLVYVLNHAEGLGAAHTTITMAVMCVAGLFFIPVIGLTGFHVVLVTRGRTTNEQVTGKFRGGVNPFTRGCCGNVEHVLCSPLAPRYVVEPPRLPLAVSLKPPFLRPELLDRAAPLKVKLSDNGLKAGLGRSKSKGSLDRLDEKPLDLGPPLPPKIEAGTFSSDLQTPRPGSAESALSVQRTSPPTPAMYKFRPAFPTGPKVPFCGPGEQVPGPDSLTLGDDSIRSLDFVSEPSLDLPDYGPGGLHAAYPPSPPLSASDAFSGALRSLSLKASSRRGGDHVALQPLRSEGGPPTPHRSIFAPHALPNRNGSLSYDSLLNPGSPGGHACPAHPAVGVAGYHSPYLHPGATGDPPRPLPRSFSPVLGPRPREPSPVRYDNLSRTIMASIQERKDREERERLLRSQADSLFGDSGVYDAPSSYSLQQASVLSEGPRGPALRYGSRDDLVAGPGFGGARNPALQTSLSSLSSSVSRAPRTSSSSLQADQASSNAPGPRPSSGSHRSPARQGLPSPPGTPHSPSYAGPKAVAFIHTDLPEPPPSLTVQRDHPQLKTPPSKLNGQSPGLARLGPATGPPGPSASPTRHTLVKKVSGVGGTTYEISV,0,,,,,,,,,,1:Q9ULC8-1:|2:Q9ULC8-2:|3:Q9ULC8-3:,,,,,,,,,,5.0
Q9BZR6,,Reticulon-4 receptor,RTN4R,Homo sapiens,473,False,NOGOR,MKRASAGGSRLLAWVLWLQAWQVAAPCPGACVCYNEPKVTTSCPQQGLQAVPVGIPAASQRIFLHGNRISHVPAASFRACRNLTILWLHSNVLARIDAAAFTGLALLEQLDLSDNAQLRSVDPATFHGLGRLHTLHLDRCGLQELGPGLFRGLAALQYLYLQDNALQALPDDTFRDLGNLTHLFLHGNRISSVPERAFRGLHSLDRLLLHQNRVAHVHPHAFRDLGRLMTLYLFANNLSALPTEALAPLRALQYLRLNDNPWVCDCRARPLWAWLQKFRGSSSEVPCSLPQRLAGRDLKRLAANDLQGCAVATGPYHPIWTGRATDEEPLGLPKCCQPDAADKASVLEPGRPASAGNALKGRVPPGDSPPGNGSGPRHINDSPFGTLPGSAEPPLTAVRPEGSEPPGFPTSGPRRRPGCSRKNRTRSHCRLGQAGSGGGGTGDSEGSGALPSLTCSLTPLGLALVLWTVLGPC,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia,P49639(HOXA1)|Q8IZA0(KIAA0319L)|P32242(OTX1),,,,,,,,,,,,5.0
P36222,,Chitinase-3-like protein 1,CHI3L1,Homo sapiens,383,False,,MGVKASQTGFVVLVLLQCCSAYKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISNDHIDTWEWNDVTLYGMLNTLKNRNPNLKTLLSVGGWNFGSQRFSKIASNTQSRRTFIKSVPPFLRTHGFDGLDLAWLYPGRRDKQHFTTLIKEMKAEFIKEAQPGKKQLLLSAALSAGKVTIDSSYDIAKISQHLDFISIMTYDFHGAWRGTTGHHSPLFRGQEDASPDRFSNTDYAVGYMLRLGAPASKLVMGIPTFGRSFTLASSETGVGAPISGPGIPGRFTKEAGTLAYYEICDFLRGATVHRILGQQVPYATKGNQWVGYDDQESVKSKVQYLKDRQLAGAMVWALDLDDFQGSFCGQDLRFPLTNAIKDALAAT,0,,,,,,"Asthma-related traits 7:Asthma-related traits include clinical symptoms of asthma, such as coughing, wheezing, dyspnea, bronchial hyperresponsiveness as assessed by methacholine challenge test, serum IgE levels, atopy and atopic dermatitis.|Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Asthma-related traits 7|Schizophrenia,Q14627(IL13RA2)|P17931(LGALS3),,,,,,,,,,,,5.0
P35462,,D(3) dopamine receptor,DRD3,Homo sapiens,400,False,,MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC,0,,,,,,"Tremor, hereditary essential 1:A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles may also be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.|Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.","Tremor, hereditary essential 1|Schizophrenia",,,1:P35462-1:|3:P35462-3:,,,,,,,,,,5.0
P21964,,Catechol O-methyltransferase,COMT,Homo sapiens,271,False,,MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRILNHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCGYSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKYDVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFECTHYQSFLEYREVVDGLEKAIYKGPGSEAGP,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Schizophrenia,Q6P5T0(AQP7)|P30518(AVPR2)|Q8NFU1(BEST2)|Q8NHW4(CCL4L2)|P34972(CNR2)|Q96BA8(CREB3L1)|P50402(EMD)|Q5JX71(FAM209A)|O14843(FFAR3)|O00258(GET1)|P08034(GJB1)|O75712(GJB3)|Q9NTQ9(GJB4)|O95377(GJB5)|Q8TDT2(GPR152)|Q8N6U8(GPR161)|O15529(GPR42)|P31937(HIBADH)|Q9H2F3(HSD3B7)|O95279(KCNK5)|Q5SR56(MFSD14B)|A6NDP7(MYADML2)|Q0D2K0(NIPAL4)|Q7RTS5(OTOP3)|Q9UHJ9-5(PGAP2)|Q8IY26(PLPP6)|Q9H6H4(REEP4)|Q6NTF9-3(RHBDD2)|O75783(RHBDL1)|Q99500(S1PR3)|Q9Y6D0(SELENOK)|Q3KNW5(SLC10A6)|O60669(SLC16A7)|P22732(SLC2A5)|Q96G79(SLC35A4)|Q5T1Q4(SLC35F1)|Q9NY26(SLC39A1)|Q9NP94(SLC39A2)|Q6P1K1(SLC48A1)|P30825(SLC7A1)|Q9UHI5(SLC7A8)|B2RUZ4(SMIM1)|Q9UPZ6(THSD7A)|Q96MV1(TLCD4)|Q9NV29(TMEM100)|A0PK00(TMEM120B)|Q9NUH8(TMEM14B)|Q9P0S9(TMEM14C)|Q14656(TMEM187)|Q6UW68(TMEM205)|Q9H0R3(TMEM222)|O95807(TMEM50A)|P34981(TRHR)|Q15645(TRIP13)|Q15836(VAMP3)|O95183(VAMP5)|O76024(WFS1)|P30260(CDC27)|Q9H816(DCLRE1B)|Q92997(DVL3)|P29323-3(EPHB2)|P22607(FGFR3)|P06396(GSN)|Q15323(KRT31)|Q6A162(KRT40)|P26371(KRTAP5-9)|O15116(LSM1)|P20645(M6PR)|O14744(PRMT5)|Q5T160(RARS2)|Q9UJD0(RIMS3)|Q2MKA7(RSPO1)|Q8N488(RYBP)|O75880(SCO1)|Q14141(SEPTIN6)|Q9UNE7(STUB1)|Q15645(TRIP13)|Q9NYH9(UTP6)|Q8NA23-2(WDR31),,Membrane-bound:P21964-1:|Soluble:P21964-2:,,,,,,,,,,5.0
P51531,,Probable global transcription activator SNF2L2,SMARCA2,Homo sapiens,1590,False,BAF190B|BRM|SNF2A|SNF2L2,MSTPTDPGAMPHPGPSPGPGPSPGPILGPSPGPGPSPGSVHSMMGPSPGPPSVSHPMPTMGSTDFPQEGMHQMHKPIDGIHDKGIVEDIHCGSMKGTGMRPPHPGMGPPQSPMDQHSQGYMSPHPSPLGAPEHVSSPMSGGGPTPPQMPPSQPGALIPGDPQAMSQPNRGPSPFSPVQLHQLRAQILAYKMLARGQPLPETLQLAVQGKRTLPGLQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPQTQQQQQPALVNYNRPSGPGPELSGPSTPQKLPVPAPGGRPSPAPPAAAQPPAAAVPGPSVPQPAPGQPSPVLQLQQKQSRISPIQKPQGLDPVEILQEREYRLQARIAHRIQELENLPGSLPPDLRTKATVELKALRLLNFQRQLRQEVVACMRRDTTLETALNSKAYKRSKRQTLREARMTEKLEKQQKIEQERKRRQKHQEYLNSILQHAKDFKEYHRSVAGKIQKLSKAVATWHANTEREQKKETERIEKERMRRLMAEDEEGYRKLIDQKKDRRLAYLLQQTDEYVANLTNLVWEHKQAQAAKEKKKRRRRKKKAEENAEGGESALGPDGEPIDESSQMSDLPVKVTHTETGKVLFGPEAPKASQLDAWLEMNPGYEVAPRSDSEESDSDYEEEDEEEESSRQETEEKILLDPNSEEVSEKDAKQIIETAKQDVDDEYSMQYSARGSQSYYTVAHAISERVEKQSALLINGTLKHYQLQGLEWMVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHKRLNGPYLIIVPLSTLSNWTYEFDKWAPSVVKISYKGTPAMRRSLVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRILLTGTPLQNKLPELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGERVDLNEEETILIIRRLHKVLRPFLLRRLKKEVESQLPEKVEYVIKCDMSALQKILYRHMQAKGILLTDGSEKDKKGKGGAKTLMNTIMQLRKICNHPYMFQHIEESFAEHLGYSNGVINGAELYRASGKFELLDRILPKLRATNHRVLLFCQMTSLMTIMEDYFAFRNFLYLRLDGTTKSEDRAALLKKFNEPGSQYFIFLLSTRAGGLGLNLQAADTVVIFDSDWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILEHEEENEEEDEVPDDETLNQMIARREEEFDLFMRMDMDRRREDARNPKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKIFGRGSRQRRDVDYSDALTEKQWLRAIEDGNLEEMEEEVRLKKRKRRRNVDKDPAKEDVEKAKKRRGRPPAEKLSPNPPKLTKQMNAIIDTVINYKDRCNVEKVPSNSQLEIEGNSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCHNAQTFNLEGSQIYEDSIVLQSVFKSARQKIAKEEESEDESNEEEEEEDEEESESEAKSVKVKIKLNKKDDKGRDKGKGKKRPNRGKAKPVVSDFDSDEEQDEREQSEGSGTDDE,0,,,,,,"Nicolaides-Baraitser syndrome:A rare disorder characterized by severe intellectual disability with absent or limited speech, seizures, short stature, sparse hair, typical facial characteristics, brachydactyly, prominent finger joints and broad distal phalanges. Some of the features are progressive with time.|Blepharophimosis-impaired intellectual development syndrome:An autosomal dominant congenital syndrome characterized by blepharophimosis, facial dysmorphism, global development delay, delayed motor skills, impaired intellectual development with poor or absent speech, and behavioral abnormalities in some patients. Additional variable features include distal skeletal anomalies, feeding difficulties with poor growth, respiratory infections, and hypotonia with peripheral spasticity.|Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.",Nicolaides-Baraitser syndrome|Blepharophimosis-impaired intellectual development syndrome|Schizophrenia,O14497(ARID1A)|Q8NFD5(ARID1B)|Q07666(KHDRBS1)|P51608(MECP2)|Q9NRD5(PICK1)|O00560(SDCBP)|Q8TAQ2(SMARCC2)|P04326(tat)|Q8N7W2-2(BEND7)|O00560(SDCBP),,Long:P51531-1:|Short:P51531-2:,,,,,,,,,,5.0
Q96C45,,Serine/threonine-protein kinase ULK4,ULK4,Homo sapiens,1275,False,,MENFILYEEIGRGSKTVVYKGRRKGTINFVAILCTDKCKRPEITNWVRLTREIKHKNIVTFHEWYETSNHLWLVVELCTGGSLKTVIAQDENLPEDVVREFGIDLISGLHHLHKLGILFCDISPRKILLEGPGTLKFSNFCLAKVEGENLEEFFALVAAEEGGGDNGENVLKKSMKSRVKGSPVYTAPEVVRGADFSISSDLWSLGCLLYEMFSGKPPFFSESISELTEKILCEDPLPPIPKDSSRPKASSDFINLLDGLLQRDPQKRLTWTRLLQHSFWKKAFAGADQESSVEDLSLSRNTMECSGPQDSKELLQNSQSRQAKGHKSGQPLGHSFRLENPTEFRPKSTLEGQLNESMFLLSSRPTPRTSTAVEVSPGEDMTHCSPQKTSPLTKITSGHLSQQDLESQMRELIYTDSDLVVTPIIDNPKIMKQPPVKFDAKILHLPTYSVDKLLFLKDQDWNDFLQQVCSQIDSTEKSMGASRAKLNLLCYLCVVAGHQEVATRLLHSPLFQLLIQHLRIAPNWDIRAKVAHVIGLLASHTAELQENTPVVEAIVLLTELIRENFRNSKLKQCLLPTLGELIYLVATQEEKKKNPRECWAVPLAAYTVLMRCLREGEERVVNHMAAKIIENVCTTFSAQSQGFITGEIGPILWYLFRHSTADSLRITAVSALCRITRHSPTAFQNVIEKVGLNSVINSLASAICKVQQYMLTLFAAMLSCGIHLQRLIQEKGFVSTIIRLLDSPSTCIRAKAFLVLLYILIYNREMLLLSCQARLVMYIERDSRKTTPGKEQQSGNEYLSKCLDLLICHIVQELPRILGDILNSLANVSGRKHPSTVQVKQLKLCLPLMPVVLHLVTSQVFRPQVVTEEFLFSYGTILSHIKSVDSGETNIDGAIGLTASEEFIKITLSAFEAIIQYPILLKDYRSTVVDYILPPLVSLVQSQNVEWRLFSLRLLSETTSLLVNQEFGDGKEKASVDSDSNLLALIRDVLLPQYEHILLEPDPVPAYALKLLVAMTEHNPTFTRLVEESKLIPLIFEVTLEHQESILGNTMQSVIALLSNLVACKDSNMELLYEQGLVSHICNLLTETATLCLDVDNKNNNEMAAPLLFSLLDILHSMLTYTSGIVRLALQAQKSGSGEDPQAAEDLLLLNRPLTDLISLLIPLLPNEDPEIFDVSSKCLSILVQLYGGENPDSLSPENVEIFAHLLTSKEDPKEQKLLLRILRRMITSNEKHLESLKNAGSLLRALERLAPGSGSFADSAVAPLALEILQAVGH,0,,,,,,:,,Q6AI12(ANKRD40),,,,,,,,,,,,5.0
P42898,,Methylenetetrahydrofolate reductase (NADPH),MTHFR,Homo sapiens,656,False,,MVNEARGNSSLNPCLEGSASSGSESSKDSSRCSTPGLDPERHERLREKMRRRLESGDKWFSLEFFPPRTAEGAVNLISRFDRMAAGGPLYIDVTWHPAGDPGSDKETSSMMIASTAVNYCGLETILHMTCCRQRLEEITGHLHKAKQLGLKNIMALRGDPIGDQWEEEEGGFNYAVDLVKHIRSEFGDYFDICVAGYPKGHPEAGSFEADLKHLKEKVSAGADFIITQLFFEADTFFRFVKACTDMGITCPIVPGIFPIQGYHSLRQLVKLSKLEVPQEIKDVIEPIKDNDAAIRNYGIELAVSLCQELLASGLVPGLHFYTLNREMATTEVLKRLGMWTEDPRRPLPWALSAHPKRREEDVRPIFWASRPKSYIYRTQEWDEFPNGRWGNSSSPAFGELKDYYLFYLKSKSPKEELLKMWGEELTSEESVFEVFVLYLSGEPNRNGHKVTCLPWNDEPLAAETSLLKEELLRVNRQGILTINSQPNINGKPSSDPIVGWGPSGGYVFQKAYLEFFTSRETAEALLQVLKKYELRVNYHLVNVKGENITNAPELQPNAVTWGIFPGREIIQPTVVDPVSFMFWKDEAFALWIERWGKLYEEESPSRTIIQYIHDNYFLVNLVDNDFPLDNCLWQVVEDTLELLNRPTQNARETEAP,0,,,,,,"Homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase activity:An autosomal recessive inborn error of folate metabolism. Clinical severity is variable, ranging from severe neurologic features to absence of symptoms. Clinical features include homocysteinuria, homocysteinemia, developmental delay, severe intellectual disability, perinatal death, psychiatric disturbances, and later-onset neurodegenerative disorders.|Ischemic stroke:A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.|Neural tube defects, folate-sensitive:The most common NTDs are open spina bifida (myelomeningocele) and anencephaly.|Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.","Homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase activity|Ischemic stroke|Neural tube defects, folate-sensitive|Schizophrenia",O60906(SMPD2),,1:P42898-1:|2:P42898-2:,,,,,,,,,,5.0
P14920,,D-amino-acid oxidase,DAO,Homo sapiens,347,False,DAMOX,MRVVVIGAGVIGLSTALCIHERYHSVLQPLDIKVYADRFTPLTTTDVAAGLWQPYLSDPNNPQEADWSQQTFDYLLSHVHSPNAENLGLFLISGYNLFHEAIPDPSWKDTVLGFRKLTPRELDMFPDYGYGWFHTSLILEGKNYLQWLTERLTERGVKFFQRKVESFEEVAREGADVIVNCTGVWAGALQRDPLLQPGRGQIMKVDAPWMKHFILTHDPERGIYNSPYIIPGTQTVTLGGIFQLGNWSELNNIQDHNTIWEGCCRLEPTLKNARIIGERTGFRPVRPQIRLEREQLRTGPSNTEVIHNYGHGGYGLTIHWGCALEAAKLFGRILEEKKLSRMPPSHL,0,,,,,,"Schizophrenia:A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.|Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Schizophrenia|Amyotrophic lateral sclerosis,Q9P2K6(KLHL42)|O43741(PRKAB2),,,,,,,,,,,,5.0
O14810,,Complexin-1,CPLX1,Homo sapiens,134,False,,MEFVMKQALGGATKDMGKMLGGDEEKDPDAAKKEEERQEALRQAEEERKAKYAKMEAEREAVRQGIRDKYGIKKKEEREAEAQAAMEANSEGSLTRPKKAIPPGCGDEVEEEDESILDTVIKYLPGPLQDMLKK,0,,,,,,"Developmental and epileptic encephalopathy 63:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE63 is an autosomal recessive disease with onset in infancy.",Developmental and epileptic encephalopathy 63,P60880-2(SNAP25),,,,,,,,,,,,5.0
P47870,,Gamma-aminobutyric acid receptor subunit beta-2,GABRB2,Homo sapiens,512,False,,MWRVRKRGYFGIWSFPLIIAAVCAQSVNDPSNMSLVKETVDRLLKGYDIRLRPDFGGPPVAVGMNIDIASIDMVSEVNMDYTLTMYFQQAWRDKRLSYNVIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGDDNAVTGVTKIELPQFSIVDYKLITKKVVFSTGSYPRLSLSFKLKRNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIPYVKAIDMYLMGCFVFVFMALLEYALVNYIFFGRGPQRQKKAAEKAASANNEKMRLDVNKIFYKDIKQNGTQYRSLWDPTGNLSPTRRTTNYDFSLYTMDPHENILLSTLEIKNEMATSEAVMGLGDPRSTMLAYDASSIQYRKAGLPRHSFGRNALERHVAQKKSRLRRRASQLKITIPDLTDVNAIDRWSRIFFPVVFSFFNIVYWLYYVN,0,,,,,,"Epileptic encephalopathy, infantile or early childhood, 2:A form of epileptic encephalopathy, a heterogeneous group of severe childhood onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. IECEE2 is an autosomal dominant condition with variable age at seizure onset, ranging from early infancy to 6 years.","Epileptic encephalopathy, infantile or early childhood, 2",,,1:P47870-2:|2:P47870-1:|3:P47870-3:|4:P47870-4:,,,,,,,,,,5.0
P78509,,Reelin,RELN,Homo sapiens,3460,False,,MERSGWARQTFLLALLLGATLRARAAAGYYPRFSPFFFLCTHHGELEGDGEQGEVLISLHIAGNPTYYVPGQEYHVTISTSTFFDGLLVTGLYTSTSVQASQSIGGSSAFGFGIMSDHQFGNQFMCSVVASHVSHLPTTNLSFIWIAPPAGTGCVNFMATATHRGQVIFKDALAQQLCEQGAPTDVTVHPHLAEIHSDSIILRDDFDSYHQLQLNPNIWVECNNCETGEQCGAIMHGNAVTFCEPYGPRELITTGLNTTTASVLQFSIGSGSCRFSYSDPSIIVLYAKNNSADWIQLEKIRAPSNVSTIIHILYLPEDAKGENVQFQWKQENLRVGEVYEACWALDNILIINSAHRQVVLEDSLDPVDTGNWLFFPGATVKHSCQSDGNSIYFHGNEGSEFNFATTRDVDLSTEDIQEQWSEEFESQPTGWDVLGAVIGTECGTIESGLSMVFLKDGERKLCTPSMDTTGYGNLRFYFVMGGICDPGNSHENDIILYAKIEGRKEHITLDTLSYSSYKVPSLVSVVINPELQTPATKFCLRQKNHQGHNRNVWAVDFFHVLPVLPSTMSHMIQFSINLGCGTHQPGNSVSLEFSTNHGRSWSLLHTECLPEICAGPHLPHSTVYSSENYSGWNRITIPLPNAALTRNTRIRWRQTGPILGNMWAIDNVYIGPSCLKFCSGRGQCTRHGCKCDPGFSGPACEMASQTFPMFISESFGSSRLSSYHNFYSIRGAEVSFGCGVLASGKALVFNKDGRRQLITSFLDSSQSRFLQFTLRLGSKSVLSTCRAPDQPGEGVLLHYSYDNGITWKLLEHYSYLSYHEPRIISVELPGDAKQFGIQFRWWQPYHSSQREDVWAIDEIIMTSVLFNSISLDFTNLVEVTQSLGFYLGNVQPYCGHDWTLCFTGDSKLASSMRYVETQSMQIGASYMIQFSLVMGCGQKYTPHMDNQVKLEYSTNHGLTWHLVQEECLPSMPSCQEFTSASIYHASEFTQWRRVIVLLPQKTWSSATRFRWSQSYYTAQDEWALDSIYIGQQCPNMCSGHGSCDHGICRCDQGYQGTECHPEAALPSTIMSDFENQNGWESDWQEVIGGEIVKPEQGCGVISSGSSLYFSKAGKRQLVSWDLDTSWVDFVQFYIQIGGESASCNKPDSREEGVLLQYSNNGGIQWHLLAEMYFSDFSKPRFVYLELPAAAKTPCTRFRWWQPVFSGEDYDQWAVDDIIILSEKQKQIIPVINPTLPQNFYEKPAFDYPMNQMSVWLMLANEGMVKNETFCAATPSAMIFGKSDGDRFAVTRDLTLKPGYVLQFKLNIGCANQFSSTAPVLLQYSHDAGMSWFLVKEGCYPASAGKGCEGNSRELSEPTMYHTGDFEEWTRITIVIPRSLASSKTRFRWIQESSSQKNVPPFGLDGVYISEPCPSYCSGHGDCISGVCFCDLGYTAAQGTCVSNVPNHNEMFDRFEGKLSPLWYKITGAQVGTGCGTLNDGKSLYFNGPGKREARTVPLDTRNIRLVQFYIQIGSKTSGITCIKPRTRNEGLIVQYSNDNGILWHLLRELDFMSFLEPQIISIDLPQDAKTPATAFRWWQPQHGKHSAQWALDDVLIGMNDSSQTGFQDKFDGSIDLQANWYRIQGGQVDIDCLSMDTALIFTENIGKPRYAETWDFHVSASTFLQFEMSMGCSKPFSNSHSVQLQYSLNNGKDWHLVTEECVPPTIGCLHYTESSIYTSERFQNWKRITVYLPLSTISPRTRFRWIQANYTVGADSWAIDNVVLASGCPWMCSGRGICDAGRCVCDRGFGGPYCVPVVPLPSILKDDFNGNLHPDLWPEVYGAERGNLNGETIKSGTSLIFKGEGLRMLISRDLDCTNTMYVQFSLRFIAKSTPERSHSILLQFSISGGITWHLMDEFYFPQTTNILFINVPLPYTAQTNATRFRLWQPYNNGKKEEIWIVDDFIIDGNNVNNPVMLLDTFDFGPREDNWFFYPGGNIGLYCPYSSKGAPEEDSAMVFVSNEVGEHSITTRDLNVNENTIIQFEINVGCSTDSSSADPVRLEFSRDFGATWHLLLPLCYHSSSHVSSLCSTEHHPSSTYYAGTMQGWRREVVHFGKLHLCGSVRFRWYQGFYPAGSQPVTWAIDNVYIGPQCEEMCNGQGSCINGTKCICDPGYSGPTCKISTKNPDFLKDDFEGQLESDRFLLMSGGKPSRKCGILSSGNNLFFNEDGLRMLMTRDLDLSHARFVQFFMRLGCGKGVPDPRSQPVLLQYSLNGGLSWSLLQEFLFSNSSNVGRYIALEIPLKARSGSTRLRWWQPSENGHFYSPWVIDQILIGGNISGNTVLEDDFTTLDSRKWLLHPGGTKMPVCGSTGDALVFIEKASTRYVVSTDVAVNEDSFLQIDFAASCSVTDSCYAIELEYSVDLGLSWHPLVRDCLPTNVECSRYHLQRILVSDTFNKWTRITLPLPPYTRSQATRFRWHQPAPFDKQQTWAIDNVYIGDGCIDMCSGHGRCIQGNCVCDEQWGGLYCDDPETSLPTQLKDNFNRAPSSQNWLTVNGGKLSTVCGAVASGMALHFSGGCSRLLVTVDLNLTNAEFIQFYFMYGCLITPNNRNQGVLLEYSVNGGITWNLLMEIFYDQYSKPGFVNILLPPDAKEIATRFRWWQPRHDGLDQNDWAIDNVLISGSADQRTVMLDTFSSAPVPQHERSPADAGPVGRIAFDMFMEDKTSVNEHWLFHDDCTVERFCDSPDGVMLCGSHDGREVYAVTHDLTPTEGWIMQFKISVGCKVSEKIAQNQIHVQYSTDFGVSWNYLVPQCLPADPKCSGSVSQPSVFFPTKGWKRITYPLPESLVGNPVRFRFYQKYSDMQWAIDNFYLGPGCLDNCRGHGDCLREQCICDPGYSGPNCYLTHTLKTFLKERFDSEEIKPDLWMSLEGGSTCTECGILAEDTALYFGGSTVRQAVTQDLDLRGAKFLQYWGRIGSENNMTSCHRPICRKEGVLLDYSTDGGITWTLLHEMDYQKYISVRHDYILLPEDALTNTTRLRWWQPFVISNGIVVSGVERAQWALDNILIGGAEINPSQLVDTFDDEGTSHEENWSFYPNAVRTAGFCGNPSFHLYWPNKKKDKTHNALSSRELIIQPGYMMQFKIVVGCEATSCGDLHSVMLEYTKDARSDSWQLVQTQCLPSSSNSIGCSPFQFHEATIYNSVNSSSWKRITIQLPDHVSSSATQFRWIQKGEETEKQSWAIDHVYIGEACPKLCSGHGYCTTGAICICDESFQGDDCSVFSHDLPSYIKDNFESARVTEANWETIQGGVIGSGCGQLAPYAHGDSLYFNGCQIRQAATKPLDLTRASKIMFVLQIGSMSQTDSCNSDLSGPHAVDKAVLLQYSVNNGITWHVIAQHQPKDFTQAQRVSYNVPLEARMKGVLLRWWQPRHNGTGHDQWALDHVEVVLVSTRKQNYMMNFSRQHGLRHFYNRRRRSLRRYP,0,,,,,,"Lissencephaly 2:A classic type lissencephaly associated with ataxia, intellectual disability, seizures and abnormalities of the cerebellum, hippocampus and brainstem.|Epilepsy, familial temporal lobe, 7:A focal form of epilepsy characterized by recurrent seizures that arise from foci within the temporal lobe. Seizures are usually accompanied by sensory symptoms, most often auditory in nature.","Lissencephaly 2|Epilepsy, familial temporal lobe, 7",,,1:P78509-1:|2:P78509-2:|3:P78509-3:,,,,,,,,,,5.0
Q8WZ19,,BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 1,KCTD13,Homo sapiens,329,False,BACURD1|PDIP1|POLDIP1,MSAEASGPAAAAAPSLEAPKPSGLEPGPAAYGLKPLTPNSKYVKLNVGGSLHYTTLRTLTGQDTMLKAMFSGRVEVLTDAGGWVLIDRSGRHFGTILNYLRDGSVPLPESTRELGELLGEARYYLVQGLIEDCQLALQQKRETLSPLCLIPMVTSPREEQQLLASTSKPVVKLLHNRSNNKYSYTSTSDDNLLKNIELFDKLALRFHGRLLFLKDVLGDEICCWSFYGQGRKIAEVCCTSIVYATEKKQTKVEFPEARIFEETLNILIYETPRGPDPALLEATGGAAGAGGAGRGEDEENREHRVRRIHVRRHITHDERPHGQQIVFKD,0,,,,,,:,,Q9H6L4(ARMC7)|O95817(BAG3)|Q16543(CDC37)|Q13618(CUL3)|Q9NQT4(EXOSC5)|P21333-2(FLNA)|P51114(FXR1)|Q9H8Y8(GORASP2)|P04792(HSPB1)|Q9H3F6(KCTD10)|Q8WZ19(KCTD13)|O60333-2(KIF1B)|Q8TBB1(LNX1)|P31153(MAT2A)|Q96HA8(NTAQ1)|Q8N2W9(PIAS4)|O15160(POLR1C)|P60891(PRPS1)|P25786(PSMA1)|Q9Y3C5(RNF11)|Q13829(TNFAIP1)|O76024(WFS1)|Q96E35(ZMYND19),,,,,,,,,,,,5.0
Q96EV8,,Dysbindin,DTNBP1,Homo sapiens,351,False,BLOC1S8,MLETLRERLLSVQQDFTSGLKTLSDKSREAKVKSKPRTVPFLPKYSAGLELLSRYEDTWAALHRRAKDCASAGELVDSEVVMLSAHWEKKKTSLVELQEQLQQLPALIADLESMTANLTHLEASFEEVENNLLHLEDLCGQCELERCKHMQSQQLENYKKNKRKELETFKAELDAEHAQKVLEMEHTQQMKLKERQKFFEEAFQQDMEQYLSTGYLQIAERREPIGSMSSMEVNVDMLEQMDLMDISDQEALDVFLNSGGEENTVLSPALGPESSTCQNEITLQVPNPSELRAKPPSSSSTCTDSATRDISEGGESPVVQSDEEEVQVDTALATSHTDREATPDGGEDSDS,0,,,,,,"Hermansky-Pudlak syndrome 7:A form of Hermansky-Pudlak syndrome, a genetically heterogeneous autosomal recessive disorder characterized by oculocutaneous albinism, bleeding due to platelet storage pool deficiency, and lysosomal storage defects. This syndrome results from defects of diverse cytoplasmic organelles including melanosomes, platelet dense granules and lysosomes. Ceroid storage in the lungs is associated with pulmonary fibrosis, a common cause of premature death in individuals with HPS.|:",Hermansky-Pudlak syndrome 7,Q8TDH9(BLOC1S5)|Q9UL45(BLOC1S6)|Q8WUW1(BRK1)|Q8IYE0-2(CCDC146)|Q8TD31-3(CCHCR1)|Q494R4(DRC12)|O60941(DTNB)|A1L3X0(ELOVL7)|Q96CS2(HAUS1)|Q8IY31(IFT20)|Q7Z3B3(KANSL1)|Q9BVG8(KIFC3)|O95678(KRT75)|Q7Z6G3-2(NECAB2)|O43482(OIP5)|Q7Z4N8(P4HA3)|O00560(SDCBP)|Q9NUL5(SHFL)|O95295(SNAPIN)|A1L4H1(SSC5D)|Q9NX95(SYBU)|P14373(TRIM27)|Q8N3L3(TXLNB)|Q9Y3C0(WASHC3)|P13010(XRCC5),,1:Q96EV8-1:|2:Q96EV8-2:|3:Q96EV8-3:,,,,,,,,,,5.0
Q13224,,"Glutamate receptor ionotropic, NMDA 2B",GRIN2B,Homo sapiens,1484,False,NMDAR2B,MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFHHLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTLTPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQDFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYIFEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAIITTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHPKLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVESVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYLVTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSRSNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSFTIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYVDQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLSLKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAILQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEHLFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILRLLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFSDYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISKKPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKRRKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTKENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKNLTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSLQELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPRSVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPDRVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPARFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV,0,,,,,,"Intellectual developmental disorder, autosomal dominant 6, with or without seizures:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD6 additional features may include seizures, hypotonia, abnormal movements, such as dystonia, and autistic features.|Developmental and epileptic encephalopathy 27:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.|:","Intellectual developmental disorder, autosomal dominant 6, with or without seizures|Developmental and epileptic encephalopathy 27",Q9UQM7(CAMK2A)|Q12959(DLG1)|P78352(DLG4)|Q05586-1(GRIN1)|Q62936(Dlg3)|P31016(Dlg4)|P62139(PPP1CA),,,,,,,,,,,,5.0
Q5JVL4,,EF-hand domain-containing protein 1,EFHC1,Homo sapiens,640,False,,MVSNPVHGLPFLPGTSFKDSTKTAFHRSQTLSYRNGYAIVRRPTVGIGGDRLQFNQLSQAELDELASKAPVLTYGQPKQAPPADFIPAHVAFDKKVLKFDAYFQEDVPMSTEEQYRIRQVNIYYYLEDDSMSVIEPVVENSGILQGKLIKRQRLAKNDRGDHYHWKDLNRGINITIYGKTFRVVDCDQFTQVFLESQGIELNPPEKMALDPYTELRKQPLRKYVTPSDFDQLKQFLTFDKQVLRFYAIWDDTDSMYGECRTYIIHYYLMDDTVEIREVHERNDGRDPFPLLMNRQRVPKVLVENAKNFPQCVLEISDQEVLEWYTAKDFIVGKSLTILGRTFFIYDCDPFTRRYYKEKFGITDLPRIDVSKREPPPVKQELPPYNGFGLVEDSAQNCFALIPKAPKKDVIKMLVNDNKVLRYLAVLESPIPEDKDRRFVFSYFLATDMISIFEPPVRNSGIIGGKYLGRTKVVKPYSTVDNPVYYGPSDFFIGAVIEVFGHRFIILDTDEYVLKYMESNAAQYSPEALASIQNHVRKREAPAPEAESKQTEKDPGVQELEALIDTIQKQLKDHSCKDNIREAFQIYDKEASGYVDRDMFFKICESLNVPVDDSLVKELIRMCSHGEGKINYYNFVRAFSN,0,,,,,,"Juvenile myoclonic epilepsy 1:A subtype of idiopathic generalized epilepsy. Patients have afebrile seizures only, with onset in adolescence (rather than in childhood) and myoclonic jerks which usually occur after awakening and are triggered by sleep deprivation and fatigue.|Juvenile absence epilepsy 1:A subtype of idiopathic generalized epilepsy characterized by onset occurring around puberty, absence seizures, generalized tonic-clonic seizures (GTCS), GTCS on awakening, and myoclonic seizures.|:",Juvenile myoclonic epilepsy 1|Juvenile absence epilepsy 1,Q7Z569(BRAP)|Q13137(CALCOCO2)|Q6P656(CFAP161)|Q9NX63(CHCHD3)|Q9H1P6(CIMIP1)|Q5JST6(EFHC2)|Q9NRA8(EIF4ENIF1)|Q8IXW7(FMR1)|O75293(GADD45B)|Q8NHY3(GAS2L2)|Q08379(GOLGA2)|Q9NSC5(HOMER3)|Q8IYA8(IHO1)|Q9UKT9(IKZF3)|Q9NV31(IMP3)|Q13352(ITGB3BP)|Q8TAV5(KCNJ5-AS1)|Q8WVF5(KCTD4)|O14901(KLF11)|P19012(KRT15)|P05783(KRT18)|O95678(KRT75)|P25791-3(LMO2)|Q9BV99(LRRC61)|Q7Z304(MAMDC2)|Q8WWY6(MBD3L1)|Q8N6F8(METTL27)|Q5JXC2(MIIP)|Q6NTE8(MRNIP)|Q9H019(MTFR1L)|P16083(NQO2)|Q9NQ35(NRIP3)|Q7Z3B4(NUP54)|O43482(OIP5)|P26367(PAX6)|P40424(PBX1)|P40425(PBX2)|Q6P1K2(PMF1)|Q6MZQ0(PRR5L)|Q15293(RCN1)|Q04864(REL)|Q04864-2(REL)|Q9UFD9(RIMBP3)|Q5SSQ6-2(SAPCD1)|P59797(SELENOV)|Q9NR46(SH3GLB2)|Q8ND83(SLAIN1)|O95863(SNAI1)|O60504(SORBS3)|Q9UM82(SPATA2)|Q96PV0(SYNGAP1)|P15884(TCF4)|P15884-3(TCF4)|Q969V4(TEKT1)|Q8IYF3-3(TEX11)|Q08117-2(TLE5)|Q05BL1(TP53BP2)|Q12933(TRAF2)|Q15654(TRIP6)|Q3SY00(TSGA10IP)|Q6PF05(TTC23L)|Q5T6F2(UBAP2)|P61758(VBP1)|Q92558(WASF1)|Q9P202(WHRN)|P13994(YJU2B)|O96006(ZBED1),,1:Q5JVL4-1:|2:Q5JVL4-2:|3:Q5JVL4-3:,,,,,,,,,,5.0
P16615,,Sarcoplasmic/endoplasmic reticulum calcium ATPase 2,ATP2A2,Homo sapiens,1042,False,ATP2B,MENAHTKTVEEVLGHFGVNESTGLSLEQVKKLKERWGSNELPAEEGKTLLELVIEQFEDLLVRILLLAACISFVLAWFEEGEETITAFVEPFVILLILVANAIVGVWQERNAENAIEALKEYEPEMGKVYRQDRKSVQRIKAKDIVPGDIVEIAVGDKVPADIRLTSIKSTTLRVDQSILTGESVSVIKHTDPVPDPRAVNQDKKNMLFSGTNIAAGKAMGVVVATGVNTEIGKIRDEMVATEQERTPLQQKLDEFGEQLSKVISLICIAVWIINIGHFNDPVHGGSWIRGAIYYFKIAVALAVAAIPEGLPAVITTCLALGTRRMAKKNAIVRSLPSVETLGCTSVICSDKTGTLTTNQMSVCRMFILDRVEGDTCSLNEFTITGSTYAPIGEVHKDDKPVNCHQYDGLVELATICALCNDSALDYNEAKGVYEKVGEATETALTCLVEKMNVFDTELKGLSKIERANACNSVIKQLMKKEFTLEFSRDRKSMSVYCTPNKPSRTSMSKMFVKGAPEGVIDRCTHIRVGSTKVPMTSGVKQKIMSVIREWGSGSDTLRCLALATHDNPLRREEMHLEDSANFIKYETNLTFVGCVGMLDPPRIEVASSVKLCRQAGIRVIMITGDNKGTAVAICRRIGIFGQDEDVTSKAFTGREFDELNPSAQRDACLNARCFARVEPSHKSKIVEFLQSFDEITAMTGDGVNDAPALKKAEIGIAMGSGTAVAKTASEMVLADDNFSTIVAAVEEGRAIYNNMKQFIRYLISSNVGEVVCIFLTAALGFPEALIPVQLLWVNLVTDGLPATALGFNPPDLDIMNKPPRNPKEPLISGWLFFRYLAIGCYVGAATVGAAAWWFIAADGGPRVSFYQLSHFLQCKEDNPDFEGVDCAIFESPYPMTMALSVLVTIEMCNALNSLSENQSLLRMPPWENIWLVGSICLSMSLHFLILYVEPLPLIFQITPLNVTQWLMVLKISLPVILMDETLKFVARNYLEPGKECVQPATKSCSFSACTDGISWPFVLLIMPLVIWVYSTDTNFSDMFWS,0,,,,,,"Acrokeratosis verruciformis:A localized disorder of keratinization, which is inherited as an autosomal dominant trait. Its onset is early in life with multiple flat-topped, flesh-colored papules on the hands and feet, punctate keratoses on the palms and soles, with varying degrees of nail involvement. The histopathology shows a distinctive pattern of epidermal features with hyperkeratosis, hypergranulosis and acanthosis together with papillomatosis. These changes are frequently associated with circumscribed elevations of the epidermis that are said to resemble church spires. There are no features of dyskeratosis or acantholysis, the typical findings in lesions of Darier disease.|Darier disease:A skin disorder characterized by warty papules and plaques in seborrheic areas (central trunk, flexures, scalp and forehead), palmoplantar pits and distinctive nail abnormalities. It is due to loss of adhesion between epidermal cells (acantholysis) and abnormal keratinization. Patients with mild disease may have no more than a few scattered keratotic papules or subtle nail changes, whereas those with severe disease are handicapped by widespread malodorous keratotic plaques. Some patients present with hemorrhage into acantholytic vesicles on the palms and dorsal aspects of the fingers which gives rise to black macules. In a few families affected by Darier disease, neuropsychiatric abnormalities such as mild intellectual disability, schizophrenia, bipolar disorder and epilepsy have been reported. Stress, UV exposure, heat, sweat, friction and oral contraception exacerbate disease symptoms. Clinical variants of Darier disease include hypertrophic, vesicobullous, hypopigmented, cornifying, zosteriform or linear, acute and comedonal subtypes. Comedonal Darier disease is characterized by the coexistence of acne-like comedonal lesions with typical Darier hyperkeratotic papules on light-exposed areas. At histopathologic level, comedonal Darier disease differs from classic Darier disease in the prominent follicular involvement and the presence of greatly elongated dermal villi.",Acrokeratosis verruciformis|Darier disease,P55085(F2RL1)|P41143(OPRD1)|O76024(WFS1)|P13569(CFTR)|E2JF22(Piezo1),,1:P16615-1:|2:P16615-2:|3:P16615-3:|4:P16615-4:|5:P16615-5:,,,,,,,,,,5.0
Q96MT3,,Prickle-like protein 1,PRICKLE1,Homo sapiens,831,False,RILP,MPLEMEPKMSKLAFGCQRSSTSDDDSGCALEEYAWVPPGLRPEQIQLYFACLPEEKVPYVNSPGEKHRIKQLLYQLPPHDNEVRYCQSLSEEEKKELQVFSAQRKKEALGRGTIKLLSRAVMHAVCEQCGLKINGGEVAVFASRAGPGVCWHPSCFVCFTCNELLVDLIYFYQDGKIHCGRHHAELLKPRCSACDEIIFADECTEAEGRHWHMKHFCCLECETVLGGQRYIMKDGRPFCCGCFESLYAEYCETCGEHIGVDHAQMTYDGQHWHATEACFSCAQCKASLLGCPFLPKQGQIYCSKTCSLGEDVHASDSSDSAFQSARSRDSRRSVRMGKSSRSADQCRQSLLLSPALNYKFPGLSGNADDTLSRKLDDLSLSRQGTSFASEEFWKGRVEQETPEDPEEWADHEDYMTQLLLKFGDKSLFQPQPNEMDIRASEHWISDNMVKSKTELKQNNQSLASKKYQSDMYWAQSQDGLGDSAYGSHPGPASSRRLQELELDHGASGYNHDETQWYEDSLECLSDLKPEQSVRDSMDSLALSNITGASVDGENKPRPSLYSLQNFEEMETEDCEKMSNMGTLNSSMLHRSAESLKSLSSELCPEKILPEEKPVHLPVLRRSKSQSRPQQVKFSDDVIDNGNYDIEIRQPPMSERTRRRVYNFEERGSRSHHHRRRRSRKSRSDNALNLVTERKYSPKDRLRLYTPDNYEKFIQNKSAREIQAYIQNADLYGQYAHATSDYGLQNPGMNRFLGLYGEDDDSWCSSSSSSSDSEEEGYFLGQPIPQPRPQRFAYYTDDLSSPPSALPTPQFGQRTTKSKKKKGHKGKNCIIS,0,,,,,,"Epilepsy, progressive myoclonic 1B:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM1B is an autosomal recessive form characterized by myoclonus that progressed in severity over time, tonic-clonic seizures and ataxia.|Neural tube defects:Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy. Failure of neural tube closure can occur at any level of the embryonic axis. Common NTD forms include anencephaly, myelomeningocele and spina bifida, which result from the failure of fusion in the cranial and spinal region of the neural tube. NTDs have a multifactorial etiology encompassing both genetic and environmental components.","Epilepsy, progressive myoclonic 1B|Neural tube defects",Q13895(BYSL)|Q92997(DVL3)|O75564-2(JRK)|Q9HAQ2(KIF9)|Q8WWY3(PRPF31)|Q08E77(UTP14C)|Q8VIG1(Rest),,,,,,,,,,,,5.0
Q14831,,Metabotropic glutamate receptor 7,GRM7,Homo sapiens,915,False,GPRC1G|MGLUR7,MVQLRKLLRVLTLMKFPCCVLEVLLCALAAAARGQEMYAPHSIRIEGDVTLGGLFPVHAKGPSGVPCGDIKRENGIHRLEAMLYALDQINSDPNLLPNVTLGARILDTCSRDTYALEQSLTFVQALIQKDTSDVRCTNGEPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQIPQISYASTAPELSDDRRYDFFSRVVPPDSFQAQAMVDIVKALGWNYVSTLASEGSYGEKGVESFTQISKEAGGLCIAQSVRIPQERKDRTIDFDRIIKQLLDTPNSRAVVIFANDEDIKQILAAAKRADQVGHFLWVGSDSWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAYFTSRTLENNRRNVWFAEYWEENFNCKLTISGSKKEDTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMAHALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRNVNFNGSAGTPVMFNKNGDAPGRYDIFQYQTTNTSNPGYRLIGQWTDELQLNIEDMQWGKGVREIPASVCTLPCKPGQRKKTQKGTPCCWTCEPCDGYQYQFDEMTCQHCPYDQRPNENRTGCQDIPIIKLEWHSPWAVIPVFLAMLGIIATIFVMATFIRYNDTPIVRASGRELSYVLLTGIFLCYIITFLMIAKPDVAVCSFRRVFLGLGMCISYAALLTKTNRIYRIFEQGKKSVTAPRLISPTSQLAITSSLISVQLLGVFIWFGVDPPNIIIDYDEHKTMNPEQARGVLKCDITDLQIICSLGYSILLMVTCTVYAIKTRGVPENFNEAKPIGFTMYTTCIVWLAFIPIFFGTAQSAEKLYIQTTTLTISMNLSASVALGMLYMPKVYIIIFHPELNVQKRKRSFKAVVTAATMSSRLSHKPSDRPNGEAKTELCENVDPNSPAAKKKYVSYNNLVI,0,,,,,,"Neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities:An autosomal recessive neurodevelopmental disorder characterized by global developmental delay, hypotonia, severe to profound intellectual disability, early-onset epilepsy, and microcephaly. Neuroimaging shows cerebral atrophy, thin corpus callosum and hypomyelination in a majority of cases. Death in childhood may occur.","Neurodevelopmental disorder with seizures, hypotonia, and brain imaging abnormalities",,,1:Q14831-1:|2:Q14831-2:|3:Q14831-3:|4:Q14831-4:|5:Q14831-5:,,,,,,,,,,5.0
P18505,,Gamma-aminobutyric acid receptor subunit beta-1,GABRB1,Homo sapiens,474,False,,MWTVQNRESLGLLSFPVMITMVCCAHSTNEPSNMSYVKETVDRLLKGYDIRLRPDFGGPPVDVGMRIDVASIDMVSEVNMDYTLTMYFQQSWKDKRLSYSGIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWNGGEGAVTGVNKIELPQFSIVDYKMVSKKVEFTTGAYPRLSLSFRLKRNIGYFILQTYMPSTLITILSWVSFWINYDASAARVALGITTVLTMTTISTHLRETLPKIPYVKAIDIYLMGCFVFVFLALLEYAFVNYIFFGKGPQKKGASKQDQSANEKNKLEMNKVQVDAHGNILLSTLEIRNETSGSEVLTSVSDPKATMYSYDSASIQYRKPLSSREAYGRALDRHGVPSKGRIRRRASQLKVKIPDLTDVNSIDKWSRMFFPITFSLFNVVYWLYYVH,0,,,,,,"Developmental and epileptic encephalopathy 45:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.",Developmental and epileptic encephalopathy 45,,,1:P18505-1:|2:P18505-2:,,,,,,,,,,5.0
P35498,,Sodium channel protein type 1 subunit alpha,SCN1A,Homo sapiens,2009,False,NAC1|SCN1,MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTPFNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKIIARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPPTNASLEEHSIEKNITVNYNGTLINETVFEFDWKSYIQDSRYHYFLEGFLDALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLKKQQEAAQQAATATASEHSREPSAAGRLSDSSSEASKLSSKSAKERRNRRKKRKQKEQSGGEEKDEDEFQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFSPRRNSRTSLFSFRGRAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNLSQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLPEVIIDKPATDDNGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNTVEELEESRQKCPPCWYKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNNVLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKDCVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSFIRKQKILDEIKPLDDLNNKKDSCMSNHTAEIGKDLDYLKDVNGTTSGIGTGSSVEKYIIDESDYMSFINNPSLTVTVPIAVGESDFENLNTEDFSSESDLEESKEKLNESSSSSEGSTVDIGAPVEEQPVVEPEETLEPEACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFEDIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINTTTGDRFDIEDVNNHTDCLKLIERNETARWKNVKVNFDNVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLRHYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALEPPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIKGGANLLIKEDMIIDRINENSITEKTDLTMSTAACPPSYDRVTKPIVEKHEQEGKDEKAKGK,0,,,,,,"Generalized epilepsy with febrile seizures plus 2:A rare autosomal dominant, familial condition with incomplete penetrance and large intrafamilial variability. Patients display febrile seizures persisting sometimes beyond the age of 6 years and/or a variety of afebrile seizure types. This disease combines febrile seizures, generalized seizures often precipitated by fever at age 6 years or more, and partial seizures, with a variable degree of severity.|Dravet syndrome:A severe form of epileptic encephalopathy characterized by generalized tonic, clonic, and tonic-clonic seizures that are initially induced by fever and begin during the first year of life. Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development delay is observed around the second year of life. Some patients manifest a borderline disease phenotype and do not necessarily fulfill all diagnostic criteria for core DRVT. DRVT is considered to be the most severe phenotype within the spectrum of generalized epilepsies with febrile seizures-plus.|Intractable childhood epilepsy with generalized tonic-clonic seizures:A disorder characterized by generalized tonic-clonic seizures beginning usually in infancy and induced by fever. Seizures are associated with subsequent mental decline, as well as ataxia or hypotonia. ICEGTC is similar to SMEI, except for the absence of myoclonic seizures.|Migraine, familial hemiplegic, 3:A subtype of migraine associated with transient blindness in some families. Migraine is a disabling symptom complex of periodic headaches, usually temporal and unilateral. Headaches are often accompanied by irritability, nausea, vomiting and photophobia, preceded by constriction of the cranial arteries. The two major subtypes are common migraine (migraine without aura) and classic migraine (migraine with aura). Classic migraine is characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred vision, hallucinations, vertigo, numbness and difficulty in concentrating and speaking.|Febrile seizures, familial, 3A:Seizures associated with febrile episodes in childhood without any evidence of intracranial infection or defined pathologic or traumatic cause. It is a common condition, affecting 2-5% of children aged 3 months to 5 years. The majority are simple febrile seizures (generally defined as generalized onset, single seizures with a duration of less than 30 minutes). Complex febrile seizures are characterized by focal onset, duration greater than 30 minutes, and/or more than one seizure in a 24 hour period. The likelihood of developing epilepsy following simple febrile seizures is low. Complex febrile seizures are associated with a moderately increased incidence of epilepsy.|Developmental and epileptic encephalopathy 6B:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE6B is an autosomal dominant condition characterized by onset of seizures in early infancy, profoundly impaired intellectual development, and a hyperkinetic movement disorder.|:","Generalized epilepsy with febrile seizures plus 2|Dravet syndrome|Intractable childhood epilepsy with generalized tonic-clonic seizures|Migraine, familial hemiplegic, 3|Febrile seizures, familial, 3A|Developmental and epileptic encephalopathy 6B",,,1:P35498-1:|2:P35498-2:|3:P35498-3:,,,,,,,,,,5.0
O43602,,Neuronal migration protein doublecortin,DCX,Homo sapiens,365,False,DBCN|LISX,MELDFGHFDERDKTSRNMRGSRMNGLPSPTHSAHCSFYRTRTLQALSNEKKAKKVRFYRNGDRYFKGIVYAVSSDRFRSFDALLADLTRSLSDNINLPQGVRYIYTIDGSRKIGSMDELEEGESYVCSSDNFFKKVEYTKNVNPNWSVNVKTSANMKAPQSLASSNSAQARENKDFVRPKLVTIIRSGVKPRKAVRVLLNKKTAHSFEQVLTDITEAIKLETGVVKKLYTLDGKQVTCLHDFFGDDDVFIACGPEKFRYAQDDFSLDENECRVMKGNPSATAGPKASPTPQKTSAKSPGPMRRSKSPADSGNDQDANGTSSSQLSTPKSKQSPISTPTSPGSLRKHKDLYLPLSLDDSDSLGDSM,0,,,,,,"Lissencephaly, X-linked 1:A classic lissencephaly characterized by intellectual disability and seizures that are more severe in male patients. Affected boys show an abnormally thick cortex with absent or severely reduced gyri. Clinical manifestations include feeding problems, abnormal muscular tone, seizures and severe to profound psychomotor retardation. Female patients display a less severe phenotype referred to as 'doublecortex'.|Subcortical band heterotopia X-linked:SBHX is a mild brain malformation of the lissencephaly spectrum. It is characterized by bilateral and symmetric plates or bands of gray matter found in the central white matter between the cortex and cerebral ventricles, cerebral convolutions usually appearing normal.|:","Lissencephaly, X-linked 1|Subcortical band heterotopia X-linked",Q9BSE5(AGMAT)|Q13137(CALCOCO2)|Q08379(GOLGA2)|Q13422(IKZF1)|Q9BVG8(KIFC3)|Q6A162(KRT40)|P60410(KRTAP10-8)|P50221(MEOX1)|Q9UJV3-2(MID2)|Q6NUQ1(RINT1)|Q96R06(SPAG5)|Q9BSI4(TINF2)|P36406(TRIM23)|P14373(TRIM27)|O15062(ZBTB5)|Q8TD16-2(BICD2)|A1L4K1(FSD2)|Q08379(GOLGA2)|Q96ED9-2(HOOK2)|Q13422-7(IKZF1)|P45984(MAPK9)|P50221(MEOX1)|Q6FHY5(MEOX2)|Q9UJV3-2(MID2)|Q5JR59-3(MTUS2)|Q8N1B4(VPS52)|Q96DT7-3(ZBTB10)|O15062(ZBTB5)|Q9UGI0(ZRANB1),,1:O43602-1:|2:O43602-2:,,,,,,,,,,5.0
Q08AD1,,Calmodulin-regulated spectrin-associated protein 2,CAMSAP2,Homo sapiens,1489,False,CAMSAP1L1|KIAA1078,MGDAADPREMRKTFIVPAIKPFDHYDFSRAKIACNLAWLVAKAFGTENVPEELQEPFYTDQYDQEHIKPPVVNLLLSAELYCRAGSLILKSDAAKPLLGHDAVIQALAQKGLYVTDQEKLVTERDLHKKPIQMSAHLAMIDTLMMAYTVEMVSIEKVIACAQQYSAFFQATDLPYDIEDAVMYWINKVNEHLKDIMEQEQKLKEHHTVEAPGGQKSPSKWFWKLVPARYRKEQTLLKQLPCIPLVENLLKDGTDGCALAALIHFYCPDVVRLEDICLKETMSLADSLYNLQLIQEFCQEYLNQCCHFTLEDMLYAASSIKSNYLVFMAELFWWFEVVKPSFVQPRVVRPQGAEPVKDMPSIPVLNAAKRNVLDSSSDFPSSGEGATFTQSHHHLPSRYSRPQAHSSASGGIRRSSSMSYVDGFIGTWPKEKRSSVHGVSFDISFDKEDSVQRSTPNRGITRSISNEGLTLNNSHVSKHIRKNLSFKPINGEEEAESIEEELNIDSHSDLKSCVPLNTNELNSNENIHYKLPNGALQNRILLDEFGNQIETPSIEEALQIIHDTEKSPHTPQPDQIANGFFLHSQEMSILNSNIKLNQSSPDNVTDTKGALSPITDNTEVDTGIHVPSEDIPETMDEDSSLRDYTVSLDSDMDDASKFLQDYDIRTGNTREALSPCPSTVSTKSQPGSSASSSSGVKMTSFAEQKFRKLNHTDGKSSGSSSQKTTPEGSELNIPHVVAWAQIPEETGLPQGRDTTQLLASEMVHLRMKLEEKRRAIEAQKKKMEAAFTKQRQKMGRTAFLTVVKKKGDGISPLREEAAGAEDEKVYTDRAKEKESQKTDGQRSKSLADIKESMENPQAKWLKSPTTPIDPEKQWNLASPSEETLNEGEILEYTKSIEKLNSSLHFLQQEMQRLSLQQEMLMQMREQQSWVISPPQPSPQKQIRDFKPSKQAGLSSAIAPFSSDSPRPTHPSPQSSNRKSASFSVKSQRTPRPNELKITPLNRTLTPPRSVDSLPRLRRFSPSQVPIQTRSFVCFGDDGEPQLKESKPKEEVKKEELESKGTLEQRGHNPEEKEIKPFESTVSEVLSLPVTETVCLTPNEDQLNQPTEPPPKPVFPPTAPKNVNLIEVSLSDLKPPEKADVPVEKYDGESDKEQFDDDQKVCCGFFFKDDQKAENDMAMKRAALLEKRLRREKETQLRKQQLEAEMEHKKEETRRKTEEERQKKEDERARREFIRQEYMRRKQLKLMEDMDTVIKPRPQVVKQKKQRPKSIHRDHIESPKTPIKGPPVSSLSLASLNTGDNESVHSGKRTPRSESVEGFLSPSRCGSRNGEKDWENASTTSSVASGTEYTGPKLYKEPSAKSNKHIIQNALAHCCLAGKVNEGQKKKILEEMEKSDANNFLILFRDSGCQFRSLYTYCPETEEINKLTGIGPKSITKKMIEGLYKYNSDRKQFSHIPAKTLSASVDAITIHSHLWQTKRPVTPKKLLPTKA,0,,,,,,:,,P29692(EEF1D),,1:Q08AD1-1:|2:Q08AD1-2:|3:Q08AD1-3:,,,,,,,,,,5.0
Q15858,,Sodium channel protein type 9 subunit alpha,SCN9A,Homo sapiens,1988,False,NENA,MAMLPPPGPQSFVHFTKQSLALIEQRIAERKSKEPKEEKKDDDEEAPKPSSDLEAGKQLPFIYGDIPPGMVSEPLEDLDPYYADKKTFIVLNKGKTIFRFNATPALYMLSPFSPLRRISIKILVHSLFSMLIMCTILTNCIFMTMNNPPDWTKNVEYTFTGIYTFESLVKILARGFCVGEFTFLRDPWNWLDFVVIVFAYLTEFVNLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLKHKCFRNSLENNETLESIMNTLESEEDFRKYFYYLEGSKDALLCGFSTDSGQCPEGYTCVKIGRNPDYGYTSFDTFSWAFLALFRLMTQDYWENLYQQTLRAAGKTYMIFFVVVIFLGSFYLINLILAVVAMAYEEQNQANIEEAKQKELEFQQMLDRLKKEQEEAEAIAAAAAEYTSIRRSRIMGLSESSSETSKLSSKSAKERRNRRKKKNQKKLSSGEEKGDAEKLSKSESEDSIRRKSFHLGVEGHRRAHEKRLSTPNQSPLSIRGSLFSARRSSRTSLFSFKGRGRDIGSETEFADDEHSIFGDNESRRGSLFVPHRPQERRSSNISQASRSPPMLPVNGKMHSAVDCNGVVSLVDGRSALMLPNGQLLPEVIIDKATSDDSGTTNQIHKKRRCSSYLLSEDMLNDPNLRQRAMSRASILTNTVEELEESRQKCPPWWYRFAHKFLIWNCSPYWIKFKKCIYFIVMDPFVDLAITICIVLNTLFMAMEHHPMTEEFKNVLAIGNLVFTGIFAAEMVLKLIAMDPYEYFQVGWNIFDSLIVTLSLVELFLADVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKECVCKINDDCTLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLIVYMMVMVIGNLVVLNLFLALLLSSFSSDNLTAIEEDPDANNLQIAVTRIKKGINYVKQTLREFILKAFSKKPKISREIRQAEDLNTKKENYISNHTLAEMSKGHNFLKEKDKISGFGSSVDKHLMEDSDGQSFIHNPSLTVTVPIAPGESDLENMNAEELSSDSDSEYSKVRLNRSSSSECSTVDNPLPGEGEEAEAEPMNSDEPEACFTDGCVWRFSCCQVNIESGKGKIWWNIRKTCYKIVEHSWFESFIVLMILLSSGALAFEDIYIERKKTIKIILEYADKIFTYIFILEMLLKWIAYGYKTYFTNAWCWLDFLIVDVSLVTLVANTLGYSDLGPIKSLRTLRALRPLRALSRFEGMRVVVNALIGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYECINTTDGSRFPASQVPNRSECFALMNVSQNVRWKNLKVNFDNVGLGYLSLLQVATFKGWTIIMYAAVDSVNVDKQPKYEYSLYMYIYFVVFIIFGSFFTLNLFIGVIIDNFNQQKKKLGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKIQGCIFDLVTNQAFDISIMVLICLNMVTMMVEKEGQSQHMTEVLYWINVVFIILFTGECVLKLISLRHYYFTVGWNIFDFVVVIISIVGMFLADLIETYFVSPTLFRVIRLARIGRILRLVKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKKEDGINDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPKKVHPGSSVEGDCGNPSVGIFYFVSYIIISFLVVVNMYIAVILENFSVATEESTEPLSEDDFEMFYEVWEKFDPDATQFIEFSKLSDFAAALDPPLLIAKPNKVQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDSLRSQMEERFMSANPSKVSYEPITTTLKRKQEDVSATVIQRAYRRYRLRQNVKNISSIYIKDGDRDDDLLNKKDMAFDNVNENSSPEKTDATSSTTSPPSYDSVTKPDKEKYEQDRTEKEDKGKDSKESKK,0,,,,,,"Primary erythermalgia:Autosomal dominant disease characterized by recurrent episodes of severe pain associated with redness and warmth in the feet or hands.|Indifference to pain, congenital, autosomal recessive:A disorder characterized by congenital inability to perceive any form of pain, in any part of the body. All other sensory modalities are preserved and the peripheral and central nervous systems are apparently intact. Patients perceive the sensations of touch, warm and cold temperature, proprioception, tickle and pressure, but not painful stimuli. There is no evidence of a motor or sensory neuropathy, either axonal or demyelinating.|Paroxysmal extreme pain disorder:An autosomal dominant paroxysmal disorder of pain and autonomic dysfunction. The distinctive features are paroxysmal episodes of burning pain in the rectal, ocular, and mandibular areas accompanied by autonomic manifestations such as skin flushing.","Primary erythermalgia|Indifference to pain, congenital, autosomal recessive|Paroxysmal extreme pain disorder",,,1:Q15858-1:|2:Q15858-2:|3:Q15858-3:|4:Q15858-4:,,,,,,,,,,5.0
Q9H2X9,,Solute carrier family 12 member 5,SLC12A5,Homo sapiens,1139,False,KCC2|KIAA1176,MSRRFTVTSLPPAGPARSPDPESRRHSVADPRHLPGEDVKGDGNPKESSPFINSTDTEKGKEYDGKNMALFEEEMDTSPMVSSLLSGLANYTNLPQGSREHEEAENNEGGKKKPVQAPRMGTFMGVYLPCLQNIFGVILFLRLTWVVGIAGIMESFCMVFICCSCTMLTAISMSAIATNGVVPAGGSYYMISRSLGPEFGGAVGLCFYLGTTFAGAMYILGTIEILLAYLFPAMAIFKAEDASGEAAAMLNNMRVYGTCVLTCMATVVFVGVKYVNKFALVFLGCVILSILAIYAGVIKSAFDPPNFPICLLGNRTLSRHGFDVCAKLAWEGNETVTTRLWGLFCSSRFLNATCDEYFTRNNVTEIQGIPGAASGLIKENLWSSYLTKGVIVERSGMTSVGLADGTPIDMDHPYVFSDMTSYFTLLVGIYFPSVTGIMAGSNRSGDLRDAQKSIPTGTILAIATTSAVYISSVVLFGACIEGVVLRDKFGEAVNGNLVVGTLAWPSPWVIVIGSFFSTCGAGLQSLTGAPRLLQAISRDGIVPFLQVFGHGKANGEPTWALLLTACICEIGILIASLDEVAPILSMFFLMCYMFVNLACAVQTLLRTPNWRPRFRYYHWTLSFLGMSLCLALMFICSWYYALVAMLIAGLIYKYIEYRGAEKEWGDGIRGLSLSAARYALLRLEEGPPHTKNWRPQLLVLVRVDQDQNVVHPQLLSLTSQLKAGKGLTIVGSVLEGTFLENHPQAQRAEESIRRLMEAEKVKGFCQVVISSNLRDGVSHLIQSGGLGGLQHNTVLVGWPRNWRQKEDHQTWRNFIELVRETTAGHLALLVTKNVSMFPGNPERFSEGSIDVWWIVHDGGMLMLLPFLLRHHKVWRKCKMRIFTVAQMDDNSIQMKKDLTTFLYHLRITAEVEVVEMHESDISAYTYEKTLVMEQRSQILKQMHLTKNEREREIQSITDESRGSIRRKNPANTRLRLNVPEETAGDSEEKPEEEVQLIHDQSAPSCPSSSPSPGEEPEGEGETDPEKVHLTWTKDKSVAEKNKGPSPVSSEGIKDFFSMKPEWENLNQSNVRRMHTAVRLNEVIVKKSRDAKLVLLNMPGPPRNRNGDENYMEFLEVLTEHLDRVMLVRGGGREVITIYS,0,,,,,,"Developmental and epileptic encephalopathy 34:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE34 is characterized by onset of refractory migrating focal seizures in infancy. Affected children show developmental regression and are severely impaired globally.|Epilepsy, idiopathic generalized 14:An autosomal dominant form of idiopathic generalized epilepsy, a disorder characterized by recurring generalized seizures in the absence of detectable brain lesions and/or metabolic abnormalities. Generalized seizures arise diffusely and simultaneously from both hemispheres of the brain. Seizure types include juvenile myoclonic seizures, absence seizures, and generalized tonic-clonic seizures.","Developmental and epileptic encephalopathy 34|Epilepsy, idiopathic generalized 14",,,1:Q9H2X9-1:|2:Q9H2X9-2:,,,,,,,,,,5.0
Q05586,,"Glutamate receptor ionotropic, NMDA 1",GRIN1,Homo sapiens,938,False,NMDAR1,MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQLNATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLGLTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRLETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNMTGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKENITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRKLVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTCKEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVADGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTILVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDALTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRPEERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQAVRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSHENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRHKDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDTSTGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES,0,,,,,,"Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant:An autosomal dominant neurodevelopmental disorder characterized by severe intellectual disability and developmental delay, absent speech, muscular hypotonia, dyskinesia, and hyperkinetic movements. Cortical blindness, cerebral atrophy, and seizures are present in some patients.|Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive:An autosomal recessive neurodevelopmental disorder characterized by severe intellectual disability and psychomotor developmental delay, involuntary and stereotypic movements, spasticity, and inability to walk without support. Intractable seizures manifest in some patients.|Developmental and epileptic encephalopathy 101:A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE101 is an autosomal recessive, severe form characterized by onset of seizures in early infancy. Death in infancy may occur.","Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant|Neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive|Developmental and epileptic encephalopathy 101",P05067(APP)|P35637(FUS)|Q12879-1(GRIN2A)|Q13224(GRIN2B)|Q62936(Dlg3),,3:Q05586-1:|1:Q05586-2:|2:Q05586-3:|4:Q05586-4:|5:Q05586-5:|6:Q05586-6:|7:Q05586-7:,,,,,,,,,,5.0
Q9BTU6,,Phosphatidylinositol 4-kinase type 2-alpha,PI4K2A,Homo sapiens,479,False,,MDETSPLVSPERAQPPDYTFPSGSGAHFPQVPGGAVRVAAAAGSGPSPPGSPGHDRERQPLLDRARGAAAQGQTQTVAAQAQALAAQAAAAAHAAQAHRERNEFPEDPEFEAVVRQAELAIERCIFPERIYQGSSGSYFVKDPQGRIIAVFKPKNEEPYGHLNPKWTKWLQKLCCPCCFGRDCLVLNQGYLSEAGASLVDQKLELNIVPRTKVVYLASETFNYSAIDRVKSRGKRLALEKVPKVGQRFNRIGLPPKVGSFQLFVEGYKDADYWLRRFEAEPLPENTNRQLLLQFERLVVLDYIIRNTDRGNDNWLIKYDCPMDSSSSRDTDWVVVKEPVIKVAAIDNGLAFPLKHPDSWRAYPFYWAWLPQAKVPFSQEIKDLILPKISDPNFVKDLEEDLYELFKKDPGFDRGQFHKQIAVMRGQILNLTQALKDNKSPLHLVQMPPVIVETARSHQRSSSESYTQSFQSRKPFFSWW,0,,,,,,"Neurodevelopmental disorder with hyperkinetic movements, seizures, and structural brain abnormalities:An autosomal recessive disorder characterized by failure to thrive, global developmental delay with intellectual disability and absent speech, seizures, hypotonia, inability to walk, orofacial dyskinesia, involuntary movements, and structural brain abnormalities.","Neurodevelopmental disorder with hyperkinetic movements, seizures, and structural brain abnormalities",Q96J02(ITCH),,,,,,,,,,,,5.0
Q9Y2M0,,Fanconi-associated nuclease 1,FAN1,Homo sapiens,1017,False,KIAA1018|MTMR15,MMSEGKPPDKKRPRRSLSISKNKKKASNSIISCFNNAPPAKLACPVCSKMVPRYDLNRHLDEMCANNDFVQVDPGQVGLINSNVSMVDLTSVTLEDVTPKKSPPPKTNLTPGQSDSAKREVKQKISPYFKSNDVVCKNQDELRNRSVKVICLGSLASKLSRKYVKAKKSIDKDEEFAGSSPQSSKSTVVKSLIDNSSEIEDEDQILENSSQKENVFKCDSLKEECIPEHMVRGSKIMEAESQKATRECEKSALTPGFSDNAIMLFSPDFTLRNTLKSTSEDSLVKQECIKEVVEKREACHCEEVKMTVASEAKIQLSDSEAKSHSSADDASAWSNIQEAPLQDDSCLNNDIPHSIPLEQGSSCNGPGQTTGHPYYLRSFLVVLKTVLENEDDMLLFDEQEKGIVTKFYQLSATGQKLYVRLFQRKLSWIKMTKLEYEEIALDLTPVIEELTNAGFLQTESELQELSEVLELLSAPELKSLAKTFHLVNPNGQKQQLVDAFLKLAKQRSVCTWGKNKPGIGAVILKRAKALAGQSVRICKGPRAVFSRILLLFSLTDSMEDEDAACGGQGQLSTVLLVNLGRMEFPSYTINRKTHIFQDRDDLIRYAAATHMLSDISSAMANGNWEEAKELAQCAKRDWNRLKNHPSLRCHEDLPLFLRCFTVGWIYTRILSRFVEILQRLHMYEEAVRELESLLSQRIYCPDSRGRWWDRLALNLHQHLKRLEPTIKCITEGLADPEVRTGHRLSLYQRAVRLRESPSCKKFKHLFQQLPEMAVQDVKHVTITGRLCPQRGMCKSVFVMEAGEAADPTTVLCSVEELALAHYRRSGFDQGIHGEGSTFSTLYGLLLWDIIFMDGIPDVFRNACQAFPLDLCTDSFFTSRRPALEARLQLIHDAPEESLRAWVAATWHEQEGRVASLVSWDRFTSLQQAQDLVSCLGGPVLSGVCRHLAADFRHCRGGLPDLVVWNSQSRHFKLVEVKGPNDRLSHKQMIWLAELQKLGAEVEVCHVVAVGAKSQSLS,0,,,,,,"Interstitial nephritis, karyomegalic:A rare kidney disease characterized by chronic tubulointerstitial nephritis associated with massively enlarged tubular epithelial cell nuclei. The clinical picture is associated with recurrent upper respiratory tract infections in addition to chronic kidney disease beginning in the third decade of life.|:","Interstitial nephritis, karyomegalic",,,1:Q9Y2M0-1:|2:Q9Y2M0-2:,,,,,,,,,,5.0
Q02297,,"Pro-neuregulin-1, membrane-bound isoform",NRG1,Homo sapiens,640,False,GGF|HGL|HRGA|NDF|SMDF,MSERKEGRGKGKGKKKERGSGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFKWFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLGNDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSSTSTSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGARCTENVPMKVQNQEKAEELYQKRVLTITGICIALLVVGIMCVVAYCKTKKQRKKLHDRLRQSLRSERNNMMNIANGPHHPNPPPENVQLVNQYVSKNVISSEHIVEREAETSFSTSHYTSTAHHSTTVTQTPSHSWSNGHTESILSESHSVIVMSSVENSRHSSPTGGPRGRLNGTGGPRECNSFLRHARETPDSYRDSPHSERYVSAMTTPARMSPVDFHTPSSPKSPPSEMSPPVSSMTVSMPSMAVSPFMEEERPLLLVTPPRLREKKFDHHPQQFSSFHHNPAHDSNSLPASPLRIVEDEEYETTQEYEPAQEPVKKLANSRRAKRTKPNGHIANRLEVDSNTSSQSSNSESETEDERVGEDTPFLGIQNPLAASLEATPAFRLADSRTNPAGRFSTQEEIQARLSSVIANQDPIAV,0,,,,,,:,,P21860(ERBB3)|Q15303(ERBB4)|P04626(ERBB2)|P21860(ERBB3)|P07307-3(ASGR2)|P21854(CD72)|Q8N5M9(JAGN1)|Q86VI4(LAPTM4B)|Q96JQ5(MS4A4A)|P60201-2(PLP1)|Q969K7(TMEM54),,1:Q02297-1:|2:Q02297-2:|3:Q02297-3:|4:Q02297-4:|6:Q02297-6:|7:Q02297-7:|8:Q02297-8:|9:Q02297-9:|10:Q02297-10:|11:Q02297-11:|12:Q02297-12:,,,,,,,,,,5.0
Q14677,,Clathrin interactor 1,CLINT1,Homo sapiens,625,False,ENTH|EPN4|EPNR|KIAA0171,MLNMWKVRELVDKATNVVMNYSEIESKVREATNDDPWGPSGQLMGEIAKATFMYEQFPELMNMLWSRMLKDNKKNWRRVYKSLLLLAYLIRNGSERVVTSAREHIYDLRSLENYHFVDEHGKDQGINIRQKVKELVEFAQDDDRLREERKKAKKNKDKYVGVSSDSVGGFRYSERYDPEPKSKWDEEWDKNKSAFPFSDKLGELSDKIGSTIDDTISKFRRKDREDSPERCSDSDEEKKARRGRSPKGEFKDEEETVTTKHIHITQATETTTTRHKRTANPSKTIDLGAAAHYTGDKASPDQNASTHTPQSSVKTSVPSSKSSGDLVDLFDGTSQSTGGSADLFGGFADFGSAAASGSFPSQVTATSGNGDFGDWSAFNQAPSGPVASSGEFFGSASQPAVELVSGSQSALGPPPAASNSSDLFDLMGSSQATMTSSQSMNFSMMSTNTVGLGLPMSRSQNTDMVQKSVSKTLPSTWSDPSVNISLDNLLPGMQPSKPQQPSLNTMIQQQNMQQPMNVMTQSFGAVNLSSPSNMLPVRPQTNALIGGPMPMSMPNVMTGTMGMAPLGNTPMMNQSMMGMNMNIGMSAAGMGLTGTMGMGMPNIAMTSGTVQPKQDAFANFANFSK,0,,,,,,,,Q9NSY1(BMP2K)|Q9H0R8(GABARAPL1)|Q8WTR4-3(GDPD5)|O60333-2(KIF1B)|Q9GZQ8(MAP1LC3B)|O76024(WFS1)|P22892(Ap1g1)|O88384(Vti1b)|P29991(),,1:Q14677-1:|2:Q14677-2:|3:Q14677-3:,,,,,,,,,,5.0
Q29980,,MHC class I polypeptide-related sequence B,MICB,Homo sapiens,383,False,PERB11.2,MGLGRVLLFLAVAFPFAPPAAAAEPHSLRYNLMVLSQDGSVQSGFLAEGHLDGQPFLRYDRQKRRAKPQGQWAENVLGAKTWDTETEDLTENGQDLRRTLTHIKDQKGGLHSLQEIRVCEIHEDSSTRGSRHFYYDGELFLSQNLETQESTVPQSSRAQTLAMNVTNFWKEDAMKTKTHYRAMQADCLQKLQRYLKSGVAIRRTVPPMVNVTCSEVSEGNITVTCRASSFYPRNITLTWRQDGVSLSHNTQQWGDVLPDGNGTYQTWVATRIRQGEEQRFTCYMEHSGNHGTHPVPSGKALVLQSQRTDFPYVSAAMPCFVIIIILCVPCCKKKTSAAEGPELVSLQVLDQHPVGTGDHRDAAQLGFQPLMSATGSTGSTEGT,0,,,,,,"Rheumatoid arthritis:An inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.|:",Rheumatoid arthritis,,,1:Q29980-1:|2:Q29980-2:|3:Q29980-3:,,,,,,,,,,5.0
Q9H2D6,,TRIO and F-actin-binding protein,TRIOBP,Homo sapiens,2365,False,KIAA1662|TARA,MEEVPGDALCEHFEANILTQNRCQNCFHPEEAHGARYQELRSPSGAEVPYCDLPRCPPAPEDPLSASTSGCQSVVDPGLRPGPKRGPSPSAGLPEEGPTAAPRSRSRELEAVPYLEGLTTSLCGSCNEDPGSDPTSSPDSATPDDTSNSSSVDWDTVERQEEEAPSWDELAVMIPRRPREGPRADSSQRAPSLLTRSPVGGDAAGQKKEDTGGGGRSAGQHWARLRGESGLSLERHRSTLTQASSMTPHSGPRSTTSQASPAQRDTAQAASTREIPRASSPHRITQRDTSRASSTQQEISRASSTQQETSRASSTQEDTPRASSTQEDTPRASSTQWNTPRASSPSRSTQLDNPRTSSTQQDNPQTSFPTCTPQRENPRTPCVQQDDPRASSPNRTTQRENSRTSCAQRDNPKASRTSSPNRATRDNPRTSCAQRDNPRASSPSRATRDNPTTSCAQRDNPRASRTSSPNRATRDNPRTSCAQRDNPRASSPSRATRDNPTTSCAQRDNPRASRTSSPNRATRDNPRTSCAQRDNPRASSPNRAARDNPTTSCAQRDNPRASRTSSPNRATRDNPRTSCAQRDNPRASSPNRATRDNPTTSCAQRDNPRASRTSSPNRATRDNPRTSCAQRDNPRASSPNRTTQQDSPRTSCARRDDPRASSPNRTIQQENPRTSCALRDNPRASSPSRTIQQENPRTSCAQRDDPRASSPNRTTQQENPRTSCARRDNPRASSRNRTIQRDNPRTSCAQRDNPRASSPNRTIQQENLRTSCTRQDNPRTSSPNRATRDNPRTSCAQRDNLRASSPIRATQQDNPRTCIQQNIPRSSSTQQDNPKTSCTKRDNLRPTCTQRDRTQSFSFQRDNPGTSSSQCCTQKENLRPSSPHRSTQWNNPRNSSPHRTNKDIPWASFPLRPTQSDGPRTSSPSRSKQSEVPWASIALRPTQGDRPQTSSPSRPAQHDPPQSSFGPTQYNLPSRATSSSHNPGHQSTSRTSSPVYPAAYGAPLTSPEPSQPPCAVCIGHRDAPRASSPPRYLQHDPFPFFPEPRAPESEPPHHEPPYIPPAVCIGHRDAPRASSPPRHTQFDPFPFLPDTSDAEHQCQSPQHEPLQLPAPVCIGYRDAPRASSPPRQAPEPSLLFQDLPRASTESLVPSMDSLHECPHIPTPVCIGHRDAPSFSSPPRQAPEPSLFFQDPPGTSMESLAPSTDSLHGSPVLIPQVCIGHRDAPRASSPPRHPPSDLAFLAPSPSPGSSGGSRGSAPPGETRHNLEREEYTVLADLPPPRRLAQRQPGPQAQCSSGGRTHSPGRAEVERLFGQERRKSEAAGAFQAQDEGRSQQPSQGQSQLLRRQSSPAPSRQVTMLPAKQAELTRRSQAEPPHPWSPEKRPEGDRQLQGSPLPPRTSARTPERELRTQRPLESGQAGPRQPLGVWQSQEEPPGSQGPHRHLERSWSSQEGGLGPGGWWGCGEPSLGAAKAPEGAWGGTSREYKESWGQPEAWEEKPTHELPRELGKRSPLTSPPENWGGPAESSQSWHSGTPTAVGWGAEGACPYPRGSERRPELDWRDLLGLLRAPGEGVWARVPSLDWEGLLELLQARLPRKDPAGHRDDLARALGPELGPPGTNDVPEQESHSQPEGWAEATPVNGHSPALQSQSPVQLPSPACTSTQWPKIKVTRGPATATLAGLEQTGPLGSRSTAKGPSLPELQFQPEEPEESEPSRGQDPLTDQKQADSADKRPAEGKAGSPLKGRLVTSWRMPGDRPTLFNPFLLSLGVLRWRRPDLLNFKKGWMSILDEPGEPPSPSLTTTSTSQWKKHWFVLTDSSLKYYRDSTAEEADELDGEIDLRSCTDVTEYAVQRNYGFQIHTKDAVYTLSAMTSGIRRNWIEALRKTVRPTSAPDVTKLSDSNKENALHSYSTQKGPLKAGEQRAGSEVISRGGPRKADGQRQALDYVELSPLTQASPQRARTPARTPDRLAKQEELERDLAQRSEERRKWFEATDSRTPEVPAGEGPRRGLGAPLTEDQQNRLSEEIEKKWQELEKLPLRENKRVPLTALLNQSRGERRGPPSDGHEALEKEVQALRAQLEAWRLQGEAPQSALRSQEDGHIPPGYISQEACERSLAEMESSHQQVMEELQRHHERELQRLQQEKEWLLAEETAATASAIEAMKKAYQEELSRELSKTRSLQQGPDGLRKQHQSDVEALKRELQVLSEQYSQKCLEIGALMRQAEEREHTLRRCQQEGQELLRHNQELHGRLSEEIDQLRGFIASQGMGNGCGRSNERSSCELEVLLRVKENELQYLKKEVQCLRDELQMMQKDKRFTSGKYQDVYVELSHIKTRSEREIEQLKEHLRLAMAALQEKESMRNSLAE,0,,,,,,"Deafness, autosomal recessive, 28:A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information.","Deafness, autosomal recessive, 28",,,2:Q9H2D6-1:|3:Q9H2D6-2:|4:Q9H2D6-3:|5:Q9H2D6-4:|1:Q9H2D6-5:|6:Q9H2D6-6:|7:Q9H2D6-7:,,,,,,,,,,5.0
Q504Y0,,Zinc transporter ZIP12,SLC39A12,Homo sapiens,691,False,ZIP12,MCFRTKLSVSWVPLFLLLSRVFSTETDKPSAQDSRSRGSSGQPADLLQVLSAGDHPPHNHSRSLIKTLLEKTGCPRRRNGMQGDCNLCFEPDALLLIAGGNFEDQLREEVVQRVSLLLLYYIIHQEEICSSKLNMSNKEYKFYLHSLLSLRQDEDSSFLSQNETEDILAFTRQYFDTSQSQCMETKTLQKKSGIVSSEGANESTLPQLAAMIITLSLQGVCLGQGNLPSPDYFTEYIFSSLNRTNTLRLSELDQLLNTLWTRSTCIKNEKIHQFQRKQNNIITHDQDYSNFSSSMEKESEDGPVSWDQTCFSARQLVEIFLQKGLSLISKEDFKQMSPGIIQQLLSCSCHLPKDQQAKLPPTTLEKYGYSTVAVTLLTLGSMLGTALVLFHSCEENYRLILQLFVGLAVGTLSGDALLHLIPQVLGLHKQEAPEFGHFHESKGHIWKLMGLIGGIHGFFLIEKCFILLVSPNDKQGLSLVNGHVGHSHHLALNSELSDQAGRGKSASTIQLKSPEDSQAAEMPIGSMTASNRKCKAISLLAIMILVGDSLHNFADGLAIGAAFSSSSESGVTTTIAILCHEIPHEMGDFAVLLSSGLSMKTAILMNFISSLTAFMGLYIGLSVSADPCVQDWIFTVTAGMFLYLSLVEMLPEMTHVQTQRPWMMFLLQNFGLILGWLSLLLLAIYEQNIKI,0,,,,,,,,,,1:Q504Y0-1:|2:Q504Y0-2:|3:Q504Y0-3:|4:Q504Y0-4:|5:Q504Y0-5:,,,,,,,,,,5.0
Q9NRR3,,CDC42 small effector protein 2,CDC42SE2,Homo sapiens,84,False,SPEC2,MSEFWLCFNCCIAEQPQPKRRRRIDRSMIGEPTNFVHTAHVGSGDLFSGMNSVSSIQNQMQSKGGYGGGMPANVQMQLVDTKAG,0,,,,,,,,,,,,,,,,,,,,5.0
P42345,,Serine/threonine-protein kinase mTOR,MTOR,Homo sapiens,2549,False,FRAP|FRAP1|FRAP2|RAFT1|RAPT1,MLGTGPAAATTAATTSSNVSVLQQFASGLKSRNEETRAKAAKELQHYVTMELREMSQEESTRFYDQLNHHIFELVSSSDANERKGGILAIASLIGVEGGNATRIGRFANYLRNLLPSNDPVVMEMASKAIGRLAMAGDTFTAEYVEFEVKRALEWLGADRNEGRRHAAVLVLRELAISVPTFFFQQVQPFFDNIFVAVWDPKQAIREGAVAALRACLILTTQREPKEMQKPQWYRHTFEEAEKGFDETLAKEKGMNRDDRIHGALLILNELVRISSMEGERLREEMEEITQQQLVHDKYCKDLMGFGTKPRHITPFTSFQAVQPQQSNALVGLLGYSSHQGLMGFGTSPSPAKSTLVESRCCRDLMEEKFDQVCQWVLKCRNSKNSLIQMTILNLLPRLAAFRPSAFTDTQYLQDTMNHVLSCVKKEKERTAAFQALGLLSVAVRSEFKVYLPRVLDIIRAALPPKDFAHKRQKAMQVDATVFTCISMLARAMGPGIQQDIKELLEPMLAVGLSPALTAVLYDLSRQIPQLKKDIQDGLLKMLSLVLMHKPLRHPGMPKGLAHQLASPGLTTLPEASDVGSITLALRTLGSFEFEGHSLTQFVRHCADHFLNSEHKEIRMEAARTCSRLLTPSIHLISGHAHVVSQTAVQVVADVLSKLLVVGITDPDPDIRYCVLASLDERFDAHLAQAENLQALFVALNDQVFEIRELAICTVGRLSSMNPAFVMPFLRKMLIQILTELEHSGIGRIKEQSARMLGHLVSNAPRLIRPYMEPILKALILKLKDPDPDPNPGVINNVLATIGELAQVSGLEMRKWVDELFIIIMDMLQDSSLLAKRQVALWTLGQLVASTGYVVEPYRKYPTLLEVLLNFLKTEQNQGTRREAIRVLGLLGALDPYKHKVNIGMIDQSRDASAVSLSESKSSQDSSDYSTSEMLVNMGNLPLDEFYPAVSMVALMRIFRDQSLSHHHTMVVQAITFIFKSLGLKCVQFLPQVMPTFLNVIRVCDGAIREFLFQQLGMLVSFVKSHIRPYMDEIVTLMREFWVMNTSIQSTIILLIEQIVVALGGEFKLYLPQLIPHMLRVFMHDNSPGRIVSIKLLAAIQLFGANLDDYLHLLLPPIVKLFDAPEAPLPSRKAALETVDRLTESLDFTDYASRIIHPIVRTLDQSPELRSTAMDTLSSLVFQLGKKYQIFIPMVNKVLVRHRINHQRYDVLICRIVKGYTLADEEEDPLIYQHRMLRSGQGDALASGPVETGPMKKLHVSTINLQKAWGAARRVSKDDWLEWLRRLSLELLKDSSSPSLRSCWALAQAYNPMARDLFNAAFVSCWSELNEDQQDELIRSIELALTSQDIAEVTQTLLNLAEFMEHSDKGPLPLRDDNGIVLLGERAAKCRAYAKALHYKELEFQKGPTPAILESLISINNKLQQPEAAAGVLEYAMKHFGELEIQATWYEKLHEWEDALVAYDKKMDTNKDDPELMLGRMRCLEALGEWGQLHQQCCEKWTLVNDETQAKMARMAAAAAWGLGQWDSMEEYTCMIPRDTHDGAFYRAVLALHQDLFSLAQQCIDKARDLLDAELTAMAGESYSRAYGAMVSCHMLSELEEVIQYKLVPERREIIRQIWWERLQGCQRIVEDWQKILMVRSLVVSPHEDMRTWLKYASLCGKSGRLALAHKTLVLLLGVDPSRQLDHPLPTVHPQVTYAYMKNMWKSARKIDAFQHMQHFVQTMQQQAQHAIATEDQQHKQELHKLMARCFLKLGEWQLNLQGINESTIPKVLQYYSAATEHDRSWYKAWHAWAVMNFEAVLHYKHQNQARDEKKKLRHASGANITNATTAATTAATATTTASTEGSNSESEAESTENSPTPSPLQKKVTEDLSKTLLMYTVPAVQGFFRSISLSRGNNLQDTLRVLTLWFDYGHWPDVNEALVEGVKAIQIDTWLQVIPQLIARIDTPRPLVGRLIHQLLTDIGRYHPQALIYPLTVASKSTTTARHNAANKILKNMCEHSNTLVQQAMMVSEELIRVAILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKQLPQLTSLELQYVSPKLLMCRDLELAVPGTYDPNQPIIRIQSIAPSLQVITSKQRPRKLTLMGSNGHEFVFLLKGHEDLRQDERVMQLFGLVNTLLANDPTSLRKNLSIQRYAVIPLSTNSGLIGWVPHCDTLHALIRDYREKKKILLNIEHRIMLRMAPDYDHLTLMQKVEVFEHAVNNTAGDDLAKLLWLKSPSSEVWFDRRTNYTRSLAVMSMVGYILGLGDRHPSNLMLDRLSGKILHIDFGDCFEVAMTREKFPEKIPFRLTRMLTNAMEVTGLDGNYRITCHTVMEVLREHKDSVMAVLEAFVYDPLLNWRLMDTNTKGNKRSRTRTDSYSAGQSVEILDGVELGEPAHKKTGTTVPESIHSFIGDGLVKPEALNKKAIQIINRVRDKLTGRDFSHDDTLDVPTQVELLIKQATSHENLCQCYIGWCPFW,0,,,,,,"Smith-Kingsmore syndrome:An autosomal dominant syndrome characterized by intellectual disability, macrocephaly, seizures, umbilical hernia, and facial dysmorphic features.|Focal cortical dysplasia 2:A form of focal cortical dysplasia, a malformation of cortical development that results in medically refractory epilepsy in the pediatric population and in adults. FCORD2 is a severe form, with onset usually in childhood, characterized by disrupted cortical lamination and specific cytological abnormalities. It is classified in 2 subtypes: type IIA characterized by dysmorphic neurons and lack of balloon cells; type IIB with dysmorphic neurons and balloon cells.",Smith-Kingsmore syndrome|Focal cortical dysplasia 2,P31749(AKT1)|Q07817-1(BCL2L1)|Q6UXB4(CLEC4G)|Q8TB45(DEPTOR)|Q13541(EIF4EBP1)|P62942(FKBP1A)|Q8WUA4(GTF3C2)|Q9BVC4(MLST8)|Q9BVC4-1(MLST8)|Q13615(MTMR3)|P42345(MTOR)|Q9Y4G2(PLEKHM1)|Q8TCU6(PREX1)|P62820(RAB1A)|Q15382(RHEB)|Q6R327(RICTOR)|Q8N122(RPTOR)|Q96EB6(SIRT1)|O14894(TM4SF5)|Q92544(TM9SF4)|Q8NHX9(TPCN2)|O75385(ULK1)|P63104(YWHAZ),,,,,,,,,,,,5.0
O60610,,Protein diaphanous homolog 1,DIAPH1,Homo sapiens,1272,False,DIAP1,MEPPGGSLGPGRGTRDKKKGRSPDELPSAGGDGGKSKKFTLKRLMADELERFTSMRIKKEKEKPNSAHRNSSASYGDDPTAQSLQDVSDEQVLVLFEQMLLDMNLNEEKQQPLREKDIIIKREMVSQYLYTSKAGMSQKESSKSAMMYIQELRSGLRDMPLLSCLESLRVSLNNNPVSWVQTFGAEGLASLLDILKRLHDEKEETAGSYDSRNKHEIIRCLKAFMNNKFGIKTMLETEEGILLLVRAMDPAVPNMMIDAAKLLSALCILPQPEDMNERVLEAMTERAEMDEVERFQPLLDGLKSGTTIALKVGCLQLINALITPAEELDFRVHIRSELMRLGLHQVLQDLREIENEDMRVQLNVFDEQGEEDSYDLKGRLDDIRMEMDDFNEVFQILLNTVKDSKAEPHFLSILQHLLLVRNDYEARPQYYKLIEECISQIVLHKNGADPDFKCRHLQIEIEGLIDQMIDKTKVEKSEAKAAELEKKLDSELTARHELQVEMKKMESDFEQKLQDLQGEKDALHSEKQQIATEKQDLEAEVSQLTGEVAKLTKELEDAKKEMASLSAAAITVPPSVPSRAPVPPAPPLPGDSGTIIPPPPAPGDSTTPPPPPPPPPPPPPLPGGVCISSPPSLPGGTAISPPPPLSGDATIPPPPPLPEGVGIPSPSSLPGGTAIPPPPPLPGSARIPPPPPPLPGSAGIPPPPPPLPGEAGMPPPPPPLPGGPGIPPPPPFPGGPGIPPPPPGMGMPPPPPFGFGVPAAPVLPFGLTPKKLYKPEVQLRRPNWSKLVAEDLSQDCFWTKVKEDRFENNELFAKLTLTFSAQTKTSKAKKDQEGGEEKKSVQKKKVKELKVLDSKTAQNLSIFLGSFRMPYQEIKNVILEVNEAVLTESMIQNLIKQMPEPEQLKMLSELKDEYDDLAESEQFGVVMGTVPRLRPRLNAILFKLQFSEQVENIKPEIVSVTAACEELRKSESFSNLLEITLLVGNYMNAGSRNAGAFGFNISFLCKLRDTKSTDQKMTLLHFLAELCENDYPDVLKFPDELAHVEKASRVSAENLQKNLDQMKKQISDVERDVQNFPAATDEKDKFVEKMTSFVKDAQEQYNKLRMMHSNMETLYKELGEYFLFDPKKLSVEEFFMDLHNFRNMFLQAVKENQKRRETEEKMRRAKLAKEKAEKERLEKQQKREQLIDMNAEGDETGVMDSLLEALQSGAAFRRKRGPRQANRKAGCAVTSLLASELTKDDAMAAVPAKVSKNSETFPTILEEAKELVGRAS,0,,,,,,"Deafness, autosomal dominant 1, with or without thrombocytopenia:A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. Patients may have mild thrombocytopenia and enlarged platelets, although most of DFNA1 affected individuals do not have significant bleeding tendencies.|Seizures, cortical blindness, and microcephaly syndrome:A severe autosomal recessive neurodevelopmental disorder characterized by microcephaly, early-onset seizures, severely delayed psychomotor development, short stature, and cortical blindness.","Deafness, autosomal dominant 1, with or without thrombocytopenia|Seizures, cortical blindness, and microcephaly syndrome",Q15109(AGER)|P49593(PPM1F)|P61586(RHOA)|P08134(RHOC)|O00212(RHOD)|Q9Q2G4(ORF),,1:O60610-1:|2:O60610-2:|3:O60610-3:,,,,,,,,,,5.0
O75140,,GATOR1 complex protein DEPDC5,DEPDC5,Homo sapiens,1603,False,KIAA0645,MRTTKVYKLVIHKKGFGGSDDELVVNPKVFPHIKLGDIVEIAHPNDEYSPLLLQVKSLKEDLQKETISVDQTVTQVFRLRPYQDVYVNVVDPKDVTLDLVELTFKDQYIGRGDMWRLKKSLVSTCAYITQKVEFAGIRAQAGELWVKNEKVMCGYISEDTRVVFRSTSAMVYIFIQMSCEMWDFDIYGDLYFEKAVNGFLADLFTKWKEKNCSHEVTVVLFSRTFYDAKSVDEFPEINRASIRQDHKGRFYEDFYKVVVQNERREEWTSLLVTIKKLFIQYPVLVRLEQAEGFPQGDNSTSAQGNYLEAINLSFNVFDKHYINRNFDRTGQMSVVITPGVGVFEVDRLLMILTKQRMIDNGIGVDLVCMGEQPLHAVPLFKLHNRSAPRDSRLGDDYNIPHWINHSFYTSKSQLFCNSFTPRIKLAGKKPASEKAKNGRDTSLGSPKESENALPIQVDYDAYDAQVFRLPGPSRAQCLTTCRSVRERESHSRKSASSCDVSSSPSLPSRTLPTEEVRSQASDDSSLGKSANILMIPHPHLHQYEVSSSLGYTSTRDVLENMMEPPQRDSSAPGRFHVGSAESMLHVRPGGYTPQRALINPFAPSRMPMKLTSNRRRWMHTFPVGPSGEAIQIHHQTRQNMAELQGSGQRDPTHSSAELLELAYHEAAGRHSNSRQPGDGMSFLNFSGTEELSVGLLSNSGAGMNPRTQNKDSLEDSVSTSPDPILTLSAPPVVPGFCCTVGVDWKSLTTPACLPLTTDYFPDRQGLQNDYTEGCYDLLPEADIDRRDEDGVQMTAQQVFEEFICQRLMQGYQIIVQPKTQKPNPAVPPPLSSSPLYSRGLVSRNRPEEEDQYWLSMGRTFHKVTLKDKMITVTRYLPKYPYESAQIHYTYSLCPSHSDSEFVSCWVEFSHERLEEYKWNYLDQYICSAGSEDFSLIESLKFWRTRFLLLPACVTATKRITEGEAHCDIYGDRPRADEDEWQLLDGFVRFVEGLNRIRRRHRSDRMMRKGTAMKGLQMTGPISTHSLESTAPPVGKKGTSALSALLEMEASQKCLGEQQAAVHGGKSSAQSAESSSVAMTPTYMDSPRKDGAFFMEFVRSPRTASSAFYPQVSVDQTATPMLDGTSLGICTGQSMDRGNSQTFGNSQNIGEQGYSSTNSSDSSSQQLVASSLTSSSTLTEILEAMKHPSTGVQLLSEQKGLSPYCFISAEVVHWLVNHVEGIQTQAMAIDIMQKMLEEQLITHASGEAWRTFIYGFYFYKIVTDKEPDRVAMQQPATTWHTAGVDDFASFQRKWFEVAFVAEELVHSEIPAFLLPWLPSRPASYASRHSSFSRSFGGRSQAAALLAATVPEQRTVTLDVDVNNRTDRLEWCSCYYHGNFSLNAAFEIKLHWMAVTAAVLFEMVQGWHRKATSCGFLLVPVLEGPFALPSYLYGDPLRAQLFIPLNISCLLKEGSEHLFDSFEPETYWDRMHLFQEAIAHRFGFVQDKYSASAFNFPAENKPQYIHVTGTVFLQLPYSKRKFSGQQRRRRNSTSSTNQNMFCEERVGYNWAYNTMLTKTWRSSATGDEKFADRLLKDFTDFCINRDNRLVTFWTSCLEKMHASAP,0,,,,,,"Epilepsy, familial focal, with variable foci 1:An autosomal dominant form of epilepsy characterized by focal seizures arising from different cortical regions in different family members. Many patients have an aura and show automatisms during the seizures, whereas others may have nocturnal seizures. There is often secondary generalization. Some patients show abnormal interictal EEG, and some patients may have intellectual disability or autism spectrum disorders. Seizure onset usually occurs in the first or second decades, although later onset has been reported, and there is phenotypic variability within families. Penetrance of the disorder is incomplete.|Developmental and epileptic encephalopathy 111:A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE111 is an autosomal recessive form characterized by the onset of seizures in the first days, months, or years of life. Brain imaging shows frontal, parietal, and perisylvian polymicrogyria, dysmorphic basal ganglia and corpus callosum, and hypoplastic pons. Death in early childhood may occur.|:","Epilepsy, familial focal, with variable foci 1|Developmental and epileptic encephalopathy 111",P49368(CCT3)|Q6W0C5(DPPA3)|Q13257(MAD2L1)|Q9UI95(MAD2L2)|Q6FHY5(MEOX2)|Q96QG7(MTMR9)|Q9BSW7(SYT17)|O75604(USP2),,10:O75140-10:|2:O75140-2:|4:O75140-4:|5:O75140-5:|6:O75140-6:|8:O75140-8:|9:O75140-9:|1:O75140-1:,,,,,,,,,,5.0
Q96Q42,,Alsin,ALS2,Homo sapiens,1657,False,ALS2CR6|KIAA1563,MDSKKRSSTEAEGSKERGLVHIWQAGSFPITPERLPGWGGKTVLQAALGVKHGVLLTEDGEVYSFGTLPWRSGPVEICPSSPILENALVGQYVITVATGSFHSGAVTDNGVAYMWGENSAGQCAVANQQYVPEPNPVSIADSEASPLLAVRILQLACGEEHTLALSISREIWAWGTGCQLGLITTAFPVTKPQKVEHLAGRVVLQVACGAFHSLALVQCLPSQDLKPVPERCNQCSQLLITMTDKEDHVIISDSHCCPLGVTLTESQAENHASTALSPSTETLDRQEEVFENTLVANDQSVATELNAVSAQITSSDAMSSQQNVMGTTEISSARNIPSYPDTQAVNEYLRKLSDHSVREDSEHGEKPVPSQPLLEEAIPNLHSPPTTSTSALNSLVVSCASAVGVRVAATYEAGALSLKKVMNFYSTTPCETGAQAGSSAIGPEGLKDSREEQVKQESMQGKKSSSLVDIREEETEGGSRRLSLPGLLSQVSPRLLRKAARVKTRTVVLTPTYSGEADALLPSLRTEVWTWGKGKEGQLGHGDVLPRLQPLCVKCLDGKEVIHLEAGGYHSLALTAKSQVYSWGSNTFGQLGHSDFPTTVPRLAKISSENGVWSIAAGRDYSLFLVDTEDFQPGLYYSGRQDPTEGDNLPENHSGSKTPVLLSCSKLGYISRVTAGKDSYLALVDKNIMGYIASLHELATTERRFYSKLSDIKSQILRPLLSLENLGTTTTVQLLQEVASRFSKLCYLIGQHGASLSSFLHGVKEARSLVILKHSSLFLDSYTEYCTSITNFLVMGGFQLLAKPAIDFLNKNQELLQDLSEVNDENTQLMEILNTLFFLPIRRLHNYAKVLLKLATCFEVASPEYQKLQDSSSCYECLALHLGRKRKEAEYTLGFWKTFPGKMTDSLRKPERRLLCESSNRALSLQHAGRFSVNWFILFNDALVHAQFSTHHVFPLATLWAEPLSEEAGGVNGLKITTPEEQFTLISSTPQEKTKWLRAISQAVDQALRGMSDLPPYGSGSSVQRQEPPISRSAKYTFYKDPRLKDATYDGRWLSGKPHGRGVLKWPDGKMYSGMFRNGLEDGYGEYRIPNKAMNKEDHYVGHWKEGKMCGQGVYSYASGEVFEGCFQDNMRHGHGLLRSGKLTSSSPSMFIGQWVMDKKAGYGVFDDITRGEKYMGMWQDDVCQGNGVVVTQFGLYYEGNFHLNKMMGNGVLLSEDDTIYEGEFSDDWTLSGKGTLTMPNGDYIEGYFSGEWGSGIKITGTYFKPSLYESDKDRPKVFRKLGNLAVPADEKWKAVFDECWRQLGCEGPGQGEVWKAWDNIAVALTTSRRQHRDSPEILSRSQTQTLESLEFIPQHVGAFSVEKYDDIRKYLIKACDTPLHPLGRLVETLVAVYRMTYVGVGANRRLLQEAVKEIKSYLKRIFQLVRFLFPELPEEGSTIPLSAPLPTERKSFCTGKSDSRSESPEPGYVVTSSGLLLPVLLPRLYPPLFMLYALDNDREEDIYWECVLRLNKQPDIALLGFLGVQRKFWPATLSILGESKKVLPTTKDACFASAVECLQQISTTFTPSDKLKVIQQTFEEISQSVLASLHEDFLWSMDDLFPVFLYVVLRARIRNLGSEVHLIEDLMDPYLQHGEQGIMFTTLKACYYQIQREKLN,0,,,,,,"Amyotrophic lateral sclerosis 2:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Juvenile primary lateral sclerosis:A neurodegenerative disorder which is closely related to but clinically distinct from amyotrophic lateral sclerosis. It is a progressive paralytic disorder which results from dysfunction of the upper motor neurons while the lower neurons are unaffected.|Infantile-onset ascending spastic paralysis:Characterized by progressive spasticity and weakness of limbs.",Amyotrophic lateral sclerosis 2|Juvenile primary lateral sclerosis|Infantile-onset ascending spastic paralysis,Q96PY6(NEK1)|P20339(RAB5A),,1:Q96Q42-1:|2:Q96Q42-2:|3:Q96Q42-3:,,,,,,,,,,5.0
Q7Z333,,Probable helicase senataxin,SETX,Homo sapiens,2677,False,ALS4|KIAA0625|SCAR1,MSTCCWCTPGGASTIDFLKRYASNTPSGEFQTADEDLCYCLECVAEYHKARDELPFLHEVLWELETLRLINHFEKSMKAEIGDDDELYIVDNNGEMPLFDITGQDFENKLRVPLLEILKYPYLLLHERVNELCVEALCRMEQANCSFQVFDKHPGIYLFLVHPNEMVRRWAILTARNLGKVDRDDYYDLQEVLLCLFKVIELGLLESPDIYTSSVLEKGKLILLPSHMYDTTNYKSYWLGICMLLTILEEQAMDSLLLGSDKQNDFMQSILHTMEREADDDSVDPFWPALHCFMVILDRLGSKVWGQLMDPIVAFQTIINNASYNREIRHIRNSSVRTKLEPESYLDDMVTCSQIVYNYNPEKTKKDSGWRTAICPDYCPNMYEEMETLASVLQSDIGQDMRVHNSTFLWFIPFVQSLMDLKDLGVAYIAQVVNHLYSEVKEVLNQTDAVCDKVTEFFLLILVSVIELHRNKKCLHLLWVSSQQWVEAVVKCAKLPTTAFTRSSEKSSGNCSKGTAMISSLSLHSMPSNSVQLAYVQLIRSLLKEGYQLGQQSLCKRFWDKLNLFLRGNLSLGWQLTSQETHELQSCLKQIIRNIKFKAPPCNTFVDLTSACKISPASYNKEESEQMGKTSRKDMHCLEASSPTFSKEPMKVQDSVLIKADNTIEGDNNEQNYIKDVKLEDHLLAGSCLKQSSKNIFTERAEDQIKISTRKQKSVKEISSYTPKDCTSRNGPERGCDRGIIVSTRLLTDSSTDALEKVSTSNEDFSLKDDALAKTSKRKTKVQKDEICAKLSHVIKKQHRKSTLVDNTINLDENLTVSNIESFYSRKDTGVQKGDGFIHNLSLDPSGVLDDKNGEQKSQNNVLPKEKQLKNEELVIFSFHENNCKIQEFHVDGKELIPFTEMTNASEKKSSPFKDLMTVPESRDEEMSNSTSVIYSNLTREQAPDISPKSDTLTDSQIDRDLHKLSLLAQASVITFPSDSPQNSSQLQRKVKEDKRCFTANQNNVGDTSRGQVIIISDSDDDDDERILSLEKLTKQDKICLEREHPEQHVSTVNSKEEKNPVKEEKTETLFQFEESDSQCFEFESSSEVFSVWQDHPDDNNSVQDGEKKCLAPIANTTNGQGCTDYVSEVVKKGAEGIEEHTRPRSISVEEFCEIEVKKPKRKRSEKPMAEDPVRPSSSVRNEGQSDTNKRDLVGNDFKSIDRRTSTPNSRIQRATTVSQKKSSKLCTCTEPIRKVPVSKTPKKTHSDAKKGQNRSSNYLSCRTTPAIVPPKKFRQCPEPTSTAEKLGLKKGPRKAYELSQRSLDYVAQLRDHGKTVGVVDTRKKTKLISPQNLSVRNNKKLLTSQELQMQRQIRPKSQKNRRRLSDCESTDVKRAGSHTAQNSDIFVPESDRSDYNCTGGTEVLANSNRKQLIKCMPSEPETIKAKHGSPATDDACPLNQCDSVVLNGTVPTNEVIVSTSEDPLGGGDPTARHIEMAALKEGEPDSSSDAEEDNLFLTQNDPEDMDLCSQMENDNYKLIELIHGKDTVEVEEDSVSRPQLESLSGTKCKYKDCLETTKNQGEYCPKHSEVKAADEDVFRKPGLPPPASKPLRPTTKIFSSKSTSRIAGLSKSLETSSALSPSLKNKSKGIQSILKVPQPVPLIAQKPVGEMKNSCNVLHPQSPNNSNRQGCKVPFGESKYFPSSSPVNILLSSQSVSDTFVKEVLKWKYEMFLNFGQCGPPASLCQSISRPVPVRFHNYGDYFNVFFPLMVLNTFETVAQEWLNSPNRENFYQLQVRKFPADYIKYWEFAVYLEECELAKQLYPKENDLVFLAPERINEEKKDTERNDIQDLHEYHSGYVHKFRRTSVMRNGKTECYLSIQTQENFPANLNELVNCIVISSLVTTQRKLKAMSLLGSRNQLARAVLNPNPMDFCTKDLLTTTSERIIAYLRDFNEDQKKAIETAYAMVKHSPSVAKICLIHGPPGTGKSKTIVGLLYRLLTENQRKGHSDENSNAKIKQNRVLVCAPSNAAVDELMKKIILEFKEKCKDKKNPLGNCGDINLVRLGPEKSINSEVLKFSLDSQVNHRMKKELPSHVQAMHKRKEFLDYQLDELSRQRALCRGGREIQRQELDENISKVSKERQELASKIKEVQGRPQKTQSIIILESHIICCTLSTSGGLLLESAFRGQGGVPFSCVIVDEAGQSCEIETLTPLIHRCNKLILVGDPKQLPPTVISMKAQEYGYDQSMMARFCRLLEENVEHNMISRLPILQLTVQYRMHPDICLFPSNYVYNRNLKTNRQTEAIRCSSDWPFQPYLVFDVGDGSERRDNDSYINVQEIKLVMEIIKLIKDKRKDVSFRNIGIITHYKAQKTMIQKDLDKEFDRKGPAEVDTVDAFQGRQKDCVIVTCVRANSIQGSIGFLASLQRLNVTITRAKYSLFILGHLRTLMENQHWNQLIQDAQKRGAIIKTCDKNYRHDAVKILKLKPVLQRSLTHPPTIAPEGSRPQGGLPSSKLDSGFAKTSVAASLYHTPSDSKEITLTVTSKDPERPPVHDQLQDPRLLKRMGIEVKGGIFLWDPQPSSPQHPGATPPTGEPGFPVVHQDLSHIQQPAAVVAALSSHKPPVRGEPPAASPEASTCQSKCDDPEEELCHRREARAFSEGEQEKCGSETHHTRRNSRWDKRTLEQEDSSSKKRKLL,0,,,,,,"Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2:A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.|Amyotrophic lateral sclerosis 4:A form of amyotrophic lateral sclerosis with childhood- or adolescent-onset, and characterized by slow disease progression and the sparing of bulbar and respiratory muscles. Amyotrophic lateral sclerosis is a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.","Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2|Amyotrophic lateral sclerosis 4",P24928(POLR2A)|Q8N6K7-2(SAMD3)|Q7Z333(SETX)|Q9GZS3(SKIC8)|Q16637(SMN2)|P63279(UBE2I)|O75604-3(USP2),,1:Q7Z333-1:|3:Q7Z333-3:|4:Q7Z333-4:,,,,,,,,,,5.0
Q8NDH6,,Islet cell autoantigen 1-like protein,ICA1L,Homo sapiens,482,False,ALS2CR14|ALS2CR15,MDSFGQPRPEDNQSVVRRMQKKYWKTKQVFIKATGKKEDEHLVASDAELDAKLEVFHSVQETCTELLKIIEKYQLRLNVISEEENELGLFLKFQAERDATQAGKMMDATGKALCSSAKQRLALCTPLSRLKQEVATFSQRAVSDTLMTINRMEQARTEYRGALLWMKDVSQELDPDTLKQMEKFRKVQMQVRNSKASFDKLKMDVCQKVDLLGASRCNMLSHSLTTYQRTLLGFWKKTARMMSQIHEACIGFHPYDFVALKQLQDTPSKISEDNKDEQIGGFLTEQLNKLVLSDEEASFESEQANKDHNEKHSQMREFGAPQFSNSENVAKDLPVDSLEGEDFEKEFSFLNNLLSSGSSSTSEFTQECQTAFGSPSASLTSQEPSMGSEPLAHSSRFLPSQLFDLGFHVAGAFNNWVSQEESELCLSHTDNQPVPSQSPKKLTRSPNNGNQDMSAWFNLFADLDPLSNPDAIGHSDDELLNA,0,,,,,,,,Q9BVG8(KIFC3)|Q9C005(DPY30)|P22607(FGFR3)|Q96CN9(GCC1)|P14136(GFAP)|Q14957(GRIN2C)|O14964(HGS)|P01112(HRAS)|Q8WXH2(JPH3)|O14901(KLF11)|Q7Z3Y8(KRT27)|P25791-3(LMO2)|Q9BVL2(NUP58)|Q9P2K3-2(RCOR3)|Q9Y5L0(TNPO3)|Q9Y649(),,1:Q8NDH6-1:|2:Q8NDH6-2:,,,,,,,,,,5.0
Q6P1L5,,Protein FAM117B,FAM117B,Homo sapiens,589,False,ALS2CR13,MSQRVRRNGSPTPAGSLGGGAVATAGGPGSRLQPMRATVPFQLKQQQQQQHGSPTRSGGGGGGNNNGGCCGGASGPAGGGGGGGPRTASRSTSPTRGGGNAAARTSPTVATQTGASATSTRGTSPTRSAAPGARGSPPRPPPPPPLLGTVSSPSSSPTHLWTGEVSAAPPPARVRHRRRSPEQSRSSPEKRSPSAPVCKAGDKTRQPSSSPSSIIRRTSSLDTLAAPYLAGHWPRDSHGQAAPCMRDKATQTESAWAEEYSEKKKGSHKRSASWGSTDQLKEIAKLRQQLQRSKHSSRHHRDKERQSPFHGNHAAINQCQAPVPKSALIPVIPITKSTGSRFRNSVEGLNQEIEIIIKETGEKEEQLIPQDIPDGHRAPPPLVQRSSSTRSIDTQTPGGADRGSNNSSRSQSVSPTSFLTISNEGSEESPCSADDLLVDPRDKENGNNSPLPKYATSPKPNNSYMFKREPPEGCERVKVFEECSPKQLHEIPAFYCPDKNKVNFIPKSGSAFCLVSILKPLLPTPDLTLKGSGHSLTVTTGMTTTLLQPIAVASLSTNTEQDRVSRGTSTVMPSASLLPPPEPIEEAEG,0,,,,,,,,O95994(AGR2)|P24539(ATP5PB)|P46379-2(BAG6)|Q8N9N5(BANP)|Q8N9N5-2(BANP)|O75190(DNAJB6)|Q01658(DR1)|P63167(DYNLL1)|Q96FJ2(DYNLL2)|P21333-2(FLNA)|P78333(GPC5)|Q9Y5Q9(GTF3C3)|P04792(HSPB1)|Q9UMF0(ICAM5)|Q14145(KEAP1)|O60333-2(KIF1B)|O14901(KLF11)|P31153(MAT2A)|Q8N2W9(PIAS4)|O60260-5(PRKN)|P60891(PRPS1)|Q9Y3C5(RNF11)|P31947(SFN)|Q13148(TARDBP)|O76024(WFS1),,1:Q6P1L5-1:|2:Q6P1L5-2:,,,,,,,,,,5.0
Q96Q45,,Transmembrane protein 237,TMEM237,Homo sapiens,408,False,ALS2CR4,MRTDSGARLEEGHLRPPRALPPVPSQDDIPLSRPKKKKPRTKNTPASASLEGLAQTAGRRPSEGNEPSTKELKEHPEAPVQRRQKKTRLPLELETSSTQKKSSSSSLLRNENGIDAEPAEEAVIQKPRRKTKKTQPAELQYANELGVEDEDIITDEQTTVEQQSVFTAPTGISQPVGKVFVEKSRRFQAADRSELIKTTENIDVSMDVKPSWTTRDVALTVHRAFRMIGLFSHGFLAGCAVWNIVVIYVLAGDQLSNLSNLLQQYKTLAYPFQSLLYLLLALSTISAFDRIDFAKISVAIRNFLALDPTALASFLYFTALILSLSQQMTSDRIHLYTPSSVNGSLWEAGIEEQILQPWIVVNLVVALLVGLSWLFLSYRPGMDLSEELMFSSEVEEYPDKEKEIKASS,0,,,,,,"Joubert syndrome 14:An autosomal recessive disorder characterized by severe intellectual disability, hypotonia, breathing abnormalities in infancy, and dysmorphic facial features. Neuroradiologically, it is characterized by cerebellar vermian hypoplasia/aplasia, thickened and reoriented superior cerebellar peduncles, and an abnormally large interpeduncular fossa, giving the appearance of a molar tooth on transaxial slices (molar tooth sign). Additional variable features include renal disease, abnormal eye movements, and postaxial polydactyly.",Joubert syndrome 14,P13569(CFTR)|O95870(ABHD16A)|Q08AM2(ADAM33)|Q15848(ADIPOQ)|P05090(APOD)|O95236-2(APOL3)|P29972(AQP1)|Q9HD20-3(ATP13A1)|O15155(BET1)|P62952(BLCAP)|Q12982(BNIP2)|Q8WVV5(BTN2A2)|Q8WVX3-2(C4orf3)|P27352(CBLIF)|Q9P0B6(CCDC167)|P19397(CD53)|Q92903(CDS1)|Q9BXR6(CFHR5)|O14493(CLDN4)|Q9NWW5(CLN6)|Q8TBE1(CNIH3)|Q07325(CXCL9)|O43169(CYB5B)|P52803(EFNA5)|Q9BV81(EMC6)|Q7Z2K6(ERMP1)|Q92935(EXTL1)|Q9NWM8(FKBP14)|Q9H0Q3(FXYD6)|O75084(FZD7)|P29033(GJB2)|Q86XP6(GKN2)|Q8TDT2(GPR152)|O00155(GPR25)|O15529(GPR42)|Q14416(GRM2)|Q02747(GUCA2A)|P02724(GYPA)|Q9Y5U9(IER3IP1)|P15260(IFNGR1)|P24593(IGFBP5)|O15503(INSIG1)|Q9Y5U4(INSIG2)|Q8N5M9(JAGN1)|O43561-2(LAT)|O95214(LEPROTL1)|Q9UBY5(LPAR3)|Q7Z4F1(LRP10)|P01374(LTA)|Q9GZY8-5(MFF)|Q6N075(MFSD5)|Q6ZSS7(MFSD6)|Q5J8X5(MS4A13)|P41143(OPRD1)|Q8N138(ORMDL3)|Q7RTS6(OTOP2)|Q7RTS5(OTOP3)|Q96GM1(PLPPR2)|P54315(PNLIPRP1)|Q8WZA1(POMGNT1)|Q59EV6(PPGB)|A5D903(PRB1)|Q86VR2(RETREG3)|Q02161-2(RHD)|Q9HCK4(ROBO2)|Q9NS64(RPRM)|Q96GQ5(RUSF1)|Q96IW7(SEC22A)|Q8N6R1(SERP2)|P05121(SERPINE1)|Q8TD22(SFXN5)|Q9Y666-2(SLC12A7)|O15374-3(SLC16A4)|P22732(SLC2A5)|Q8IWU4(SLC30A8)|Q96G79(SLC35A4)|Q8TB61(SLC35B2)|Q969S0(SLC35B4)|Q6ICL7(SLC35E4)|Q2M3R5(SLC35G1)|Q96QD8(SLC38A2)|Q9NVC3(SLC38A7)|Q9NP94(SLC39A2)|Q9NUM3(SLC39A9)|Q8IVJ1(SLC41A1)|Q96JW4(SLC41A2)|Q9NWF4(SLC52A1)|Q9NY91(SLC5A4)|P30825(SLC7A1)|Q8WY07(SLC7A3)|Q96JF0-2(ST6GAL2)|P0DN84(STRIT1)|Q9UNK0(STX8)|Q96MV1(TLCD4)|Q96DZ7(TM4SF19)|Q9BZW4(TM6SF2)|Q9UIK5(TMEFF2)|Q6UX40(TMEM107)|P17152(TMEM11)|Q5BJH2-2(TMEM128)|Q7Z5S9(TMEM144)|Q9BVK8(TMEM147)|Q7Z7N9(TMEM179B)|Q5SNT2-2(TMEM201)|Q8TBM7(TMEM254)|Q69YG0(TMEM42)|Q9H2L4(TMEM60)|A0PK05(TMEM72)|Q8N661(TMEM86B)|Q5BVD1(TTMP)|A5PKU2(TUSC5)|Q86WB7-2(UNC93A)|Q9H1C4(UNC93B1)|O75841(UPK1B)|Q15836(VAMP3)|P15692-12(VEGFA)|Q96EC8(YIPF6)|O95159(ZFPL1)|Q96FB2(),,1:Q96Q45-1:|2:Q96Q45-2:|3:Q96Q45-3:|4:Q96Q45-4:|5:Q96Q45-5:,,,,,,,,,,5.0
Q9GZT8,,NIF3-like protein 1,NIF3L1,Homo sapiens,377,False,ALS2CR1,MLSSCVRPVPTTVRFVDSLICNSSRSFMDLKALLSSLNDFASLSFAESWDNVGLLVEPSPPHTVNTLFLTNDLTEEVMEEVLQKKADLILSYHPPIFRPMKRITWNTWKERLVIRALENRVGIYSPHTAYDAAPQGVNNWLAKGLGACTSRPIHPSKAPNYPTEGNHRVEFNVNYTQDLDKVMSAVKGIDGVSVTSFSARTGNEEQTRINLNCTQKALMQVVDFLSRNKQLYQKTEILSLEKPLLLHTGMGRLCTLDESVSLATMIDRIKRHLKLSHIRLALGVGRTLESQVKVVALCAGSGSSVLQGVEADLYLTGEMSHHDTLDAASQGINVILCEHSNTERGFLSDLRDMLDSHLENKINIILSETDRDPLQVV,0,,,,,,,,Q9NXW9(ALKBH4)|Q2VPB7(AP5B1)|Q7Z6K5(ARPIN)|Q8N7W2(BEND7)|Q9NWQ9(C14orf119)|P55210(CASP7)|Q68D86(CCDC102B)|P42772(CDKN2B)|P42773(CDKN2C)|P55273(CDKN2D)|Q9NUQ9(CYRIB)|Q9UHG0(DCDC2)|P49366(DHPS)|Q14565(DMC1)|Q86UW9(DTX2)|Q9BVJ7(DUSP23)|Q68J44(DUSP29)|P51808(DYNLT3)|P38919(EIF4A3)|Q9GZV4(EIF5A2)|O15197-2(EPHB6)|Q8NFF5-2(FLAD1)|P51116(FXR2)|P62993(GRB2)|Q96PC2(IP6K3)|Q9NZI2-2(KCNIP1)|Q96MP8-2(KCTD7)|Q7L273(KCTD9)|Q9UHA4(LAMTOR3)|P25791(LMO2)|Q8TAP4-4(LMO3)|Q8N6N6(NATD1)|Q9HC98-4(NEK6)|Q9NPG2(NGB)|Q9GZT8(NIF3L1)|Q9Y5B8(NME7)|O95848(NUDT14)|A4D0P7(ORC5L)|Q15102(PAFAH1B3)|O15160(POLR1C)|O43447(PPIH)|Q15257-2(PTPA)|Q9UI14(RABAC1)|P21673(SAT1)|Q8WYJ6(SEPTIN1)|Q9NZD8(SPG21)|O75716(STK16)|P50226(SULT1A2)|P0DMN0(SULT1A4)|Q06520(SULT2A1)|Q9BSW7(SYT17)|P56279(TCL1A)|P14373(TRIM27)|Q15645(TRIP13)|P10599(TXN)|P07947(YES1)|P14079(tax)|Q85601(),,1:Q9GZT8-1:|2:Q9GZT8-2:|3:Q9GZT8-3:,,,,,,,,,,5.0
O60296,,Trafficking kinesin-binding protein 2,TRAK2,Homo sapiens,914,False,ALS2CR3|KIAA0549,MSQSQNAIFTSPTGEENLMNSNHRDSESITDVCSNEDLPEVELVSLLEEQLPQYRLKVDTLFLYENQDWTQSPHQRQHASDALSPVLAEETFRYMILGTDRVEQMTKTYNDIDMVTHLLAERDRDLELAARIGQALLKRNHVLSEQNESLEEQLGQAFDQVNQLQHELCKKDELLRIVSIASEESETDSSCSTPLRFNESFSLSQGLLQLEMLQEKLKELEEENMALRSKACHIKTETVTYEEKEQQLVSDCVKELRETNAQMSRMTEELSGKSDELIRYQEELSSLLSQIVDLQHKLKEHVIEKEELKLHLQASKDAQRQLTMELHELQDRNMECLGMLHESQEEIKELRSRSGPTAHLYFSQSYGAFTGESLAAEIEGTMRKKLSLDEESSLFKQKAQQKRVFDTVRIANDTRGRSISFPALLPIPGSNRSSVIMTAKPFESGLQQTEDKSLLNQGSSSEEVAGSSQKMGQPGPSGDSDLATALHRLSLRRQNYLSEKQFFAEEWQRKIQVLADQKEGVSGCVTPTESLASLCTTQSEITDLSSASCLRGFMPEKLQIVKPLEGSQTLYHWQQLAQPNLGTILDPRPGVITKGFTQLPGDAIYHISDLEEDEEEGITFQVQQPLEVEEKLSTSKPVTGIFLPPITSAGGPVTVATANPGKCLSCTNSTFTFTTCRILHPSDITQVTPSSGFPSLSCGSSGSSSSNTAVNSPALSYRLSIGESITNRRDSTTTFSSTMSLAKLLQERGISAKVYHSPISENPLQPLPKSLAIPSTPPNSPSHSPCPSPLPFEPRVHLSENFLASRPAETFLQEMYGLRPSRNPPDVGQLKMNLVDRLKRLGIARVVKNPGAQENGRCQEAEIGPQKPDSAVYLNSGSSLLGGLRRNQSLPVIMGSFAAPVCTSSPKMGVLKED,0,,,,,,,,,,1:O60296-1:|2:O60296-2:,,,,,,,,,,5.0
Q96Q35,,Flagellum-associated coiled-coil domain-containing protein 1,FLACC1,Homo sapiens,445,False,ALS2CR12,MYPNPLIYCTCWDPWNLGPRKLIKTPQLPRKNSTGSSKLTPLVPAPKNHNYLQPTKPVVSPKMKIHSARQEETNKSFYEVINVSPGYQLVRNREQISVTLGDEMFDRKKRWESEIPDKGRFSRTNIISDLEEQISELTAIIEQMNRDHQSAQKLLSSEMDLRCAEMKQNFENKNRELKEAHEAELSELENNYKAALKAEKLAAQEKLEEMGKEYKYLKNMFRTYQDSIYDEMEEKWSKQKAKWKKDEKFERENILLQQKKKMTKKFEMESGEEDKKINESCSAVFENFIQEKEELLKQHQSDTLQLEELRKTKEVPWRRDQINRHWHDVLQQLLLMQVMQEELHAQALILESLNTNLYYTQLELQKEKAIVGNLEKMLQTKFAETEEKYKHTIQILTEENIHLKQKIISKNEEICEGCSGRLASITVSKDDSDTVQDGSKKGQES,0,,,,,,,,O75716(STK16)|O00204(SULT2B1)|P56279(TCL1A)|Q86UY0(TXNDC5)|Q9UI12(ATP6V1H)|P51451(BLK)|P46108(CRK)|Q9NRI5-2(DISC1)|Q92997(DVL3)|Q86YD7(FAM90A1)|Q9C086(INO80B)|Q8TCE9(LGALS14)|Q17RB8(LONRF1)|Q8WWY3(PRPF31)|Q9NZD8(SPG21)|Q16385-2(SSX2B)|O60224(SSX4B)|O00204(SULT2B1)|Q96N21(TEPSIN)|Q8WV44(TRIM41)|P07947(YES1),,1:Q96Q35-1:|2:Q96Q35-2:,,,,,,,,,,5.0
Q70E73,,Ras-associated and pleckstrin homology domains-containing protein 1,RAPH1,Homo sapiens,1250,False,ALS2CR18|ALS2CR9|KIAA1681|LPD|PREL2|RMO1,MEQLSDEEIDHGAEEDSDKEDQDLDKMFGAWLGELDKLTQSLDSDKPMEPVKRSPLRQETNMANFSYRFSIYNLNEALNQGETVDLDALMADLCSIEQELSSIGSGNSKRQITETKATQKLPVSRHTLKHGTLKGLSSSSNRIAKPSHASYSLDDVTAQLEQASLSMDEAAQQSVLEDTKPLVTNQHRRTASAGTVSDAEVHSISNSSHSSITSAASSMDSLDIDKVTRPQELDLTHQGQPITEEEQAAKLKAEKIRVALEKIKEAQVKKLVIRVHMSDDSSKTMMVDERQTVRQVLDNLMDKSHCGYSLDWSLVETVSELQMERIFEDHENLVENLLNWTRDSQNKLIFMERIEKYALFKNPQNYLLGKKETAEMADRNKEVLLEECFCGSSVTVPEIEGVLWLKDDGKKSWKKRYFLLRASGIYYVPKGKAKVSRDLVCFLQLDHVNVYYGQDYRNKYKAPTDYCLVLKHPQIQKKSQYIKYLCCDDVRTLHQWVNGIRIAKYGKQLYMNYQEALKRTESAYDWTSLSSSSIKSGSSSSSIPESQSNHSNQSDSGVSDTQPAGHVRSQSIVSSVFSEAWKRGTQLEESSKARMESMNRPYTSLVPPLSPQPKIVTPYTASQPSPPLPPPPPPPPPPPPPPPPPPPPLPSQSAPSAGSAAPMFVKYSTITRLQNASQHSGALFKPPTPPVMQSQSVKPQILVPPNGVVPPPPPPPPPPTPGSAMAQLKPAPCAPSLPQFSAPPPPLKIHQVQHITQVAPPTPPPPPPIPAPLPPQAPPKPLVTIPAPTSTKTVAPVVTQAAPPTPTPPVPPAKKQPAFPASYIPPSPPTPPVPVPPPTLPKQQSFCAKPPPSPLSPVPSVVKQIASQFPPPPTPPAMESQPLKPVPANVAPQSPPAVKAKPKWQPSSIPVPSPDFPPPPPESSLVFPPPPPSPVPAPPPPPPPTASPTPDKSGSPGKKTSKTSSPGGKKPPPTPQRNSSIKSSSGAEHPEPKRPSVDSLVSKFTPPAESGSPSKETLPPPAAPPKPGKLNLSGVNLPGVLQQGCVSAKAPVLSGRGKDSVVEFPSPPSDSDFPPPPPETELPLPPIEIPAVFSGNTSPKVAVVNPQPQQWSKMSVKKAPPPTRPKRNDSTRLTQAEISEQPTMATVVPQVPTSPKSSLSVQPGFLADLNRTLQRKSITRHGSLSSRMSRAEPTATMDDMALPPPPPELLSDQQKAGYGGSHISGYATLRRGPPPAPPKRDQNTKLSRDW,0,,,,,,,,P00533(EGFR)|Q99962(SH3GL2)|Q99963(SH3GL3)|O35964(Sh3gl1),,RMO1-RAPH1:Q70E73-10:|RMO1:Q70E73-2:|RMO1a:Q70E73-3:|RMO1b:Q70E73-4:|RMO1c:Q70E73-5:|RMO1ab:Q70E73-6:|RMO1ac:Q70E73-7:|RMO1bc:Q70E73-8:|RMO1abc:Q70E73-9:,,,,,,,,,,5.0
Q96JB8,,MAGUK p55 subfamily member 4,MPP4,Homo sapiens,637,False,ALS2CR5|DLG6,MIQSDKGADPPDKKDMKLSTATNPQNGLSQILRLVLQELSLFYGRDVNGVCLLYDLLHSPWLQALLKIYDCLQEFKEKKLVPATPHAQVLSYEVVELLRETPTSPEIQELRQMLQAPHFKALLSAHDTIAQKDFEPLLPPLPDNIPESEEAMRIVCLVKNQQPLGATIKRHEMTGDILVARIIHGGLAERSGLLYAGDKLVEVNGVSVEGLDPEQVIHILAMSRGTIMFKVVPVSDPPVNSQQMVYVRAMTEYWPQEDPDIPCMDAGLPFQKGDILQIVDQNDALWWQARKISDPATCAGLVPSNHLLKRKQREFWWSQPYQPHTCLKSTLSISMEEEDDMKIDEKCVEADEETFESEELSEDKEEFVGYGQKFFIAGFRRSMRLCRRKSHLSPLHASVCCTGSCYSAVGAPYEEVVRYQRRPSDKYRLIVLMGPSGVGVNELRRQLIEFNPSHFQSAVPHTTRTKKSYEMNGREYHYVSKETFENLIYSHRMLEYGEYKGHLYGTSVDAVQTVLVEGKICVMDLEPQDIQGVRTHELKPYVIFIKPSNMRCMKQSRKNAKVITDYYVDMKFKDEDLQEMENLAQRMETQFGQFFDHVIVNDSLHDACAQLLSAIQKAQEEPQWVPATWISSDTESQ,0,,,,,,,,P82279(CRB1)|Q8N3R9(PALS1),,1:Q96JB8-1:|2:Q96JB8-2:|3:Q96JB8-3:|4:Q96JB8-4:|5:Q96JB8-5:,,,,,,,,,,5.0
Q8N187,,Calcium-responsive transcription factor,CARF,Homo sapiens,725,False,ALS2CR8,MEQSNDSLRVNHNDGEESKTSAQVFEHLICMDSRDSSFGQNDSPTVLPITTREANNSLISQNIPGPLTQTQTLSAEQFHLVDQNGQAIQYELQSLGESNAQMMIVASPTENGQVLRVIPPTQTGMAQVIIPQGQLVDVNSPRDVPEEKPSNRNLPTVRVDTLADNTSNYILHPQTSFPLPKKSVTGMLEEPLLGPLQPLSSNTPIWACRLRSCEKIGDSYRGYCVSETELESVLTFHKQQTQSVWGTRQSPSPAKPATRLMWKSQYVPYDGIPFVNAGSRAVVMECQYGPRRKGFQLKKVSEQESRSCQLYKATCPARIYIKKVQKFPEYRVPTDPKIDKKIIRMEQEKAFNMLKKNLVDAGGVLRWYVQLPTQQAHQYHELETPCLTLSPSPFPVSSLEEEETAVRDENCALPSRLHPQVAHKIQELVSQGIEQVYAVRKQLRKFVERELFKPDEVPERHNLSFFPTVNDIKNHIHEVQKSLRNGDTVYNSEIIPATLQWTTDSGNILKETMTVTFAEGNSPGESITTKVETNQTRGSLSPEPTHLLSSLSSFQPKIFTQLQGLQLQPRYTSPDESPAVVSVNNQPSSSPSGLLDTIGSAVMNNNSLLLGQSHSLQRDTCLTQNNSTASTMGNLPEPDQNLVAMDELVEVGDVEDTGNLEGTVHRILLGDVQTIPIQIIDNHSALIEENPESTISVSQVKQEPKEPALSMEAKKTVDYKKLSAT,0,,,,,,,,Q53EZ4(CEP55)|Q9NSE2(CISH)|Q9NR30(DDX21)|Q9BUZ4(TRAF4)|Q8NAP3(ZBTB38),,1:Q8N187-1:|2:Q8N187-2:|3:Q8N187-3:,,,,,,,,,,5.0
Q15303,,Receptor tyrosine-protein kinase erbB-4,ERBB4,Homo sapiens,1308,False,HER4,MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV,0,,,,,,"Amyotrophic lateral sclerosis 19:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis 19,P42684(ABL2)|Q13895(BYSL)|P78352(DLG4)|P00533(EGFR)|P04626(ERBB2)|P21860(ERBB3)|Q99075(HBEGF)|P08238(HSP90AB1)|Q96J02-2(ITCH)|Q96JA1(LRIG1)|Q02297-6(NRG1)|P26447(S100A4)|P29353(SHC1)|Q12815(TROAP)|P46937(YAP1)|P62258(YWHAE)|Q96J02-2(ITCH),,JM-A CYT-1:Q15303-1:|JM-B CYT-1:Q15303-2:|JM-A CYT-2:Q15303-3:|JM-B CYT-2:Q15303-4:,,,,,,,,,,5.0
Q92562,,Polyphosphoinositide phosphatase,FIG4,Homo sapiens,907,False,KIAA0274|SAC3,MPTAAAPIISSVQKLVLYETRARYFLVGSNNAETKYRVLKIDRTEPKDLVIIDDRHVYTQQEVRELLGRLDLGNRTKMGQKGSSGLFRAVSAFGVVGFVRFLEGYYIVLITKRRKMADIGGHAIYKVEDTNMIYIPNDSVRVTHPDEARYLRIFQNVDLSSNFYFSYSYDLSHSLQYNLTVLRMPLEMLKSEMTQNRQESFDIFEDEGLITQGGSGVFGICSEPYMKYVWNGELLDIIKSTVHRDWLLYIIHGFCGQSKLLIYGRPVYVTLIARRSSKFAGTRFLKRGANCEGDVANEVETEQILCDASVMSFTAGSYSSYVQVRGSVPLYWSQDISTMMPKPPITLDQADPFAHVAALHFDQMFQRFGSPIIILNLVKEREKRKHERILSEELVAAVTYLNQFLPPEHTIVYIPWDMAKYTKSKLCNVLDRLNVIAESVVKKTGFFVNRPDSYCSILRPDEKWNELGGCVIPTGRLQTGILRTNCVDCLDRTNTAQFMVGKCALAYQLYSLGLIDKPNLQFDTDAVRLFEELYEDHGDTLSLQYGGSQLVHRVKTYRKIAPWTQHSKDIMQTLSRYYSNAFSDADRQDSINLFLGVFHPTEGKPHLWELPTDFYLHHKNTMRLLPTRRSYTYWWTPEVIKHLPLPYDEVICAVNLKKLIVKKFHKYEEEIDIHNEFFRPYELSSFDDTFCLAMTSSARDFMPKTVGIDPSPFTVRKPDETGKSVLGNKSNREEAVLQRKTAASAPPPPSEEAVSSSSEDDSGTDREEEGSVSQRSTPVKMTDAGDSAKVTENVVQPMKELYGINLSDGLSEEDFSIYSRFVQLGQSQHKQDKNSQQPCSRCSDGVIKLTPISAFSQDNIYEVQPPRVDRKSTEIFQAHIQASQGIMQPLGKEDSSMYREYIRNRYL,0,,,,,,"Charcot-Marie-Tooth disease, demyelinating, 4J:A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.|Amyotrophic lateral sclerosis 11:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Yunis-Varon syndrome:A severe autosomal recessive disorder characterized by skeletal defects, including cleidocranial dysplasia and digital anomalies, and severe neurologic involvement with neuronal loss. Enlarged cytoplasmic vacuoles are found in neurons, muscle, and cartilage. The disorder is usually lethal in infancy.|Polymicrogyria, bilateral temporooccipital:A disease characterized by temporo-occipital polymicrogyria, psychiatric manifestations, and epilepsy.","Charcot-Marie-Tooth disease, demyelinating, 4J|Amyotrophic lateral sclerosis 11|Yunis-Varon syndrome|Polymicrogyria, bilateral temporooccipital",Q9H8Y8(GORASP2)|Q9Y2I7(PIKFYVE)|Q08AM6(VAC14),,,,,,,,,,,,5.0
Q96PY6,,Serine/threonine-protein kinase Nek1,NEK1,Homo sapiens,1258,False,KIAA1901,MEKYVRLQKIGEGSFGKAILVKSTEDGRQYVIKEINISRMSSKEREESRREVAVLANMKHPNIVQYRESFEENGSLYIVMDYCEGGDLFKRINAQKGVLFQEDQILDWFVQICLALKHVHDRKILHRDIKSQNIFLTKDGTVQLGDFGIARVLNSTVELARTCIGTPYYLSPEICENKPYNNKSDIWALGCVLYELCTLKHAFEAGSMKNLVLKIISGSFPPVSLHYSYDLRSLVSQLFKRNPRDRPSVNSILEKGFIAKRIEKFLSPQLIAEEFCLKTFSKFGSQPIPAKRPASGQNSISVMPAQKITKPAAKYGIPLAYKKYGDKKLHEKKPLQKHKQAHQTPEKRVNTGEERRKISEEAARKRRLEFIEKEKKQKDQIISLMKAEQMKRQEKERLERINRAREQGWRNVLSAGGSGEVKAPFLGSGGTIAPSSFSSRGQYEHYHAIFDQMQQQRAEDNEAKWKREIYGRGLPERGILPGVRPGFPYGAAGHHHFPDADDIRKTLKRLKAVSKQANANRQKGQLAVERAKQVEEFLQRKREAMQNKARAEGHMVYLARLRQIRLQNFNERQQIKAKLRGEKKEANHSEGQEGSEEADMRRKKIESLKAHANARAAVLKEQLERKRKEAYEREKKVWEEHLVAKGVKSSDVSPPLGQHETGGSPSKQQMRSVISVTSALKEVGVDSSLTDTRETSEEMQKTNNAISSKREILRRLNENLKAQEDEKGKQNLSDTFEINVHEDAKEHEKEKSVSSDRKKWEAGGQLVIPLDELTLDTSFSTTERHTVGEVIKLGPNGSPRRAWGKSPTDSVLKILGEAELQLQTELLENTTIRSEISPEGEKYKPLITGEKKVQCISHEINPSAIVDSPVETKSPEFSEASPQMSLKLEGNLEEPDDLETEILQEPSGTNKDESLPCTITDVWISEEKETKETQSADRITIQENEVSEDGVSSTVDQLSDIHIEPGTNDSQHSKCDVDKSVQPEPFFHKVVHSEHLNLVPQVQSVQCSPEESFAFRSHSHLPPKNKNKNSLLIGLSTGLFDANNPKMLRTCSLPDLSKLFRTLMDVPTVGDVRQDNLEIDEIEDENIKEGPSDSEDIVFEETDTDLQELQASMEQLLREQPGEEYSEEEESVLKNSDVEPTANGTDVADEDDNPSSESALNEEWHSDNSDGEIASECECDSVFNHLEELRLHLEQEMGFEKFFEVYEKIKAIHEDEDENIEICSKIVQNILGNEHQHLYAKILHLVMADGAYQEDNDE,0,,,,,,"Short-rib thoracic dysplasia 6 with or without polydactyly:A form of short-rib thoracic dysplasia, a group of autosomal recessive ciliopathies that are characterized by a constricted thoracic cage, short ribs, shortened tubular bones, and a 'trident' appearance of the acetabular roof. Polydactyly is variably present. Non-skeletal involvement can include cleft lip/palate as well as anomalies of major organs such as the brain, eye, heart, kidneys, liver, pancreas, intestines, and genitalia. Some forms of the disease are lethal in the neonatal period due to respiratory insufficiency secondary to a severely restricted thoracic cage, whereas others are compatible with life. Disease spectrum encompasses Ellis-van Creveld syndrome, asphyxiating thoracic dystrophy (Jeune syndrome), Mainzer-Saldino syndrome, and short rib-polydactyly syndrome.|Amyotrophic lateral sclerosis 24:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Orofaciodigital syndrome 2:A form of orofaciodigital syndrome, a group of heterogeneous disorders characterized by malformations of the oral cavity, face and digits, and associated phenotypic abnormalities that lead to the delineation of various subtypes. OFD2 is an autosomal recessive form characterized by cleft lip/palate, lobulated tongue with nodules, dental anomalies, maxillary hypoplasia, conductive hearing loss, polydactyly, syndactyly, brachydactyly, and mesomelic lower limb shortening.",Short-rib thoracic dysplasia 6 with or without polydactyly|Amyotrophic lateral sclerosis 24|Orofaciodigital syndrome 2,Q96Q42(ALS2)|Q99689(FEZ1)|Q9UHY8(FEZ2)|Q5S007(LRRK2)|Q04917(YWHAH),,1:Q96PY6-1:|2:Q96PY6-2:|3:Q96PY6-3:|4:Q96PY6-4:|5:Q96PY6-5:|6:Q96PY6-6:,,,,,,,,,,5.0
Q96QT4,,Transient receptor potential cation channel subfamily M member 7,TRPM7,Homo sapiens,1865,False,CHAK1|LTRPC7,MSQKSWIESTLTKRECVYIIPSSKDPHRCLPGCQICQQLVRCFCGRLVKQHACFTASLAMKYSDVKLGDHFNQAIEEWSVEKHTEQSPTDAYGVINFQGGSHSYRAKYVRLSYDTKPEVILQLLLKEWQMELPKLVISVHGGMQKFELHPRIKQLLGKGLIKAAVTTGAWILTGGVNTGVAKHVGDALKEHASRSSRKICTIGIAPWGVIENRNDLVGRDVVAPYQTLLNPLSKLNVLNNLHSHFILVDDGTVGKYGAEVRLRRELEKTINQQRIHARIGQGVPVVALIFEGGPNVILTVLEYLQESPPVPVVVCEGTGRAADLLAYIHKQTEEGGNLPDAAEPDIISTIKKTFNFGQNEALHLFQTLMECMKRKELITVFHIGSDEHQDIDVAILTALLKGTNASAFDQLILTLAWDRVDIAKNHVFVYGQQWLVGSLEQAMLDALVMDRVAFVKLLIENGVSMHKFLTIPRLEELYNTKQGPTNPMLFHLVRDVKQGNLPPGYKITLIDIGLVIEYLMGGTYRCTYTRKRFRLIYNSLGGNNRRSGRNTSSSTPQLRKSHESFGNRADKKEKMRHNHFIKTAQPYRPKIDTVMEEGKKKRTKDEIVDIDDPETKRFPYPLNELLIWACLMKRQVMARFLWQHGEESMAKALVACKIYRSMAYEAKQSDLVDDTSEELKQYSNDFGQLAVELLEQSFRQDETMAMKLLTYELKNWSNSTCLKLAVSSRLRPFVAHTCTQMLLSDMWMGRLNMRKNSWYKVILSILVPPAILLLEYKTKAEMSHIPQSQDAHQMTMDDSENNFQNITEEIPMEVFKEVRILDSNEGKNEMEIQMKSKKLPITRKFYAFYHAPIVKFWFNTLAYLGFLMLYTFVVLVQMEQLPSVQEWIVIAYIFTYAIEKVREIFMSEAGKVNQKIKVWFSDYFNISDTIAIISFFIGFGLRFGAKWNFANAYDNHVFVAGRLIYCLNIIFWYVRLLDFLAVNQQAGPYVMMIGKMVANMFYIVVIMALVLLSFGVPRKAILYPHEAPSWTLAKDIVFHPYWMIFGEVYAYEIDVCANDSVIPQICGPGTWLTPFLQAVYLFVQYIIMVNLLIAFFNNVYLQVKAISNIVWKYQRYHFIMAYHEKPVLPPPLIILSHIVSLFCCICKRRKKDKTSDGPKLFLTEEDQKKLHDFEEQCVEMYFNEKDDKFHSGSEERIRVTFERVEQMCIQIKEVGDRVNYIKRSLQSLDSQIGHLQDLSALTVDTLKTLTAQKASEASKVHNEITRELSISKHLAQNLIDDGPVRPSVWKKHGVVNTLSSSLPQGDLESNNPFHCNILMKDDKDPQCNIFGQDLPAVPQRKEFNFPEAGSSSGALFPSAVSPPELRQRLHGVELLKIFNKNQKLGSSSTSIPHLSSPPTKFFVSTPSQPSCKSHLETGTKDQETVCSKATEGDNTEFGAFVGHRDSMDLQRFKETSNKIKILSNNNTSENTLKRVSSLAGFTDCHRTSIPVHSKQAEKISRRPSTEDTHEVDSKAALIPDWLQDRPSNREMPSEEGTLNGLTSPFKPAMDTNYYYSAVERNNLMRLSQSIPFTPVPPRGEPVTVYRLEESSPNILNNSMSSWSQLGLCAKIEFLSKEEMGGGLRRAVKVQCTWSEHDILKSGHLYIIKSFLPEVVNTWSSIYKEDTVLHLCLREIQQQRAAQKLTFAFNQMKPKSIPYSPRFLEVFLLYCHSAGQWFAVEECMTGEFRKYNNNNGDEIIPTNTLEEIMLAFSHWTYEYTRGELLVLDLQGVGENLTDPSVIKAEEKRSCDMVFGPANLGEDAIKNFRAKHHCNSCCRKLKLPDLKRNDYTPDKIIFPQDEPSDLNLQPGNSTKESESTNSVRLML,0,,,,,,"Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1:A neurodegenerative disorder characterized by chronic, progressive and uniformly fatal amyotrophic lateral sclerosis and parkinsonism-dementia. Both diseases are known to occur in the same kindred, the same sibship and even the same individual.|:",Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1,,,,,,,,,,,,,5.0
Q9UHD2,,Serine/threonine-protein kinase TBK1,TBK1,Homo sapiens,729,False,NAK,MQSTSNHLWLLSDILGQGATANVFRGRHKKTGDLFAIKVFNNISFLRPVDVQMREFEVLKKLNHKNIVKLFAIEEETTTRHKVLIMEFCPCGSLYTVLEEPSNAYGLPESEFLIVLRDVVGGMNHLRENGIVHRDIKPGNIMRVIGEDGQSVYKLTDFGAARELEDDEQFVSLYGTEEYLHPDMYERAVLRKDHQKKYGATVDLWSIGVTFYHAATGSLPFRPFEGPRRNKEVMYKIITGKPSGAISGVQKAENGPIDWSGDMPVSCSLSRGLQVLLTPVLANILEADQEKCWGFDQFFAETSDILHRMVIHVFSLQQMTAHKIYIHSYNTATIFHELVYKQTKIISSNQELIYEGRRLVLEPGRLAQHFPKTTEENPIFVVSREPLNTIGLIYEKISLPKVHPRYDLDGDASMAKAITGVVCYACRIASTLLLYQELMRKGIRWLIELIKDDYNETVHKKTEVVITLDFCIRNIEKTVKVYEKLMKINLEAAELGEISDIHTKLLRLSSSQGTIETSLQDIDSRLSPGGSLADAWAHQEGTHPKDRNVEKLQVLLNCMTEIYYQFKKDKAERRLAYNEEQIHKFDKQKLYYHATKAMTHFTDECVKKYEAFLNKSEEWIRKMLHLRKQLLSLTNQCFDIEEEVSKYQEYTNELQETLPQKMFTASSGIKHTMTPIYPSSNTLVEMTLGMKKLKEEMEGVVKELAENNHILERFGSLTMDGGLRNVDCL,0,,,,,,"Glaucoma 1, open angle, P:A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. GLC1P is characterized by early onset, thin central corneas and low intraocular pressure.|Frontotemporal dementia and/or amyotrophic lateral sclerosis 4:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.|Encephalopathy, acute, infection-induced, 8, herpes-specific:A rare, often fatal complication of herpes simplex infection, caused by virus spreading in the central nervous system. Disease manifestations include low-grade fever, severe headache, nausea, vomiting, and lethargy. Neurological features include confusion, acute memory disturbances, disorientation, behavioral changes, hemiparesis and seizures.|Autoinflammation with arthritis and vasculitis:An autosomal recessive disorder characterized by onset of chronic and systemic autoinflammation in infancy or early childhood. Affected individuals have recurrent fever, erythematous skin rashes, vasculitis, oral aphthous lesions, and polyarthritis. Additional variable features are poor overall growth, microcytic anemia, mild intellectual disability, and seizures.","Glaucoma 1, open angle, P|Frontotemporal dementia and/or amyotrophic lateral sclerosis 4|Encephalopathy, acute, infection-induced, 8, herpes-specific|Autoinflammation with arthritis and vasculitis",Q9UKV8(AGO2)|Q7Z3C6(ATG9A)|Q9H6S1(AZI2)|Q13137(CALCOCO2)|Q6DT37(CDC42BPG)|P08238(HSP90AB1)|Q9Y6W8(ICOS)|Q14164(IKBKE)|Q9Y6K9(IKBKG)|Q14653(IRF3)|Q92985(IRF7)|Q9H492(MAP1LC3A)|Q9GZQ8(MAP1LC3B)|Q7Z434(MAVS)|Q86YT6(MIB1)|Q96AX9(MIB2)|Q9NVV4(MTPAP)|Q96CV9(OPTN)|O14730(RIOK3)|P42226(STAT6)|Q86WV6(STING1)|O75558(STX11)|Q92844(TANK)|A7MCY6(TBKBP1)|Q8IUC6(TICAM1)|Q12933(TRAF2)|Q13114(TRAF3)|O95801(TTC4)|P40222(TXLNA)|Q62167(Ddx3x)|O41932(GAMMAHV.ORF11)|P0DTC5(M)|P59596(M)|W5VXH5(NSs)|P0DTD1(rep)|Q60803(Traf3)|Q8BHN1(Txlng)|Q05127(VP35)|I6W9F2()|K7Y1A2()|P27958()|P27958(),,,,,,,,,,,,5.0
Q9UHD9,,Ubiquilin-2,UBQLN2,Homo sapiens,624,False,N4BP4|PLIC2,MAENGESSGPPRPSRGPAAAQGSAAAPAEPKIIKVTVKTPKEKEEFAVPENSSVQQFKEAISKRFKSQTDQLVLIFAGKILKDQDTLIQHGIHDGLTVHLVIKSQNRPQGQSTQPSNAAGTNTTSASTPRSNSTPISTNSNPFGLGSLGGLAGLSSLGLSSTNFSELQSQMQQQLMASPEMMIQIMENPFVQSMLSNPDLMRQLIMANPQMQQLIQRNPEISHLLNNPDIMRQTLEIARNPAMMQEMMRNQDLALSNLESIPGGYNALRRMYTDIQEPMLNAAQEQFGGNPFASVGSSSSSGEGTQPSRTENRDPLPNPWAPPPATQSSATTSTTTSTGSGSGNSSSNATGNTVAAANYVASIFSTPGMQSLLQQITENPQLIQNMLSAPYMRSMMQSLSQNPDLAAQMMLNSPLFTANPQLQEQMRPQLPAFLQQMQNPDTLSAMSNPRAMQALMQIQQGLQTLATEAPGLIPSFTPGVGVGVLGTAIGPVGPVTPIGPIGPIVPFTPIGPIGPIGPTGPAAPPGSTGSGGPTGPTVSSAAPSETTSPTSESGPNQQFIQQMVQALAGANAPQLPNPEVRFQQQLEQLNAMGFLNREANLQALIATGGDINAAIERLLGSQPS,0,,,,,,"Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Patients with ALS15 may develop frontotemporal dementia.","Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia",Q9NYB9-2(ABI2)|O00154-4(ACOT7)|O15072(ADAMTS3)|Q16186(ADRM1)|O95994(AGR2)|Q8TD06(AGR3)|Q9NP70(AMBN)|Q7Z3H0-1(ANKRD33)|P55056(APOC4)|Q96B67(ARRDC3)|P50553(ASCL1)|P45381(ASPA)|Q9UBB4(ATXN10)|P25311(AZGP1)|P46379-2(BAG6)|O43521(BCL2L11)|Q9NP55(BPIFA1)|Q6P1W5(C1orf94)|P02745(C1QA)|P02746(C1QB)|P02747(C1QC)|Q86Z23(C1QL4)|Q9BXJ5(C1QTNF2)|Q9BXJ3(C1QTNF4)|Q6UXA7(C6orf15)|P07360(C8G)|O75808(CAPN15)|P06307(CCK)|O15467(CCL16)|P10147(CCL3)|P80098(CCL7)|O00622(CCN1)|Q8TCZ2(CD99L2)|P55291(CDH15)|Q12864(CDH17)|Q9H305(CDIP1)|P40199(CEACAM6)|Q9Y240(CLEC11A)|Q6UWE3(CLPSL2)|Q8NE01(CNNM3)|Q03692(COL10A1)|Q9UMD9(COL17A1)|P08123(COL1A2)|P27658(COL8A1)|Q14055(COL9A2)|Q8IYK4(COLGALT2)|P47710(CSN1S1)|P05814(CSN2)|P07498(CSN3)|P01037(CST1)|P01036(CST4)|P33240(CSTF2)|Q9H0L4(CSTF2T)|P78358(CTAG1B)|O95476(CTDNEP1)|Q15038(DAZAP2)|Q08345-2(DDR1)|P59665(DEFA1B)|Q01524(DEFA6)|Q30KQ5(DEFB115)|Q6ICB0(DESI1)|Q6E0U4(DMKN)|Q9H596(DUSP21)|Q16610(ECM1)|Q9H1Z8(ECRG4)|Q12805(EFEMP1)|Q8IUX8(EGFL6)|Q96DN0(ERP27)|P30040(ERP29)|Q9HBU6(ETNK1)|P00742(F10)|Q92567-2(FAM168A)|Q8WU58(FAM222B)|Q8NFU4(FDCSP)|O60258(FGF17)|P26885(FKBP2)|Q9BVV2(FNDC11)|P04066(FUCA1)|O75084(FZD7)|P22466(GAL)|Q9UBC7(GALP)|Q9UBU3(GHRL)|Q16538(GPR162)|Q96SL4(GPX7)|Q02747(GUCA2A)|Q16661(GUCA2B)|Q9Y5R4(HEMK1)|P07686(HEXB)|O14964(HGS)|P09651(HNRNPA1)|P09651-2(HNRNPA1)|Q00839(HNRNPU)|Q53GQ0(HSD17B12)|P48723(HSPA13)|P42858(HTT)|P05362(ICAM1)|P01562(IFNA1)|P24592(IGFBP6)|P15814(IGLL1)|P20809(IL11)|P0C7M6(IQCF3)|P53990-3(IST1)|P27987(ITPKB)|Q6GPH6-2(ITPRIPL1)|Q96JJ6(JPH4)|Q15726(KISS1)|Q9NVR0(KLHL11)|Q9P2K6(KLHL42)|P02538(KRT6A)|P59990(KRTAP12-1)|Q7Z4W3(KRTAP19-3)|Q3LI72(KRTAP19-5)|Q6ISS4(LAIR2)|Q14847-2(LASP1)|O95835-2(LATS1)|P31025(LCN1)|P80188(LCN2)|Q99732(LITAF)|P61968(LMO4)|O95868(LY6G6D)|Q9Y5V3(MAGED1)|P11226(MBL2)|P21741(MDK)|Q9NQG6(MIEF1)|Q96C03-3(MIEF2)|Q9UNW1(MINPP1)|Q96BY2(MOAP1)|O75431(MTX2)|Q969H8(MYDGF)|Q96JP2(MYO15B)|Q8IW45(NAXD)|P41271-2(NBL1)|Q9UHB4(NDOR1)|Q13232(NME3)|Q9BVI4(NOC4L)|O60936(NOL3)|P48145(NPBWR1)|P01160(NPPA)|Q9HCQ7(NPVF)|P01303(NPY)|Q496H8(NRN1L)|Q9H0P0(NT5C3A)|Q9BVL2(NUP58)|Q17RF5(ODAPH)|Q9UHM6(OPN4)|Q8NG98(OR7D4)|Q99650(OSMR)|Q6UWI2(PARM1)|Q9Y5G4-2(PCDHGA9)|Q8IYJ0(PIANP)|Q96FE7(PIK3IP1)|Q13526(PIN1)|Q9NWW9(PLAAT2)|P53816(PLAAT3)|Q96CS7(PLEKHB2)|Q969W9-2(PMEPA1)|Q9UL41(PNMA3)|O00592-2(PODXL)|P56282(POLE2)|Q96HA1-2(POM121)|P23284(PPIB)|P45877(PPIC)|O43447(PPIH)|Q96NZ9(PRAP1)|Q16378(PRR4)|Q13200(PSMD2)|Q9UIG4(PSORS1C2)|P41222(PTGDS)|Q16769(QPCT)|P54725(RAD23A)|P54727(RAD23B)|O43251-10(RBFOX2)|Q9BX46-2(RBM24)|Q9Y3C5(RNF11)|Q8TEB7(RNF128)|Q9H0X6(RNF208)|P78317(RNF4)|P62979(RPS27A)|Q7L4I2(RSRC2)|Q9BWD3(RTL8A)|Q17RB0(RTL8B)|A6ZKI3(RTL8C)|P05408(SCG5)|Q4G0G5(SCGB2B2)|P04279-2(SEMG1)|P05121(SERPINE1)|O75830(SERPINI2)|Q53EL9(SEZ6)|Q9BYH1-5(SEZ6L)|Q8IWL1(SFTPA2)|O43765(SGTA)|O15427(SLC16A3)|Q96PX8(SLITRK1)|P03973(SLPI)|P58511(SMIM11)|Q96E16(SMIM19)|Q9BVW6(SMIM2)|P02814(SMR3B)|P14678-2(SNRPB)|P08294(SOD3)|Q08648-4(SPAG11B)|O43278-2(SPINT1)|P16150(SPN)|P10124(SRGN)|Q9UHB9-2(SRP68)|O75886(STAM2)|P51687(SUOX)|Q5VX71-3(SUSD4)|Q96A09(TENT5B)|Q07654(TFF3)|Q9BVV7(TIMM21)|P16035(TIMP2)|Q8N131(TMEM123)|Q9Y5U5-2(TNFRSF18)|Q6UXN7(TOMM20L)|Q9BUZ4(TRAF4)|Q13049(TRIM32)|O95881(TXNDC12)|Q8NBS9(TXNDC5)|Q9BZF9(UACA)|P62987(UBA52)|Q9BSL1(UBAC1)|P0CG47(UBB)|P0CG48(UBC)|Q7KZS0(UBE2I)|Q13404(UBE2V1)|Q9UMX0(UBQLN1)|Q9UHD9(UBQLN2)|Q04323-2(UBXN1)|O94888(UBXN7)|Q6NVU6(UFSP1)|O95231(VENTX)|P01282-2(VIP)|P04004(VTN)|Q2TAL6(VWC2)|Q8IUB3(WFDC10B)|Q8WWY7(WFDC12)|Q8N6M9(ZFAND2A)|Q8WV99(ZFAND2B)|O60844(ZG16)|Q96DA0(ZG16B)|O95201(ZNF205)|A0A1U9X8X8()|Q96FB2()|P0DTC6(6)|P0DTD3(9c)|O48726(RPN13),,,,,,,,,,,,5.0
Q14203,,Dynactin subunit 1,DCTN1,Homo sapiens,1278,False,,MAQSKRHVYSRTPSGSRMSAEASARPLRVGSRVEVIGKGHRGTVAYVGATLFATGKWVGVILDEAKGKNDGTVQGRKYFTCDEGHGIFVRQSQIQVFEDGADTTSPETPDSSASKVLKREGTDTTAKTSKLRGLKPKKAPTARKTTTRRPKPTRPASTGVAGASSSLGPSGSASAGELSSSEPSTPAQTPLAAPIIPTPVLTSPGAVPPLPSPSKEEEGLRAQVRDLEEKLETLRLKRAEDKAKLKELEKHKIQLEQVQEWKSKMQEQQADLQRRLKEARKEAKEALEAKERYMEEMADTADAIEMATLDKEMAEERAESLQQEVEALKERVDELTTDLEILKAEIEEKGSDGAASSYQLKQLEEQNARLKDALVRMRDLSSSEKQEHVKLQKLMEKKNQELEVVRQQRERLQEELSQAESTIDELKEQVDAALGAEEMVEMLTDRNLNLEEKVRELRETVGDLEAMNEMNDELQENARETELELREQLDMAGARVREAQKRVEAAQETVADYQQTIKKYRQLTAHLQDVNRELTNQQEASVERQQQPPPETFDFKIKFAETKAHAKAIEMELRQMEVAQANRHMSLLTAFMPDSFLRPGGDHDCVLVLLLMPRLICKAELIRKQAQEKFELSENCSERPGLRGAAGEQLSFAAGLVYSLSLLQATLHRYEHALSQCSVDVYKKVGSLYPEMSAHERSLDFLIELLHKDQLDETVNVEPLTKAIKYYQHLYSIHLAEQPEDCTMQLADHIKFTQSALDCMSVEVGRLRAFLQGGQEATDIALLLRDLETSCSDIRQFCKKIRRRMPGTDAPGIPAALAFGPQVSDTLLDCRKHLTWVVAVLQEVAAAAAQLIAPLAENEGLLVAALEELAFKASEQIYGTPSSSPYECLRQSCNILISTMNKLATAMQEGEYDAERPPSKPPPVELRAAALRAEITDAEGLGLKLEDRETVIKELKKSLKIKGEELSEANVRLSLLEKKLDSAAKDADERIEKVQTRLEETQALLRKKEKEFEETMDALQADIDQLEAEKAELKQRLNSQSKRTIEGLRGPPPSGIATLVSGIAGEEQQRGAIPGQAPGSVPGPGLVKDSPLLLQQISAMRLHISQLQHENSILKGAQMKASLASLPPLHVAKLSHEGPGSELPAGALYRKTSQLLETLNQLSTHTHVVDITRTSPAAKSPSAQLMEQVAQLKSLSDTVEKLKDEVLKETVSQRPGATVPTDFATFPSSAFLRAKEEQQDDTVYMGKVTFSCAAGFGQRHRLVLTQEQLHQLHSRLIS,0,,,,,,"Neuronopathy, distal hereditary motor, autosomal dominant 14:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.|Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Perry syndrome:A neuropsychiatric disorder characterized by mental depression not responsive to antidepressant drugs or electroconvulsive therapy, sleep disturbances, exhaustion and marked weight loss. Parkinsonism develops later and respiratory failure occurred terminally.","Neuronopathy, distal hereditary motor, autosomal dominant 14|Amyotrophic lateral sclerosis|Perry syndrome",P42025(ACTR1B)|Q96RK4(BBS4)|P30622-1(CLIP1)|Q15691(MAPRE1)|P10636-8(MAPT)|Q9UNH7(SNX6)|P54256(Hap1)|Q6ZTN6-2(ANKRD13D)|P63010-2(AP2B1)|P05067(APP)|O95671(ASMTL)|P18847(ATF3)|P46379-2(BAG6)|Q8NFJ9(BBS1)|O15392(BIRC5)|Q8WUW1(BRK1)|P42574(CASP3)|Q9UNS2(COPS3)|O75935-2(DCTN3)|O60479(DLX3)|O14576-2(DYNC1I1)|Q8TC29(ENKUR)|Q6NXG1(ESRP1)|Q9UHY8(FEZ2)|Q9UBN7(HDAC6)|Q8IY31-3(IFT20)|Q6DN90-2(IQSEC1)|Q96EK5(KIFBP)|Q9Y2M5(KLHL20)|Q96JM7-2(L3MBTL3)|Q9BYZ2(LDHAL6B)|O95777(LSM8)|P43360(MAGEA6)|P10636-6(MAPT)|A4FUJ8(MKL1)|Q8N594(MPND)|O15381-5(NVL)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|Q9BR81(PCDHGC3)|Q9NV79(PCMTD2)|P17980(PSMC3)|Q9UJ41-4(RABGEF1)|Q9ULX5(RNF112)|Q8IYW5(RNF168)|Q96D59(RNF183)|Q92834-6(RPGR)|Q8N488(RYBP)|Q15436(SEC23A)|Q9GZS3(SKIC8)|Q9HCE7-2(SMURF1)|Q99932-2(SPAG8)|O75886(STAM2)|Q15554-4(TERF2)|Q71RG4-4(TMUB2)|Q9H0E2(TOLLIP)|P19474(TRIM21)|Q8WVJ9(TWIST2)|P62987(UBA52)|Q9BSL1(UBAC1)|Q8NBM4-4(UBAC2)|P57075-2(UBASH3A)|Q04323-2(UBXN1)|Q96RL1-2(UIMC1)|O00308(WWP2),,p150:Q14203-1:|p135:Q14203-2:|3:Q14203-3:|4:Q14203-4:|5:Q14203-5:|6:Q14203-6:,,,,,,,,,,5.0
P31483,,Cytotoxic granule associated RNA binding protein TIA1,TIA1,Homo sapiens,386,False,,MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAAAALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTEDIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDAENAIQQMGGQWLGGRQIRTNWATRKPPAPKSTYESNTKQLSYDEVVNQSSPSNCTVYCGGVTSGLTEQLMRQTFSPFGQIMEIRVFPDKGYSFVRFNSHESAAHAIVSVNGTTIEGHVVKCYWGKETLDMINPVQQQNQIGYPQPYGQWGQWYGNAQQIGQYMPNGWQVPAYGMYGQAWNQQGFNQTQSSAPWMGPNYGVQPPQGQNGSMLPNQPSGYRVAGYETQ,0,,,,,,"Welander distal myopathy:An autosomal dominant disorder characterized by adult onset of distal muscle weakness predominantly affecting the distal long extensors of the hands, with slow progression to involve all small hand muscles and the lower legs. Skeletal muscle biopsy shows myopathic changes and prominent rimmed vacuoles. Rare homozygous patients showed earlier onset, faster progression, and proximal muscle involvement.|Amyotrophic lateral sclerosis 26, with or without frontotemporal dementia:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS26 inheritance is autosomal dominant. Some patients may develop frontotemporal dementia.","Welander distal myopathy|Amyotrophic lateral sclerosis 26, with or without frontotemporal dementia",P08621(SNRNP70)|P09012(SNRPA)|P09234(SNRPC),,Long:P31483-1:|Short:P31483-2:|3:P31483-3:,,,,,,,,,,5.0
Q12840,,Kinesin heavy chain isoform 5A,KIF5A,Homo sapiens,1032,False,NKHC1,MAETNNECSIKVLCRFRPLNQAEILRGDKFIPIFQGDDSVVIGGKPYVFDRVFPPNTTQEQVYHACAMQIVKDVLAGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIARDIFNHIYSMDENLEFHIKVSYFEIYLDKIRDLLDVTKTNLSVHEDKNRVPFVKGCTERFVSSPEEILDVIDEGKSNRHVAVTNMNEHSSRSHSIFLINIKQENMETEQKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKSYVPYRDSKMTRILQDSLGGNCRTTMFICCSPSSYNDAETKSTLMFGQRAKTIKNTASVNLELTAEQWKKKYEKEKEKTKAQKETIAKLEAELSRWRNGENVPETERLAGEEAALGAELCEETPVNDNSSIVVRIAPEERQKYEEEIRRLYKQLDDKDDEINQQSQLIEKLKQQMLDQEELLVSTRGDNEKVQRELSHLQSENDAAKDEVKEVLQALEELAVNYDQKSQEVEEKSQQNQLLVDELSQKVATMLSLESELQRLQEVSGHQRKRIAEVLNGLMKDLSEFSVIVGNGEIKLPVEISGAIEEEFTVARLYISKIKSEVKSVVKRCRQLENLQVECHRKMEVTGRELSSCQLLISQHEAKIRSLTEYMQSVELKKRHLEESYDSLSDELAKLQAQETVHEVALKDKEPDTQDADEVKKALELQMESHREAHHRQLARLRDEINEKQKTIDELKDLNQKLQLELEKLQADYEKLKSEEHEKSTKLQELTFLYERHEQSKQDLKGLEETVARELQTLHNLRKLFVQDVTTRVKKSAEMEPEDSGGIHSQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALEGALKEAKEGAMKDKRRYQQEVDRIKEAVRYKSSGKRGHSAQIAKPVRPGHYPASSPTNPYGTRSPECISYTNSLFQNYQNLYLQATPSSTSDMYFANSCTSSGATSSGGPLASYQKANMDNGNATDINDNRSDLPCGYEAEDQAKLFPLHQETAAS,0,,,,,,"Spastic paraplegia 10, autosomal dominant:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.|Myoclonus, intractable, neonatal:An autosomal dominant neurologic disorder characterized by severe, infantile-onset myoclonic seizures, hypotonia, optic nerve abnormalities, dysphagia, apnea, and early developmental arrest. Brain imaging shows a progressive leukoencephalopathy. Some patients may die in infancy.|Amyotrophic lateral sclerosis 25:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS25 is an autosomal dominant form with variable adult onset and incomplete penetrance.","Spastic paraplegia 10, autosomal dominant|Myoclonus, intractable, neonatal|Amyotrophic lateral sclerosis 25",Q96NW4(ANKRD27)|Q9UPV9(TRAK1)|Q8R2H7(Trak2),,,,,,,,,,,,5.0
Q13501,,Sequestosome-1,SQSTM1,Homo sapiens,440,False,ORCA|OSIL,MASLTVKAYLLGKEDAAREIRRFSFCCSPEPEAEAEAAAGPGPCERLLSRVAALFPALRPGGFQAHYRDEDGDLVAFSSDEELTMAMSYVKDDIFRIYIKEKKECRRDHRPPCAQEAPRNMVHPNVICDGCNGPVVGTRYKCSVCPDYDLCSVCEGKGLHRGHTKLAFPSPFGHLSEGFSHSRWLRKVKHGHFGWPGWEMGPPGNWSPRPPRAGEARPGPTAESASGPSEDPSVNFLKNVGESVAAALSPLGIEVDIDVEHGGKRSRLTPVSPESSSTEEKSSSQPSSCCSDPSKPGGNVEGATQSLAEQMRKIALESEGRPEEQMESDNCSGGDDDWTHLSSKEVDPSTGELQSLQMPESEGPSSLDPSQEGPTGLKEAALYPHLPPEADPRLIESLSQMLSMGFSDEGGWLTRLLQTKNYDIGAALDTIQYSKHPPPL,0,,,,,,"Paget disease of bone 3:A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.|:|Frontotemporal dementia and/or amyotrophic lateral sclerosis 3:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. Some FTDALS3 patients may also develop Paget disease of bone.|Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset:A neurodegenerative disorder characterized by gait abnormalities, ataxia, dysarthria, dystonia, vertical gaze palsy, and cognitive decline. Disease onset is in childhood or adolescence. NADGP transmission pattern is consistent with autosomal recessive inheritance.|Myopathy, distal, with rimmed vacuoles:An autosomal dominant myopathy with adult onset, characterized by muscle weakness of the distal upper and lower limbs, walking difficulties, and proximal weakness of the shoulder girdle muscles. Muscle biopsy shows rimmed vacuoles.|:","Paget disease of bone 3|Frontotemporal dementia and/or amyotrophic lateral sclerosis 3|Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset|Myopathy, distal, with rimmed vacuoles",P05067(APP)|P54253(ATXN1)|O95817(BAG3)|Q16543(CDC37)|P57739(CLDN2)|P34972(CNR2)|Q15038(DAZAP2)|O14576-2(DYNC1I1)|O14682(ENC1)|Q2V2M9(FHOD3)|Q2V2M9-4(FHOD3)|O95166(GABARAP)|Q9H0R8(GABARAPL1)|P60520(GABARAPL2)|P0DMV8(HSPA1A)|P42858(HTT)|Q9Y6K9(IKBKG)|Q14145(KEAP1)|Q5S007(LRRK2)|Q9UDY8(MALT1)|Q9H492(MAP1LC3A)|Q9GZQ8(MAP1LC3B)|Q9BXW4(MAP1LC3C)|Q13163(MAP2K5)|Q14596(NBR1)|Q9BPW8(NIPSNAP1)|P04629(NTRK1)|Q96CV9(OPTN)|P50542-3(PEX5)|Q9UGJ0(PRKAG2)|P41743(PRKCI)|Q12923(PTPN13)|P54725(RAD23A)|P58004(SESN2)|Q96B97(SH3KBP1)|P84022(SMAD3)|P37840(SNCA)|Q13501(SQSTM1)|Q9UNE7(STUB1)|Q9Y4K3(TRAF6)|P07437(TUBB)|P0CG48(UBC)|P11473(VDR)|Q9UBQ0-2(VPS29)|Q8IZQ1(WDFY3)|P19544-6(WT1)|P17028(ZNF24)|A8K2U6()|P38182(ATG8)|Q9Z2X8(Keap1)|P28700(Rxra)|O70405(Ulk1)|P12504(vif),,1:Q13501-1:|2:Q13501-2:,,,,,,,,,,5.0
Q96C11,,FGGY carbohydrate kinase domain-containing protein,FGGY,Homo sapiens,551,False,,MSGGEQKPERYYVGVDVGTGSVRAALVDQSGVLLAFADQPIKNWEPQFNHHEQSSEDIWAACCVVTKKVVQGIDLNQIRGLGFDATCSLVVLDKQFHPLPVNQEGDSHRNVIMWLDHRAVSQVNRINETKHSVLQYVGGVMSVEMQAPKLLWLKENLREICWDKAGHFFDLPDFLSWKATGVTARSLCSLVCKWTYSAEKGWDDSFWKMIGLEDFVADNYSKIGNQVLPPGASLGNGLTPEAARDLGLLPGIAVAASLIDAHAGGLGVIGADVRGHGLICEGQPVTSRLAVICGTSSCHMGISKDPIFVPGVWGPYFSAMVPGFWLNEGGQSVTGKLIDHMVQGHAAFPELQVKATARCQSIYAYLNSHLDLIKKAQPVGFLTVDLHVWPDFHGNRSPLADLTLKGMVTGLKLSQDLDDLAILYLATVQAIALGTRFIIEAMEAAGHSISTLFLCGGLSKNPLFVQMHADITGMPVVLSQEVESVLVGAAVLGACASGDFASVQEAMAKMSKVGKVVFPRLQDKKYYDKKYQVFLKLVEHQKEYLAIMNDD,0,,,,,,"Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis,,,1:Q96C11-1:|2:Q96C11-2:|3:Q96C11-4:|4:Q96C11-3:|5:Q96C11-5:|6:Q96C11-6:,,,,,,,,,,5.0
Q96LT7,,Guanine nucleotide exchange factor C9orf72,C9orf72,Homo sapiens,481,False,DENND9|DENNL72,MSTLCPPPSPAVAKTEIALSGKSPLLAATFAYWDNILGPRVRHIWAPKTEQVLLSDGEITFLANHTLNGEILRNAESGAIDVKFFVLSEKGVIIVSLIFDGNWNGDRSTYGLSIILPQTELSFYLPLHRVCVDRLTHIIRKGRIWMHKERQENVQKIILEGTERMEDQGQSIIPMLTGEVIPVMELLSSMKSHSVPEEIDIADTVLNDDDIGDSCHEGFLLNAISSHLQTCGCSVVVGSSAEKVNKIVRTLCLFLTPAERKCSRLCEAESSFKYESGLFVQGLLKDSTGSFVLPFRQVMYAPYPTTHIDVDVNTVKQMPPCHEHIYNQRRYMRSELTAFWRATSEEDMAQDTIIYTDESFTPDLNIFQDVLHRDTLVKAFLDQVFQLKPGLSLRSTFLAQFLLVLHRKALTLIKYIEDDTQKGKKPFKSLRNLKIDLDLTAEGDLNIIMALAEKIKPGLHSFIFGRPFYTSVQERDVLMTF,0,,,,,,"Frontotemporal dementia and/or amyotrophic lateral sclerosis 1:An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia and/or amyotrophic lateral sclerosis in an affected individual. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.",Frontotemporal dementia and/or amyotrophic lateral sclerosis 1,P38432(COIL)|O43186(CRX)|P49770(EIF2B2)|Q53XC2(EIF2B2)|Q9BPX4(EIF2B2)|Q9NP66(HMG20A)|Q13287(NMI)|O75817(POP7)|Q04864(REL)|Q8TEV9(SMCR8)|Q17R54(SYN3)|Q86UV6-2(TRIM74)|Q9H8Y1(VRTN)|O75143(ATG13)|P62820(RAB1A)|Q8TDY2(RB1CC1)|Q8TEV9(SMCR8)|O75385(ULK1)|O75143(ATG13)|P62820(RAB1A)|Q8TDY2(RB1CC1)|O75385(ULK1),,1:Q96LT7-1:|2:Q96LT7-2:,,,,,,,,,,5.0
Q9UQN3,,Charged multivesicular body protein 2b,CHMP2B,Homo sapiens,213,False,,MASLFKKKTVDDVIKEQNRELRGTQRAIIRDRAALEKQEKQLELEIKKMAKIGNKEACKVLAKQLVHLRKQKTRTFAVSSKVTSMSTQTKVMNSQMKMAGAMSTTAKTMQAVNKKMDPQKTLQTMQNFQKENMKMEMTEEMINDTLDDIFDGSDDEEESQDIVNQVLDEIGIEISGKMAKAPSAARSLPSASTSKATISDEEIERQLKALGVD,0,,,,,,"Frontotemporal dementia and/or amyotrophic lateral sclerosis 7:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS7 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. A few patients may have both phenotypes.",Frontotemporal dementia and/or amyotrophic lateral sclerosis 7,Q9Y3E7(CHMP3)|Q9H444(CHMP4B)|Q9NYB0(TERF2IP)|P0C6X7(rep)|P0C6X7(rep)|O75351(VPS4B),,1:Q9UQN3-1:|2:Q9UQN3-2:,,,,,,,,,,5.0
Q9Y561,,Low-density lipoprotein receptor-related protein 12,LRP12,Homo sapiens,859,False,ST7,MACRWSTKESPRWRSALLLLFLAGVYGNGALAEHSENVHISGVSTACGETPEQIRAPSGIITSPGWPSEYPAKINCSWFIRANPGEIITISFQDFDIQGSRRCNLDWLTIETYKNIESYRACGSTIPPPYISSQDHIWIRFHSDDNISRKGFRLAYFSGKSEEPNCACDQFRCGNGKCIPEAWKCNNMDECGDSSDEEICAKEANPPTAAAFQPCAYNQFQCLSRFTKVYTCLPESLKCDGNIDCLDLGDEIDCDVPTCGQWLKYFYGTFNSPNYPDFYPPGSNCTWLIDTGDHRKVILRFTDFKLDGTGYGDYVKIYDGLEENPHKLLRVLTAFDSHAPLTVVSSSGQIRVHFCADKVNAARGFNATYQVDGFCLPWEIPCGGNWGCYTEQQRCDGYWHCPNGRDETNCTMCQKEEFPCSRNGVCYPRSDRCNYQNHCPNGSDEKNCFFCQPGNFHCKNNRCVFESWVCDSQDDCGDGSDEENCPVIVPTRVITAAVIGSLICGLLLVIALGCTCKLYSLRMFERRSFETQLSRVEAELLRREAPPSYGQLIAQGLIPPVEDFPVCSPNQASVLENLRLAVRSQLGFTSVRLPMAGRSSNIWNRIFNFARSRHSGSLALVSADGDEVVPSQSTSREPERNHTHRSLFSVESDDTDTENERRDMAGASGGVAAPLPQKVPPTTAVEATVGACASSSTQSTRGGHADNGRDVTSVEPPSVSPARHQLTSALSRMTQGLRWVRFTLGRSSSLSQNQSPLRQLDNGVSGREDDDDVEMLIPISDGSSDFDVNDCSRPLLDLASDQGQGLRQPYNATNPGVRPSNRDGPCERCGIVHTAQIPDTCLEVTLKNETSDDEALLLC,0,,,,,,"Oculopharyngodistal myopathy 1:A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM1 inheritance pattern is autosomal dominant.|Amyotrophic lateral sclerosis 28:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS28 is an autosomal dominant form characterized by adult onset of slowly progressive limb muscle weakness and atrophy resulting in gait difficulties, loss of ambulation, and distal upper limb weakness. Facial involvement is rare, but some patients may have respiratory insufficiency.",Oculopharyngodistal myopathy 1|Amyotrophic lateral sclerosis 28,Q9NPI5(NMRK2)|P63244(RACK1)|O95405(ZFYVE9),,1:Q9Y561-1:|2:Q9Y561-2:,,,,,,,,,,5.0
O15269,,Serine palmitoyltransferase 1,SPTLC1,Homo sapiens,473,False,LCB1,MATATEQWVLVEMVQALYEAPAYHLILEGILILWIIRLLFSKTYKLQERSDLTVKEKEELIEEWQPEPLVPPVPKDHPALNYNIVSGPPSHKTVVNGKECINFASFNFLGLLDNPRVKAAALASLKKYGVGTCGPRGFYGTFDVHLDLEDRLAKFMKTEEAIIYSYGFATIASAIPAYSKRGDIVFVDRAACFAIQKGLQASRSDIKLFKHNDMADLERLLKEQEIEDQKNPRKARVTRRFIVVEGLYMNTGTICPLPELVKLKYKYKARIFLEESLSFGVLGEHGRGVTEHYGINIDDIDLISANMENALASIGGFCCGRSFVIDHQRLSGQGYCFSASLPPLLAAAAIEALNIMEENPGIFAVLKEKCGQIHKALQGISGLKVVGESLSPAFHLQLEESTGSREQDVRLLQEIVDQCMNRSIALTQARYLEKEEKCLPPPSIRVVVTVEQTEEELERAASTIKEVAQAVLL,0,,,,,,"Amyotrophic lateral sclerosis 27, juvenile:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS27 is an autosomal dominant form manifesting as toe walking and gait abnormalities in early childhood.|Neuropathy, hereditary sensory and autonomic, 1A:A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by prominent sensory abnormalities with a variable degree of motor and autonomic dysfunction. The neurological phenotype is often complicated by severe infections, osteomyelitis, and amputations. HSAN1A is an autosomal dominant axonal form with onset in the second or third decades. Initial symptoms are loss of pain, touch, heat, and cold sensation over the feet, followed by distal muscle wasting and weakness. Loss of pain sensation leads to chronic skin ulcers and distal amputations.","Amyotrophic lateral sclerosis 27, juvenile|Neuropathy, hereditary sensory and autonomic, 1A",Q8N138(ORMDL3)|O15270(SPTLC2)|Q9NUV7(SPTLC3)|Q86SG2(ANKRD23)|Q6ZR37(PLEKHG7)|Q8IYM2(SLFN12)|Q8WXH5(SOCS4)|Q9UNE7(STUB1),,1:O15269-1:|2:O15269-2:,,,,,,,,,,5.0
P07737,,Profilin-1,PFN1,Homo sapiens,140,False,,MAGWNAYIDNLMADGTCQDAAIVGYKDSPSVWAAVPGKTFVNITPAEVGVLVGKDRSSFYVNGLTLGGQKCSVIRDSLLQDGEFSMDLRTKSTGGAPTFNVTVTKTDKTLVLLMGKEGVHGGLINKKCYEMASHLRRSQY,0,,,,,,"Amyotrophic lateral sclerosis 18:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis 18,P60709(ACTB)|P50552(VASP)|Q92558(WASF1)|P07830(act21)|P68135(ACTA1)|O08816(Wasl),,,,,,,,,,,,5.0
P12036,,Neurofilament heavy polypeptide,NEFH,Homo sapiens,1020,False,KIAA0845|NFH,MMSFGGADALLGAPFAPLHGGGSLHYALARKGGAGGTRSAAGSSSGFHSWTRTSVSSVSASPSRFRGAGAASSTDSLDTLSNGPEGCMVAVATSRSEKEQLQALNDRFAGYIDKVRQLEAHNRSLEGEAAALRQQQAGRSAMGELYEREVREMRGAVLRLGAARGQLRLEQEHLLEDIAHVRQRLDDEARQREEAEAAARALARFAQEAEAARVDLQKKAQALQEECGYLRRHHQEEVGELLGQIQGSGAAQAQMQAETRDALKCDVTSALREIRAQLEGHAVQSTLQSEEWFRVRLDRLSEAAKVNTDAMRSAQEEITEYRRQLQARTTELEALKSTKDSLERQRSELEDRHQADIASYQEAIQQLDAELRNTKWEMAAQLREYQDLLNVKMALDIEIAAYRKLLEGEECRIGFGPIPFSLPEGLPKIPSVSTHIKVKSEEKIKVVEKSEKETVIVEEQTEETQVTEEVTEEEEKEAKEEEGKEEEGGEEEEAEGGEEETKSPPAEEAASPEKEAKSPVKEEAKSPAEAKSPEKEEAKSPAEVKSPEKAKSPAKEEAKSPPEAKSPEKEEAKSPAEVKSPEKAKSPAKEEAKSPAEAKSPEKAKSPVKEEAKSPAEAKSPVKEEAKSPAEVKSPEKAKSPTKEEAKSPEKAKSPEKEEAKSPEKAKSPVKAEAKSPEKAKSPVKAEAKSPEKAKSPVKEEAKSPEKAKSPVKEEAKSPEKAKSPVKEEAKTPEKAKSPVKEEAKSPEKAKSPEKAKTLDVKSPEAKTPAKEEARSPADKFPEKAKSPVKEEVKSPEKAKSPLKEDAKAPEKEIPKKEEVKSPVKEEEKPQEVKVKEPPKKAEEEKAPATPKTEEKKDSKKEEAPKKEAPKPKVEEKKEPAVEKPKESKVEAKKEEAEDKKKVPTPEKEAPAKVEVKEDAKPKEKTEVAKKEPDDAKAKEPSKPAEKKEAAPEKKDTKEEKAKKPEEKPKTEAKAKEDDKTLSKEPSKPKAEKAEKSSSTDQKDSKPPEKATEDKAAKGK,0,,,,,,"Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Charcot-Marie-Tooth disease, axonal, 2CC:An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.","Amyotrophic lateral sclerosis|Charcot-Marie-Tooth disease, axonal, 2CC",P05067(APP)|P10809(HSPD1),,1:P12036-1:|2:P12036-2:,,,,,,,,,,5.0
P35637,,RNA-binding protein FUS,FUS,Homo sapiens,526,False,TLS,MASNDYTQQATQSYGAYPTQPGQGYSQQSSQPYGQQSYSGYSQSTDTSGYGQSSYSSYGQSQNTGYGTQSTPQGYGSTGGYGSSQSSQSSYGQQSSYPGYGQQPAPSSTSGSYGSSSQSSSYGQPQSGSYSQQPSYGGQQQSYGQQQSYNPPQGYGQQNQYNSSSGGGGGGGGGGNYGQDQSSMSSGGGSGGGYGNQDQSGGGGSGGYGQQDRGGRGRGGSGGGGGGGGGGYNRSSGGYEPRGRGGGRGGRGGMGGSDRGGFNKFGGPRDQGSRHDSEQDNSDNNTIFVQGLGENVTIESVADYFKQIGIIKTNKKTGQPMINLYTDRETGKLKGEATVSFDDPPSAKAAIDWFDGKEFSGNPIKVSFATRRADFNRGGGNGRGGRGRGGPMGRGGYGGGGSGGGGRGGFPSGGGGGGGQQRAGDWKCPNPTCENMNFSWRNECNQCKAPKPDGPGGGPGGSHMGGNYGDDRRGGRGGYDRGGYRGRGGDRGGFRGGRGGGDRGGFGPGKMDSRGEHRQDRRERPY,0,,,,,,":|:|Angiomatoid fibrous histiocytoma:A distinct variant of malignant fibrous histiocytoma that typically occurs in children and adolescents and is manifest by nodular subcutaneous growth. Characteristic microscopic features include lobulated sheets of histiocyte-like cells intimately associated with areas of hemorrhage and cystic pseudovascular spaces, as well as a striking cuffing of inflammatory cells, mimicking a lymph node metastasis.|Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Tremor, hereditary essential 4:A common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles may also be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. Inheritance is autosomal dominant.","Angiomatoid fibrous histiocytoma|Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia|Tremor, hereditary essential 4",P46379-2(BAG6)|O75815(BCAR3)|Q13191(CBLB)|P48730-2(CSNK1D)|Q9NRR4(DROSHA)|O60739(EIF1B)|Q09472(EP300)|Q01844(EWSR1)|P35637(FUS)|Q05586(GRIN1)|P49841-2(GSK3B)|Q92993(KAT5)|O15479(MAGEB2)|Q96FW1(OTUB1)|Q9BYU1(PBX4)|Q15149(PLEC)|Q99873(PRMT1)|Q99873-3(PRMT1)|Q9UKA9-2(PTBP2)|Q9UKM9(RALY)|P38159(RBMX)|Q04206-3(RELA)|Q9BUL9(RPP25)|P19793(RXRA)|Q8N488(RYBP)|Q15424(SAFB)|P60896(SEM1)|Q16637(SMN2)|Q8NHS9(SPATA22)|Q92804(TAF15)|Q13148(TARDBP)|Q92973-2(TNPO1)|Q9H3D4(TP63)|P18206-2(VCL)|P45481(Crebbp)|P97801(Smn1),,Long:P35637-1:|Short:P35637-2:,,,,,,,,,,5.0
P55072,,Transitional endoplasmic reticulum ATPase,VCP,Homo sapiens,806,False,HEL-220|HEL-S-70,MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG,0,,,,,,"Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1:An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.|Frontotemporal dementia and/or amyotrophic lateral sclerosis 6:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia (FTD) is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis (ALS) is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS6 is an autosomal dominant form characterized by onset of ALS or FTD in adulthood. Some patients with the disorder may have features of both diseases.|Charcot-Marie-Tooth disease, axonal, 2Y:An autosomal dominant, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.","Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 1|Frontotemporal dementia and/or amyotrophic lateral sclerosis 6|Charcot-Marie-Tooth disease, axonal, 2Y",Q9UKV5(AMFR)|Q9BZE9(ASPSCR1)|A9UGY9(ATG5)|P54253(ATXN1)|P54252(ATXN3)|P54252-1(ATXN3)|Q96LK0(CEP19)|O96017(CHEK2)|O75175(CNOT3)|Q13619(CUL4A)|O60941(DTNB)|O60941-5(DTNB)|P26378-2(ELAVL4)|Q96J88-3(EPSTI1)|Q9UNN5(FAF1)|Q9UNN5-1(FAF1)|Q96CS3(FAF2)|O94868(FCHSD2)|P09471(GNAO1)|P62993(GRB2)|P42858(HTT)|Q8TBB1(LNX1)|Q8WZA0(LZIC)|Q9H7H0-2(METTL17)|Q9HC29(NOD2)|Q8TAT6(NPLOC4)|Q9UNZ2(NSFL1C)|Q96HA8(NTAQ1)|Q9Y263(PLAA)|Q07869(PPARA)|P62136(PPP1CA)|P07602-1(PSAP)|P25786(PSMA1)|P62191(PSMC1)|P26045(PTPN3)|Q9Y4L5(RNF115)|Q96EQ8(RNF125)|O76064(RNF8)|P32969(RPL9P9)|Q9H0K1(SIK2)|Q8NBI5(SLC43A3)|Q16560-2(SNRNP35)|P46977(STT3A)|P51668(UBE2D1)|B1AQ61(UBE4B)|O94941(UBOX5)|Q04323(UBXN1)|Q96LJ8(UBXN10)|Q5T124-6(UBXN11)|P68543(UBXN2A)|Q14CS0(UBXN2B)|Q92575(UBXN4)|Q9BZV1(UBXN6)|O94888(UBXN7)|O00124(UBXN8)|Q92890(UFD1)|P63027(VAMP2)|Q969W3(VCF1)|P55072(VCP)|Q6GPH4(XAF1)|Q5VVQ6(YOD1)|P63104(YWHAZ)|P24278(ZBTB25)|Q9WTX6(Cul1),,,,,,,,,,,,5.0
Q96CV9,,Optineurin,OPTN,Homo sapiens,577,False,FIP2|GLC1E|HIP7|HYPL|NRP,MSHQPLSCLTEKEDSPSESTGNGPPHLAHPNLDTFTPEELLQQMKELLTENHQLKEAMKLNNQAMKGRFEELSAWTEKQKEERQFFEIQSKEAKERLMALSHENEKLKEELGKLKGKSERSSEDPTDDSRLPRAEAEQEKDQLRTQVVRLQAEKADLLGIVSELQLKLNSSGSSEDSFVEIRMAEGEAEGSVKEIKHSPGPTRTVSTGTALSKYRSRSADGAKNYFEHEELTVSQLLLCLREGNQKVERLEVALKEAKERVSDFEKKTSNRSEIETQTEGSTEKENDEEKGPETVGSEVEALNLQVTSLFKELQEAHTKLSEAELMKKRLQEKCQALERKNSAIPSELNEKQELVYTNKKLELQVESMLSEIKMEQAKTEDEKSKLTVLQMTHNKLLQEHNNALKTIEELTRKESEKVDRAVLKELSEKLELAEKALASKQLQMDEMKQTIAKQEEDLETMTILRAQMEVYCSDFHAERAAREKIHEEKEQLALQLAVLLKENDAFEDGGRQSLMEMQSRHGARTSDSDQQAYLVQRGAEDRDWRQQRNIPIHSCPKCGEVLPDIDTLQIHVMDCII,0,,,,,,"Glaucoma 1, open angle, E:A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place.|Glaucoma, normal pressure:A primary glaucoma characterized by intraocular pression consistently within the statistically normal population range.|Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS12 inheritance can be autosomal dominant or autosomal recessive. There is also sporadic occurrence. ALS12 patients may develop frontotemporal dementia.","Glaucoma 1, open angle, E|Glaucoma, normal pressure|Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia",Q6PCB6(ABHD17C)|P24666-2(ACP1)|Q9H6R3(ACSS3)|Q8N302-2(AGGF1)|Q12904-2(AIMP1)|Q5TZF3-1(ANKRD45)|P08758(ANXA5)|O00203(AP3B1)|Q0P5N6(ARL16)|Q96B67(ARRDC3)|Q9Y574-2(ASB4)|Q6XD76(ASCL4)|O95671(ASMTL)|Q8WXF7(ATL1)|Q9BUH8(BEGAIN)|O15392(BIRC5)|Q9NSI6-4(BRWD1)|Q96G97-4(BSCL2)|P78410(BTN3A2)|Q9UIR0-4(BTNL2)|Q32M92-2(C15orf32)|Q0P5P2(C17orf67)|Q96LL4(C8orf48)|A2RRN7(CADPS)|P07384(CAPN1)|Q8IYE1(CCDC13)|Q9UJX2(CDC23)|P49450(CENPA)|Q9BV73(CEP250)|Q9P209(CEP72)|P23528(CFL1)|Q3SX64(CIMAP1D)|Q8TBE1(CNIH3)|P15169(CPN1)|Q14894(CRYM)|Q15038(DAZAP2)|Q9UBT3(DKK4)|Q86TI2-2(DPP9)|Q96G46(DUS3L)|Q9Y5L3(ENTPD2)|Q6NXG1-3(ESRP1)|Q3KNW7(FKSG83)|P51116(FXR2)|Q8N1C3(GABRG1)|Q49A26-4(GLYR1)|O95872(GPANK1)|Q71DI3(H3C15)|Q8IYU2(HACE1)|P61296-2(HAND2)|Q969S8(HDAC10)|A0A1C3PI11(HLA-DPB1)|P04440(HLA-DPB1)|O75031(HSF2BP)|P28566(HTR1E)|P42858(HTT)|Q13123(IK)|Q96RQ9(IL4I1)|Q02556(IRF8)|A1A4Y4(IRGM)|Q6IE81-3(JADE1)|Q8IV33(KIAA0825)|Q9BYQ4(KRTAP9-2)|Q14847-2(LASP1)|Q9BYZ2(LDHAL6B)|Q99732(LITAF)|Q8N448(LNX2)|A2RU56(LOC401296)|O60711(LPXN)|P51608(MECP2)|Q8TDB4(MGARP)|Q9UQ53(MGAT4B)|A4FUJ8(MKL1)|Q9BUB5(MKNK1)|Q96EY8(MMAB)|Q00013(MPP1)|Q9UDX5(MTFP1)|Q96EZ4(MYEOV)|Q9Y6Q9-5(NCOA3)|Q9Y221(NIP7)|Q9HBL8(NMRAL1)|P54845-1(NRL)|Q8WVJ2(NUDCD2)|Q8IZS5(OFCC1)|Q96CV9(OPTN)|P51582(P2RY4)|Q8IVL6-2(P3H3)|Q9Y2D5(PALM2AKAP2)|O95340(PAPSS2)|Q9BUH6(PAXX)|Q08499-8(PDE4D)|Q13113(PDZK1IP1)|Q9Y5Y5(PEX16)|Q9NRD5(PICK1)|P55058-2(PLTP)|P78424(POU6F2)|O60927(PPP1R11)|P07225(PROS1)|P35998(PSMC2)|Q96PU8(QKI)|P61026(RAB10)|P61006(RAB8A)|P52306-4(RAP1GDS1)|Q13702-2(RAPSN)|P10276-2(RARA)|P50749(RASSF2)|Q9NTZ6(RBM12)|Q86VR2(RETREG3)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q9NWF9(RNF216)|Q9BWG1(RNF220)|Q99942(RNF5)|Q9BUL9(RPP25)|P23297(S100A1)|O00560(SDCBP)|Q2NKQ1-4(SGSM1)|Q96QE2(SLC2A13)|Q9NY26(SLC39A1)|Q15797(SMAD1)|Q96GM5(SMARCD1)|Q53HV7-2(SMUG1)|Q13573(SNW1)|Q496A3(SPATS1)|Q9NRA0(SPHK2)|Q13501(SQSTM1)|Q92185(ST8SIA1)|Q13586(STIM1)|Q9P2R7(SUCLA2)|Q8N205-2(SYNE4)|P26639(TARS1)|Q8TC07(TBC1D15)|Q9HA65(TBC1D17)|Q9UHD2(TBK1)|P28347-2(TEAD1)|P54274-2(TERF1)|Q6YHU6(THADA)|Q8TBB0(THAP6)|P52888(THOP1)|Q15025(TNIP1)|I6L9D0(TTLL7)|Q5VYS8-5(TUT7)|P49459(UBE2A)|O75604(USP2)|P18206-2(VCL)|O15195-2(VILL)|Q9Y3C0(WASHC3)|Q8IZQ1-2(WDFY3)|Q6ZS81-2(WDFY4)|O43829(ZBTB14)|P10074(ZBTB48)|Q8N5A5-2(ZGPAT)|Q96EF9(ZHX1-C8orf76)|P17029(ZKSCAN1)|Q96NC0(ZMAT2)|Q5VZL5-4(ZMYM4)|O95789(ZMYM6)|P17021(ZNF17)|Q9Y2X9(ZNF281)|Q9NR11-2(ZNF302)|Q86UD4(ZNF329)|Q8TD17(ZNF398)|Q96HQ0(ZNF419)|Q9BUY5(ZNF426)|Q8N0Y2-2(ZNF444)|Q9NWS9-2(ZNF446)|Q96MN9-2(ZNF488)|Q96LX8(ZNF597)|Q9BS34(ZNF670)|Q9C0D3(ZYG11B)|Q8N1Y9()|Q29122(MYO6)|Q99IB8()|Q92870-2(APBB2)|P50570-2(DNM2)|Q8TB36(GDAP1)|P42858(HTT)|Q99732(LITAF)|P49821(NDUFV1)|O14656-2(TOR1A)|O76024(WFS1)|Q8IUH5(ZDHHC17),,1:Q96CV9-1:|2:Q96CV9-2:|3:Q96CV9-3:,,,,,,,,,,5.0
Q96JI7,,Spatacsin,SPG11,Homo sapiens,2443,False,KIAA1840,MAAEEGVASAASAGGSWGTAAMGRVLPMLLVPVPAEAMGQLGSRAQLRTQPEALGSLTAAGSLQVLSLTPGSRGGGRCCLEGPFWHFLWEDSRNSSTPTEKPKLLALGENYELLIYEFNLKDGRCDATILYSCSREALQKLIDDQDISISLLSLRILSFHNNTSLLFINKCVILHIIFPERDAAIRVLNCFTLPLPAQAVDMIIDTQLCRGILFVLSSLGWIYIFDVVDGTYVAHVDLALHKEDMCNEQQQEPAKISSFTSLKVSQDLDVAVIVSSSNSAVALNLNLYFRQHPGHLLCERILEDLPIQGPKGVDEDDPVNSAYNMKLAKFSFQIDRSWKAQLSSLNETIKNSKLEVSCCAPWFQDILHLESPESGNHSTSVQSWAFIPQDIMHGQYNVLQKDHAKTSDPGRSWKIMHISEQEEPIELKCVSVTGFTALFTWEVERMGYTITLWDLETQGMQCFSLGTKCIPVDSSGDQQLCFVLTENGLSLILFGLTQEEFLNRLMIHGSASTVDTLCHLNGWGRCSIPIHALEAGIENRQLDTVNFFLKSKENLFNPSSKSSVSDQFDHLSSHLYLRNVEELIPALDLLCSAIRESYSEPQSKHFSEQLLNLTLSFLNNQIKELFIHTEELDEHLQKGVNILTSYINELRTFMIKFPWKLTDAIDEYDVHENVPKVKESNIWKKLSFEEVIASAILNNKIPEAQTFFRIDSHSAQKLEELIGIGLNLVFDNLKKNNIKEASELLKNMGFDVKGQLLKICFYTTNKNIRDFLVEILKEKNYFSEKEKRTIDFVHQVEKLYLGHFQENMQIQSFPRYWIKEQDFFKHKSVLDSFLKYDCKDEFNKQDHRIVLNWALWWDQLTQESILLPRISPEEYKSYSPEALWRYLTARHDWLNIILWIGEFQTQHSYASLQQNKWPLLTVDVINQNTSCNNYMRNEILDKLARNGVFLASELEDFECFLLRLSRIGGVIQDTLPVQNYKTKEGWDFHSQFILYCLEHSLQHLLYVYLDCYKLSPENCPFLEKKELHEAHPWFEFLVQCRQVASNLTDPKLIFQASLANAQILIPTNQASVSSMLLEGHTLLALATTMYSPGGVSQVVQNEENENCLKKVDPQLLKMALTPYPKLKTALFPQCTPPSVLPSDITIYHLIQSLSPFDPSRLFGWQSANTLAIGDAWSHLPHFSSPDLVNKYAIVERLNFAYYLHNGRPSFAFGTFLVQELIKSKTPKQLIQQVGNEAYVIGLSSFHIPSIGAACVCFLELLGLDSLKLRVDMKVANIILSYKCRNEDAQYSFIRESVAEKLSKLADGEKTTTEELLVLLEEGTWNSIQQQEIKRLSSESSSQWALVVQFCRLHNMKLSISYLRECAKANDWLQFIIHSQLHNYHPAEVKSLIQYFSPVIQDHLRLAFENLPSVPTSKMDSDQVCNKCPQELQGSKQEMTDLFEILLQCSEEPDSWHWLLVEAVKQQAPILSVLASCLQGASAISCLCVWIITSVEDNVATEAMGHIQDSTEDHTWNLEDLSVIWRTLLTRQKSKTLIRGFQLFFKDSPLLLVMEMYELCMFFRNYKEAEAKLLEFQKSLETLNTAATKVHPVIPAMWLEDQVCFLLKLMLQQCKTQYELGKLLQLFVEREHLFSDGPDVKKLCILCQILKDTSIAINHTIITSYSIENLQHECRSILERLQTDGQFALARRVAELAELPVDNLVIKEITQEMQTLKHIEQWSLKQARIDFWKKCHENFKKNSISSKAASSFFSTQAHVACEHPTGWSSMEERHLLLTLAGHWLAQEDVVPLDKLEELEKQIWLCRITQHTLGRNQEETEPRFSRQISTSGELSFDSLASEFSFSKLAALNTSKYLELNSLPSKETCENRLDWKEQESLNFLIGRLLDDGCVHEASRVCRYFHFYNPDVALVLHCRALASGEASMEDLHPEIHALLQSAELLEEEAPDIPLRRVHSTSSLDSQKFVTVPSSNEVVTNLEVLTSKCLHGKNYCRQVLCLYDLAKELGCSYTDVAAQDGEAMLRKILASQQPDRCKRAQAFISTQGLKPDTVAELVAEEVTRELLTSSQGTGHKQMFNPTEESQTFLQLTTLCQDRTLVGMKLLDKISSVPHGELSCTTELLILAHHCFTLTCHMEGIIRVLQAAHMLTDNHLAPSEEYGLVVRLLTGIGRYNEMTYIFDLLHKKHYFEVLMRKKLDPSGTLKTALLDYIKRCRPGDSEKHNMIALCFSMCREIGENHEAAARIQLKLIESQPWEDSLKDGHQLKQLLLKALTLMLDAAESYAKDSCVRQAQHCQRLTKLITLQIHFLNTGQNTMLINLGRHKLMDCILALPRFYQASIVAEAYDFVPDWAEILYQQVILKGDFNYLEEFKQQRLLKSSIFEEISKKYKQHQPTDMVMENLKKLLTYCEDVYLYYKLAYEHKFYEIVNVLLKDPQTGCCLKDMLAG,0,,,,,,"Spastic paraplegia 11, autosomal recessive:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.|Amyotrophic lateral sclerosis 5, juvenile:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS5 is an autosomal recessive, juvenile form characterized by onset of upper and lower motor neuron signs before age 25.|Charcot-Marie-Tooth disease, axonal, 2X:An autosomal recessive, axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2X patients manifest a slowly progressive, peripheral neuropathy affecting the lower limbs and resulting in gait difficulties and distal sensory impairment. Some patients also have upper limb involvement.","Spastic paraplegia 11, autosomal recessive|Amyotrophic lateral sclerosis 5, juvenile|Charcot-Marie-Tooth disease, axonal, 2X",Q05193(DNM1)|Q9UJW9(SERTAD3)|P31946(YWHAB)|P62258(YWHAE)|P61981(YWHAG)|Q04917(YWHAH)|P27348(YWHAQ)|P63104(YWHAZ),,1:Q96JI7-1:|2:Q96JI7-2:|3:Q96JI7-3:,,,,,,,,,,5.0
Q9NQC7,,Ubiquitin carboxyl-terminal hydrolase CYLD,CYLD,Homo sapiens,956,False,CYLD1|KIAA0849,MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRIPSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLSKGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGVYQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKVGETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHINDIIPALSESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSVDSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSLTKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPPFYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDSRFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYLDSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLRKILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNEKVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLEDTPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKDLPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNIPQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK,0,,,,,,"Cylindromatosis, familial:A disorder characterized by multiple skin tumors that develop from skin appendages, such as hair follicles and sweat glands. Affected individuals typically develop large numbers of tumors called cylindromas that arise predominantly in hairy parts of the body with approximately 90% on the head and neck. In severely affected individuals, cylindromas may combine into a confluent mass which may ulcerate or become infected (turban tumor syndrome). Individuals with familial cylindromatosis occasionally develop other types of tumors including spiradenomas that begin in sweat glands, and trichoepitheliomas arising from hair follicles.|Trichoepithelioma, multiple familial, 1:An autosomal dominant dermatosis characterized by the presence of many skin tumors predominantly on the face. Since histologic examination shows dermal aggregates of basaloid cells with connection to or differentiation toward hair follicles, this disorder has been thought to represent a benign hamartoma of the pilosebaceous apparatus. Trichoepitheliomas can degenerate into basal cell carcinoma.|Brooke-Spiegler syndrome:An autosomal dominant disorder characterized by the appearance of multiple skin appendage tumors such as cylindroma, trichoepithelioma, and spiradenoma. These tumors are typically located in the head and neck region, appear in early adulthood, and gradually increase in size and number throughout life.|Frontotemporal dementia and/or amyotrophic lateral sclerosis 8:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS8 is an autosomal dominant form.","Cylindromatosis, familial|Trichoepithelioma, multiple familial, 1|Brooke-Spiegler syndrome|Frontotemporal dementia and/or amyotrophic lateral sclerosis 8",Q9UBN7(HDAC6)|Q96J02(ITCH)|Q96J02-2(ITCH)|O95786(RIGI)|Q9UM82(SPATA2)|Q71U36(TUBA1A),,1:Q9NQC7-1:|2:Q9NQC7-2:,,,,,,,,,,5.0
P00441,,Superoxide dismutase [Cu-Zn],SOD1,Homo sapiens,154,False,,MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTSAGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ,0,,,,,,"Amyotrophic lateral sclerosis 1:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Spastic tetraplegia and axial hypotonia, progressive:An autosomal recessive, neurologic disorder characterized by loss of motor abilities in the first year of life, after which severe, progressive spastic tetraparesis develops. Affected individuals have severe axial hypotonia, hyperekplexia, hypertonia, and myokymia, reflecting upper motor neuron involvement. Cognitive development may be affected.","Amyotrophic lateral sclerosis 1|Spastic tetraplegia and axial hypotonia, progressive",P13928(ANXA8)|P63010-2(AP2B1)|Q0P5N6(ARL16)|Q16611(BAK1)|P10415(BCL2)|Q9BXK5(BCL2L13)|Q5SZD1(C6orf141)|P02748(C9)|Q8N5S9-2(CAMKK1)|Q13191(CBLB)|O14618(CCS)|P53672(CRYBA2)|P48730-2(CSNK1D)|P98082(DAB2)|Q8TCX1(DYNC2LI1)|P29692(EEF1D)|Q8TC29(ENKUR)|P02671-2(FGA)|Q8WW76(FGA)|F2Z2M7(GALNT10)|P04406(GAPDH)|P62879(GNB2)|Q9Y4H4(GPSM3)|Q8WVV9-3(HNRNPLL)|P09017(HOXC4)|P80217-2(IFI35)|Q6DN90-2(IQSEC1)|O14713(ITGB1BP1)|Q15046(KARS1)|Q9NVX7-2(KBTBD4)|Q8N4N3-2(KLHL36)|Q96JM7-2(L3MBTL3)|Q9BYZ2(LDHAL6B)|Q8N448(LNX2)|O95777(LSM8)|Q8TDB4(MGARP)|A4FUJ8(MKL1)|Q8N594(MPND)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|Q9BYU1(PBX4)|Q13113(PDZK1IP1)|Q08209-2(PPP3CA)|P30044(PRDX5)|P28062-2(PSMB8)|P62191(PSMC1)|P17980(PSMC3)|P43686-2(PSMC4)|Q09028(RBBP4)|Q6ZNA4-2(RNF111)|Q9ULX5(RNF112)|Q9NV58(RNF19A)|Q9BUL9(RPP25)|P08865(RPSA)|Q8N488(RYBP)|P60896(SEM1)|Q15393(SF3B3)|Q2NKQ1-4(SGSM1)|Q9GZS3(SKIC8)|P37840(SNCA)|P00441(SOD1)|Q3SY56(SP6)|Q8NHS9(SPATA22)|Q96MF2(STAC3)|Q92797-2(SYMPK)|Q9BZK7(TBL1XR1)|Q15554-4(TERF2)|Q9H3N1(TMX1)|Q13829(TNFAIP1)|P07951-2(TPM2)|P07437(TUBB)|P0CG47(UBB)|O75604-3(USP2)|Q96NC0(ZMAT2)|O95789-4(ZMYM6)|Q8NBB4-2(ZSCAN1)|Q2QGD7(ZXDC)|P26339(Chga)|P16014(Chgb)|P01041(Cstb)|P20029(Hspa5),,,,,,,,,,,,5.0
P09651,,Heterogeneous nuclear ribonucleoprotein A1,HNRNPA1,Homo sapiens,372,False,HNRPA1,MSKSESPKEPEQLRKLFIGGLSFETTDESLRSHFEQWGTLTDCVVMRDPNTKRSRGFGFVTYATVEEVDAAMNARPHKVDGRVVEPKRAVSREDSQRPGAHLTVKKIFVGGIKEDTEEHHLRDYFEQYGKIEVIEIMTDRGSGKKRGFAFVTFDDHDSVDKIVIQKYHTVNGHNCEVRKALSKQEMASASSSQRGRSGSGNFGGGRGGGFGGNDNFGRGGNFSGRGGFGGSRGGGGYGGSGDGYNGFGNDGGYGGGGPGYSGGSRGYGSGGQGYGNQGSGYGGSGSYDSYNNGGGGGFGGGSGSNFGGGGSYNDFGNYNNQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGYGGSSSSSSYGSGRRF,0,,,,,,"Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3:An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.|Amyotrophic lateral sclerosis 20:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Myopathy, distal, 3:An autosomal dominant skeletal muscle disorder characterized by adult onset of slowly progressive distal muscular weakness and atrophy affecting the upper and lower limbs, leading to difficulties using the hands and walking difficulties. Proximal muscle involvement may occur later in the disease, but patients typically remain ambulatory. Muscle biopsy shows myopathic changes with rimmed vacuoles.","Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3|Amyotrophic lateral sclerosis 20|Myopathy, distal, 3",Q9NR30(DDX21)|Q32P51(HNRNPA1L2)|P22626(HNRNPA2B1)|P51991(HNRNPA3)|P07910(HNRNPC)|P31942(HNRNPH3)|Q07666(KHDRBS1)|Q8IUH3(RBM45)|Q14141(SEPTIN6)|Q9UHD9(UBQLN2)|P27958()|P09651-2(HNRNPA1)|O00233(PSMD9)|Q92973(TNPO1)|Q9UHD9(UBQLN2),,A1-B:P09651-1:|A1-A:P09651-2:|2:P09651-3:,,,,,,,,,,5.0
P43243,,Matrin-3,MATR3,Homo sapiens,847,False,KIAA0723,MSKSFQQSSLSRDSQGHGRDLSAAGIGLLAAATQSLSMPASLGRMNQGTARLASLMNLGMSSSLNQQGAHSALSSASTSSHNLQSIFNIGSRGPLPLSSQHRGDADQASNILASFGLSARDLDELSRYPEDKITPENLPQILLQLKRRRTEEGPTLSYGRDGRSATREPPYRVPRDDWEEKRHFRRDSFDDRGPSLNPVLDYDHGSRSQESGYYDRMDYEDDRLRDGERCRDDSFFGETSHNYHKFDSEYERMGRGPGPLQERSLFEKKRGAPPSSNIEDFHGLLPKGYPHLCSICDLPVHSNKEWSQHINGASHSRRCQLLLEIYPEWNPDNDTGHTMGDPFMLQQSTNPAPGILGPPPPSFHLGGPAVGPRGNLGAGNGNLQGPRHMQKGRVETSRVVHIMDFQRGKNLRYQLLQLVEPFGVISNHLILNKINEAFIEMATTEDAQAAVDYYTTTPALVFGKPVRVHLSQKYKRIKKPEGKPDQKFDQKQELGRVIHLSNLPHSGYSDSAVLKLAEPYGKIKNYILMRMKSQAFIEMETREDAMAMVDHCLKKALWFQGRCVKVDLSEKYKKLVLRIPNRGIDLLKKDKSRKRSYSPDGKESPSDKKSKTDGSQKTESSTEGKEQEEKSGEDGEKDTKDDQTEQEPNMLLESEDELLVDEEEAAALLESGSSVGDETDLANLGDVASDGKKEPSDKAVKKDGSASAAAKKKLKKVDKIEELDQENEAALENGIKNEENTEPGAESSENADDPNKDTSENADGQSDENKDDYTIPDEYRIGPYQPNVPVGIDYVIPKTGFYCKLCSLFYTNEEVAKNTHCSSLPHYQKLKKFLNKLAEERRQKKET,0,,,,,,"Amyotrophic lateral sclerosis 21:A neurodegenerative disorder affecting upper and lower motor neurons, resulting in muscle weakness and respiratory failure. Some patients may develop myopathic features or dementia.",Amyotrophic lateral sclerosis 21,Q9NRI5(DISC1)|P61978(HNRNPK)|P61978-2(HNRNPK)|P34969(HTR7)|P42858(HTT)|Q7Z3Y8(KRT27)|O76011(KRT34)|P43243(MATR3)|P22736(NR4A1)|P57721-2(PCBP3)|Q58EX7(PLEKHG4)|Q9UKA9-2(PTBP2)|Q9Y272(RASD1)|Q8IUH3(RBM45)|Q13148(TARDBP)|Q13077(TRAF1)|Q9BZW7(TSGA10),,1:P43243-1:|2:P43243-2:,,,,,,,,,,5.0
P68366,,Tubulin alpha-4A chain,TUBA4A,Homo sapiens,448,False,TUBA1,MRECISVHVGQAGVQMGNACWELYCLEHGIQPDGQMPSDKTIGGGDDSFTTFFCETGAGKHVPRAVFVDLEPTVIDEIRNGPYRQLFHPEQLITGKEDAANNYARGHYTIGKEIIDPVLDRIRKLSDQCTGLQGFLVFHSFGGGTGSGFTSLLMERLSVDYGKKSKLEFSIYPAPQVSTAVVEPYNSILTTHTTLEHSDCAFMVDNEAIYDICRRNLDIERPTYTNLNRLISQIVSSITASLRFDGALNVDLTEFQTNLVPYPRIHFPLATYAPVISAEKAYHEQLSVAEITNACFEPANQMVKCDPRHGKYMACCLLYRGDVVPKDVNAAIAAIKTKRSIQFVDWCPTGFKVGINYQPPTVVPGGDLAKVQRAVCMLSNTTAIAEAWARLDHKFDLMYAKRAFVHWYVGEGMEEGEFSEAREDMAALEKDYEEVGIDSYEDEDEGEE,0,,,,,,"Amyotrophic lateral sclerosis 22, with or without frontotemporal dementia:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. Patients with ALS22 may develop frontotemporal dementia.","Amyotrophic lateral sclerosis 22, with or without frontotemporal dementia",P05067(APP)|P30622(CLIP1)|Q8NA72(POC5)|Q99426(TBCB)|Q8N4U5(TCP11L2),,1:P68366-1:|2:P68366-2:,,,,,,,,,,5.0
Q8WYQ3,,"Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrial",CHCHD10,Homo sapiens,142,False,C22orf16,MPRGSRSAASRPASRPAAPSAHPPAHPPPSAAAPAPAPSGQPGLMAQMATTAAGVAVGSAVGHVMGSALTGAFSGGSSEPSQPAVQQAPTPAAPQPLQMGPCAYEIRQFLDCSTTQSDLSLCEGFSEALKQCKYYHGLSSLP,0,,,,,,"Frontotemporal dementia and/or amyotrophic lateral sclerosis 2:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.|Spinal muscular atrophy, Jokela type:An autosomal dominant, slowly progressive, lower motor neuron disease. SMAJ is characterized by adult-onset of muscle cramps and fasciculations affecting the proximal and distal muscles of the upper and lower limbs. The disorder results in weakness and mild muscle atrophy later in life.|Myopathy, isolated mitochondrial, autosomal dominant:A mitochondrial myopathy presenting with severe exercise intolerance, progressive proximal weakness, and lactic acidemia. The disorder is slowly progressive, with later involvement of facial muscles, muscles of the upper limbs, and distal muscles.","Frontotemporal dementia and/or amyotrophic lateral sclerosis 2|Spinal muscular atrophy, Jokela type|Myopathy, isolated mitochondrial, autosomal dominant",Q9Y6H1(CHCHD2)|Q16891(IMMT),,,,,,,,,,,,5.0
Q99700,,Ataxin-2,ATXN2,Homo sapiens,1313,False,ATX2|SCA2|TNRC13,MRSAAAAPRSPAVATESRRFAAARWPGWRSLQRPARRSGRGGGGAAPGPYPSAAPPPPGPGPPPSRQSSPPSASDCFGSNGNGGGAFRPGSRRLLGLGGPPRPFVVLLLPLASPGAPPAAPTRASPLGARASPPRSGVSLARPAPGCPRPACEPVYGPLTMSLKPQQQQQQQQQQQQQQQQQQQQQQQPPPAAANVRKPGGSGLLASPAAAPSPSSSSVSSSSATAPSSVVAATSGGGRPGLGRGRNSNKGLPQSTISFDGIYANMRMVHILTSVVGSKCEVQVKNGGIYEGVFKTYSPKCDLVLDAAHEKSTESSSGPKREEIMESILFKCSDFVVVQFKDMDSSYAKRDAFTDSAISAKVNGEHKEKDLEPWDAGELTANEELEALENDVSNGWDPNDMFRYNEENYGVVSTYDSSLSSYTVPLERDNSEEFLKREARANQLAEEIESSAQYKARVALENDDRSEEEKYTAVQRNSSEREGHSINTRENKYIPPGQRNREVISWGSGRQNSPRMGQPGSGSMPSRSTSHTSDFNPNSGSDQRVVNGGVPWPSPCPSPSSRPPSRYQSGPNSLPPRAATPTRPPSRPPSRPSRPPSHPSAHGSPAPVSTMPKRMSSEGPPRMSPKAQRHPRNHRVSAGRGSISSGLEFVSHNPPSEAATPPVARTSPSGGTWSSVVSGVPRLSPKTHRPRSPRQNSIGNTPSGPVLASPQAGIIPTEAVAMPIPAASPTPASPASNRAVTPSSEAKDSRLQDQRQNSPAGNKENIKPNETSPSFSKAENKGISPVVSEHRKQIDDLKKFKNDFRLQPSSTSESMDQLLNKNREGEKSRDLIKDKIEPSAKDSFIENSSSNCTSGSSKPNSPSISPSILSNTEHKRGPEVTSQGVQTSSPACKQEKDDKEEKKDAAEQVRKSTLNPNAKEFNPRSFSQPKPSTTPTSPRPQAQPSPSMVGHQQPTPVYTQPVCFAPNMMYPVPVSPGVQPLYPIPMTPMPVNQAKTYRAVPNMPQQRQDQHHQSAMMHPASAAGPPIAATPPAYSTQYVAYSPQQFPNQPLVQHVPHYQSQHPHVYSPVIQGNARMMAPPTHAQPGLVSSSATQYGAHEQTHAMYACPKLPYNKETSPSFYFAISTGSLAQQYAHPNATLHPHTPHPQPSATPTGQQQSQHGGSHPAPSPVQHHQHQAAQALHLASPQQQSAIYHAGLAPTPPSMTPASNTQSPQNSFPAAQQTVFTIHPSHVQPAYTNPPHMAHVPQAHVQSGMVPSHPTAHAPMMLMTTQPPGGPQAALAQSALQPIPVSTTAHFPYMTHPSVQAHHQQQL,0,,,,,,"Spinocerebellar ataxia 2:Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA2 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA2 is characterized by hyporeflexia, myoclonus and action tremor and dopamine-responsive parkinsonism. In some patients, SCA2 presents as pure familial parkinsonism without cerebellar signs.|Amyotrophic lateral sclerosis 13:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Spinocerebellar ataxia 2|Amyotrophic lateral sclerosis 13,P54253(ATXN1)|P26196(DDX6)|Q13283(G3BP1)|P11940(PABPC1)|Q99962(SH3GL2)|Q99963(SH3GL3)|Q13148(TARDBP)|P54253(ATXN1)|P46379-2(BAG6)|Q9BTH3(BIN1)|Q8WUW1(BRK1)|P20963(CD247)|P11940(PABPC1)|Q9NWB1-5(RBFOX1)|Q8IVP1(SH3GL3)|Q9UJZ1(STOML2)|P55854(SUMO3)|P40337-2(VHL)|Q96E88(),,1:Q99700-1:|2:Q99700-2:|3:Q99700-3:|4:Q99700-4:|5:Q99700-5:,,,,,,,,,,5.0
Q9H9T3,,Elongator complex protein 3,ELP3,Homo sapiens,547,False,,MRQKRKGDLSPAELMMLTIGDVIKQLIEAHEQGKDIDLNKVKTKTAAKYGLSAQPRLVDIIAAVPPQYRKVLMPKLKAKPIRTASGIAVVAVMCKPHRCPHISFTGNICVYCPGGPDSDFEYSTQSYTGYEPTSMRAIRARYDPFLQTRHRIEQLKQLGHSVDKVEFIVMGGTFMALPEEYRDYFIRNLHDALSGHTSNNIYEAVKYSERSLTKCIGITIETRPDYCMKRHLSDMLTYGCTRLEIGVQSVYEDVARDTNRGHTVKAVCESFHLAKDSGFKVVAHMMPDLPNVGLERDIEQFTEFFENPAFRPDGLKLYPTLVIRGTGLYELWKSGRYKSYSPSDLVELVARILALVPPWTRVYRVQRDIPMPLVSSGVEHGNLRELALARMKDLGIQCRDVRTREVGIQEIHHKVRPYQVELVRRDYVANGGWETFLSYEDPDQDILIGLLRLRKCSEETFRFELGGGVSIVRELHVYGSVVPVSSRDPTKFQHQGFGMLLMEEAERIAREEHGSGKIAVISGVGTRNYYRKIGYRLQGPYMVKMLK,0,,,,,,"Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis,O95163(ELP1),,1:Q9H9T3-1:|2:Q9H9T3-2:|3:Q9H9T3-4:|4:Q9H9T3-5:,,,,,,,,,,5.0
Q9NRR5,,Ubiquilin-4,UBQLN4,Homo sapiens,601,False,C1orf6|CIP75|UBIN,MAEPSGAETRPPIRVTVKTPKDKEEIVICDRASVKEFKEEISRRFKAQQDQLVLIFAGKILKDGDTLNQHGIKDGLTVHLVIKTPQKAQDPAAATASSPSTPDPASAPSTTPASPATPAQPSTSGSASSDAGSGSRRSSGGGPSPGAGEGSPSATASILSGFGGILGLGSLGLGSANFMELQQQMQRQLMSNPEMLSQIMENPLVQDMMSNPDLMRHMIMANPQMQQLMERNPEISHMLNNPELMRQTMELARNPAMMQEMMRNQDRALSNLESIPGGYNALRRMYTDIQEPMFSAAREQFGNNPFSSLAGNSDSSSSQPLRTENREPLPNPWSPSPPTSQAPGSGGEGTGGSGTSQVHPTVSNPFGINAASLGSGMFNSPEMQALLQQISENPQLMQNVISAPYMRSMMQTLAQNPDFAAQMMVNVPLFAGNPQLQEQLRLQLPVFLQQMQNPESLSILTNPRAMQALLQIQQGLQTLQTEAPGLVPSLGSFGISRTPAPSAGSNAGSTPEAPTSSPATPATSSPTGASSAQQQLMQQMIQLLAGSGNSQVQTPEVRFQQQLEQLNSMGFINREANLQALIATGGDINAAIERLLGSQLS,0,,,,,,"Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|:",Amyotrophic lateral sclerosis,P54253(ATXN1)|P26885(FKBP2)|P48723(HSPA13)|Q9H492(MAP1LC3A)|P55198(MLLT6)|Q9NR12(PDLIM7)|Q9Y5P3(RAI2)|Q13049(TRIM32)|Q9UMX0(UBQLN1)|Q9NRR5(UBQLN4)|O95201(ZNF205)|P08050(Gja1),,1:Q9NRR5-1:|2:Q9NRR5-2:,,,,,,,,,,5.0
Q9NUM4,,Transmembrane protein 106B,TMEM106B,Homo sapiens,274,False,,MGKSLSHLPLHSSKEDAYDGVTSENMRNGLVNSEVHNEDGRNGDVSQFPYVEFTGRDSVTCPTCQGTGRIPRGQENQLVALIPYSDQRLRPRRTKLYVMASVFVCLLLSGLAVFFLFPRSIDVKYIGVKSAYVSYDVQKRTIYLNITNTLNITNNNYYSVEVENITAQVQFSKTVIGKARLNNITIIGPLDMKQIDYTVPTVIAEEMSYMYDFCTLISIKVHNIVLMMQVTVTTTYFGHSEQISQERYQYVDCGRNTTYQLGQSEYLNVLQPQQ,0,,,,,,"Frontotemporal dementia 2:A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. Gestural apraxia, parkinsonism, visual loss, and visual hallucinations are present in 25 to 40% of patients.|Frontotemporal dementia and/or amyotrophic lateral sclerosis 1:An autosomal dominant neurodegenerative disorder characterized by adult onset of frontotemporal dementia and/or amyotrophic lateral sclerosis in an affected individual. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.|Leukodystrophy, hypomyelinating, 16:An autosomal dominant disorder characterized by hypomyelination, leukodystrophy, and thin corpus callosum observed on brain imaging. Clinical features include hypotonia, nystagmus, and mildly delayed motor development with onset in infancy, ataxic or broad-based gait, hyperreflexia, intention tremor, dysmetria, and a mild pyramidal syndrome. Some patients have cognitive impairment, whereas others may have normal cognition or mild intellectual disability with speech difficulties.|:","Frontotemporal dementia 2|Frontotemporal dementia and/or amyotrophic lateral sclerosis 1|Leukodystrophy, hypomyelinating, 16",P42858(HTT)|Q9BVX2(TMEM106C),,,,,,,,,,,,5.0
O95292,,Vesicle-associated membrane protein-associated protein B/C,VAPB,Homo sapiens,243,False,,MAKVEQVLSLEPQHELKFRGPFTDVVTTNLKLGNPTDRNVCFKVKTTAPRRYCVRPNSGIIDAGASINVSVMLQPFDYDPNEKSKHKFMVQSMFAPTDTSDMEAVWKEAKPEDLMDSKLRCVFELPAENDKPHDVEINKIISTTASKTETPIVSKSLSSSLDDTEVKKVMEECKRLQGEVQRLREENKQFKEEDGLRMRKTVQSNSPISALAPTGKEEGLSTRLLALVVLFFIVGVIIGKIAL,0,,,,,,"Amyotrophic lateral sclerosis 8:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Spinal muscular atrophy, proximal, adult, autosomal dominant:A form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. SMAPAD is characterized by proximal muscle weakness that begins in the lower limbs and then progresses to upper limbs, onset in late adulthood (after third decade) and a benign course. Most of the patients remain ambulatory 10 to 40 years after clinical onset.","Amyotrophic lateral sclerosis 8|Spinal muscular atrophy, proximal, adult, autosomal dominant",Q9NVV5-2(AIG1)|P63010-2(AP2B1)|Q13520(AQP6)|Q0P5N6(ARL16)|P11912(CD79A)|P13569(CFTR)|P49447(CYB561)|Q53TN4(CYBRD1)|O00559(EBAG9)|Q15125(EBP)|Q9GZR5(ELOVL4)|P50402(EMD)|Q8TBP5(FAM174A)|O00155(GPR25)|Q7Z5P4(HSD17B13)|Q8N5M9(JAGN1)|Q9BYQ4(KRTAP9-2)|Q9BXW6(OSBPL1A)|Q9H1P3(OSBPL2)|O14684(PTGES)|Q9H6H4(REEP4)|Q86VR2(RETREG3)|Q96LZ7(RMDN2)|Q6P5S7(RNASEK)|Q9NY72(SCN3B)|O00560(SDCBP)|Q9GZS3(SKIC8)|Q9NQQ7-3(SLC35C2)|Q96IK0(TMEM101)|Q8N6L7(TMEM252)|Q9Y320(TMX2)|Q5VTQ0(TTC39B)|Q9Y2K6(USP20)|Q9P0L0(VAPA)|O95070(YIF1A)|O15209(ZBTB22)|Q96MV8(ZDHHC15)|Q5T4F4(ZFYVE27)|Q03137(Epha4)|Q03463()|Q99IB8()|Q9P0L0(VAPA)|Q03463()|Q03463(),,1:O95292-1:|2:O95292-2:,,,,,,,,,,5.0
P03950,,Angiogenin,ANG,Homo sapiens,147,False,RNASE5,MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP,0,,,,,,"Amyotrophic lateral sclerosis 9:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis 9,P35609(ACTN2)|P19883(FST)|P12004(PCNA)|Q03405(PLAUR)|P13489(RNH1),,,,,,,,,,,,5.0
P41002,,Cyclin-F,CCNF,Homo sapiens,786,False,FBX1|FBXO1,MGSGGVVHCRCAKCFCYPTKRRIRRRPRNLTILSLPEDVLFHILKWLSVEDILAVRAVHSQLKDLVDNHASVWACASFQELWPSPGNLKLFERAAEKGNFEAAVKLGIAYLYNEGLSVSDEARAEVNGLKASRFFSLAERLNVGAAPFIWLFIRPPWSVSGSCCKAVVHESLRAECQLQRTHKASILHCLGRVLSLFEDEEKQQQAHDLFEEAAHQGCLTSSYLLWESDRRTDVSDPGRCLHSFRKLRDYAAKGCWEAQLSLAKACANANQLGLEVRASSEIVCQLFQASQAVSKQQVFSVQKGLNDTMRYILIDWLVEVATMKDFTSLCLHLTVECVDRYLRRRLVPRYRLQLLGIACMVICTRFISKEILTIREAVWLTDNTYKYEDLVRMMGEIVSALEGKIRVPTVVDYKEVLLTLVPVELRTQHLCSFLCELSLLHTSLSAYAPARLAAAALLLARLTHGQTQPWTTQLWDLTGFSYEDLIPCVLSLHKKCFHDDAPKDYRQVSLTAVKQRFEDKRYGEISQEEVLSYSQLCAALGVTQDSPDPPTFLSTGEIHAFLSSPSGRRTKRKRENSLQEDRGSFVTTPTAELSSQEETLLGSFLDWSLDCCSGYEGDQESEGEKEGDVTAPSGILDVTVVYLNPEQHCCQESSDEEACPEDKGPQDPQALALDTQIPATPGPKPLVRTSREPGKDVTTSGYSSVSTASPTSSVDGGLGALPQPTSVLSLDSDSHTQPCHHQARKSCLQCRPPSPPESSVPQQQVKRINLCIHSEEEDMNLGLVRL,0,,,,,,"Frontotemporal dementia and/or amyotrophic lateral sclerosis 5:A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis. FTDALS5 is an autosomal dominant form with age-dependent penetrance. Penetrance is estimated to be 50% by age 56 and 100% by age 61.",Frontotemporal dementia and/or amyotrophic lateral sclerosis 5,O43303(CCP110)|Q13616(CUL1)|P31350(RRM2)|P63208(SKP1)|P63208-1(SKP1),,,,,,,,,,,,5.0
P41219,,Peripherin,PRPH,Homo sapiens,470,False,NEF4|PRPH1,MSHHPSGLRAGFSSTSYRRTFGPPPSLSPGAFSYSSSSRFSSSRLLGSASPSSSVRLGSFRSPRAGAGALLRLPSERLDFSMAEALNQEFLATRSNEKQELQELNDRFANFIEKVRFLEQQNAALRGELSQARGQEPARADQLCQQELRELRRELELLGRERDRVQVERDGLAEDLAALKQRLEEETRKREDAEHNLVLFRKDVDDATLSRLELERKIESLMDEIEFLKKLHEEELRDLQVSVESQQVQQVEVEATVKPELTAALRDIRAQYESIAAKNLQEAEEWYKSKYADLSDAANRNHEALRQAKQEMNESRRQIQSLTCEVDGLRGTNEALLRQLRELEEQFALEAGGYQAGAARLEEELRQLKEEMARHLREYQELLNVKMALDIEIATYRKLLEGEESRISVPVHSFASLNIKTTVPEVEPPQDSHSRKTVLIKTIETRNGEVVTESQKEQRSELDKSSAHSY,0,,,,,,"Amyotrophic lateral sclerosis:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis,Q86TN1(ARNT2)|Q8WXF7(ATL1)|Q8WUW1(BRK1)|Q96HB5(CCDC120)|Q16543(CDC37)|Q7Z7K6(CENPV)|Q9UNS2(COPS3)|P02489(CRYAA)|Q8WUE5(CT55)|P26196(DDX6)|P17661(DES)|Q8TC29(ENKUR)|Q96KS9(FAM167A)|A0A0C3SFZ9(FCHO1)|Q99871(HAUS7)|Q8IY31-2(IFT20)|Q0VD86(INCA1)|Q8N5Z5(KCTD17)|Q6ZU52(KIAA0408)|Q5T5P2-6(KIAA1217)|Q9BVG8-5(KIFC3)|Q6P597(KLC3)|P02533(KRT14)|P08779(KRT16)|P08727(KRT19)|P35900(KRT20)|Q2M2I5(KRT24)|Q7Z3Y8(KRT27)|Q15323(KRT31)|Q14525(KRT33B)|O95678(KRT75)|O95447(LCA5L)|Q96BZ8(LENG1)|Q8TBB1(LNX1)|Q8IV03(LURAP1L)|Q96A72(MAGOHB)|Q13562(NEUROD1)|O15381-5(NVL)|Q9UBU9(NXF1)|Q9HBE1-4(PATZ1)|O14813(PHOX2A)|O75925(PIAS1)|O75928-2(PIAS2)|Q8WWB5(PIH1D2)|Q96KQ4(PPP1R13B)|Q96T49(PPP1R16B)|Q6NYC8(PPP1R18)|P54646(PRKAA2)|P25786(PSMA1)|P57052(RBM11)|Q9ULX5(RNF112)|Q96D59(RNF183)|Q96GQ5(RUSF1)|Q8N6K7-2(SAMD3)|Q96GM5(SMARCD1)|Q13573(SNW1)|Q15560(TCEA2)|Q8TDR4(TCP10L)|Q86WV5(TEN1)|Q969K7(TMEM54)|Q5W5X9-3(TTC23)|Q9UGJ1-2(TUBGCP4)|Q495M9(USH1G)|P08670(VIM)|Q15007-2(WTAP)|Q53FD0-2(ZC2HC1C)|Q9NQZ6(ZC4H2)|Q96NC0(ZMAT2)|Q9UNY5(ZNF232)|Q8N0Y2-2(ZNF444)|Q7Z3I7(ZNF572)|P0DTD1(rep),,1:P41219-1:|2:P41219-2:,,,,,,,,,,5.0
P50995,,Annexin A11,ANXA11,Homo sapiens,505,False,ANX11,MSYPGYPPPPGGYPPAAPGGGPWGGAAYPPPPSMPPIGLDNVATYAGQFNQDYLSGMAANMSGTFGGANMPNLYPGAPGAGYPPVPPGGFGQPPSAQQPVPPYGMYPPPGGNPPSRMPSYPPYPGAPVPGQPMPPPGQQPPGAYPGQPPVTYPGQPPVPLPGQQQPVPSYPGYPGSGTVTPAVPPTQFGSRGTITDAPGFDPLRDAEVLRKAMKGFGTDEQAIIDCLGSRSNKQRQQILLSFKTAYGKDLIKDLKSELSGNFEKTILALMKTPVLFDIYEIKEAIKGVGTDEACLIEILASRSNEHIRELNRAYKAEFKKTLEEAIRSDTSGHFQRLLISLSQGNRDESTNVDMSLAQRDAQELYAAGENRLGTDESKFNAVLCSRSRAHLVAVFNEYQRMTGRDIEKSICREMSGDLEEGMLAVVKCLKNTPAFFAERLNKAMRGAGTKDRTLIRIMVSRSETDLLDIRSEYKRMYGKSLYHDISGDTSGDYRKILLKICGGND,0,,,,,,"Amyotrophic lateral sclerosis 23:A form of amyotrophic lateral sclerosis, a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases. ALS23 is an autosomal dominant form with incomplete penetrance.|Inclusion body myopathy and brain white matter abnormalities:An autosomal dominant, adult-onset disorder characterized predominantly by proximal limb girdle muscle weakness affecting the lower and upper limbs and resulting in gait difficulties and scapular winging. Additional features may include dysarthria, dysphagia, low back pain, and hyporeflexia. Muscle biopsy shows fiber type variation, internal nuclei, rimmed vacuoles, and cytoplasmic protein aggregates or inclusions. Cognitive impairment or frontotemporal dementia occurs in some patients.",Amyotrophic lateral sclerosis 23|Inclusion body myopathy and brain white matter abnormalities,P15289(ARSA)|Q53EZ4(CEP55)|Q96AE4-2(FUBP1)|Q52LG2(KRTAP13-2)|Q3LI66(KRTAP6-2)|Q8NI38(NFKBID)|O75340(PDCD6)|Q92734(TFG)|Q9NZC7-5(WWOX),,1:P50995-1:|2:P50995-2:,,,,,,,,,,5.0
Q13148,,TAR DNA-binding protein 43,TARDBP,Homo sapiens,414,False,TDP43,MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQCMRGVRLVEGILHAPDAGWGNLVYVVNYPKDNKRKMDETDASSAVKVKRAVQKTSDLIVLGLPWKTTEQDLKEYFSTFGEVLMVQVKKDLKTGHSKGFGFVRFTEYETQVKVMSQRHMIDGRWCDCKLPNSKQSQDEPLRSRKVFVGRCTEDMTEDELREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEPKHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM,0,,,,,,"Amyotrophic lateral sclerosis 10:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.",Amyotrophic lateral sclerosis 10,Q969K4(ABTB1)|P55265(ADAR)|Q6ZTN6-2(ANKRD13D)|P13928(ANXA8)|P63010-2(AP2B1)|P05067(APP)|P05067-2(APP)|Q0P5N6(ARL16)|Q8WXK3(ASB13)|Q9Y575-3(ASB3)|Q96DX5(ASB9)|Q96DX5-3(ASB9)|Q96FT7-4(ASIC4)|P18847(ATF3)|O95352-2(ATG7)|P15313(ATP6V1B1)|Q99700(ATXN2)|P46379-2(BAG6)|Q8TBE0(BAHD1)|Q5H9J7(BEX5)|O15392(BIRC5)|Q9H0C5(BTBD1)|Q5SZD1(C6orf141)|Q96LL4(C8orf48)|Q13191(CBLB)|Q9ULV8(CBLC)|Q14781-2(CBX2)|Q13939(CCIN)|Q13042(CDC16)|Q13042-2(CDC16)|Q9UJX2(CDC23)|Q92879-3(CELF1)|Q8NHQ1-3(CEP70)|Q494V2-2(CFAP100)|O14647(CHD2)|Q16740(CLPP)|Q8IUI8(CRLF3)|P48730-2(CSNK1D)|P61962(DCAF7)|Q5TAQ9-2(DCAF8)|Q5TDH0-2(DDI2)|Q92841(DDX17)|O00571(DDX3X)|P17844(DDX5)|O75398(DEAF1)|Q96EY1-3(DNAJA3)|Q92782-2(DPF1)|Q86TI2-2(DPP9)|O75530-2(EED)|O00303(EIF3F)|Q15717(ELAVL1)|Q8TC29(ENKUR)|P29323-3(EPHB2)|Q6NXG1(ESRP1)|O00471(EXOC5)|Q6P1L5(FAM117B)|Q17RN3(FAM98C)|Q8IZU1(FAM9A)|Q9UKA1(FBXL5)|Q9UKT5(FBXO4)|P35637(FUS)|Q06547-2(GABPB1)|Q96IJ6(GMPPA)|P62879(GNB2)|Q9Y4H4(GPSM3)|Q969Y2(GTPBP3)|Q9UBN7(HDAC6)|Q9HCC6(HES4)|P07910(HNRNPC)|P07910-2(HNRNPC)|O14979(HNRNPDL)|P31943(HNRNPH1)|P61978(HNRNPK)|P61978-2(HNRNPK)|O43390-2(HNRNPR)|Q00839-2(HNRNPU)|Q9BUJ2(HNRNPUL1)|Q9BUJ2-2(HNRNPUL1)|Q9BTB7(HNRPUL1)|Q02363(ID2)|P80217-2(IFI35)|Q9Y6M1(IGF2BP2)|O00425(IGF2BP3)|Q12906-6(ILF3)|Q9NXX0(ILF3)|Q6DN90-2(IQSEC1)|O43187(IRAK2)|Q92613(JADE3)|Q9NVX7-2(KBTBD4)|Q96SI1-2(KCTD15)|Q8N5Z5(KCTD17)|Q9UIH9(KLF15)|Q6TDP4(KLHL17)|Q9Y2M5(KLHL20)|Q53GT1(KLHL22)|Q53HC5(KLHL26)|Q96NJ5(KLHL32)|Q8N4N3-2(KLHL36)|O00629(KPNA4)|Q9BYQ4(KRTAP9-2)|Q96JM7-2(L3MBTL3)|Q9BYZ2(LDHAL6B)|Q6DKI2(LGALS9C)|Q8TBB1(LNX1)|Q8N448(LNX2)|Q1L5Z9(LONRF2)|O95777(LSM8)|Q8TD91-2(MAGEC3)|Q15759(MAPK11)|P43243(MATR3)|A0JLT2-2(MED19)|Q8N6F8(METTL27)|Q8TDB4(MGARP)|Q8N108-16(MIER1)|A4FUJ8(MKL1)|Q9H000(MKRN2)|Q13064(MKRN3)|Q15049(MLC1)|P51948(MNAT1)|O95396(MOCS3)|Q8N594(MPND)|Q9Y483-4(MTF2)|P01106(MYC)|O00746(NME4)|Q9UNZ2(NSFL1C)|Q8NFH3(NUP43)|O15381-5(NVL)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|P32242(OTX1)|Q6VY07(PACS1)|Q9NR21-5(PARP11)|Q9HBE1-4(PATZ1)|Q9BYU1(PBX4)|Q9NV79(PCMTD2)|Q6ZMN7-2(PDZRN4)|P09565(PP9974)|O75807(PPP1R15A)|Q6ZMI0-5(PPP1R21)|O60260-5(PRKN)|Q6P2Q9(PRPF8)|P60891(PRPS1)|P28070(PSMB4)|P28062-2(PSMB8)|Q13200(PSMD2)|P26599-3(PTBP1)|Q9NS91(RAD18)|Q09028(RBBP4)|Q9BYM8(RBCK1)|P98175(RBM10)|Q8TBY0(RBM46)|P38159(RBMX)|Q04206(RELA)|Q9H871(RMND5A)|Q96G75(RMND5B)|Q8N5U6(RNF10)|Q9ULX5(RNF112)|Q8WVD3(RNF138)|Q9UBS8(RNF14)|Q96A37(RNF166)|Q96D59(RNF183)|Q8N488(RYBP)|Q15393(SF3B3)|Q8IUQ4-2(SIAH1)|Q9GZS3(SKIC8)|Q8NCS7(SLC44A5)|Q96GM5(SMARCD1)|Q9HCE7-2(SMURF1)|O14544(SOCS6)|Q99932-2(SPAG8)|Q8NHS9(SPATA22)|Q96BD6(SPSB1)|O95630(STAMBP)|Q92797-2(SYMPK)|O60506-4(SYNCRIP)|Q13148(TARDBP)|Q5VWN6(TASOR2)|Q9Y458(TBX22)|Q15554-4(TERF2)|Q8WTV1(THAP3)|Q92956-2(TNFRSF14)|P50616(TOB1)|P36406(TRIM23)|Q9H8W5-2(TRIM45)|L8E9Q5(TRIM65)|Q86WT6-2(TRIM69)|Q86UV6-2(TRIM74)|Q9BZR9(TRIM8)|Q9C026(TRIM9)|P41226(UBA7)|Q13404(UBE2V1)|O94941(UBOX5)|Q8IYU4(UBQLNL)|Q92995(USP13)|O75604-3(USP2)|Q86UV5(USP48)|P40337-2(VHL)|Q8NEZ2(VPS37A)|Q8NEZ2-2(VPS37A)|P58304(VSX2)|Q9GZL7(WDR12)|Q9BRX9(WDR83)|O00308(WWP2)|Q9H0D6(XRN2)|P67809(YBX1)|O43167-2(ZBTB24)|P24278(ZBTB25)|Q8N895(ZNF366)|Q9P0T4(ZNF581)|Q8NBB4-2(ZSCAN1)|A0A384ME25()|Q9H669()|Q9WMX2(),,1:Q13148-1:|2:Q13148-4:,,,,,,,,,,5.0
Q99720,,Sigma non-opioid intracellular receptor 1,SIGMAR1,Homo sapiens,223,False,OPRS1|SRBP,MQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYAGLDHELAFSRLIVELRRLHPGHVLPDEELQWVFVNAGGWMGAMCLLHASLSEYVLLFGTALGSRGHSGRYWAEISDTIISGTFHQWREGTTKSEVFYPGETVVHGPGEATAVEWGPNTWMVEYGRGVIPSTLAFALADTVFSTQDFLTLFYTLRSYARGLRLELTTYLFGQDP,0,,,,,,"Amyotrophic lateral sclerosis 16, juvenile:A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.|Neuronopathy, distal hereditary motor, autosomal recessive 2:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR2 is characterized by onset of distal muscle weakness and wasting affecting the lower and upper limbs in the first decade.","Amyotrophic lateral sclerosis 16, juvenile|Neuronopathy, distal hereditary motor, autosomal recessive 2",Q92847-1(GHSR)|Q99720-1(SIGMAR1)|O00213-2(APBB1)|P17612(PRKACA)|P50454(SERPINH1)|P37173(TGFBR2),,1:Q99720-1:|2:Q99720-2:|3:Q99720-3:|4:Q99720-4:|5:Q99720-5:,,,,,,,,,,5.0
O75323,,Protein NipSnap homolog 2,NIPSNAP2,Homo sapiens,286,False,GBAS,MAARVLRARGAAWAGGLLQRAAPCSLLPRLRTWTSSSNRSREDSWLKSLFVRKVDPRKDAHSNLLAKKETSNLYKLQFHNVKPECLEAYNKICQEVLPKIHEDKHYPCTLVGTWNTWYGEQDQAVHLWRYEGGYPALTEVMNKLRENKEFLEFRKARSDMLLSRKNQLLLEFSFWNEPVPRSGPNIYELRSYQLRPGTMIEWGNYWARAIRFRQDGNEAVGGFFSQIGQLYMVHHLWAYRDLQTREDIRNAAWHKHGWEELVYYTVPLIQEMESRIMIPLKTSPLQ,0,,,,,,,,O95166(GABARAP)|Q9H0R8(GABARAPL1)|P60520(GABARAPL2)|Q9GZQ8(MAP1LC3B)|Q9BXW4(MAP1LC3C),,1:O75323-1:|2:O75323-2:,,,,,,,,,,5.0
P60484,,"Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN",PTEN,Homo sapiens,403,False,MMAC1|TEP1,MTAIIKEIVSRNKRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTVEEPSNPEASSSTSVTPDVSDNEPDHYRYSDTTDSDPENEPFDEDQHTQITKV,0,,,,,,"Cowden syndrome 1:An autosomal dominant hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid.|Lhermitte-Duclos disease:A rare disease characterized by the occurrence of a slowly enlarging mass within the cerebellar cortex corresponding histologically to a cerebellar hamartoma. It manifests, most commonly in the third and fourth decades of life, with increased intracranial pressure, headache, nausea, cerebellar dysfunction, occlusive hydrocephalus, ataxia, visual disturbances and other cranial nerve palsies. Various associated abnormalities may be present such as megalencephaly, microgyria, hydromyelia, polydactyly, partial gigantism, macroglossia. LDD is part of the PTEN hamartoma tumor syndromes spectrum that also includes Cowden syndrome.|Squamous cell carcinoma of the head and neck:A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.|Endometrial cancer:A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.|:|Glioma 2:Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.|Prostate cancer:A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.|Macrocephaly/autism syndrome:Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).|:",Cowden syndrome 1|Lhermitte-Duclos disease|Squamous cell carcinoma of the head and neck|Endometrial cancer|Glioma 2|Prostate cancer|Macrocephaly/autism syndrome,Q9ULX6(AKAP8L)|P35226(BMI1)|P30260(CDC27)|Q9P0U4(CXXC1)|Q16643(DBN1)|P42685(FRK)|O60307(MAST3)|Q9Y6Q9(NCOA3)|P46934(NEDD4)|O14745(NHERF1)|Q15599(NHERF2)|P09619(PDGFRB)|Q9NRD5(PICK1)|P62136(PPP1CA)|Q06830(PRDX1)|P60484(PTEN)|O43791(SPOP)|Q62696(Dlg1)|O88382(Magi2)|Q9JK71(Magi3)|Q9R1L5(Mast1)|Q60592(Mast2)|Q9JHL1(Nherf2)|Q19T08(ECSCR)|Q5T2D3(OTUD3)|P60484-1(PTEN)|Q93009(USP7),,1:P60484-1:|alpha:P60484-2:|3:P60484-3:,,,,,,,,,,5.0
Q9HD26,,Golgi-associated PDZ and coiled-coil motif-containing protein,GOPC,Homo sapiens,462,False,CAL|FIG,MSAGGPCPAAAGGGPGGASCSVGAPGGVSMFRWLEVLEKEFDKAFVDVDLLLGEIDPDQADITYEGRQKMTSLSSCFAQLCHKAQSVSQINHKLEAQLVDLKSELTETQAEKVVLEKEVHDQLLQLHSIQLQLHAKTGQSADSGTIKAKLSGPSVEELERELEANKKEKMKEAQLEAEVKLLRKENEALRRHIAVLQAEVYGARLAAKYLDKELAGRVQQIQLLGRDMKGPAHDKLWNQLEAEIHLHRHKTVIRACRGRNDLKRPMQAPPGHDQDSLKKSQGVGPIRKVLLLKEDHEGLGISITGGKEHGVPILISEIHPGQPADRCGGLHVGDAILAVNGVNLRDTKHKEAVTILSQQRGEIEFEVVYVAPEVDSDDENVEYEDESGHRYRLYLDELEGGGNPGASCKDTSGEIKVLQGFNKKAVTDTHENGDLGTASETPLDDGASKLDDLHTLYHKKSY,0,,,,,,:,,Q9H9L7(AKIRIN1)|Q16520(BATF)|Q0P5P2(C17orf67)|Q68D86(CCDC102B)|P13569(CFTR)|Q12882(DPYD)|P22794(EVI2A)|Q86YD7(FAM90A1)|P15408(FOSL2)|P08631(HCK)|V9HWD0(HEL-S-42)|P05412(JUN)|Q6UWP7(LCLAT1)|Q8WVZ3(MORN4)|Q9BYD6(MRPL1)|Q15746(MYLK)|Q8IZQ8(MYOCD)|Q99497(PARK7)|Q7Z2X4(PID1)|Q2TAK8-2(PWWP3A)|Q96D59(RNF183)|Q9BWG1(RNF220)|Q9NTN9(SEMA4G)|Q9H1K4(SLC25A18)|Q7LBE3-1(SLC26A9)|Q6RVD6(SPATA8)|O43805(SSNA1)|Q14849(STARD3)|P04004(VTN)|Q6ZSB9(ZBTB49)|Q32MK9(ZNF509)|Q8TBZ8(ZNF564)|Q9P0T4(ZNF581)|Q96SQ5(ZNF587)|Q8NBB4(ZSCAN1)|Q9R0W0(mGluR1a)|Q7Z3C6-3(ATG9A)|Q68D86(CCDC102B)|E9PSE9(CCDC198)|Q8IZU0(FAM9B)|P55040(GEM)|P08631-2(HCK)|Q15746-7(MYLK)|Q969R2-2(OSBP2)|Q6NYC8(PPP1R18)|Q86X10(RALGAPB)|Q96D59(RNF183)|Q8N9S9-2(SNX31)|P04004(VTN)|Q6ZSB9(ZBTB49)|Q8WTX9(ZDHHC1)|Q9Y2P0(ZNF835),,1:Q9HD26-1:|2:Q9HD26-2:|3:Q9HD26-3:,,,,,,,,,,5.0
Q9BZR9,,E3 ubiquitin-protein ligase TRIM8,TRIM8,Homo sapiens,551,False,GERP|RNF27,MAENWKNCFEEELICPICLHVFVEPVQLPCKHNFCRGCIGEAWAKDSGLVRCPECNQAYNQKPGLEKNLKLTNIVEKFNALHVEKPPAALHCVFCRRGPPLPAQKVCLRCEAPCCQSHVQTHLQQPSTARGHLLVEADDVRAWSCPQHNAYRLYHCEAEQVAVCQYCCYYSGAHQGHSVCDVEIRRNEIRKMLMKQQDRLEEREQDIEDQLYKLESDKRLVEEKVNQLKEEVRLQYEKLHQLLDEDLRQTVEVLDKAQAKFCSENAAQALHLGERMQEAKKLLGSLQLLFDKTEDVSFMKNTKSVKILMDRTQTCTSSSLSPTKIGHLNSKLFLNEVAKKEKQLRKMLEGPFSTPVPFLQSVPLYPCGVSSSGAEKRKHSTAFPEASFLETSSGPVGGQYGAAGTASGEGQSGQPLGPCSSTQHLVALPGGAQPVHSSPVFPPSQYPNGSAAQQPMLPQYGGRKILVCSVDNCYCSSVANHGGHQPYPRSGHFPWTVPSQEYSHPLPPTPSVPQSLPSLAVRDWLDASQQPGHQDFYRVYGQPSTKHYVTS,0,,,,,,"Focal segmental glomerulosclerosis and neurodevelopmental syndrome:An autosomal dominant disorder characterized by global developmental delay associated with variable features of focal segmental glomerulosclerosis, a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Some patients have transient proteinuria and others require renal transplant. Neurodevelopmental features are also variable, with some patients having only mildly impaired intellectual development, and others having a severe developmental disorder associated with early-onset refractory seizures or epileptic encephalopathy. Additional features, including feeding difficulties, poor overall growth, and non-specific dysmorphic facial features, are commonly observed.",Focal segmental glomerulosclerosis and neurodevelopmental syndrome,Q8NEC5(CATSPER1)|Q96GG9(DCUN1D1)|Q9H5Z6-2(FAM124B)|P49639(HOXA1)|Q8TBB1(LNX1)|Q17RB8(LONRF1)|Q8N3F0(MTURN)|Q8NFP7(NUDT10)|Q96DC9(OTUB2)|P54725(RAD23A)|Q8IYW5(RNF168)|Q13148(TARDBP)|Q96KP6(TNIP3)|O14787-2(TNPO2)|Q63HR2(TNS2)|Q9BZR9(TRIM8)|P57075-2(UBASH3A)|P51668(UBE2D1)|Q9Y2X8(UBE2D4)|O14933(UBE2L6)|O94888(UBXN7)|P45974-2(USP5)|Q5VVQ6(YOD1),,,,,,,,,,,,5.0
P61812,,Transforming growth factor beta-2 proprotein,TGFB2,Homo sapiens,414,False,,MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS,0,,,,,,":|Loeys-Dietz syndrome 4:An aortic aneurysm syndrome with widespread systemic involvement. LDS4 is characterized by arterial tortuosity, aortic dissection, intracranial aneurysm and subarachnoid hemorrhage, hypertelorism, bifid uvula, pectus deformity, bicuspid aortic valve, arachnodactyly, scoliosis, foot deformities, dural ectasia, joint hyperflexibility, and thin skin with easy bruising and striae.|:",Loeys-Dietz syndrome 4,P05067(APP)|P13051-2(UNG),,"A:P61812-1,P08112-1:|B:P61812-2,P08112-2:",,,,,,,,,,5.0
Q96AW1,,WW domain binding protein VOPP1,VOPP1,Homo sapiens,172,False,ECOP|GASP,MRRQPAKVAALLLGLLLECTEAKKHCWYFEGLYPTYYICRSYEDCCGSRCCVRALSIQRLWYFWFLLMMGVLFCCGAGFFIRRRMYPPPLIEEPAFNVSYTRQPPNPGPGAQQPGPPYYTDPGGPGMNPVGNSMAMAFQVPPNSPQGSVACPPPPAYCNTPPPPYEQVVKAK,0,,,,,,,,Q9NZC7(WWOX),,1:Q96AW1-1:|2:Q96AW1-2:|3:Q96AW1-3:|4:Q96AW1-4:,,,,,,,,,,5.0
Q9Y530,,ADP-ribose glycohydrolase OARD1,OARD1,Homo sapiens,152,False,C6orf130|TARG1,MASSLNEDPEGSRITYVKGDLFACPKTDSLAHCISEDCRMGAGIAVLFKKKFGGVQELLNQQKKSGEVAVLKRDGRYIYYLITKKRASHKPTYENLQKSLEAMKSHCLKNGVTDLSMPRIGCGLDRLQWENVSAMIEEVFEATDIKITVYTL,0,,,,,,:,,P09874(PARP1)|Q53GL7(PARP10)|Q9NRD5(PICK1)|O95271(TNKS),,,,,,,,,,,,5.0
Q9UJY1,,Heat shock protein beta-8,HSPB8,Homo sapiens,196,False,CRYAC|E2IG1|HSP22,MADGQMPFSCHYPSRLRRDPFRDSPLSSRLLDDGFGMDPFPDDLTASWPDWALPRLSSAWPGTLRSGMVPRGPTATARFGVPAEGRTPPPFPGEPWKVCVNVHSFKPEELMVKTKDGYVEVSGKHEEKQQEGGIVSKNFTKKIQLPAEVDPVTVFASLSPEGLLIIEAPQVPPYSTFGESSFNNELPQDSQEVTCT,0,,,,,,"Neuronopathy, distal hereditary motor, autosomal dominant 2:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.|Charcot-Marie-Tooth disease, axonal, 2L:An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.","Neuronopathy, distal hereditary motor, autosomal dominant 2|Charcot-Marie-Tooth disease, axonal, 2L",Q7L5A3(ATOSB)|O95817(BAG3)|Q53TS8(C2CD6)|Q9UNI6(DUSP12)|P04792(HSPB1)|Q16082(HSPB2)|Q9UBY9(HSPB7)|Q9UJY1(HSPB8)|Q8IVT2(MISP)|Q15773(MLF2)|Q9HC29-1(NOD2)|Q2TAL8(QRICH1)|P49247(RPIA)|O15375(SLC16A5)|O14512(SOCS7)|O75865-2(TRAPPC6A),,,,,,,,,,,,5.0
O94827,,Pleckstrin homology domain-containing family G member 5,PLEKHG5,Homo sapiens,1006,False,KIAA0720,MHYDGHVRFDLPPQGSVLARNVSTRSCPPRTSPAVDLEEEEEESSVDGKGDRKSTGLKLSKKKARRRHTDDPSKECFTLKFDLNVDIETEIVPAMKKKSLGEVLLPVFERKGIALGKVDIYLDQSNTPLSLTFEAYRFGGHYLRVKAPAKPGDEGKVEQGMKDSKSLSLPILRPAGTGPPALERVDAQSRRESLDILAPGRRRKNMSEFLGEASIPGQEPPTPSSCSLPSGSSGSTNTGDSWKNRAASRFSGFFSSGPSTSAFGREVDKMEQLEGKLHTYSLFGLPRLPRGLRFDHDSWEEEYDEDEDEDNACLRLEDSWRELIDGHEKLTRRQCHQQEAVWELLHTEASYIRKLRVIINLFLCCLLNLQESGLLCEVEAERLFSNIPEIAQLHRRLWASVMAPVLEKARRTRALLQPGDFLKGFKMFGSLFKPYIRYCMEEEGCMEYMRGLLRDNDLFRAYITWAEKHPQCQRLKLSDMLAKPHQRLTKYPLLLKSVLRKTEEPRAKEAVVAMIGSVERFIHHVNACMRQRQERQRLAAVVSRIDAYEVVESSSDEVDKLLKEFLHLDLTAPIPGASPEETRQLLLEGSLRMKEGKDSKMDVYCFLFTDLLLVTKAVKKAERTRVIRPPLLVDKIVCRELRDPGSFLLIYLNEFHSAVGAYTFQASGQALCRGWVDTIYNAQNQLQQLRAQEPPGSQQPLQSLEEEEDEQEEEEEEEEEEEEGEDSGTSAASSPTIMRKSSGSPDSQHCASDGSTETLAMVVVEPGDTLSSPEFDSGPFSSQSDETSLSTTASSATPTSELLPLGPVDGRSCSMDSAYGTLSPTSLQDFVAPGPMAELVPRAPESPRVPSPPPSPRLRRRTPVQLLSCPPHLLKSKSEASLLQLLAGAGTHGTPSAPSRSLSELCLAVPAPGIRTQGSPQEAGPSWDCRGAPSPGSGPGLVGCLAGEPAGSHRKRCGDLPSGASPRVQPEPPPGVSAQHRKLTLAQLYRIRTTLLLNSTLTASEV,0,,,,,,"Neuronopathy, distal hereditary motor, autosomal recessive 4:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMNR4 is characterized by childhood onset, generalized muscle weakness and atrophy with denervation and normal sensation. Bulbar symptoms and pyramidal signs are absent.|Charcot-Marie-Tooth disease, recessive intermediate C:A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Recessive intermediate forms of Charcot-Marie-Tooth disease are characterized by clinical and pathologic features intermediate between demyelinating and axonal peripheral neuropathies, and motor median nerve conduction velocities ranging from 25 to 45 m/sec.","Neuronopathy, distal hereditary motor, autosomal recessive 4|Charcot-Marie-Tooth disease, recessive intermediate C",O43865(AHCYL1)|Q15669(RHOH)|P61587(RND3),,1:O94827-5:|2:O94827-3:|3:O94827-4:|4:O94827-7:,,,,,,,,,,5.0
Q9BVI0,,PHD finger protein 20,PHF20,Homo sapiens,1012,False,C20orf104|GLEA2|HCA58|NZF|TZP,MTKHPPNRRGISFEVGAQLEARDRLKNWYPAHIEDIDYEEGKVLIHFKRWNHRYDEWFCWDSPYLRPLEKIQLRKEGLHEEDGSSEFQINEQVLACWSDCRFYPAKVTAVNKDGTYTVKFYDGVVQTVKHIHVKAFSKDQNIVGNARPKETDHKSLSSSPDKREKFKEQRKATVNVKKDKEDKPLKTEKRPKQPDKEGKLICSEKGKVSEKSLPKNEKEDKENISENDREYSGDAQVDKKPENDIVKSPQENLREPKRKRGRPPSIAPTAVDSNSQTLQPITLELRRRKISKGCEVPLKRPRLDKNSSQEKSKNYSENTDKDLSRRRSSRLSTNGTHEILDPDLVVSDLVDTDPLQDTLSSTKESEEGQLKSALEAGQVSSALTCHSFGDGSGAAGLELNCPSMGENTMKTEPTSPLVELQEISTVEVTNTFKKTDDFGSSNAPAVDLDHKFRCKVVDCLKFFRKAKLLHYHMKYFHGMEKSLEPEESPGKRHVQTRGPSASDKPSQETLTRKRVSASSPTTKDKEKNKEKKFKEFVRVKPKKKKKKKKKTKPECPCSEEISDTSQEPSPPKAFAVTRCGSSHKPGVHMSPQLHGPESGHHKGKVKALEEDNLSESSSESFLWSDDEYGQDVDVTTNPDEELDGDDRYDFEVVRCICEVQEENDFMIQCEECQCWQHGVCMGLLEENVPEKYTCYVCQDPPGQRPGFKYWYDKEWLSRGHMHGLAFLEENYSHQNAKKIVATHQLLGDVQRVIEVLHGLQLKMSILQSREHPDLPLWCQPWKQHSGEGRSHFRNIPVTDTRSKEEAPSYRTLNGAVEKPRPLALPLPRSVEESYITSEHCYQKPRAYYPAVEQKLVVETRGSALDDAVNPLHENGDDSLSPRLGWPLDQDRSKGDSDPKPGSPKVKEYVSKKALPEEAPARKLLDRGGEGLLSSQHQWQFNLLTHVESLQDEVTHRMDSIEKELDVLESWLDYTGELEPPEPLARLPQLKHCIKQLLMDLGKVQQIALCCST,0,,,,,,,,P68431(H3C12)|P62805(H4C9)|Q9P2N6(KANSL3),,1:Q9BVI0-1:|2:Q9BVI0-2:,,,,,,,,,,5.0
P15328,,Folate receptor alpha,FOLR1,Homo sapiens,257,False,FOLR,MAQRMTTQLLLLLVWVAVVGEAQTRIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWRKNACCSTNTSQEAHKDVSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIQQVDQSWRKERVLNVPLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVGAACQPFHFYFPTPTVLCNEIWTHSYKVSNYSRGSGRCIQMWFDPAQGNPNEEVARFYAAAMSGAGPWAAWPFLLSLALMLLWLLS,0,,,,,,"Neurodegeneration due to cerebral folate transport deficiency:An autosomal recessive neurodegenerative disorder resulting from brain-specific folate deficiency early in life. Onset is apparent in late infancy with severe developmental regression, movement disturbances, epilepsy and leukodystrophy.",Neurodegeneration due to cerebral folate transport deficiency,Q8N357(SLC35F6),,,,,,,,,,,,5.0
Q8NFU7,,Methylcytosine dioxygenase TET1,TET1,Homo sapiens,2136,False,CXXC6|KIAA1676|LCX,MSRSRHARPSRLVRKEDVNKKKKNSQLRKTTKGANKNVASVKTLSPGKLKQLIQERDVKKKTEPKPPVPVRSLLTRAGAARMNLDRTEVLFQNPESLTCNGFTMALRSTSLSRRLSQPPLVVAKSKKVPLSKGLEKQHDCDYKILPALGVKHSENDSVPMQDTQVLPDIETLIGVQNPSLLKGKSQETTQFWSQRVEDSKINIPTHSGPAAEILPGPLEGTRCGEGLFSEETLNDTSGSPKMFAQDTVCAPFPQRATPKVTSQGNPSIQLEELGSRVESLKLSDSYLDPIKSEHDCYPTSSLNKVIPDLNLRNCLALGGSTSPTSVIKFLLAGSKQATLGAKPDHQEAFEATANQQEVSDTTSFLGQAFGAIPHQWELPGADPVHGEALGETPDLPEIPGAIPVQGEVFGTILDQQETLGMSGSVVPDLPVFLPVPPNPIATFNAPSKWPEPQSTVSYGLAVQGAIQILPLGSGHTPQSSSNSEKNSLPPVMAISNVENEKQVHISFLPANTQGFPLAPERGLFHASLGIAQLSQAGPSKSDRGSSQVSVTSTVHVVNTTVVTMPVPMVSTSSSSYTTLLPTLEKKKRKRCGVCEPCQQKTNCGECTYCKNRKNSHQICKKRKCEELKKKPSVVVPLEVIKENKRPQREKKPKVLKADFDNKPVNGPKSESMDYSRCGHGEEQKLELNPHTVENVTKNEDSMTGIEVEKWTQNKKSQLTDHVKGDFSANVPEAEKSKNSEVDKKRTKSPKLFVQTVRNGIKHVHCLPAETNVSFKKFNIEEFGKTLENNSYKFLKDTANHKNAMSSVATDMSCDHLKGRSNVLVFQQPGFNCSSIPHSSHSIINHHASIHNEGDQPKTPENIPSKEPKDGSPVQPSLLSLMKDRRLTLEQVVAIEALTQLSEAPSENSSPSKSEKDEESEQRTASLLNSCKAILYTVRKDLQDPNLQGEPPKLNHCPSLEKQSSCNTVVFNGQTTTLSNSHINSATNQASTKSHEYSKVTNSLSLFIPKSNSSKIDTNKSIAQGIITLDNCSNDLHQLPPRNNEVEYCNQLLDSSKKLDSDDLSCQDATHTQIEEDVATQLTQLASIIKINYIKPEDKKVESTPTSLVTCNVQQKYNQEKGTIQQKPPSSVHNNHGSSLTKQKNPTQKKTKSTPSRDRRKKKPTVVSYQENDRQKWEKLSYMYGTICDIWIASKFQNFGQFCPHDFPTVFGKISSSTKIWKPLAQTRSIMQPKTVFPPLTQIKLQRYPESAEEKVKVEPLDSLSLFHLKTESNGKAFTDKAYNSQVQLTVNANQKAHPLTQPSSPPNQCANVMAGDDQIRFQQVVKEQLMHQRLPTLPGISHETPLPESALTLRNVNVVCSGGITVVSTKSEEEVCSSSFGTSEFSTVDSAQKNFNDYAMNFFTNPTKNLVSITKDSELPTCSCLDRVIQKDKGPYYTHLGAGPSVAAVREIMENRYGQKGNAIRIEIVVYTGKEGKSSHGCPIAKWVLRRSSDEEKVLCLVRQRTGHHCPTAVMVVLIMVWDGIPLPMADRLYTELTENLKSYNGHPTDRRCTLNENRTCTCQGIDPETCGASFSFGCSWSMYFNGCKFGRSPSPRRFRIDPSSPLHEKNLEDNLQSLATRLAPIYKQYAPVAYQNQVEYENVARECRLGSKEGRPFSGVTACLDFCAHPHRDIHNMNNGSTVVCTLTREDNRSLGVIPQDEQLHVLPLYKLSDTDEFGSKEGMEAKIKSGAIEVLAPRRKKRTCFTQPVPRSGKKRAAMMTEVLAHKIRAVEKKPIPRIKRKNNSTTTNNSKPSSLPTLGSNTETVQPEVKSETEPHFILKSSDNTKTYSLMPSAPHPVKEASPGFSWSPKTASATPAPLKNDATASCGFSERSSTPHCTMPSGRLSGANAAAADGPGISQLGEVAPLPTLSAPVMEPLINSEPSTGVTEPLTPHQPNHQPSFLTSPQDLASSPMEEDEQHSEADEPPSDEPLSDDPLSPAEEKLPHIDEYWSDSEHIFLDANIGGVAIAPAHGSVLIECARRELHATTPVEHPNRNHPTRLSLVFYQHKNLNKPQHGFELNKIKFEAKEAKNKKMKASEQKDQAANEGPEQSSEVNELNQIPSHKALTLTHDNVVTVSPYALTHVAGPYNHWV,0,,,,,,:,,,,1:Q8NFU7-1:|2:Q8NFU7-2:|3:Q8NFU7-3:|4:Q8NFU7-4:,,,,,,,,,,5.0
Q9H3T3,,Semaphorin-6B,SEMA6B,Homo sapiens,888,False,SEMAN|SEMAZ,MQTPRASPPRPALLLLLLLLGGAHGLFPEEPPPLSVAPRDYLNHYPVFVGSGPGRLTPAEGADDLNIQRVLRVNRTLFIGDRDNLYRVELEPPTSTELRYQRKLTWRSNPSDINVCRMKGKQEGECRNFVKVLLLRDESTLFVCGSNAFNPVCANYSIDTLQPVGDNISGMARCPYDPKHANVALFSDGMLFTATVTDFLAIDAVIYRSLGDRPTLRTVKHDSKWFKEPYFVHAVEWGSHVYFFFREIAMEFNYLEKVVVSRVARVCKNDVGGSPRVLEKQWTSFLKARLNCSVPGDSHFYFNVLQAVTGVVSLGGRPVVLAVFSTPSNSIPGSAVCAFDLTQVAAVFEGRFREQKSPESIWTPVPEDQVPRPRPGCCAAPGMQYNASSALPDDILNFVKTHPLMDEAVPSLGHAPWILRTLMRHQLTRVAVDVGAGPWGNQTVVFLGSEAGTVLKFLVRPNASTSGTSGLSVFLEEFETYRPDRCGRPGGGETGQRLLSLELDAASGGLLAAFPRCVVRVPVARCQQYSGCMKNCIGSQDPYCGWAPDGSCIFLSPGTRAAFEQDVSGASTSGLGDCTGLLRASLSEDRAGLVSVNLLVTSSVAAFVVGAVVSGFSVGWFVGLRERRELARRKDKEAILAHGAGEAVLSVSRLGERRAQGPGGRGGGGGGGAGVPPEALLAPLMQNGWAKATLLQGGPHDLDSGLLPTPEQTPLPQKRLPTPHPHPHALGPRAWDHGHPLLPASASSSLLLLAPARAPEQPPAPGEPTPDGRLYAARPGRASHGDFPLTPHASPDRRRVVSAPTGPLDPASAADGLPRPWSPPPTGSLRRPLGPHAPPAATLRRTHTFNSGEARPGDRHRGCHARPGTDLAHLLPYGGADRTAPPVP,0,,,,,,"Epilepsy, progressive myoclonic 11:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM11 is an autosomal dominant form. Clinical features include normal or mildly delayed early development, developmental regression after seizures onset, inability to walk, severely impaired intellectual development, poor or absent speech, spasticity, ataxia, and intention tremor. Brain imaging shows cerebellar atrophy in some patients.","Epilepsy, progressive myoclonic 11",,,1:Q9H3T3-1:|2:Q9H3T3-3:,,,,,,,,,,5.0
P31751,,RAC-beta serine/threonine-protein kinase,AKT2,Homo sapiens,481,False,,MNEVSVIKEGWLHKRGEYIKTWRPRYFLLKSDGSFIGYKERPEAPDQTLPPLNNFSVAECQLMKTERPRPNTFVIRCLQWTTVIERTFHVDSPDEREEWMRAIQMVANSLKQRAPGEDPMDYKCGSPSDSSTTEEMEVAVSKARAKVTMNDFDYLKLLGKGTFGKVILVREKATGRYYAMKILRKEVIIAKDEVAHTVTESRVLQNTRHPFLTALKYAFQTHDRLCFVMEYANGGELFFHLSRERVFTEERARFYGAEIVSALEYLHSRDVVYRDIKLENLMLDKDGHIKITDFGLCKEGISDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHERLFELILMEEIRFPRTLSPEAKSLLAGLLKKDPKQRLGGGPSDAKEVMEHRFFLSINWQDVVQKKLLPPFKPQVTSEVDTRYFDDEFTAQSITITPPDRYDSLGLLELDQRTHFPQFSYSASIRE,0,,,,,,":|Type 2 diabetes mellitus:A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.|Hypoinsulinemic hypoglycemia with hemihypertrophy:A disorder characterized by hypoglycemia, low insulin levels, low serum levels of ketone bodies and branched-chain amino acids, left-sided hemihypertrophy, neonatal macrosomia, reduced consciousness and hypoglycemic seizures.",Type 2 diabetes mellitus|Hypoinsulinemic hypoglycemia with hemihypertrophy,P31749(AKT1)|P49841(GSK3B)|P08238(HSP90AB1)|Q6FHY5(MEOX2)|Q9NRD5(PICK1)|Q04864-2(REL)|O60504(SORBS3)|P53804(TTC3)|Q9C0C9(UBE2O)|P08670(VIM)|Q15118-1(PDK1),,1:P31751-1:|2:P31751-2:,,,,,,,,,,5.0
Q9UM73,,ALK tyrosine kinase receptor,ALK,Homo sapiens,1620,False,,MGAIGLLWLLPLLLSTAAVGSGMGTGQRAGSPAAGPPLQPREPLSYSRLQRKSLAVDFVVPSLFRVYARDLLLPPSSSELKAGRPEARGSLALDCAPLLRLLGPAPGVSWTAGSPAPAEARTLSRVLKGGSVRKLRRAKQLVLELGEEAILEGCVGPPGEAAVGLLQFNLSELFSWWIRQGEGRLRIRLMPEKKASEVGREGRLSAAIRASQPRLLFQIFGTGHSSLESPTNMPSPSPDYFTWNLTWIMKDSFPFLSHRSRYGLECSFDFPCELEYSPPLHDLRNQSWSWRRIPSEEASQMDLLDGPGAERSKEMPRGSFLLLNTSADSKHTILSPWMRSSSEHCTLAVSVHRHLQPSGRYIAQLLPHNEAAREILLMPTPGKHGWTVLQGRIGRPDNPFRVALEYISSGNRSLSAVDFFALKNCSEGTSPGSKMALQSSFTCWNGTVLQLGQACDFHQDCAQGEDESQMCRKLPVGFYCNFEDGFCGWTQGTLSPHTPQWQVRTLKDARFQDHQDHALLLSTTDVPASESATVTSATFPAPIKSSPCELRMSWLIRGVLRGNVSLVLVENKTGKEQGRMVWHVAAYEGLSLWQWMVLPLLDVSDRFWLQMVAWWGQGSRAIVAFDNISISLDCYLTISGEDKILQNTAPKSRNLFERNPNKELKPGENSPRQTPIFDPTVHWLFTTCGASGPHGPTQAQCNNAYQNSNLSVEVGSEGPLKGIQIWKVPATDTYSISGYGAAGGKGGKNTMMRSHGVSVLGIFNLEKDDMLYILVGQQGEDACPSTNQLIQKVCIGENNVIEEEIRVNRSVHEWAGGGGGGGGATYVFKMKDGVPVPLIIAAGGGGRAYGAKTDTFHPERLENNSSVLGLNGNSGAAGGGGGWNDNTSLLWAGKSLQEGATGGHSCPQAMKKWGWETRGGFGGGGGGCSSGGGGGGYIGGNAASNNDPEMDGEDGVSFISPLGILYTPALKVMEGHGEVNIKHYLNCSHCEVDECHMDPESHKVICFCDHGTVLAEDGVSCIVSPTPEPHLPLSLILSVVTSALVAALVLAFSGIMIVYRRKHQELQAMQMELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKVPVRPKDPEGVPPLLVSQQAKREEERSPAAPPPLPTTSSGKAAKKPTAAEISVRVPRGPAVEGGHVNMAFSQSNPPSELHKVHGSRNKPTSLWNPTYGSWFTEKPTKKNNPIAKKEPHDRGNLGLEGSCTVPPNVATGRLPGASLLLEPSSLTANMKEVPLFRLRHFPCGNVNYGYQQQGLPLEAATAPGAGHYEDTILKSKNSMNQPGP,0,,,,,,:|:|:|Neuroblastoma 3:A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.|:|:|:,Neuroblastoma 3,Q9UM73(ALK)|Q6UXT8(ALKAL1)|Q6UX46(ALKAL2)|P08238(HSP90AB1)|P23471(PTPRZ1)|P07949(RET),,,,,,,,,,,,5.0
O00291,,Huntingtin-interacting protein 1,HIP1,Homo sapiens,1037,False,,MDRMASSMKQVPNPLPKVLSRRGVGAGLEAAERESFERTQTVSINKAINTQEVAVKEKHARTCILGTHHEKGAQTFWSVVNRLPLSSNAVLCWKFCHVFHKLLRDGHPNVLKDSLRYRNELSDMSRMWGHLSEGYGQLCSIYLKLLRTKMEYHTKNPRFPGNLQMSDRQLDEAGESDVNNFFQLTVEMFDYLECELNLFQTVFNSLDMSRSVSVTAAGQCRLAPLIQVILDCSHLYDYTVKLLFKLHSCLPADTLQGHRDRFMEQFTKLKDLFYRSSNLQYFKRLIQIPQLPENPPNFLRASALSEHISPVVVIPAEASSPDSEPVLEKDDLMDMDASQQNLFDNKFDDIFGSSFSSDPFNFNSQNGVNKDEKDHLIERLYREISGLKAQLENMKTESQRVVLQLKGHVSELEADLAEQQHLRQQAADDCEFLRAELDELRRQREDTEKAQRSLSEIERKAQANEQRYSKLKEKYSELVQNHADLLRKNAEVTKQVSMARQAQVDLEREKKELEDSLERISDQGQRKTQEQLEVLESLKQELATSQRELQVLQGSLETSAQSEANWAAEFAELEKERDSLVSGAAHREEELSALRKELQDTQLKLASTEESMCQLAKDQRKMLLVGSRKAAEQVIQDALNQLEEPPLISCAGSADHLLSTVTSISSCIEQLEKSWSQYLACPEDISGLLHSITLLAHLTSDAIAHGATTCLRAPPEPADSLTEACKQYGRETLAYLASLEEEGSLENADSTAMRNCLSKIKAIGEELLPRGLDIKQEELGDLVDKEMAATSAAIETATARIEEMLSKSRAGDTGVKLEVNERILGCCTSLMQAIQVLIVASKDLQREIVESGRGTASPKEFYAKNSRWTEGLISASKAVGWGATVMVDAADLVVQGRGKFEELMVCSHEIAASTAQLVAASKVKADKDSPNLAQLQQASRGVNQATAGVVASTISGKSQIEETDNMDFSSMTLTQIKRQEMDSQVRVLELENELQKERQKLGELRKKHYELAGVAEGWEEGTEASPPTLQEVVTEKE,0,,,,,,:,,Q9Y614(ACTL7B)|Q96MA6(AK8)|Q9Y303-2(AMDHD2)|Q9H0Y0(ATG10)|Q14032(BAAT)|Q9NSI6-4(BRWD1)|Q8WZ55(BSND)|Q13901(C1D)|Q3SXR2(C3orf36)|O00257-3(CBX4)|P42773(CDKN2C)|Q96M91(CFAP53)|P09496-2(CLTA)|P02458-1(COL2A1)|Q9UKG9-2(CROT)|P35222(CTNNB1)|Q9NUQ9(CYRIB)|Q15038(DAZAP2)|Q9BPU6(DPYSL5)|Q08426(EHHADH)|Q96KS9(FAM167A)|Q92567-2(FAM168A)|Q8IZU1(FAM9A)|Q06547-3(GABPB1)|Q9UI32(GLS2)|Q49A26-4(GLYR1)|Q96EW2-2(HSPBAP1)|P42858(HTT)|Q9UK76(JPT1)|Q8N5Z5(KCTD17)|Q8N4N3-2(KLHL36)|Q9H2C1(LHX5)|Q99732(LITAF)|Q8TBB1(LNX1)|Q16609(LPAL2)|Q8IYG6(LRRC56)|P34949-2(MPI)|Q15742-2(NAB2)|Q8NDH3-5(NPEPL1)|P36639-4(NUDT1)|Q6N063-2(OGFOD2)|Q8NCQ7-2(PROCA1)|Q8WUD1-2(RAB2B)|P54727(RAD23B)|Q09028(RBBP4)|Q04864(REL)|P47804-3(RGR)|Q15382(RHEB)|Q8N5U6(RNF10)|Q9NS64(RPRM)|P22307-3(SCP2)|Q15393(SF3B3)|Q9BZQ2(SHCBP1L)|Q86US8(SMG6)|Q13573(SNW1)|Q8N0X7(SPART)|Q9P2T0(SPMAP2)|Q5W111-2(SPRYD7)|Q96BD6(SPSB1)|O60506-4(SYNCRIP)|Q9BSW7(SYT17)|O15273(TCAP)|Q15560(TCEA2)|Q8N8B7-2(TCEANC)|Q96A09(TENT5B)|P54274-2(TERF1)|O43548(TGM5)|Q9NQ88(TIGAR)|P36406(TRIM23)|Q9P1Q0-4(VPS54)|Q8NA23-2(WDR31)|O43829(ZBTB14)|Q8IWT0-2(ZBTB8OS)|Q53FD0-2(ZC2HC1C)|Q5JTY5(ZNG1C)|Q9EPV5(Apaf1)|Q9CR95(Necap1),,HIP1-1:O00291-1:|HIP1-2:O00291-2:|3:O00291-3:|4:O00291-4:,,,,,,,,,,5.0
O00400,,Acetyl-coenzyme A transporter 1,SLC33A1,Homo sapiens,549,False,ACATN|AT1,MSPTISHKDSSRQRRPGNFSHSLDMKSGPLPPGGWDDSHLDSAGREGDREALLGDTGTGDFLKAPQSFRAELSSILLLLFLYVLQGIPLGLAGSIPLILQSKNVSYTDQAFFSFVFWPFSLKLLWAPLVDAVYVKNFGRRKSWLVPTQYILGLFMIYLSTQVDRLLGNTDDRTPDVIALTVAFFLFEFLAATQDIAVDGWALTMLSRENVGYASTCNSVGQTAGYFLGNVLFLALESADFCNKYLRFQPQPRGIVTLSDFLFFWGTVFLITTTLVALLKKENEVSVVKEETQGITDTYKLLFAIIKMPAVLTFCLLILTAKIGFSAADAVTGLKLVEEGVPKEHLALLAVPMVPLQIILPLIISKYTAGPQPLNTFYKAMPYRLLLGLEYALLVWWTPKVEHQGGFPIYYYIVVLLSYALHQVTVYSMYVSIMAFNAKVSDPLIGGTYMTLLNTVSNLGGNWPSTVALWLVDPLTVKECVGASNQNCRTPDAVELCKKLGGSCVTALDGYYVESIICVFIGFGWWFFLGPKFKKLQDEGSSSWKCKRNN,0,,,,,,"Spastic paraplegia 42, autosomal dominant:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.|Huppke-Brendel syndrome:An autosomal recessive disorder characterized by congenital cataracts, severe psychomotor retardation, and hearing loss associated with decreased serum ceruloplasmin and copper. Brain MRI shows cerebral and cerebellar atrophy and hypomyelination.","Spastic paraplegia 42, autosomal dominant|Huppke-Brendel syndrome",P13569(CFTR),,,,,,,,,,,,5.0
O00505,,Importin subunit alpha-4,KPNA3,Homo sapiens,521,False,QIP2,MAENPSLENHRIKSFKNKGRDVETMRRHRNEVTVELRKNKRDEHLLKKRNVPQEESLEDSDVDADFKAQNVTLEAILQNATSDNPVVQLSAVQAARKLLSSDRNPPIDDLIKSGILPILVKCLERDDNPSLQFEAAWALTNIASGTSAQTQAVVQSNAVPLFLRLLRSPHQNVCEQAVWALGNIIGDGPQCRDYVISLGVVKPLLSFISPSIPITFLRNVTWVIVNLCRNKDPPPPMETVQEILPALCVLIYHTDINILVDTVWALSYLTDGGNEQIQMVIDSGVVPFLVPLLSHQEVKVQTAALRAVGNIVTGTDEQTQVVLNCDVLSHFPNLLSHPKEKINKEAVWFLSNITAGNQQQVQAVIDAGLIPMIIHQLAKGDFGTQKEAAWAISNLTISGRKDQVEYLVQQNVIPPFCNLLSVKDSQVVQVVLDGLKNILIMAGDEASTIAEIIEECGGLEKIEVLQQHENEDIYKLAFEIIDQYFSGDDIDEDPCLIPEATQGGTYNFDPTANLQTKEFNF,0,,,,,,"Spastic paraplegia 88, autosomal dominant:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG88 is characterized by onset of symptoms in the first year of life. Most SPG88 patients have a pure form of the disorder, although rarely patients may manifest additional features, including peripheral neuropathy, speech delay, attention deficit-hyperactivity disorder, and non-specific brain imaging abnormalities.","Spastic paraplegia 88, autosomal dominant",Q9GZX7(AICDA)|X5D778(ANKRD11)|B3KTP4(ApoL6)|Q7L5A3(ATOSB)|Q8TBE0(BAHD1)|Q15059-2(BRD3)|Q68D86(CCDC102B)|P46527(CDKN1B)|Q9NR30(DDX21)|P19447(ERCC3)|Q92731-3(ESR2)|Q86YD7(FAM90A1)|P02792(FTL)|Q13322-4(GRB10)|Q96MH2(HEXIM2)|P07910(HNRNPC)|P42858(HTT)|Q92993(KAT5)|Q14974(KPNB1)|Q8NA19-2(L3MBTL4)|P45984(MAPK9)|Q9NZL9(MAT2B)|Q13330(MTA1)|Q9HAN9(NMNAT1)|P06748(NPM1)|Q9UKX7(NUP50)|Q9BUI4(POLR3C)|P43351(RAD52)|Q96P16(RPRD1A)|Q8WWX8(SLC5A11)|Q8WWX8-3(SLC5A11)|Q96LM6(SPMIP9)|P0DTL5(TMEM276)|Q96KP6(TNIP3)|Q9Y5U2(TSSC4)|Q2YD98(UVSSA)|O43167(ZBTB24)|Q8TBK6(ZCCHC10)|Q6PEW1(ZCCHC12)|P36508(ZNF76)|Q96H86(ZNF764)|Q9BRL8()|K9N643(ORF4b)|P03427(PB2),,,,,,,,,,,,5.0
O15265,,Ataxin-7,ATXN7,Homo sapiens,892,False,SCA7,MSERAADDVRGEPRRAAAAAGGAAAAAARQQQQQQQQQQPPPPQPQRQQHPPPPPRRTRPEDGGPGAASTSAAAMATVGERRPLPSPEVMLGQSWNLWVEASKLPGKDGTELDESFKEFGKNREVMGLCREDMPIFGFCPAHDDFYLVVCNDCNQVVKPQAFQSHYERRHSSSSKPPLAVPPTSVFSFFPSLSKSKGGSASGSNRSSSGGVLSASSSSSKLLKSPKEKLQLRGNTRPMHPIQQSRVPHGRIMTPSVKVEKIHPKMDGTLLKSAVGPTCPATVSSLVKPGLNCPSIPKPTLPSPGQILNGKGLPAPPTLEKKPEDNSNNRKFLNKRLSEREFDPDIHCGVIDLDTKKPCTRSLTCKTHSLTQRRAVQGRRKRFDVLLAEHKNKTREKELIRHPDSQQPPQPLRDPHPAPPRTSQEPHQNPHGVIPSESKPFVASKPKPHTPSLPRPPGCPAQQGGSAPIDPPPVHESPHPPLPATEPASRLSSEEGEGDDKEESVEKLDCHYSGHHPQPASFCTFGSRQIGRGYYVFDSRWNRLRCALNLMVEKHLNAQLWKKIPPVPSTTSPISTRIPHRTNSVPTSQCGVSYLAAATVSTSPVLLSSTCISPNSKSVPAHGTTLNAQPAASGAMDPVCSMQSRQVSSSSSSPSTPSGLSSVPSSPMSRKPQKLKSSKSLRPKESSGNSTNCQNASSSTSGGSGKKRKNSSPLLVHSSSSSSSSSSSSHSMESFRKNCVAHSGPPYPSTVTSSHSIGLNCVTNKANAVNVRHDQSGRGPPTGSPAESIKRMSVMVNSSDSTLSLGPFIHQSNELPVNSHGSFSHSHTPLDKLIGKKRKCSPSSSSINNSSSKPTKVAKVPAVNNVHMKHTGTIPGAQGLMNSSLLHQPKARP,0,,,,,,"Spinocerebellar ataxia 7:Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCA7 belongs to the autosomal dominant cerebellar ataxias type II (ADCA II) which are characterized by cerebellar ataxia with retinal degeneration and pigmentary macular dystrophy.",Spinocerebellar ataxia 7,O00468(AGRN)|Q9P209(CEP72)|Q8N2S1(LTBP4)|O00339(MATN2)|O75095(MEGF6)|Q7Z7M0(MEGF8)|Q9Y3T9(NOC2L)|P37198(NUP62)|Q8IUQ4(SIAH1)|Q9BX66(SORBS1)|Q12962(TAF10)|Q9Y4A5(TRRAP)|P02283(His2B:CG33910),,a:O15265-1:|b:O15265-2:|3:O15265-3:,,,,,,,,,,5.0
O75503,,Bis(monoacylglycero)phosphate synthase CLN5,CLN5,Homo sapiens,358,False,BMPS,MAQEVDTAQGAEMRRGAGAARGRASWCWALALLWLAVVPGWSRVSGIPSRRHWPVPYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLGHLKIMHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHWKENGTLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSKFVLRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPFKPHLPTKEFLLSLLQIFDAVIVHKQFYLFYNFEYWFLPMKFPFIKITYEEIPLPIRNKTLSGL,0,,,,,,"Ceroid lipofuscinosis, neuronal, 5:A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 5 comprise mixed combinations of granular, curvilinear, and fingerprint profiles.","Ceroid lipofuscinosis, neuronal, 5",Q13286(CLN3)|P37268(FDFT1)|Q8TDT2(GPR152)|P01344-3(IGF2)|Q8IY26(PLPP6)|Q8IVJ1(SLC41A1)|Q96JW4(SLC41A2),,,,,,,,,,,,5.0
O95248,,Myotubularin-related protein 5,SBF1,Homo sapiens,1868,False,MTMR5,MARLADYFVLVAFGPHPRGSGEGQGQILQRFPEKDWEDNPFPQGIELFCQPSGWQLCPERNPPTFFVAVLTDINSERHYCACLTFWEPAEPSQQETTRVEDATEREEEGDEGGQTHLSPTAPAPSAQLFAPKTLVLVSRLDHTEVFRNSLGLIYAIHVEGLNVCLENVIGNLLTCTVPLAGGSQRTISLGAGDRQVIQTPLADSLPVSRCSVALLFRQLGITNVLSLFCAALTEHKVLFLSRSYQRLADACRGLLALLFPLRYSFTYVPILPAQLLEVLSTPTPFIIGVNAAFQAETQELLDVIVADLDGGTVTIPECVHIPPLPEPLQSQTHSVLSMVLDPELELADLAFPPPTTSTSSLKMQDKELRAVFLRLFAQLLQGYRWCLHVVRIHPEPVIRFHKAAFLGQRGLVEDDFLMKVLEGMAFAGFVSERGVPYRPTDLFDELVAHEVARMRADENHPQRVLRHVQELAEQLYKNENPYPAVAMHKVQRPGESSHLRRVPRPFPRLDEGTVQWIVDQAAAKMQGAPPAVKAERRTTVPSGPPMTAILERCSGLHVNSARRLEVVRNCISYVFEGKMLEAKKLLPAVLRALKGRAARRCLAQELHLHVQQNRAVLDHQQFDFVVRMMNCCLQDCTSLDEHGIAAALLPLVTAFCRKLSPGVTQFAYSCVQEHVVWSTPQFWEAMFYGDVQTHIRALYLEPTEDLAPAQEVGEAPSQEDERSALDVASEQRRLWPTLSREKQQELVQKEESTVFSQAIHYANRMSYLLLPLDSSKSRLLRERAGLGDLESASNSLVTNSMAGSVAESYDTESGFEDAETCDVAGAVVRFINRFVDKVCTESGVTSDHLKGLHVMVPDIVQMHIETLEAVQRESRRLPPIQKPKLLRPRLLPGEECVLDGLRVYLLPDGREEGAGGSAGGPALLPAEGAVFLTTYRVIFTGMPTDPLVGEQVVVRSFPVAALTKEKRISVQTPVDQLLQDGLQLRSCTFQLLKMAFDEEVGSDSAELFRKQLHKLRYPPDIRATFAFTLGSAHTPGRPPRVTKDKGPSLRTLSRNLVKNAKKTIGRQHVTRKKYNPPSWEHRGQPPPEDQEDEISVSEELEPSTLTPSSALKPSDRMTMSSLVERACCRDYQRLGLGTLSSSLSRAKSEPFRISPVNRMYAICRSYPGLLIVPQSVQDNALQRVSRCYRQNRFPVVCWRSGRSKAVLLRSGGLHGKGVVGLFKAQNAPSPGQSQADSSSLEQEKYLQAVVSSMPRYADASGRNTLSGFSSAHMGSHGKWGSVRTSGRSSGLGTDVGSRLAGRDALAPPQANGGPPDPGFLRPQRAALYILGDKAQLKGVRSDPLQQWELVPIEVFEARQVKASFKKLLKACVPGCPAAEPSPASFLRSLEDSEWLIQIHKLLQVSVLVVELLDSGSSVLVGLEDGWDITTQVVSLVQLLSDPFYRTLEGFRLLVEKEWLSFGHRFSHRGAHTLAGQSSGFTPVFLQFLDCVHQVHLQFPMEFEFSQFYLKFLGYHHVSRRFRTFLLDSDYERIELGLLYEEKGERRGQVPCRSVWEYVDRLSKRTPVFHNYMYAPEDAEVLRPYSNVSNLKVWDFYTEETLAEGPPYDWELAQGPPEPPEEERSDGGAPQSRRRVVWPCYDSCPRAQPDAISRLLEELQRLETELGQPAERWKDTWDRVKAAQRLEGRPDGRGTPSSLLVSTAPHHRRSLGVYLQEGPVGSTLSLSLDSDQSSGSTTSGSRQAARRSTSTLYSQFQTAESENRSYEGTLYKKGAFMKPWKARWFVLDKTKHQLRYYDHRVDTECKGVIDLAEVEAVAPGTPTMGAPKTVDEKAFFDVKTTRRVYNFCAQDVPSAQQWVDRIQSCLSDA,0,,,,,,"Charcot-Marie-Tooth disease, demyelinating, 4B3:A recessive demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. By convention autosomal recessive forms of demyelinating Charcot-Marie-Tooth disease are designated CMT4.","Charcot-Marie-Tooth disease, demyelinating, 4B3",,,1:O95248-1:|4:O95248-4:|5:O95248-5:,,,,,,,,,,5.0
O95352,,Ubiquitin-like modifier-activating enzyme ATG7,ATG7,Homo sapiens,703,False,APG7L,MAAATGDPGLSKLQFAPFSSALDVGFWHELTQKKLNEYRLDEAPKDIKGYYYNGDSAGLPARLTLEFSAFDMSAPTPARCCPAIGTLYNTNTLESFKTADKKLLLEQAANEIWESIKSGTALENPVLLNKFLLLTFADLKKYHFYYWFCYPALCLPESLPLIQGPVGLDQRFSLKQIEALECAYDNLCQTEGVTALPYFLIKYDENMVLVSLLKHYSDFFQGQRTKITIGVYDPCNLAQYPGWPLRNFLVLAAHRWSSSFQSVEVVCFRDRTMQGARDVAHSIIFEVKLPEMAFSPDCPKAVGWEKNQKGGMGPRMVNLSECMDPKRLAESSVDLNLKLMCWRLVPTLDLDKVVSVKCLLLGAGTLGCNVARTLMGWGVRHITFVDNAKISYSNPVRQPLYEFEDCLGGGKPKALAAADRLQKIFPGVNARGFNMSIPMPGHPVNFSSVTLEQARRDVEQLEQLIESHDVVFLLMDTRESRWLPAVIAASKRKLVINAALGFDTFVVMRHGLKKPKQQGAGDLCPNHPVASADLLGSSLFANIPGYKLGCYFCNDVVAPGDSTRDRTLDQQCTVSRPGLAVIAGALAVELMVSVLQHPEGGYAIASSSDDRMNEPPTSLGLVPHQIRGFLSRFDNVLPVSLAFDKCTACSSKVLDQYEREGFNFLAKVFNSSHSFLEDLTGLTLLHQETQAAEIWDMSDDETI,0,,,,,,"Spinocerebellar ataxia, autosomal recessive, 31:A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR30 is characterized by global developmental delay, hypotonia, variably impaired intellectual and language development, ataxic gait, tremor, and dysarthria. Most affected individuals have optic atrophy. Additional features may include retinitis pigmentosa, sensorineural deafness, dysmorphic facial features, and possibly endocrine dysfunction.","Spinocerebellar ataxia, autosomal recessive, 31",P29692(EEF1D)|O95166(GABARAP)|Q9H0R8(GABARAPL1)|P60520(GABARAPL2)|P14316(IRF2)|Q9GZQ8(MAP1LC3B)|Q9UIY3(RWDD2A)|Q96EB6(SIRT1)|Q13148(TARDBP)|P04637(TP53),,1:O95352-1:|2:O95352-2:|3:O95352-3:,,,,,,,,,,5.0
P04080,,Cystatin-B,CSTB,Homo sapiens,98,False,CST6|STFB,MMCGAPSATQPATAETQHIADQVRSQLEEKENKKFPVFKAVSFKSQVVAGTNYFIKVHVGDEDFVHLRVFQSLPHENKPLTLSNYQTNKAKHDELTYF,0,,,,,,"Epilepsy, progressive myoclonic 1:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM1 is an autosomal recessive form characterized by severe, stimulus-sensitive myoclonus and tonic-clonic seizures. The onset, occurring between 6 and 13 years of age, is characterized by convulsions. Myoclonus begins 1 to 5 years later. The twitchings occur predominantly in the proximal muscles of the extremities and are bilaterally symmetrical, although asynchronous. At first small, they become late in the clinical course so violent that the victim is thrown to the floor. Mental deterioration and eventually dementia develop.","Epilepsy, progressive myoclonic 1",,,,,,,,,,,,,5.0
P06865,,Beta-hexosaminidase subunit alpha,HEXA,Homo sapiens,529,False,,MTSSRLWFSLLLAAAFAGRATALWPWPQNFQTSDQRYVLYPNNFQFQYDVSSAAQPGCSVLDEAFQRYRDLLFGSGSWPRPYLTGKRHTLEKNVLVVSVVTPGCNQLPTLESVENYTLTINDDQCLLLSETVWGALRGLETFSQLVWKSAEGTFFINKTEIEDFPRFPHRGLLLDTSRHYLPLSSILDTLDVMAYNKLNVFHWHLVDDPSFPYESFTFPELMRKGSYNPVTHIYTAQDVKEVIEYARLRGIRVLAEFDTPGHTLSWGPGIPGLLTPCYSGSEPSGTFGPVNPSLNNTYEFMSTFFLEVSSVFPDFYLHLGGDEVDFTCWKSNPEIQDFMRKKGFGEDFKQLESFYIQTLLDIVSSYGKGYVVWQEVFDNKVKIQPDTIIQVWREDIPVNYMKELELVTKAGFRALLSAPWYLNRISYGPDWKDFYIVEPLAFEGTPEQKALVIGGEACMWGEYVDNTNLVPRLWPRAGAVAERLWSNKLTSDLTFAYERLSHFRCELLRRGVQAQPLNVGFCEQEFEQT,0,,,,,,"GM2-gangliosidosis 1:An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).",GM2-gangliosidosis 1,P07686(HEXB),,1:P06865-1:|2:P06865-2:,,,,,,,,,,5.0
P07384,,Calpain-1 catalytic subunit,CAPN1,Homo sapiens,714,False,CANPL1,MSEEIITPVYCTGVSAQVQKQRARELGLGRHENAIKYLGQDYEQLRVRCLQSGTLFRDEAFPPVPQSLGYKDLGPNSSKTYGIKWKRPTELLSNPQFIVDGATRTDICQGALGDCWLLAAIASLTLNDTLLHRVVPHGQSFQNGYAGIFHFQLWQFGEWVDVVVDDLLPIKDGKLVFVHSAEGNEFWSALLEKAYAKVNGSYEALSGGSTSEGFEDFTGGVTEWYELRKAPSDLYQIILKALERGSLLGCSIDISSVLDMEAITFKKLVKGHAYSVTGAKQVNYRGQVVSLIRMRNPWGEVEWTGAWSDSSSEWNNVDPYERDQLRVKMEDGEFWMSFRDFMREFTRLEICNLTPDALKSRTIRKWNTTLYEGTWRRGSTAGGCRNYPATFWVNPQFKIRLDETDDPDDYGDRESGCSFVLALMQKHRRRERRFGRDMETIGFAVYEVPPELVGQPAVHLKRDFFLANASRARSEQFINLREVSTRFRLPPGEYVVVPSTFEPNKEGDFVLRFFSEKSAGTVELDDQIQANLPDEQVLSEEEIDENFKALFRQLAGEDMEISVKELRTILNRIISKHKDLRTKGFSLESCRSMVNLMDRDGNGKLGLVEFNILWNRIRNYLSIFRKFDLDKSGSMSAYEMRMAIESAGFKLNKKLYELIITRYSEPDLAVDFDNFVCCLVRLETMFRFFKTLDTDLDGVVTFDLFKWLQLTMFA,0,,,,,,"Spastic paraplegia 76, autosomal recessive:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.","Spastic paraplegia 76, autosomal recessive",P05067(APP)|Q92934(BAD)|P13569(CFTR)|P30085-3(CMPK1)|P15311(EZR)|P27816(MAP4)|Q96CV9(OPTN)|P18031(PTPN1)|P40763(STAT3),,,,,,,,,,,,5.0
P09543,,"2',3'-cyclic-nucleotide 3'-phosphodiesterase",CNP,Homo sapiens,421,False,,MNRGFSRKSHTFLPKIFFRKMSSSGAKDKPELQFPFLQDEDTVATLLECKTLFILRGLPGSGKSTLARVIVDKYRDGTKMVSADAYKITPGARGAFSEEYKRLDEDLAAYCRRRDIRILVLDDTNHERERLEQLFEMADQYQYQVVLVEPKTAWRLDCAQLKEKNQWQLSADDLKKLKPGLEKDFLPLYFGWFLTKKSSETLRKAGQVFLEELGNHKAFKKELRQFVPGDEPREKMDLVTYFGKRPPGVLHCTTKFCDYGKAPGAEEYAQQDVLKKSYSKAFTLTISALFVTPKTTGARVELSEQQLQLWPSDVDKLSPTDNLPRGSRAHITLGCAADVEAVQTGLDLLEILRQEKGGSRGEEVGELSRGKLYSLGNGRWMLTLAKNMEVRAIFTGYYGKGKPVPTQGSRKGGALQSCTII,0,,,,,,"Leukodystrophy, hypomyelinating, 20:An autosomal recessive disorder characterized by neuroregression and loss of motor, language and cognitive skills, after a normal early development. Disease onset is between 12 and 18 month of age. Patients show poor overall growth, microcephaly, feeding difficulties and spastic quadriplegia. Some patients may have seizures. Death in childhood may occur. Hypomyelinating leukodystrophy with subcortical and periventricular white matter abnormalities is seen on brain imaging.","Leukodystrophy, hypomyelinating, 20",P42858(HTT),,CNPII:P09543-1:|CNPI:P09543-2:,,,,,,,,,,5.0
P0DPK4,,Notch homolog 2 N-terminal-like protein C,NOTCH2NLC,Homo sapiens,293,False,,MWICPGGGGGGGGGGGGGDREDARPAPLCCGRCWRSGCAARPPRMCRDGYEPCVNEGMCVTYHNGTGYCKCPEGFLGEYCQHRDPCEKNRCQNGGTCVAQAMLGKATCRCASGFTGEDCQYSTSHPCFVSRPCLNGGTCHMLSRDTYECTCQVGFTGKECQWTDACLSHPCANGSTCTTVANQFSCKCLTGFTGQKCETDVNECDIPGHCQHGGTCLNLPGSYQCQCLQGFTGQYCDSLYVPCAPSPCVNGGTCRQTGDFTFECNCLPETVRRGTELWERDREVWNGKEHDEN,0,,,,,,"Neuronal intranuclear inclusion disease:An autosomal dominant, slowly progressive, neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in the central and peripheral nervous system, and also in the visceral organs. Clinical manifestations are variable and include pyramidal and extrapyramidal symptoms, cerebellar ataxia, cognitive decline and dementia, peripheral neuropathy, and autonomic dysfunction.|:|Tremor, hereditary essential 6:A form of essential tremor, a common movement disorder mainly characterized by postural tremor of the arms. Head, legs, trunk, voice, jaw, and facial muscles may also be involved. The condition can be aggravated by emotions, hunger, fatigue and temperature extremes, and may cause a functional disability or even incapacitation. ETM6 inheritance is autosomal dominant.|Oculopharyngodistal myopathy 3:A form of oculopharyngodistal myopathy, a rare hereditary muscle disease characterized by progressive distal limb weakness, ptosis, ophthalmoplegia, bulbar muscle weakness and rimmed vacuoles on muscle biopsy. In addition to muscular features, OPDM3 patients may develop pigmentary retinopathy, peripheral neuropathy, or hearing loss. Cognition is usually not affected, but there may be deficits or psychiatric manifestations. Brain imaging tends to show a leukoencephalopathy, often with a characteristic linear signal along the corticomedullary junction on brain imaging. OPDM3 is a slowly progressive form with an autosomal dominant transmission pattern, and variable age at onset ranging from childhood to late adulthood.","Neuronal intranuclear inclusion disease|Tremor, hereditary essential 6|Oculopharyngodistal myopathy 3",O43184-4(ADAM12)|Q6UY14-3(ADAMTSL4)|P21549(AGXT)|Q8IZ83(ALDH16A1)|P05187(ALPP)|Q49AR9(ANKS1A)|P29972(AQP1)|Q7Z3C6-3(ATG9A)|P30049(ATP5F1D)|P50895(BCAM)|P18075(BMP7)|Q0VDD7-2(BRME1)|Q9Y2V2(CARHSP1)|Q8NEC5(CATSPER1)|Q8TC90(CCER1)|Q04900(CD164)|Q8N6W0(CELF5)|Q8TCT0(CERK)|Q9NX63(CHCHD3)|Q9UKJ5(CHIC2)|Q9H2X0(CHRD)|P07510-2(CHRNG)|Q8NE01(CNNM3)|P27658(COL8A1)|Q02930-3(CREB5)|P06850(CRH)|Q49AN0(CRY2)|P09228(CST2)|Q9H4G1(CST9L)|Q9NSA3(CTNNBIP1)|Q9UBR2(CTSZ)|Q08AG9(CYP21A2)|A8MQ03(CYSRT1)|Q8NCG7(DAGLB)|Q5D0E6-2(DALRD3)|P09172(DBH)|P52824(DGKQ)|Q96LJ7(DHRS1)|Q9NQL9(DMRT3)|Q92608(DOCK2)|P21918(DRD5)|Q9NPA0(EMC7)|P00742(F10)|O95864-3(FADS2)|A4D161(FAM221A)|Q86YD7(FAM90A1)|Q969U6(FBXW5)|O43559(FRS3)|Q9BXU8(FTHL17)|Q9ULW2(FZD10)|Q8NEG0(GARIN6)|P43220(GLP1R)|Q6IB77-2(GLYAT)|Q9Y223-2(GNE)|P09211(GSTP1)|Q9GZV7(HAPLN2)|P69905(HBA2)|P02008(HBZ)|P08631-2(HCK)|Q03014(HHEX)|P49639(HOXA1)|P17482(HOXB9)|P31273(HOXC8)|P37235(HPCAL1)|Q96MM6(HSPA12B)|Q14773-3(ICAM4)|P22301(IL10)|Q9C086(INO80B)|P01308(INS)|P05107(ITGB2)|P16144-2(ITGB4)|P18084(ITGB5)|Q15040(JOSD1)|Q9ULS6(KCNS2)|Q96SI1-2(KCTD15)|Q2WGJ6(KLHL38)|O60259(KLK8)|Q5T749(KPRP)|P78385(KRT83)|P60014(KRTAP10-10)|P60370(KRTAP10-5)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|P59990(KRTAP12-1)|P59991(KRTAP12-2)|P60328(KRTAP12-3)|P60329(KRTAP12-4)|Q52LG2(KRTAP13-2)|Q3SY46(KRTAP13-3)|Q3LI77(KRTAP13-4)|Q9BYR9(KRTAP2-4)|Q6PEX3(KRTAP26-1)|Q9BYQ6(KRTAP4-11)|Q9BYR5(KRTAP4-2)|Q9BYR3(KRTAP4-4)|Q9BYR2(KRTAP4-5)|Q6L8G4(KRTAP5-11)|Q6L8H2(KRTAP5-3)|Q6L8H1(KRTAP5-4)|Q6L8G9(KRTAP5-6)|P26371(KRTAP5-9)|Q9BYQ4(KRTAP9-2)|Q9BYQ3(KRTAP9-3)|Q9BYQ0(KRTAP9-8)|Q5T7P2(LCE1A)|Q5T7P3(LCE1B)|Q5T752(LCE1D)|Q5T753(LCE1E)|Q5T754(LCE1F)|O14633(LCE2B)|Q5TA81(LCE2C)|Q5TA82(LCE2D)|Q5TA76(LCE3A)|Q5T5A8(LCE3C)|Q9BYE3(LCE3D)|Q5T5B0(LCE3E)|Q5TA78(LCE4A)|Q5TCM9(LCE5A)|Q8IXW0(LMNTD2)|Q8TBB1(LNX1)|Q6PJG9(LRFN4)|Q9Y5Y7(LYVE1)|Q8N5G2(MACO1)|O60336(MAPKBP1)|P08582-2(MELTF)|Q14CX5(MFSD13A)|P00540(MOS)|Q9NV56(MRGBP)|Q9NQ50(MRPL40)|Q13330(MTA1)|Q9BW11(MXD3)|P50539-3(MXI1)|Q96JP2(MYO15B)|Q86VE0(MYPOP)|Q92692-2(NECTIN2)|Q9NQS3-2(NECTIN3)|Q14511-2(NEDD9)|P48645(NMU)|Q9NQX5(NPDC1)|Q6NSM0(NR1D2)|Q9P121-3(NTM)|Q9HB63(NTN4)|O95897(OLFM2)|P32242(OTX1)|Q99571(P2RX4)|Q99572(P2RX7)|Q15077(P2RY6)|Q92824-2(PCSK5)|Q9HCN3(PGAP6)|A2BDE7(PHLDA1)|Q96S52(PIGS)|Q494U1-3(PLEKHN1)|P14222(PRF1)|P0CG20(PRR35)|P25786(PSMA1)|Q13308(PTK7)|Q8WUK0(PTPMT1)|P15151(PVR)|Q9Y2K5(R3HDM2)|Q8TBN0(RAB3IL1)|O60896(RAMP3)|Q9Y272(RASD1)|Q6P9E2(RECK)|Q86WX3(RPS19BP1)|Q86UN2(RTN4RL1)|Q9BWG6(SCNM1)|Q13214-2(SEMA3B)|Q9C0C4(SEMA4C)|Q9NUL5-4(SHFL)|O76082(SLC22A5)|Q9UHI7-3(SLC23A1)|Q8N370(SLC43A2)|Q92911(SLC5A5)|Q9NP91(SLC6A20)|P49901(SMCP)|Q86W54-2(SPATA24)|Q6RVD6(SPATA8)|Q9UQ90(SPG7)|Q8IUH8(SPPL2C)|O43609(SPRY1)|Q99469(STAC)|O75716(STK16)|Q9BX59(TAPBPL)|Q9Y4C2-2(TCAF1)|Q9BT49(THAP7)|Q08117-2(TLE5)|Q9UIK5(TMEFF2)|Q86TG1(TMEM150A)|P0DTL5(TMEM276)|Q96KP6(TNIP3)|Q63HR2(TNS2)|Q8WVR3(TRAPPC14)|Q8IWZ5(TRIM42)|Q12815(TROAP)|O14817(TSPAN4)|P49638(TTPA)|Q9BRU9(UTP23)|Q9UBK9(UXT)|Q6EMK4(VASN)|Q64LD2-2(WDR25)|Q8WTX9(ZDHHC1)|Q15973(ZNF124)|Q9P2F9(ZNF319)|Q9Y3S2(ZNF330)|Q9H9D4(ZNF408)|Q96IQ9(ZNF414)|Q8TAU3(ZNF417)|Q8IYI8(ZNF440)|Q9NWS9-2(ZNF446)|Q6ZNH5(ZNF497)|Q9UK33(ZNF580)|Q9P0T4(ZNF581)|Q96SQ5(ZNF587)|Q5T619(ZNF648)|Q499Z4(ZNF672)|Q8N393(ZNF786)|Q96EG3(ZNF837),,1:P0DPK4-1:|2:P0DPK4-2:,,,,,,,,,,5.0
P12004,,Proliferating cell nuclear antigen,PCNA,Homo sapiens,261,False,,MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS,0,,,,,,"Ataxia-telangiectasia-like disorder 2:A neurodegenerative disorder due to defects in DNA excision repair. ATLD2 is characterized by developmental delay, ataxia, sensorineural hearing loss, short stature, cutaneous and ocular telangiectasia, and photosensitivity.",Ataxia-telangiectasia-like disorder 2,P04075(ALDOA)|P03950(ANG)|P07355(ANXA2)|P61769(B2M)|P38936(CDKN1A)|P42771(CDKN2A)|Q9H211(CDT1)|Q13111(CHAF1A)|Q96DZ9-2(CMTM5)|P68104(EEF1A1)|P06733(ENO1)|P39748(FEN1)|P24522(GADD45A)|P04406(GAPDH)|Q14527(HLTF)|Q9H160(ING2)|Q9H063(MAF1)|P20585(MSH3)|O95944(NCR2)|P61970(NUTF2)|Q15004(PCLAF)|P12004(PCNA)|P18669(PGAM1)|P00558(PGK1)|P28340(POLD1)|P49005(POLD2)|Q15054(POLD3)|Q9HCU8(POLD4)|P30041(PRDX6)|Q9UBF6(RNF7)|Q86TU7(SETD3)|Q8IWU4(SLC30A8)|Q9NZD8(SPG21)|A2RU14(TMEM218)|P60174(TPI1)|Q5FWF4(ZRANB3)|Q8TE30()|Q9Z111(Gadd45g)|Q1K9H5(PB1)|B4URF7(PB2),,,,,,,,,,,,5.0
P17405,,Sphingomyelin phosphodiesterase,SMPD1,Homo sapiens,631,False,ASM,MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLALALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC,0,,,,,,"Niemann-Pick disease A:An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.|Niemann-Pick disease B:A late-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Clinical signs involve only visceral organs. The most constant sign is hepatosplenomegaly which can be associated with pulmonary symptoms. Patients remain free of neurologic manifestations. However, a phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B. In Niemann-Pick disease type B, onset of the first symptoms occurs in early childhood and patients can survive into adulthood.",Niemann-Pick disease A|Niemann-Pick disease B,P55210(CASP7),,1:P17405-1:|2:P17405-2:|3:P17405-3:|4:P17405-4:,,,,,,,,,,5.0
P19367,,Hexokinase-1,HK1,Homo sapiens,917,False,,MIAAQLLAYYFTELKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKNGLSRDFNPTATVKMLPTFVRSIPDGSEKGDFIALDLGGSSFRILRVQVNHEKNQNVHMESEVYDTPENIVHGSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAILITWTKRFKASGVEGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVGLIIGTGTNACYMEELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDREIDRGSLNPGKQLFEKMVSGMYLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKEGLHNAKEILTRLGVEPSDDDCVSVQHVCTIVSFRSANLVAATLGAILNRLRDNKGTPRLRTTVGVDGSLYKTHPQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQHRQIEETLAHFHLTKDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLGGTNFRVLLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMGIKGPRMPLGFTFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAVVNDTVGTMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCINMEWGAFGDNGCLDDIRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISETLKTRGIFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGVVSRRAAQLCGAGMAAVVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPKCNVSFLLSEDGSGKGAALITAVGVRLRTEASS,0,,,,,,"Anemia, congenital, non-spherocytic hemolytic, 5:An autosomal recessive disorder characterized by hemolytic anemia as the predominant clinical feature, and decreased red cell hexokinase activity.|Neuropathy, hereditary motor and sensory, Russe type:An autosomal recessive progressive complex peripheral neuropathy characterized by onset in the first decade of distal lower limb weakness and muscle atrophy resulting in walking difficulties. Distal impairment of the upper limbs usually occurs later, as does proximal lower limb weakness. There is distal sensory impairment, with pes cavus and areflexia. Laboratory studies suggest that it is a myelinopathy resulting in reduced nerve conduction velocities in the demyelinating range as well as a length-dependent axonopathy.|Retinitis pigmentosa 79:A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP79 inheritance is autosomal dominant.|Neurodevelopmental disorder with visual defects and brain anomalies:A disorder characterized by global developmental delay, speech delay, intellectual disability, structural brain abnormalities, and visual impairments including retinitis pigmentosa and optic atrophy.","Anemia, congenital, non-spherocytic hemolytic, 5|Neuropathy, hereditary motor and sensory, Russe type|Retinitis pigmentosa 79|Neurodevelopmental disorder with visual defects and brain anomalies",P13569(CFTR)|P12931(SRC)|P21796(VDAC1)|P05480(Src),,1:P19367-1:|2:P19367-2:|3:P19367-3:|4:P19367-4:,,,,,,,,,,5.0
P19634,,Sodium/hydrogen exchanger 1,SLC9A1,Homo sapiens,815,False,APNH1|NHE1,MVLRSGICGLSPHRIFPSLLVVVALVGLLPVLRSHGLQLSPTASTIRSSEPPRERSIGDVTTAPPEVTPESRPVNHSVTDHGMKPRKAFPVLGIDYTHVRTPFEISLWILLACLMKIGFHVIPTISSIVPESCLLIVVGLLVGGLIKGVGETPPFLQSDVFFLFLLPPIILDAGYFLPLRQFTENLGTILIFAVVGTLWNAFFLGGLMYAVCLVGGEQINNIGLLDNLLFGSIISAVDPVAVLAVFEEIHINELLHILVFGESLLNDAVTVVLYHLFEEFANYEHVGIVDIFLGFLSFFVVALGGVLVGVVYGVIAAFTSRFTSHIRVIEPLFVFLYSYMAYLSAELFHLSGIMALIASGVVMRPYVEANISHKSHTTIKYFLKMWSSVSETLIFIFLGVSTVAGSHHWNWTFVISTLLFCLIARVLGVLGLTWFINKFRIVKLTPKDQFIIAYGGLRGAIAFSLGYLLDKKHFPMCDLFLTAIITVIFFTVFVQGMTIRPLVDLLAVKKKQETKRSINEEIHTQFLDHLLTGIEDICGHYGHHHWKDKLNRFNKKYVKKCLIAGERSKEPQLIAFYHKMEMKQAIELVESGGMGKIPSAVSTVSMQNIHPKSLPSERILPALSKDKEEEIRKILRNNLQKTRQRLRSYNRHTLVADPYEEAWNQMLLRRQKARQLEQKINNYLTVPAHKLDSPTMSRARIGSDPLAYEPKEDLPVITIDPASPQSPESVDLVNEELKGKVLGLSRDPAKVAEEDEDDDGGIMMRSKETSSPGTDDVFTPAPSDSPSSQRIQRCLSDPGPHPEPGEGEPFFPKGQ,0,,,,,,Lichtenstein-Knorr syndrome:An autosomal recessive neurologic disorder characterized by progressive cerebellar ataxia and severe progressive sensorineural hearing loss.,Lichtenstein-Knorr syndrome,Q99653(CHP1)|O43745(CHP2)|Q96BS2(TESC),,1:P19634-1:|2:P19634-2:,,,,,,,,,,5.0
P22570,,"NADPH:adrenodoxin oxidoreductase, mitochondrial",FDXR,Homo sapiens,491,False,ADXR,MASRCWRWWGWSAWPRTRLPPAGSTPSFCHHFSTQEKTPQICVVGSGPAGFYTAQHLLKHPQAHVDIYEKQPVPFGLVRFGVAPDHPEVKNVINTFTQTAHSGRCAFWGNVEVGRDVTVPELREAYHAVVLSYGAEDHRALEIPGEELPGVCSARAFVGWYNGLPENQELEPDLSCDTAVILGQGNVALDVARILLTPPEHLERTDITKAALGVLRQSRVKTVWLVGRRGPLQVAFTIKELREMIQLPGARPILDPVDFLGLQDKIKEVPRPRKRLTELLLRTATEKPGPAEAARQASASRAWGLRFFRSPQQVLPSPDGRRAAGVRLAVTRLEGVDEATRAVPTGDMEDLPCGLVLSSIGYKSRPVDPSVPFDSKLGVIPNVEGRVMDVPGLYCSGWVKRGPTGVIATTMTDSFLTGQMLLQDLKAGLLPSGPRPGYAAIQALLSSRGVRPVSFSDWEKLDAEEVARGQGTGKPREKLVDPQEMLRLLGH,0,,,,,,"Auditory neuropathy and optic atrophy:An autosomal recessive disease characterized by hearing loss, visual impairment and optic atrophy, with onset in the first or second decades of life. Optic atrophy is caused by degeneration of nerve fibers which arise in the retina and converge to form the optic disk, optic nerve, optic chiasm and optic tracts.|Multiple mitochondrial dysfunctions syndrome 9B:An autosomal recessive disorder characterized by optic and/or auditory neuropathy with onset in the first two decades of life, in some cases associated with developmental delay or regression, global hypotonia, pyramidal, cerebellar signs, and seizures.",Auditory neuropathy and optic atrophy|Multiple mitochondrial dysfunctions syndrome 9B,,,Short:P22570-1:|Long:P22570-2:|3:P22570-3:|4:P22570-4:|5:P22570-5:|6:P22570-6:|7:P22570-7:,,,,,,,,,,5.0
P31040,,"Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial",SDHA,Homo sapiens,664,False,SDH2|SDHF,MSGVRGLSRLLSARRLALAKAWPTVLQTGTRGFHFTVDGNKRASAKVSDSISAQYPVVDHEFDAVVVGAGGAGLRAAFGLSEAGFNTACVTKLFPTRSHTVAAQGGINAALGNMEEDNWRWHFYDTVKGSDWLGDQDAIHYMTEQAPAAVVELENYGMPFSRTEDGKIYQRAFGGQSLKFGKGGQAHRCCCVADRTGHSLLHTLYGRSLRYDTSYFVEYFALDLLMENGECRGVIALCIEDGSIHRIRAKNTVVATGGYGRTYFSCTSAHTSTGDGTAMITRAGLPCQDLEFVQFHPTGIYGAGCLITEGCRGEGGILINSQGERFMERYAPVAKDLASRDVVSRSMTLEIREGRGCGPEKDHVYLQLHHLPPEQLATRLPGISETAMIFAGVDVTKEPIPVLPTVHYNMGGIPTNYKGQVLRHVNGQDQIVPGLYACGEAACASVHGANRLGANSLLDLVVFGRACALSIEESCRPGDKVPPIKPNAGEESVMNLDKLRFADGSIRTSELRLSMQKSMQNHAAVFRVGSVLQEGCGKISKLYGDLKHLKTFDRGMVWNTDLVETLELQNLMLCALQTIYGAEARKESRGAHAREDYKVRIDEYDYSKPIQGQQKKPFEEHWRKHTLSYVDVGTGKVTLEYRPVIDKTLNEADCATVPPAIRSY,0,,,,,,"Mitochondrial complex II deficiency, nuclear type 1:A disorder of the mitochondrial respiratory chain with heterogeneous clinical manifestations. Clinical features include psychomotor regression in infants, poor growth with lack of speech development, severe spastic quadriplegia, dystonia, progressive leukoencephalopathy, muscle weakness, exercise intolerance, cardiomyopathy. Some patients manifest Leigh syndrome or Kearns-Sayre syndrome. MC2DN1 inheritance is autosomal recessive.|Leigh syndrome:An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.|Cardiomyopathy, dilated, 1GG:A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.|Pheochromocytoma/paraganglioma syndrome 5:A form of pheochromocytoma/paraganglioma syndrome, a tumor predisposition syndrome characterized by the development of neuroendocrine tumors, usually in adulthood. Pheochromocytomas are catecholamine-producing tumors that arise from chromaffin cells in the adrenal medulla. Paragangliomas develop from sympathetic paraganglia in the thorax, abdomen, and pelvis, as well as from parasympathetic paraganglia in the head and neck. PPGL5 inheritance is autosomal dominant.|Neurodegeneration with ataxia and late-onset optic atrophy:An autosomal dominant disorder characterized by slowly progressive cerebellar and gait ataxia, optic atrophy, and myopathy or myalgia. Additional features can include cardiomyopathy, psychiatric disturbances, and peripheral sensory impairment. Disease onset is usually in mid-adulthood.","Mitochondrial complex II deficiency, nuclear type 1|Leigh syndrome|Cardiomyopathy, dilated, 1GG|Pheochromocytoma/paraganglioma syndrome 5|Neurodegeneration with ataxia and late-onset optic atrophy",P13569(CFTR)|P26045(PTPN3)|Q9NX18(SDHAF2)|P21912(SDHB),,1:P31040-1:|2:P31040-2:|3:P31040-3:,,,,,,,,,,5.0
P38935,,DNA-binding protein SMUBP-2,IGHMBP2,Homo sapiens,993,False,SMBP2|SMUBP2,MASAAVESFVTKQLDLLELERDAEVEERRSWQENISLKELQSRGVCLLKLQVSSQRTGLYGRLLVTFEPRRYGSAAALPSNSFTSGDIVGLYDAANEGSQLATGILTRVTQKSVTVAFDESHDFQLSLDRENSYRLLKLANDVTYRRLKKALIALKKYHSGPASSLIEVLFGRSAPSPASEIHPLTFFNTCLDTSQKEAVLFALSQKELAIIHGPPGTGKTTTVVEIILQAVKQGLKVLCCAPSNIAVDNLVERLALCKQRILRLGHPARLLESIQQHSLDAVLARSDSAQIVADIRKDIDQVFVKNKKTQDKREKSNFRNEIKLLRKELKEREEAAMLESLTSANVVLATNTGASADGPLKLLPESYFDVVVIDECAQALEASCWIPLLKARKCILAGDHKQLPPTTVSHKAALAGLSLSLMERLAEEYGARVVRTLTVQYRMHQAIMRWASDTMYLGQLTAHSSVARHLLRDLPGVAATEETGVPLLLVDTAGCGLFELEEEDEQSKGNPGEVRLVSLHIQALVDAGVPARDIAVVSPYNLQVDLLRQSLVHRHPELEIKSVDGFQGREKEAVILSFVRSNRKGEVGFLAEDRRINVAVTRARRHVAVICDSRTVNNHAFLKTLVEYFTQHGEVRTAFEYLDDIVPENYSHENSQGSSHAATKPQGPATSTRTGSQRQEGGQEAAAPARQGRKKPAGKSLASEAPSQPSLNGGSPEGVESQDGVDHFRAMIVEFMASKKMQLEFPPSLNSHDRLRVHQIAEEHGLRHDSSGEGKRRFITVSKRAPRPRAALGPPAGTGGPAPLQPVPPTPAQTEQPPREQRGPDQPDLRTLHLERLQRVRSAQGQPASKEQQASGQQKLPEKKKKKAKGHPATDLPTEEDFEALVSAAVKADNTCGFAKCTAGVTTLGQFCQLCSRRYCLSHHLPEIHGCGERARAHARQRISREGVLYAGSGTKNGSLDPAKRAQLQRRLDKKLSELSNQRTSRRKERGT,0,,,,,,"Neuronopathy, distal hereditary motor, autosomal recessive 1:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.|Charcot-Marie-Tooth disease, axonal, 2S:An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.","Neuronopathy, distal hereditary motor, autosomal recessive 1|Charcot-Marie-Tooth disease, axonal, 2S",,,,,,,,,,,,,5.0
P42658,,A-type potassium channel modulatory protein DPP6,DPP6,Homo sapiens,865,False,,MASLYQRFTGKINTSRSFPAPPEASHLLGGQGPEEDGGAGAKPLGPRAQAAAPRERGGGGGGAGGRPRFQYQARSDGDEEDELVGSNPPQRNWKGIAIALLVILVICSLIVTSVILLTPAEDNSLSQKKKVTVEDLFSEDFKIHDPEAKWISDTEFIYREQKGTVRLWNVETNTSTVLIEGKKIESLRAIRYEISPDREYALFSYNVEPIYQHSYTGYYVLSKIPHGDPQSLDPPEVSNAKLQYAGWGPKGQQLIFIFENNIYYCAHVGKQAIRVVSTGKEGVIYNGLSDWLYEEEILKTHIAHWWSPDGTRLAYAAINDSRVPIMELPTYTGSIYPTVKPYHYPKAGSENPSISLHVIGLNGPTHDLEMMPPDDPRMREYYITMVKWATSTKVAVTWLNRAQNVSILTLCDATTGVCTKKHEDESEAWLHRQNEEPVFSKDGRKFFFIRAIPQGGRGKFYHITVSSSQPNSSNDNIQSITSGDWDVTKILAYDEKGNKIYFLSTEDLPRRRQLYSANTVGNFNRQCLSCDLVENCTYFSASFSHSMDFFLLKCEGPGVPMVTVHNTTDKKKMFDLETNEHVKKAINDRQMPKVEYRDIEIDDYNLPMQILKPATFTDTTHYPLLLVVDGTPGSQSVAEKFEVSWETVMVSSHGAVVVKCDGRGSGFQGTKLLHEVRRRLGLLEEKDQMEAVRTMLKEQYIDRTRVAVFGKDYGGYLSTYILPAKGENQGQTFTCGSALSPITDFKLYASAFSERYLGLHGLDNRAYEMTKVAHRVSALEEQQFLIIHPTADEKIHFQHTAELITQLIRGKANYSLQIYPDESHYFTSSSLKQHLYRSIINFFVECFRIQDKLLTVTAKEDEEED,0,,,,,,"Familial paroxysmal ventricular fibrillation 2:A cardiac arrhythmia marked by fibrillary contractions of the ventricular muscle due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricle and by absence of atrial activity.|Intellectual developmental disorder, autosomal dominant 33:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD33 patients manifest microcephaly in addition to intellectual disability.","Familial paroxysmal ventricular fibrillation 2|Intellectual developmental disorder, autosomal dominant 33",,,DPPX-L:P42658-1:|DPPX-S:P42658-2:,,,,,,,,,,5.0
P48547,,Voltage-gated potassium channel KCNC1,KCNC1,Homo sapiens,511,False,,MGQGDESERIVINVGGTRHQTYRSTLRTLPGTRLAWLAEPDAHSHFDYDPRADEFFFDRHPGVFAHILNYYRTGKLHCPADVCGPLYEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDSFGGAPLDNSADDADADGPGDSGDGEDELEMTKRLALSDSPDGRPGGFWRRWQPRIWALFEDPYSSRYARYVAFASLFFILVSITTFCLETHERFNPIVNKTEIENVRNGTQVRYYREAETEAFLTYIEGVCVVWFTFEFLMRVIFCPNKVEFIKNSLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERIGAQPNDPSASEHTHFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPKKKKKHIPRPPQLGSPNYCKSVVNSPHHSTQSDTCPLAQEEILEINRAGRKPLRGMSI,0,,,,,,"Epilepsy, progressive myoclonic 7:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM7 is an autosomal dominant form characterized by myoclonic epilepsy apparent in the first or second decades of life. Cognitive function may decline in some patients.","Epilepsy, progressive myoclonic 7",Q9UBY5(LPAR3)|P55061(TMBIM6)|A5PKU2(TUSC5),,1:P48547-1:|2:P48547-2:,,,,,,,,,,5.0
P50897,,Palmitoyl-protein thioesterase 1,PPT1,Homo sapiens,306,False,CLN1|PPT,MASPGCLWLLAVALLPWTCASRALQHLDPPAPLPLVIWHGMGDSCCNPLSMGAIKKMVEKKIPGIYVLSLEIGKTLMEDVENSFFLNVNSQVTTVCQALAKDPKLQQGYNAMGFSQGGQFLRAVAQRCPSPPMINLISVGGQHQGVFGLPRCPGESSHICDFIRKTLNAGAYSKVVQERLVQAEYWHDPIKEDVYRNHSIFLADINQERGINESYKKNLMALKKFVMVKFLNDSIVDPVDSEWFGFYRSGQAKETIPLQETSLYTQDRLGLKEMDNAGQLVFLATEGDHLQLSEEWFYAHIIPFLG,0,,,,,,"Ceroid lipofuscinosis, neuronal, 1:A form of neuronal ceroid lipofuscinosis with variable age at onset. Infantile, late-infantile, juvenile, and adult onset have been reported. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment pattern seen most often in CLN1 is referred to as granular osmiophilic deposits (GROD).","Ceroid lipofuscinosis, neuronal, 1",P26436(ACRV1)|Q9Y575-3(ASB3)|Q8WXF7(ATL1)|O75925(PIAS1)|Q6ZR37(PLEKHG7)|Q99932-2(SPAG8)|Q3KNS6-3(ZNF829)|Q76RH3(ORF38),,1:P50897-1:|2:P50897-2:,,,,,,,,,,5.0
P51797,,H(+)/Cl(-) exchange transporter 6,CLCN6,Homo sapiens,869,False,KIAA0046,MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYESLDYDRCINDPYLEVLETMDNKKGRRYEAVKWMVVFAIGVCTGLVGLFVDFFVRLFTQLKFGVVQTSVEECSQKGCLALSLLELLGFNLTFVFLASLLVLIEPVAAGSGIPEVKCYLNGVKVPGIVRLRTLLCKVLGVLFSVAGGLFVEKEGPMIHSGSVVGAGLPQFQSISLRKIQFNFPYFRSDRDKRDFVSAGAAAGVAAAFGAPIGGTLFSLEEGSSFWNQGLTWKVLFCSMSATFTLNFFRSGIQFGSWGSFQLPGLLNFGEFKCSDSDKKCHLWTAMDLGFFVVMGVIGGLLGATFNCLNKRLAKYRMRNVHPKPKLVRVLESLLVSLVTTVVVFVASMVLGECRQMSSSSQIGNDSFQLQVTEDVNSSIKTFFCPNDTYNDMATLFFNPQESAILQLFHQDGTFSPVTLALFFVLYFLLACWTYGISVPSGLFVPSLLCGAAFGRLVANVLKSYIGLGHIYSGTFALIGAAAFLGGVVRMTISLTVILIESTNEITYGLPIMVTLMVAKWTGDFFNKGIYDIHVGLRGVPLLEWETEVEMDKLRASDIMEPNLTYVYPHTRIQSLVSILRTTVHHAFPVVTENRGNEKEFMKGNQLISNNIKFKKSSILTRAGEQRKRSQSMKSYPSSELRNMCDEHIASEEPAEKEDLLQQMLERRYTPYPNLYPDQSPSEDWTMEERFRPLTFHGLILRSQLVTLLVRGVCYSESQSSASQPRLSYAEMAEDYPRYPDIHDLDLTLLNPRMIVDVTPYMNPSPFTVSPNTHVSQVFNLFRTMGLRHLPVVNAVGEIVGIITRHNLTYEFLQARLRQHYQTI,0,,,,,,"Ceroid lipofuscinosis, neuronal, 15:An autosomal dominant, progressive, neurodegenerative disorder characterized by severe global developmental delay, impaired intellectual development, poor or absent speech, hypotonia, impaired motor development, respiratory insufficiency, and feeding difficulties. Most patients have visual defects, including cortical visual blindness, nystagmus, and esotropia. Brain imaging shows abnormalities affecting the brainstem, cerebellum, and corticospinal tracts. Disease onset is in infancy or early childhood.","Ceroid lipofuscinosis, neuronal, 15",,,1:P51797-1:|2:P51797-2:|3:P51797-3:|4:P51797-4:|5:P51797-5:|6:P51797-6:,,,,,,,,,,5.0
P54098,,DNA polymerase subunit gamma-1,POLG,Homo sapiens,1239,False,MDP1|POLG1|POLGA,MSRLLWRKVAGATVGPGPVPAPGRWVSSSVPASDPSDGQRRRQQQQQQQQQQQQQPQQPQVLSSEGGQLRHNPLDIQMLSRGLHEQIFGQGGEMPGEAAVRRSVEHLQKHGLWGQPAVPLPDVELRLPPLYGDNLDQHFRLLAQKQSLPYLEAANLLLQAQLPPKPPAWAWAEGWTRYGPEGEAVPVAIPEERALVFDVEVCLAEGTCPTLAVAISPSAWYSWCSQRLVEERYSWTSQLSPADLIPLEVPTGASSPTQRDWQEQLVVGHNVSFDRAHIREQYLIQGSRMRFLDTMSMHMAISGLSSFQRSLWIAAKQGKHKVQPPTKQGQKSQRKARRGPAISSWDWLDISSVNSLAEVHRLYVGGPPLEKEPRELFVKGTMKDIRENFQDLMQYCAQDVWATHEVFQQQLPLFLERCPHPVTLAGMLEMGVSYLPVNQNWERYLAEAQGTYEELQREMKKSLMDLANDACQLLSGERYKEDPWLWDLEWDLQEFKQKKAKKVKKEPATASKLPIEGAGAPGDPMDQEDLGPCSEEEEFQQDVMARACLQKLKGTTELLPKRPQHLPGHPGWYRKLCPRLDDPAWTPGPSLLSLQMRVTPKLMALTWDGFPLHYSERHGWGYLVPGRRDNLAKLPTGTTLESAGVVCPYRAIESLYRKHCLEQGKQQLMPQEAGLAEEFLLTDNSAIWQTVEELDYLEVEAEAKMENLRAAVPGQPLALTARGGPKDTQPSYHHGNGPYNDVDIPGCWFFKLPHKDGNSCNVGSPFAKDFLPKMEDGTLQAGPGGASGPRALEINKMISFWRNAHKRISSQMVVWLPRSALPRAVIRHPDYDEEGLYGAILPQVVTAGTITRRAVEPTWLTASNARPDRVGSELKAMVQAPPGYTLVGADVDSQELWIAAVLGDAHFAGMHGCTAFGWMTLQGRKSRGTDLHSKTATTVGISREHAKIFNYGRIYGAGQPFAERLLMQFNHRLTQQEAAEKAQQMYAATKGLRWYRLSDEGEWLVRELNLPVDRTEGGWISLQDLRKVQRETARKSQWKKWEVVAERAWKGGTESEMFNKLESIATSDIPRTPVLGCCISRALEPSAVQEEFMTSRVNWVVQSSAVDYLHLMLVAMKWLFEEFAIDGRFCISIHDEVRYLVREEDRYRAALALQITNLLTRCMFAYKLGLNDLPQSVAFFSAVDIDRCLRKEVTMDCKTPSNPTGMERRYGIPQGEALDIYQIIELTKGSLEKRSQPGP,0,,,,,,"Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1:A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.|Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 1:A severe form of progressive external ophthalmoplegia, a disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. It is clinically more heterogeneous than the autosomal dominant forms.|Sensory ataxic neuropathy dysarthria and ophthalmoparesis:A systemic disorder resulting from mitochondrial dysfunction associated with mitochondrial depletion in skeletal muscle and peripheral nerve tissue. The clinical triad of symptoms consists of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis. However, the phenotype varies widely, even within the same family, and can also include myopathy, seizures, and hearing loss.|Mitochondrial DNA depletion syndrome 4A:An autosomal recessive hepatocerebral syndrome due to mitochondrial dysfunction. The typical course of the disease includes severe developmental delay, intractable seizures, liver failure, and death in childhood. Refractory seizures, cortical blindness, progressive liver dysfunction, and acute liver failure after exposure to valproic acid are considered diagnostic features. The neuropathological hallmarks are neuronal loss, spongiform degeneration, and astrocytosis of the visual cortex. Liver biopsy results show steatosis, often progressing to cirrhosis.|Mitochondrial DNA depletion syndrome 4B:An autosomal recessive progressive multisystem disorder due to mitochondrial dysfunction. It is clinically characterized by chronic gastrointestinal dysmotility and pseudo-obstruction, cachexia, progressive external ophthalmoplegia, axonal sensory ataxic neuropathy, and muscle weakness.|Leigh syndrome:An early-onset progressive neurodegenerative disorder characterized by the presence of focal, bilateral lesions in one or more areas of the central nervous system including the brainstem, thalamus, basal ganglia, cerebellum and spinal cord. Clinical features depend on which areas of the central nervous system are involved and include subacute onset of psychomotor retardation, hypotonia, ataxia, weakness, vision loss, eye movement abnormalities, seizures, and dysphagia.|Spinocerebellar ataxia with epilepsy:An autosomal recessive syndrome characterized by headaches and/or seizures manifesting in childhood or adolescence, cerebellar and sensory ataxia, dysarthria, and myoclonus manifesting in early adulthood. Neuropathological findings include spinocerebellar degeneration associated with cortical neuronal degeneration in advanced cases.","Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1|Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive, 1|Sensory ataxic neuropathy dysarthria and ophthalmoparesis|Mitochondrial DNA depletion syndrome 4A|Mitochondrial DNA depletion syndrome 4B|Leigh syndrome|Spinocerebellar ataxia with epilepsy",Q9UHN1(POLG2),,,,,,,,,,,,5.0
Q8WXX7,,Autism susceptibility gene 2 protein,AUTS2,Homo sapiens,1259,False,KIAA0442,MDGPTRGHGLRKKRRSRSQRDRERRSRGGLGAGAAGGGGAGRTRALSLASSSGSDKEDNGKPPSSAPSRPRPPRRKRRESTSAEEDIIDGFAMTSFVTFEALEKDVALKPQERVEKRQTPLTKKKREALTNGLSFHSKKSRLSHPHHYSSDRENDRNLCQHLGKRKKMPKALRQLKPGQNSCRDSDSESASGESKGFHRSSSRERLSDSSAPSSLGTGYFCDSDSDQEEKASDASSEKLFNTVIVNKDPELGVGTLPEHDSQDAGPIVPKISGLERSQEKSQDCCKEPIFEPVVLKDPCPQVAQPIPQPQTEPQLRAPSPDPDLVQRTEAPPQPPPLSTQPPQGPPEAQLQPAPQPQVQRPPRPQSPTQLLHQNLPPVQAHPSAQSLSQPLSAYNSSSLSLNSLSSSRSSTPAKTQPAPPHISHHPSASPFPLSLPNHSPLHSFTPTLQPPAHSHHPNMFAPPTALPPPPPLTSGSLQVAGHPAGSTYSEQDILRQELNTRFLASQSADRGASLGPPPYLRTEFHQHQHQHQHTHQHTHQHTFTPFPHAIPPTAIMPTPAPPMFDKYPTKVDPFYRHSLFHSYPPAVSGIPPMIPPTGPFGSLQGAFQPKTSNPIDVAARPGTVPHTLLQKDPRLTDPFRPMLRKPGKWCAMHVHIAWQIYHHQQKVKKQMQSDPHKLDFGLKPEFLSRPPGPSLFGAIHHPHDLARPSTLFSAAGAAHPTGTPFGPPPHHSNFLNPAAHLEPFNRPSTFTGLAAVGGNAFGGLGNPSVTPNSMFGHKDGPSVQNFSNPHEPWNRLHRTPPSFPTPPPWLKPGELERSASAAAHDRDRDVDKRDSSVSKDDKERESVEKRHSSHPSPAPVLPVNALGHTRSSTEQIRAHLNTEAREKDKPKERERDHSESRKDLAADEHKAKEGHLPEKDGHGHEGRAAGEEAKQLARVPSPYVRTPVVESARPNSTSSREAEPRKGEPAYENPKKSSEVKVKEERKEDHDLPPEAPQTHRASEPPPPNSSSSVHPGPLASMPMTVGVTGIHPMNSISSLDRTRMMTPFMGISPLPGGERFPYPSFHWDPIRDPLRDPYRELDIHRRDPLGRDFLLRNDPLHRLSTPRLYEADRSFRDREPHDYSHHHHHHHHPLSVDPRREHERGGHLDERERLHMLREDYEHTRLHSVHPASLDGHLPHPSLITPGLPSMHYPRISPTAGNQNGLLNKTPPTAALSAPPPLISTLGGRPVSPRRTTPLSAEIRERPPSHTLKDIEAR,0,,,,,,"Intellectual developmental disorder, autosomal dominant 26:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Additional MRD26 features include autism, short stature, microcephaly, cerebral palsy, and facial dysmorphisms.","Intellectual developmental disorder, autosomal dominant 26",Q09472(EP300)|Q86SE9(PCGF5)|Q99496(RNF2)|A8MQ03(CYSRT1)|Q3LI67(KRTAP6-3),,1:Q8WXX7-1:|2:Q8WXX7-2:|3:Q8WXX7-3:|5:Q8WXX7-5:,,,,,,,,,,5.0
Q8NDZ4,,Divergent protein kinase domain 2A,DIPK2A,Homo sapiens,430,False,C3orf58|DIA1,MWRLVPPKLGRLSRSLKLAALGSLLVLMVLHSPSLLASWQRNELTDRRFLQLNKCPACFGTSWCRRFLNGQVVFEAWGRLRLLDFLNVKNVYFAQYGEPREGGRRRVVLKRLGSQRELAQLDQSICKRATGRPRCDLLQAMPRTEFARLNGDVRLLTPEAVEGWSDLVHCPSQRLLDRLVRRYAETKDSGSFLLRNLKDSERMQLLLTLAFNPEPLVLQSFPSDEGWPFAKYLGACGRMVAVNYVGEELWSYFNAPWEKRVDLAWQLMEIAEQLTNNDFEFALYLLDVSFDNFAVGPRDGKVIIVDAENVLVADKRLIRQNKPENWDVWYESKFDDCDKEACLSFSKEILCARATVDHNYYAVCQNLLSRHATWRGTSGGLLHDPPSEIAKDGRLEALLDECANPKKRYGRFQAAKELREYLAQLSNNVR,0,,,,,,:,,,,1:Q8NDZ4-1:|2:Q8NDZ4-2:,,,,,,,,,,5.0
Q9BSQ5,,Cerebral cavernous malformations 2 protein,CCM2,Homo sapiens,444,False,C7orf22,MEEEGKKGKKPGIVSPFKRVFLKGEKSRDKKAHEKVTERRPLHTVVLSLPERVEPDRLLSDYIEKEVKYLGQLTSIPGYLNPSSRTEILHFIDNAKRAHQLPGHLTQEHDAVLSLSAYNVKLAWRDGEDIILRVPIHDIAAVSYVRDDAAHLVVLKTAQDPGISPSQSLCAESSRGLSAGSLSESAVGPVEACCLVILAAESKVAAEELCCLLGQVFQVVYTESTIDFLDRAIFDGASTPTHHLSLHSDDSSTKVDIKETYEVEASTFCFPESVDVGGASPHSKTISESELSASATELLQDYMLTLRTKLSSQEIQQFAALLHEYRNGASIHEFCINLRQLYGDSRKFLLLGLRPFIPEKDSQHFENFLETIGVKDGRGIITDSFGRHRRALSTTSSSTTNGNRATGSSDDRSAPSEGDEWDRMISDISSDIEALGCSMDQDSA,0,,,,,,"Cerebral cavernous malformations 2:A form of cerebral cavernous malformations, a congenital vascular anomaly of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. CCM2 inheritance is autosomal dominant.",Cerebral cavernous malformations 2,Q8TEW6(DOK4)|P31273(HOXC8)|O00522(KRIT1)|Q9BUL8(PDCD10)|Q13671(RIN1)|Q9H1K6(TLNRD1)|Q8WVJ9(TWIST2)|Q96N03(VSTM2L)|O00522(KRIT1)|Q99759(MAP3K3),,1:Q9BSQ5-1:|2:Q9BSQ5-2:|3:Q9BSQ5-3:|4:Q9BSQ5-4:,,,,,,,,,,5.0
Q96JS3,,PiggyBac transposable element-derived protein 1,PGBD1,Homo sapiens,809,False,,MYEALPGPAPENEDGLVKVKEEDPTWEQVCNSQEGSSHTQEICRLRFRHFCYQEAHGPQEALAQLRELCHQWLRPEMHTKEQIMELLVLEQFLTILPKELQPCVKTYPLESGEEAVTVLENLETGSGDTGQQASVYIQGQDMHPMVAEYQGVSLECQSLQLLPGITTLKCEPPQRPQGNPQEVSGPVPHGSAHLQEKNPRDKAVVPVFNPVRSQTLVKTEEETAQAVAAEKWSHLSLTRRNLCGNSAQETVMSLSPMTEEIVTKDRLFKAKQETSEEMEQSGEASGKPNRECAPQIPCSTPIATERTVAHLNTLKDRHPGDLWARMHISSLEYAAGDITRKGRKKDKARVSELLQGLSFSGDSDVEKDNEPEIQPAQKKLKVSCFPEKSWTKRDIKPNFPSWSALDSGLLNLKSEKLNPVELFELFFDDETFNLIVNETNNYASQKNVSLEVTVQEMRCVFGVLLLSGFMRHPRREMYWEVSDTDQNLVRDAIRRDRFELIFSNLHFADNGHLDQKDKFTKLRPLIKQMNKNFLLYAPLEEYYCFDKSMCECFDSDQFLNGKPIRIGYKIWCGTTTQGYLVWFEPYQEESTMKVDEDPDLGLGGNLVMNFADVLLERGQYPYHLCFDSFFTSVKLLSALKKKGVRATGTIRENRTEKCPLMNVEHMKKMKRGYFDFRIEENNEIILCRWYGDGIISLCSNAVGIEPVNEVSCCDADNEEIPQISQPSIVKVYDECKEGVAKMDQIISKYRVRIRSKKWYSILVSYMIDVAMNNAWQLHRACNPGASLDPLDFRRFVAHFYLEHNAHLSD,0,,,,,,,,P50222(MEOX2)|P22736(NR4A1)|P22736-2(NR4A1)|Q96JS3(PGBD1)|P57086(SCAND1)|Q12933(TRAF2)|Q969J2(ZKSCAN4)|Q9P0L1-2(ZKSCAN7)|P17028(ZNF24)|Q9NWS9(ZNF446)|Q9NWS9-2(ZNF446)|Q96IT1(ZNF496)|O43309(ZSCAN12)|Q8TBC5(ZSCAN18)|P10073(ZSCAN22),,,,,,,,,,,,5.0
Q9UNW9,,RNA-binding protein Nova-2,NOVA2,Homo sapiens,492,False,ANOVA|NOVA3,MEPEAPDSRKRPLETPPEVVCTKRSNTGEEGEYFLKVLIPSYAAGSIIGKGGQTIVQLQKETGATIKLSKSKDFYPGTTERVCLVQGTAEALNAVHSFIAEKVREIPQAMTKPEVVNILQPQTTMNPDRAKQAKLIVPNSTAGLIIGKGGATVKAVMEQSGAWVQLSQKPEGINLQERVVTVSGEPEQVHKAVSAIVQKVQEDPQSSSCLNISYANVAGPVANSNPTGSPYASPADVLPAAAAASAAAASGLLGPAGLAGVGAFPAALPAFSGTDLLAISTALNTLASYGYNTNSLGLGLNSAAASGVLAAVAAGANPAAAAAANLLASYAGEAGAGPAGGAAPPPPPPPGALGSFALAAAANGYLGAGAGGGAGGGGGPLVAAAAAAGAAGGFLTAEKLAAESAKELVEIAVPENLVGAILGKGGKTLVEYQELTGARIQISKKGEFLPGTRNRRVTITGSPAATQAAQYLISQRVTYEQGVRASNPQKVG,0,,,,,,"Neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities:An early-onset neurodevelopmental disorder characterized by intellectual disability, motor and speech delay, autistic features, hypotonia, feeding difficulties, spasticity or ataxic gait, and structural brain abnormalities including cerebral atrophy, cerebellar atrophy, and/or thin corpus callosum.",Neurodevelopmental disorder with or without autistic features and/or structural brain abnormalities,,,,,,,,,,,,,5.0
Q92560,,Ubiquitin carboxyl-terminal hydrolase BAP1,BAP1,Homo sapiens,729,False,KIAA0272,MNKGWLELESDPGLFTLLVEDFGVKGVQVEEIYDLQSKCQGPVYGFIFLFKWIEERRSRRKVSTLVDDTSVIDDDIVNNMFFAHQLIPNSCATHALLSVLLNCSSVDLGPTLSRMKDFTKGFSPESKGYAIGNAPELAKAHNSHARPEPRHLPEKQNGLSAVRTMEAFHFVSYVPITGRLFELDGLKVYPIDHGPWGEDEEWTDKARRVIMERIGLATAGEPYHDIRFNLMAVVPDRRIKYEARLHVLKVNRQTVLEALQQLIRVTQPELIQTHKSQESQLPEESKSASNKSPLVLEANRAPAASEGNHTDGAEEAAGSCAQAPSHSPPNKPKLVVKPPGSSLNGVHPNPTPIVQRLPAFLDNHNYAKSPMQEEEDLAAGVGRSRVPVRPPQQYSDDEDDYEDDEEDDVQNTNSALRYKGKGTGKPGALSGSADGQLSVLQPNTINVLAEKLKESQKDLSIPLSIKTSSGAGSPAVAVPTHSQPSPTPSNESTDTASEIGSAFNSPLRSPIRSANPTRPSSPVTSHISKVLFGEDDSLLRVDCIRYNRAVRDLGPVISTGLLHLAEDGVLSPLALTEGGKGSSPSIRPIQGSQGSSSPVEKEVVEATDSREKTGMVRPGEPLSGEKYSPKELLALLKCVEAEIANYEACLKEEVEKRKKFKIDDQRRTHNYDEFICTFISMLAQEGMLANLVEQNISVRRRQGVSIGRLHKQRKPDRRKRSRPYKAKRQ,0,,,,,,"Mesothelioma, malignant:An aggressive neoplasm of the serosal lining of the chest. It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos.|Tumor predisposition syndrome 1:An autosomal dominant condition characterized by predisposition to develop a variety of tumors, including benign melanocytic tumors as well as several malignant tumors, including uveal melanoma, cutaneous melanoma, malignant mesothelioma on exposure to asbestos, lung adenocarcinoma and meningioma.|Melanoma, uveal, 2:Most common intraocular malignancy, arising from melanocytes in the iris, ciliary body, or choroid. Metastases develop in more than 30% of case patients, almost invariably in the liver, with poor prognosis.|Kury-Isidor syndrome:An autosomal dominant neurodevelopmental disorder characterized mainly by mild global developmental delay apparent from infancy or early childhood, and behavioral problems, including autism in most patients. Intellectual development may be mildly delayed, borderline, or even normal. Additional variable systemic features may include poor overall growth, hypotonia, distal skeletal anomalies, seizures, and non-specific dysmorphic facial features.","Mesothelioma, malignant|Tumor predisposition syndrome 1|Melanoma, uveal, 2|Kury-Isidor syndrome",Q8IXJ9(ASXL1)|P38398(BRCA1)|P38398-5(BRCA1)|P51610(HCFC1)|Q14573(ITPR3),,,,,,,,,,,,5.0
O75069,,Transmembrane and coiled-coil domains protein 2,TMCC2,Homo sapiens,709,False,KIAA0481,MKRCRSDELQQQQGEEDGAGLEDAASHLPGADLRPGETTGANSAGGPTSDAGAAAAPNPGPRSKPPDLKKIQQLSEGSMFGHGLKHLFHSRRRSREREHQTSQDSQQHQQQQGMSDHDSPDEKERSPEMHRVSYAMSLHDLPARPTAFNRVLQQIRSRPSIKRGASLHSSSGGGSSGSSSRRTKSSSLEPQRGSPHLLRKAPQDSSLAAILHQHQCRPRSSSTTDTALLLADGSNVYLLAEEAEGIGDKVDKGDLVALSLPAGHGDTDGPISLDVPDGAPDPQRTKAAIDHLHQKILKITEQIKIEQEARDDNVAEYLKLANNADKQQVSRIKQVFEKKNQKSAQTIAQLHKKLEHYRRRLKEIEQNGPSRQPKDVLRDMQQGLKDVGANVRAGISGFGGGVVEGVKGSLSGLSQATHTAVVSKPREFASLIRNKFGSADNIAHLKDPLEDGPPEEAARALSGSATLVSSPKYGSDDECSSASASSAGAGSNSGAGPGGALGSPKSNALYGAPGNLDALLEELREIKEGQSHLEDSMEDLKTQLQRDYTYMTQCLQEERYRYERLEEQLNDLTELHQNEMTNLKQELASMEEKVAYQSYERARDIQEAVESCLTRVTKLELQQQQQQVVQLEGVENANARALLGKFINVILALMAVLLVFVSTIANFITPLMKTRLRITSTTLLVLVLFLLWKHWDSLTYLLEHVLLPS,0,,,,,,,,P02649(APOE),,1:O75069-1:|2:O75069-2:|3:O75069-3:|5:O75069-5:,,,,,,,,,,5.0
O43159,,Ribosomal RNA-processing protein 8,RRP8,Homo sapiens,456,False,KIAA0409|NML,MFEEPEWAEAAPVAAGLGPVISRPPPAASSQNKGSKRRQLLATLRALEAASLSQHPPSLCISDSEEEEEERKKKCPKKASFASASAEVGKKGKKKCQKQGPPCSDSEEEVERKKKCHKQALVGSDSAEDEKRKRKCQKHAPINSAQHLDNVDQTGPKAWKGSTTNDPPKQSPGSTSPKPPHTLSRKQWRNRQKNKRRCKNKFQPPQVPDQAPAEAPTEKTEVSPVPRTDSHEARAGALRARMAQRLDGARFRYLNEQLYSGPSSAAQRLFQEDPEAFLLYHRGFQSQVKKWPLQPVDRIARDLRQRPASLVVADFGCGDCRLASSIRNPVHCFDLASLDPRVTVCDMAQVPLEDESVDVAVFCLSLMGTNIRDFLEEANRVLKPGGLLKVAEVSSRFEDVRTFLRAVTKLGFKIVSKDLTNSHFFLFDFQKTGPPLVGPKAQLSGLQLQPCLYKRR,0,,,,,,,,Q92997(DVL3)|Q6FHY5(MEOX2)|Q9NRD5(PICK1)|Q96EB6(SIRT1)|O43463(SUV39H1),,,,,,,,,,,,5.0
Q5T4B2,,Inactive glycosyltransferase 25 family member 3,CERCAM,Homo sapiens,595,False,CEECAM1|GLT25D3|KIAA1502,MRAARAAPLLQLLLLLGPWLEAAGVAESPLPAVVLAILARNAEHSLPHYLGALERLDYPRARMALWCATDHNVDNTTEMLQEWLAAVGDDYAAVVWRPEGEPRFYPDEEGPKHWTKERHQFLMELKQEALTFARNWGADYILFADTDNILTNNQTLRLLMGQGLPVVAPMLDSQTYYSNFWCGITPQGYYRRTAEYFPTKNRQRRGCFRVPMVHSTFLASLRAEGADQLAFYPPHPNYTWPFDDIIVFAYACQAAGVSVHVCNEHRYGYMNVPVKSHQGLEDERVNFIHLILEALVDGPRMQASAHVTRPSKRPSKIGFDEVFVISLARRPDRRERMLASLWEMEISGRVVDAVDGWMLNSSAIRNLGVDLLPGYQDPYSGRTLTKGEVGCFLSHYSIWEEVVARGLARVLVFEDDVRFESNFRGRLERLMEDVEAEKLSWDLIYLGRKQVNPEKETAVEGLPGLVVAGYSYWTLAYALRLAGARKLLASQPLRRMLPVDEFLPIMFDQHPNEQYKAHFWPRDLVAFSAQPLLAAPTHYAGDAEWLSDTETSSPWDDDSGRLISWSGSQKTLRSPRLDLTGSSGHSLQPQPRDEL,0,,,,,,,,Q8WTS1(ABHD5)|Q7Z3C6-3(ATG9A)|Q9UJX2(CDC23)|Q5T4B2(CERCAM)|Q02930-3(CREB5)|A8MQ03(CYSRT1)|Q9NW38(FANCL)|Q9Y680(FKBP7)|Q9BVV2(FNDC11)|P57678(GEMIN4)|O76003(GLRX3)|P49639(HOXA1)|Q2WGJ6(KLHL38)|Q3LI76(KRTAP15-1)|Q6PEX3(KRTAP26-1)|Q9BYR6(KRTAP3-3)|Q3LI66(KRTAP6-2)|Q8IUC2(KRTAP8-1)|Q9BYQ3(KRTAP9-3)|Q14847-2(LASP1)|Q9Y5V3(MAGED1)|Q13064(MKRN3)|P32242(OTX1)|Q7Z4N8(P4HA3)|Q7Z3K3(POGZ)|Q12837(POU4F2)|Q9BQY4(RHOXF2)|Q8WV19(SFT2D1)|Q5JUK2(SOHLH1)|Q96A09(TENT5B)|Q9BZL1(UBL5)|O95231(VENTX)|A8MV65-2(VGLL3)|Q96MV8(ZDHHC15),,1:Q5T4B2-1:|2:Q5T4B2-2:,,,,,,,,,,5.0
P51608,,Methyl-CpG-binding protein 2,MECP2,Homo sapiens,486,False,,MVAGMLGLREEKSEDQDLQGLKDKPLKFKKVKKDKKEEKEGKHEPVQPSAHHSAEPAEAGKAETSEGSGSAPAVPEASASPKQRRSIIRDRGPMYDDPTLPEGWTRKLKQRKSGRSAGKYDVYLINPQGKAFRSKVELIAYFEKVGDTSLDPNDFDFTVTGRGSPSRREQKPPKKPKSPKAPGTGRGRGRPKGSGTTRPKAATSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLPIKKRKTRETVSIEVKEVVKPLLVSTLGEKSGKGLKTCKSPGRKSKESSPKGRSSSASSPPKKEHHHHHHHSESPKAPVPLLPPLPPPPPEPESSEDPTSPPEPQDLSSSVCKEEKMPRGGSLESDGCPKEPAKTQPAVATAATAAEKYKHRGEGERKDIVSSSMPRPNREEPVDSRTPVTERVS,0,,,,,,"Angelman syndrome:A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue.|Intellectual developmental disorder, X-linked, syndromic 13:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXS13 patients manifest intellectual disability associated with other variable features such as spasticity, episodes of manic depressive psychosis, increased tone and macroorchidism.|Rett syndrome:An X-linked dominant neurodevelopmental disorder, and one of the most common causes of intellectual disability in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements, and develop microcephaly, seizures, autism, ataxia, intellectual disability and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood.|Autism, X-linked 3:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.|Encephalopathy, neonatal severe, due to MECP2 mutations:A neurodevelopmental disorder characterized by severe neonatal encephalopathy, developmental delay, intellectual disability, microcephaly, seizures. Additional features include respiratory insufficiency and central hypoventilation, gastroesophageal reflux, axial hypotonia, hyperreflexia and dyskinetic movements.|Intellectual developmental disorder, X-linked, syndromic, Lubs type:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXSL patients manifest intellectual disability associated with variable features. They include swallowing dysfunction and gastroesophageal reflux with secondary recurrent respiratory infections, hypotonia, mild myopathy and characteristic facies such as downslanting palpebral fissures, hypertelorism and a short nose with a low nasal bridge.","Angelman syndrome|Intellectual developmental disorder, X-linked, syndromic 13|Rett syndrome|Autism, X-linked 3|Encephalopathy, neonatal severe, due to MECP2 mutations|Intellectual developmental disorder, X-linked, syndromic, Lubs type",Q6PCB6(ABHD17C)|P63010-2(AP2B1)|Q9Y575-3(ASB3)|Q9UII2(ATP5IF1)|Q8WUW1(BRK1)|Q9UNS2(COPS3)|P35222(CTNNB1)|Q7L576(CYFIP1)|Q9UHI6(DDX20)|O75398(DEAF1)|Q99504(EYA3)|Q6PIV2(FOXR1)|Q9H2X6(HIPK2)|P04792(HSPB1)|P42858(HTT)|Q6DN90-2(IQSEC1)|Q92993-2(KAT5)|Q9Y2M5(KLHL20)|Q8IUC2(KRTAP8-1)|P07948(LYN)|P61244(MAX)|Q8TDB4(MGARP)|O43196-2(MSH5)|Q99457(NAP1L3)|P07196(NEFL)|Q96CV9(OPTN)|Q96FW1(OTUB1)|Q6GQQ9-2(OTUD7B)|O75925(PIAS1)|P60891(PRPS1)|P57729(RAB38)|Q9NS23-4(RASSF1)|Q8WWW0-2(RASSF5)|Q9ULX5(RNF112)|Q96D59(RNF183)|Q96ST3(SIN3A)|P51531(SMARCA2)|Q12824(SMARCB1)|Q16637-3(SMN2)|Q7Z6I5(SPATA12)|O75558(STX11)|P63165(SUMO1)|Q86WT6-2(TRIM69)|Q86UV6-2(TRIM74)|P10599(TXN)|O76024(WFS1)|Q9QZR5(Hipk2)|Q60974(Ncor1)|Q9WU42(Ncor2)|Q9QXE7(Tbl1x)|Q8BHJ5(Tbl1xr1)|O88508(Dnmt3a),,A:P51608-1:|B:P51608-2:,,,,,,,,,,5.0
P29375,,Lysine-specific demethylase 5A,KDM5A,Homo sapiens,1690,False,JARID1A|RBBP2|RBP2,MAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRLDFLDQLAKFWELQGSTLKIPVVERKILDLYALSKIVASKGGFEMVTKEKKWSKVGSRLGYLPGKGTGSLLKSHYERILYPYELFQSGVSLMGVQMPNLDLKEKVEPEVLSTDTQTSPEPGTRMNILPKRTRRVKTQSESGDVSRNTELKKLQIFGAGPKVVGLAMGTKDKEDEVTRRRKVTNRSDAFNMQMRQRKGTLSVNFVDLYVCMFCGRGNNEDKLLLCDGCDDSYHTFCLIPPLPDVPKGDWRCPKCVAEECSKPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYRRLRRHCVFSHEELIFKMAADPECLDVGLAAMVCKELTLMTEEETRLRESVVQMGVLMSEEEVFELVPDDERQCSACRTTCFLSALTCSCNPERLVCLYHPTDLCPCPMQKKCLRYRYPLEDLPSLLYGVKVRAQSYDTWVSRVTEALSANFNHKKDLIELRVMLEDAEDRKYPENDLFRKLRDAVKEAETCASVAQLLLSKKQKHRQSPDSGRTRTKLTVEELKAFVQQLFSLPCVISQARQVKNLLDDVEEFHERAQEAMMDETPDSSKLQMLIDMGSSLYVELPELPRLKQELQQARWLDEVRLTLSDPQQVTLDVMKKLIDSGVGLAPHHAVEKAMAELQELLTVSERWEEKAKVCLQARPRHSVASLESIVNEAKNIPAFLPNVLSLKEALQKAREWTAKVEAIQSGSNYAYLEQLESLSAKGRPIPVRLEALPQVESQVAAARAWRERTGRTFLKKNSSHTLLQVLSPRTDIGVYGSGKNRRKKVKELIEKEKEKDLDLEPLSDLEEGLEETRDTAMVVAVFKEREQKEIEAMHSLRAANLAKMTMVDRIEEVKFCICRKTASGFMLQCELCKDWFHNSCVPLPKSSSQKKGSSWQAKEVKFLCPLCMRSRRPRLETILSLLVSLQKLPVRLPEGEALQCLTERAMSWQDRARQALATDELSSALAKLSVLSQRMVEQAAREKTEKIISAELQKAAANPDLQGHLPSFQQSAFNRVVSSVSSSPRQTMDYDDEETDSDEDIRETYGYDMKDTASVKSSSSLEPNLFCDEEIPIKSEEVVTHMWTAPSFCAEHAYSSASKSCSQGSSTPRKQPRKSPLVPRSLEPPVLELSPGAKAQLEELMMVGDLLEVSLDETQHIWRILQATHPPSEDRFLHIMEDDSMEEKPLKVKGKDSSEKKRKRKLEKVEQLFGEGKQKSKELKKMDKPRKKKLKLGADKSKELNKLAKKLAKEEERKKKKEKAAAAKVELVKESTEKKREKKVLDIPSKYDWSGAEESDDENAVCAAQNCQRPCKDKVDWVQCDGGCDEWFHQVCVGVSPEMAENEDYICINCAKKQGPVSPGPAPPPSFIMSYKLPMEDLKETS,0,,,,,,":|:|El Hayek-Chahrour neurodevelopmental syndrome:An autosomal recessive neurodevelopmental disorder characterized by lack of speech, intellectual disability, autism, and developmental delay.",El Hayek-Chahrour neurodevelopmental syndrome,P06400(RB1),,1:P29375-1:|2:P29375-2:,,,,,,,,,,5.0
Q14202,,Zinc finger MYM-type protein 3,ZMYM3,Homo sapiens,1370,False,DXS6673E|KIAA0385|ZNF261,MDPSDFPSPFDPLTLPEKPLAGDLPVDMEFGEDLLESQTAPTRGWAPPGPSPSSGALDLLDTPAGLEKDPGVLDGATELLGLGGLLYKAPSPPEVDHGPEGTLAWDAGDQTLEPGPGGQTPEVVPPDPGAGANSCSPEGLLEPLAPDSPITLQSPHIEEEETTSIATARRGSPGQEEELPQGQPQSPNAPPSPSVGETLGDGINSSQTKPGGSSPPAHPSLPGDGLTAKASEKPPERKRSERVRRAEPPKPEVVDSTESIPVSDEDSDAMVDDPNDEDFVPFRPRRSPRMSLRSSVSQRAGRSAVGTKMTCAHCRTPLQKGQTAYQRKGLPQLFCSSSCLTTFSKKPSGKKTCTFCKKEIWNTKDSVVAQTGSGGSFHEFCTSVCLSLYEAQQQRPIPQSGDPADATRCSICQKTGEVLHEVSNGSVVHRLCSDSCFSKFRANKGLKTNCCDQCGAYIYTKTGSPGPELLFHEGQQKRFCNTTCLGAYKKKNTRVYPCVWCKTLCKNFEMLSHVDRNGKTSLFCSLCCTTSYKVKQAGLTGPPRPCSFCRRSLSDPCYYNKVDRTVYQFCSPSCWTKFQRTSPEGGIHLSCHYCHSLFSGKPEVLDWQDQVFQFCCRDCCEDFKRLRGVVSQCEHCRQEKLLHEKLRFSGVEKSFCSEGCVLLYKQDFTKKLGLCCITCTYCSQTCQRGVTEQLDGSTWDFCSEDCKSKYLLWYCKAARCHACKRQGKLLETIHWRGQIRHFCNQQCLLRFYSQQNQPNLDTQSGPESLLNSQSPESKPQTPSQTKVENSNTVRTPEENGNLGKIPVKTRSAPTAPTPPPPPPPATPRKNKAAMCKPLMQNRGVSCKVEMKSKGSQTEEWKPQVIVLPIPVPIFVPVPMHLYCQKVPVPFSMPIPVPVPMFLPTTLESTDKIVETIEELKVKIPSNPLEADILAMAEMIAEAEELDKASSDLCDLVSNQSAEGLLEDCDLFGPARDDVLAMAVKMANVLDEPGQDLEADFPKNPLDINPSVDFLFDCGLVGPEDVSTEQDLPRTMRKGQKRLVLSESCSRDSMSSQPSCTGLNYSYGVNAWKCWVQSKYANGETSKGDELRFGPKPMRIKEDILACSAAELNYGLAQFVREITRPNGERYEPDSIYYLCLGIQQYLLENNRMVNIFTDLYYLTFVQELNKSLSTWQPTLLPNNTVFSRVEEEHLWECKQLGVYSPFVLLNTLMFFNTKFFGLQTAEEHMQLSFTNVVRQSRKCTTPRGTTKVVSIRYYAPVRQRKGRDTGPGKRKREDEAPILEQRENRMNPLRCPVKFYEFYLSKCPESLRTRNDVFYLQPERSCIAESPLWYSVIPMDRSMLESMLNRILAVREIYEELGRPGEEDLD,0,,,,,,"Intellectual developmental disorder, X-linked 112:A neurodevelopmental disorder characterized by developmental delay, impaired intellectual development, language and motor delay, autism or autistic traits, and variable dysmorphic features.|:","Intellectual developmental disorder, X-linked 112",Q16778(H2BC21)|Q92993(KAT5)|Q8TAP4-4(LMO3)|Q5TBB1(RNASEH2B)|Q15047-2(SETDB1)|P61981(YWHAG),,1:Q14202-1:|2:Q14202-2:|3:Q14202-3:,,,,,,,,,,5.0
O00522,,Krev interaction trapped protein 1,KRIT1,Homo sapiens,736,False,CCM1,MGNPENIEDAYVAVIRPKNTASLNSREYRAKSYEILLHEVPIEGQKKKRKKVLLETKLQGNSEITQGILDYVVETTKPISPANQGIRGKRVVLMKKFPLDGEKMGREASLFIVPSVVKDNTKYTYTPGCPIFYCLQDIMRVCSESSTHFATLTARMLIALDKWLDERHAQSHFIPALFRPSPLERIKTNVINPAYATESGQTENSLHMGYSALEIKSKMLALEKADTCIYNPLFGSDLQYTNRVDKVVINPYFGLGAPDYSKIQIPKQEKWQRSMSSVTEDKERQWVDDFPLHRSACEGDSELLSRLLSERFSVNQLDSDHWAPIHYACWYGKVEATRILLEKGKCNPNLLNGQLSSPLHFAAGGGHAEIVQILLNHPETDRHITDQQGRSPLNICEENKQNNWEEAAKLLKEAINKPYEKVRIYRMDGSYRSVELKHGNNTTVQQIMEGMRLSQETQQYFTIWICSENLSLQLKPYHKPLQHVRDWPEILAELTNLDPQRETPQLFLRRDVRLPLEVEKQIEDPLAILILFDEARYNLLKGFYTAPDAKLITLASLLLQIVYGNYESKKHKQGFLNEENLKSIVPVTKLKSKAPHWTNRILHEYKNLSTSEGVSKEMHHLQRMFLQNCWEIPTYGAAFFTGQIFTKASPSNHKVIPVYVGVNIKGLHLLNMETKALLISLKYGCFMWQLGDTDTCFQIHSMENKMSFIVHTKQAGLVVKLLMKLNGQLMPTERNS,0,,,,,,"Cerebral cavernous malformations 1:A form of cerebral cavernous malformations, a congenital vascular anomaly of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. CCM1 inheritance is autosomal dominant.",Cerebral cavernous malformations 1,Q9BSQ5(CCM2)|Q9BSQ5-1(CCM2)|Q9ULI3(HEG1)|O14713(ITGB1BP1)|P61086(UBE2K),,1:O00522-1:|2:O00522-2:|3:O00522-3:,,,,,,,,,,5.0
Q14444,,Caprin-1,CAPRIN1,Homo sapiens,709,False,GPIAP1|GPIP137|M11S1|RNG105,MPSATSHSGSGSKSSGPPPPSGSSGSEAAAGAGAAAPASQHPATGTGAVQTEAMKQILGVIDKKLRNLEKKKGKLDDYQERMNKGERLNQDQLDAVSKYQEVTNNLEFAKELQRSFMALSQDIQKTIKKTARREQLMREEAEQKRLKTVLELQYVLDKLGDDEVRTDLKQGLNGVPILSEEELSLLDEFYKLVDPERDMSLRLNEQYEHASIHLWDLLEGKEKPVCGTTYKVLKEIVERVFQSNYFDSTHNHQNGLCEEEEAASAPAVEDQVPEAEPEPAEEYTEQSEVESTEYVNRQFMAETQFTSGEKEQVDEWTVETVEVVNSLQQQPQAASPSVPEPHSLTPVAQADPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTLDPAIVSAQPMNPTQNMDMPQLVCPPVHSESRLAQPNQVPVQPEATQVPLVSSTSEGYTASQPLYQPSHATEQRPQKEPIDQIQATISLNTDQTTASSSLPAASQPQVFQAGTSKPLHSSGINVNAAPFQSMQTVFNMNAPVPPVNEPETLKQQNQYQASYNQSFSSQPHQVEQTELQQEQLQTVVGTYHGSPDQSHQVTGNHQQPPQQNTGFPRSNQPYYNSRGVSRGGSRGARGLMNGYRGPANGFRGGYDGYRPSFSNTPNSGYTQSQFSAPRDYSGYQRDGYQQNFKRGSGQSGPRGAPRGRGGPPRPNRGMPQMNTQQVN,0,,,,,,"Neurodegeneration, childhood-onset, with cerebellar ataxia and cognitive decline:A neurodegenerative disorder characterized by early-onset ataxia, dysarthria, cognitive decline, sensorimotor axonal neuropathy and muscle weakness. Brain imaging shows cerebellar atrophy.|Neurodevelopmental disorder with language impairment, autism, and attention deficit-hyperactivity disorder:An autosomal dominant disorder with variable expressivity and incomplete penetrance. It is characterized by language impairment, speech delay, intellectual disability, attention deficit hyperactivity disorder and autism spectrum disorder. Additional variable features include developmental delay, seizures, skeletal anomalies, respiratory difficulties, and ophthalmologic anomalies.","Neurodegeneration, childhood-onset, with cerebellar ataxia and cognitive decline|Neurodevelopmental disorder with language impairment, autism, and attention deficit-hyperactivity disorder",P51116(FXR2)|Q13283(G3BP1),,1:Q14444-1:|2:Q14444-2:,,,,,,,,,,5.0
Q96NR3,,Patched domain-containing protein 1,PTCHD1,Homo sapiens,888,False,,MLRQVLHRGLRTCFSRLGHFIASHPVFFASAPVLISILLGASFSRYQVEESVEHLLAPQHSLAKIERNLVNSLFPVNRSKHRLYSDLQTPGRYGRVIVTSFQKANMLDQHHTDLILKLHAAVTKIQVPRPGFNYTFAHICILNNDKTCIVDDIVHVLEELKNARATNRTNFAITYPITHLKDGRAVYNGHQLGGVTVHSKDRVKSAEAIQLTYYLQSINSLNDMVAERWESSFCDTVRLFQKSNSKVKMYPYTSSSLREDFQKTSRVSERYLVTSLILVVTMAILCCSMQDCVRSKPWLGLLGLVTISLATLTAAGIINLTGGKYNSTFLGVPFVMLGHGLYGTFEMLSSWRKTREDQHVKERTAAVYADSMLSFSLTTAMYLVTFGIGASPFTNIEAARIFCCNSCIAIFFNYLYVLSFYGSSLVFTGYIENNYQHSIFCRKVPKPEALQEKPAWYRFLLTARFSEDTAEGEEANTYESHLLVCFLKRYYCDWITNTYVKPFVVLFYLIYISFALMGYLQVSEGSDLSNIVATATQTIEYTTAQQKYFSNYSPVIGFYIYESIEYWNTSVQEDVLEYTKGFVRISWFESYLNYLRKLNVSTGLPKKNFTDMLRNSFLKAPQFSHFQEDIIFSKKYNDEVDVVASRMFLVAKTMETNREELYDLLETLRRLSVTSKVKFIVFNPSFVYMDRYASSLGAPLHNSCISALFLLFFSAFLVADSLINVWITLTVVSVEFGVIGFMTLWKVELDCISVLCLIYGINYTIDNCAPMLSTFVLGKDFTRTKWVKNALEVHGVAILQSYLCYIVGLIPLAAVPSNLTCTLFRCLFLIAFVTFFHCFAILPVILTFLPPSKKKRKEKKNPENREEIECVEMVDIDSTRVVDQITTV,0,,,,,,"Autism, X-linked 4:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.","Autism, X-linked 4",,,1:Q96NR3-1:|2:Q96NR3-2:|3:Q96NR3-3:,,,,,,,,,,5.0
Q9HCI7,,E3 ubiquitin-protein ligase MSL2,MSL2,Homo sapiens,577,False,KIAA1585|MSL2L1|RNF184,MNPVNATALYISASRLVLNYDPGDPKAFTEINRLLPYFRQSLSCCVCGHLLQDPIAPTNSTCQHYVCKTCKGKKMMMKPSCSWCKDYEQFEENKQLSILVNCYKKLCEYITQTTLARDIIEAVDCSSDILALLNDGSLFCEETEKPSDSSFTLCLTHSPLPSTSEPTTDPQASLSPMSESTLSIAIGSSVINGLPTYNGLSIDRFGINIPSPEHSNTIDVCNTVDIKTEDLSDSLPPVCDTVATDLCSTGIDICSFSEDIKPGDSLLLSVEEVLRSLETVSNTEVCCPNLQPNLEATVSNGPFLQLSSQSLSHNVFMSTSPALHGLSCTAATPKIAKLNRKRSRSESDSEKVQPLPISTIIRGPTLGASAPVTVKRESKISLQPIATVPNGGTTPKISKTVLLSTKSMKKSHEHGSKKSHSKTKPGILKKDKAVKEKIPSHHFMPGSPTKTVYKKPQEKKGCKCGRATQNPSVLTCRGQRCPCYSNRKACLDCICRGCQNSYMANGEKKLEAFAVPEKALEQTRLTLGINVTSIAVRNASTSTSVINVTGSPVTTFLAASTHDDKSLDEAIDMRFDC,0,,,,,,"Karayol-Borroto-Haghshenas neurodevelopmental syndrome:An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, intellectual disability, psychiatric manifestations including autism spectrum disorder and attention deficit, dysmorphic features, and motor issues such as coordination problems, feeding difficulties, and gait disturbance.",Karayol-Borroto-Haghshenas neurodevelopmental syndrome,Q68DK7(MSL1),,1:Q9HCI7-1:|2:Q9HCI7-2:,,,,,,,,,,5.0
Q9BR61,,Acyl-CoA-binding domain-containing protein 6,ACBD6,Homo sapiens,282,False,,MASSFLPAGAITGDSGGELSSGDDSGEVEFPHSPEIEETSCLAELFEKAAAHLQGLIQVASREQLLYLYARYKQVKVGNCNTPKPSFFDFEGKQKWEAWKALGDSSPSQAMQEYIAVVKKLDPGWNPQIPEKKGKEANTGFGGPVISSLYHEETIREEDKNIFDYCRENNIDHITKAIKSKNVDVNVKDEEGRALLHWACDRGHKELVTVLLQHRADINCQDNEGQTALHYASACEFLDIVELLLQSGADPTLRDQDGCLPEEVTGCKTVSLVLQRHTTGKA,0,,,,,,"Neurodevelopmental disorder with progressive movement abnormalities:An autosomal recessive, progressive disorder characterized by global developmental delay, intellectual disability, significant expressive language impairment, behavioral abnormalities, and movement disorders including dystonia, spasticity and cerebellar ataxia associated with gait impairment. Additional features include facial dysmorphism, oculomotor anomalies, microcephaly, seizures and brain imaging abnormalities. Parkinsonism may develop in older patients.",Neurodevelopmental disorder with progressive movement abnormalities,P30419(NMT1)|O60551(NMT2),,,,,,,,,,,,5.0
Q9NQX7,,Integral membrane protein 2C,ITM2C,Homo sapiens,267,False,BRI3,MVKISFQPAVAGIKGDKADKASASAPAPASATEILLTPAREEQPPQHRSKRGGSVGGVCYLSMGMVVLLMGLVFASVYIYRYFFLAQLARDNFFRCGVLYEDSLSSQVRTQMELEEDVKIYLDENYERINVPVPQFGGGDPADIIHDFQRGLTAYHDISLDKCYVIELNTTIVLPPRNFWELLMNVKRGTYLPQTYIIQEEMVVTEHVSDKEALGSFIYHLCNGKDTYRLRRRATRRRINKRGAKNCNAIRHFENTFVVETLICGVV,0,,,,,,,,Q8NHW4(CCL4L2)|Q07325(CXCL9)|Q8TBE3(FNDC9)|Q6UX06(OLFM4)|O00526(UPK2),,1:Q9NQX7-1:|2:Q9NQX7-2:|3:Q9NQX7-3:,,,,,,,,,,5.0
Q6U841,,Sodium-driven chloride bicarbonate exchanger,SLC4A10,Homo sapiens,1118,False,NBCN2|NCBE,MEIKDQGAQMEPLLPTRNDEEAVVDRGGTRSILKTHFEKEDLEGHRTLFIGVHVPLGGRKSHRRHRHRGHKHRKRDRERDSGLEDGRESPSFDTPSQRVQFILGTEDDDEEHIPHDLFTELDEICWREGEDAEWRETARWLKFEEDVEDGGERWSKPYVATLSLHSLFELRSCILNGTVLLDMHANTLEEIADMVLDQQVSSGQLNEDVRHRVHEALMKQHHHQNQKKLTNRIPIVRSFADIGKKQSEPNSMDKNAGQVVSPQSAPACVENKNDVSRENSTVDFSKGLGGQQKGHTSPCGMKQRHEKGPPHQQEREVDLHFMKKIPPGAEASNILVGELEFLDRTVVAFVRLSPAVLLQGLAEVPIPTRFLFILLGPLGKGQQYHEIGRSIATLMTDEVFHDVAYKAKDRNDLVSGIDEFLDQVTVLPPGEWDPSIRIEPPKNVPSQEKRKIPAVPNGTAAHGEAEPHGGHSGPELQRTGRIFGGLILDIKRKAPYFWSDFRDAFSLQCLASFLFLYCACMSPVITFGGLLGEATEGRISAIESLFGASMTGIAYSLFGGQPLTILGSTGPVLVFEKILFKFCKEYGLSYLSLRASIGLWTATLCIILVATDASSLVCYITRFTEEAFASLICIIFIYEALEKLFELSEAYPINMHNDLELLTQYSCNCVEPHNPSNGTLKEWRESNISASDIIWENLTVSECKSLHGEYVGRACGHDHPYVPDVLFWSVILFFSTVTLSATLKQFKTSRYFPTKVRSIVSDFAVFLTILCMVLIDYAIGIPSPKLQVPSVFKPTRDDRGWFVTPLGPNPWWTVIAAIIPALLCTILIFMDQQITAVIINRKEHKLKKGCGYHLDLLMVAVMLGVCSIMGLPWFVAATVLSITHVNSLKLESECSAPGEQPKFLGIREQRVTGLMIFILMGSSVFMTSILKFIPMPVLYGVFLYMGASSLKGIQFFDRIKLFWMPAKHQPDFIYLRHVPLRKVHLFTIIQMSCLGLLWIIKVSRAAIVFPMMVLALVFVRKLMDLLFTKRELSWLDDLMPESKKKKLEDAEKEEEQSMLAMEDEGTVQLPLEGHYRDDPSVINISDEMSKTALWRNLLITADNSKDKESSFPSKSSPS,0,,,,,,"Neurodevelopmental disorder with hypotonia and characteristic brain abnormalities:An autosomal recessive disorder characterized by hypotonia in infancy, delayed psychomotor development and intellectual impairment. Affected individuals commonly display traits associated with autistic spectrum disorder including anxiety, hyperactivity and stereotyped movements. Episodes of seizures in the first few years of life may occur. Brain imaging shows abnormalities of the lateral ventricles.",Neurodevelopmental disorder with hypotonia and characteristic brain abnormalities,,,1:Q6U841-1:|2:Q6U841-2:|3:Q6U841-3:|4:Q6U841-4:,,,,,,,,,,5.0
Q9UHC6,,Contactin-associated protein-like 2,CNTNAP2,Homo sapiens,1331,False,CASPR2|KIAA0868,MQAAPRAGCGAALLLWIVSSCLCRAWTAPSTSQKCDEPLVSGLPHVAFSSSSSISGSYSPGYAKINKRGGAGGWSPSDSDHYQWLQVDFGNRKQISAIATQGRYSSSDWVTQYRMLYSDTGRNWKPYHQDGNIWAFPGNINSDGVVRHELQHPIIARYVRIVPLDWNGEGRIGLRIEVYGCSYWADVINFDGHVVLPYRFRNKKMKTLKDVIALNFKTSESEGVILHGEGQQGDYITLELKKAKLVLSLNLGSNQLGPIYGHTSVMTGSLLDDHHWHSVVIERQGRSINLTLDRSMQHFRTNGEFDYLDLDYEITFGGIPFSGKPSSSSRKNFKGCMESINYNGVNITDLARRKKLEPSNVGNLSFSCVEPYTVPVFFNATSYLEVPGRLNQDLFSVSFQFRTWNPNGLLVFSHFADNLGNVEIDLTESKVGVHINITQTKMSQIDISSGSGLNDGQWHEVRFLAKENFAILTIDGDEASAVRTNSPLQVKTGEKYFFGGFLNQMNNSSHSVLQPSFQGCMQLIQVDDQLVNLYEVAQRKPGSFANVSIDMCAIIDRCVPNHCEHGGKCSQTWDSFKCTCDETGYSGATCHNSIYEPSCEAYKHLGQTSNYYWIDPDGSGPLGPLKVYCNMTEDKVWTIVSHDLQMQTPVVGYNPEKYSVTQLVYSASMDQISAITDSAEYCEQYVSYFCKMSRLLNTPDGSPYTWWVGKANEKHYYWGGSGPGIQKCACGIERNCTDPKYYCNCDADYKQWRKDAGFLSYKDHLPVSQVVVGDTDRQGSEAKLSVGPLRCQGDRNYWNAASFPNPSSYLHFSTFQGETSADISFYFKTLTPWGVFLENMGKEDFIKLELKSATEVSFSFDVGNGPVEIVVRSPTPLNDDQWHRVTAERNVKQASLQVDRLPQQIRKAPTEGHTRLELYSQLFVGGAGGQQGFLGCIRSLRMNGVTLDLEERAKVTSGFISGCSGHCTSYGTNCENGGKCLERYHGYSCDCSNTAYDGTFCNKDVGAFFEEGMWLRYNFQAPATNARDSSSRVDNAPDQQNSHPDLAQEEIRFSFSTTKAPCILLYISSFTTDFLAVLVKPTGSLQIRYNLGGTREPYNIDVDHRNMANGQPHSVNITRHEKTIFLKLDHYPSVSYHLPSSSDTLFNSPKSLFLGKVIETGKIDQEIHKYNTPGFTGCLSRVQFNQIAPLKAALRQTNASAHVHIQGELVESNCGASPLTLSPMSSATDPWHLDHLDSASADFPYNPGQGQAIRNGVNRNSAIIGGVIAVVIFTILCTLVFLIRYMFRHKGTYHTNEAKGAESAESADAAIMNNDPNFTETIDESKKEWLI,0,,,,,,"Autism 15:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.|:|Pitt-Hopkins-like syndrome 1:A syndrome characterized by severe intellectual disability and variable additional symptoms, such as impaired speech development, seizures, autistic behavior, breathing anomalies and a broad mouth, resembling Pitt-Hopkins syndrome. In contrast to patients with Pitt-Hopkins syndrome, PTHSL1 patients present with normal or only mildly to moderately delayed motor milestones.",Autism 15|Pitt-Hopkins-like syndrome 1,Q12860(CNTN1)|Q9H8Y8(GORASP2)|P50222(MEOX2)|P62487(POLR2G)|P27824(CANX),,1:Q9UHC6-1:|2:Q9UHC6-2:,,,,,,,,,,5.0
Q8NEN9,,PDZ domain-containing protein 8,PDZD8,Homo sapiens,1154,False,PDZK8,MGLLLMILASAVLGSFLTLLAQFFLLYRRQPEPPADEAARAGEGFRYIKPVPGLLLREYLYGGGRDEEPSGAAPEGGATPTAAPETPAPPTRETCYFLNATILFLFRELRDTALTRRWVTKKIKVEFEELLQTKTAGRLLEGLSLRDVFLGETVPFIKTIRLVRPVVPSATGEPDGPEGEALPAACPEELAFEAEVEYNGGFHLAIDVDLVFGKSAYLFVKLSRVVGRLRLVFTRVPFTHWFFSFVEDPLIDFEVRSQFEGRPMPQLTSIIVNQLKKIIKRKHTLPNYKIRFKPFFPYQTLQGFEEDEEHIHIQQWALTEGRLKVTLLECSRLLIFGSYDREANVHCTLELSSSVWEEKQRSSIKTVELIKGNLQSVGLTLRLVQSTDGYAGHVIIETVAPNSPAAIADLQRGDRLIAIGGVKITSTLQVLKLIKQAGDRVLVYYERPVGQSNQGAVLQDNFGQLEENFLSSSCQSGYEEEAAGLTVDTESRELDSEFEDLASDVRAQNEFKDEAQSLSHSPKRVPTTLSIKPLGAISPVLNRKLAVGSHPLPPKIQSKDGNKPPPLKTSEITDPAQVSKPTQGSAFKPPVPPRPQAKVPLPSADAPNQAEPDVLVEKPEKVVPPPLVDKSAEKQAKNVDAIDDAAAPKQFLAKQEVAKDVTSETSCPTKDSSDDRQTWESSEILYRNKLGKWTRTRASCLFDIEACHRYLNIALWCRDPFKLGGLICLGHVSLKLEDVALGCLATSNTEYLSKLRLEAPSPKAIVTRTALRNLSMQKGFNDKFCYGDITIHFKYLKEGESDHHVVTNVEKEKEPHLVEEVSVLPKEEQFVGQMGLTENKHSFQDTQFQNPTWCDYCKKKVWTKAASQCMFCAYVCHKKCQEKCLAETSVCGATDRRIDRTLKNLRLEGQETLLGLPPRVDAEASKSVNKTTGLTRHIINTSSRLLNLRQVSKTRLSEPGTDLVEPSPKHTPNTSDNEGSDTEVCGPNSPSKRGNSTGIKLVRKEGGLDDSVFIAVKEIGRDLYRGLPTEERIQKLEFMLDKLQNEIDQELEHNNSLVREEKETTDTRKKSLLSAALAKSGERLQALTLLMIHYRAGIEDIETLESLSLDQHSKKISKYTDDTEEDLDNEISQLIDSQPFSSISDDLFGPSESV,0,,,,,,"Intellectual developmental disorder with autism and dysmorphic facies:An autosomal recessive neurodevelopmental disorder characterized by moderate to severe intellectual disability with autistic features, myopathy, and facial dysmorphism.",Intellectual developmental disorder with autism and dysmorphic facies,A0A0F6AZQ1(pipB),,,,,,,,,,,,5.0
Q16650,,T-box brain protein 1,TBR1,Homo sapiens,682,False,,MQLEHCLSPSIMLSKKFLNVSSSYPHSGGSELVLHDHPIISTTDNLERSSPLKKITRGMTNQSDTDNFPDSKDSPGDVQRSKLSPVLDGVSELRHSFDGSAADRYLLSQSSQPQSAATAPSAMFPYPGQHGPAHPAFSIGSPSRYMAHHPVITNGAYNSLLSNSSPQGYPTAGYPYPQQYGHSYQGAPFYQFSSTQPGLVPGKAQVYLCNRPLWLKFHRHQTEMIITKQGRRMFPFLSFNISGLDPTAHYNIFVDVILADPNHWRFQGGKWVPCGKADTNVQGNRVYMHPDSPNTGAHWMRQEISFGKLKLTNNKGASNNNGQMVVLQSLHKYQPRLHVVEVNEDGTEDTSQPGRVQTFTFPETQFIAVTAYQNTDITQLKIDHNPFAKGFRDNYDTIYTGCDMDRLTPSPNDSPRSQIVPGARYAMAGSFLQDQFVSNYAKARFHPGAGAGPGPGTDRSVPHTNGLLSPQQAEDPGAPSPQRWFVTPANNRLDFAASAYDTATDFAGNAATLLSYAAAGVKALPLQAAGCTGRPLGYYADPSGWGARSPPQYCGTKSGSVLPCWPNSAAAAARMAGANPYLGEEAEGLAAERSPLPPGAAEDAKPKDLSDSSWIETPSSIKSIDSSDSGIYEQAKRRRISPADTPVSESSSPLKSEVLAQRDCEKNCAKDISGYYGFYSHS,0,,,,,,"Intellectual developmental disorder with autism and speech delay:An autosomal dominant neurodevelopmental disorder characterized by varying degrees of intellectual disability, autism spectrum disorder, and language deficits.",Intellectual developmental disorder with autism and speech delay,P05067(APP)|P05067-2(APP)|P54253(ATXN1)|P42858(HTT)|O60260-5(PRKN)|P37840(SNCA),,1:Q16650-1:|2:Q16650-2:,,,,,,,,,,5.0
Q96JP0,,Protein fem-1 homolog C,FEM1C,Homo sapiens,617,False,KIAA1785,MDLKTAVFNAARDGKLRLLTKLLASKSKEEVSSLISEKTNGATPLLMAARYGHLDMVEFLLEQCSASIEVGGSVNFDGETIEGAPPLWAASAAGHLKVVQSLLNHGASVNNTTLTNSTPLRAACFDGHLEIVKYLVEHKADLEVSNRHGHTCLMISCYKGHKEIAQYLLEKGADVNRKSVKGNTALHDCAESGSLDIMKMLLMYCAKMEKDGYGMTPLLSASVTGHTNIVDFLTHHAQTSKTERINALELLGATFVDKKRDLLGALKYWKKAMNMRYSDRTNIISKPVPQTLIMAYDYAKEVNSAEELEGLIADPDEMRMQALLIRERILGPSHPDTSYYIRYRGAVYADSGNFKRCINLWKYALDMQQSNLDPLSPMTASSLLSFAELFSFMLQDRAKGLLGTTVTFDDLMGILCKSVLEIERAIKQTQCPADPLQLNKALSIILHLICLLEKVPCTLEQDHFKKQTIYRFLKLHPRGKNNFSPLHLAVDKNTTCVGRYPVCKFPSLQVTAILIECGADVNVRDSDDNSPLHIAALNNHPDIMNLLIKSGAHFDATNLHKQTASDLLDEKEIAKNLIQPINHTTLQCLAARVIVNHRIYYKGHIPEKLETFVSLHR,0,,,,,,:,,Q96MT8-3(CEP63)|Q9BRK4(LZTS2)|Q9UDY8-2(MALT1)|Q9UJA3-4(MCM8)|Q8ND90(PNMA1)|Q96KN7(RPGRIP1),,,,,,,,,,,,5.0
Q8N2Q7,,Neuroligin-1,NLGN1,Homo sapiens,863,False,KIAA1070,MALPRCTWPNYVWRAVMACLVHRGLGAPLTLCMLGCLLQAGHVLSQKLDDVDPLVATNFGKIRGIKKELNNEILGPVIQFLGVPYAAPPTGERRFQPPEPPSPWSDIRNATQFAPVCPQNIIDGRLPEVMLPVWFTNNLDVVSSYVQDQSEDCLYLNIYVPTEDVKRISKECARKPGKKICRKGGPLTKKQTDDLGDNDGAEDEDIRDSGGPKPVMVYIHGGSYMEGTGNLYDGSVLASYGNVIVITVNYRLGVLGFLSTGDQAAKGNYGLLDLIQALRWTSENIGFFGGDPLRITVFGSGAGGSCVNLLTLSHYSEGNRWSNSTKGLFQRAIAQSGTALSSWAVSFQPAKYARMLATKVGCNVSDTVELVECLQKKPYKELVDQDIQPARYHIAFGPVIDGDVIPDDPQILMEQGEFLNYDIMLGVNQGEGLKFVENIVDSDDGISASDFDFAVSNFVDNLYGYPEGKDVLRETIKFMYTDWADRHNPETRRKTLLALFTDHQWVAPAVATADLHSNFGSPTYFYAFYHHCQTDQVPAWADAAHGDEVPYVLGIPMIGPTELFPCNFSKNDVMLSAVVMTYWTNFAKTGDPNQPVPQDTKFIHTKPNRFEEVAWTRYSQKDQLYLHIGLKPRVKEHYRANKVNLWLELVPHLHNLNDISQYTSTTTKVPSTDITFRPTRKNSVPVTSAFPTAKQDDPKQQPSPFSVDQRDYSTELSVTIAVGASLLFLNILAFAALYYKKDKRRHDVHRRCSPQRTTTNDLTHAQEEEIMSLQMKHTDLDHECESIHPHEVVLRTACPPDYTLAMRRSPDDVPLMTPNTITMIPNTIPGIQPLHTFNTFTGGQNNTLPHPHPHPHSHSTTRV,0,,,,,,"Autism 20:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability. The transmission pattern of AUTS20 is consistent with autosomal dominant inheritance.",Autism 20,,,1:Q8N2Q7-3:|2:Q8N2Q7-2:,,,,,,,,,,5.0
Q96CW9,,Netrin-G2,NTNG2,Homo sapiens,530,False,KIAA1857|LMNT2,MLHLLALFLHCLPLASGDYDICKSWVTTDEGPTWEFYACQPKVMRLKDYVKVKVEPSGITCGDPPERFCSHENPYLCSNECDASNPDLAHPPRLMFDKEEEGLATYWQSITWSRYPSPLEANITLSWNKTVELTDDVVMTFEYGRPTVMVLEKSLDNGRTWQPYQFYAEDCMEAFGMSARRARDMSSSSAHRVLCTEEYSRWAGSKKEKHVRFEVRDRFAIFAGPDLRNMDNLYTRLESAKGLKEFFTLTDLRMRLLRPALGGTYVQRENLYKYFYAISNIEVIGRCKCNLHANLCSMREGSLQCECEHNTTGPDCGKCKKNFRTRSWRAGSYLPLPHGSPNACATAGSFGNCECYGHSNRCSYIDFLNVVTCVSCKHNTRGQHCQHCRLGYYRNGSAELDDENVCIECNCNQIGSVHDRCNETGFCECREGAAGPKCDDCLPTHYWRQGCYPNVCDDDQLLCQNGGTCLQNQRCACPRGYTGVRCEQPRCDPADDDGGLDCDRAPGAAPRPATLLGCLLLLGLAARLGR,0,,,,,,"Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia:An autosomal recessive disorder characterized by global developmental delay with severely impaired intellectual development, impaired motor development, axial and peripheral hypotonia, poor speech and significant behavioral abnormalities, including autism spectrum disorder, hyperactivity, mood disorders, aggression, hand and face stereotypies, sleep disturbances, anxiety, self-injurious behavior, and bruxism.","Neurodevelopmental disorder with behavioral abnormalities, absent speech, and hypotonia",Q9HBW1(LRRC4)|Q9HCJ2(LRRC4C),,1:Q96CW9-1:|2:Q96CW9-2:,,,,,,,,,,5.0
P16389,,Potassium voltage-gated channel subfamily A member 2,KCNA2,Homo sapiens,499,False,,MTVATGDPADEAAALPGHPQDTYDPEADHECCERVVINISGLRFETQLKTLAQFPETLLGDPKKRMRYFDPLRNEYFFDRNRPSFDAILYYYQSGGRLRRPVNVPLDIFSEEIRFYELGEEAMEMFREDEGYIKEEERPLPENEFQRQVWLLFEYPESSGPARIIAIVSVMVILISIVSFCLETLPIFRDENEDMHGSGVTFHTYSNSTIGYQQSTSFTDPFFIVETLCIIWFSFEFLVRFFACPSKAGFFTNIMNIIDIVAIIPYFITLGTELAEKPEDAQQGQQAMSLAILRVIRLVRVFRIFKLSRHSKGLQILGQTLKASMRELGLLIFFLFIGVILFSSAVYFAEADERESQFPSIPDAFWWAVVSMTTVGYGDMVPTTIGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETEGEEQAQYLQVTSCPKIPSSPDLKKSRSASTISKSDYMEIQEGVNNSNEDFREENLKTANCTLANTNYVNITKMLTDV,0,,,,,,"Developmental and epileptic encephalopathy 32:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE32 inheritance is autosomal dominant.|Nizon-Isidor syndrome:An autosomal dominant neurodevelopmental disorder characterized by intellectual disability, global developmental delay, speech impairment, and behavioral abnormalities including autism spectrum disorder and aggressive behavior. Other features include a thin corpus callosum, and mild facial dysmorphism. Disease onset is in infancy or early childhood.",Developmental and epileptic encephalopathy 32|Nizon-Isidor syndrome,P49069(CAMLG)|Q13303(KCNAB2)|P49069(CAMLG)|Q92520(FAM3C),,1:P16389-1:|2:P16389-2:,,,,,,,,,,5.0
Q9HCD6,,Protein TANC2,TANC2,Homo sapiens,1990,False,KIAA1148|KIAA1636,MFRNSLKMLLTGGKSSRKNRSSDGGSEEPPDRRQSSVDSRQSRSGQGGISTESDCAFEPDYAVPPLPVSEGDAEQELGPPPSVDEAANTLMTRLGFLLGEKVTEVQPGDQYSMEVQDENQTSAITQRISPCSTLTSSTASPPASSPCSTLPPISTNATAKDCSYGAVTSPTSTLESRDSGIIATLTSYSENVERTKYAGESSKELGSGGNIKPWQSQKSSMDSCLYRVDENMTASTYSLNKIPERNLETVLSQSVQSIPLYLMPRPNSVAATSSAHLEDLAYLDEQRHTPLRTSLRMPRQSMGGARTQQDLRVRFAPYRPPDISLKPLLFEVPSITTESVFVGRDWVFHEIDAQLQSSNASVNQGVVIVGNIGFGKTAIISRLVALSCHGTRMRQIASDSPHASPKHVDANRELPLTQPPSAHSSITSGSCPGTPEMRRRQEEAMRRLASQVVAYHYCQADNAYTCLVPEFVHNVAALLCRSPQLTAYREQLLREPHLQSMLSLRSCVQDPMASFRRGVLEPLENLHKERKIPDEDFIILIDGLNEAEFHKPDYGDTIVSFLSKMIGKFPSWLKLIVTVRTSLQEITKLLPFHRIFLDRLEENEAIDQDLQAYILHRIHSSSEIQNNISLNGKMDNTTFGKLSSHLKTLSQGSYLYLKLTFDLIEKGYLVLKSSSYKVVPVSLSEVYLLQCNMKFPTQSSFDRVMPLLNVAVASLHPLTDEHIFQAINAGSIEGTLEWEDFQQRMENLSMFLIKRRDMTRMFVHPSFREWLIWREEGEKTKFLCDPRSGHTLLAFWFSRQEGKLNRQQTIELGHHILKAHIFKGLSKKVGVSSSILQGLWISYSTEGLSMALASLRNLYTPNIKVSRLLILGGANINYRTEVLNNAPILCVQSHLGYTEMVALLLEFGANVDASSESGLTPLGYAAAAGYLSIVVLLCKKRAKVDHLDKNGQCALVHAALRGHLEVVKFLIQCDWTMAGQQQGVFKKSHAIQQALIAAASMGYTEIVSYLLDLPEKDEEEVERAQINSFDSLWGETALTAAAGRGKLEVCRLLLEQGAAVAQPNRRGAVPLFSTVRQGHWQIVDLLLTHGADVNMADKQGRTPLMMAASEGHLGTVDFLLAQGASIALMDKEGLTALSWACLKGHLSVVRSLVDNGAATDHADKNGRTPLDLAAFYGDAEVVQFLVDHGAMIEHVDYSGMRPLDRAVGCRNTSVVVTLLKKGAKIGPATWAMATSKPDIMIILLSKLMEEGDMFYKKGKVKEAAQRYQYALKKFPREGFGEDLKTFRELKVSLLLNLSRCRRKMNDFGMAEEFATKALELKPKSYEAYYARARAKRSSRQFAAALEDLNEAIKLCPNNREIQRLLLRVEEECRQMQQPQQPPPPPQPQQQLPEEAEPEPQHEDIYSVQDIFEEEYLEQDVENVSIGLQTEARPSQGLPVIQSPPSSPPHRDSAYISSSPLGSHQVFDFRSSSSVGSPTRQTYQSTSPALSPTHQNSHYRPSPPHTSPAHQGGSYRFSPPPVGGQGKEYPSPPPSPLRRGPQYRASPPAESMSVYRSQSGSPVRYQQETSVSQLPGRPKSPLSKMAQRPYQMPQLPVAVPQQGLRLQPAKAQIVRSNQPSPAVHSSTVIPTGAYGQVAHSMASKYQSSQGDIGVSQSRLVYQGSIGGIVGDGRPVQHVQASLSAGAICQHGGLTKEDLPQRPSSAYRGGVRYSQTPQIGRSQSASYYPVCHSKLDLERSSSQLGSPDVSHLIRRPISVNPNEIKPHPPTPRPLLHSQSVGLRFSPSSNSISSTSNLTPTFRPSSSIQQMEIPLKPAYERSCDELSPVSPTQGGYPSEPTRSRTTPFMGIIDKTARTQQYPHLHQQNRTWAVSSVDTVLSPTSPGNLPQPESFSPPSSISNIAFYNKTNNAQNGHLLEDDYYSPHGMLANGSRGDLLERVSQASSYPDVKVARTLPVAQAYQDNLYRQLSRDSRQGQTSPIKPKRPFVESNV,0,,,,,,"Intellectual developmental disorder with autistic features and language delay, with or without seizures:An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, varying degrees of intellectual disability, autism spectrum disorder, and delayed language. Some patients develop seizures.|:","Intellectual developmental disorder with autistic features and language delay, with or without seizures",,,1:Q9HCD6-1:|2:Q9HCD6-2:|3:Q9HCD6-3:|4:Q9HCD6-4:,,,,,,,,,,5.0
Q05639,,Elongation factor 1-alpha 2,EEF1A2,Homo sapiens,463,False,EEF1AL|STN,MGKEKTHINIVVIGHVDSGKSTTTGHLIYKCGGIDKRTIEKFEKEAAEMGKGSFKYAWVLDKLKAERERGITIDISLWKFETTKYYITIIDAPGHRDFIKNMITGTSQADCAVLIVAAGVGEFEAGISKNGQTREHALLAYTLGVKQLIVGVNKMDSTEPAYSEKRYDEIVKEVSAYIKKIGYNPATVPFVPISGWHGDNMLEPSPNMPWFKGWKVERKEGNASGVSLLEALDTILPPTRPTDKPLRLPLQDVYKIGGIGTVPVGRVETGILRPGMVVTFAPVNITTEVKSVEMHHEALSEALPGDNVGFNVKNVSVKDIRRGNVCGDSKSDPPQEAAQFTSQVIILNHPGQISAGYSPVIDCHTAHIACKFAELKEKIDRRSGKKLEDNPKSLKSGDAAIVEMVPGKPMCVESFSQYPPLGRFAVRDMRQTVAVGVIKNVEKKSGGAGKVTKSAQKAQKAGK,0,,,,,,"Developmental and epileptic encephalopathy 33:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent.|Intellectual developmental disorder, autosomal dominant 38:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD38 common features are severe intellectual disability, autistic behavior, absent speech, neonatal hypotonia, epilepsy and progressive microcephaly.","Developmental and epileptic encephalopathy 33|Intellectual developmental disorder, autosomal dominant 38",Q969K4(ABTB1)|P42858(HTT)|Q5S007(LRRK2)|Q86YT5(SLC13A5)|Q9NSC7(ST6GALNAC1)|P24557(TBXAS1)|Q14166(TTLL12)|P59595(N),,,,,,,,,,,,5.0
Q9BUL8,,Programmed cell death protein 10,PDCD10,Homo sapiens,212,False,CCM3|TFAR15,MRMTMEEMKNEAETTSMVSMPLYAVMYPVFNELERVNLSAAQTLRAAFIKAEKENPGLTQDIIMKILEKKSVEVNFTESLLRMAADDVEEYMIERPEPEFQDLNEKARALKQILSKIPDEINDRVRFLQTIKDIASAIKELLDTVNNVFKKYQYQNRRALEHQKKEFVKYSKSFSDTLKTYFKDGKAINVFVSANRLIHQTNLILQTFKTVA,0,,,,,,"Cerebral cavernous malformations 3:A form of cerebral cavernous malformations, a congenital vascular anomaly of the central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. The lesions are characterized by grossly enlarged blood vessels consisting of a single layer of endothelium and without any intervening neural tissue, ranging in diameter from a few millimeters to several centimeters. CCM3 inheritance is autosomal dominant.",Cerebral cavernous malformations 3,Q8IY42(C4orf19)|Q9BSQ5(CCM2)|Q9BPY3(FAM118B)|Q9Y285(FARSA)|O94915-2(FRYL)|Q9UPX6(MINAR1)|Q499L9(MST4)|Q5SXH7-1(PLEKHS1)|Q86WR7-2(PROSER2)|Q12923(PTPN13)|Q9Y6E0(STK24)|Q9Y6E0-2(STK24)|O00506(STK25)|Q9P289(STK26)|Q9P289-1(STK26)|O43815(STRN)|O43815-2(STRN)|Q96BA2(),,,,,,,,,,,,5.0
Q2KHR2,,DNA-binding protein RFX7,RFX7,Homo sapiens,1460,False,RFXDC2,MAEEQQQPPPQQPDAHQQLPPSAPNSGVALPALVPGLPGTEASALQHKIKNSICKTVQSKVDCILQEVEKFTDLEKLYLYLQLPSGLSNGEKSDQNAMSSSRAQQMHAFSWIRNTLEEHPETSLPKQEVYDEYKSYCDNLGYHPLSAADFGKIMKNVFPNMKARRLGTRGKSKYCYSGLRKKAFVHMPTLPNLDFHKTGDGLEGAEPSGQLQNIDEEVISSACRLVCEWAQKVLSQPFDTVLELARFLVKSHYIGTKSMAALTVMAAAPAGMKGITQPSAFIPTAESNSFQPQVKTLPSPIDAKQQLQRKIQKKQQEQKLQSPLPGESAAKKSESATSNGVTNLPNGNPSILSPQPIGIVVAAVPSPIPVQRTRQLVTSPSPMSSSDGKVLPLNVQVVTQHMQSVKQAPKTPQNVPASPGGDRSARHRYPQILPKPANTSALTIRSPTTVLFTSSPIKTAVVPASHMSSLNVVKMTTISLTPSNSNTPLKHSASVSSATGTTEESRSVPQIKNGSVVSLQSPGSRSSSAGGTSAVEVKVEPETSSDEHPVQCQENSDEAKAPQTPSALLGQKSNTDGALQKPSNEGVIEIKATKVCDQRTKCKSRCNEMLPGTSTGNNQSTITLSVASQNLTFTSSSSPPNGDSINKDPKLCTKSPRKRLSSTLQETQVPPVKKPIVEQLSAATIEGQKQGSVKKDQKVPHSGKTEGSTAGAQIPSKVSVNVSSHIGANQPLNSSALVISDSALEQQTTPSSSPDIKVKLEGSVFLLDSDSKSVGSFNPNGWQQITKDSEFISASCEQQQDISVMTIPEHSDINDLEKSVWELEGMPQDTYSQQLHSQIQESSLNQIQAHSSDQLPLQSELKEFEPSVSQTNESYFPFDDELTQDSIVEELVLMEQQMSMNNSHSYGNCLGMTLQSQSVTPGAPMSSHTSSTHFYHPIHSNGTPIHTPTPTPTPTPTPTPTPTPTSEMIAGSQSLSRESPCSRLAQTTPVDSALGSSRHTPIGTPHSNCSSSVPPSPVECRNPFAFTPISSSMAYHDASIVSSSPVKPMQRPMATHPDKTKLEWMNNGYSGVGNSSVSGHGILPSYQELVEDRFRKPHAFAVPGQSYQSQSRHHDTHFGRLTPVSPVQHQGATVNNTNKQEGFAVPAPLDNKGTNSSASSNFRCRSVSPAVHRQRNLSGSTLYPVSNIPRSNVTPFGSPVTPEVHVFTNVHTDACANNIAQRSQSVPLTVMMQTAFPNALQKQANSKKITNVLLSKLDSDNDDAVRGLGMNNLPSNYTARMNLTQILEPSTVFPSANPQNMIDSSTSVYEFQTPSYLTKSNSTGQINFSPGDNQAQSEIGEQQLDFNSTVKDLLSGDSLQTNQQLVGQGASDLTNTASDFSSDIRLSSELSGSINDLNTLDPNLLFDPGRQQGQDDEATLEELKNDPLFQQICSESMNSMTSSGFEWIESKDHPTVEMLG,0,,,,,,"Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities:An autosomal dominant neurodevelopmental disorder characterized by global developmental delay, hypotonia, speech delay, and impaired intellectual development. Most patients manifest neurobehavioral features including autism spectrum disorder and attention-deficit/hyperactivity disorder. Other frequent features include hypersensitivity to sensory stimuli and sleep problems.","Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities",Q9H9E1(ANKRA2)|O14593(RFXANK),,1:Q2KHR2-3:|3:Q2KHR2-1:|2:Q2KHR2-2:,,,,,,,,,,5.0
Q86YW9,,Mediator of RNA polymerase II transcription subunit 12-like protein,MED12L,Homo sapiens,2145,False,KIAA1635|TNRC11L|TRALP|TRALPUSH,MAAFGLLSYEQRPLKRPRLGPPDVYPQDPKQKEDELTAVNVKQGFNNQPAFTGDEHGSARNIVINPSKIGAYFSSILAEKLKLNTFQDTGKKKPQVNAKDNYWLVTARSQSAIHSWFSDLAGNKPLSILAKKVPILSKKEDVFAYLAKYSVPMVRATWLIKMTCAYYSAISEAKIKKRQAPDPNLEWTQISTRYLREQLAKISDFYHMASSTGDGPVPVPPEVEQAMKQWEYNEKLAFHMFQEGMLEKHEYLTWILDVLEKIRPMDDDLLKLLLPLMLQYSDEFVQSAYLSRRLAYFCARRLSLLLSDSPNLLAAHSPHMMIGPNNSSIGAPSPGPPGPGMSPVQLAFSDFLSCAQHGPLVYGLSCMLQTVTLCCPSALVWNYSTNENKSANPGSPLDLLQVAPSSLPMPGGNTAFNQQVRARIYEVEQQIKQRGRAVEVRWSFDKCQESTAGVTISRVLHTLEVLDRHCFDRTDSSNSMETLYHKIFWANQNKDNQEVAPNDEAVVTLLCEWAVSCKRSGKHRAMAVAKLLEKRQAEIEAERCGESEVLDEKESISSSSLAGSSLPVFQNVLLRFLDTQAPSLSDPNSECEKVEFVNLVLLFCEFIRHDVFSHDAYMCTLISRGDLSVTASTRPRSPVGENADEHYSKDHDVKMEIFSPMPGESCENANTSLGRRMSVNCEKLVKREKPRELIFPSNYDLLRHLQYATHFPIPLDESSSHECNQRTILLYGVGKERDEARHQLKKITKDILKILNKKSTTETGVGDEGQKARKNKQETFPTLETVFTKLQLLSYFDQHQVTSQISNNVLEQITSFASGTSYHLPLAHHIQLIFDLMEPALNINGLIDFAIQLLNELSVVEAELLLKSSSLAGSYTTGLCVCIVAVLRRYHSCLILNPDQTAQVFEGLCGVVKHVVNPSECSSPERCILAYLYDLYVSCSHLRSKFGDLFSSACSKVKQTIYNNVMPANSNLRWDPDFMMDFIENPSARSINYSMLGKILSDNAANRYSFVCNTLMNVCMGHQDAGRINDIANFSSELTACCTVLSSEWLGVLKALCCSSNHVWGFNDVLCTVDVSDLSFHDSLATFIAILIARQCFSLEDVVQHVALPSLLAAACGDADAEPGARMTCRLLLHLFRAPQACFLPQATGKPFPGIRSSCDRHLLAAAHNSIEVGAVFAVLKAIMMLGDAKIGNNSVSSLKNDDFTMRGLRCDGNADDIWTASQNPKSCGKSISIETANLREYARYVLRTICQQEWVGEHCLKEPERLCTDKELILDPVLSNMQAQKLLQLICYPHGIKECTEGDNLQRQHIKRILQNLEQWTLRQSWLELQLMIKQCLKDPGSGSVAEMNNLLDNIAKATIEVFQQSADLNNSSNSGMSLFNPNSIGSADTSSTRQNGIKTFLSSSERRGVWLVAPLIARLPTSVQGRVLKAAGEELEKGQHLGSSSKKERDRQKQKSMSLLSQQPFLSLVLTCLKGQDEQREGLLTSLQNQVNQILSNWREERYQDDIKARQMMHEALQLRLNLVGGMFDTVQRSTQWTTDWALLLLQIITSGTVDMHTNNELFTTVLDMLGVLINGTLASDLSNASPGGSEENKRAYMNLVKKLKKELGDKRSESIDKVRQLLPLPKQTCDVITCEPMGSLIDTKGNKIAGFDSIDKKQGLQVSTKQKVSPWDLFEGQKNPAPLSWAWFGTVRVDRRVIKYEEQHHLLLYHTHPMPKPRSYYLQPLPLPPEEEEEEPTSPVSQEPERKSAELSDQGKTTTDEEKKTKGRKRKTKSSSRVDEYPQSNIYRVPPNYSPISSQMMHHPQSTLWGYNLVGQPQQPGFFLQNQSLTPGGSRLDPAGSFVPTNTKQALSNMLQRRSGAMMQPPSLHAITSQQQLIQMKLLQQQQQQRLLRQAQTRPFQQGQPGDQAALFAAQARPSPQLPQYPGLQQAQTMPQGYTMYGTQMPLQQTSQQQAGSVVLSPSYNSRAYPAAHSNPVLMERLRQIQQQPSGYVQQQASPYLQPLTGSQRLNHQALQQSPLVGGGIDAVLTSAHPNLPSVPLPQDPMRPRQPQVRQQQRLLQMQQPQQPQPQQPPQPQQSSQSQSQTLGLQAMQPQQPLFPRQGLQQTQQQQQTAALVRQLQKQLSSNQPQQGVTPYGHPSHF,0,,,,,,"Nizon-Isidor syndrome:An autosomal dominant neurodevelopmental disorder characterized by intellectual disability, global developmental delay, speech impairment, and behavioral abnormalities including autism spectrum disorder and aggressive behavior. Other features include a thin corpus callosum, and mild facial dysmorphism. Disease onset is in infancy or early childhood.",Nizon-Isidor syndrome,P61024(CKS1B)|P45984(MAPK9)|Q8IXL7-2(MSRB3)|Q08117-2(TLE5)|Q5W5X9-3(TTC23),,1:Q86YW9-1:|2:Q86YW9-2:|3:Q86YW9-3:|4:Q86YW9-4:,,,,,,,,,,5.0
O15297,,Protein phosphatase 1D,PPM1D,Homo sapiens,605,False,WIP1,MAGLYSLGVSVFSDQGGRKYMEDVTQIVVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGPAVAAREARDPLPDAGASPAPSRCCRRRSSVAFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHNGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGEFVVSPEPDTSVHTLDPQKHKYIILGSDGLWNMIPPQDAISMCQDQEEKKYLMGEHGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELYLNLTDSPSYNSQETCVMTPSPCSTPPVKSLEEDPWPRVNSKDHIPALVRSNAFSENFLEVSAEIARENVQGVVIPSKDPEPLEENCAKALTLRIHDSLNNSLPIGLVPTNSTNTVMDQKNLKMSTPGQMKAQEIERTPPTNFKRTLEESNSGPLMKKHRRNGLSRSSGAQPASLPTTSQRKNSVKLTMRRRLRGQKKIGNPLLHQHRKTVCVC,0,,,,,,"Jansen-de Vries syndrome:An autosomal dominant neurodevelopmental disorder characterized by mild to severe intellectual disability, psychomotor developmental delay, speech delay, and behavioral manifestations including attention deficit-hyperactivity disorder, autism and anxiety disorders. Most patients have variable additional features, including feeding and gastrointestinal difficulties, high pain threshold, hypersensitivity to sound, hypotonia, broad-based gait, and dysmorphic features, including mild facial abnormalities, strabismus, and small hands and feet.|Breast cancer:A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.|Ovarian cancer:The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.",Jansen-de Vries syndrome|Breast cancer|Ovarian cancer,P16104(H2AX)|Q00987(MDM2)|Q13950(RUNX2),,1:O15297-1:|2:O15297-2:,,,,,,,,,,5.0
Q9C0A6,,Histone-lysine N-methyltransferase SETD5,SETD5,Homo sapiens,1442,False,KIAA1757,MSIAIPLGVTTSDTSYSDMAAGSDPESVEASPAVNEKSVYSTHNYGTTQRHGCRGLPYATIIPRSDLNGLPSPVEERCGDSPNSEGETVPTWCPCGLSQDGFLLNCDKCRGMSRGKVIRLHRRKQDNISGGDSSATESWDEELSPSTVLYTATQHTPTSITLTVRRTKPKKRKKSPEKGRAAPKTKKIKNSPSEAQNLDENTTEGWENRIRLWTDQYEEAFTNQYSADVQNALEQHLHSSKEFVGKPTILDTINKTELACNNTVIGSQMQLQLGRVTRVQKHRKILRAARDLALDTLIIEYRGKVMLRQQFEVNGHFFKKPYPFVLFYSKFNGVEMCVDARTFGNDARFIRRSCTPNAEVRHMIADGMIHLCIYAVSAITKDAEVTIAFDYEYSNCNYKVDCACHKGNRNCPIQKRNPNATELPLLPPPPSLPTIGAETRRRKARRKELEMEQQNEASEENNDQQSQEVPEKVTVSSDHEEVDNPEEKPEEEKEEVIDDQENLAHSRRTREDRKVEAIMHAFENLEKRKKRRDQPLEQSNSDVEITTTTSETPVGEETKTEAPESEVSNSVSNVTIPSTPQSVGVNTRRSSQAGDIAAEKLVPKPPPAKPSRPRPKSRISRYRTSSAQRLKRQKQANAQQAELSQAALEEGGSNSLVTPTEAGSLDSSGENRPLTGSDPTVVSITGSHVNRAASKYPKTKKYLVTEWLNDKAEKQECPVECPLRITTDPTVLATTLNMLPGLIHSPLICTTPKHYIRFGSPFIPERRRRPLLPDGTFSSCKKRWIKQALEEGMTQTSSVPQETRTQHLYQSNENSSSSSICKDNADLLSPLKKWKSRYLMEQNVTKLLRPLSPVTPPPPNSGSKSPQLATPGSSHPGEEECRNGYSLMFSPVTSLTTASRCNTPLQFELCHRKDLDLAKVGYLDSNTNSCADRPSLLNSGHSDLAPHPSLGPTSETGFPSRSGDGHQTLVRNSDQAFRTEFNLMYAYSPLNAMPRADGLYRGSPLVGDRKPLHLDGGYCSPAEGFSSRYEHGLMKDLSRGSLSPGGERACEGVPSAPQNPPQRKKVSLLEYRKRKQEAKENSAGGGGDSAQSKSKSAGAGQGSSNSVSDTGAHGVQGSSARTPSSPHKKFSPSHSSMSHLEAVSPSDSRGTSSSHCRPQENISSRWMVPTSVERLREGGSIPKVLRSSVRVAQKGEPSPTWESNITEKDSDPADGEGPETLSSALSKGATVYSPSRYSYQLLQCDSPRTESQSLLQQSSSPFRGHPTQSPGYSYRTTALRPGNPPSHGSSESSLSSTSYSSPAHPVSTDSLAPFTGTPGYFSSQPHSGNSTGSNLPRRSCPSSAASPTLQGPSDSPTSDSVSQSSTGTLSSTSFPQNSRSSLPSDLRTISLPSAGQSAVYQASRVSAVSNSQHYPHRGSGGVHQYRLQPLQGSGVKTQTGLS,0,,,,,,"Intellectual developmental disorder, autosomal dominant 23:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD23 patients manifest moderate to severe intellectual disability with additional variable features of brachycephaly, a low hairline, depressed nasal bridge, prominent high nasal root, tubular nose, upslanting palpebral fissures, long and smooth philtrum, micrognathia, thin upper lip, and crowded teeth. Behavioral problems, including obsessive-compulsive disorder, hand flapping with ritualized behavior, and autism, are prominent features.","Intellectual developmental disorder, autosomal dominant 23",Q8NHQ1(CEP70)|Q6A162(KRT40)|Q5JR59(MTUS2)|Q13137(CALCOCO2)|Q58EX7(PLEKHG4)|O60504(SORBS3)|Q05BL1(TP53BP2),,1:Q9C0A6-1:|2:Q9C0A6-2:|3:Q9C0A6-3:,,,,,,,,,,5.0
Q13936,,Voltage-dependent L-type calcium channel subunit alpha-1C,CACNA1C,Homo sapiens,2221,False,CACH2|CACN2|CACNL1A1|CCHL1A1,MVNENTRMYIPEENHQGSNYGSPRPAHANMNANAAAGLAPEHIPTPGAALSWQAAIDAARQAKLMGSAGNATISTVSSTQRKRQQYGKPKKQGSTTATRPPRALLCLTLKNPIRRACISIVEWKPFEIIILLTIFANCVALAIYIPFPEDDSNATNSNLERVEYLFLIIFTVEAFLKVIAYGLLFHPNAYLRNGWNLLDFIIVVVGLFSAILEQATKADGANALGGKGAGFDVKALRAFRVLRPLRLVSGVPSLQVVLNSIIKAMVPLLHIALLVLFVIIIYAIIGLELFMGKMHKTCYNQEGIADVPAEDDPSPCALETGHGRQCQNGTVCKPGWDGPKHGITNFDNFAFAMLTVFQCITMEGWTDVLYWVNDAVGRDWPWIYFVTLIIIGSFFVLNLVLGVLSGEFSKEREKAKARGDFQKLREKQQLEEDLKGYLDWITQAEDIDPENEDEGMDEEKPRNMSMPTSETESVNTENVAGGDIEGENCGARLAHRISKSKFSRYWRRWNRFCRRKCRAAVKSNVFYWLVIFLVFLNTLTIASEHYNQPNWLTEVQDTANKALLALFTAEMLLKMYSLGLQAYFVSLFNRFDCFVVCGGILETILVETKIMSPLGISVLRCVRLLRIFKITRYWNSLSNLVASLLNSVRSIASLLLLLFLFIIIFSLLGMQLFGGKFNFDEMQTRRSTFDNFPQSLLTVFQILTGEDWNSVMYDGIMAYGGPSFPGMLVCIYFIILFICGNYILLNVFLAIAVDNLADAESLTSAQKEEEEEKERKKLARTASPEKKQELVEKPAVGESKEEKIELKSITADGESPPATKINMDDLQPNENEDKSPYPNPETTGEEDEEEPEMPVGPRPRPLSELHLKEKAVPMPEASAFFIFSSNNRFRLQCHRIVNDTIFTNLILFFILLSSISLAAEDPVQHTSFRNHILFYFDIVFTTIFTIEIALKILGNADYVFTSIFTLEIILKMTAYGAFLHKGSFCRNYFNILDLLVVSVSLISFGIQSSAINVVKILRVLRVLRPLRAINRAKGLKHVVQCVFVAIRTIGNIVIVTTLLQFMFACIGVQLFKGKLYTCSDSSKQTEAECKGNYITYKDGEVDHPIIQPRSWENSKFDFDNVLAAMMALFTVSTFEGWPELLYRSIDSHTEDKGPIYNYRVEISIFFIIYIIIIAFFMMNIFVGFVIVTFQEQGEQEYKNCELDKNQRQCVEYALKARPLRRYIPKNQHQYKVWYVVNSTYFEYLMFVLILLNTICLAMQHYGQSCLFKIAMNILNMLFTGLFTVEMILKLIAFKPKGYFSDPWNVFDFLIVIGSIIDVILSETNHYFCDAWNTFDALIVVGSIVDIAITEVNPAEHTQCSPSMNAEENSRISITFFRLFRVMRLVKLLSRGEGIRTLLWTFIKSFQALPYVALLIVMLFFIYAVIGMQVFGKIALNDTTEINRNNNFQTFPQAVLLLFRCATGEAWQDIMLACMPGKKCAPESEPSNSTEGETPCGSSFAVFYFISFYMLCAFLIINLFVAVIMDNFDYLTRDWSILGPHHLDEFKRIWAEYDPEAKGRIKHLDVVTLLRRIQPPLGFGKLCPHRVACKRLVSMNMPLNSDGTVMFNATLFALVRTALRIKTEGNLEQANEELRAIIKKIWKRTSMKLLDQVVPPAGDDEVTVGKFYATFLIQEYFRKFKKRKEQGLVGKPSQRNALSLQAGLRTLHDIGPEIRRAISGDLTAEEELDKAMKEAVSAASEDDIFRRAGGLFGNHVSYYQSDGRSAFPQTFTTQRPLHINKAGSSQGDTESPSHEKLVDSTFTPSSYSSTGSNANINNANNTALGRLPRPAGYPSTVSTVEGHGPPLSPAIRVQEVAWKLSSNRERHVPMCEDLELRRDSGSAGTQAHCLLLRKANPSRCHSRESQAAMAGQEETSQDETYEVKMNHDTEACSEPSLLSTEMLSYQDDENRQLTLPEEDKRDIRQSPKRGFLRSASLGRRASFHLECLKRQKDRGGDISQKTVLPLHLVHHQALAVAGLSPLLQRSHSPASFPRPFATPPATPGSRGWPPQPVPTLRLEGVESSEKLNSSFPSIHCGSWAETTPGGGGSSAARRVRPVSLMVPSQAGAPGRQFHGSASSLVEAVLISEGLGQFAQDPKFIEVTTQELADACDMTIEEMESAADNILSGGAPQSPNGALLPFVNCRDAGQDRAGGEEDAGCVRARGRPSEEELQDSRVYVSSL,0,,,,,,"Timothy syndrome:Disorder characterized by multiorgan dysfunction including lethal arrhythmias, webbing of fingers and toes, congenital heart disease, immune deficiency, intermittent hypoglycemia, cognitive abnormalities and autism.|Brugada syndrome 3:A heart disease characterized by the association of Brugada syndrome with shortened QT intervals. Brugada syndrome is a tachyarrhythmia characterized by right bundle branch block and ST segment elevation on an electrocardiogram (ECG). It can cause the ventricles to beat so fast that the blood is prevented from circulating efficiently in the body. When this situation occurs, the individual will faint and may die in a few minutes if the heart is not reset.|Long QT syndrome 8:A form of long QT syndrome, a heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. LQT8 transmission pattern is consistent with autosomal dominant inheritance with incomplete penetrance.|Neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures:An autosomal dominant disorder characterized by global developmental delay apparent from infancy, intellectual disability, poor or absent speech, behavioral abnormalities, and hypotonia with delayed walking or inability to walk. Additional features include epilepsy, mild skeletal defects, and non-specific dysmorphic features.","Timothy syndrome|Brugada syndrome 3|Long QT syndrome 8|Neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures",P12814(ACTN1)|Q06481(APLP2)|P01024(C3)|Q9NZU7(CABP1)|Q02641-1(CACNB1)|Q08289-1(CACNB2)|P54284(CACNB3)|P62158(CALM3)|P51114(FXR1)|P22626(HNRNPA2B1)|Q9HCM3(KIAA1549)|Q06413(MEF2C)|Q96DH6(MSI2)|P42857(NSG1)|Q9Y5H9(PCDHA2)|Q9Y5E4(PCDHB5)|Q07343(PDE4B)|Q9NRD5(PICK1)|Q9UKM9(RALY)|Q9C0C4(SEMA4C)|O75533(SF3B1)|P62161(Calm3)|Q9NZU7-2(CABP1),,1:Q13936-1:|2:Q13936-2:|3:Q13936-3:|4:Q13936-4:|5:Q13936-5:|6:Q13936-6:|7:Q13936-7:|8:Q13936-8:|9:Q13936-9:|10:Q13936-10:|11:Q13936-11:|12:Q13936-12:|13:Q13936-13:|14:Q13936-14:|15:Q13936-15:|16:Q13936-16:|17:Q13936-17:|18:Q13936-18:|19:Q13936-19:|20:Q13936-20:|21:Q13936-21:|22:Q13936-22:|23:Q13936-23:|24:Q13936-24:|25:Q13936-25:|26:Q13936-26:|27:Q13936-27:|28:Q13936-28:|29:Q13936-29:|30:Q13936-30:|31:Q13936-31:|32:Q13936-32:|33:Q13936-33:|34:Q13936-34:|35:Q13936-35:|36:Q13936-36:|37:Q13936-37:,,,,,,,,,,5.0
Q5H9F3,,BCL-6 corepressor-like protein 1,BCORL1,Homo sapiens,1785,False,,MISTAPLYSGVHNWTSSDRIRMCGINEERRAPLSDEESTTGDCQHFGSQEFCVSSSFSKVELTAVGSGSNARGADPDGSATEKLGHKSEDKPDDPQPKMDYAGNVAEAEGLLVPLSSPGDGLKLPASDSAEASNSRADCSWTPLNTQMSKQVDCSPAGVKALDSRQGVGEKNTFILATLGTGVPVEGTLPLVTTNFSPLPAPICPPAPGSASVPHSVPDAFQVPLSVPAPVPHSGLVPVQVATSVPAPSPPLAPVPALAPAPPSVPTLISDSNPLSVSASVLVPVPASAPPSGPVPLSAPAPAPLSVPVSAPPLALIQAPVPPSAPTLVLAPVPTPVLAPMPASTPPAAPAPPSVPMPTPTPSSGPPSTPTLIPAFAPTPVPAPTPAPIFTPAPTPMPAATPAAIPTSAPIPASFSLSRVCFPAAQAPAMQKVPLSFQPGTVLTPSQPLVYIPPPSCGQPLSVATLPTTLGVSSTLTLPVLPSYLQDRCLPGVLASPELRSYPYAFSVARPLTSDSKLVSLEVNRLPCTSPSGSTTTQPAPDGVPGPLADTSLVTASAKVLPTPQPLLPAPSGSSAPPHPAKMPSGTEQQTEGTSVTFSPLKSPPQLEREMASPPECSEMPLDLSSKSNRQKLPLPNQRKTPPMPVLTPVHTSSKALLSTVLSRSQRTTQAAGGNVTSCLGSTSSPFVIFPEIVRNGDPSTWVKNSTALISTIPGTYVGVANPVPASLLLNKDPNLGLNRDPRHLPKQEPISIIDQGEPKGTGATCGKKGSQAGAEGQPSTVKRYTPARIAPGLPGCQTKELSLWKPTGPANIYPRCSVNGKPTSTQVLPVGWSPYHQASLLSIGISSAGQLTPSQGAPIRPTSVVSEFSGVPSLSSSEAVHGLPEGQPRPGGSFVPEQDPVTKNKTCRIAAKPYEEQVNPVLLTLSPQTGTLALSVQPSGGDIRMNQGPEESESHLCSDSTPKMEGPQGACGLKLAGDTKPKNQVLATYMSHELVLATPQNLPKMPELPLLPHDSHPKELILDVVPSSRRGSSTERPQLGSQVDLGRVKMEKVDGDVVFNLATCFRADGLPVAPQRGQAEVRAKAGQARVKQESVGVFACKNKWQPDDVTESLPPKKMKCGKEKDSEEQQLQPQAKAVVRSSHRPKCRKLPSDPQESTKKSPRGASDSGKEHNGVRGKHKHRKPTKPESQSPGKRADSHEEGSLEKKAKSSFRDFIPVVLSTRTRSQSGSICSSFAGMADSDMGSQEVFPTEEEEEVTPTPAKRRKVRKTQRDTQYRSHHAQDKSLLSQGRRHLWRAREMPWRTEAARQMWDTNEEEEEEEEEGLLKRKKRRRQKSRKYQTGEYLTEQEDEQRRKGRADLKARKQKTSSSQSLEHRLRNRNLLLPNKVQGISDSPNGFLPNNLEEPACLENSEKPSGKRKCKTKHMATVSEEAKGKGRWSQQKTRSPKSPTPVKPTEPCTPSKSRSASSEEASESPTARQIPPEARRLIVNKNAGETLLQRAARLGYKDVVLYCLQKDSEDVNHRDNAGYTALHEACSRGWTDILNILLEHGANVNCSAQDGTRPVHDAVVNDNLETIWLLLSYGADPTLATYSGQTAMKLASSDTMKRFLSDHLSDLQGRAEGDPGVSWDFYSSSVLEEKDGFACDLLHNPPGSSDQEGDDPMEEDDFMFELSDKPLLPCYNLQVSVSRGPCNWFLFSDVLKRLKLSSRIFQARFPHFEITTMPKAEFYRQVASSQLLTPAERPGGLDDRSPPGSSETVELVRYEPDLLRLLGSEVEFQSCNS,0,,,,,,"Shukla-Vernon syndrome:An X-linked neurodevelopmental disorder manifesting in affected males with intellectual and learning disability, motor and language delay, autism spectrum disorder, attention deficit and hyperactivity disorder, and dysmorphic features. Some patients may have seizures and/or cerebellar atrophy on brain imaging. Carrier females may have mild disease manifestations.|:",Shukla-Vernon syndrome,Q9BSM1-1(PCGF1),,3:Q5H9F3-3:|1:Q5H9F3-1:|4:Q5H9F3-4:,,,,,,,,,,5.0
O14874,,Branched-chain alpha-ketoacid dehydrogenase kinase,BCKDK,Homo sapiens,412,False,,MILASVLRSGPGGGLPLRPLLGPALALRARSTSATDTHHVEMARERSKTVTSFYNQSAIDAAAEKPSVRLTPTMMLYAGRSQDGSHLLKSARYLQQELPVRIAHRIKGFRCLPFIIGCNPTILHVHELYIRAFQKLTDFPPIKDQADEAQYCQLVRQLLDDHKDVVTLLAEGLRESRKHIEDEKLVRYFLDKTLTSRLGIRMLATHHLALHEDKPDFVGIICTRLSPKKIIEKWVDFARRLCEHKYGNAPRVRINGHVAARFPFIPMPLDYILPELLKNAMRATMESHLDTPYNVPDVVITIANNDVDLIIRISDRGGGIAHKDLDRVMDYHFTTAEASTQDPRISPLFGHLDMHSGAQSGPMHGFGFGLPTSRAYAEYLGGSLQLQSLQGIGTDVYLRLRHIDGREESFRI,0,,,,,,"Branched-chain ketoacid dehydrogenase kinase deficiency:A metabolic disorder characterized by autism, epilepsy, intellectual disability, and reduced branched-chain amino acids.",Branched-chain ketoacid dehydrogenase kinase deficiency,Q5VZV1(METTL21C)|P02549(SPTA1)|P40763(STAT3)|Q9WMX2()|Q8WUW1(BRK1),,1:O14874-1:|2:O14874-2:|3:O14874-3:,,,,,,,,,,5.0
P27635,,Large ribosomal subunit protein uL16,RPL10,Homo sapiens,214,False,DXS648E|QM,MGRRPARCYRYCKNKPYPKSRFCRGVPDAKIRIFDLGRKKAKVDEFPLCGHMVSDEYEQLSSEALEAARICANKYMVKSCGKDGFHIRVRLHPFHVIRINKMLSCAGADRLQTGMRGAFGKPQGTVARVHIGQVIMSIRTKLQNKEHVIEALRRAKFKFPGRQKIHISKKWGFTKFNADEFEDMVAEKRLIPDGCGVKYIPSRGPLDKWRALHS,0,,,,,,"Autism, X-linked 5:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.|Intellectual developmental disorder, X-linked, syndromic 35:A syndrome characterized by intellectual deficit, delayed psychomotor development, poor speech, and dysmorphic features.","Autism, X-linked 5|Intellectual developmental disorder, X-linked, syndromic 35",P54253(ATXN1)|P12931(SRC),,,,,,,,,,,,5.0
P06730,,Eukaryotic translation initiation factor 4E,EIF4E,Homo sapiens,217,False,EIF4EL1|EIF4F,MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV,0,,,,,,"Autism 19:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.|:",Autism 19,Q13541(EIF4EBP1)|Q13542(EIF4EBP2)|O60516(EIF4EBP3)|Q9NRA8(EIF4ENIF1)|Q04637(EIF4G1)|O43432-1(EIF4G3)|Q04743(EMX2)|Q8TEQ6(GEMIN5)|Q63ZY3(KANK2)|P42704(LRPPRC)|P11940(PABPC1)|P67775(PPP2CA)|P63165(SUMO1)|P48775(TDO2)|P14373(TRIM27)|Q5T124(UBXN11)|O70552(Btg4)|Q60809(Cnot7)|O73557(Z)|Q13541(EIF4EBP1)|Q9NRA8(EIF4ENIF1),,1:P06730-1:|2:P06730-2:|3:P06730-3:,,,,,,,,,,5.0
Q9NZV8,,A-type voltage-gated potassium channel KCND2,KCND2,Homo sapiens,630,False,KIAA1044,MAAGVAAWLPFARAAAIGWMPVASGPMPAPPRQERKRTQDALIVLNVSGTRFQTWQDTLERYPDTLLGSSERDFFYHPETQQYFFDRDPDIFRHILNFYRTGKLHYPRHECISAYDEELAFFGLIPEIIGDCCYEEYKDRRRENAERLQDDADTDTAGESALPTMTARQRVWRAFENPHTSTMALVFYYVTGFFIAVSVIANVVETVPCGSSPGHIKELPCGERYAVAFFCLDTACVMIFTVEYLLRLAAAPSRYRFVRSVMSIIDVVAILPYYIGLVMTDNEDVSGAFVTLRVFRVFRIFKFSRHSQGLRILGYTLKSCASELGFLLFSLTMAIIIFATVMFYAEKGSSASKFTSIPAAFWYTIVTMTTLGYGDMVPKTIAGKIFGSICSLSGVLVIALPVPVIVSNFSRIYHQNQRADKRRAQKKARLARIRAAKSGSANAYMQSKRNGLLSNQLQSSEDEQAFVSKSGSSFETQHHHLLHCLEKTTNHEFVDEQVFEESCMEVATVNRPSSHSPSLSSQQGVTSTCCSRRHKKTFRIPNANVSGSHQGSIQELSTIQIRCVERTPLSNSRSSLNAKMEECVKLNCEQPYVTTAIISIPTPPVTTPEGDDRPESPEYSGGNIVRVSAL,0,,,,,,:|:,,Q9NZI2(KCNIP1)|Q9NS61(KCNIP2)|Q9NS61-3(KCNIP2),,,,,,,,,,,,5.0
Q9P0L2,,Serine/threonine-protein kinase MARK1,MARK1,Homo sapiens,795,False,KIAA1477|MARK,MSARTPLPTVNERDTENHTSVDGYTEPHIQPTKSSSRQNIPRCRNSITSATDEQPHIGNYRLQKTIGKGNFAKVKLARHVLTGREVAVKIIDKTQLNPTSLQKLFREVRIMKILNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKYIVHRDLKAENLLLDGDMNIKIADFGFSNEFTVGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKKLLVLNPIKRGSLEQIMKDRWMNVGHEEEELKPYTEPDPDFNDTKRIDIMVTMGFARDEINDALINQKYDEVMATYILLGRKPPEFEGGESLSSGNLCQRSRPSSDLNNSTLQSPAHLKVQRSISANQKQRRFSDHAGPSIPPAVSYTKRPQANSVESEQKEEWDKDVARKLGSTTVGSKSEMTASPLVGPERKKSSTIPSNNVYSGGSMARRNTYVCERTTDRYVALQNGKDSSLTEMSVSSISSAGSSVASAVPSARPRHQKSMSTSGHPIKVTLPTIKDGSEAYRPGTTQRVPAASPSAHSISTATPDRTRFPRGSSSRSTFHGEQLRERRSVAYNGPPASPSHETGAFAHARRGTSTGIISKITSKFVRRDPSEGEASGRTDTSRSTSGEPKERDKEEGKDSKPRSLRFTWSMKTTSSMDPNDMMREIRKVLDANNCDYEQKERFLLFCVHGDARQDSLVQWEMEVCKLPRLSLNGVRFKRISGTSIAFKNIASKIANELKL,0,,,,,,:,,P05067(APP)|P63172(DYNLT1)|Q0VD86(INCA1)|O95988(TCL1B)|Q8IY57-5(YAF2),,1:Q9P0L2-1:|2:Q9P0L2-2:|3:Q9P0L2-3:,,,,,,,,,,5.0
Q9UPX8,,SH3 and multiple ankyrin repeat domains protein 2,SHANK2,Homo sapiens,1849,False,CORTBP1|KIAA1022|PROSAP1,MPRSPTSSEDEMAQSFSDYSVGSESDSSKEETIYDTIRATAEKPGGARTEESQGNTLVIRVVIHDLQQTKCIRFNPDATVWVAKQRILCTLTQSLKDVLNYGLFQPASNGRDGKFLDEERLLREYPQPVGEGVPSLEFRYKKRVYKQASLDEKQLAKLHTKTNLKKCMDHIQHRLVEKITKMLDRGLDPNFHDPETGETPLTLAAQLDDSVEVIKALKNGGAHLDFRAKDGMTALHKAARARNQVALKTLLELGASPDYKDSYGLTPLYHTAIVGGDPYCCELLLHEHATVCCKDENGWHEIHQACRYGHVQHLEHLLFYGADMSAQNASGNTALHICALYNQDSCARVLLFRGGNKELKNYNSQTPFQVAIIAGNFELAEYIKNHKETDIVPFREAPAYSNRRRRPPNTLAAPRVLLRSNSDNNLNASAPDWAVCSTATSHRSLSPQLLQQMPSKPEGAAKTIGSYVPGPRSRSPSLNRLGGAGEDGKRPQPLWHVGSPFALGANKDSLSAFEYPGPKRKLYSAVPGRLFVAVKPYQPQVDGEIPLHRGDRVKVLSIGEGGFWEGSARGHIGWFPAECVEEVQCKPRDSQAETRADRSKKLFRHYTVGSYDSFDTSSDCIIEEKTVVLQKKDNEGFGFVLRGAKADTPIEEFTPTPAFPALQYLESVDEGGVAWQAGLRTGDFLIEVNNENVVKVGHRQVVNMIRQGGNHLVLKVVTVTRNLDPDDTARKKAPPPPKRAPTTALTLRSKSMTSELEELVDKASVRKKKDKPEEIVPASKPSRAAENMAVEPRVATIKQRPSSRCFPAGSDMNSVYERQGIAVMTPTVPGSPKAPFLGIPRGTMRRQKSIDSRIFLSGITEEERQFLAPPMLKFTRSLSMPDTSEDIPPPPQSVPPSPPPPSPTTYNCPKSPTPRVYGTIKPAFNQNSAAKVSPATRSDTVATMMREKGMYFRRELDRYSLDSEDLYSRNAGPQANFRNKRGQMPENPYSEVGKIASKAVYVPAKPARRKGMLVKQSNVEDSPEKTCSIPIPTIIVKEPSTSSSGKSSQGSSMEIDPQAPEPPSQLRPDESLTVSSPFAAAIAGAVRDREKRLEARRNSPAFLSTDLGDEDVGLGPPAPRTRPSMFPEEGDFADEDSAEQLSSPMPSATPREPENHFVGGAEASAPGEAGRPLNSTSKAQGPESSPAVPSASSGTAGPGNYVHPLTGRLLDPSSPLALALSARDRAMKESQQGPKGEAPKADLNKPLYIDTKMRPSLDAGFPTVTRQNTRGPLRRQETENKYETDLGRDRKGDDKKNMLIDIMDTSQQKSAGLLMVHTVDATKLDNALQEEDEKAEVEMKPDSSPSEVPEGVSETEGALQISAAPEPTTVPGRTIVAVGSMEEAVILPFRIPPPPLASVDLDEDFIFTEPLPPPLEFANSFDIPDDRAASVPALSDLVKQKKSDTPQSPSLNSSQPTNSADSKKPASLSNCLPASFLPPPESFDAVADSGIEEVDSRSSSDHHLETTSTISTVSSISTLSSEGGENVDTCTVYADGQAFMVDKPPVPPKPKMKPIIHKSNALYQDALVEEDVDSFVIPPPAPPPPPGSAQPGMAKVLQPRTSKLWGDVTEIKSPILSGPKANVISELNSILQQMNREKLAKPGEGLDSPMGAKSASLAPRSPEIMSTISGTRSTTVTFTVRPGTSQPITLQSRPPDYESRTSGTRRAPSPVVSPTEMNKETLPAPLSAATASPSPALSDVFSLPSQPPSGDLFGLNPAGRSRSPSPSILQQPISNKPFTTKPVHLWTKPDVADWLESLNLGEHKEAFMDNEIDGSHLPNLQKEDLIDLGVTRVGHRMNIERALKQLLDR,0,,,,,,"Autism 17:A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate intellectual disability.",Autism 17,P46108(CRK)|P62993(GRB2)|P16333(NCK1)|P27986(PIK3R1)|P19174(PLCG1)|Q8IWW6-4(ARHGAP12)|Q9UQB8-6(BAIAP2)|Q86YM7(HOMER1)|Q08209-2(PPP3CA)|Q96MK2(RIPOR3),,3:Q9UPX8-3:|1:Q9UPX8-1:|2:Q9UPX8-2:|4:Q9UPX8-4:,,,,,,,,,,5.0
Q9UQB3,,Catenin delta-2,CTNND2,Homo sapiens,1225,False,NPRAP,MFARKPPGAAPLGAMPVPDQPSSASEKTSSLSPGLNTSNGDGSETETTSAILASVKEQELQFERLTRELEAERQIVASQLERCKLGSETGSMSSMSSAEEQFQWQSQDGQKDIEDELTTGLELVDSCIRSLQESGILDPQDYSTGERPSLLSQSALQLNSKPEGSFQYPASYHSNQTLALGETTPSQLPARGTQARATGQSFSQGTTSRAGHLAGPEPAPPPPPPPREPFAPSLGSAFHLPDAPPAAAAAALYYSSSTLPAPPRGGSPLAAPQGGSPTKLQRGGSAPEGATYAAPRGSSPKQSPSRLAKSYSTSSPINIVVSSAGLSPIRVTSPPTVQSTISSSPIHQLSSTIGTYATLSPTKRLVHASEQYSKHSQELYATATLQRPGSLAAGSRASYSSQHGHLGPELRALQSPEHHIDPIYEDRVYQKPPMRSLSQSQGDPLPPAHTGTYRTSTAPSSPGVDSVPLQRTGSQHGPQNAAAATFQRASYAAGPASNYADPYRQLQYCPSVESPYSKSGPALPPEGTLARSPSIDSIQKDPREFGWRDPELPEVIQMLQHQFPSVQSNAAAYLQHLCFGDNKIKAEIRRQGGIQLLVDLLDHRMTEVHRSACGALRNLVYGKANDDNKIALKNCGGIPALVRLLRKTTDLEIRELVTGVLWNLSSCDALKMPIIQDALAVLTNAVIIPHSGWENSPLQDDRKIQLHSSQVLRNATGCLRNVSSAGEEARRRMRECDGLTDALLYVIQSALGSSEIDSKTVENCVCILRNLSYRLAAETSQGQHMGTDELDGLLCGEANGKDAESSGCWGKKKKKKKSQDQWDGVGPLPDCAEPPKGIQMLWHPSIVKPYLTLLSECSNPDTLEGAAGALQNLAAGSWKWSVYIRAAVRKEKGLPILVELLRIDNDRVVCAVATALRNMALDVRNKELIGKYAMRDLVHRLPGGNNSNNTASKAMSDDTVTAVCCTLHEVITKNMENAKALRDAGGIEKLVGISKSKGDKHSPKVVKAASQVLNSMWQYRDLRSLYKKDGWSQYHFVASSSTIERDRQRPYSSSRTPSISPVRVSPNNRSASAPASPREMISLKERKTDYECTGSNATYHGAKGEHTSRKDAMTAQNTGISTLYRNSYGAPAEDIKHNQVSAQPVPQEPSRKDYETYQPFQNSTRNYDESFFEDQVHHRPPASEYTMHLGLKSTGNYVDFYSAARPYSELNYETSHYPASPDSWV,0,,,,,,:,,Q12959(DLG1)|Q14160(SCRIB),,1:Q9UQB3-1:|2:Q9UQB3-2:,,,,,,,,,,5.0
O94910,,Adhesion G protein-coupled receptor L1,ADGRL1,Homo sapiens,1474,False,KIAA0821|LEC2|LPHN1,MARLAAVLWNLCVTAVLVTSATQGLSRAGLPFGLMRRELACEGYPIELRCPGSDVIMVENANYGRTDDKICDADPFQMENVQCYLPDAFKIMSQRCNNRTQCVVVAGSDAFPDPCPGTYKYLEVQYDCVPYKVEQKVFVCPGTLQKVLEPTSTHESEHQSGAWCKDPLQAGDRIYVMPWIPYRTDTLTEYASWEDYVAARHTTTYRLPNRVDGTGFVVYDGAVFYNKERTRNIVKYDLRTRIKSGETVINTANYHDTSPYRWGGKTDIDLAVDENGLWVIYATEGNNGRLVVSQLNPYTLRFEGTWETGYDKRSASNAFMVCGVLYVLRSVYVDDDSEAAGNRVDYAFNTNANREEPVSLTFPNPYQFISSVDYNPRDNQLYVWNNYFVVRYSLEFGPPDPSAGPATSPPLSTTTTARPTPLTSTASPAATTPLRRAPLTTHPVGAINQLGPDLPPATAPVPSTRRPPAPNLHVSPELFCEPREVRRVQWPATQQGMLVERPCPKGTRGIASFQCLPALGLWNPRGPDLSNCTSPWVNQVAQKIKSGENAANIASELARHTRGSIYAGDVSSSVKLMEQLLDILDAQLQALRPIERESAGKNYNKMHKRERTCKDYIKAVVETVDNLLRPEALESWKDMNATEQVHTATMLLDVLEEGAFLLADNVREPARFLAAKENVVLEVTVLNTEGQVQELVFPQEEYPRKNSIQLSAKTIKQNSRNGVVKVVFILYNNLGLFLSTENATVKLAGEAGPGGPGGASLVVNSQVIAASINKESSRVFLMDPVIFTVAHLEDKNHFNANCSFWNYSERSMLGYWSTQGCRLVESNKTHTTCACSHLTNFAVLMAHREIYQGRINELLLSVITWVGIVISLVCLAICISTFCFLRGLQTDRNTIHKNLCINLFLAELLFLVGIDKTQYEIACPIFAGLLHYFFLAAFSWLCLEGVHLYLLLVEVFESEYSRTKYYYLGGYCFPALVVGIAAAIDYRSYGTEKACWLRVDNYFIWSFIGPVSFVIVVNLVFLMVTLHKMIRSSSVLKPDSSRLDNIKSWALGAIALLFLLGLTWAFGLLFINKESVVMAYLFTTFNAFQGVFIFVFHCALQKKVHKEYSKCLRHSYCCIRSPPGGTHGSLKTSAMRSNTRYYTGTQSRIRRMWNDTVRKQTESSFMAGDINSTPTLNRGTMGNHLLTNPVLQPRGGTSPYNTLIAESVGFNPSSPPVFNSPGSYREPKHPLGGREACGMDTLPLNGNFNNSYSLRSGDFPPGDGGPEPPRGRNLADAAAFEKMIISELVHNNLRGSSSAAKGPPPPEPPVPPVPGGGGEEEAGGPGGADRAEIELLYKALEEPLLLPRAQSVLYQSDLDESESCTAEDGATSRPLSSPPGRDSLYASGANLRDSPSYPDSSPEGPSEALPPPPPAPPGPPEIYYTSRPPALVARNPLQGYYQVRRPSHEGYLAAPGLEGPGPDGDGQMQLVTSL,0,,,,,,"Developmental delay, behavioral abnormalities, and neuropsychiatric disorders:An autosomal dominant disorder characterized by mild global developmental delay, normal or variably impaired intellectual development, and behavioral or neuropsychiatric disorders, including autism spectrum disorder, attention deficit-hyperactivity disorder, and executive functioning deficits. Additional features may include speech delay, dysmorphic features, hypotonia, sleep disturbances, and seizures.","Developmental delay, behavioral abnormalities, and neuropsychiatric disorders",O00555(CACNA1A),,1:O94910-1:|2:O94910-2:,,,,,,,,,,5.0
O60281,,Zinc finger protein 292,ZNF292,Homo sapiens,2723,False,KIAA0530,MADEEAEQERLSCGEGGCVAELQRLGERLQELELQLRESRVPAVEAATDYCQQLCQTLLEYAEKWKTSEDPLPLLEVYTVAIQSYVKARPYLTSECENVALVLERLALSCVELLLCLPVELSDKQWEQFQTLVQVAHEKLMENGSCELHFLATLAQETGVWKNPVLCTILSQEPLDKDKVNEFLAFEGPILLDMRIKHLIKTNQLSQATALAKLCSDHPEIGIKGSFKQTYLVCLCTSSPNGKLIEEISEVDCKDALEMICNLESEGDEKSALVLCTAFLSRQLQQGDMYCAWELTLFWSKLQQRVEPSIQVYLERCRQLSLLTKTVYHIFFLIKVINSETEGAGLATCIELCVKALRLESTENTEVKISICKTISCLLPDDLEVKRACQLSEFLIEPTVDAYYAVEMLYNQPDQKYDEENLPIPNSLRCELLLVLKTQWPFDPEFWDWKTLKRQCLALMGEEASIVSSIDELNDSEVYEKVVDYQEESKETSMNGLSGGVGANSGLLKDIGDEKQKKREIKQLRERGFISARFRNWQAYMQYCVLCDKEFLGHRIVRHAQKHYKDGIYSCPICAKNFNSKETFVPHVTLHVKQSSKERLAAMKPLRRLGRPPKITTTNENQKTNTVAKQEQRPIKKNSLYSTDFIVFNDNDGSDDENDDKDKSYEPEVIPVQKPVPVNEFNCPVTFCKKGFKYFKNLIAHVKGHKDNEDAKRFLEMQSKKVICQYCRRHFVSVTHLNDHLQMHCGSKPYICIQMKCKAGFNSYAELLTHRKEHQVFRAKCMFPKCGRIFSEAYLLYDHEAQHYNTYTCKFTGCGKVYRSQGELEKHLDDHSTPPEKVLPPEAQLNSSGDSIQPSEVNQNTAENIEKERSMLPSENNIENSLLADRSDAWDKSKAESAVTKQDQISASELRQANGPLSNGLENPATTPLLQSSEVAVSIKVSLNQGIEDNFGKQENSTVEGSGEALVTDLHTPVEDTCNDLCHPGFQERKEQDCFNDAHVTQNSLVNSETLKIGDLTPQNLERQVNNLMTFSVQNQAAFQNNLPTSKFECGDNVKTSSNLYNLPLKTLESIAFVPPQSDLSNSLGTPSVPPKAPVQKFSCQVEGCTRTYNSSQSIGKHMKTAHPDQYAAFKMQRKSKKGQKANNLNTPNNGKFVYFLPSPVNSSNPFFTSQTKANGNPACSAQLQHVSPPIFPAHLASVSTPLLSSMESVINPNITSQDKNEQGGMLCSQMENLPSTALPAQMEDLTKTVLPLNIDSGSDPFLPLPAESSSMSLFPSPADSGTNSVFSQLENNTNHYSSQIEGNTNSSFLKGGNGENAVFPSQVNVANNFSSTNAQQSAPEKVKKDRGRGPNGKERKPKHNKRAKWPAIIRDGKFICSRCYRAFTNPRSLGGHLSKRSYCKPLDGAEIAQELLQSNGQPSLLASMILSTNAVNLQQPQQSTFNPEACFKDPSFLQLLAENRSPAFLPNTFPRSGVTNFNTSVSQEGSEIIKQALETAGIPSTFEGAEMLSHVSTGCVSDASQVNATVMPNPTVPPLLHTVCHPNTLLTNQNRTSNSKTSSIEECSSLPVFPTNDLLLKTVENGLCSSSFPNSGGPSQNFTSNSSRVSVISGPQNTRSSHLNKKGNSASKRRKKVAPPLIAPNASQNLVTSDLTTMGLIAKSVEIPTTNLHSNVIPTCEPQSLVENLTQKLNNVNNQLFMTDVKENFKTSLESHTVLAPLTLKTENGDSQMMALNSCTTSINSDLQISEDNVIQNFEKTLEIIKTAMNSQILEVKSGSQGAGETSQNAQINYNIQLPSVNTVQNNKLPDSSPFSSFISVMPTKSNIPQSEVSHKEDQIQEILEGLQKLKLENDLSTPASQCVLINTSVTLTPTPVKSTADITVIQPVSEMINIQFNDKVNKPFVCQNQGCNYSAMTKDALFKHYGKIHQYTPEMILEIKKNQLKFAPFKCVVPTCTKTFTRNSNLRAHCQLVHHFTTEEMVKLKIKRPYGRKSQSENVPASRSTQVKKQLAMTEENKKESQPALELRAETQNTHSNVAVIPEKQLVEKKSPDKTESSLQVITVTSEQCNTNALTNTQTKGRKIRRHKKEKEEKKRKKPVSQSLEFPTRYSPYRPYRCVHQGCFAAFTIQQNLILHYQAVHKSDLPAFSAEVEEESEAGKESEETETKQTLKEFRCQVSDCSRIFQAITGLIQHYMKLHEMTPEEIESMTASVDVGKFPCDQLECKSSFTTYLNYVVHLEADHGIGLRASKTEEDGVYKCDCEGCDRIYATRSNLLRHIFNKHNDKHKAHLIRPRRLTPGQENMSSKANQEKSKSKHRGTKHSRCGKEGIKMPKTKRKKKNNLENKNAKIVQIEENKPYSLKRGKHVYSIKARNDALSECTSRFVTQYPCMIKGCTSVVTSESNIIRHYKCHKLSKAFTSQHRNLLIVFKRCCNSQVKETSEQEGAKNDVKDSDTCVSESNDNSRTTATVSQKEVEKNEKDEMDELTELFITKLINEDSTSVETQANTSSNVSNDFQEDNLCQSERQKASNLKRVNKEKNVSQNKKRKVEKAEPASAAELSSVRKEEETAVAIQTIEEHPASFDWSSFKPMGFEVSFLKFLEESAVKQKKNTDKDHPNTGNKKGSHSNSRKNIDKTAVTSGNHVCPCKESETFVQFANPSQLQCSDNVKIVLDKNLKDCTELVLKQLQEMKPTVSLKKLEVHSNDPDMSVMKDISIGKATGRGQY,0,,,,,,"Intellectual developmental disorder, autosomal dominant 64:An autosomal dominant form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD64 is characterized by mildly to severely impaired intellectual development, speech delay, and autism spectrum disorder in most patients. Additional variable features may include motor delay, attention deficit-hyperactivity disorder, and non-specific dysmorphic features.","Intellectual developmental disorder, autosomal dominant 64",,,1:O60281-1:|2:O60281-2:,,,,,,,,,,5.0
P42262,,Glutamate receptor 2,GRIA2,Homo sapiens,883,False,GluA2|GLUR2,MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLFPRGADQEYSAFRVGMVQFSTSEFRLTPHIDNLEVANSFAVTNAFCSQFSRGVYAIFGFYDKKSVNTITSFCGTLHVSFITPSFPTDGTHPFVIQMRPDLKGALLSLIEYYQWDKFAYLYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLELKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYIIANLGFTDGDLLKIQFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTTIKYTSALTYDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVEIERALKQVQVEGLSGNIKFDQNGKRINYTINIMELKTNGPRKIGYWSEVDKMVVTLTELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIWMCIVFAYIGVSVVLFLVSRFSPYEWHTEEFEDGRETQSSESTNEFGIFNSLWFSLGAFMQQGCDISPRSLSGRIVGGVWWFFTLIIISSYTANLAAFLTVERMVSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLRNAVNLAVLKLNEQGLLDKLKNKWWYDKGECGSGGGDSKEKTSALSLSNVAGVFYILVGGLGLAMLVALIEFCYKSRAEAKRMKVAKNAQNINPSSSQNSQNFATYKEGYNVYGIESVKI,0,,,,,,"Neurodevelopmental disorder with language impairment and behavioral abnormalities:A neurodevelopmental disorder characterized by global developmental delay, impaired intellectual development, poor or absent speech, and behavioral abnormalities, such as autism spectrum disorder, repetitive behaviors, and hyperactivity. Some patients develop seizures and manifest developmental regression.",Neurodevelopmental disorder with language impairment and behavioral abnormalities,P46459(NSF)|Q9EP80(Pick1),,Flop:P42262-1:|Flip:P42262-2:|3:P42262-3:|4:P42262-4:,,,,,,,,,,5.0
Q53R12,,Transmembrane 4 L6 family member 20,TM4SF20,Homo sapiens,229,False,,MTCCEGWTSCNGFSLLVLLLLGVVLNAIPLIVSLVEEDQFSQNPISCFEWWFPGIIGAGLMAIPATTMSLTARKRACCNNRTGMFLSSLFSVITVIGALYCMLISIQALLKGPLMCNSPSNSNANCEFSLKNISDIHPESFNLQWFFNDSCAPPTGFNKPTSNDTMASGWRASSFHFDSEENKHRLIHFSVFLGLLLVGILEVLFGLSQIVIGFLGCLCGVSKRRSQIV,0,,,,,,"Specific language impairment 5:A disorder characterized by a delay in early speech acquisition. It is usually associated with cerebral white matter abnormalities on brain MRI. Some individuals may show disorders in communication, consistent with autism spectrum disorder, or global developmental delay, although others ultimately show normal cognitive function. Penetrance is incomplete and expressivity is variable.",Specific language impairment 5,Q9NZG7(NINJ2)|Q15836(VAMP3),,,,,,,,,,,,5.0
P19622,,Homeobox protein engrailed-2,EN2,Homo sapiens,333,False,,MEENDPKPGEAAAAVEGQRQPESSPGGGSGGGGGSSPGEADTGRRRALMLPAVLQAPGNHQHPHRITNFFIDNILRPEFGRRKDAGTCCAGAGGGRGGGAGGEGGASGAEGGGGAGGSEQLLGSGSREPRQNPPCAPGAGGPLPAAGSDSPGDGEGGSKTLSLHGGAKKGGDPGGPLDGSLKARGLGGGDLSVSSDSDSSQAGANLGAQPMLWPAWVYCTRYSDRPSSGPRSRKPKKKNPNKEDKRPRTAFTAEQLQRLKAEFQTNRYLTEQRRQSLAQELSLNESQIKIWFQNKRAKIKKATGNKNTLAVHLMAQGLYNHSTTAKEGKSDSE,0,,,,,,:,,,,,,,,,,,,,,5.0
P09104,,Gamma-enolase,ENO2,Homo sapiens,434,False,,MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVL,0,,,,,,,,P06733(ENO1)|Q9BSI4(TINF2),,1:P09104-1:|2:P09104-2:,,,,,,,,,,5.0
Q8IYJ0,,PILR alpha-associated neural protein,PIANP,Homo sapiens,282,False,C12orf53|PANP,MESRMWPALLLSHLLPLWPLLLLPLPPPAQGSSSSPRTPPAPARPPCARGGPSAPRHVCVWERAPPPSRSPRVPRSRRQVLPGTAPPATPSGFEEGPPSSQYPWAIVWGPTVSREDGGDPNSANPGFLDYGFAAPHGLATPHPNSDSMRGDGDGLILGEAPATLRPFLFGGRGEGVDPQLYVTITISIIIVLVATGIIFKFCWDRSQKRRRPSGQQGALRQEESQQPLTDLSPAGVTVLGAFGDSPTPTPDHEEPRGGPRPGMPHPKGAPAFQLNRIPLVNL,0,,,,,,,,Q96FZ5(CMTM7)|Q9H1M4(DEFB127)|P55061(TMBIM6)|Q9UHD9(UBQLN2),,1:Q8IYJ0-1:|2:Q8IYJ0-2:,,,,,,,,,,5.0
Q9NYX4,,Neuron-specific vesicular protein calcyon,CALY,Homo sapiens,217,False,DRD1IP,MVKLGCSFSGKPGKDPGDQDGAAMDSVPLISPLDISQLQPPLPDQVVIKTQTEYQLSSPDQQNFPDLEGQRLNCSHPEEGRRLPTARMIAFAMALLGCVLIMYKAIWYDQFTCPDGFLLRHKICTPLTLEMYYTEMDPERHRSILAAIGAYPLSRKHGTETPAAWGDGYRAAKEERKGPTQAGAAAAATEPPGKPSAKAEKEAARKAAGSAAPPPAQ,0,,,,,,,,P09496(CLTA),,1:Q9NYX4-1:|2:Q9NYX4-2:|3:Q9NYX4-3:,,,,,,,,,,5.0
O00533,,Neural cell adhesion molecule L1-like protein,CHL1,Homo sapiens,1208,False,CALL,MEPLLLGRGLIVYLMFLLLKFSKAIEIPSSVQQVPTIIKQSKVQVAFPFDEYFQIECEAKGNPEPTFSWTKDGNPFYFTDHRIIPSNNSGTFRIPNEGHISHFQGKYRCFASNKLGIAMSEEIEFIVPSVPKFPKEKIDPLEVEEGDPIVLPCNPPKGLPPLHIYWMNIELEHIEQDERVYMSQKGDLYFANVEEKDSRNDYCCFAAFPRLRTIVQKMPMKLTVNSSNSIKQRKPKLLLPPTESGSESSITILKGEILLLECFAEGLPTPQVDWNKIGGDLPKGRETKENYGKTLKIENVSYQDKGNYRCTASNFLGTATHDFHVIVEEPPRWTKKPQSAVYSTGSNGILLCEAEGEPQPTIKWRVNGSPVDNHPFAGDVVFPREISFTNLQPNHTAVYQCEASNVHGTILANANIDVVDVRPLIQTKDGENYATVVGYSAFLHCEFFASPEAVVSWQKVEEVKPLEGRRYHIYENGTLQINRTTEEDAGSYSCWVENAIGKTAVTANLDIRNATKLRVSPKNPRIPKLHMLELHCESKCDSHLKHSLKLSWSKDGEAFEINGTEDGRIIIDGANLTISNVTLEDQGIYCCSAHTALDSAADITQVTVLDVPDPPENLHLSERQNRSVRLTWEAGADHNSNISEYIVEFEGNKEEPGRWEELTRVQGKKTTVILPLAPFVRYQFRVIAVNEVGRSQPSQPSDHHETPPAAPDRNPQNIRVQASQPKEMIIKWEPLKSMEQNGPGLEYRVTWKPQGAPVEWEEETVTNHTLRVMTPAVYAPYDVKVQAINQLGSGPDPQSVTLYSGEDYPDTAPVIHGVDVINSTLVKVTWSTVPKDRVHGRLKGYQINWWKTKSLLDGRTHPKEVNILRFSGQRNSGMVPSLDAFSEFHLTVLAYNSKGAGPESEPYIFQTPEGVPEQPTFLKVIKVDKDTATLSWGLPKKLNGNLTGYLLQYQIINDTYEIGELNDINITTPSKPSWHLSNLNATTKYKFYLRACTSQGCGKPITEESSTLGEGSKGIGKISGVNLTQKTHPIEVFEPGAEHIVRLMTKNWGDNDSIFQDVIETRGREYAGLYDDISTQGWFIGLMCAIALLTLLLLTVCFVKRNRGGKYSVKEKEDLHPDPEIQSVKDETFGEYSDSDEKPLKGSLRSLNRDMQPTESADSLVEYGEGDHGLFSEDGSFIGAYAGSKEKGSVESNGSSTATFPLRA,0,,,,,,,,,,1:O00533-1:|2:O00533-2:,,,,,,,,,,5.0
Q16623,,Syntaxin-1A,STX1A,Homo sapiens,288,False,STX1,MKDRTQELRTAKDSDDDDDVAVTVDRDRFMDEFFEQVEEIRGFIDKIAENVEEVKRKHSAILASPNPDEKTKEELEELMSDIKKTANKVRSKLKSIEQSIEQEEGLNRSSADLRIRKTQHSTLSRKFVEVMSEYNATQSDYRERCKGRIQRQLEITGRTTTSEELEDMLESGNPAIFASGIIMDSSISKQALSEIETRHSEIIKLENSIRELHDMFMDMAMLVESQGEMIDRIEYNVEHAVDYVERAVSDTKKAVKYQSKARRKKIMIIICCVILGIVIASTVGGIFA,0,,,,,,:,,Q4LEZ3(AARD)|Q9P2A4(ABI3)|Q6RW13-2(AGTRAP)|Q9NVV5-2(AIG1)|Q86W74-2(ANKRD46)|Q16853(AOC3)|Q9BQE5(APOL2)|O95236-2(APOL3)|Q92482(AQP3)|Q3SXY8(ARL13B)|O15155(BET1)|Q9UL45(BLOC1S6)|Q12981(BNIP1)|Q8WVV5(BTN2A2)|Q8WVX3-2(C4orf3)|P60033(CD81)|Q16543(CDC37)|Q8NC01(CLEC1A)|Q9NWW5(CLN6)|Q96FZ5(CMTM7)|O43169(CYB5B)|Q9Y6V7(DDX49)|O00559(EBAG9)|P50402(EMD)|Q9UKR5(ERG28)|Q9NVF9(ETNK2)|Q92520(FAM3C)|Q8WWP7(GIMAP1)|Q96F15(GIMAP5)|O14653(GOSR2)|Q13491-3(GPM6B)|P09601(HMOX1)|Q8N5M9(JAGN1)|Q9BVG8-5(KIFC3)|P21145(MAL)|Q13021(MALL)|P30301(MIP)|Q8N4V1(MMGT1)|Q9H115(NAPB)|Q9NZG7(NINJ2)|Q16617(NKG7)|Q8IXM6(NRM)|Q9UHJ9-5(PGAP2)|P26678(PLN)|P60201-2(PLP1)|Q5VZY2(PLPP4)|Q8IY26(PLPP6)|P54315(PNLIPRP1)|Q8TBN0(RAB3IL1)|Q96LZ7(RMDN2)|P78317(RNF4)|Q5QGT7(RTP2)|Q96IW7(SEC22A)|O75396(SEC22B)|Q9Y6X1(SERP1)|Q8N6R1(SERP2)|B2RUZ4(SMIM1)|Q9BZL3(SMIM3)|P60880(SNAP25)|P60880-2(SNAP25)|Q5SQN1(SNAP47)|P37840(SNCA)|Q6UX34(SNORC)|P0DN84(STRIT1)|O60499-2(STX10)|O75558(STX11)|Q86Y82(STX12)|O14662-5(STX16)|Q16623(STX1A)|P32856-2(STX2)|Q13277(STX3)|Q12846(STX4)|Q13190(STX5)|O43752(STX6)|O15400(STX7)|Q9UNK0(STX8)|Q8N8B7-2(TCEANC)|Q9NV29(TMEM100)|Q9BXJ8(TMEM120A)|Q5BJH2-2(TMEM128)|Q9P0S9(TMEM14C)|Q8N511(TMEM199)|Q9H0R3(TMEM222)|Q8TBM7(TMEM254)|Q96HV5(TMEM41A)|Q9H2L4(TMEM60)|P01375(TNF)|Q9Y228(TRAF3IP3)|Q3SY00(TSGA10IP)|A0AVG3(TSNARE1)|P40222(TXLNA)|Q7KZS0(UBE2I)|P0CB47(UBTFL1)|O75841(UPK1B)|Q9NZ43(USE1)|P23763-3(VAMP1)|P63027(VAMP2)|Q15836(VAMP3)|O75379(VAMP4)|O95183(VAMP5)|Q8IW00(VSTM4)|Q9UEU0(VTI1B)|O95159(ZFPL1)|P17014(ZNF12)|P52737(ZNF136)|P15622-3(ZNF250)|Q8IYI8(ZNF440)|Q8N8Z8(ZNF441)|Q96JC4(ZNF479)|Q9ULM2(ZNF490)|Q8N988-2(ZNF557)|Q9H7X3(ZNF696)|Q96C28(ZNF707)|A8K8V0(ZNF785)|Q9Y2P0(ZNF835),,1:Q16623-1:|2:Q16623-2:|3:Q16623-3:,,,,,,,,,,5.0
P42857,,Neuronal vesicle trafficking-associated protein 1,NSG1,Homo sapiens,185,False,D4S234|NEEP21,MVKLGNNFAEKGTKQPLLEDGFDTIPLMTPLDVNQLQFPPPDKVVVKTKTEYEPDRKKGKARPPQIAEFTVSITEGVTERFKVSVLVLFALAFLTCVVFLVVYKVYKYDRACPDGFVLKNTQCIPEGLESYYAEQDSSAREKFYTVINHYNLAKQSITRSVSPWMSVLSEEKLSEQETEAAEKSA,0,,,,,,,,O75787(ATP6AP2)|J3KQ12(BSCL2)|Q96G97-4(BSCL2)|Q7KYR7-4(BTN2A1)|Q13936(CACNA1C)|Q8N5K1(CISD2)|Q96BA8(CREB3L1)|P00387(CYB5R3)|Q9Y282(ERGIC3)|P34910-2(EVI2B)|P12318-2(FCGR2A)|O15552(FFAR2)|Q96LL3(FIMP)|Q8TBE3(FNDC9)|Q99795(GPA33)|O15529(GPR42)|Q8N6L0(KASH5)|P43628(KIR2DL3)|O14880(MGST3)|P35372-10(OPRM1)|Q13113(PDZK1IP1)|O43688(PLPP2)|Q8NC24(RELL2)|O14863(SLC30A4)|Q8TBB6(SLC7A14)|Q9HBV2(SPACA1)|Q96CE8(TM4SF18)|Q8IV31(TMEM139)|Q6UWW9(TMEM207)|Q96B21(TMEM45B)|Q4KMG9(TMEM52B)|Q9Y320(TMX2),,1:P42857-1:|2:P42857-2:,,,,,,,,,,5.0
O15394,,Neural cell adhesion molecule 2,NCAM2,Homo sapiens,837,False,NCAM21,MSLLLSFYLLGLLVSSGQALLQVTISLSKVELSVGESKFFTCTAIGEPESIDWYNPQGEKIISTQRVVVQKEGVRSRLTIYNANIEDAGIYRCQATDAKGQTQEATVVLEIYQKLTFREVVSPQEFKQGEDAEVVCRVSSSPAPAVSWLYHNEEVTTISDNRFAMLANNNLQILNINKSDEGIYRCEGRVEARGEIDFRDIIVIVNVPPAISMPQKSFNATAERGEEMTFSCRASGSPEPAISWFRNGKLIEENEKYILKGSNTELTVRNIINSDGGPYVCRATNKAGEDEKQAFLQVFVQPHIIQLKNETTYENGQVTLVCDAEGEPIPEITWKRAVDGFTFTEGDKSLDGRIEVKGQHGSSSLHIKDVKLSDSGRYDCEAASRIGGHQKSMYLDIEYAPKFISNQTIYYSWEGNPINISCDVKSNPPASIHWRRDKLVLPAKNTTNLKTYSTGRKMILEIAPTSDNDFGRYNCTATNHIGTRFQEYILALADVPSSPYGVKIIELSQTTAKVSFNKPDSHGGVPIHHYQVDVKEVASEIWKIVRSHGVQTMVVLNNLEPNTTYEIRVAAVNGKGQGDYSKIEIFQTLPVREPSPPSIHGQPSSGKSFKLSITKQDDGGAPILEYIVKYRSKDKEDQWLEKKVQGNKDHIILEHLQWTMGYEVQITAANRLGYSEPTVYEFSMPPKPNIIKDTLFNGLGLGAVIGLGVAALLLILVVTDVSCFFIRQCGLLMCITRRMCGKKSGSSGKSKELEEGKAAYLKDGSKEPIVEMRTEDERVTNHEDGSPVNEPNETTPLTEPEKLPLKEEDGKEALNPETIEIKVSNDIIQSKEDDSKA,0,,,,,,,,O15394(NCAM2),,1:O15394-1:|2:O15394-2:,,,,,,,,,,5.0
Q12860,,Contactin-1,CNTN1,Homo sapiens,1018,False,,MKMWLLVSHLVIISITTCLAEFTWYRRYGHGVSEEDKGFGPIFEEQPINTIYPEESLEGKVSLNCRARASPFPVYKWRMNNGDVDLTSDRYSMVGGNLVINNPDKQKDAGIYYCLASNNYGMVRSTEATLSFGYLDPFPPEERPEVRVKEGKGMVLLCDPPYHFPDDLSYRWLLNEFPVFITMDKRRFVSQTNGNLYIANVEASDKGNYSCFVSSPSITKSVFSKFIPLIPIPERTTKPYPADIVVQFKDVYALMGQNVTLECFALGNPVPDIRWRKVLEPMPSTAEISTSGAVLKIFNIQLEDEGIYECEAENIRGKDKHQARIYVQAFPEWVEHINDTEVDIGSDLYWPCVATGKPIPTIRWLKNGYAYHKGELRLYDVTFENAGMYQCIAENTYGAIYANAELKILALAPTFEMNPMKKKILAAKGGRVIIECKPKAAPKPKFSWSKGTEWLVNSSRILIWEDGSLEINNITRNDGGIYTCFAENNRGKANSTGTLVITDPTRIILAPINADITVGENATMQCAASFDPALDLTFVWSFNGYVIDFNKENIHYQRNFMLDSNGELLIRNAQLKHAGRYTCTAQTIVDNSSASADLVVRGPPGPPGGLRIEDIRATSVALTWSRGSDNHSPISKYTIQTKTILSDDWKDAKTDPPIIEGNMEAARAVDLIPWMEYEFRVVATNTLGRGEPSIPSNRIKTDGAAPNVAPSDVGGGGGRNRELTITWAPLSREYHYGNNFGYIVAFKPFDGEEWKKVTVTNPDTGRYVHKDETMSPSTAFQVKVKAFNNKGDGPYSLVAVINSAQDAPSEAPTEVGVKVLSSSEISVHWEHVLEKIVESYQIRYWAAHDKEEAANRVQVTSQEYSARLENLLPDTQYFIEVGACNSAGCGPPSDMIEAFTKKAPPSQPPRIISSVRSGSRYIITWDHVVALSNESTVTGYKVLYRPDGQHDGKLYSTHKHSIEVPIPRDGEYVVEVRAHSDGGDGVVSQVKISGAPTLSPSLLGLLLPAFGILVYLEF,0,,,,,,"Congenital myopathy 12:A lethal, autosomal recessive, congenital myopathy characterized by fetal akinesia, neonatal hypotonia, severe muscle weakness, loss of beta2-syntrophin and alpha-dystrobrevin from the muscle sarcolemma and disruption of sarcomeres with disorganization of the Z band.",Congenital myopathy 12,Q9UHC6(CNTNAP2)|P23471(PTPRZ1),,1:Q12860-1:|2:Q12860-2:|3:Q12860-3:,,,,,,,,,,5.0
Q8TB73,,Protein NDNF,NDNF,Homo sapiens,568,False,C4orf31,MVLLHWCLLWLLFPLSSRTQKLPTRDEELFQMQIRDKAFFHDSSVIPDGAEISSYLFRDTPKRYFFVVEEDNTPLSVTVTPCDAPLEWKLSLQELPEDRSGEGSGDLEPLEQQKQQIINEEGTELFSYKGNDVEYFISSSSPSGLYQLDLLSTEKDTHFKVYATTTPESDQPYPELPYDPRVDVTSLGRTTVTLAWKPSPTASLLKQPIQYCVVINKEHNFKSLCAVEAKLSADDAFMMAPKPGLDFSPFDFAHFGFPSDNSGKERSFQAKPSPKLGRHVYSRPKVDIQKICIGNKNIFTVSDLKPDTQYYFDVFVVNINSNMSTAYVGTFARTKEEAKQKTVELKDGKITDVFVKRKGAKFLRFAPVSSHQKVTFFIHSCLDAVQIQVRRDGKLLLSQNVEGIQQFQLRGKPKAKYLVRLKGNKKGASMLKILATTRPTKQSFPSLPEDTRIKAFDKLRTCSSATVAWLGTQERNKFCIYKKEVDDNYNEDQKKREQNQCLGPDIRKKSEKVLCKYFHSQNLQKAVTTETIKGLQPGKSYLLDVYVIGHGGHSVKYQSKVVKTRKFC,0,,,,,,"Hypogonadotropic hypogonadism 25 with anosmia:A form of hypogonadotropic hypogonadism, a group of disorders characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone, and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). HH25 is an autosomal dominant form with anosmia, characterized by intrafamilial variable expressivity and incomplete penetrance.",Hypogonadotropic hypogonadism 25 with anosmia,,,,,,,,,,,,,5.0
Q9NQX5,,Neural proliferation differentiation and control protein 1,NPDC1,Homo sapiens,325,False,,MATPLPPPSPRHLRLLRLLLSGLVLGAALRGAAAGHPDVAACPGSLDCALKRRARCPPGAHACGPCLQPFQEDQQGLCVPRMRRPPGGGRPQPRLEDEIDFLAQELARKESGHSTPPLPKDRQRLPEPATLGFSARGQGLELGLPSTPGTPTPTPHTSLGSPVSSDPVHMSPLEPRGGQGDGLALVLILAFCVAGAAALSVASLCWCRLQREIRLTQKADYATAKAPGSPAAPRISPGDQRLAQSAEMYHYQHQRQQMLCLERHKEPPKELDTASSDEENEDGDFTVYECPGLAPTGEMEVRNPLFDHAALSAPLPAPSSPPALP,0,,,,,,,,A8MQ03(CYSRT1)|P50402(EMD)|Q5TD97(FHL5)|P61978-2(HNRNPK)|Q5VWX1(KHDRBS2)|Q07627(KRTAP1-1)|Q8IUG1(KRTAP1-3)|P60370(KRTAP10-5)|P60371(KRTAP10-6)|P60409(KRTAP10-7)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|P59991(KRTAP12-2)|P60328(KRTAP12-3)|Q9BYR9(KRTAP2-4)|Q9BYQ7(KRTAP4-1)|Q9BYR3(KRTAP4-4)|P26371(KRTAP5-9)|Q9BYQ3(KRTAP9-3)|P21145(MAL)|Q99750(MDFI)|Q5J8X5(MS4A13)|Q7Z3S9(NOTCH2NLA)|P0DPK4(NOTCH2NLC)|Q9UKJ1(PILRA)|Q15415(RBMY1J)|Q5BVD1(TTMP),,,,,,,,,,,,5.0
P54845,,Neural retina-specific leucine zipper protein,NRL,Homo sapiens,237,False,D14S46E,MALPPSPLAMEYVNDFDLMKFEVKREPSEGRPGPPTASLGSTPYSSVPPSPTFSEPGMVGATEGTRPGLEELYWLATLQQQLGAGEALGLSPEEAMELLQGQGPVPVDGPHGYYPGSPEETGAQHVQLAERFSDAALVSMSVRELNRQLRGCGRDEALRLKQRRRTLKNRGYAQACRSKRLQQRRGLEAERARLAAQLDALRAEVARLARERDLYKARCDRLTSSGPGSGDPSHLFL,0,,,,,,"Retinitis pigmentosa 27:A retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.|Retinal degeneration autosomal recessive clumped pigment type:A retinopathy characterized by night blindness since early childhood, consistent with a severe reduction in rod function. Color vision is normal although there is a relatively enhanced function of short-wavelength-sensitive cones in the macula. Signs of retinal degeneration and clusters of clumped pigment deposits in the peripheral fundus at the level of the retinal pigment epithelium are present.",Retinitis pigmentosa 27|Retinal degeneration autosomal recessive clumped pigment type,Q9XSK0(CRX)|Q96CV9(OPTN),,1:P54845-1:|2:P54845-2:,,,,,,,,,,5.0
Q9NZV1,,Cysteine-rich motor neuron 1 protein,CRIM1,Homo sapiens,1036,False,S52,MYLVAGDRGLAGCGHLLVSLLGLLLLLARSGTRALVCLPCDESKCEEPRNCPGSIVQGVCGCCYTCASQRNESCGGTFGIYGTCDRGLRCVIRPPLNGDSLTEYEAGVCEDENWTDDQLLGFKPCNENLIAGCNIINGKCECNTIRTCSNPFEFPSQDMCLSALKRIEEEKPDCSKARCEVQFSPRCPEDSVLIEGYAPPGECCPLPSRCVCNPAGCLRKVCQPGNLNILVSKASGKPGECCDLYECKPVFGVDCRTVECPPVQQTACPPDSYETQVRLTADGCCTLPTRCECLSGLCGFPVCEVGSTPRIVSRGDGTPGKCCDVFECVNDTKPACVFNNVEYYDGDMFRMDNCRFCRCQGGVAICFTAQCGEINCERYYVPEGECCPVCEDPVYPFNNPAGCYANGLILAHGDRWREDDCTFCQCVNGERHCVATVCGQTCTNPVKVPGECCPVCEEPTIITVDPPACGELSNCTLTGKDCINGFKRDHNGCRTCQCINTEELCSERKQGCTLNCPFGFLTDAQNCEICECRPRPKKCRPIICDKYCPLGLLKNKHGCDICRCKKCPELSCSKICPLGFQQDSHGCLICKCREASASAGPPILSGTCLTVDGHHHKNEESWHDGCRECYCLNGREMCALITCPVPACGNPTIHPGQCCPSCADDFVVQKPELSTPSICHAPGGEYFVEGETWNIDSCTQCTCHSGRVLCETEVCPPLLCQNPSRTQDSCCPQCTDQPFRPSLSRNNSVPNYCKNDEGDIFLAAESWKPDVCTSCICIDSVISCFSESCPSVSCERPVLRKGQCCPYCIEDTIPKKVVCHFSGKAYADEERWDLDSCTHCYCLQGQTLCSTVSCPPLPCVEPINVEGSCCPMCPEMYVPEPTNIPIEKTNHRGEVDLEVPLWPTPSENDIVHLPRDMGHLQVDYRDNRLHPSEDSSLDSIASVVVPIIICLSIIIAFLFINQKKQWIPLLCWYRTPTKPSSLNNQLVSVDCKKGTRVQVDSSQRMLRIAEPDARFSGFYSMQKQNHLQADNFYQTV,0,,,,,,,,,,,,,,,,,,,,5.0
P19022,,Cadherin-2,CDH2,Homo sapiens,906,False,CDHN|NCAD,MCRIAGALRTLLPLLAALLQASVEASGEIALCKTGFPEDVYSAVLSKDVHEGQPLLNVKFSNCNGKRKVQYESSEPADFKVDEDGMVYAVRSFPLSSEHAKFLIYAQDKETQEKWQVAVKLSLKPTLTEESVKESAEVEEIVFPRQFSKHSGHLQRQKRDWVIPPINLPENSRGPFPQELVRIRSDRDKNLSLRYSVTGPGADQPPTGIFIINPISGQLSVTKPLDREQIARFHLRAHAVDINGNQVENPIDIVINVIDMNDNRPEFLHQVWNGTVPEGSKPGTYVMTVTAIDADDPNALNGMLRYRIVSQAPSTPSPNMFTINNETGDIITVAAGLDREKVQQYTLIIQATDMEGNPTYGLSNTATAVITVTDVNDNPPEFTAMTFYGEVPENRVDIIVANLTVTDKDQPHTPAWNAVYRISGGDPTGRFAIQTDPNSNDGLVTVVKPIDFETNRMFVLTVAAENQVPLAKGIQHPPQSTATVSVTVIDVNENPYFAPNPKIIRQEEGLHAGTMLTTFTAQDPDRYMQQNIRYTKLSDPANWLKIDPVNGQITTIAVLDRESPNVKNNIYNATFLASDNGIPPMSGTGTLQIYLLDINDNAPQVLPQEAETCETPDPNSINITALDYDIDPNAGPFAFDLPLSPVTIKRNWTITRLNGDFAQLNLKIKFLEAGIYEVPIIITDSGNPPKSNISILRVKVCQCDSNGDCTDVDRIVGAGLGTGAIIAILLCIIILLILVLMFVVWMKRRDKERQAKQLLIDPEDDVRDNILKYDEEGGGEEDQDYDLSQLQQPDTVEPDAIKPVGIRRMDERPIHAEPQYPVRSAAPHPGDIGDFINEGLKAADNDPTAPPYDSLLVFDYEGSGSTAGSLSSLNSSSSGGEQDYDYLNDWGPRFKKLADMYGGGDD,0,,,,,,"Arrhythmogenic right ventricular dysplasia, familial, 14:A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.|Agenesis of corpus callosum, cardiac, ocular, and genital syndrome:An autosomal dominant, syndromic neurodevelopmental disorder characterized by global developmental delay and/or intellectual disability, corpus callosum agenesis or hypoplasia, mirror movements, dysmorphic features, and ocular, cardiac, and genital anomalies.|Attention deficit-hyperactivity disorder 8:A form of attention deficit-hyperactivity disorder, a neurobehavioral developmental condition primarily characterized by the coexistence of attentional problems and hyperactivity, with each feature occurring infrequently alone. ADHD8 is an autosomal recessive form with onset in early childhood, usually by age 3 years. ADHD8 patients may manifest mild developmental delay with autism.","Arrhythmogenic right ventricular dysplasia, familial, 14|Agenesis of corpus callosum, cardiac, ocular, and genital syndrome|Attention deficit-hyperactivity disorder 8",P35222(CTNNB1)|O60716(CTNND1)|P14923(JUP),,1:P19022-1:|2:P19022-2:,,,,,,,,,,5.0
Q9UQ52,,Contactin-6,CNTN6,Homo sapiens,1028,False,,MRLLWKLVILLPLINSSAGDGLLSRPIFTQEPHDVIFPLDLSKSEVILNCAANGYPSPHYRWKQNGTDIDFTMSYHYRLDGGSLAINSPHTDQDIGMYQCLATNLLGTILSRKAKLQFAYIEDFETKTRSTVSVREGQGVVLLCGPPPHFGDLSYAWTFNDNPLYVQEDNRRFVSQETGNLYIAKVEPSDVGNYTCFITNKEAQRSVQGPPTPLVQRTDGVMGEYEPKIEVRFPETIQAAKDSSVKLECFALGNPVPDISWRRLDGSPLPGKVKYSKSQAILEIPNFQQEDEGFYECIASNLRGRNLAKGQLIFYAPPEWEQKIQNTHLSIYDNLLWECKASGKPNPWYTWLKNGERLNPEERIQIENGTLIITMLNVSDSGVYQCAAENKYQIIYANAELRVLASAPDFSKSPVKKKSFVQVGGDIVIGCKPNAFPRAAISWKRGTETLRQSKRIFLLEDGSLKIYNITRSDAGSYTCIATNQFGTAKNTGSLIVKERTVITVPPSKMDVTVGESIVLPCQVSHDPSIEVVFVWFFNGDVIDLKKGVAHFERIGGESVGDLMIRNIQLHHSGKYLCTVQTTLESLSAVADIIVRGPPGPPEDVQVEDISSTTSQLSWRAGPDNNSPIQIFTIQTRTPFSVGWQAVATVPEILNGKTYNATVVGLSPWVEYEFRVVAGNSIGIGEPSEPSELLRTKASVPVVAPVNIHGGGGSRSELVITWESIPEELQNGEGFGYIIMFRPVGSTTWSKEKVSSVESSRFVYRNESIIPLSPFEVKVGVYNNEGEGSLSTVTIVYSGEDEPQLAPRGTSLQSFSASEMEVSWNAIAWNRNTGRVLGYEVLYWTDDSKESMIGKIRVSGNVTTKNITGLKANTIYFASVRAYNTAGTGPSSPPVNVTTKKSPPSQPPANIAWKLTNSKLCLNWEHVKTMENESEVLGYKILYRQNRQSKTHILETNNTSAELLVPFEEDYLIEIRTVSDGGDGSSSEEIRIPKMSSLSSRGIQFLEPSTHFLSIVIVIFHCFAIQPLI,0,,,,,,,,,,,,,,,,,,,,5.0
O94779,,Contactin-5,CNTN5,Homo sapiens,1100,False,,MASSWKLMLFLSVTMCLSEYSKSLPGLSTSYAALLRIKKSSSSSLFGSKTRPRYSSPSLGTLSASSPSWLGAAQNYYSPINLYHSSDAFKQDESVDYGPVFVQEPDDIIFPTDSDEKKVALNCEVRGNPVPSYRWLRNGTEIDLESDYRYSLIDGTFIISNPSEAKDSGHYQCLATNTVGSILSREATLQFAYLGNFSGRTRSAVSVREGQGVVLMCSPPPHSPEIIYSWVFNEFPSFVAEDSRRFISQETGNLYISKVQTSDVGSYICLVKNTVTNARVLSPPTPLTLRNDGVMGEYEPKIEVHFPFTVTAAKGTTVKMECFALGNPVPTITWMKVNGYIPSKARLRKSQAVLEIPNVQLDDAGIYECRAENSRGKNSFRGQLQVYTYPHWVEKLNDTQLDSGSPLRWECKATGKPRPTYRWLKNGVPLSPQSRVEMVNGVLMIHNVNQSDAGMYQCLAENKYGAIYASAELKILASAPTFALNQLKKTIIVTKDQEVVIECKPQGSPKPTISWKKGDRAVRENKRIAILPDGSLRILNASKSDEGKYVCRGENVFGSAEIIASLSVKEPTRIELTPKRTELTVGESIVLNCKAIHDASLDVTFYWTLKGQPIDFEEEGGHFESIRAQASSADLMIRNILLMHAGRYGCRVQTTADSVSDEAELLVRGPPGPPGIVIVEEITESTATLSWSPAADNHSPISSYNLQARSPFSLGWQTVKTVPEIITGDMESAMAVDLNPWVEYEFRVVATNPIGTGDPSTPSRMIRTNEAVPKTAPTNVSGRSGRRHELVIAWEPVSEEFQNGEGFGYIVAFRPNGTRGWKEKMVTSSEASKFIYRDESVPPLTPFEVKVGVYNNKGDGPFSQIVVICSAEGEPSAAPTDVKATSVSVSEILVAWKHIKESLGRPQGFEVGYWKDMEQEDTAETVKTRGNESFVILTGLEGNTLYHFTVRAYNGAGYGPPSSEVSATTKKSPPSQAPSNLRWEQQGSQVSLGWEPVIPLANESEVVGYKVFYRQEGHSNSQVIETQKLQAVVPLPDAGVYIIEVRAYSEGGDGTASSQIRVPSYSGGKITSAQSTLHSLSTSSSSVTLLLALMIPSTSW,0,,,,,,,,,,1:O94779-1:|2:O94779-2:|3:O94779-4:,,,,,,,,,,5.0
Q6P5X5,,Synaptic plasticity regulator PANTS,C22orf39,Homo sapiens,105,False,,MADGSGWQPPRPCEAYRAEWKLCRSARHFLHHYYVHGERPACEQWQRDLASCRDWEERRNAEAQQSLCESERARVRAARKHILVWAPRQSPPPDWHLPLPQEKDE,0,,,,,,,,Q49AR9(ANKS1A)|P15289(ARSA)|Q8N9N5(BANP)|Q9NPB3(CABP2)|Q8TAP6(CEP76)|P28329-3(CHAT)|P27658(COL8A1)|P53672(CRYBA2)|A8MQ03(CYSRT1)|G5E9A7(DMWD)|Q86UW9(DTX2)|Q96B26(EXOSC8)|P22607(FGFR3)|O43559(FRS3)|Q9Y223-2(GNE)|P28799(GRN)|Q9H2F3(HSD3B7)|Q02363(ID2)|Q02535(ID3)|Q0VD86(INCA1)|P60412(KRTAP10-11)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|P60328(KRTAP12-3)|Q52LG2(KRTAP13-2)|Q6L8G9(KRTAP5-6)|Q9BYQ4(KRTAP9-2)|P43364(MAGEA11)|Q99750(MDFI)|Q8NCF5-2(NFATC2IP)|Q92824-2(PCSK5)|Q99471(PFDN5)|Q9NRY6(PLSCR3)|P25786(PSMA1)|Q93062(RBPMS)|Q6P9E2(RECK)|Q9UFD9(RIMBP3)|Q86XE0(SNX32)|Q7Z699(SPRED1)|Q63HR2(TNS2)|Q96RU7(TRIB3)|B2RUY7(VWC2L)|Q6ZNG0(ZNF620)|P28799(GRN)|P42858(HTT)|O76024(WFS1),,1:Q6P5X5-1:|2:Q6P5X5-2:,,,,,,,,,,5.0
A7MD48,,Serine/arginine repetitive matrix protein 4,SRRM4,Homo sapiens,611,False,KIAA1853,MASVQQGEKQLFEKFWRGTFKAVATPRPESIIVASITARKPLPRTEPQNNPVVPAQDGPSEKLGQHLATEPLGTNSWERDKTCRELGATRGHSASHDKDLTPPPSSRGKKKKKKSTRKKRRRSSSYSPSPVKKKKKKSSKKHKRRRSFSKKRRHSSSSPKSKRRDEKRHKKQSRSRPRKSHRHRHHRCPSRSQSSESRPSSCESRHRGRSPEEGQKSRRRHSRRCSKTLCKDSPEAQSSRPPSQPLQMLGYLSARGVITGSGSAADLFTKTASPLTTSRGRSQEYDSGNDTSSPPSTQTSSARSRGQEKGSPSGGLSKSRELNSGNTSDSGNSFTTSSPQNKGAMLENLSPTSRGRESRGFQSPCLECAEVKKSSLVPSTARSSPMKGCSRSSSYASTRSSSHSSRSPNPRASPRYTQSRSTSSEKRSYSRSPSYSSKSGKRSPPSRSSRSRRSPSYSRYSPSRERDPKYSEKDSQQRERERARRRRRSYSPMRKRRRDSPSHLEARRITSARKRPIPYYRPSPSSSGSLSSTSSWYSSSSSRSASRSYSRSRSRSRSRRRSRTRTSSSSSSRSPSPGSRSRSRSRSRSRSRSRSQSRSYSSADSYSSTRR,0,,,,,,,,Q02040(AKAP17A)|A0A0C4DG62(ARL6IP4)|Q6PH81(C16orf87)|Q16543(CDC37)|P49759-3(CLK1)|Q9HAZ1(CLK4)|Q8IZU0(FAM9B)|Q9Y383(LUC7L2)|Q9P127(LUZP4)|Q96EZ8(MCRS1)|Q9BU76(MMTAG2)|P49756(RBM25)|Q14498(RBM39)|Q9Y388(RBMX2)|Q15287(RNPS1)|Q96IZ7(RSRC1)|Q8TAD8(SNIP1)|P08621(SNRNP70)|Q8IYB3(SRRM1)|A7MD48(SRRM4)|Q05519-2(SRSF11)|Q01081(U2AF1)|P61964(WDR5)|Q15973(ZNF124)|Q9HBT8(ZNF286A)|Q32M78(ZNF699)|Q15696(ZRSR2)|Q15695(ZRSR2P1),,,,,,,,,,,,5.0
P13591,,Neural cell adhesion molecule 1,NCAM1,Homo sapiens,858,False,NCAM,MLQTKDLIWTLFFLGTAVSLQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMFKNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGFPEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATIHLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKASWTRPEKQETLDGHMVVRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCTAVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAVGEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQGEPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAENQQGKSKAAHFVFRTSAQPTAIPANGSPTSGLSTGAIVGILIVIFVLLLVVVDITCYFLNKCGLFMCIAVNLCGKAGPGAKGKDMEEGKAAFSKDESKEPIVEVRTEEERTPNHDGGKHTEPNETTPLTEPEKGPVEAKPECQETETKPAPAEVKTVPNDATQTKENESKA,0,,,,,,,,P25098(GRK2)|Q9UNE7(STUB1),,"1:P13591-2:|2:P13591-1:|3:P13591-3,P13592-2:|4:P13591-4:|5:P13591-5,P13592-1:|6:P13591-6:",,,,,,,,,,5.0
P50219,,Motor neuron and pancreas homeobox protein 1,MNX1,Homo sapiens,401,False,HLXB9,MEKSKNFRIDALLAVDPPRAASAQSAPLALVTSLAAAASGTGGGGGGGGASGGTSGSCSPASSEPPAAPADRLRAESPSPPRLLAAHCALLPKPGFLGAGGGGGGTGGGHGGPHHHAHPGAAAAAAAAAAAAAAGGLALGLHPGGAQGGAGLPAQAALYGHPVYGYSAAAAAAALAGQHPALSYSYPQVQGAHPAHPADPIKLGAGTFQLDQWLRASTAGMILPKMPDFNSQAQSNLLGKCRRPRTAFTSQQLLELEHQFKLNKYLSRPKRFEVATSLMLTETQVKIWFQNRRMKWKRSKKAKEQAAQEAEKQKGGGGGAGKGGAEEPGAEELLGPPAPGDKGSGRRLRDLRDSDPEEDEDEDDEDHFPYSNGASVHAASSDCSSEDDSPPPRPSHQPAPQ,0,,,,,,"Currarino syndrome:The triad of a presacral tumor, sacral agenesis and anorectal malformation constitutes the Currarino syndrome which is caused by dorsal-ventral patterning defects during embryonic development. The syndrome occurs in the majority of patients as an autosomal dominant trait.",Currarino syndrome,,,1:P50219-1:|2:P50219-2:,,,,,,,,,,5.0
O75940,,Survival of motor neuron-related-splicing factor 30,SMNDC1,Homo sapiens,238,False,SMNR|SPF30,MSEDLAKQLASYKAQLQQVEAALSGNGENEDLLKLKKDLQEVIELTKDLLSTQPSETLASSDSFASTQPTHSWKVGDKCMAVWSEDGQCYEAEIEEIDEENGTAAITFAGYGNAEVTPLLNLKPVEEGRKAKEDSGNKPMSKKEMIAQQREYKKKKALKKAQRIKELEQEREDQKVKWQQFNNRAYSKNKKGQVKRSIFASPESVTGKVGVGTCGIADKPMTQYQDTSKYNVRHLMPQ,0,,,,,,,,Q14974(KPNB1)|O43395(PRPF3)|Q15428(SF3A2),,,,,,,,,,,,5.0
Q9Y2V3,,Retinal homeobox protein Rx,RAX,Homo sapiens,346,False,RX,MHLPGCAPAMADGSFSLAGHLLRSPGGSTSRLHSIEAILGFTKDDGILGTFPAERGARGAKERDRRLGARPACPKAPEEGSEPSPPPAPAPAPEYEAPRPYCPKEPGEARPSPGLPVGPATGEAKLSEEEQPKKKHRRNRTTFTTYQLHELERAFEKSHYPDVYSREELAGKVNLPEVRVQVWFQNRRAKWRRQEKLEVSSMKLQDSPLLSFSRSPPSATLSPLGAGPGSGGGPAGGALPLESWLGPPLPGGGATALQSLPGFGPPAQSLPASYTPPPPPPPFLNSPPLGPGLQPLAPPPPSYPCGPGFGDKFPLDEADPRNSSIAALRLKAKEHIQAIGKPWQAL,0,,,,,,"Microphthalmia, syndromic 16:An autosomal recessive disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues. Ocular abnormalities like opacities of the cornea and lens, scaring of the retina and choroid, and other abnormalities may also be present. Some patients exhibit developmental delay and intellectual disability or autism.","Microphthalmia, syndromic 16",,,1:Q9Y2V3-1:|2:Q9Y2V3-2:,,,,,,,,,,5.0
Q13127,,RE1-silencing transcription factor,REST,Homo sapiens,1097,False,NRSF|XBR,MATQVMGQSSGGGGLFTSSGNIGMALPNDMYDLHDLSKAELAAPQLIMLANVALTGEVNGSCCDYLVGEERQMAELMPVGDNNFSDSEEGEGLEESADIKGEPHGLENMELRSLELSVVEPQPVFEASGAPDIYSSNKDLPPETPGAEDKGKSSKTKPFRCKPCQYEAESEEQFVHHIRVHSAKKFFVEESAEKQAKARESGSSTAEEGDFSKGPIRCDRCGYNTNRYDHYTAHLKHHTRAGDNERVYKCIICTYTTVSEYHWRKHLRNHFPRKVYTCGKCNYFSDRKNNYVQHVRTHTGERPYKCELCPYSSSQKTHLTRHMRTHSGEKPFKCDQCSYVASNQHEVTRHARQVHNGPKPLNCPHCDYKTADRSNFKKHVELHVNPRQFNCPVCDYAASKKCNLQYHFKSKHPTCPNKTMDVSKVKLKKTKKREADLPDNITNEKTEIEQTKIKGDVAGKKNEKSVKAEKRDVSKEKKPSNNVSVIQVTTRTRKSVTEVKEMDVHTGSNSEKFSKTKKSKRKLEVDSHSLHGPVNDEESSTKKKKKVESKSKNNSQEVPKGDSKVEENKKQNTCMKKSTKKKTLKNKSSKKSSKPPQKEPVEKGSAQMDPPQMGPAPTEAVQKGPVQVEPPPPMEHAQMEGAQIRPAPDEPVQMEVVQEGPAQKELLPPVEPAQMVGAQIVLAHMELPPPMETAQTEVAQMGPAPMEPAQMEVAQVESAPMQVVQKEPVQMELSPPMEVVQKEPVQIELSPPMEVVQKEPVKIELSPPIEVVQKEPVQMELSPPMGVVQKEPAQREPPPPREPPLHMEPISKKPPLRKDKKEKSNMQSERARKEQVLIEVGLVPVKDSWLLKESVSTEDLSPPSPPLPKENLREEASGDQKLLNTGEGNKEAPLQKVGAEEADESLPGLAANINESTHISSSGQNLNTPEGETLNGKHQTDSIVCEMKMDTDQNTRENLTGINSTVEEPVSPMLPPSAVEEREAVSKTALASPPATMAANESQEIDEDEGIHSHEGSDLSDNMSEGSDDSGLHGARPVPQESSRKNAKEALAVKAAKGDFVCIFCDRSFRKGKDYSKHLNRHLVNVYYLEEAAQGQE,0,,,,,,"Wilms tumor 6:A pediatric malignancy of kidney, and the most common childhood abdominal malignancy. It is caused by the uncontrolled multiplication of renal stem, stromal, and epithelial cells.|Fibromatosis, gingival, 5:An autosomal dominant form of hereditary gingival fibromatosis, a rare condition characterized by a slow, progressive overgrowth of the gingiva. The excess gingival tissue can cover part of or the entire crown, and can result in diastemas, teeth displacement, or retention of primary or impacted teeth.|:|Deafness, autosomal dominant, 27:A form of non-syndromic deafness characterized by postlingual, progressive, moderate to profound sensorineural hearing loss.","Wilms tumor 6|Fibromatosis, gingival, 5|Deafness, autosomal dominant, 27",Q9Y297(BTRC)|Q9UKB1(FBXW11)|P07900(HSP90AA1)|P41229(KDM5C)|P51532(SMARCA4),,1:Q13127-1:|2:Q13127-2:|3:Q13127-3:|4:Q13127-4:,,,,,,,,,,5.0
Q96IS3,,Retina and anterior neural fold homeobox protein 2,RAX2,Homo sapiens,184,False,QRX|RAXL1,MFLSPGEGPATEGGGLGPGEEAPKKKHRRNRTTFTTYQLHQLERAFEASHYPDVYSREELAAKVHLPEVRVQVWFQNRRAKWRRQERLESGSGAVAAPRLPEAPALPFARPPAMSLPLEPWLGPGPPAVPGLPRLLGPGPGLQASFGPHAFAPTFADGFALEEASLRLLAKEHAQALDRAWPPA,0,,,,,,"Macular degeneration, age-related, 6:A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.|Cone-rod dystrophy 11:An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa, due to cone photoreceptors degenerating at a higher rate than rod photoreceptors.|Retinitis pigmentosa 95:A form of retinitis pigmentosa, a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. RP95 is an autosomal recessive form characterized by pale optic disks, attenuation of retinal vessels, and atrophy of the retinal pigment epithelium with bone-spicule pigmentation.","Macular degeneration, age-related, 6|Cone-rod dystrophy 11|Retinitis pigmentosa 95",,,,,,,,,,,,,5.0
P84074,,Neuron-specific calcium-binding protein hippocalcin,HPCA,Homo sapiens,193,False,BDR2,MGKQNSKLRPEMLQDLRENTEFSELELQEWYKGFLKDCPTGILNVDEFKKIYANFFPYGDASKFAEHVFRTFDTNSDGTIDFREFIIALSVTSRGRLEQKLMWAFSMYDLDGNGYISREEMLEIVQAIYKMVSSVMKMPEDESTPEKRTEKIFRQMDTNNDGKLSLEEFIRGAKSDPSIVRLLQCDPSSASQF,0,,,,,,"Dystonia 2, torsion, autosomal recessive:A form of torsion dystonia, a disease defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. 'Torsion' refers to the twisting nature of body movements, often affecting the trunk. DYT2 is a slowly progressive form that first affects distal limbs and later involves the neck, orofacial, and craniocervical regions.","Dystonia 2, torsion, autosomal recessive",Q9BXJ5(C1QTNF2)|P12532(CKMT1B)|Q03060-25(CREM)|Q86UW9(DTX2)|Q9BWX5(GATA5)|Q9UBH0(IL36RN)|P55197-2(MLLT10)|Q969H8(MYDGF)|P0CG20(PRR35)|O15427(SLC16A3)|Q96N21(TEPSIN)|P14927(UQCRB)|Q2TAL6(VWC2),,,,,,,,,,,,5.0
P61296,,Heart- and neural crest derivatives-expressed protein 2,HAND2,Homo sapiens,217,False,BHLHA26|DHAND,MSLVGGFPHHPVVHHEGYPFAAAAAAAAAAAASRCSHEENPYFHGWLIGHPEMSPPDYSMALSYSPEYASGAAGLDHSHYGGVPPGAGPPGLGGPRPVKRRGTANRKERRRTQSINSAFAELRECIPNVPADTKLSKIKTLRLATSYIAYLMDLLAKDDQNGEAEAFKAEIKKTDVKEEKRKKELNEILKSTVSSNDKKTKGRTGWPQHVWALELKQ,0,,,,,,,,P15884(TCF4)|Q86YD7(FAM90A1)|Q63ZY3(KANK2)|Q96CV9(OPTN)|Q0D2K3(RIPPLY1)|Q5MJ09(SPANXN3)|Q99081-3(TCF12)|Q9Y2K6(USP20),,1:P61296-1:|2:P61296-2:,,,,,,,,,,5.0
O60477,,BMP/retinoic acid-inducible neural-specific protein 1,BRINP1,Homo sapiens,761,False,DBC1|DBCCR1|FAM5A,MNWRFVELLYFLFIWGRISVQPSHQEPAGTDQHVSKEFDWLISDRGPFHHSRSYLSFVERHRQGFTTRYKIYREFARWKVRNTAIERRDLVRHPVPLMPEFQRSIRLLGRRPTTQQFIDTIIKKYGTHLLISATLGGEEALTMYMDKSRLDRKSGNATQSVEALHQLASSYFVDRDGTMRRLHEIQISTGAIKVTETRTGPLGCNSYDNLDSVSSVLLQSTESKLHLQGLQIIFPQYLQEKFVQSALSYIMCNGEGEYLCQNSQCRCQCAEEFPQCNCPITDIQIMEYTLANMAKSWAEAYKDLENSDEFKSFMKRLPSNHFLTIGSIHQHWGNDWDLQNRYKLLQSATEAQRQKIQRTARKLFGLSVRCRHNPNHQLPRERTIQQWLARVQSLLYCNENGFWGTFLESQRSCVCHGSTTLCQRPIPCVIGGNNSCAMCSLANISLCGSCNKGYKLYRGRCEPQNVDSERSEQFISFETDLDFQDLELKYLLQKMDSRLYVHTTFISNEIRLDTFFDPRWRKRMSLTLKSNKNRMDFIHMVIGMSMRICQMRNSSLDPMFFVYVNPFSGSHSEGWNMPFGEFGYPRWEKIRLQNSQCYNWTLLLGNRWKTFFETVHIYLRSRTRLPTLLRNETGQGPVDLSDPSKRQFYIKISDVQVFGYSLRFNADLLRSAVQQVNQSYTQGGQFYSSSSVMLLLLDIRDRINRLAPPVAPGKPQLDLFSCMLKHRLKLTNSEIIRVNHALDLYNTEILKQSDQMTAKLC,0,,,,,,,,Q5BKZ1(ZNF326),,1:O60477-1:|2:O60477-2:|3:O60477-3:,,,,,,,,,,5.0
Q8N3F0,,Maturin,MTURN,Homo sapiens,131,False,C7orf41,MDFQQLADVAEKWCSNTPFELIATEETERRMDFYADPGVSFYVLCPDNGCGDNFHVWSESEDCLPFLQLAQDYISSCGKKTLHEVLEKVFKSFRPLLGLPDADDDAFEEYSADVEEEEPEADHPQMGVSQQ,0,,,,,,,,Q96CW1(AP2M1)|Q8N5I2(ARRDC1)|Q15038(DAZAP2)|Q9UHC7(MKRN1)|Q96CS7(PLEKHB2)|Q04864-2(REL)|Q9NWF9(RNF216)|Q9H4P4(RNF41)|P62979(RPS27A)|Q16384(SSX1)|Q92537(SUSD6)|Q8WW34-2(TMEM239)|Q9NS68-2(TNFRSF19)|Q05BL1(TP53BP2)|Q9Y4K3(TRAF6)|O00635(TRIM38)|Q9HCM9-2(TRIM39)|Q9C035-3(TRIM5)|Q9BZR9(TRIM8)|P62987(UBA52)|P0CG47(UBB)|P0CG48(UBC),,1:Q8N3F0-1:|2:Q8N3F0-2:|3:Q8N3F0-3:|4:Q8N3F0-4:,,,,,,,,,,5.0
P17677,,Neuromodulin,GAP43,Homo sapiens,238,False,,MLCCMRRTKQVEKNDDDQKIEQDGIKPEDKAHKAATKIQASFRGHITRKKLKGEKKDDVQAAEAEANKKDEAPVADGVEKKGEGTTTAEAAPATGSKPDEPGKAGETPSEEKKGEGDAATEQAAPQAPASSEEKAGSAETESATKASTDNSPSSKAEDAPAKEEPKQADVPAAVTAAAATTPAAEDAAAKATAQPPTETGESSQAEENIEAVDETKPKESARQDEGKEEEPEADQEHA,0,,,,,,,,P05067-8(APP)|P21917(DRD4)|Q05655(PRKCD),,1:P17677-1:|2:P17677-2:,,,,,,,,,,5.0
P32004,,Neural cell adhesion molecule L1,L1CAM,Homo sapiens,1257,False,CAML1|MIC5,MVVALRYVWPLLLCSPCLLIQIPEEYEGHHVMEPPVITEQSPRRLVVFPTDDISLKCEASGKPEVQFRWTRDGVHFKPKEELGVTVYQSPHSGSFTITGNNSNFAQRFQGIYRCFASNKLGTAMSHEIRLMAEGAPKWPKETVKPVEVEEGESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLTSDNHSDYICHAHFPGTRTIIQKEPIDLRVKATNSMIDRKPRLLFPTNSSSHLVALQGQPLVLECIAEGFPTPTIKWLRPSGPMPADRVTYQNHNKTLQLLKVGEEDDGEYRCLAENSLGSARHAYYVTVEAAPYWLHKPQSHLYGPGETARLDCQVQGRPQPEVTWRINGIPVEELAKDQKYRIQRGALILSNVQPSDTMVTQCEARNRHGLLLANAYIYVVQLPAKILTADNQTYMAVQGSTAYLLCKAFGAPVPSVQWLDEDGTTVLQDERFFPYANGTLGIRDLQANDTGRYFCLAANDQNNVTIMANLKVKDATQITQGPRSTIEKKGSRVTFTCQASFDPSLQPSITWRGDGRDLQELGDSDKYFIEDGRLVIHSLDYSDQGNYSCVASTELDVVESRAQLLVVGSPGPVPRLVLSDLHLLTQSQVRVSWSPAEDHNAPIEKYDIEFEDKEMAPEKWYSLGKVPGNQTSTTLKLSPYVHYTFRVTAINKYGPGEPSPVSETVVTPEAAPEKNPVDVKGEGNETTNMVITWKPLRWMDWNAPQVQYRVQWRPQGTRGPWQEQIVSDPFLVVSNTSTFVPYEIKVQAVNSQGKGPEPQVTIGYSGEDYPQAIPELEGIEILNSSAVLVKWRPVDLAQVKGHLRGYNVTYWREGSQRKHSKRHIHKDHVVVPANTTSVILSGLRPYSSYHLEVQAFNGRGSGPASEFTFSTPEGVPGHPEALHLECQSNTSLLLRWQPPLSHNGVLTGYVLSYHPLDEGGKGQLSFNLRDPELRTHNLTDLSPHLRYRFQLQATTKEGPGEAIVREGGTMALSGISDFGNISATAGENYSVVSWVPKEGQCNFRFHILFKALGEEKGGASLSPQYVSYNQSSYTQWDLQPDTDYEIHLFKERMFRHQMAVKTNGTGRVRLPPAGFATEGWFIGFVSAIILLLLVLLILCFIKRSKGGKYSVKDKEDTQVDSEARPMKDETFGEYRSLESDNEEKAFGSSQPSLNGDIKPLGSDDSLADYGGSVDVQFNEDGSFIGQYSGKKEKEAAGGNDSSGATSPINPAVALE,0,,,,,,"Hydrocephalus, congenital, X-linked:An X-linked recessive form of congenital hydrocephalus, a disease characterized by in utero onset of enlarged ventricles due to accumulation of ventricular cerebrospinal fluid. HYCX is the most common inherited form and occurs in approximately 1/30000 male births. The primary diagnostic criteria of intellectual disability and enlarged cerebral ventricles are often accompanied by spastic paraparesis and adducted thumbs and, occasionally, visual defects or seizures. The most severe cases die pre- or perinatally with gross hydrocephalus and enlarged head circumference. Stenosis of the aqueduct of Sylvius is frequently associated with the disorder.|MASA syndrome:An X-linked recessive syndrome with a highly variable clinical spectrum. Main clinical features include spasticity and hyperreflexia of lower limbs, shuffling gait, intellectual disability, aphasia and adducted thumbs. The features of spasticity have been referred to as complicated spastic paraplegia type 1 (SPG1). Some patients manifest corpus callosum hypoplasia and hydrocephalus. Inter- and intrafamilial variability is very wide, such that patients with hydrocephalus, MASA, SPG1, and agenesis of corpus callosum can be present within the same family.|:|Agenesis of the corpus callosum, X-linked, partial:A syndrome characterized by partial corpus callosum agenesis, hypoplasia of inferior vermis and cerebellum, intellectual disability, seizures and spasticity. Other features include microcephaly, unusual facies, and Hirschsprung disease in some patients.|:","Hydrocephalus, congenital, X-linked|MASA syndrome|Agenesis of the corpus callosum, X-linked, partial",,,1:P32004-1:|2:P32004-2:|3:P32004-3:,,,,,,,,,,5.0
Q08499,,"3',5'-cyclic-AMP phosphodiesterase 4D",PDE4D,Homo sapiens,809,False,DPDE3,MEAEGSSAPARAGSGEGSDSAGGATLKAPKHLWRHEQHHQYPLRQPQFRLLHPHHHLPPPPPPSPQPQPQCPLQPPPPPPLPPPPPPPGAARGRYASSGATGRVRHRGYSDTERYLYCRAMDRTSYAVETGHRPGLKKSRMSWPSSFQGLRRFDVDNGTSAGRSPLDPMTSPGSGLILQANFVHSQRRESFLYRSDSDYDLSPKSMSRNSSIASDIHGDDLIVTPFAQVLASLRTVRNNFAALTNLQDRAPSKRSPMCNQPSINKATITEEAYQKLASETLEELDWCLDQLETLQTRHSVSEMASNKFKRMLNRELTHLSEMSRSGNQVSEFISNTFLDKQHEVEIPSPTQKEKEKKKRPMSQISGVKKLMHSSSLTNSSIPRFGVKTEQEDVLAKELEDVNKWGLHVFRIAELSGNRPLTVIMHTIFQERDLLKTFKIPVDTLITYLMTLEDHYHADVAYHNNIHAADVVQSTHVLLSTPALEAVFTDLEILAAIFASAIHDVDHPGVSNQFLINTNSELALMYNDSSVLENHHLAVGFKLLQEENCDIFQNLTKKQRQSLRKMVIDIVLATDMSKHMNLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLQNMVHCADLSNPTKPLQLYRQWTDRIMEEFFRQGDRERERGMEISPMCDKHNASVEKSQVGFIDYIVHPLWETWADLVHPDAQDILDTLEDNREWYQSTIPQSPSPAPDDPEEGRQGQTEKFQFELTLEEDGESDTEKDSGSQVEEDTSCSDSKTLCTQDSESTEIPLDEQVEEEAVGEEEESQPEACVIDDRSPDT,0,,,,,,":|Acrodysostosis 2, with or without hormone resistance:A pleiotropic disorder characterized by skeletal, endocrine, and neurological abnormalities. Skeletal features include brachycephaly, midface hypoplasia with a small upturned nose, brachydactyly, and lumbar spinal stenosis. Endocrine abnormalities include hypothyroidism and hypogonadism in males and irregular menses in females. Developmental disability is a common finding but is variable in severity and can be associated with significant behavioral problems.","Acrodysostosis 2, with or without hormone resistance",P32121(ARRB2)|P38432(COIL)|Q0D2H9(GOLGA8DP)|Q08AF8(GOLGA8G)|P43360(MAGEA6)|Q07343(PDE4B)|Q13077(TRAF1)|P32121(ARRB2)|P26769(Adcy2)|P38432(COIL)|Q96CV9(OPTN)|Q8IUH5(ZDHHC17),,4:Q08499-1:|3:Q08499-2:|10:Q08499-3:|1:Q08499-4:|2:Q08499-5:|5:Q08499-6:|N3:Q08499-7:|6:Q08499-8:|8:Q08499-9:|9:Q08499-10:|7:Q08499-11:|12:Q08499-12:,,,,,,,,,,5.0
O00401,,Actin nucleation-promoting factor WASL,WASL,Homo sapiens,505,False,,MSSVQQQPPPPRRVTNVGSLLLTPQENESLFTFLGKKCVTMSSAVVQLYAADRNCMWSKKCSGVACLVKDNPQRSYFLRIFDIKDGKLLWEQELYNNFVYNSPRGYFHTFAGDTCQVALNFANEEEAKKFRKAVTDLLGRRQRKSEKRRDPPNGPNLPMATVDIKNPEITTNRFYGPQVNNISHTKEKKKGKAKKKRLTKADIGTPSNFQHIGHVGWDPNTGFDLNNLDPELKNLFDMCGISEAQLKDRETSKVIYDFIEKTGGVEAVKNELRRQAPPPPPPSRGGPPPPPPPPHNSGPPPPPARGRGAPPPPPSRAPTAAPPPPPPSRPSVAVPPPPPNRMYPPPPPALPSSAPSGPPPPPPSVLGVGPVAPPPPPPPPPPPGPPPPPGLPSDGDHQVPTTAGNKAALLDQIREGAQLKKVEQNSRPVSCSGRDALLDQIRQGIQLKSVADGQESTPPTPAPTSGIVGALMEVMQKRSKAIHSSDEDEDEDDEEDFEDDDEWED,0,,,,,,,,Q9NYB9-2(ABI2)|Q8IWW6-4(ARHGAP12)|O15145(ARPC3)|P59998(ARPC4)|P60953(CDC42)|Q99828(CIB1)|Q6XZF7-1(DNMBP)|P62993(GRB2)|A0A0S2Z4D7(NCK1)|P16333(NCK1)|P16333-1(NCK1)|E7ERP6(NCK2)|O43639(NCK2)|Q9UNF0(PACSIN2)|Q9UKS6(PACSIN3)|O96013(PAK4)|Q13882(PTK6)|Q9H4E5(RHOJ)|O76064(RNF8)|O00560(SDCBP)|Q9Y5X1(SNX9)|O94875-10(SORBS2)|O60504-2(SORBS3)|Q15642-2(TRIP10)|P57075-2(UBASH3A)|Q8TF42(UBASH3B)|O43516(WIPF1)|Q8TF74(WIPF2)|A6NGB9(WIPF3)|P68135(ACTA1)|P61157(ACTR3)|P0DJ88(espF(U))|Q8X482(espF(U))|Q8R511(Fnbp1),,,,,,,,,,,,5.0
Q9H0H3,,Kelch-like protein 25,KLHL25,Homo sapiens,589,False,ENC2,MSVSVHETRKSRSSTGSMNVTLFHKASHPDCVLAHLNTLRKHCMFTDVTLWAGDRAFPCHRAVLAASSRYFEAMFSHGLRESRDDTVNFQDNLHPEVLELLLDFAYSSRIAINEENAESLLEAGDMLQFHDVRDAAAEFLEKNLFPSNCLGMMLLSDAHQCRRLYEFSWRMCLVHFETVRQSEDFNSLSKDTLLDLISSDELETEDERVVFEAILQWVKHDLEPRKVHLPELLRSVRLALLPSDCLQEAVSSEALLMADERTKLIMDEALRCKTRILQNDGVVTSPCARPRKAGHTLLILGGQTFMCDKIYQVDHKAKEIIPKADLPSPRKEFSASAIGCKVYVTGGRGSENGVSKDVWVYDTVHEEWSKAAPMLIARFGHGSAELENCLYVVGGHTSLAGVFPASPSVSLKQVEKYDPGANKWMMVAPLRDGVSNAAVVSAKLKLFVFGGTSIHRDMVSKVQCYDPSENRWTIKAECPQPWRYTAAAVLGSQIFIMGGDTEFTAASAYRFDCETNQWTRIGDMTAKRMSCHALASGNKLYVVGGYFGTQRCKTLDCYDPTSDTWNCITTVPYSLIPTAFVSTWKHLPA,0,,,,,,,,,,,,,,,,,,,,5.0
Q16637,,Survival motor neuron protein,SMN1,Homo sapiens,294,False,SMN|SMNT|SMNC,MAMSSGGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICEVANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN,0,,,,,,"Spinal muscular atrophy 1:A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.|Spinal muscular atrophy 2:An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. It has intermediate severity, with onset between 6 and 18 months. Patients do not reach the motor milestone of standing, and survive into adulthood.|Spinal muscular atrophy 3:An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is after 18 months. Patients develop ability to stand and walk and survive into adulthood.|Spinal muscular atrophy 4:An autosomal recessive form of spinal muscular atrophy, a neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Onset is in adulthood, disease progression is slow, and patients can stand and walk.",Spinal muscular atrophy 1|Spinal muscular atrophy 2|Spinal muscular atrophy 3|Spinal muscular atrophy 4,Q6PCB6(ABHD17C)|Q96GX9(APIP)|Q96DX5(ASB9)|Q8WXF7(ATL1)|Q9UL45(BLOC1S6)|Q13895(BYSL)|Q96FZ7(CHMP6)|Q9Y3Y2(CHTOP)|Q9Y3Y2-3(CHTOP)|P38432(COIL)|Q9NR90-2(DAZ3)|Q9UHI6(DDX20)|Q08426(EHHADH)|O75616(ERAL1)|Q8IZU0(FAM9B)|Q9UHY8(FEZ2)|Q9BVV2(FNDC11)|Q6PIV2(FOXR1)|P35637(FUS)|P06241-3(FYN)|O14893(GEMIN2)|Q8TEQ6(GEMIN5)|Q8WVV9-3(HNRNPLL)|Q9BUJ2(HNRNPUL1)|P09017(HOXC4)|Q6DN90-2(IQSEC1)|Q8NA54(IQUB)|Q14974-1(KPNB1)|Q3SY46(KRTAP13-3)|Q8IUB9(KRTAP19-1)|Q3LI72(KRTAP19-5)|Q3LI70(KRTAP19-6)|Q3SYF9(KRTAP19-7)|Q3LI59(KRTAP21-2)|Q3LI64(KRTAP6-1)|Q3LI66(KRTAP6-2)|Q8IUC2(KRTAP8-1)|Q9Y5V3(MAGED1)|Q99683(MAP3K5)|Q15759(MAPK11)|Q9UBB5(MBD2)|Q8TDB4(MGARP)|O43196-2(MSH5)|Q9NV92(NDFIP2)|Q9NPJ8-3(NXT2)|O75925(PIAS1)|O15160(POLR1C)|P24928(POLR2A)|O75817(POP7)|Q13427(PPIG)|Q86UA1(PRPF39)|P57729(RAB38)|Q7Z333(SETX)|Q13435(SF3B2)|Q2NKQ1-4(SGSM1)|Q12824(SMARCB1)|Q16637(SMN2)|Q16637-3(SMN2)|P08621(SNRNP70)|P62314(SNRPD1)|P55769(SNU13)|O60749(SNX2)|Q5MJ10(SPANXN2)|Q7Z6I5(SPATA12)|P37802(TAGLN2)|Q9NX07-2(TRNAU1AP)|Q99598(TSNAX)|Q548N1(VPS28)|Q9UK41(VPS28)|Q9BUR4(WRAP53)|Q9VV74(Smn)|A0A142I5B9()|O14893(GEMIN2)|P01023(A2M)|P50570-2(DNM2)|Q8TB36(GDAP1)|O43464(HTRA2)|P42858(HTT)|Q14974(KPNB1)|P51608(MECP2)|P14678-1(SNRPB)|Q9UK41(VPS28),,SMN:Q16637-1:|SMN-delta5:Q16637-2:|SMN-delta7:Q16637-3:|SMN-delta57:Q16637-4:,,,,,,,,,,5.0
Q8ND90,,Paraneoplastic antigen Ma1,PNMA1,Homo sapiens,353,False,MA1,MAMTLLEDWCRGMDVNSQRALLVWGIPVNCDEAEIEETLQAAMPQVSYRMLGRMFWREENAKAALLELTGAVDYAAIPREMPGKGGVWKVLFKPPTSDAEFLERLHLFLAREGWTVQDVARVLGFQNPTPTPGPEMPAEMLNYILDNVIQPLVESIWYKRLTLFSGRDIPGPGEETFDPWLEHTNEVLEEWQVSDVEKRRRLMESLRGPAADVIRILKSNNPAITTAECLKALEQVFGSVESSRDAQIKFLNTYQNPGEKLSAYVIRLEPLLQKVVEKGAIDKDNVNQARLEQVIAGANHSGAIRRQLWLTGAGEGPAPNLFQLLVQIREEEAKEEEEEAEATLLQLGLEGHF,0,,,,,,,,Q9NX04(AIRIM)|Q96IX9(ANKRD36BP1)|Q7Z2E3(APTX)|Q7Z2E3-7(APTX)|Q15052(ARHGEF6)|Q03989(ARID5A)|O95671(ASMTL)|P48047(ATP5PO)|O75348(ATP6V1G1)|Q9BXY8(BEX2)|Q13895(BYSL)|Q0VAL7(C21orf58)|Q9H7E9(C8orf33)|Q9Y2V2(CARHSP1)|Q9HC52(CBX8)|Q8IYE0-2(CCDC146)|E9PSE9(CCDC198)|Q9NVL8(CCDC198)|P51959(CCNG1)|Q07002(CDK18)|Q96M91(CFAP53)|Q9UKJ5(CHIC2)|Q8NE01(CNNM3)|Q8NE01-3(CNNM3)|P10606(COX5B)|Q9GZU7(CTDSP1)|Q9UI47-2(CTNNA3)|Q9UER7(DAXX)|Q9UJW0(DCTN4)|Q08426(EHHADH)|Q9H0I2(ENKD1)|O95990-3(FAM107A)|Q9BQ89(FAM110A)|Q3B820(FAM161A)|Q96MY7(FAM161B)|Q8TES7-6(FBF1)|Q96D16(FBXL18)|Q96JP0(FEM1C)|Q9NU39(FOXD4L1)|Q6VB84(FOXD4L3)|Q8TAE8(GADD45GIP1)|P55040(GEM)|O95872(GPANK1)|O00155(GPR25)|A4D1E9(GTPBP10)|Q9GZV7(HAPLN2)|P08631-2(HCK)|P56524(HDAC4)|A0A0S2Z4Q4(HGS)|P17482(HOXB9)|Q86VF2-5(IGFN1)|Q9C086(INO80B)|Q7Z3B3(KANSL1)|Q14657(LAGE3)|Q96GY3(LIN37)|Q8TAP4-4(LMO3)|Q8TBB1(LNX1)|Q9Y586(MAB21L2)|Q96GV9(MACIR)|Q96L34(MARK4)|P33993(MCM7)|Q96G25-2(MED8)|Q9H7H0(METTL17)|Q9H7H0-2(METTL17)|Q8IVT4(MGC50722)|Q7Z7H8(MRPL10)|Q9Y3B7(MRPL11)|Q16540(MRPL23)|Q96JP2(MYO15B)|Q9NP98(MYOZ1)|P48146(NPBWR2)|Q6X4W1-2(NSMF)|Q96HA8(NTAQ1)|Q9BRJ7(NUDT16L1)|Q8TEW0(PARD3)|Q9NPB6(PARD6A)|Q9BYG5(PARD6B)|J3QSH9(PER1)|Q13526(PIN1)|Q9Y237(PIN4)|Q16512(PKN1)|Q6P5Z2(PKN3)|Q96PV4(PNMA5)|P0CW24(PNMA6A)|Q8WUT1(POLDIP3)|Q9UGP5-2(POLL)|Q6PIY2(POLM)|P41743(PRKCI)|Q99633(PRPF18)|Q8WWY3(PRPF31)|P25786(PSMA1)|O75771(RAD51D)|Q96IZ5(RBM41)|Q9BUL9(RPP25)|Q8N5L8(RPP25L)|Q9H1X1(RSPH9)|Q7L4I2-2(RSRC2)|Q14D33(RTP5)|Q9BVN2(RUSC1)|P57086(SCAND1)|Q9BWG6(SCNM1)|O00560(SDCBP)|Q9C0C4(SEMA4C)|Q9H788(SH2D4A)|Q92529(SHC3)|A0PJX4(SHISA3)|Q6ZT89(SLC25A48)|Q9GZT3(SLIRP)|Q9BZL3(SMIM3)|P14678-2(SNRPB)|P08579(SNRPB2)|Q9H0A9(SPATC1L)|Q9H0A9-2(SPATC1L)|Q9UQ90(SPG7)|Q96FJ0(STAMBPL1)|Q9H5I1(SUV39H2)|Q5VWN6(TASOR2)|Q15560(TCEA2)|Q8N8B7(TCEANC)|Q8N8B7-2(TCEANC)|O95988(TCL1B)|A0A0S2Z4F2(TEAD4)|D3DUQ6(TEAD4)|Q15561(TEAD4)|Q0P5Q0(TMSB4X)|P19237(TNNI1)|Q8IWZ5(TRIM42)|Q86UV6-2(TRIM74)|Q9NRE2(TSHZ2)|Q9UJ04(TSPYL4)|Q5W5X9-3(TTC23)|Q8N5M4(TTC9C)|O14530(TXNDC9)|Q9UMX0(UBQLN1)|Q9UMX0-2(UBQLN1)|Q96HZ7(URB1-AS1)|O75604(USP2)|P61758(VBP1)|Q9Y2B5(VPS9D1)|Q64LD2(WDR25)|Q06250(WT1-AS)|Q53FD0(ZC2HC1C)|Q6PEW1(ZCCHC12)|Q9Y260(ZFAB)|Q68DK2-5(ZFYVE26)|Q96DA0(ZG16B)|Q9UQR1-2(ZNF148)|P13682(ZNF35)|Q7Z4V0(ZNF438)|Q8TBZ8(ZNF564)|Q9P0T4(ZNF581)|A0A0S2Z5X4(ZNF688)|Q6ZN96()|P0DTD1(rep),,,,,,,,,,,,5.0
P55289,,Cadherin-12,CDH12,Homo sapiens,794,False,,MLTRNCLSLLLWVLFDGGLLTPLQPQPQQTLATEPRENVIHLPGQRSHFQRVKRGWVWNQFFVLEEYVGSEPQYVGKLHSDLDKGEGTVKYTLSGDGAGTVFTIDETTGDIHAIRSLDREEKPFYTLRAQAVDIETRKPLEPESEFIIKVQDINDNEPKFLDGPYVATVPEMSPVGAYVLQVKATDADDPTYGNSARVVYSILQGQPYFSIDPKTGVIRTALPNMDREVKEQYQVLIQAKDMGGQLGGLAGTTIVNITLTDVNDNPPRFPKSIFHLKVPESSPIGSAIGRIRAVDPDFGQNAEIEYNIVPGDGGNLFDIVTDEDTQEGVIKLKKPLDFETKKAYTFKVEASNLHLDHRFHSAGPFKDTATVKISVLDVDEPPVFSKPLYTMEVYEDTPVGTIIGAVTAQDLDVGSSAVRYFIDWKSDGDSYFTIDGNEGTIATNELLDRESTAQYNFSIIASKVSNPLLTSKVNILINVLDVNEFPPEISVPYETAVCENAKPGQIIQIVSAADRDLSPAGQQFSFRLSPEAAIKPNFTVRDFRNNTAGIETRRNGYSRRQQELYFLPVVIEDSSYPVQSSTNTMTIRVCRCDSDGTILSCNVEAIFLPVGLSTGALIAILLCIVILLAIVVLYVALRRQKKKDTLMTSKEDIRDNVIHYDDEGGGEEDTQAFDIGALRNPKVIEENKIRRDIKPDSLCLPRQRPPMEDNTDIRDFIHQRLQENDVDPTAPPYDSLATYAYEGSGSVAESLSSIDSLTTEADQDYDYLTDWGPRFKVLADMFGEEESYNPDKVT,0,,,,,,,,,,1:P55289-1:|2:P55289-2:,,,,,,,,,,5.0
Q8NHV4,,Protein NEDD1,NEDD1,Homo sapiens,660,False,,MQENLRFASSGDDIKIWDASSMTLVDKFNPHTSPHGISSICWSSNNNFLVTASSSGDKIVVSSCKCKPVPLLELAEGQKQTCVNLNSTSMYLVSGGLNNTVNIWDLKSKRVHRSLKDHKDQVTCVTYNWNDCYIASGSLSGEIILHSVTTNLSSTPFGHGSNQSVRHLKYSLFKKSLLGSVSDNGIVTLWDVNSQSPYHNFDSVHKAPASGICFSPVNELLFVTIGLDKRIILYDTSSKKLVKTLVADTPLTAVDFMPDGATLAIGSSRGKIYQYDLRMLKSPVKTISAHKTSVQCIAFQYSTVLTKSSLNKGCSNKPTTVNKRSVNVNAASGGVQNSGIVREAPATSIATVLPQPMTSAMGKGTVAVQEKAGLPRSINTDTLSKETDSGKNQDFSSFDDTGKSSLGDMFSPIRDDAVVNKGSDESIGKGDGFDFLPQLNSVFPPRKNPVTSSTSVLHSSPLNVFMGSPGKEENENRDLTAESKKIYMGKQESKDSFKQLAKLVTSGAESGNLNTSPSSNQTRNSEKFEKPENEIEAQLICEPPINGSSTPNPKIASSVTAGVASSLSEKIADSIGNNRQNAPLTSIQIRFIQNMIQETLDDFREACHRDIVNLQVEMIKQFHMQLNEMHSLLERYSVNEGLVAEIERLREENKRLRAHF,0,,,,,,,,Q7Z4H7(HAUS6),,1:Q8NHV4-1:|2:Q8NHV4-2:|3:Q8NHV4-3:,,,,,,,,,,5.0
O60282,,Kinesin heavy chain isoform 5C,KIF5C,Homo sapiens,957,False,KIAA0531|NKHC2,MADPAECSIKVMCRFRPLNEAEILRGDKFIPKFKGDETVVIGQGKPYVFDRVLPPNTTQEQVYNACAKQIVKDVLEGYNGTIFAYGQTSSGKTHTMEGKLHDPQLMGIIPRIAHDIFDHIYSMDENLEFHIKVSYFEIYLDKIRDLLDVSKTNLAVHEDKNRVPYVKGCTERFVSSPEEVMDVIDEGKANRHVAVTNMNEHSSRSHSIFLINIKQENVETEKKLSGKLYLVDLAGSEKVSKTGAEGAVLDEAKNINKSLSALGNVISALAEGTKTHVPYRDSKMTRILQDSLGGNCRTTIVICCSPSVFNEAETKSTLMFGQRAKTIKNTVSVNLELTAEEWKKKYEKEKEKNKTLKNVIQHLEMELNRWRNGEAVPEDEQISAKDQKNLEPCDNTPIIDNIAPVVAGISTEEKEKYDEEISSLYRQLDDKDDEINQQSQLAEKLKQQMLDQDELLASTRRDYEKIQEELTRLQIENEAAKDEVKEVLQALEELAVNYDQKSQEVEDKTRANEQLTDELAQKTTTLTTTQRELSQLQELSNHQKKRATEILNLLLKDLGEIGGIIGTNDVKTLADVNGVIEEEFTMARLYISKMKSEVKSLVNRSKQLESAQMDSNRKMNASERELAACQLLISQHEAKIKSLTDYMQNMEQKRRQLEESQDSLSEELAKLRAQEKMHEVSFQDKEKEHLTRLQDAEEMKKALEQQMESHREAHQKQLSRLRDEIEEKQKIIDEIRDLNQKLQLEQEKLSSDYNKLKIEDQEREMKLEKLLLLNDKREQAREDLKGLEETVSRELQTLHNLRKLFVQDLTTRVKKSVELDNDDGGGSAAQKQKISFLENNLEQLTKVHKQLVRDNADLRCELPKLEKRLRATAERVKALESALKEAKENAMRDRKRYQQEVDRIKEAVRAKNMARRAHSAQIAKPIRPGHYPASSPTAVHAIRGGGGSSSNSTHYQK,0,,,,,,"Cortical dysplasia, complex, with other brain malformations 2:A disorder of aberrant neuronal migration and disturbed axonal guidance. Clinical features include intrauterine growth retardation, fetal akinesia, seizures, microcephaly, lack of psychomotor development, and arthrogryposis. Brain imaging shows malformations of cortical development, including polymicrogyria, gyral simplification, and thin corpus callosum.","Cortical dysplasia, complex, with other brain malformations 2",P68400(CSNK2A1)|P19784(CSNK2A2)|Q8IXI2(RHOT1)|Q6FHY5(MEOX2),,1:O60282-1:|2:O60282-2:,,,,,,,,,,5.0
Q8NI22,,Multiple coagulation factor deficiency protein 2,MCFD2,Homo sapiens,146,False,SDNSF,MTMRSLLRTPFLCGLLWAFCAPGARAEEPAASFSQPGSMGLDKNTVHDQEHIMEHLEGVINKPEAEMSPQELQLHYFKMHDYDGNNLLDGLELSTAITHVHKEEGSEQAPLMSEDELINIIDGVLRDDDKNNDGYIDYAEFAKSLQ,0,,,,,,"Factor V and factor VIII combined deficiency 2:A blood coagulation disorder characterized by bleeding symptoms similar to those in hemophilia or parahemophilia, that are caused by single deficiency of FV or FVIII, respectively. The most common symptoms are epistaxis, menorrhagia, and excessive bleeding during or after trauma. Plasma levels of coagulation factors V and VIII are in the range of 5 to 30% of normal.",Factor V and factor VIII combined deficiency 2,P06307(CCK)|Q96DZ9-2(CMTM5)|Q01638-2(IL1RL1)|P13473-2(LAMP2)|P49257(LMAN1)|Q15077(P2RY6)|P54315(PNLIPRP1)|O00767(SCD)|Q9Y371(SH3GLB1)|P78382(SLC35A1)|Q8N2H4(SYS1)|Q9TU32(LMAN1),,1:Q8NI22-1:|2:Q8NI22-2:|3:Q8NI22-3:,,,,,,,,,,5.0
Q9Y328,,Neuronal vesicle trafficking-associated protein 2,NSG2,Homo sapiens,171,False,CALY3,MVKLNSNPSEKGTKPPSVEDGFQTVPLITPLEVNHLQLPAPEKVIVKTRTEYQPEQKNKGKFRVPKIAEFTVTILVSLALAFLACIVFLVVYKAFTYDHSCPEGFVYKHKRCIPASLDAYYSSQDPNSRSRFYTVISHYSVAKQSTARAIGPWLSAAAVIHEPKPPKTQGH,0,,,,,,,,Q86W74-2(ANKRD46)|Q9BXN2-6(CLEC7A)|P11021(HSPA5)|O14718(RRH)|Q5BVD1(TTMP),,,,,,,,,,,,5.0
Q8TDI0,,Chromodomain-helicase-DNA-binding protein 5,CHD5,Homo sapiens,1954,False,KIAA0444,MRGPVGTEEELPRLFAEEMENEDEMSEEEDGGLEAFDDFFPVEPVSLPKKKKPKKLKENKCKGKRKKKEGSNDELSENEEDLEEKSESEGSDYSPNKKKKKKLKDKKEKKAKRKKKDEDEDDNDDGCLKEPKSSGQLMAEWGLDDVDYLFSEEDYHTLTNYKAFSQFLRPLIAKKNPKIPMSKMMTVLGAKWREFSANNPFKGSSAAAAAAAVAAAVETVTISPPLAVSPPQVPQPVPIRKAKTKEGKGPGVRKKIKGSKDGKKKGKGKKTAGLKFRFGGISNKRKKGSSSEEDEREESDFDSASIHSASVRSECSAALGKKSKRRRKKKRIDDGDGYETDHQDYCEVCQQGGEIILCDTCPRAYHLVCLDPELEKAPEGKWSCPHCEKEGIQWEPKDDDDEEEEGGCEEEEDDHMEFCRVCKDGGELLCCDACPSSYHLHCLNPPLPEIPNGEWLCPRCTCPPLKGKVQRILHWRWTEPPAPFMVGLPGPDVEPSLPPPKPLEGIPEREFFVKWAGLSYWHCSWVKELQLELYHTVMYRNYQRKNDMDEPPPFDYGSGDEDGKSEKRKNKDPLYAKMEERFYRYGIKPEWMMIHRILNHSFDKKGDVHYLIKWKDLPYDQCTWEIDDIDIPYYDNLKQAYWGHRELMLGEDTRLPKRLLKKGKKLRDDKQEKPPDTPIVDPTVKFDKQPWYIDSTGGTLHPYQLEGLNWLRFSWAQGTDTILADEMGLGKTVQTIVFLYSLYKEGHSKGPYLVSAPLSTIINWEREFEMWAPDFYVVTYTGDKESRSVIRENEFSFEDNAIRSGKKVFRMKKEVQIKFHVLLTSYELITIDQAILGSIEWACLVVDEAHRLKNNQSKFFRVLNSYKIDYKLLLTGTPLQNNLEELFHLLNFLTPERFNNLEGFLEEFADISKEDQIKKLHDLLGPHMLRRLKADVFKNMPAKTELIVRVELSQMQKKYYKFILTRNFEALNSKGGGNQVSLLNIMMDLKKCCNHPYLFPVAAVEAPVLPNGSYDGSSLVKSSGKLMLLQKMLKKLRDEGHRVLIFSQMTKMLDLLEDFLEYEGYKYERIDGGITGGLRQEAIDRFNAPGAQQFCFLLSTRAGGLGINLATADTVIIYDSDWNPHNDIQAFSRAHRIGQNKKVMIYRFVTRASVEERITQVAKRKMMLTHLVVRPGLGSKSGSMTKQELDDILKFGTEELFKDDVEGMMSQGQRPVTPIPDVQSSKGGNLAASAKKKHGSTPPGDNKDVEDSSVIHYDDAAISKLLDRNQDATDDTELQNMNEYLSSFKVAQYVVREEDGVEEVEREIIKQEENVDPDYWEKLLRHHYEQQQEDLARNLGKGKRIRKQVNYNDASQEDQEWQDELSDNQSEYSIGSEDEDEDFEERPEGQSGRRQSRRQLKSDRDKPLPPLLARVGGNIEVLGFNARQRKAFLNAIMRWGMPPQDAFNSHWLVRDLRGKSEKEFRAYVSLFMRHLCEPGADGAETFADGVPREGLSRQHVLTRIGVMSLVRKKVQEFEHVNGKYSTPDLIPEGPEGKKSGEVISSDPNTPVPASPAHLLPAPLGLPDKMEAQLGYMDEKDPGAQKPRQPLEVQALPAALDRVESEDKHESPASKERAREERPEETEKAPPSPEQLPREEVLPEKEKILDKLELSLIHSRGDSSELRPDDTKAEEKEPIETQQNGDKEEDDEGKKEDKKGKFKFMFNIADGGFTELHTLWQNEERAAVSSGKIYDIWHRRHDYWLLAGIVTHGYARWQDIQNDPRYMILNEPFKSEVHKGNYLEMKNKFLARRFKLLEQALVIEEQLRRAAYLNMTQDPNHPAMALNARLAEVECLAESHQHLSKESLAGNKPANAVLHKVLNQLEELLSDMKADVTRLPSMLSRIPPVAARLQMSERSILSRLTNRAGDPTIQQGAFGSSQMYSNNFGPNFRGPGPGGIVNYNQMPLGPYVTDI,0,,,,,,":|Parenti-Mignot neurodevelopmental syndrome:An autosomal dominant neurodevelopmental disorder characterized by intellectual disability, speech delay, motor delay, behavioral problems, and epilepsy.",Parenti-Mignot neurodevelopmental syndrome,,,,,,,,,,,,,5.0
Q9UMX5,,Neudesin,NENF,Homo sapiens,172,False,CIR2|SPUF,MVGPAPRRRLRPLAALALVLALAPGLPTARAGQTPRPAERGPPVRLFTEEELARYGGEEEDQPIYLAVKGVVFDVTSGKEFYGRGAPYNALTGKDSTRGVAKMSLDPADLTHDTTGLTAKELEALDEVFTKVYKAKYPIVGYTARRILNEDGSPNLDFKPEDQPHFDIKDEF,0,,,,,,,,,,,,,,,,,,,,5.0
O96004,,Heart- and neural crest derivatives-expressed protein 1,HAND1,Homo sapiens,215,False,BHLHA27|EHAND,MNLVGSYAHHHHHHHPHPAHPMLHEPFLFGPASRCHQERPYFQSWLLSPADAAPDFPAGGPPPAAAAAATAYGPDARPGQSPGRLEALGGRLGRRKGSGPKKERRRTESINSAFAELRECIPNVPADTKLSKIKTLRLATSYIAYLMDVLAKDAQSGDPEAFKAELKKADGGRESKRKRELQQHEGFPPALGPVEKRIKGRTGWPQQVWALELNQ,0,,,,,,,,G5E9A7(DMWD)|P60371(KRTAP10-6)|A0A6Q8PF08(PMP22)|Q7Z699(SPRED1)|Q99081-3(TCF12)|P15923-3(TCF3)|Q86WV8(TSC1),,,,,,,,,,,,5.0
O43623,,Zinc finger protein SNAI2,SNAI2,Homo sapiens,268,False,SLUG|SLUGH,MPRSFLVKKHFNASKKPNYSELDTHTVIISPYLYESYSMPVIPQPEILSSGAYSPITVWTTAAPFHAQLPNGLSPLSGYSSSLGRVSPPPPSDTSSKDHSGSESPISDEEERLQSKLSDPHAIEAEKFQCNLCNKTYSTFSGLAKHKQLHCDAQSRKSFSCKYCDKEYVSLGALKMHIRTHTLPCVCKICGKAFSRPWLLQGHIRTHTGEKPFSCPHCNRAFADRSNLRAHLQTHSDVKKYQCKNCSKTFSRMSLLHKHEESGCCVAH,0,,,,,,"Waardenburg syndrome 2D:WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1.|Piebald trait:Autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes.",Waardenburg syndrome 2D|Piebald trait,Q9NPB3(CABP2)|P68400(CSNK2A1)|P21673(SAT1)|P36406(TRIM23)|P36508(ZNF76),,,,,,,,,,,,5.0
A0A1B0GTB2,,Protein TUNAR,TUNAR,Homo sapiens,48,False,,MVITSENDEDRGGQEKESKEESVLAMLGIIGTILNLIVIIFVYIYTTL,0,,,,,,,,,,,,,,,,,,,,4.0
Q9BWQ8,,Protein lifeguard 2,FAIM2,Homo sapiens,316,False,KIAA0950|LFG|LFG2|NMP35|TMBIM2,MTQGKLSVANKAPGTEGQQQVHGEKKEAPAVPSAPPSYEEATSGEGMKAGAFPPAPTAVPLHPSWAYVDPSSSSSYDNGFPTGDHELFTTFSWDDQKVRRVFVRKVYTILLIQLLVTLAVVALFTFCDPVKDYVQANPGWYWASYAVFFATYLTLACCSGPRRHFPWNLILLTVFTLSMAYLTGMLSSYYNTTSVLLCLGITALVCLSVTVFSFQTKFDFTSCQGVLFVLLMTLFFSGLILAILLPFQYVPWLHAVYAALGAGVFTLFLALDTQLLMGNRRHSLSPEEYIFGALNIYLDIIYIFTFFLQLFGTNRE,0,,,,,,,,O95208-2(EPN2)|Q6P531(GGT6),,1:Q9BWQ8-1:|2:Q9BWQ8-2:,,,,,,,,,,5.0
Q9ULJ8,,Neurabin-1,PPP1R9A,Homo sapiens,1098,False,KIAA1222,MLKTESSGERTTLRSASPHRNAYRTEFQALKSTFDKPKSDGEQKTKEGEGSQQSRGRKYGSNVNRIKNLFMQMGMEPNENAAVIAKTRGKGGHSSPQRRMKPKEFLEKTDGSVVKLESSVSERISRFDTMYDGPSYSKFTETRKMFERSVHESGQNNRYSPKKEKAGGSEPQDEWGGSKSNRGSTDSLDSLSSRTEAVSPTVSQLSAVFENTDSPSAIISEKAENNEYSVTGHYPLNLPSVTVTNLDTFGHLKDSNSWPPSNKRGVDTEDAHKSNATPVPEVASKSTSLASIPGEEIQQSKEPEDSTSNQQTPDSIDKDGPEEPCAESKAMPKSEIPSPQSQLLEDAEANLVGREAAKQQRKELAGGDFTSPDASASSCGKEVPEDSNNFDGSHVYMHSDYNVYRVRSRYNSDWGETGTEQDEEEDSDENSYYQPDMEYSEIVGLPEEEEIPANRKIKFSSAPIKVFNTYSNEDYDRRNDEVDPVAASAEYELEKRVEKLELFPVELEKDEDGLGISIIGMGVGADAGLEKLGIFVKTVTEGGAAQRDGRIQVNDQIVEVDGISLVGVTQNFAATVLRNTKGNVRFVIGREKPGQVSEVAQLISQTLEQERRQRELLEQHYAQYDADDDETGEYATDEEEDEVGPVLPGSDMAIEVFELPENEDMFSPSELDTSKLSHKFKELQIKHAVTEAEIQKLKTKLQAAENEKVRWELEKTQLQQNIEENKERMLKLESYWIEAQTLCHTVNEHLKETQSQYQALEKKYNKAKKLIKDFQQKELDFIKRQEAERKKIEDLEKAHLVEVQGLQVRIRDLEAEVFRLLKQNGTQVNNNNNIFERRTSLGEVSKGDTMENLDGKQTSCQDGLSQDLNEAVPETERLDSKALKTRAQLSVKNRRQRPSRTRLYDSVSSTDGEDSLERKNFTFNDDFSPSSTSSADLSGLGAEPKTPGLSQSLALSSDESLDMIDDEILDDGQSPKHSQCQNRAVQEWSVQQVSHWLMSLNLEQYVSEFSAQNITGEQLLQLDGNKLKALGMTASQDRAVVKKKLKEMKMSLEKARKAQEKMEKQREKLRRKEQEQMQRKSKKTEKMTSTTAEGAGEQ,0,,,,,,,,P41220(RGS2),,1:Q9ULJ8-1:|2:Q9ULJ8-2:|3:Q9ULJ8-3:|4:Q9ULJ8-4:|5:Q9ULJ8-5:,,,,,,,,,,5.0
Q15843,,Ubiquitin-like protein NEDD8,NEDD8,Homo sapiens,81,False,,MLIKVKTLTGKEIEIDIEPTDKVERIKERVEEKEGIPPQQQRLIYSGKQMNDEKTAADYKILGGSVLHLVLALRGGGGLRQ,0,,,,,,,,Q9Y297(BTRC)|Q13616(CUL1)|P06396(GSN)|O15037(KHNYN)|Q9UNA4(POLI)|P63151(PPP2R2A)|P54725(RAD23A)|P62913(RPL11)|P18124(RPL7)|P60866(RPS20)|P23396(RPS3)|P62081(RPS7)|P04271(S100B)|Q8WXE9(STON2)|P07437(TUBB)|P61086(UBE2K)|P61081(UBE2M)|O94888(UBXN7)|P09936(UCHL1),,,,,,,,,,,,5.0
Q496J9,,Synaptic vesicle glycoprotein 2C,SV2C,Homo sapiens,727,False,KIAA1054,MEDSYKDRTSLMKGAKDIAREVKKQTVKKVNQAVDRAQDEYTQRSYSRFQDEEDDDDYYPAGETYNGEANDDEGSSEATEGHDEDDEIYEGEYQGIPSMNQAKDSIVSVGQPKGDEYKDRRELESERRADEEELAQQYELIIQECGHGRFQWALFFVLGMALMADGVEVFVVGFVLPSAETDLCIPNSGSGWLGSIVYLGMMVGAFFWGGLADKVGRKQSLLICMSVNGFFAFLSSFVQGYGFFLFCRLLSGFGIGGAIPTVFSYFAEVLAREKRGEHLSWLCMFWMIGGIYASAMAWAIIPHYGWSFSMGSAYQFHSWRVFVIVCALPCVSSVVALTFMPESPRFLLEVGKHDEAWMILKLIHDTNMRARGQPEKVFTVNKIKTPKQIDELIEIESDTGTWYRRCFVRIRTELYGIWLTFMRCFNYPVRDNTIKLTIVWFTLSFGYYGLSVWFPDVIKPLQSDEYALLTRNVERDKYANFTINFTMENQIHTGMEYDNGRFIGVKFKSVTFKDSVFKSCTFEDVTSVNTYFKNCTFIDTVFDNTDFEPYKFIDSEFKNCSFFHNKTGCQITFDDDYSAYWIYFVNFLGTLAVLPGNIVSALLMDRIGRLTMLGGSMVLSGISCFFLWFGTSESMMIGMLCLYNGLTISAWNSLDVVTVELYPTDRRATGFGFLNALCKAAAVLGNLIFGSLVSITKSIPILLASTVLVCGGLVGLCLPDTRTQVLM,0,,,,,,,,P0DPI0(botA),,,,,,,,,,,,5.0
Q7L1I2,,Synaptic vesicle glycoprotein 2B,SV2B,Homo sapiens,683,False,KIAA0735,MDDYKYQDNYGGYAPSDGYYRGNESNPEEDAQSDVTEGHDEEDEIYEGEYQGIPHPDDVKAKQAKMAPSRMDSLRGQTDLMAERLEDEEQLAHQYETIMDECGHGRFQWILFFVLGLALMADGVEVFVVSFALPSAEKDMCLSSSKKGMLGMIVYLGMMAGAFILGGLADKLGRKRVLSMSLAVNASFASLSSFVQGYGAFLFCRLISGIGIGGALPIVFAYFSEFLSREKRGEHLSWLGIFWMTGGLYASAMAWSIIPHYGWGFSMGTNYHFHSWRVFVIVCALPCTVSMVALKFMPESPRFLLEMGKHDEAWMILKQVHDTNMRAKGTPEKVFTVSNIKTPKQMDEFIEIQSSTGTWYQRWLVRFKTIFKQVWDNALYCVMGPYRMNTLILAVVWFAMAFSYYGLTVWFPDMIRYFQDEEYKSKMKVFFGEHVYGATINFTMENQIHQHGKLVNDKFTRMYFKHVLFEDTFFDECYFEDVTSTDTYFKNCTIESTIFYNTDLYEHKFINCRFINSTFLEQKEGCHMDLEQDNDFLIYLVSFLGSLSVLPGNIISALLMDRIGRLKMIGGSMLISAVCCFFLFFGNSESAMIGWQCLFCGTSIAAWNALDVITVELYPTNQRATAFGILNGLCKFGAILGNTIFASFVGITKVVPILLAAASLVGGGLIALRLPETREQVLM,0,,,,,,,,Q96LI6(HSFY2),,1:Q7L1I2-1:|2:Q7L1I2-2:,,,,,,,,,,5.0
Q7L0J3,,Synaptic vesicle glycoprotein 2A,SV2A,Homo sapiens,742,False,KIAA0736,MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFEEEDDDDDFPAPSDGYYRGEGTQDEEEGGASSDATEGHDEDDEIYEGEYQGIPRAESGGKGERMADGAPLAGVRGGLSDGEGPPGGRGEAQRRKEREELAQQYEAILRECGHGRFQWTLYFVLGLALMADGVEVFVVGFVLPSAEKDMCLSDSNKGMLGLIVYLGMMVGAFLWGGLADRLGRRQCLLISLSVNSVFAFFSSFVQGYGTFLFCRLLSGVGIGGSIPIVFSYFSEFLAQEKRGEHLSWLCMFWMIGGVYAAAMAWAIIPHYGWSFQMGSAYQFHSWRVFVLVCAFPSVFAIGALTTQPESPRFFLENGKHDEAWMVLKQVHDTNMRAKGHPERVFSVTHIKTIHQEDELIEIQSDTGTWYQRWGVRALSLGGQVWGNFLSCFGPEYRRITLMMMGVWFTMSFSYYGLTVWFPDMIRHLQAVDYASRTKVFPGERVEHVTFNFTLENQIHRGGQYFNDKFIGLRLKSVSFEDSLFEECYFEDVTSSNTFFRNCTFINTVFYNTDLFEYKFVNSRLINSTFLHNKEGCPLDVTGTGEGAYMVYFVSFLGTLAVLPGNIVSALLMDKIGRLRMLAGSSVMSCVSCFFLSFGNSESAMIALLCLFGGVSIASWNALDVLTVELYPSDKRTTAFGFLNALCKLAAVLGISIFTSFVGITKAAPILFASAALALGSSLALKLPETRGQVLQ,0,,,,,,"Developmental and epileptic encephalopathy 113:A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE113 is an autosomal recessive form characterized by severe early-onset recurrent epilepsy.",Developmental and epileptic encephalopathy 113,,,1:Q7L0J3-1:|2:Q7L0J3-2:,,,,,,,,,,5.0
O95936,,Eomesodermin homolog,EOMES,Homo sapiens,686,False,TBR2,MQLGEQLLVSSVNLPGAHFYPLESARGGSGGSAGHLPSAAPSPQKLDLDKASKKFSGSLSCEAVSGEPAAASAGAPAAMLSDTDAGDAFASAAAVAKPGPPDGRKGSPCGEEELPSAAAAAAAAAAAAAATARYSMDSLSSERYYLQSPGPQGSELAAPCSLFPYQAAAGAPHGPVYPAPNGARYPYGSMLPPGGFPAAVCPPGRAQFGPGAGAGSGAGGSSGGGGGPGTYQYSQGAPLYGPYPGAAAAGSCGGLGGLGVPGSGFRAHVYLCNRPLWLKFHRHQTEMIITKQGRRMFPFLSFNINGLNPTAHYNVFVEVVLADPNHWRFQGGKWVTCGKADNNMQGNKMYVHPESPNTGSHWMRQEISFGKLKLTNNKGANNNNTQMIVLQSLHKYQPRLHIVEVTEDGVEDLNEPSKTQTFTFSETQFIAVTAYQNTDITQLKIDHNPFAKGFRDNYDSSHQIVPGGRYGVQSFFPEPFVNTLPQARYYNGERTVPQTNGLLSPQQSEEVANPPQRWLVTPVQQPGTNKLDISSYESEYTSSTLLPYGIKSLPLQTSHALGYYPDPTFPAMAGWGGRGSYQRKMAAGLPWTSRTSPTVFSEDQLSKEKVKEEIGSSWIETPPSIKSLDSNDSGVYTSACKRRRLSPSNSSNENSPSIKCEDINAEEYSKDTSKGMGGYYAFYTTP,0,,,,,,:,,Q5XKR4(OTP),,1:O95936-1:|2:O95936-2:|3:O95936-3:|4:O95936-4:,,,,,,,,,,5.0
P17600,,Synapsin-1,SYN1,Homo sapiens,705,False,,MNYLRRRLSDSNFMANLPNGYMTDLQRPQPPPPPPGAHSPGATPGPGTATAERSSGVAPAASPAAPSPGSSGGGGFFSSLSNAVKQTTAAAAATFSEQVGGGSGGAGRGGAASRVLLVIDEPHTDWAKYFKGKKIHGEIDIKVEQAEFSDLNLVAHANGGFSVDMEVLRNGVKVVRSLKPDFVLIRQHAFSMARNGDYRSLVIGLQYAGIPSVNSLHSVYNFCDKPWVFAQMVRLHKKLGTEEFPLIDQTFYPNHKEMLSSTTYPVVVKMGHAHSGMGKVKVDNQHDFQDIASVVALTKTYATAEPFIDAKYDVRVQKIGQNYKAYMRTSVSGNWKTNTGSAMLEQIAMSDRYKLWVDTCSEIFGGLDICAVEALHGKDGRDHIIEVVGSSMPLIGDHQDEDKQLIVELVVNKMAQALPRQRQRDASPGRGSHGQTPSPGALPLGRQTSQQPAGPPAQQRPPPQGGPPQPGPGPQRQGPPLQQRPPPQGQQHLSGLGPPAGSPLPQRLPSPTSAPQQPASQAAPPTQGQGRQSRPVAGGPGAPPAARPPASPSPQRQAGPPQATRQTSVSGPAPPKASGAPPGGQQRQGPPQKPPGPAGPTRQASQAGPVPRTGPPTTQQPRPSGPGPAGRPKPQLAQKPSQDVPPPATAAAGGPPHPQLNKSQSLTNAFNLPEPAPPRPSLSQDEVKAETIRSLRKSFASLFSD,0,,,,,,"Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders:A neurologic disorder characterized by variable combinations of epilepsy, learning difficulties, macrocephaly, and aggressive behavior.|Intellectual developmental disorder, X-linked 50:A form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked forms, while syndromic forms present with associated physical, neurological and/or psychiatric manifestations.","Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders|Intellectual developmental disorder, X-linked 50",,,IA:P17600-1:|IB:P17600-2:,,,,,,,,,,5.0
P16860,,Natriuretic peptides B,NPPB,Homo sapiens,134,False,,MDPQTAPSRALLLLLFLHLAFLGGRSHPLGSPGSASDLETSGLQEQRNHLQGKLSELQVEQTSLEPLQESPRPTGVWKSREVATEGIRGHRKMVLYTLRAPRSPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH,0,,,,,,,,A8MQ03(CYSRT1)|P57678(GEMIN4)|Q6A162(KRT40)|P60411(KRTAP10-9)|Q7Z3S9(NOTCH2NLA)|P25788(PSMA3)|Q9UJW9(SERTAD3),,,,,,,,,,,,5.0
Q9UJD0,,Regulating synaptic membrane exocytosis protein 3,RIMS3,Homo sapiens,308,False,KIAA0237,MFNGEPGPASSGASRNVVRSSSISGEICGSQQAGGGAGTTTAKKRRSSLGAKMVAIVGLTQWSKSTLQLPQPEGATKKLRSNIRRSTETGIAVEMRSRVTRQGSRESTDGSTNSNSSDGTFIFPTTRLGAESQFSDFLDGLGPAQIVGRQTLATPPMGDVHIAIMDRSGQLEVEVIEARGLTPKPGSKSLPATYIKVYLLENGACLAKKKTKMTKKTCDPLYQQALLFDEGPQGKVLQVIVWGDYGRMDHKCFMGMAQIMLDELDLSAAVTGWYKLFPTSSVADSTLGSLTRRLSQSSLESATSPSCS,0,,,,,,,,P21964-2(COMT)|Q5SUL5(HLA-A)|Q92993(KAT5)|Q8TAP4-4(LMO3)|Q6FHY5(MEOX2)|P16284(PECAM1)|Q9NRD5(PICK1)|Q15047-2(SETDB1)|P08670(VIM)|P61981(YWHAG),,1:Q9UJD0-1:|2:Q9UJD0-2:,,,,,,,,,,5.0
Q9H1V8,,Sodium-dependent neutral amino acid transporter SLC6A17,SLC6A17,Homo sapiens,727,False,NTT4,MPKNSKVTQREHSSEHVTESVADLLALEEPVDYKQSVLNVAGEAGGKQKAVEEELDAEDRPAWNSKLQYILAQIGFSVGLGNIWRFPYLCQKNGGGAYLVPYLVLLIIIGIPLFFLELAVGQRIRRGSIGVWHYICPRLGGIGFSSCIVCLFVGLYYNVIIGWSIFYFFKSFQYPLPWSECPVVRNGSVAVVEAECEKSSATTYFWYREALDISDSISESGGLNWKMTLCLLVAWSIVGMAVVKGIQSSGKVMYFSSLFPYVVLACFLVRGLLLRGAVDGILHMFTPKLDKMLDPQVWREAATQVFFALGLGFGGVIAFSSYNKQDNNCHFDAALVSFINFFTSVLATLVVFAVLGFKANIMNEKCVVENAEKILGYLNTNVLSRDLIPPHVNFSHLTTKDYMEMYNVIMTVKEDQFSALGLDPCLLEDELDKSVQGTGLAFIAFTEAMTHFPASPFWSVMFFLMLINLGLGSMIGTMAGITTPIIDTFKVPKEMFTVGCCVFAFLVGLLFVQRSGNYFVTMFDDYSATLPLTLIVILENIAVAWIYGTKKFMQELTEMLGFRPYRFYFYMWKFVSPLCMAVLTTASIIQLGVTPPGYSAWIKEEAAERYLYFPNWAMALLITLIVVATLPIPVVFVLRHFHLLSDGSNTLSVSYKKGRMMKDISNLEENDETRFILSKVPSEAPSPMPTHRSYLGPGSTSPLETSGNPNGRYGSGYLLASTPESEL,0,,,,,,"Intellectual developmental disorder, autosomal recessive 48:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT48 patients show moderate to severe intellectual disability and additional features including progressive tremor, speech impairment, and sometimes behavioral problems.","Intellectual developmental disorder, autosomal recessive 48",Q12983(BNIP3),,,,,,,,,,,,5.0
Q9P2U7,,Vesicular glutamate transporter 1,SLC17A7,Homo sapiens,560,False,BNPI|VGLUT1,MEFRQEEFRKLAGRALGKLHRLLEKRQEGAETLELSADGRPVTTQTRDPPVVDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVSMVNNSTTHRGGHVVVQKAQFSWDPETVGLIHGSFFWGYIVTQIPGGFICQKFAANRVFGFAIVATSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPPLERSRLATTAFCGSYAGAVVAMPLAGVLVQYSGWSSVFYVYGSFGIFWYLFWLLVSYESPALHPSISEEERKYIEDAIGESAKLMNPLTKFSTPWRRFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGLVSALPHLVMTIIVPIGGQIADFLRSRRIMSTTNVRKLMNCGGFGMEATLLLVVGYSHSKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKHKTREEWQYVFLIASLVHYGGVIFYGVFASGEKQPWAEPEEMSEEKCGFVGHDQLAGSDDSEMEDEAEPPGAPPAPPPSYGATHSTFQPPRPPPPVRDY,0,,,,,,,,,,1:Q9P2U7-1:|2:Q9P2U7-2:|3:Q9P2U7-3:,,,,,,,,,,5.0
P08247,,Synaptophysin,SYP,Homo sapiens,313,False,,MLLLADMDVVNQLVAGGQFRVVKEPLGFVKVLQWVFAIFAFATCGSYSGELQLSVDCANKTESDLSIEVEFEYPFRLHQVYFDAPTCRGGTTKVFLVGDYSSSAEFFVTVAVFAFLYSMGALATYIFLQNKYRENNKGPMLDFLATAVFAFMWLVSSSAWAKGLSDVKMATDPENIIKEMPVCRQTGNTCKELRDPVTSGLNTSVVFGFLNLVLWVGNLWFVFKETGWAAPFLRAPPGAPEKQPAPGDAYGDAGYGQGPGGYGPQDSYGPQGGYQPDYGQPAGSGGSGYGPQGDYGQQGYGPQGAPTSFSNQM,0,,,,,,"Intellectual developmental disorder, X-linked 96:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.","Intellectual developmental disorder, X-linked 96",P05067(APP)|P53365(ARFIP2)|O75155(CAND2)|O95971(CD160)|Q9NR28(DIABLO)|O95363(FARS2)|P39905-3(GDNF)|Q9UBD0(HSFX2)|P42858(HTT)|Q8TAC2(JOSD2)|P13473-2(LAMP2)|Q9C0E8-2(LNPK)|Q9NQG6(MIEF1)|Q96C03-3(MIEF2)|Q6IN84(MRM1)|Q96E11(MRRF)|Q96E29(MTERF3)|Q9HB07(MYG1)|Q9ULP0-2(NDRG4)|Q96AL5(PBX3)|Q9UKF7-2(PITPNC1)|O60664(PLIN3)|Q96T60(PNKP)|P30405(PPIF)|O75127(PTCD1)|P43378(PTPN9)|Q8N0V3(RBFA)|Q9Y371(SH3GLB1)|Q9H0W8(SMG9)|Q13596(SNX1)|Q9NZD8(SPG21)|O60225-2(SSX5)|Q96DR4(STARD4)|Q8WY91(THAP4)|Q13885(TUBB2A)|A0A384ME17(TUFM)|Q96P53(WDFY2)|Q9Y4P8-4(WIPI2),,1:P08247-1:|2:P08247-2:,,,,,,,,,,5.0
Q86UR5,,Regulating synaptic membrane exocytosis protein 1,RIMS1,Homo sapiens,1692,False,KIAA0340|RAB3IP2|RIM1,MSSAVGPRGPRPPTVPPPMQELPDLSHLTEEERNIIMAVMDRQKEEEEKEEAMLKCVVRDMAKPAACKTPRNAENQPHQPSPRLHQQFESYKEQVRKIGEEARRYQGEHKDDAPTCGICHKTKFADGCGHLCSYCRTKFCARCGGRVSLRSNNEDKVVMWVCNLCRKQQEILTKSGAWFFGSGPQQTSQDGTLSDTATGAGSEVPREKKARLQERSRSQTPLSTAAASSQDAAPPSAPPDRSKGAEPSQQALGPEQKQASSRSRSEPPRERKKTPGLSEQNGKGALKSERKRVPKTSAQPVEGAVEERERKERRESRRLEKGRSQDYPDTPEKRDEGKAADEEKQRKEEDYQTRYRSDPNLARYPVKPPPEEQQMRMHARVSRARHERRHSDVALPRTEAGAALPEGKAGKRAPAAARASPPDSPRAYSAERTAETRAPGAKQLTNHSPPAPRHGPVPAEAPELKAQEPLRKQSRLDPSSAVLMRKAKREKVETMLRNDSLSSDQSESVRPSPPKPHRSKRGGKKRQMSVSSSEEEGVSTPEYTSCEDVELESESVSEKGDLDYYWLDPATWHSRETSPISSHPVTWQPSKEGDRLIGRVILNKRTTMPKDSGALLGLKVVGGKMTDLGRLGAFITKVKKGSLADVVGHLRAGDEVLEWNGKPLPGATNEEVYNIILESKSEPQVEIIVSRPIGDIPRIPESSHPPLESSSSSFESQKMERPSISVISPTSPGALKDAPQVLPGQLSVKLWYDKVGHQLIVNVLQATDLPARVDGRPRNPYVKMYFLPDRSDKSKRRTKTVKKILEPKWNQTFVYSHVHRRDFRERMLEITVWDQPRVQEEESEFLGEILIELETALLDDEPHWYKLQTHDESSLPLPQPSPFMPRRHIHGESSSKKLQRSQRISDSDISDYEVDDGIGVVPPVGYRSSARESKSTTLTVPEQQRTTHHRSRSVSPHRGNDQGKPRSRLPNVPLQRSLDEIHPTRRSRSPTRHHDASRSPVDHRTRDVDSQYLSEQDSELLMLPRAKRGRSAECLHTTRHLVRHYKTLPPKMPLLQSSSHWNIYSSILPAHTKTKSVTRQDISLHHECFNSTVLRFTDEILVSELQPFLDRARSASTNCLRPDTSLHSPERERGRWSPSLDRRRPPSPRIQIQHASPENDRHSRKSERSSIQKQTRKGTASDAERVLPTCLSRRGHAAPRATDQPVIRGKHPARSRSSEHSSIRTLCSMHHLVPGGSAPPSPLLTRMHRQRSPTQSPPADTSFSSRRGRQLPQVPVRSGSIEQASLVVEERTRQMKMKVHRFKQTTGSGSSQELDREQYSKYNIHKDQYRSCDNVSAKSSDSDVSDVSAISRTSSASRLSSTSFMSEQSERPRGRISSFTPKMQGRRMGTSGRSIMKSTSVSGEMYTLEHNDGSQSDTAVGTVGAGGKKRRSSLSAKVVAIVSRRSRSTSQLSQTESGHKKLKSTIQRSTETGMAAEMRKMVRQPSRESTDGSINSYSSEGNLIFPGVRLGADSQFSDFLDGLGPAQLVGRQTLATPAMGDIQIGMEDKKGQLEVEVIRARSLTQKPGSKSTPAPYVKVYLLENGACIAKKKTRIARKTLDPLYQQSLVFDESPQGKVLQVIVWGDYGRMDHKCFMGVAQILLEELDLSSMVIGWYKLFPPSSLVDPTLTPLTRRASQSSLESSTGPPCIRS,0,,,,,,,,P00519(ABL1)|P51114(FXR1)|P06241(FYN)|O75899(GABBR2)|P27448(MARK3)|Q9UKM9(RALY)|P78362(SRPK2),,1:Q86UR5-1:|2:Q86UR5-2:|3:Q86UR5-3:|4:Q86UR5-4:|5:Q86UR5-5:|6:Q86UR5-6:|7:Q86UR5-7:|8:Q86UR5-8:|9:Q86UR5-9:|10:Q86UR5-10:|11:Q86UR5-11:|12:Q86UR5-12:|13:Q86UR5-13:,,,,,,,,,,5.0
Q05940,,Synaptic vesicular amine transporter,SLC18A2,Homo sapiens,514,False,SVMT|VMAT2,MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKNATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSDCPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMFAFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGPPFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILIAAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMGRWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVSVYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAKEEKMAILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD,0,,,,,,"Parkinsonism-dystonia 2, infantile-onset:An autosomal recessive disorder characterized by infantile onset of abnormal movements, including parkinsonism, dystonia, and poor fine motor skills, as well as autonomic dysfunction, including abnormal sweating, cold extremities, and poor sleep. Some patients have variable degrees of developmental delay.","Parkinsonism-dystonia 2, infantile-onset",Q6PL45-2(BRICD5)|Q9BXR6(CFHR5)|Q96DZ9-2(CMTM5)|P25025(CXCR2)|Q8TDV0(GPR151)|Q6N075(MFSD5)|Q16617(NKG7)|P30825(SLC7A1)|Q9BVC6(TMEM109)|Q96B49(TOMM6),,1:Q05940-1:|2:Q05940-2:,,,,,,,,,,5.0
Q99536,,Synaptic vesicle membrane protein VAT-1 homolog,VAT1,Homo sapiens,393,False,,MSDEREVAEAATGEDASSPPPKTEAASDPQHPAASEGAAAAAASPPLLRCLVLTGFGGYDKVKLQSRPAAPPAPGPGQLTLRLRACGLNFADLMARQGLYDRLPPLPVTPGMEGAGVVIAVGEGVSDRKAGDRVMVLNRSGMWQEEVTVPSVQTFLIPEAMTFEEAAALLVNYITAYMVLFDFGNLQPGHSVLVHMAAGGVGMAAVQLCRTVENVTVFGTASASKHEALKENGVTHPIDYHTTDYVDEIKKISPKGVDIVMDPLGGSDTAKGYNLLKPMGKVVTYGMANLLTGPKRNLMALARTWWNQFSVTALQLLQANRAVCGFHLGYLDGEVELVSGVVARLLALYNQGHIKPHIDSVWPFEKVADAMKQMQEKKNVGKVLLVPGPEKEN,0,,,,,,,,P60201-2(PLP1),,1:Q99536-1:|2:Q99536-2:|3:Q99536-3:,,,,,,,,,,5.0
P11216,,"Glycogen phosphorylase, brain form",PYGB,Homo sapiens,843,False,,MAKPLTDSEKRKQISVRGLAGLGDVAEVRKSFNRHLHFTLVKDRNVATPRDYFFALAHTVRDHLVGRWIRTQQHYYERDPKRIYYLSLEFYMGRTLQNTMVNLGLQNACDEAIYQLGLDLEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKIVNGWQVEEADDWLRYGNPWEKARPEYMLPVHFYGRVEHTPDGVKWLDTQVVLAMPYDTPVPGYKNNTVNTMRLWSAKAPNDFKLQDFNVGDYIEAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTCFETFPDKVAIQLNDTHPALSIPELMRILVDVEKVDWDKAWEITKKTCAYTNHTVLPEALERWPVSMFEKLLPRHLEIIYAINQRHLDHVAALFPGDVDRLRRMSVIEEGDCKRINMAHLCVIGSHAVNGVARIHSEIVKQSVFKDFYELEPEKFQNKTNGITPRRWLLLCNPGLADTIVEKIGEEFLTDLSQLKKLLPLVSDEVFIRDVAKVKQENKLKFSAFLEKEYKVKINPSSMFDVHVKRIHEYKRQLLNCLHVVTLYNRIKRDPAKAFVPRTVMIGGKAAPGYHMAKLIIKLVTSIGDVVNHDPVVGDRLKVIFLENYRVSLAEKVIPAADLSQQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGAENLFIFGLRVEDVEALDRKGYNAREYYDHLPELKQAVDQISSGFFSPKEPDCFKDIVNMLMHHDRFKVFADYEAYMQCQAQVDQLYRNPKEWTKKVIRNIACSGKFSSDRTITEYAREIWGVEPSDLQIPPPNIPRD,0,,,,,,,,Q13451(FKBP5)|O60741(HCN1)|Q86XI6(PPP1R3B)|P06737(PYGL)|P11217(PYGM)|Q8IUQ4(SIAH1),,,,,,,,,,,,5.0
Q96PV0,,Ras/Rap GTPase-activating protein SynGAP,SYNGAP1,Homo sapiens,1343,False,KIAA1938,MSRSRASIHRGSIPAMSYAPFRDVRGPSMHRTQYVHSPYDRPGWNPRFCIISGNQLLMLDEDEIHPLLIRDRRSESSRNKLLRRTVSVPVEGRPHGEHEYHLGRSRRKSVPGGKQYSMEGAPAAPFRPSQGFLSRRLKSSIKRTKSQPKLDRTSSFRQILPRFRSADHDRARLMQSFKESHSHESLLSPSSAAEALELNLDEDSIIKPVHSSILGQEFCFEVTTSSGTKCFACRSAAERDKWIENLQRAVKPNKDNSRRVDNVLKLWIIEARELPPKKRYYCELCLDDMLYARTTSKPRSASGDTVFWGEHFEFNNLPAVRALRLHLYRDSDKKRKKDKAGYVGLVTVPVATLAGRHFTEQWYPVTLPTGSGGSGGMGSGGGGGSGGGSGGKGKGGCPAVRLKARYQTMSILPMELYKEFAEYVTNHYRMLCAVLEPALNVKGKEEVASALVHILQSTGKAKDFLSDMAMSEVDRFMEREHLIFRENTLATKAIEEYMRLIGQKYLKDAIGEFIRALYESEENCEVDPIKCTASSLAEHQANLRMCCELALCKVVNSHCVFPRELKEVFASWRLRCAERGREDIADRLISASLFLRFLCPAIMSPSLFGLMQEYPDEQTSRTLTLIAKVIQNLANFSKFTSKEDFLGFMNEFLELEWGSMQQFLYEISNLDTLTNSSSFEGYIDLGRELSTLHALLWEVLPQLSKEALLKLGPLPRLLNDISTALRNPNIQRQPSRQSERPRPQPVVLRGPSAEMQGYMMRDLNSSIDLQSFMARGLNSSMDMARLPSPTKEKPPPPPPGGGKDLFYVSRPPLARSSPAYCTSSSDITEPEQKMLSVNKSVSMLDLQGDGPGGRLNSSSVSNLAAVGDLLHSSQASLTAALGLRPAPAGRLSQGSGSSITAAGMRLSQMGVTTDGVPAQQLRIPLSFQNPLFHMAADGPGPPGGHGGGGGHGPPSSHHHHHHHHHHRGGEPPGDTFAPFHGYSKSEDLSSGVPKPPAASILHSHSYSDEFGPSGTDFTRRQLSLQDNLQHMLSPPQITIGPQRPAPSGPGGGSGGGSGGGGGGQPPPLQRGKSQQLTVSAAQKPRPSSGNLLQSPEPSYGPARPRQQSLSKEGSIGGSGGSGGGGGGGLKPSITKQHSQTPSTLNPTMPASERTVAWVSNMPHLSADIESAHIEREEYKLKEYSKSMDESRLDRVKEYEEEIHSLKERLHMSNRKLEEYERRLLSQEEQTSKILMQYQARLEQSEKRLRQQQAEKDSQIKSIIGRLMLVEEELRRDHPAMAEPLPEPKKRLLDAQERQLPPLGPTNPRVTLAPPWNGLAPPAPPPPPRLQITENGEFRNTADH,0,,,,,,"Intellectual developmental disorder, autosomal dominant 5:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD5 patients show global developmental delay with delayed motor development, hypotonia, moderate-to-severe intellectual disability, and severe language impairment. Epilepsy and autism can be present in some patients.","Intellectual developmental disorder, autosomal dominant 5",O60716(CTNND1)|Q5JVL4(EFHC1)|Q14576(ELAVL3)|O95208(EPN2)|Q06787(FMR1)|P51114(FXR1)|P09471(GNAO1)|Q96NT3-2(GUCD1)|P10412(H1-4)|O60741(HCN1)|P22626(HNRNPA2B1)|O75031(HSF2BP)|P61371(ISL1)|Q86U70(LDB1)|Q9UJV3-2(MID2)|Q13064(MKRN3)|O43639(NCK2)|Q7Z3B1(NEGR1)|Q96HA8(NTAQ1)|Q8TAQ2(SMARCC2)|Q99932-2(SPAG8)|P51687(SUOX)|O43711(TLX3)|P14373(TRIM27)|Q96PN8(TSSK3)|O95231(VENTX),,1:Q96PV0-1:|2:Q96PV0-2:|3:Q96PV0-3:|4:Q96PV0-4:,,,,,,,,,,5.0
Q8WXS3,,Brain and acute leukemia cytoplasmic protein,BAALC,Homo sapiens,145,False,,MGCGGSRADAIEPRYYESWTRETESTWLTYTDSDAPPSAAAPDSGPEAGGLHSGMLEDGLPSNGVPRSTAPGGIPNPEKKTNCETQCPNPQSLSSGPLTQKQNGLQTTEAKRDAKRMPAKEVTINVTDSIQQMDRSRRITKNCVN,0,,,,,,,,P41227(NAA10)|Q9BSU3(NAA11),,1:Q8WXS3-2:|2:Q8WXS3-1:|3:Q8WXS3-3:|4:Q8WXS3-4:|5:Q8WXS3-5:|6:Q8WXS3-6:,,,,,,,,,,5.0
Q8TB68,,Proline-rich protein 7,PRR7,Homo sapiens,274,False,,MVMSQGTYTFLTCFAGFWLIWGLIVLLCCFCSFLRRRLKRRQEERLREQNLRALELEPLELEGSLAGSPPGLAPPQPPPHRSRLEAPAHAHSHPHVHVHPLLHHGPAQPHAHAHPHPHHHALPHPPPTHLSVPPRPWSYPRQAESDMSKPPCYEEAVLMAEPPPPYSEVLTDTRGLYRKIVTPFLSRRDSAEKQEQPPPSYKPLFLDRGYTSALHLPSAPRPAPPCPALCLQADRGRRVFPSWTDSELSSREPLEHGAWRLPVSIPLFGRTTAV,0,,,,,,,,P46934(NEDD4),,1:Q8TB68-1:|2:Q8TB68-2:,,,,,,,,,,5.0
Q9UJQ1,,Lysosome-associated membrane glycoprotein 5,LAMP5,Homo sapiens,280,False,C20orf103,MDLQGRGVPSIDRLRVLLMLFHTMAQIMAEQEVENLSGLSTNPEKDIFVVRENGTTCLMAEFAAKFIVPYDVWASNYVDLITEQADIALTRGAEVKGRCGHSQSELQVFWVDRAYALKMLFVKESHNMSKGPEATWRLSKVQFVYDSSEKTHFKDAVSAGKHTANSHHLSALVTPAGKSYECQAQQTISLASSDPQKTVTMILSAVHIQPFDIISDFVFSEEHKCPVDEREQLEETLPLILGLILGLVIMVTLAIYHVHHKMTANQVQIPRDRSQYKHMG,0,,,,,,,,,,1:Q9UJQ1-1:|2:Q9UJQ1-2:,,,,,,,,,,5.0
O95415,,Membrane protein BRI3,BRI3,Homo sapiens,125,False,,MDHKPLLQERPPAYNLEAGQGDYACGPHGYGAIPAAPPPPPYPYLVTGIPTHHPRVYNIHSRTVTRYPANSIVVVGGCPVCRVGVLEDCFTFLGIFLAIILFPFGFICCFALRKRRCPNCGATFA,0,,,,,,,,O95870(ABHD16A)|Q8WY22(BRI3BP)|Q01628(IFITM3)|Q13021(MALL)|P26572(MGAT1),,1:O95415-1:|2:O95415-2:,,,,,,,,,,5.0
Q9BUH8,,Brain-enriched guanylate kinase-associated protein,BEGAIN,Homo sapiens,593,False,KIAA1446,MEKLSALQEQKGELRKRLSYTTHKLEKLETEFDSTRHYLEIELRRAQEELEKVTEKLRRIQSNYMALQRINQELEDKLYRMGQHYEEEKRALSHEIVALNSHLLEAKVTIDKLSEDNELYRKDCNLAAQLLQCSQTYGRVHKVSELPSDFQERVSLHMEKHGCSLPSPLCHPAYADSVPTCVIAKVLEKPDPASLSSRLSDASARDLAFCDGVEKPGPRPPYKGDIYCSDTALYCPEERRRDRRPSVDAPVTDVGFLRAQNSTDSAAEEEEEAEAAAFPAGFQHEAFPSYAGSLPTSSSYSSFSATSEEKEHAQASTLTASQQAIYLNSRDELFDRKPPATTYEGSPRFAKATAAVAAPLEAEVAPGFGRTMSPYPAETFRFPASPGPQQALMPPNLWSLRAKPGTARLPGEDMRGQWRPLSVEDIGAYSYPVSAAGRASPCSFSERYYGGAGGSPGKKADGRASPLYASYKADSFSEGDDLSQGHLAEPCFLRAGGDLSLSPGRSADPLPGYAPSEGGDGDRLGVQLCGTASSPEPEQGSRDSLEPSSMEASPEMHPAARLSPQQAFPRTGGSGLSRKDSLTKAQLYGTLLN,0,,,,,,,,P29972(AQP1)|Q8N5M1(ATPAF2)|P18075(BMP7)|Q9UJX2(CDC23)|P26196(DDX6)|O60941-5(DTNB)|Q9H0I2(ENKD1)|Q3B820(FAM161A)|Q86YD7(FAM90A1)|P55040(GEM)|Q96IK5(GMCL1)|Q96NT3-2(GUCD1)|P56524-2(HDAC4)|Q9BVG8-5(KIFC3)|Q96BZ8(LENG1)|Q8N8X9(MAB21L3)|Q96CV9(OPTN)|Q99633(PRPF18)|P0CG20(PRR35)|Q86YV0(RASAL3)|P28749(RBL1)|Q8IYX7(SAXO1)|Q9BT92(TCHP)|Q9BUZ4(TRAF4)|Q9P2F9(ZNF319)|Q8TAU3(ZNF417)|Q7Z3I7(ZNF572)|Q96SQ5(ZNF587)|Q5T619(ZNF648)|Q6NX45(ZNF774)|Q9Y2P0(ZNF835)|Q96EG3(ZNF837),,,,,,,,,,,,5.0
O15056,,Synaptojanin-2,SYNJ2,Homo sapiens,1496,False,KIAA0348,MALSKGLRLLGRLGAEGDCSVLLEARGRDDCLLFEAGTVATLAPEEKEVIKGQYGKLTDAYGCLGELRLKSGGTSLSFLVLVTGCTSVGRIPDAEIYKITATDFYPLQEEAKEEERLIALKKILSSGVFYFSWPNDGSRFDLTVRTQKQGDDSSEWGNSFFWNQLLHVPLRQHQVSCCDWLLKIICGVVTIRTVYASHKQAKACLVSRVSCERTGTRFHTRGVNDDGHVSNFVETEQMIYMDDGVSSFVQIRGSVPLFWEQPGLQVGSHHLRLHRGLEANAPAFDRHMVLLKEQYGQQVVVNLLGSRGGEEVLNRAFKKLLWASCHAGDTPMINFDFHQFAKGGKLEKLETLLRPQLKLHWEDFDVFTKGENVSPRFQKGTLRMNCLDCLDRTNTVQSFIALEVLHLQLKTLGLSSKPIVDRFVESFKAMWSLNGHSLSKVFTGSRALEGKAKVGKLKDGARSMSRTIQSNFFDGVKQEAIKLLLVGDVYGEEVADKGGMLLDSTALLVTPRILKAMTERQSEFTNFKRIRIAMGTWNVNGGKQFRSNVLRTAELTDWLLDSPQLSGATDSQDDSSPADIFAVGFEEMVELSAGNIVNASTTNKKMWGEQLQKAISRSHRYILLTSAQLVGVCLYIFVRPYHVPFIRDVAIDTVKTGMGGKAGNKGAVGIRFQFHSTSFCFICSHLTAGQSQVKERNEDYKEITQKLCFPMGRNVFSHDYVFWCGDFNYRIDLTYEEVFYFVKRQDWKKLLEFDQLQLQKSSGKIFKDFHEGAINFGPTYKYDVGSAAYDTSDKCRTPAWTDRVLWWRKKHPFDKTAGELNLLDSDLDVDTKVRHTWSPGALQYYGRAELQASDHRPVLAIVEVEVQEVDVGARERVFQEVSSFQGPLDATVVVNLQSPTLEEKNEFPEDLRTELMQTLGSYGTIVLVRINQGQMLVTFADSHSALSVLDVDGMKVKGRAVKIRPKTKDWLKGLREEIIRKRDSMAPVSPTANSCLLEENFDFTSLDYESEGDILEDDEDYLVDEFNQPGVSDSELGGDDLSDVPGPTALAPPSKSPALTKKKQHPTYKDDADLVELKRELEAVGEFRHRSPSRSLSVPNRPRPPQPPQRPPPPTGLMVKKSASDASISSGTHGQYSILQTARLLPGAPQQPPKARTGISKPYNVKQIKTTNAQEAEAAIRCLLEARGGASEEALSAVAPRDLEASSEPEPTPGAAKPETPQAPPLLPRRPPPRVPAIKKPTLRRTGKPLSPEEQFEQQTVHFTIGPPETSVEAPPVVTAPRVPPVPKPRTFQPGKAAERPSHRKPASDEAPPGAGASVPPPLEAPPLVPKVPPRRKKSAPAAFHLQVLQSNSQLLQGLTYNSSDSPSGHPPAAGTVFPQGDFLSTSSATSPDSDGTKAMKPEAAPLLGDYQDPFWNLLHHPKLLNNTWLSKSSDPLDSGTRSPKRDPIDPVSAGASAAKAELPPDHEHKTLGHWVTISDQEKRTALQVFDPLAKT,0,,,,,,,,P62993(GRB2)|P16333(NCK1)|Q96B97(SH3KBP1),,2B2:O15056-1:|2B1:O15056-2:|2A:O15056-3:,,,,,,,,,,5.0
Q15319,,"POU domain, class 4, transcription factor 3",POU4F3,Homo sapiens,338,False,BRN3C,MMAMNSKQPFGMHPVLQEPKFSSLHSGSEAMRRVCLPAPQLQGNIFGSFDESLLARAEALAAVDIVSHGKNHPFKPDATYHTMSSVPCTSTSSTVPISHPAALTSHPHHAVHQGLEGDLLEHISPTLSVSGLGAPEHSVMPAQIHPHHLGAMGHLHQAMGMSHPHTVAPHSAMPACLSDVESDPRELEAFAERFKQRRIKLGVTQADVGAALANLKIPGVGSLSQSTICRFESLTLSHNNMIALKPVLQAWLEEAEAAYREKNSKPELFNGSERKRKRTSIAAPEKRSLEAYFAIQPRPSSEKIAAIAEKLDLKKNVVRVWFCNQRQKQKRMKYSAVH,0,,,,,,"Deafness, autosomal dominant, 15:A form of non-syndromic hearing loss with variable phenotype in terms of age at onset, levels of progression, and shape of audiograms.","Deafness, autosomal dominant, 15",Q9H596(DUSP21)|Q08379(GOLGA2)|Q15323(KRT31)|Q3LI67(KRTAP6-3)|P0CG21(NHLRC4)|O15496(PLA2G10),,,,,,,,,,,,5.0
Q12837,,"POU domain, class 4, transcription factor 2",POU4F2,Homo sapiens,409,False,BRN3B,MMMMSLNSKQAFSMPHGGSLHVEPKYSALHSTSPGSSAPIAPSASSPSSSSNAGGGGGGGGGGGGGGGRSSSSSSSGSSGGGGSEAMRRACLPTPPSNIFGGLDESLLARAEALAAVDIVSQSKSHHHHPPHHSPFKPDATYHTMNTIPCTSAASSSSVPISHPSALAGTHHHHHHHHHHHHQPHQALEGELLEHLSPGLALGAMAGPDGAVVSTPAHAPHMATMNPMHQAALSMAHAHGLPSHMGCMSDVDADPRDLEAFAERFKQRRIKLGVTQADVGSALANLKIPGVGSLSQSTICRFESLTLSHNNMIALKPILQAWLEEAEKSHREKLTKPELFNGAEKKRKRTSIAAPEKRSLEAYFAIQPRPSSEKIAAIAEKLDLKKNVVRVWFCNQRQKQKRMKYSAGI,0,,,,,,,,Q6UY14-3(ADAMTSL4)|P05187(ALPP)|P48745(CCN3)|P15529-3(CD46)|Q5T4B2(CERCAM)|Q9UKJ5(CHIC2)|Q9H2X0(CHRD)|Q6WN34-2(CHRDL2)|P27658(COL8A1)|Q08AG9(CYP21A2)|A8MQ03(CYSRT1)|O60479(DLX3)|Q9NVL1-2(FAM86C1P)|P28799(GRN)|Q9BSH5(HDHD3)|Q4VC39(HIGD2B)|P24592(IGFBP6)|Q6UW32(IGFL1)|Q0VD86(INCA1)|Q5T749(KPRP)|Q15323(KRT31)|Q92764(KRT35)|O76015(KRT38)|P78385(KRT83)|P60412(KRTAP10-11)|P60370(KRTAP10-5)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|P59990(KRTAP12-1)|P59991(KRTAP12-2)|P60328(KRTAP12-3)|P60329(KRTAP12-4)|Q3SY46(KRTAP13-3)|Q3LHN2(KRTAP19-2)|Q3LI70(KRTAP19-6)|Q3SYF9(KRTAP19-7)|Q3LI59(KRTAP21-2)|Q9BYR7(KRTAP3-2)|Q9BYQ6(KRTAP4-11)|Q9BQ66(KRTAP4-12)|Q9BYR5(KRTAP4-2)|Q9BYR3(KRTAP4-4)|Q9BYR2(KRTAP4-5)|Q6L8G4(KRTAP5-11)|Q6L8H2(KRTAP5-3)|Q6L8H1(KRTAP5-4)|Q6L8G9(KRTAP5-6)|P26371(KRTAP5-9)|Q3LI64(KRTAP6-1)|Q3LI67(KRTAP6-3)|Q9BYQ4(KRTAP9-2)|Q9BYQ3(KRTAP9-3)|Q9BYQ0(KRTAP9-8)|Q5T751(LCE1C)|Q5T754(LCE1F)|Q5TCM9(LCE5A)|P80188(LCN2)|Q9UHV8(LGALS13)|P50458(LHX2)|Q6UXB3(LYPD2)|Q9H3L0(MMADHC)|Q8NI38(NFKBID)|A8MTQ0(NOTO)|Q92824-2(PCSK5)|Q9NRY7(PLSCR2)|P10745(RBP3)|Q93062-3(RBPMS)|P49795(RGS19)|Q9C004(SPRY4)|P01137(TGFB1)|Q8IWZ5(TRIM42)|Q2TAL6(VWC2),,1:Q12837-1:|2:Q12837-2:,,,,,,,,,,5.0
O15540,,"Fatty acid-binding protein, brain",FABP7,Homo sapiens,132,False,BLBP|FABPB|MRG,MVEAFCATWKLTNSQNFDEYMKALGVGFATRQVGNVTKPTVIISQEGDKVVIRTLSTFKNTEISFQLGEEFDETTADDRNCKSVVSLDGDKLVHIQKWDGKETNFVREIKDGKMVMTLTFGDVVAVRHYEKA,0,,,,,,,,G5E9A7(DMWD)|O15354(GPR37)|P28799(GRN)|P28799-2(GRN)|O60333-2(KIF1B)|A0A6Q8PF08(PMP22)|Q9Y3C5(RNF11)|Q7Z699(SPRED1)|O76024(WFS1),,1:O15540-1:|2:O15540-2:,,,,,,,,,,5.0
Q9HBH7,,Protein BEX1,BEX1,Homo sapiens,125,False,,MESKEKRAVNSLSMENANQENEEKEQVANKGEPLALPLDAGEYCVPRGNRRRFRVRQPILQYRWDMMHRLGEPQARMREENMERIGEEVRQLMEKLREKQLSHSLRAVSTDPPHHDHHDEFCLMP,0,,,,,,,,Q9NZN8(CNOT2)|P78358(CTAG1B)|A8MQ03(CYSRT1)|Q9BS75(KLHL20)|Q15323(KRT31)|O76011(KRT34)|P43356(MAGEA2B)|Q99750(MDFI)|Q6FHY5(MEOX2)|Q5XKR4(OTP)|Q9NRD5(PICK1)|Q8IYF3(TEX11),,,,,,,,,,,,5.0
O95563,,Mitochondrial pyruvate carrier 2,MPC2,Homo sapiens,127,False,BRP44,MSAAGARGLRATYHRLLDKVELMLPEKLRPLYNHPAGPRTVFFWAPIMKWGLVCAGLADMARPAEKLSTAQSAVLMATGFIWSRYSLVIIPKNWSLFAVNFFVGAAGASQLFRIWRYNQELKAKAHK,0,,,,,,,,P02654(APOC1)|Q8WUW1(BRK1)|Q9UHD4(CIDEB)|Q9NR28(DIABLO)|O00429-3(DNM1L)|Q01658(DR1)|P29692-2(EEF1D)|Q9Y5Q9(GTF3C3)|Q5TGZ0(MICOS10)|Q9Y5U8(MPC1)|P0DKB6(MPC1L)|O95563(MPC2)|Q6NTF9-3(RHBDD2)|Q13596(SNX1)|Q9NZD8(SPG21)|Q17RD7(SYT16)|Q53QW1(TEX44)|O60830(TIMM17B),,,,,,,,,,,,5.0
Q4LDR2,,Cortexin-3,CTXN3,Homo sapiens,81,False,KABE,MDGGQPIPSSLVPLGNESADSSMSLEQKMTFVFVILLFIFLGILIVRCFRILLDPYRSMPTSTWADGLEGLEKGQFDHALA,0,,,,,,,,Q86Y34(ADGRG3)|Q13520(AQP6)|O43315(AQP9)|P54709(ATP1B3)|Q13323(BIK)|Q7KYR7-4(BTN2A1)|Q496F6(CD300E)|P19397(CD53)|P11912(CD79A)|Q9HA82(CERS4)|O95500(CLDN14)|Q6ZS10(CLEC17A)|Q9BXN2-6(CLEC7A)|P58418(CLRN1)|O75208(COQ9)|Q7Z7G2(CPLX4)|Q96BA8(CREB3L1)|P16410(CTLA4)|Q92838(EDA)|Q9Y282(ERGIC3)|Q5JX71(FAM209A)|O14843(FFAR3)|Q11130(FUT7)|P48165(GJA8)|P08034(GJB1)|O95377(GJB5)|Q8TDT2(GPR152)|O15529(GPR42)|Q9BZJ8(GPR61)|Q8IU57(IFNLR1)|Q8N6L0(KASH5)|Q8N743(KIR3DL3)|P26715(KLRC1)|Q86VI4(LAPTM4B)|Q5T700(LDLRAD1)|Q8TAF8(LHFPL5)|Q8N112(LSMEM2)|Q9GZY8-5(MFF)|Q99735(MGST2)|Q9H2K0(MTIF3)|Q6IBW4-4(NCAPH2)|P41143(OPRD1)|P35372-10(OPRM1)|Q9H813(PACC1)|Q8NEB5(PLPP5)|P15151(PVR)|Q9NY72(SCN3B)|Q12908(SLC10A2)|Q9HBV2(SPACA1)|P27105(STOM)|Q96MV1(TLCD4)|Q96DZ7(TM4SF19)|Q9BVX2(TMEM106C)|Q9NRX6(TMEM167B)|Q7Z7N9(TMEM179B)|O15393-2(TMPRSS2)|Q9Y320(TMX2)|O95859(TSPAN12),,,,,,,,,,,,5.0
P09972,,Fructose-bisphosphate aldolase C,ALDOC,Homo sapiens,364,False,ALDC,MPHSYPALSAEQKKELSDIALRIVAPGKGILAADESVGSMAKRLSQIGVENTEENRRLYRQVLFSADDRVKKCIGGVIFFHETLYQKDDNGVPFVRTIQDKGIVVGIKVDKGVVPLAGTDGETTTQGLDGLSERCAQYKKDGADFAKWRCVLKISERTPSALAILENANVLARYASICQQNGIVPIVEPEILPDGDHDLKRCQYVTEKVLAAVYKALSDHHVYLEGTLLKPNMVTPGHACPIKYTPEEIAMATVTALRRTVPPAVPGVTFLSGGQSEEEASFNLNAINRCPLPRPWALTFSYGRALQASALNAWRGQRDNAGAATEEFIKRAEVNGLAAQGKYEGSGEDGGAAAQSLYIANHAY,0,,,,,,,,P04075(ALDOA)|P04075-2(ALDOA)|Q49AR9(ANKS1A)|P13569(CFTR)|Q8TBB1(LNX1),,,,,,,,,,,,5.0
Q9NVN3,,Chaperone Ric-8B,RIC8B,Homo sapiens,520,False,,MDEERALYIVRAGEAGAIERVLRDYSDKHRATFKFESTDEDKRKKLCEGIFKVLIKDIPTTCQVSCLEVLRILSRDKKVLVPVTTKENMQILLRLAKLNELDDSLEKVSEFPVIVESLKCLCNIVFNSQMAQQLSLELNLAAKLCNLLRKCKDRKFINDIKCFDLRLLFLLSLLHTDIRSQLRYELQGLPLLTQILESAFSIKWTDEYESAIDHNGPPLSPQETDCAIEALKALFNVTVDSWKVHKESDSHQFRVMAAVLRHCLLIVGPTEDKTEELHSNAVNLLSNVPVSCLDVLICPLTHEETAQEATTLDELPSNKTAEKETVLKNNTMVYNGMNMEAIHVLLNFMEKRIDKGSSYREGLTPVLSLLTECSRAHRNIRKFLKDQVLPPLRDVTNRPEVGSTVRNKLVRLMTHVDLGVKQIAAEFLFVLCKERVDSLLKYTGYGNAAGLLAARGLLAGGRGDNWYSEDEDTDTEEYKNAKPKEELLKPMGLKPDGTITPLEEALNQYSVIEETSSDTD,0,,,,,,,,,,5:Q9NVN3-5:|1:Q9NVN3-1:|3:Q9NVN3-3:|4:Q9NVN3-4:,,,,,,,,,,5.0
Q8IWV2,,Contactin-4,CNTN4,Homo sapiens,1026,False,,MRLPWELLVLQSFILCLADDSTLHGPIFIQEPSPVMFPLDSEEKKVKLNCEVKGNPKPHIRWKLNGTDVDTGMDFRYSVVEGSLLINNPNKTQDAGTYQCTATNSFGTIVSREAKLQFAYLDNFKTRTRSTVSVRRGQGMVLLCGPPPHSGELSYAWIFNEYPSYQDNRRFVSQETGNLYIAKVEKSDVGNYTCVVTNTVTNHKVLGPPTPLILRNDGVMGEYEPKIEVQFPETVPTAKGATVKLECFALGNPVPTIIWRRADGKPIARKARRHKSNGILEIPNFQQEDAGLYECVAENSRGKNVARGQLTFYAQPNWIQKINDIHVAMEENVFWECKANGRPKPTYKWLKNGEPLLTRDRIQIEQGTLNITIVNLSDAGMYQCLAENKHGVIFSNAELSVIAVGPDFSRTLLKRVTLVKVGGEVVIECKPKASPKPVYTWKKGRDILKENERITISEDGNLRIINVTKSDAGSYTCIATNHFGTASSTGNLVVKDPTRVMVPPSSMDVTVGESIVLPCQVTHDHSLDIVFTWSFNGHLIDFDRDGDHFERVGGQDSAGDLMIRNIQLKHAGKYVCMVQTSVDRLSAAADLIVRGPPGPPEAVTIDEITDTTAQLSWRPGPDNHSPITMYVIQARTPFSVGWQAVSTVPELIDGKTFTATVVGLNPWVEYEFRTVAANVIGIGEPSRPSEKRRTEEALPEVTPANVSGGGGSKSELVITWETVPEELQNGRGFGYVVAFRPYGKMIWMLTVLASADASRYVFRNESVHPFSPFEVKVGVFNNKGEGPFSPTTVVYSAEEEPTKPPASIFARSLSATDIEVFWASPLEKNRGRIQGYEVKYWRHEDKEENARKIRTVGNQTSTKITNLKGSVLYHLAVKAYNSAGTGPSSATVNVTTRKPPPSQPPGNIIWNSSDSKIILNWDQVKALDNESEVKGYKVLYRWNRQSSTSVIETNKTSVELSLPFDEDYIIEIKPFSDGGDGSSSEQIRIPKISNAYARGSGASTSNACTLSAISTIMISLTARSSL,0,,,,,,:,,,,1:Q8IWV2-1:|2:Q8IWV2-2:|3:Q8IWV2-3:|4:Q8IWV2-4:,,,,,,,,,,5.0
Q9ULX5,,RING finger protein 112,RNF112,Homo sapiens,631,False,BFP|ZNF179,MPRPALSVTSFCHRLGKRERKQSFMGNSGNSWSHTPFPKLELGLGPQPMAPRELPTCSICLERLRDPISLDCGHDFCIRCFSTHRLPGCEPPCCPECRKICKQKRGLRSLGEKMKLLPQRPLPPALQETCPVRAEPLLLVRINASGGLILRMGAINRCLKHPLARDTPVCLLAVLGEQHSGKSFLLNHLLQGLPGLESGEGGRPRGGEASLQGCRWGANGLARGIWMWSHPFLLGKEGKKVAVFLVDTGDAMSPELSRETRIKLCALTTMLSSYQILSTSQELKDTDLDYLEMFVHVAEVMGKHYGMVPIQHLDLLVRDSSHPNKAGQGHVGNIFQRLSGRYPKVQELLQGKRARCCLLPAPGRRRMNQGHASPGDTDDDFRHLLGAYVSDVLSAAPQHAKSRCQGYWNEGRAVARGDRRLLTGQQLAQEIKNLSGWMGRTGPGFTSPDEMAAQLHDLRKVEAAKREFEEYVRQQDVATKRIFSALRVLPDTMRNLLSTQKDAILARHGVALLCKGRDQTLEALEAELQATAKAFMDSYTMRFCGHLAAVGGAVGAGLMGLAGGVVGAGMAAAALAAEAGMVAAGAAVGATGAAVVGGGVGAGLAATVGCMEKEEDERLLEGDREPLLQEE,0,,,,,,,,P01023(A2M)|P05067(APP)|P05067-2(APP)|P54253(ATXN1)|P09172(DBH)|Q14203-5(DCTN1)|P26378-2(ELAVL4)|P28799(GRN)|P42858(HTT)|P51608(MECP2)|P19404(NDUFV2)|Q96CV9(OPTN)|Q99497(PARK7)|Q7Z412(PEX26)|O14832(PHYH)|A0A6Q8PF08(PMP22)|O60260-5(PRKN)|P41219(PRPH)|P49768-2(PSEN1)|Q9Y3C5(RNF11)|P37840(SNCA)|P00441(SOD1)|Q13148(TARDBP)|P09936(UCHL1),,1:Q9ULX5-1:|2:Q9ULX5-2:,,,,,,,,,,5.0
Q9UQ26,,Regulating synaptic membrane exocytosis protein 2,RIMS2,Homo sapiens,1411,False,KIAA0751|RAB3IP3|RIM2,MSAPVGPRGRLAPIPAASQPPLQPEMPDLSHLTEEERKIILAVMDRQKKKVKEEHKPQLTQWFPFSGITELVNNVLQPQQKQQNEKEPQTKLHQQFEMYKEQVKKMGEESQQQQEQKGDAPTCGICHKTKFADGCGHNCSYCQTKFCARCGGRVSLRSNKVMWVCNLCRKQQEILTKSGAWFYNSGSNTPQQPDQKVLRGLRNEEAPQEKKPKLHEQTQFQGPSGDLSVPAVEKSRSHGLTRQHSIKNGSGVKHHIASDIASDRKRSPSVSRDQNRRYDQREEREEYSQYATSDTAMPRSPSDYADRRSQHEPQFYEDSDHLSYRDSNRRSHRHSKEYIVDDEDVESRDEYERQRREEEYQSRYRSDPNLARYPVKPQPYEEQMRIHAEVSRARHERRHSDVSLANADLEDSRISMLRMDRPSRQRSISERRAAMENQRSYSMERTREAQGPSSYAQRTTNHSPPTPRRSPLPIDRPDLRRTDSLRKQHHLDPSSAVRKTKREKMETMLRNDSLSSDQSESVRPPPPKPHKSKKGGKMRQISLSSSEEELASTPEYTSCDDVEIESESVSEKGDSQKGKRKTSEQAVLSDSNTRSERQKEMMYFGGHSLEEDLEWSEPQIKDSGVDTCSSTTLNEEHSHSDKHPVTWQPSKDGDRLIGRILLNKRLKDGSVPRDSGAMLGLKVVGGKMTESGRLCAFITKVKKGSLADTVGHLRPGDEVLEWNGRLLQGATFEEVYNIILESKPEPQVELVVSRPIGDIPRIPDSTHAQLESSSSSFESQKMDRPSISVTSPMSPGMLRDVPQFLSGQLSIKLWFDKVGHQLIVTILGAKDLPSREDGRPRNPYVKIYFLPDRSDKNKRRTKTVKKTLEPKWNQTFIYSPVHRREFRERMLEITLWDQARVREEESEFLGEILIELETALLDDEPHWYKLQTHDVSSLPLPHPSPYMPRRQLHGESPTRRLQRSKRISDSEVSDYDCDDGIGVVSDYRHDGRDLQSSTLSVPEQVMSSNHCSPSGSPHRVDVIGRTRSWSPSVPPPQSRNVEQGLRGTRTMTGHYNTISRMDRHRVMDDHYSPDRDRDCEAADRQPYHRSRSTEQRPLLERTTTRSRSTERPDTNLMRSMPSLMTGRSAPPSPALSRSHPRTGSVQTSPSSTPVAGRRGRQLPQLPPKGTLDRKAGGKKLRSTVQRSTETGLAVEMRNWMTRQASRESTDGSMNSYSSEGNLIFPGVRLASDSQFSDFLDGLGPAQLVGRQTLATPAMGDIQVGMMDKKGQLEVEIIRARGLVVKPGSKTLPAPYVKVYLLDNGVCIAKKKTKVARKTLEPLYQQLLSFEESPQGKVLQIIVWGDYGRMDHKSFMGVAQILLDELELSNMVIGWFKLFPPSSLVDPTLAPLTRRASQSSLESSTGPSYSRS,0,,,,,,"Cone-rod synaptic disorder syndrome, congenital non-progressive:An autosomal recessive disorder characterized by reduced visual acuity, photophobia, nystagmus, distinctive electroretinographic features, neurodevelopmental delay, poor or absent language, autistic behaviors, and abnormal glucose homeostasis.","Cone-rod synaptic disorder syndrome, congenital non-progressive",P16333(NCK1),,6:Q9UQ26-6:|1:Q9UQ26-1:|2:Q9UQ26-2:|3:Q9UQ26-3:|4:Q9UQ26-4:|5:Q9UQ26-5:|7:Q9UQ26-7:|8:Q9UQ26-8:,,,,,,,,,,5.0
Q8TDC3,,Serine/threonine-protein kinase BRSK1,BRSK1,Homo sapiens,778,False,KIAA1811|SAD1|SADB,MSSGAKEGGGGSPAYHLPHPHPHPPQHAQYVGPYRLEKTLGKGQTGLVKLGVHCITGQKVAIKIVNREKLSESVLMKVEREIAILKLIEHPHVLKLHDVYENKKYLYLVLEHVSGGELFDYLVKKGRLTPKEARKFFRQIVSALDFCHSYSICHRDLKPENLLLDEKNNIRIADFGMASLQVGDSLLETSCGSPHYACPEVIKGEKYDGRRADMWSCGVILFALLVGALPFDDDNLRQLLEKVKRGVFHMPHFIPPDCQSLLRGMIEVEPEKRLSLEQIQKHPWYLGGKHEPDPCLEPAPGRRVAMRSLPSNGELDPDVLESMASLGCFRDRERLHRELRSEEENQEKMIYYLLLDRKERYPSCEDQDLPPRNDVDPPRKRVDSPMLSRHGKRRPERKSMEVLSITDAGGGGSPVPTRRALEMAQHSQRSRSVSGASTGLSSSPLSSPRSPVFSFSPEPGAGDEARGGGSPTSKTQTLPSRGPRGGGAGEQPPPPSARSTPLPGPPGSPRSSGGTPLHSPLHTPRASPTGTPGTTPPPSPGGGVGGAAWRSRLNSIRNSFLGSPRFHRRKMQVPTAEEMSSLTPESSPELAKRSWFGNFISLDKEEQIFLVLKDKPLSSIKADIVHAFLSIPSLSHSVLSQTSFRAEYKASGGPSVFQKPVRFQVDISSSEGPEPSPRRDGSGGGGIYSVTFTLISGPSRRFKRVVETIQAQLLSTHDQPSVQALADEKNGAQTRPAGAPPRSLQPPPGRPDPELSSSPRRGPPKDKKLLATNGTPLP,0,,,,,,,,,,1:Q8TDC3-1:|2:Q8TDC3-2:|3:Q8TDC3-3:,,,,,,,,,,5.0
Q8N126,,Cell adhesion molecule 3,CADM3,Homo sapiens,398,False,IGSF4B|NECL1|SYNCAM3|TSLL1,MGAPAASLLLLLLLFACCWAPGGANLSQDDSQPWTSDETVVAGGTVVLKCQVKDHEDSSLQWSNPAQQTLYFGEKRALRDNRIQLVTSTPHELSISISNVALADEGEYTCSIFTMPVRTAKSLVTVLGIPQKPIITGYKSSLREKDTATLNCQSSGSKPAARLTWRKGDQELHGEPTRIQEDPNGKTFTVSSSVTFQVTREDDGASIVCSVNHESLKGADRSTSQRIEVLYTPTAMIRPDPPHPREGQKLLLHCEGRGNPVPQQYLWEKEGSVPPLKMTQESALIFPFLNKSDSGTYGCTATSNMGSYKAYYTLNVNDPSPVPSSSSTYHAIIGGIVAFIVFLLLIMLIFLGHYLIRHKGTYLTHEAKGSDDAPDADTAIINAEGGQSGGDDKKEYFI,0,,,,,,"Charcot-Marie-Tooth disease, axonal, 2FF:A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2FF is characterized by early-childhood onset of difficulties walking or running due to atrophy and weakness of the lower limbs. Some patients lose independent ambulation. There is also prominent involvement of the upper limbs.","Charcot-Marie-Tooth disease, axonal, 2FF",Q9BY50(SEC11C),,1:Q8N126-1:|2:Q8N126-2:|3:Q8N126-3:,,,,,,,,,,5.0
Q15413,,Ryanodine receptor 3,RYR3,Homo sapiens,4870,False,HBRR,MAEGGEGGEDEIQFLRTEDEVVLQCIATIHKEQRKFCLAAEGLGNRLCFLEPTSEAKYIPPDLCVCNFVLEQSLSVRALQEMLANTGENGGEGAAQGGGHRTLLYGHAVLLRHSFSGMYLTCLTTSRSQTDKLAFDVGLREHATGEACWWTIHPASKQRSEGEKVRIGDDLILVSVSSERYLHLSVSNGNIQVDASFMQTLWNVHPTCSGSSIEEGYLLGGHVVRLFHGHDECLTIPSTDQNDSQHRRIFYEAGGAGTRARSLWRVEPLRISWSGSNIRWGQAFRLRHLTTGHYLALTEDQGLILQDRAKSDTKSTAFSFRASKELKEKLDSSHKRDIEGMGVPEIKYGDSVCFVQHIASGLWVTYKAQDAKTSRLGPLKRKVILHQEGHMDDGLTLQRCQREESQAARIIRNTTALFSQFVSGNNRTAAPITLPIEEVLQTLQDLIAYFQPPEEEMRHEDKQNKLRSLKNRQNLFKEEGMLALVLNCIDRLNVYNSVAHFAGIAREESGMAWKEILNLLYKLLAALIRGNRNNCAQFSNNLDWLISKLDRLESSSGILEVLHCILTESPEALNLIAEGHIKSIISLLDKHGRNHKVLDILCSLCLCNGVAVRANQNLICDNLLPRRNLLLQTRLINDVTSIRPNIFLGVAEGSAQYKKWYFELIIDQVDPFLTAEPTHLRVGWASSSGYAPYPGGGEGWGGNGVGDDLYSYGFDGLHLWSGRIPRAVASINQHLLRSDDVVSCCLDLGVPSISFRINGQPVQGMFENFNTDGLFFPVMSFSAGVKVRFLMGGRHGEFKFLPPSGYAPCYEALLPKEKMRLEPVKEYKRDADGIRDLLGTTQFLSQASFIPCPVDTSQVILPPHLEKIRDRLAENIHELWGMNKIELGWTFGKIRDDNKRQHPCLVEFSKLPETEKNYNLQMSTETLKTLLALGCHIAHVNPAAEEDLKKVKLPKNYMMSNGYKPAPLDLSDVKLLPPQEILVDKLAENAHNVWAKDRIKQGWTYGIQQDLKNKRNPRLVPYALLDERTKKSNRDSLREAVRTFVGYGYNIEPSDQELADSAVEKVSIDKIRFFRVERSYAVRSGKWYFEFEVVTGGDMRVGWARPGCRPDVELGADDQAFVFEGNRGQRWHQGSGYFGRTWQPGDVVGCMINLDDASMIFTLNGELLITNKGSELAFADYEIENGFVPICCLGLSQIGRMNLGTDASTFKFYTMCGLQEGFEPFAVNMNRDVAMWFSKRLPTFVNVPKDHPHIEVMRIDGTMDSPPCLKVTHKTFGTQNSNADMIYCRLSMPVECHSSFSHSPCLDSEAFQKRKQMQEILSHTTTQCYYAIRIFAGQDPSCVWVGWVTPDYHLYSEKFDLNKNCTVTVTLGDERGRVHESVKRSNCYMVWGGDIVASSQRSNRSNVDLEIGCLVDLAMGMLSFSANGKELGTCYQVEPNTKVFPAVFLQPTSTSLFQFELGKLKNAMPLSAAIFRSEEKNPVPQCPPRLDVQTIQPVLWSRMPNSFLKVETERVSERHGWVVQCLEPLQMMALHIPEENRCVDILELCEQEDLMRFHYHTLRLYSAVCALGNSRVAYALCSHVDLSQLFYAIDNKYLPGLLRSGFYDLLISIHLASAKERKLMMKNEYIIPITSTTRNIRLFPDESKRHGLPGVGLRTCLKPGFRFSTPCFVVTGEDHQKQSPEIPLESLRTKALSMLTEAVQCSGAHIRDPVGGSVEFQFVPVLKLIGTLLVMGVFDDDDVRQILLLIDPSVFGEHSAGTEEGAEKEEVTQVEEKAVEAGEKAGKEAPVKGLLQTRLPESVKLQMCELLSYLCDCELQHRVEAIVAFGDIYVSKLQANQKFRYNELMQALNMSAALTARKTKEFRSPPQEQINMLLNFQLGENCPCPEEIREELYDFHEDLLLHCGVPLEEEEEEEEDTSWTGKLCALVYKIKGPPKPEKEQPTEEEERCPTTLKELISQTMICWAQEDQIQDSELVRMMFNLLRRQYDSIGELLQALRKTYTISHTSVSDTINLLAALGQIRSLLSVRMGKEEELLMINGLGDIMNNKVFYQHPNLMRVLGMHETVMEVMVNVLGTEKSQIAFPKMVASCCRFLCYFCRISRQNQKAMFEHLSYLLENSSVGLASPSMRGSTPLDVAASSVMDNNELALSLEEPDLEKVVTYLAGCGLQSCPMLLAKGYPDVGWNPIEGERYLSFLRFAVFVNSESVEENASVVVKLLIRRPECFGPALRGEGGNGLLAAMQGAIKISENPALDLPSQGYKREVSTGDDEEEEEIVHMGNAIMSFYSALIDLLGRCAPEMHLIQTGKGEAIRIRSILRSLVPTEDLVGIISIPLKLPSLNKDGSVSEPDMAANFCPDHKAPMVLFLDRVYGIKDQTFLLHLLEVGFLPDLRASASLDTVSLSTTEAALALNRYICSAVLPLLTRCAPLFAGTEHCTSLIDSTLQTIYRLSKGRSLTKAQRDTIEECLLAICNHLRPSMLQQLLRRLVFDVPQLNEYCKMPLKLLTNHYEQCWKYYCLPSGWGSYGLAVEEELHLTEKLFWGIFDSLSHKKYDPDLFRMALPCLSAIAGALPPDYLDTRITATLEKQISVDADGNFDPKPINTMNFSLPEKLEYIVTKYAEHSHDKWACDKSQSGWKYGISLDENVKTHPLIRPFKTLTEKEKEIYRWPARESLKTMLAVGWTVERTKEGEALVQQRENEKLRSVSQANQGNSYSPAPLDLSNVVLSRELQGMVEVVAENYHNIWAKKKKLELESKGGGSHPLLVPYDTLTAKEKFKDREKAQDLFKFLQVNGIIVSRGMKDMELDASSMEKRFAYKFLKKILKYVDSAQEFIAHLEAIVSSGKTEKSPRDQEIKFFAKVLLPLVDQYFTSHCLYFLSSPLKPLSSSGYASHKEKEMVAGLFCKLAALVRHRISLFGSDSTTMVSCLHILAQTLDTRTVMKSGSELVKAGLRAFFENAAEDLEKTSENLKLGKFTHSRTQIKGVSQNINYTTVALLPILTSIFEHVTQHQFGMDLLLGDVQISCYHILCSLYSLGTGKNIYVERQRPALGECLASLAAAIPVAFLEPTLNRYNPLSVFNTKTPRERSILGMPDTVEDMCPDIPQLEGLMKEINDLAESGARYTEMPHVIEVILPMLCNYLSYWWERGPENLPPSTGPCCTKVTSEHLSLILGNILKIINNNLGIDEASWMKRIAVYAQPIISKARPDLLRSHFIPTLEKLKKKAVKTVQEEEQLKADGKGDTQEAELLILDEFAVLCRDLYAFYPMLIRYVDNNRSNWLKSPDADSDQLFRMVAEVFILWCKSHNFKREEQNFVIQNEINNLAFLTGDSKSKMSKAMQVKSGGQDQERKKTKRRGDLYSIQTSLIVAALKKMLPIGLNMCTPGDQELISLAKSRYSHRDTDEEVREHLRNNLHLQEKSDDPAVKWQLNLYKDVLKSEEPFNPEKTVERVQRISAAVFHLEQVEQPLRSKKAVWHKLLSKQRKRAVVACFRMAPLYNLPRHRSINLFLHGYQRFWIETEEYSFEEKLVQDLAKSPKVEEEEEEETEKQPDPLHQIILYFSRNALTERSKLEDDPLYTSYSSMMAKSCQSGEDEEEDEDKEKTFEEKEMEKQKTLYQQARLHERGAAEMVLQMISASKGEMSPMVVETLKLGIAILNGGNAGVQQKMLDYLKEKKDAGFFQSLSGLMQSCSVLDLNAFERQNKAEGLGMVTEEGTLIVRERGEKVLQNDEFTRDLFRFLQLLCEGHNSDFQNFLRTQMGNTTTVNVIISTVDYLLRLQESISDFYWYYSGKDIIDESGQHNFSKALAVTKQIFNSLTEYIQGPCIGNQQSLAHSRLWDAVVGFLHVFANMQMKLSQDSSQIELLKELLDLLQDMVVMLLSLLEGNVVNGTIGKQMVDTLVESSTNVEMILKFFDMFLKLKDLTSSDTFKEYDPDGKGIISKKEFQKAMEGQKQYTQSEIDFLLSCAEADENDMFNYVDFVDRFHEPAKDIGFNVAVLLTNLSEHMPNDSRLKCLLDPAESVLNYFEPYLGRIEIMGGAKKIERVYFEISESSRTQWEKPQVKESKRQFIFDVVNEGGEQEKMELFVNFCEDTIFEMQLASQISESDSADRPEEEEEDEDSSYVLEIAGEEEEDGSLEPASAFAMACASVKRNVTDFLKRATLKNLRKQYRNVKKMTAKELVKVLFSFFWMLFVGLFQLLFTILGGIFQILWSTVFGGGLVEGAKNIRVTKILGDMPDPTQFGIHDDTMEAERAEVMEPGITTELVHFIKGEKGDTDIMSDLFGLHPKKEGSLKHGPEVGLGDLSEIIGKDEPPTLESTVQKKRKAQAAEMKAANEAEGKVESEKADMEDGEKEDKDKEEEQAEYLWTEVTKKKKRRCGQKVEKPEAFTANFFKGLEIYQTKLLHYLARNFYNLRFLALFVAFAINFILLFYKVTEEPLEEETEDVANLWNSFNDEEEEEAMVFFVLQESTGYMAPTLRALAIIHTIISLVCVVGYYCLKVPLVVFKREKEIARKLEFDGLYITEQPSEDDIKGQWDRLVINTPSFPNNYWDKFVKRKVINKYGDLYGAERIAELLGLDKNALDFSPVEETKAEAASLVSWLSSIDMKYHIWKLGVVFTDNSFLYLAWYTTMSVLGHYNNFFFAAHLLDIAMGFKTLRTILSSVTHNGKQLVLTVGLLAVVVYLYTVVAFNFFRKFYNKSEDDDEPDMKCDDMMTCYLFHMYVGVRAGGGIGDEIEDPAGDPYEMYRIVFDITFFFFVIVILLAIIQGLIIDAFGELRDQQEQVREDMETKCFICGIGNDYFDTTPHGFETHTLQEHNLANYLFFLMYLINKDETEHTGQESYVWKMYQERCWDFFPAGDCFRKQYEDQLG,0,,,,,,"Congenital myopathy 20:An autosomal recessive neuromuscular disorder characterized by variable manifestations. Some patients have congenital limb or distal contractures manifesting soon after birth, while others develop muscle weakness with difficulty running and climbing stairs in early childhood. Additional features may include facial dysmorphism, and delayed development with intellectual disability. Skeletal muscle biopsy may show variation in fiber size with type 1 fiber predominance and atrophy, hypertrophic type 2 fibers, and abundant nemaline bodies.",Congenital myopathy 20,,,1:Q15413-1:|2:Q15413-2:|3:Q15413-3:,,,,,,,,,,5.0
Q9BXY8,,Protein BEX2,BEX2,Homo sapiens,128,False,,MESKEERALNNLIVENVNQENDEKDEKEQVANKGEPLALPLNVSEYCVPRGNRRRFRVRQPILQYRWDIMHRLGEPQARMREENMERIGEEVRQLMEKLREKQLSHSLRAVSTDPPHHDHHDEFCLMP,0,,,,,,,,Q6PJH3(AKAP9)|Q9H2G9(BLZF1)|Q96GS4(BORCS6)|Q13137(CALCOCO2)|Q8NCU1(CCDC197)|Q2TAC2-2(CCDC57)|A6NC98(CCDC88B)|Q01850(CDR2)|Q8NHQ1(CEP70)|Q9H9E3(COG4)|P78358(CTAG1B)|A8MQ03(CYSRT1)|Q14204(DYNC1H1)|Q8IYI6(EXOC8)|A1L4K1(FSD2)|P19883(FST)|Q6PI77(GPRASP3)|O75031(HSF2BP)|Q16082(HSPB2)|Q9BS75(KLHL20)|Q92876(KLK6)|Q9Y448(KNSTRN)|P19012(KRT15)|P08727(KRT19)|Q7Z3Y8(KRT27)|Q15323(KRT31)|O76011(KRT34)|O76015(KRT38)|Q6A163(KRT39)|Q6A162(KRT40)|P02538(KRT6A)|O95678(KRT75)|P60410(KRTAP10-8)|Q8IUC1(KRTAP11-1)|P59991(KRTAP12-2)|Q9BYR9(KRTAP2-4)|Q3LI59(KRTAP21-2)|Q9BYR6(KRTAP3-3)|P26371(KRTAP5-9)|Q3LI66(KRTAP6-2)|Q3LI67(KRTAP6-3)|P80188(LCN2)|O95751(LDOC1)|Q9BRK4(LZTS2)|P43364-2(MAGEA11)|P43356(MAGEA2B)|Q1RN33(MAGEA4)|Q99750(MDFI)|Q8TD10(MIPOL1)|Q13064(MKRN3)|Q6PF18(MORN3)|Q96DV4(MRPL38)|Q4VC12(MSS51)|Q5JR59-3(MTUS2)|Q7Z6G3-2(NECAB2)|Q8NI38(NFKBID)|O43482(OIP5)|O15496(PLA2G10)|Q58EX7(PLEKHG4)|Q8ND90(PNMA1)|Q9GZV8(PRDM14)|Q96C74(ROPN1L)|Q9UJW9(SERTAD3)|Q7Z699(SPRED1)|O43610(SPRY3)|Q9Y2D8(SSX2IP)|Q8N0S2(SYCE1)|Q9Y6A5(TACC3)|Q13077(TRAF1)|Q12933(TRAF2)|P14373(TRIM27)|Q8IWZ5(TRIM42)|Q86WT6-2(TRIM69)|Q86UV6-2(TRIM74)|Q15654(TRIP6)|Q8N6Y0(USHBP1)|Q9UK41-2(VPS28)|P17023(ZNF19),,1:Q9BXY8-1:|2:Q9BXY8-2:,,,,,,,,,,5.0
Q14863,,"POU domain, class 6, transcription factor 1",POU6F1,Homo sapiens,301,False,BRN5|MPOU|TCFB1,MPGISSQILTNAQGQVIGTLPWVVNSASVAAPAPAQSLQVQAVTPQLLLNAQGQVIATLASSPLPPPVAVRKPSTPESPAKSEVQPIQPTPTVPQPAVVIASPAPAAKPSASAPIPITCSETPTVSQLVSKPHTPSLDEDGINLEEIREFAKNFKIRRLSLGLTQTQVGQALTATEGPAYSQSAICRFEKLDITPKSAQKLKPVLEKWLNEAELRNQEGQQNLMEFVGGEPSKKRKRRTSFTPQAIEALNAYFEKNPLPTGQEITEIAKELNYDREVVRVWFCNRRQTLKNTSKLNVFQIP,0,,,,,,,,O00154-4(ACOT7)|Q13952-2(NFYC),,,,,,,,,,,,5.0
Q9ULH4,,Leucine-rich repeat and fibronectin type-III domain-containing protein 2,LRFN2,Homo sapiens,789,False,KIAA1246|SALM1,METLLGGLLAFGMAFAVVDACPKYCVCQNLSESLGTLCPSKGLLFVPPDIDRRTVELRLGGNFIIHISRQDFANMTGLVDLTLSRNTISHIQPFSFLDLESLRSLHLDSNRLPSLGEDTLRGLVNLQHLIVNNNQLGGIADEAFEDFLLTLEDLDLSYNNLHGLPWDSVRRMVNLHQLSLDHNLLDHIAEGTFADLQKLARLDLTSNRLQKLPPDPIFARSQASALTATPFAPPLSFSFGGNPLHCNCELLWLRRLERDDDLETCGSPGGLKGRYFWHVREEEFVCEPPLITQHTHKLLVLEGQAATLKCKAIGDPSPLIHWVAPDDRLVGNSSRTAVYDNGTLDIFITTSQDSGAFTCIAANAAGEATAMVEVSIVQLPHLSNSTSRTAPPKSRLSDITGSSKTSRGGGGSGGGEPPKSPPERAVLVSEVTTTSALVKWSVSKSAPRVKMYQLQYNCSDDEVLIYRMIPASNKAFVVNNLVSGTGYDLCVLAMWDDTATTLTATNIVGCAQFFTKADYPQCQSMHSQILGGTMILVIGGIIVATLLVFIVILMVRYKVCNHEAPSKMAAAVSNVYSQTNGAQPPPPSSAPAGAPPQGPPKVVVRNELLDFTASLARASDSSSSSSLGSGEAAGLGRAPWRIPPSAPRPKPSLDRLMGAFASLDLKSQRKEELLDSRTPAGRGAGTSARGHHSDREPLLGPPAARARSLLPLPLEGKAKRSHSFDMGDFAAAAAGGVVPGGYSPPRKVSNIWTKRSLSVNGMLLPFEESDLVGARGTFGSSEWVMESTV,0,,,,,,,,,,,,,,,,,,,,5.0
Q5TCY1,,Tau-tubulin kinase 1,TTBK1,Homo sapiens,1321,False,BDTK|KIAA1855,MQCLAAALKDETNMSGGGEQADILPANYVVKDRWKVLKKIGGGGFGEIYEAMDLLTRENVALKVESAQQPKQVLKMEVAVLKKLQGKDHVCRFIGCGRNEKFNYVVMQLQGRNLADLRRSQPRGTFTLSTTLRLGKQILESIEAIHSVGFLHRDIKPSNFAMGRLPSTYRKCYMLDFGLARQYTNTTGDVRPPRNVAGFRGTVRYASVNAHKNREMGRHDDLWSLFYMLVEFAVGQLPWRKIKDKEQVGMIKEKYEHRMLLKHMPSEFHLFLDHIASLDYFTKPDYQLIMSVFENSMKERGIAENEAFDWEKAGTDALLSTSTSTPPQQNTRQTAAMFGVVNVTPVPGDLLRENTEDVLQGEHLSDQENAPPILPGRPSEGLGPSPHLVPHPGGPEAEVWEETDVNRNKLRINIGKSPCVEEEQSRGMGVPSSPVRAPPDSPTTPVRSLRYRRVNSPESERLSTADGRVELPERRSRMDLPGSPSRQACSSQPAQMLSVDTGHADRQASGRMDVSASVEQEALSNAFRSVPLAEEEDFDSKEWVIIDKETELKDFPPGAEPSTSGTTDEEPEELRPLPEEGEERRRLGAEPTVRPRGRSMQALAEEDLQHLPPQPLPPQLSQGDGRSETSQPPTPGSPSHSPLHSGPRPRRRESDPTGPQRQVFSVAPPFEVNGLPRAVPLSLPYQDFKRDLSDYRERARLLNRVRRVGFSHMLLTTPQVPLAPVQPQANGKEEEEEEEEDEEEEEEDEEEEEEEEEEEEEEEEEEEEEEEAAAAVALGEVLGPRSGSSSEGSERSTDRSQEGAPSTLLADDQKESRGRASMADGDLEPEEGSKTLVLVSPGDMKKSPVTAELAPDPDLGTLAALTPQHERPQPTGSQLDVSEPGTLSSVLKSEPKPPGPGAGLGAGTVTTGVGGVAVTSSPFTKVERTFVHIAEKTHLNVMSSGGQALRSEEFSAGGELGLELASDGGAVEEGARAPLENGLALSGLNGAEIEGSALSGAPRETPSEMATNSLPNGPALADGPAPVSPLEPSPEKVATISPRRHAMPGSRPRSRIPVLLSEEDTGSEPSGSLSAKERWSKRARPQQDLARLVMEKRQGRLLLRLASGASSSSSEEQRRASETLSGTGSEEDTPASEPAAALPRKSGRAAATRSRIPRPIGLRMPMPVAAQQPASRSHGAAPALDTAITSRLQLQTPPGSATAADLRPKQPPGRGLGPGRAQAGARPPAPRSPRLPASTSAARNASASPRSQSLSRRESPSPSHQARPGVPPPRGVPPARAQPDGTPSPGGSKKGPRGKLQAQRATTKGRAGGAEGRAGAR,0,,,,,,,,,,1:Q5TCY1-1:|2:Q5TCY1-2:,,,,,,,,,,5.0
Q15382,,GTP-binding protein Rheb,RHEB,Homo sapiens,184,False,RHEB2,MPQSKSRKIAILGYRSVGKSSLTIQFVEGQFVDSYDPTIENTFTKLITVNGQEYHLQLVDTAGQDEYSIFPQTYSIDINGYILVYSVTSIKSFEVIKVIHGKLLDMVGKVQIPIMLVGNKKDLHMERVISYEEGKALAESWNAAFLESSAKENQTAVDVFRRIILEAEKMDGAASQGKSSCSVM,0,,,,,,,,Q92624(APPBP2)|P55212(CASP6)|P06307(CCK)|P22607(FGFR3)|Q14957(GRIN2C)|O00291(HIP1)|P13473-2(LAMP2)|P42345(MTOR)|Q13393(PLD1)|O75400-2(PRPF40A)|P62826(RAN)|P13693(TPT1)|Q9UMX0(UBQLN1)|Q9Y649()|O43924(PDE6D),,,,,,,,,,,,5.0
Q16572,,Vesicular acetylcholine transporter,SLC18A3,Homo sapiens,532,False,VACHT,MESAEPAGQARAAATKLSEAVGAALQEPRRQRRLVLVIVCVALLLDNMLYMVIVPIVPDYIAHMRGGGEGPTRTPEVWEPTLPLPTPANASAYTANTSASPTAAWPAGSALRPRYPTESEDVKIGVLFASKAILQLLVNPLSGPFIDRMSYDVPLLIGLGVMFASTVLFAFAEDYATLFAARSLQGLGSAFADTSGIAMIADKYPEEPERSRALGVALAFISFGSLVAPPFGGILYEFAGKRVPFLVLAAVSLFDALLLLAVAKPFSAAARARANLPVGTPIHRLMLDPYIAVVAGALTTCNIPLAFLEPTIATWMKHTMAASEWEMGMAWLPAFVPHVLGVYLTVRLAARYPHLQWLYGALGLAVIGASSCIVPACRSFAPLVVSLCGLCFGIALVDTALLPTLAFLVDVRHVSVYGSVYAIADISYSVAYALGPIVAGHIVHSLGFEQLSLGMGLANLLYAPVLLLLRNVGLLTRSRSERDVLLDEPPQGLYDAVRLRERPVSGQDGEPRSPPGPFDACEDDYNYYYTRS,0,,,,,,"Myasthenic syndrome, congenital, 21, presynaptic:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS21 is an autosomal recessive, pre-synaptic form characterized by ptosis, ophthalmoplegia, fatigable weakness, apneic crises, and deterioration of symptoms in cold water. Learning difficulties and left ventricular dysfunction may be present in some patients.","Myasthenic syndrome, congenital, 21, presynaptic",Q9P0B6(CCDC167)|Q9GZY8-5(MFF)|I3L0A0(PEDS1-UBE2V1),,,,,,,,,,,,5.0
O94812,,BAI1-associated protein 3,BAIAP3,Homo sapiens,1187,False,KIAA0734,MRPRGAAFAAGPPGDLHLGTAIGFAGAIWRSRSPAMSTLLDIKSSVLRQVQVCPSFRRRTEQDPGSASADPQEPATGAWKPGDGVEFFAHMRLMLKKGEGRQGLPCLEVPLRSGSPAPPEPVDPSLGLRALAPEEVEMLYEEALYTVLYRAGTMGPDQVDDEEALLSYLQQVFGTSLEEHTEAIERVRKAKAPTYALKVSVMRAKNLLAKDPNGFSDPYCMLGILPASDATREPRAQKEQRFGFRKGSKRGGPLPAKCIQVTEVKSSTLNPVWKEHFLFEIEDVSTDQLHLDIWDHDDDVSLVEACRKLNEVIGLKGMGRYFKQIVKSARANGTAGPTEDHTDDFLGCLNIPVREVPVAGVDRWFKLEPRSSASRVQGHCHLVLKLITTQRDTAMSQRGRSGFLSHLLLLSHLLRLEHSAEEPNSSSWRGELSTPAATILCLHGAQSNLSPLQLAVLHWQVSSRHHQTCTLDYSYLLGLLEDMQAHWEEAPSLPQEQEESLADSLSAFSEFGLQLLRQLRDYFPATNSTAVHRLELLLKCLGKLQLFQPSFEICPFESELNMDIAAALKRGNREWYDRILNDKSPREQPGPQRLPGLVVLADAVYDDLQFCYSVYASLFHSILNVDVFTLTFRQLERLVAEEAWVLTEELSPKMTLEVASGLFELYLTLADLQRFWDSIPGRDSRSLALAGIHAPFLPAVKLWFQVLRDQAKWRLQGAVDMDTLEPVDASSRHSSSAATAGLCLSHIQELWVRLAWPDPAQAQGLGTQLGQDVCEATLFYTELLRKKVDTQPGAAGEAVSEALCVVLNNVELVRKAAGQALKGLAWPEGATGPEGVLPRPLLSCTQALDDDLQREAHTVTAHLTSKMVGDIRKYVQHISLSPDSIQNDEAVAPLMKYLDEKLALLNASLVKGNLSRVLEALWELLLQAILQALGANRDVSADFYSRFHFTLEALVSFFHAEGQGLPLESLRDGSYKRLKEELRLHKCSTRECIEQFYLDKLKQRTLEQNRFGRLSVRCHYEAAEQRLAVEVLHAADLLPLDANGLSDPFVIVELGPPHLFPLVRSQRTQVKTRTLHPVYDELFYFSVPAEACRRRAACVLFTVMDHDWLSTNDFAGEAALGLGGVTGVARPQVGGGARAGQPVTLHLCRPRAQVRSALRRLEGRTSKEAQEFVKKLKELEKCMEADP,0,,,,,,,,,,1:O94812-1:|2:O94812-2:|3:O94812-3:|4:O94812-5:|5:O94812-6:|6:O94812-7:,,,,,,,,,,5.0
Q8TAI7,,GTPase RhebL1,RHEBL1,Homo sapiens,183,False,,MPLVRYRKVVILGYRCVGKTSLAHQFVEGEFSEGYDPTVENTYSKIVTLGKDEFHLHLVDTAGQDEYSILPYSFIIGVHGYVLVYSVTSLHSFQVIESLYQKLHEGHGKTRVPVVLVGNKADLSPEREVQAVEGKKLAESWGATFMESSARENQLTQGIFTKVIQEIARVENSYGQERRCHLM,0,,,,,,,,Q9UKG1(APPL1)|P54253(ATXN1)|Q13643(FHL3)|O43741(PRKAB2)|Q7Z699(SPRED1)|P09936(UCHL1),,1:Q8TAI7-1:|2:Q8TAI7-2:,,,,,,,,,,5.0
P23560,,Neurotrophic factor BDNF precursor form,BDNF,Homo sapiens,247,False,,MTILFLTMVISYFGCMKAAPMKEANIRGQGGLAYPGVRTHGTLESVNGPKAGSRGLTSLADTFEHVIEELLDEDQKVRPNEENNKDADLYTSRVMLSSQVPLEPPLLFLLEEYKNYLDAANMSMRVRRHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQLKQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIGWRFIRIDTSCVCTLTIKRGR,0,,,,,,,,P20783(NTF3)|P34130(NTF4)|Q6UY14-3(ADAMTSL4)|Q15109(AGER)|Q9UIJ7(AK3)|Q8IWZ3-2(ANKHD1)|Q8IWZ3-3(ANKHD1)|P09525(ANXA4)|Q8WW43(APH1B)|P05067(APP)|Q9H0C5(BTBD1)|Q9UQM7(CAMK2A)|Q9BV29(CCDC32)|Q00535(CDK5)|Q6QEF8-4(CORO6)|Q14194(CRMP1)|P35222(CTNNB1)|Q15438(CYTH1)|Q9BPW9-4(DHRS9)|P49184(DNASE1L1)|P07099(EPHX1)|O00471(EXOC5)|Q5JX71(FAM209A)|O75344(FKBP6)|Q10981(FUT2)|P06241(FYN)|P22466(GAL)|Q8NEA9(GMCL2)|Q8TDT2(GPR152)|Q9UBK5(HCST)|O43365(HOXA3)|Q96LI6-3(HSFY2)|Q92993-2(KAT5)|P18428(LBP)|Q96G30(MRAP2)|Q13405(MRPL49)|Q8TBJ4(PLPPR1)|P17612(PRKACA)|P60891(PRPS1)|Q8WUY3(PRUNE2)|Q96GQ5(RUSF1)|Q96GZ6(SLC41A3)|Q8NCS7(SLC44A5)|Q7Z614-3(SNX20)|Q99523(SORT1)|Q9H808(TLE6)|P10599(TXN)|Q15386-3(UBE3C)|Q9H6R7-2(WDCP)|O60293-2(ZFC3H1)|Q6P514(ZNF468)|A0A087WZY1(),,1:P23560-1:|2:P23560-2:|3:P23560-3:|4:P23560-4:|5:P23560-5:,,,,,,,,,,5.0
Q8TDF5,,Neuropilin and tolloid-like protein 1,NETO1,Homo sapiens,533,False,BTCL1,MIHGRSVLHIVASLIILHLSGATKKGTEKQTTSETQKSVQCGTWTKHAEGGIFTSPNYPSKYPPDRECIYIIEAAPRQCIELYFDEKYSIEPSWECKFDHIEVRDGPFGFSPIIGRFCGQQNPPVIKSSGRFLWIKFFADGELESMGFSARYNFTPDPDFKDLGALKPLPACEFEMGGSEGIVESIQIMKEGKATASEAVDCKWYIRAPPRSKIYLRFLDYEMQNSNECKRNFVAVYDGSSSVEDLKAKFCSTVANDVMLRTGLGVIRMWADEGSRNSRFQMLFTSFQEPPCEGNTFFCHSNMCINNTLVCNGLQNCVYPWDENHCKEKRKTSLLDQLTNTSGTVIGVTSCIVIILIIISVIVQIKQPRKKYVQRKSDFDQTVFQEVFEPPHYELCTLRGTGATADFADVADDFENYHKLRRSSSKCIHDHHCGSQLSSTKGSRSNLSTRDASILTEMPTQPGKPLIPPMNRRNILVMKHSYSQDAADACDIDEIEEVPTTSHRLSRHDKAVQRFCLIGSLSKHESEYNTTRV,0,,,,,,,,,,3:Q8TDF5-3:|1:Q8TDF5-1:|2:Q8TDF5-2:,,,,,,,,,,5.0
Q9H426,,Regulating synaptic membrane exocytosis protein 4,RIMS4,Homo sapiens,269,False,C20orf190,MERSQSRLSLSASFEALAIYFPCMNSFDDEDAGDSRRLKGAIQRSTETGLAVEMPSRTLRQASHESIEDSMNSYGSEGNLNYGGVCLASDAQFSDFLGSMGPAQFVGRQTLATTPMGDVEIGLQERNGQLEVDIIQARGLTAKPGSKTLPAAYIKAYLLENGICIAKKKTKVARKSLDPLYNQVLLFPESPQGKVLQVIVWGNYGRMERKQFMGVARVLLEELDLTTLAVGWYKLFPTSSMVDPATGPLLRQASQLSLESTVGPCGERS,0,,,,,,,,Q96FA3(PELI1),,1:Q9H426-1:|2:Q9H426-2:,,,,,,,,,,4.0
Q401N2,,Ligand-gated cation channel ZACN,ZACN,Homo sapiens,412,False,L2|LGICZ|LGICZ1|ZAC,MMALWSLLHLTFLGFSITLLLVHGQGFQGTAAIWPSLFNVNLSKKVQESIQIPNNGSAPLLVDVRVFVSNVFNVDILRYTMSSMLLLRLSWLDTRLAWNTSAHPRHAITLPWESLWTPRLTILEALWVDWRDQSPQARVDQDGHVKLNLALATETNCNFELLHFPRDHSNCSLSFYALSNTAMELEFQAHVVNEIVSVKREYVVYDLKTQVPPQQLVPCFQVTLRLKNTALKSIIALLVPAEALLLADVCGGLLPLRAIERIGYKVTLLLSYLVLHSSLVQALPSSSSCNPLLIYYFTILLLLLFLSTIETVLLAGLLARGNLGAKSGPSPAPRGEQREHGNPGPHPAEEPSRGVKGSQRSWPETADRIFFLVYVVGVLCTQFVFAGIWMWAACKSDAAPGEAAPHGRRPRL,0,,,,,,,,,,1:Q401N2-1:|2:Q401N2-2:|3:Q401N2-3:,,,,,,,,,,5.0
Q9H5I5,,Piezo-type mechanosensitive ion channel component 2,PIEZO2,Homo sapiens,2752,False,C18orf30|C18orf58|FAM38B,MASEVVCGLIFRLLLPICLAVACAFRYNGLSFVYLIYLLLIPLFSEPTKTTMQGHTGRLLKSLCFISLSFLLLHIIFHITLVSLEAQHRIAPGYNCSTWEKTFRQIGFESLKGADAGNGIRVFVPDIGMFIASLTIWLLCRNIVQKPVTDEAAQSNPEFENEELAEGEKIDSEEALIYEEDFNGGDGVEGELEESTKLKMFRRLASVASKLKEFIGNMITTAGKVVVTILLGSSGMMLPSLTSSVYFFVFLGLCTWWSWCRTFDPLLFSCLCVLLAIFTAGHLIGLYLYQFQFFQEAVPPNDYYARLFGIKSVIQTDCSSTWKIIVNPDLSWYHHANPILLLVMYYTLATLIRIWLQEPLVQDEGTKEEDKALACSPIQITAGRRRSLWYATHYPTDERKLLSMTQDDYKPSDGLLVTVNGNPVDYHTIHPSLPMENGPGKADLYSTPQYRWEPSDESSEKREEEEEEKEEFEEERSREEKRSIKVHAMVSVFQFIMKQSYICALIAMMAWSITYHSWLTFVLLIWSCTLWMIRNRRKYAMISSPFMVVYGNLLLILQYIWSFELPEIKKVPGFLEKKEPGELASKILFTITFWLLLRQHLTEQKALQEKEALLSEVKIGSQENEEKDEELQDIQVEGEPKEEEEEEAKEEKQERKKVEQEEAEEEDEQDIMKVLGNLVVAMFIKYWIYVCGGMFFFVSFEGKIVMYKIIYMVLFLFCVALYQVHYEWWRKILKYFWMSVVIYTMLVLIFIYTYQFENFPGLWQNMTGLKKEKLEDLGLKQFTVAELFTRIFIPTSFLLVCILHLHYFHDRFLELTDLKSIPSKEDNTIYRLAHPEGSLPDLTMMHLTASLEKPEVRKLAEPGEEKLEGYSEKAQKGDLGKDSEESEEDGEEEEESEEEEETSDLRNKWHLVIDRLTVLFLKFLEYFHKLQVFMWWILELHIIKIVSSYIIWVSVKEVSLFNYVFLISWAFALPYAKLRRLASSVCTVWTCVIIVCKMLYQLQTIKPENFSVNCSLPNENQTNIPFNELNKSLLYSAPIDPTEWVGLRKSSPLLVYLRNNLLMLAILAFEVTIYRHQEYYRGRNNLTAPVSRTIFHDITRLHLDDGLINCAKYFINYFFYKFGLETCFLMSVNVIGQRMDFYAMIHACWLIAVLYRRRRKAIAEIWPKYCCFLACIITFQYFICIGIPPAPCRDYPWRFKGASFNDNIIKWLYFPDFIVRPNPVFLVYDFMLLLCASLQRQIFEDENKAAVRIMAGDNVEICMNLDAASFSQHNPVPDFIHCRSYLDMSKVIIFSYLFWFVLTIIFITGTTRISIFCMGYLVACFYFLLFGGDLLLKPIKSILRYWDWLIAYNVFVITMKNILSIGACGYIGTLVHNSCWLIQAFSLACTVKGYQMPAANSPCTLPSGEAGIIWDSICFAFLLLQRRVFMSYYFLHVVADIKASQILASRGAELFQATIVKAVKARIEEEKKSMDQLKRQMDRIKARQQKYKKGKERMLSLTQEPGEGQDMQKLSEEDDEREADKQKAKGKKKQWWRPWVDHASMVRSGDYYLFETDSEEEEEEELKKEDEEPPRRSAFQFVYQAWITDPKTALRQRHKEKKRSAREERKRRRKGSKEGPVEWEDREDEPIKKKSDGPDNIIKRIFNILKFTWVLFLATVDSFTTWLNSISREHIDISTVLRIERCMLTREIKKGNVPTRESIHMYYQNHIMNLSRESGLDTIDEHPGAASGAQTAHRMDSLDSHDSISSEPTQCTMLYSRQGTTETIEEVEAEQEEEAGSTAPEPREAKEYEATGYDVGAMGAEEASLTPEEELTQFSTLDGDVEAPPSYSKAVSFEHLSFGSQDDSAGKNRMAVSPDDSRTDKLGSSILPPLTHELTASELLLKKMFHDDELEESEKFYVGQPRFLLLFYAMYNTLVARSEMVCYFVIILNHMVSASMITLLLPILIFLWAMLSVPRPSRRFWMMAIVYTEVAIVVKYFFQFGFFPWNKNVEVNKDKPYHPPNIIGVEKKEGYVLYDLIQLLALFFHRSILKCHGLWDEDDMTESGMAREESDDELSLGHGRRDSSDSLKSINLAASVESVHVTFPEQQTAVRRKRSGSSSEPSQRSSFSSNRSQRGSTSTRNSSQKGSSVLSIKQKGKRELYMEKLQEHLIKAKAFTIKKTLEIYVPIKQFFYNLIHPEYSAVTDVYVLMFLADTVDFIIIVFGFWAFGKHSAAADITSSLSEDQVPGPFLVMVLIQFGTMVVDRALYLRKTVLGKVIFQVILVFGIHFWMFFILPGVTERKFSQNLVAQLWYFVKCVYFGLSAYQIRCGYPTRVLGNFLTKSYNYVNLFLFQGFRLVPFLTELRAVMDWVWTDTTLSLSSWICVEDIYAHIFILKCWRESEKRYPQPRGQKKKKVVKYGMGGMIIVLLICIVWFPLLFMSLIKSVAGVINQPLDVSVTITLGGYQPIFTMSAQQSQLKVMDQQSFNKFIQAFSRDTGAMQFLENYEKEDITVAELEGNSNSLWTISPPSKQKMIHELLDPNSSFSVVFSWSIQRNLSLGAKSEIATDKLSFPLKNITRKNIAKMIAGNSTESSKTPVTIEKIYPYYVKAPSDSNSKPIKQLLSENNFMDITIILSRDNTTKYNSEWWVLNLTGNRIYNPNSQALELVVFNDKVSPPSLGFLAGYGIMGLYASVVLVIGKFVREFFSGISHSIMFEELPNVDRILKLCTDIFLVRETGELELEEDLYAKLIFLYRSPETMIKWTREKTN,0,,,,,,"Arthrogryposis, distal, 5:A form of distal arthrogryposis, a disease characterized by congenital joint contractures that mainly involve two or more distal parts of the limbs, in the absence of a primary neurological or muscle disease. DA5 features include ocular abnormalities, typically ptosis, ophthalmoplegia and/or strabismus, in addition to contractures of the skeletal muscles. Some patients have pulmonary hypertension as a result of restrictive lung disease.|Arthrogryposis, distal, 3:A form of distal arthrogryposis, a disease characterized by congenital joint contractures that mainly involve two or more distal parts of the limbs, in the absence of a primary neurological or muscle disease. DA3 features include short stature and cleft palate.|Marden-Walker syndrome:A syndrome characterized by a mask-like face with blepharophimosis, micrognathia, cleft or high-arched palate, low-set ears, congenital joint contractures, kyphoscoliosis, pectus excavatum or carinatum, and arachnodactyly. Additional features include decreased muscular mass, failure to thrive, renal anomalies, hypoplastic corpus callosum, cerebellar vermis hypoplasia, enlarged cisterna magna, and psychomotor retardation.|Arthrogryposis, distal, with impaired proprioception and touch:A form of distal arthrogryposis, a disease characterized by congenital joint contractures that mainly involve two or more distal parts of the limbs, in the absence of a primary neurological or muscle disease. DAIPT is an autosomal recessive disease characterized by selective loss of discriminative touch perception, ataxia, difficulty walking, dysmetria, and progressive skeletal contractures.","Arthrogryposis, distal, 5|Arthrogryposis, distal, 3|Marden-Walker syndrome|Arthrogryposis, distal, with impaired proprioception and touch",,,1:Q9H5I5-1:|2:Q9H5I5-2:|3:Q9H5I5-3:|4:Q9H5I5-4:,,,,,,,,,,5.0
O00299,,Chloride intracellular channel protein 1,CLIC1,Homo sapiens,241,False,G6|NCC27,MAEEQPQVELFVKAGSDGAKIGNCPFSQRLFMVLWLKGVTFNVTTVDTKRRTETVQKLCPGGQLPFLLYGTEVHTDTNKIEEFLEAVLCPPRYPKLAALNPESNTAGLDIFAKFSAYIKNSNPALNDNLEKGLLKALKVLDNYLTSPLPEEVDETSAEDEGVSQRKFLDGNELTLADCNLLPKLHIVQVVCKKYRGFTIPEAFRGVHRYLSNAYAREEFASTCPDDEEIELAYEQVAKALK,0,,,,,,,,P13569(CFTR)|O15116(LSM1)|Q6FHY5(MEOX2)|Q5HYW2(NHSL2)|O75832(PSMD10)|Q4KMQ1-2(TPRN),,,,,,,,,,,,5.0
Q9Y696,,Chloride intracellular channel protein 4,CLIC4,Homo sapiens,253,False,,MALSMPLNGLKEEDKEPLIELFVKAGSDGESIGNCPFSQRLFMILWLKGVVFSVTTVDLKRKPADLQNLAPGTHPPFITFNSEVKTDVNKIEEFLEEVLCPPKYLKLSPKHPESNTAGMDIFAKFSAYIKNSRPEANEALERGLLKTLQKLDEYLNSPLPDEIDENSMEDIKFSTRKFLDGNEMTLADCNLLPKLHIVKVVAKKYRNFDIPKEMTGIWRYLTNAYSRDEFTNTCPSDKEVEIAYSDVAKRLTK,0,,,,,,,,Q4KMQ1-2(TPRN),,,,,,,,,,,,5.0
Q96FT7,,Acid-sensing ion channel 4,ASIC4,Homo sapiens,539,False,ACCN4,MPIEIVCKIKFAEEDAKPKEKEAGDEQSLLGAVAPGAAPRDLATFASTSTLHGLGRACGPGPHGLRRTLWALALLTSLAAFLYQAAGLARGYLTRPHLVAMDPAAPAPVAGFPAVTLCNINRFRHSALSDADIFHLANLTGLPPKDRDGHRAAGLRYPEPDMVDILNRTGHQLADMLKSCNFSGHHCSASNFSVVYTRYGKCYTFNADPRSSLPSRAGGMGSGLEIMLDIQQEEYLPIWRETNETSFEAGIRVQIHSQEEPPYIHQLGFGVSPGFQTFVSCQEQRLTYLPQPWGNCRAESELREPELQGYSAYSVSACRLRCEKEAVLQRCHCRMVHMPGNETICPPNIYIECADHTLDSLGGGPEGPCFCPTPCNLTRYGKEISMVRIPNRGSARYLARKYNRNETYIRENFLVLDVFFEALTSEAMEQRAAYGLSALLGDLGGQMGLFIGASILTLLEILDYIYEVSWDRLKRVWRRPKTPLRTSTGGISTLGLQELKEQSPCPSRGRVEGGGVSSLLPNHHHPHGPPGGLFEDFAC,0,,,,,,,,P32243-2(OTX2)|O76024(WFS1)|Q92870-2(APBB2)|P54253(ATXN1)|P54252(ATXN3)|P46379-2(BAG6)|O14645(DNALI1)|P50570-2(DNM2)|P41091(EIF2S3)|O75460-2(ERN1)|P22607(FGFR3)|Q0VDC6(FKBP1A)|P14136(GFAP)|Q14957(GRIN2C)|P28799(GRN)|P06396(GSN)|P54652(HSPA2)|P04792(HSPB1)|O43464(HTRA2)|P42858(HTT)|O60333-2(KIF1B)|O14901(KLF11)|P19404(NDUFV2)|P29474(NOS3)|Q9BVL2(NUP58)|O14832(PHYH)|A0A6Q8PF08(PMP22)|P60891(PRPS1)|Q9Y3C5(RNF11)|P49591(SARS1)|Q7Z699(SPRED1)|Q13148(TARDBP)|O14656(TOR1A)|O76024(WFS1),,3:Q96FT7-4:|1:Q96FT7-1:|2:Q96FT7-2:,,,,,,,,,,5.0
O14804,,Trace amine-associated receptor 5,TAAR5,Homo sapiens,337,False,PNR,MRAVFIQGAEEHPAAFCYQVNGSCPRTVHTLGIQLVIYLACAAGMLIIVLGNVFVAFAVSYFKALHTPTNFLLLSLALADMFLGLLVLPLSTIRSVESCWFFGDFLCRLHTYLDTLFCLTSIFHLCFISIDRHCAICDPLLYPSKFTVRVALRYILAGWGVPAAYTSLFLYTDVVETRLSQWLEEMPCVGSCQLLLNKFWGWLNFPLFFVPCLIMISLYVKIFVVATRQAQQITTLSKSLAGAAKHERKAAKTLGIAVGIYLLCWLPFTIDTMVDSLLHFITPPLVFDIFIWFAYFNSACNPIIYVFSYQWFRKALKLTLSQKVFSPQTRTVDLYQE,0,,,,,,,,,,,,,,,,,,,,5.0
P46098,,5-hydroxytryptamine receptor 3A,HTR3A,Homo sapiens,478,False,5HT3R|HTR3,MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTTVSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDILINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLHTIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQSTSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA,0,,,,,,,,Q8WXA8(HTR3C)|Q70Z44(HTR3D)|A5X5Y0-1(HTR3E)|A5X5Y0-3(HTR3E),,1:P46098-1:|2:P46098-2:|3:P46098-3:|4:P46098-4:|5:P46098-5:,,,,,,,,,,5.0
Q92508,,Piezo-type mechanosensitive ion channel component 1,PIEZO1,Homo sapiens,2521,False,FAM38A|KIAA0233,MEPHVLGAVLYWLLLPCALLAACLLRFSGLSLVYLLFLLLLPWFPGPTRCGLQGHTGRLLRALLGLSLLFLVAHLALQICLHIVPRLDQLLGPSCSRWETLSRHIGVTRLDLKDIPNAIRLVAPDLGILVVSSVCLGICGRLARNTRQSPHPRELDDDERDVDASPTAGLQEAATLAPTRRSRLAARFRVTAHWLLVAAGRVLAVTLLALAGIAHPSALSSVYLLLFLALCTWWACHFPISTRGFSRLCVAVGCFGAGHLICLYCYQMPLAQALLPPAGIWARVLGLKDFVGPTNCSSPHALVLNTGLDWPVYASPGVLLLLCYATASLRKLRAYRPSGQRKEAAKGYEARELELAELDQWPQERESDQHVVPTAPDTEADNCIVHELTGQSSVLRRPVRPKRAEPREASPLHSLGHLIMDQSYVCALIAMMVWSITYHSWLTFVLLLWACLIWTVRSRHQLAMLCSPCILLYGMTLCCLRYVWAMDLRPELPTTLGPVSLRQLGLEHTRYPCLDLGAMLLYTLTFWLLLRQFVKEKLLKWAESPAALTEVTVADTEPTRTQTLLQSLGELVKGVYAKYWIYVCAGMFIVVSFAGRLVVYKIVYMFLFLLCLTLFQVYYSLWRKLLKAFWWLVVAYTMLVLIAVYTFQFQDFPAYWRNLTGFTDEQLGDLGLEQFSVSELFSSILVPGFFLLACILQLHYFHRPFMQLTDMEHVSLPGTRLPRWAHRQDAVSGTPLLREEQQEHQQQQQEEEEEEEDSRDEGLGVATPHQATQVPEGAAKWGLVAERLLELAAGFSDVLSRVQVFLRRLLELHVFKLVALYTVWVALKEVSVMNLLLVVLWAFALPYPRFRPMASCLSTVWTCVIIVCKMLYQLKVVNPQEYSSNCTEPFPNSTNLLPTEISQSLLYRGPVDPANWFGVRKGFPNLGYIQNHLQVLLLLVFEAIVYRRQEHYRRQHQLAPLPAQAVFASGTRQQLDQDLLGCLKYFINFFFYKFGLEICFLMAVNVIGQRMNFLVTLHGCWLVAILTRRHRQAIARLWPNYCLFLALFLLYQYLLCLGMPPALCIDYPWRWSRAVPMNSALIKWLYLPDFFRAPNSTNLISDFLLLLCASQQWQVFSAERTEEWQRMAGVNTDRLEPLRGEPNPVPNFIHCRSYLDMLKVAVFRYLFWLVLVVVFVTGATRISIFGLGYLLACFYLLLFGTALLQRDTRARLVLWDCLILYNVTVIISKNMLSLLACVFVEQMQTGFCWVIQLFSLVCTVKGYYDPKEMMDRDQDCLLPVEEAGIIWDSVCFFFLLLQRRVFLSHYYLHVRADLQATALLASRGFALYNAANLKSIDFHRRIEEKSLAQLKRQMERIRAKQEKHRQGRVDRSRPQDTLGPKDPGLEPGPDSPGGSSPPRRQWWRPWLDHATVIHSGDYFLFESDSEEEEEAVPEDPRPSAQSAFQLAYQAWVTNAQAVLRRRQQEQEQARQEQAGQLPTGGGPSQEVEPAEGPEEAAAGRSHVVQRVLSTAQFLWMLGQALVDELTRWLQEFTRHHGTMSDVLRAERYLLTQELLQGGEVHRGVLDQLYTSQAEATLPGPTEAPNAPSTVSSGLGAEEPLSSMTDDMGSPLSTGYHTRSGSEEAVTDPGEREAGASLYQGLMRTASELLLDRRLRIPELEEAELFAEGQGRALRLLRAVYQCVAAHSELLCYFIIILNHMVTASAGSLVLPVLVFLWAMLSIPRPSKRFWMTAIVFTEIAVVVKYLFQFGFFPWNSHVVLRRYENKPYFPPRILGLEKTDGYIKYDLVQLMALFFHRSQLLCYGLWDHEEDSPSKEHDKSGEEEQGAEEGPGVPAATTEDHIQVEARVGPTDGTPEPQVELRPRDTRRISLRFRRRKKEGPARKGAAAIEAEDREEEEGEEEKEAPTGREKRPSRSGGRVRAAGRRLQGFCLSLAQGTYRPLRRFFHDILHTKYRAATDVYALMFLADVVDFIIIIFGFWAFGKHSAATDITSSLSDDQVPEAFLVMLLIQFSTMVVDRALYLRKTVLGKLAFQVALVLAIHLWMFFILPAVTERMFNQNVVAQLWYFVKCIYFALSAYQIRCGYPTRILGNFLTKKYNHLNLFLFQGFRLVPFLVELRAVMDWVWTDTTLSLSSWMCVEDIYANIFIIKCSRETEKKYPQPKGQKKKKIVKYGMGGLIILFLIAIIWFPLLFMSLVRSVVGVVNQPIDVTVTLKLGGYEPLFTMSAQQPSIIPFTAQAYEELSRQFDPQPLAMQFISQYSPEDIVTAQIEGSSGALWRISPPSRAQMKRELYNGTADITLRFTWNFQRDLAKGGTVEYANEKHMLALAPNSTARRQLASLLEGTSDQSVVIPNLFPKYIRAPNGPEANPVKQLQPNEEADYLGVRIQLRREQGAGATGFLEWWVIELQECRTDCNLLPMVIFSDKVSPPSLGFLAGYGIMGLYVSIVLVIGKFVRGFFSEISHSIMFEELPCVDRILKLCQDIFLVRETRELELEEELYAKLIFLYRSPETMIKWTREKE,0,,,,,,"Dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema:An autosomal dominant hemolytic anemia characterized by primary erythrocyte dehydration. DHS erythrocytes exhibit decreased total cation and potassium content that are not accompanied by a proportional net gain of sodium and water. DHS patients typically exhibit mild to moderate compensated hemolytic anemia, with an increased erythrocyte mean corpuscular hemoglobin concentration and a decreased osmotic fragility, both of which reflect cellular dehydration. Patients may also show perinatal edema and pseudohyperkalemia due to loss of potassium from red cells stored at room temperature. A minor proportion of red cells appear as stomatocytes on blood films. Complications such as splenomegaly and cholelithiasis, resulting from increased red cell trapping in the spleen and elevated bilirubin levels, respectively, may occur. The course of DHS is frequently associated with iron overload, which may lead to hepatosiderosis.|Lymphatic malformation 6:A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM6 is an autosomal recessive, severe form manifesting as generalized lymphatic dysplasia. It is characterized by uniform, widespread swelling of all segments of the body, with systemic involvement such as intestinal and/or pulmonary lymphangiectasia, pleural effusions, chylothoraces and/or pericardial effusions, and with a high incidence of non- immune hydrops fetalis.",Dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema|Lymphatic malformation 6,Q6UW02(CYP20A1)|P04155(TFF1),,,,,,,,,,,,5.0
P78348,,Acid-sensing ion channel 1,ASIC1,Homo sapiens,528,False,ACCN2|BNAC2,MELKAEEEEVGGVQPVSIQAFASSSTLHGLAHIFSYERLSLKRALWALCFLGSLAVLLCVCTERVQYYFHYHHVTKLDEVAASQLTFPAVTLCNLNEFRFSQVSKNDLYHAGELLALLNNRYEIPDTQMADEKQLEILQDKANFRSFKPKPFNMREFYDRAGHDIRDMLLSCHFRGEVCSAEDFKVVFTRYGKCYTFNSGRDGRPRLKTMKGGTGNGLEIMLDIQQDEYLPVWGETDETSFEAGIKVQIHSQDEPPFIDQLGFGVAPGFQTFVACQEQRLIYLPPPWGTCKAVTMDSDLDFFDSYSITACRIDCETRYLVENCNCRMVHMPGDAPYCTPEQYKECADPALDFLVEKDQEYCVCEMPCNLTRYGKELSMVKIPSKASAKYLAKKFNKSEQYIGENILVLDIFFEVLNYETIEQKKAYEIAGLLGDIGGQMGLFIGASILTVLELFDYAYEVIKHKLCRRGKCQKEAKRSSADKGVALSLDDVKRHNPCESLRGHPAGMTYAANILPHHPARGTFEDFTC,0,,,,,,,,Q8N743(KIR3DL3)|Q99735(MGST2)|Q9NRD5(PICK1),,2:P78348-2:|1:P78348-1:|3:P78348-3:,,,,,,,,,,5.0
Q8WWG9,,Potassium voltage-gated channel subfamily E member 4,KCNE4,Homo sapiens,221,False,,MHFLTIYPNCSSGVVRAQSRTEQKNPLGLDDLGIQNLGQTVSLAPAVEAASMLKMEPLNSTHPGTAASSSPLESRAAGGGSGNGNEYFYILVVMSFYGIFLIGIMLGYMKSKRREKKSSLLLLYKDEERLWGEAMKPLPVVSGLRSVQVPLMLNMLQESVAPALSCTLCSMEGDSVSSESSSPDVHLTIQEEGADDELEETSETPLNESSEGSSENIHQNS,0,,,,,,,,P49069(CAMLG)|O43681(GET3)|Q13061-2(TRDN),,1:Q8WWG9-1:|2:Q8WWG9-3:,,,,,,,,,,5.0
Q9Y6J6,,Potassium voltage-gated channel subfamily E member 2,KCNE2,Homo sapiens,123,False,,MSTLSNFTQTLEDVFRRIFITYMDNWRQNTTAEQEALQAKVDAENFYYVILYLMVMIGMFSFIIVAILVSTVKSKRREHSNDPYHQYIVEDWQEKYKSQILNLEESKATIHENIGAAGFKMSP,0,,,,,,"Long QT syndrome 6:A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy.|Atrial fibrillation, familial, 4:A familial form of atrial fibrillation, a common sustained cardiac rhythm disturbance. Atrial fibrillation is characterized by disorganized atrial electrical activity and ineffective atrial contraction promoting blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure.","Long QT syndrome 6|Atrial fibrillation, familial, 4",,,,,,,,,,,,,5.0
Q9UHC3,,Acid-sensing ion channel 3,ASIC3,Homo sapiens,531,False,ACCN3|SLNAC1|TNAC1,MKPTSGPEEARRPASDIRVFASNCSMHGLGHVFGPGSLSLRRGMWAAAVVLSVATFLYQVAERVRYYREFHHQTALDERESHRLIFPAVTLCNINPLRRSRLTPNDLHWAGSALLGLDPAEHAAFLRALGRPPAPPGFMPSPTFDMAQLYARAGHSLDDMLLDCRFRGQPCGPENFTTIFTRMGKCYTFNSGADGAELLTTTRGGMGNGLDIMLDVQQEEYLPVWRDNEETPFEVGIRVQIHSQEEPPIIDQLGLGVSPGYQTFVSCQQQQLSFLPPPWGDCSSASLNPNYEPEPSDPLGSPSPSPSPPYTLMGCRLACETRYVARKCGCRMVYMPGDVPVCSPQQYKNCAHPAIDAMLRKDSCACPNPCASTRYAKELSMVRIPSRAAARFLARKLNRSEAYIAENVLALDIFFEALNYETVEQKKAYEMSELLGDIGGQMGLFIGASLLTILEILDYLCEVFRDKVLGYFWNRQHSQRHSSTNLLQEGLGSHRTQVPHLSLGPRPPTPPCAVTKTLSASHRTCYLVTQL,0,,,,,,,,,,1:Q9UHC3-1:|2:Q9UHC3-2:|3:Q9UHC3-3:|4:Q9UHC3-4:,,,,,,,,,,5.0
Q9Y277,,Non-selective voltage-gated ion channel VDAC3,VDAC3,Homo sapiens,283,False,,MCNTPTYCDLGKAAKDVFNKGYGFGMVKIDLKTKSCSGVEFSTSGHAYTDTGKASGNLETKYKVCNYGLTFTQKWNTDNTLGTEISWENKLAEGLKLTLDTIFVPNTGKKSGKLKASYKRDCFSVGSNVDIDFSGPTIYGWAVLAFEGWLAGYQMSFDTAKSKLSQNNFALGYKAADFQLHTHVNDGTEFGGSIYQKVNEKIETSINLAWTAGSNNTRFGIAAKYMLDCRTSLSAKVNNASLIGLGYTQTLRPGVKLTLSALIDGKNFSAGGHKVGLGFELEA,0,,,,,,,,P21796(VDAC1)|P45880(VDAC2),,1:Q9Y277-1:|2:Q9Y277-2:,,,,,,,,,,5.0
P45880,,Non-selective voltage-gated ion channel VDAC2,VDAC2,Homo sapiens,294,False,,MATHGQTCARPMCIPPSYADLGKAARDIFNKGFGFGLVKLDVKTKSCSGVEFSTSGSSNTDTGKVTGTLETKYKWCEYGLTFTEKWNTDNTLGTEIAIEDQICQGLKLTFDTTFSPNTGKKSGKIKSSYKRECINLGCDVDFDFAGPAIHGSAVFGYEGWLAGYQMTFDSAKSKLTRNNFAVGYRTGDFQLHTNVNDGTEFGGSIYQKVCEDLDTSVNLAWTSGTNCTRFGIAAKYQLDPTASISAKVNNSSLIGVGYTQTLRPGVKLTLSALVDGKSINAGGHKVGLALELEA,0,,,,,,,,Q6NUP5(AGTR1)|Q92870-2(APBB2)|P42331-2(ARHGAP25)|P46379-2(BAG6)|Q8WUW1(BRK1)|P48643(CCT5)|P13569(CFTR)|P07339(CTSD)|P29692-2(EEF1D)|Q96A26(FAM162A)|Q06787-7(FMR1)|P28799(GRN)|P04792(HSPB1)|P42858(HTT)|Q9UMF0(ICAM5)|O60333-2(KIF1B)|O14901(KLF11)|P49821(NDUFV1)|P07196(NEFL)|O43933(PEX1)|A0A6Q8PF08(PMP22)|O60260-5(PRKN)|P60891(PRPS1)|Q9Y3C5(RNF11)|O94811(TPPP)|P02766(TTR)|P21796(VDAC1)|Q9Y277(VDAC3)|O76024(WFS1)|Q05996(ZP2)|P21754(ZP3),,3:P45880-3:|1:P45880-1:|2:P45880-2:,,,,,,,,,,5.0
Q16515,,Acid-sensing ion channel 2,ASIC2,Homo sapiens,512,False,ACCN|ACCN1|BNAC1|MDEG,MDLKESPSEGSLQPSSIQIFANTSTLHGIRHIFVYGPLTIRRVLWAVAFVGSLGLLLVESSERVSYYFSYQHVTKVDEVVAQSLVFPAVTLCNLNGFRFSRLTTNDLYHAGELLALLDVNLQIPDPHLADPSVLEALRQKANFKHYKPKQFSMLEFLHRVGHDLKDMMLYCKFKGQECGHQDFTTVFTKYGKCYMFNSGEDGKPLLTTVKGGTGNGLEIMLDIQQDEYLPIWGETEETTFEAGVKVQIHSQSEPPFIQELGFGVAPGFQTFVATQEQRLTYLPPPWGECRSSEMGLDFFPVYSITACRIDCETRYIVENCNCRMVHMPGDAPFCTPEQHKECAEPALGLLAEKDSNYCLCRTPCNLTRYNKELSMVKIPSKTSAKYLEKKFNKSEKYISENILVLDIFFEALNYETIEQKKAYEVAALLGDIGGQMGLFIGASILTILELFDYIYELIKEKLLDLLGKEEDEGSHDENVSTCDTMPNHSETISHTVNVPLQTTLGTLEEIAC,0,,,,,,,,Q9NRD5(PICK1),,1:Q16515-1:|2:Q16515-2:,,,,,,,,,,5.0
P62955,,Voltage-dependent calcium channel gamma-7 subunit,CACNG7,Homo sapiens,275,False,,MSHCSSRALTLLSSVFGACGLLLVGIAVSTDYWLYMEEGTVLPQNQTTEVKMALHAGLWRVCFFAGREKGRCVASEYFLEPEINLVTENTENILKTVRTATPFPMVSLFLVFTAFVISNIGHIRPQRTILAFVSGIFFILSGLSLVVGLVLYISSINDEVMNRPSSSEQYFHYRYGWSFAFAASSFLLKEGAGVMSVYLFTKRYAEEEMYRPHPAFYRPRLSDCSDYSGQFLQPEAWRRGRSPSDISSDVSIQMTQNYPPAIKYPDHLHISTSPC,0,,,,,,,,Q9HBV2(SPACA1),,,,,,,,,,,,5.0
O60359,,Voltage-dependent calcium channel gamma-3 subunit,CACNG3,Homo sapiens,315,False,,MRMCDRGIQMLITTVGAFAAFSLMTIAVGTDYWLYSRGVCRTKSTSDNETSRKNEEVMTHSGLWRTCCLEGAFRGVCKKIDHFPEDADYEQDTAEYLLRAVRASSVFPILSVTLLFFGGLCVAASEFHRSRHNVILSAGIFFVSAGLSNIIGIIVYISANAGDPGQRDSKKSYSYGWSFYFGAFSFIIAEIVGVVAVHIYIEKHQQLRAKSHSEFLKKSTFARLPPYRYRFRRRSSSRSTEPRSRDLSPISKGFHTIPSTDISMFTLSRDPSKITMGTLLNSDRDHAFLQFHNSTPKEFKESLHNNPANRRTTPV,0,,,,,,,,,,,,,,,,,,,,5.0
Q9UBN1,,Voltage-dependent calcium channel gamma-4 subunit,CACNG4,Homo sapiens,327,False,,MVRCDRGLQMLLTTAGAFAAFSLMAIAIGTDYWLYSSAHICNGTNLTMDDGPPPRRARGDLTHSGLWRVCCIEGIYKGHCFRINHFPEDNDYDHDSSEYLLRIVRASSVFPILSTILLLLGGLCIGAGRIYSRKNNIVLSAGILFVAAGLSNIIGIIVYISSNTGDPSDKRDEDKKNHYNYGWSFYFGALSFIVAETVGVLAVNIYIEKNKELRFKTKREFLKASSSSPYARMPSYRYRRRRSRSSSRSTEASPSRDVSPMGLKITGAIPMGELSMYTLSREPLKVTTAASYSPDQEASFLQVHDFFQQDLKEGFHVSMLNRRTTPV,0,,,,,,,,,,,,,,,,,,,,5.0
Q9Y698,,Voltage-dependent calcium channel gamma-2 subunit,CACNG2,Homo sapiens,323,False,,MGLFDRGVQMLLTTVGAFAAFSLMTIAVGTDYWLYSRGVCKTKSVSENETSKKNEEVMTHSGLWRTCCLEGNFKGLCKQIDHFPEDADYEADTAEYFLRAVRASSIFPILSVILLFMGGLCIAASEFYKTRHNIILSAGIFFVSAGLSNIIGIIVYISANAGDPSKSDSKKNSYSYGWSFYFGALSFIIAEMVGVLAVHMFIDRHKQLRATARATDYLQASAITRIPSYRYRYQRRSRSSSRSTEPSHSRDASPVGIKGFNTLPSTEISMYTLSRDPLKAATTPTATYNSDRDNSFLQVHNCIQKENKDSLHSNTANRRTTPV,0,,,,,,"Intellectual developmental disorder, autosomal dominant 10:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period.","Intellectual developmental disorder, autosomal dominant 10",O43516-4(WIPF1),,,,,,,,,,,,5.0
Q9Y6H6,,Potassium voltage-gated channel subfamily E member 3,KCNE3,Homo sapiens,103,False,,METTNGTETWYESLHAVLKALNATLHSNLLCRPGPGLGPDNQTEERRASLPGRDDNSYMYILFVMFLFAVTVGSLILGYTRSRKVDKRSDPYHVYIKNRVSMI,0,,,,,,"Brugada syndrome 6:A tachyarrhythmia characterized by right bundle branch block and ST segment elevation on an electrocardiogram (ECG). It can cause the ventricles to beat so fast that the blood is prevented from circulating efficiently in the body. When this situation occurs, the individual will faint and may die in a few minutes if the heart is not reset.",Brugada syndrome 6,,,,,,,,,,,,,5.0
Q8WXS5,,Voltage-dependent calcium channel gamma-8 subunit,CACNG8,Homo sapiens,425,False,CACNG6,MESLKRWNEERGLWCEKGVQVLLTTVGAFAAFGLMTIAISTDYWLYTRALICNTTNLTAGGDDGTPHRGGGGASEKKDPGGLTHSGLWRICCLEGLKRGVCVKINHFPEDTDYDHDSAEYLLRVVRASSIFPILSAILLLLGGVCVAASRVYKSKRNIILGAGILFVAAGLSNIIGVIVYISANAGEPGPKRDEEKKNHYSYGWSFYFGGLSFILAEVIGVLAVNIYIERSREAHCQSRSDLLKAGGGAGGSGGSGPSAILRLPSYRFRYRRRSRSSSRSSEPSPSRDASPGGPGGPGFASTDISMYTLSRDPSKGSVAAGLAGAGGGGGGAVGAFGGAAGGAGGGGGGGGGAGAERDRGGASGFLTLHNAFPKEAGGGVTVTVTGPPAPPAPAPPAPSAPAPGTLAKEAAASNTNTLNRKTTPV,0,,,,,,,,,,,,,,,,,,,,5.0
O75311,,Glycine receptor subunit alpha-3,GLRA3,Homo sapiens,464,False,,MAHVRHFRTLVSGFYFWEAALLLSLVATKETDSARSRSAPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAYSEYPDDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLTLSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLKEEKDLRYCTKHYNTGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRKNKTEAFALEKFYRFSDMDDEVRESRFSFTAYGMGPCLQAKDGMTPKGPNHPVQVMPKSPDEMRKVFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHQQQD,0,,,,,,,,Q14681(KCTD2),,Alpha-3L:O75311-1:|Alpha-3K:O75311-2:,,,,,,,,,,5.0
P48167,,Glycine receptor subunit beta,GLRB,Homo sapiens,497,False,,MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNILNRLLVSYDPRIRPNFKGIPVDVVVNIFINSFGSIQETTMDYRVNIFLRQKWNDPRLKLPSDFRGSDALTVDPTMYKCLWKPDLFFANEKSANFHDVTQENILLFIFRDGDVLVSMRLSITLSCPLDLTLFPMDTQRCKMQLESFGYTTDDLRFIWQSGDPVQLEKIALPQFDIKKEDIEYGNCTKYYKGTGYYTCVEVIFTLRRQVGFYMMGVYAPTLLIVVLSWLSFWINPDASAARVPLGIFSVLSLASECTTLAAELPKVSYVKALDVWLIACLLFGFASLVEYAVVQVMLNNPKRVEAEKARIAKAEQADGKGGNVAKKNTVNGTGTPVHISTLQVGETRCKKVCTSKSDLRSNDFSIVGSLPRDFELSNYDCYGKPIEVNNGLGKSQAKNNKKPPPAKPVIPTAAKRIDLYARALFPFCFLFFNVIYWSIYL,0,,,,,,"Hyperekplexia 2:A neurologic disorder characterized by muscular rigidity of central nervous system origin, particularly in the neonatal period, and by an exaggerated startle response to unexpected acoustic or tactile stimuli.",Hyperekplexia 2,P23415(GLRA1),,1:P48167-1:|2:P48167-2:,,,,,,,,,,5.0
P23416,,Glycine receptor subunit alpha-2,GLRA2,Homo sapiens,452,False,,MNRQLVNILTALFAFFLETNHFRTAFCKDHDSRSGKQPSQTLSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVTCNIFINSFGSVTETTMDYRVNIFLRQQWNDSRLAYSEYPDDSLDLDPSMLDSIWKPDLFFANEKGANFHDVTTDNKLLRISKNGKVLYSIRLTLTLSCPMDLKNFPMDVQTCTMQLESFGYTMNDLIFEWLSDGPVQVAEGLTLPQFILKEEKELGYCTKHYNTGKFTCIEVKFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFAALLEYAAVNFVSRQHKEFLRLRRRQKRQNKEEDVTRESRFNFSGYGMGHCLQVKDGTAVKATPANPLPQPPKDGDAIKKKFVDRAKRIDTISRAAFPLAFLIFNIFYWITYKIIRHEDVHKK,0,,,,,,"Intellectual developmental disorder, X-linked, syndromic, Pilorge type:A disorder characterized by global developmental delay with variably impaired intellectual development, speech delay, and behavioral abnormalities. Variable features include motor incoordination, seizures, and ocular abnormalities. Disease onset is in infancy, and severity is higly variable.","Intellectual developmental disorder, X-linked, syndromic, Pilorge type",,,Alpha-2*:P23416-1:|Alpha-2B:P23416-2:|3:P23416-3:,,,,,,,,,,5.0
P21796,,Non-selective voltage-gated ion channel VDAC1,VDAC1,Homo sapiens,283,False,VDAC,MAVPPTYADLGKSARDVFTKGYGFGLIKLDLKTKSENGLEFTSSGSANTETTKVTGSLETKYRWTEYGLTFTEKWNTDNTLGTEITVEDQLARGLKLTFDSSFSPNTGKKNAKIKTGYKREHINLGCDMDFDIAGPSIRGALVLGYEGWLAGYQMNFETAKSRVTQSNFAVGYKTDEFQLHTNVNDGTEFGGSIYQKVNKKLETAVNLAWTAGNSNTRFGIAAKYQIDPDACFSAKVNNSSLIGLGYTQTLKPGIKLTLSALLDGKNVNAGGHKLGLGLEFQA,0,,,,,,,,P02649(APOE)|P06493(CDK1)|P19367(HK1)|Q5S007(LRRK2)|P30041(PRDX6)|Q7L3V2(RTL10)|P12236(SLC25A6)|P21796(VDAC1)|P45880(VDAC2)|Q9Y277(VDAC3)|P62258(YWHAE)|P0C0U1(PB1),,,,,,,,,,,,5.0
O95264,,5-hydroxytryptamine receptor 3B,HTR3B,Homo sapiens,441,False,,MLSSVMAPLWACILVAAGILATDTHHPQDSALYHLSKQLLQKYHKEVRPVYNWTKATTVYLDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISLPLSAIWAPDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQNCSLTFKSILHTVEDVDLAFLRSPEDIQHDKKAFLNDSEWELLSVSSTYSILQSSAGGFAQIQFNVVMRRHPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTVFRVNMSNQVPRSVGSTPLIGHFFTICMAFLVLSLAKSIVLVKFLHDEQRGGQEQPFLCLRGDTDADRPRVEPRAQRAVVTESSLYGEHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSYLFMLGIYTITLCSLWALWGGV,0,,,,,,,,,,1:O95264-1:|2:O95264-2:,,,,,,,,,,5.0
Q70Z44,,5-hydroxytryptamine receptor 3D,HTR3D,Homo sapiens,454,False,,MQKHSPGPPALALLSQSLLTTGNGDTLIINCPGFGQHRVDPAAFQAVFDRKAIGPVTNYSVATHVNISFTLSAIWNCYSRIHTFNCHHARPWHNQFVQWNPDECGGIKKSGMATENLWLSDVFIEESVDQTPAGLMASMSIVKATSNTISQCGWSASANWTPSISPSMDRARAWRRMSRSFQIHHRTSFRTRREWVLLGIQKRTIKVTVATNQYEQAIFHVAIRRRCRPSPYVVNFLVPSGILIAIDALSFYLPLESGNCAPFKMTVLLGYSVFLLMMNDLLPATSTSSHASLVAPLALMQTPLPAGVYFALCLSLMVGSLLETIFITHLLHVATTQPLPLPRWLHSLLLHCTGQGRCCPTAPQKGNKGPGLTPTHLPGVKEPEVSAGQMPGPGEAELTGGSEWTRAQREHEAQKQHSVELWVQFSHAMDALLFRLYLLFMASSIITVICLWNT,0,,,,,,,,P46098(HTR3A),,1:Q70Z44-1:|2:Q70Z44-2:|3:Q70Z44-3:|4:Q70Z44-4:,,,,,,,,,,5.0
Q9UGM1,,Neuronal acetylcholine receptor subunit alpha-9,CHRNA9,Homo sapiens,479,False,NACHRA9,MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD,0,,,,,,,,P60616(),,,,,,,,,,,,5.0
Q9GZZ6,,Neuronal acetylcholine receptor subunit alpha-10,CHRNA10,Homo sapiens,450,False,NACHRA10,MGLRSHHLSLGLLLLFLLPAECLGAEGRLALKLFRDLFANYTSALRPVADTDQTLNVTLEVTLSQIIDMDERNQVLTLYLWIRQEWTDAYLRWDPNAYGGLDAIRIPSSLVWRPDIVLYNKADAQPPGSASTNVVLRHDGAVRWDAPAITRSSCRVDVAAFPFDAQHCGLTFGSWTHGGHQLDVRPRGAAASLADFVENVEWRVLGMPARRRVLTYGCCSEPYPDVTFTLLLRRRAAAYVCNLLLPCVLISLLAPLAFHLPADSGEKVSLGVTVLLALTVFQLLLAESMPPAESVPLIGKYYMATMTMVTFSTALTILIMNLHYCGPSVRPVPAWARALLLGHLARGLCVRERGEPCGQSRPPELSPSPQSPEGGAGPPAGPCHEPRCLCRQEALLHHVATIANTFRSHRAAQRCHEDWKRLARVMDRFFLAIFFSMALVMSLLVLVQAL,0,,,,,,,,,,,,,,,,,,,,5.0
Q9NY37,,Acid-sensing ion channel 5,ASIC5,Homo sapiens,505,False,ACCN5|HINAC,MEQTEKSKVYAENGLLEKIKLCLSKKPLPSPTERKKFDHDFAISTSFHGIHNIVQNRSKIRRVLWLVVVLGSVSLVTWQIYIRLLNYFTWPTTTSIEVQYVEKMEFPAVTFCNLNRFQTDAVAKFGVIFFLWHIVSKVLHLQEITANSTGSREATDFAASHQNFSIVEFIRNKGFYLNNSTLLDCEFFGKPCSPKDFAHVFTEYGNCFTFNHGETLQAKRKVSVSGRGLSLLFNVNQEAFTDNPALGFVDAGIIFVIHSPKKVPQFDGLGLLSPVGMHARVTIRQVKTVHQEYPWGECNPNIKLQNFSSYSTSGCLKECKAQHIKKQCGCVPFLLPGYGIECDLQKYFSCVSPVLDHIEFKDLCTVGTHNSSCPVSCEEIEYPATISYSSFPSQKALKYLSKKLNQSRKYIRENLVKIEINYSDLNYKITQQQKAVSVSELLADLGGQLGLFCGASLITIIEIIEYLFTNFYWICIFFLLKISEMTQWTPPPQNHLGNKNRIEEC,0,,,,,,,,,,,,,,,,,,,,4.0
Q9ULK0,,"Glutamate receptor ionotropic, delta-1",GRID1,Homo sapiens,1009,False,KIAA1220,MEALTLWLLPWICQCVSVRADSIIHIGAIFEENAAKDDRVFQLAVSDLSLNDDILQSEKITYSIKVIEANNPFQAVQEACDLMTQGILALVTSTGCASANALQSLTDAMHIPHLFVQRNPGGSPRTACHLNPSPDGEAYTLASRPPVRLNDVMLRLVTELRWQKFVMFYDSEYDIRGLQSFLDQASRLGLDVSLQKVDKNISHVFTSLFTTMKTEELNRYRDTLRRAILLLSPQGAHSFINEAVETNLASKDSHWVFVNEEISDPEILDLVHSALGRMTVVRQIFPSAKDNQKCTRNNHRISSLLCDPQEGYLQMLQISNLYLYDSVLMLANAFHRKLEDRKWHSMASLNCIRKSTKPWNGGRSMLDTIKKGHITGLTGVMEFREDSSNPYVQFEILGTTYSETFGKDMRKLATWDSEKGLNGSLQERPMGSRLQGLTLKVVTVLEEPFVMVAENILGQPKRYKGFSIDVLDALAKALGFKYEIYQAPDGRYGHQLHNTSWNGMIGELISKRADLAISAITITPERESVVDFSKRYMDYSVGILIKKPEEKISIFSLFAPFDFAVWACIAAAIPVVGVLIFVLNRIQAVRAQSAAQPRPSASATLHSAIWIVYGAFVQQGGESSVNSMAMRIVMGSWWLFTLIVCSSYTANLAAFLTVSRMDNPIRTFQDLSKQVEMSYGTVRDSAVYEYFRAKGTNPLEQDSTFAELWRTISKNGGADNCVSSPSEGIRKAKKGNYAFLWDVAVVEYAALTDDDCSVTVIGNSISSKGYGIALQHGSPYRDLFSQRILELQDTGDLDVLKQKWWPHMGRCDLTSHASAQADGKSLKLHSFAGVFCILAIGLLLACLVAALELWWNSNRCHQETPKEDKEVNLEQVHRRMNSLMDEDIAHKQISPASIELSALEMGGLAPTQTLEPTREYQNTQLSVSTFLPEQSSHGTSRTLSSGPSSNLPLPLSSSATMPSMQCKHRSPNGGLFRQSPVKTPIPMSFQPVPGGVLPEALDTSHGTSI,0,,,,,,,,P68871(HBB),,1:Q9ULK0-1:|2:Q9ULK0-2:,,,,,,,,,,5.0
P23415,,Glycine receptor subunit alpha-1,GLRA1,Homo sapiens,457,False,,MYSFNTLRLYLWETIVFFSLAASKEAEAARSAPKPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAYNEYPDDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLTLACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGAVQVADGLTLPQFILKEEKDLRYCTKHYNTGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPARVGLGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRRHHKSPMLNLFQEDEAGEGRFNFSAYGMGPACLQAKDGISVKGANNSNTTNPPPAPSKSPEEMRKLFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ,0,,,,,,"Hyperekplexia 1:A neurologic disorder characterized by muscular rigidity of central nervous system origin, particularly in the neonatal period, and by an exaggerated startle response to unexpected acoustic or tactile stimuli.",Hyperekplexia 1,P48167(GLRB)|Q9Y5V3(MAGED1)|O60504(SORBS3)|P23415-1(GLRA1),,a:P23415-1:|b:P23415-2:,,,,,,,,,,5.0
P28472,,Gamma-aminobutyric acid receptor subunit beta-3,GABRB3,Homo sapiens,473,False,,MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPPVCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLKRNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIPYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNRVDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRSLPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN,0,,,,,,"Epilepsy, childhood absence 5:A subtype of idiopathic generalized epilepsy characterized by an onset at age 6-7 years, frequent absence seizures (several per day) and bilateral, synchronous, symmetric 3-Hz spike waves on EEG. Tonic-clonic seizures often develop in adolescence. Absence seizures may either remit or persist into adulthood.|Developmental and epileptic encephalopathy 43:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE43 inheritance is autosomal dominant.","Epilepsy, childhood absence 5|Developmental and epileptic encephalopathy 43",P28472(GABRB3),,1:P28472-1:|2:P28472-2:|3:P28472-3:|4:P28472-4:,,,,,,,,,,5.0
P24046,,Gamma-aminobutyric acid receptor subunit rho-1,GABRR1,Homo sapiens,479,False,,MLAVPNMRFGIFLLWWGWVLATESRMHWPGREVHEMSKKGRPQRQRREVHEDAHKQVSPILRRSPDITKSPLTKSEQLLRIDDHDFSMRPGFGGPAIPVGVDVQVESLDSISEVDMDFTMTLYLRHYWKDERLSFPSTNNLSMTFDGRLVKKIWVPDMFFVHSKRSFIHDTTTDNVMLRVQPDGKVLYSLRVTVTAMCNMDFSRFPLDTQTCSLEIESYAYTEDDLMLYWKKGNDSLKTDERISLSQFLIQEFHTTTKLAFYSSTGWYNRLYINFTLRRHIFFFLLQTYFPATLMVMLSWVSFWIDRRAVPARVPLGITTVLTMSTIITGVNASMPRVSYIKAVDIYLWVSFVFVFLSVLEYAAVNYLTTVQERKEQKLREKLPCTSGLPPPRTAMLDGNYSDGEVNDLDNYMPENGEKPDRMMVQLTLASERSSPQRKSQRSSYVSMRIDTHAIDKYSRIIFPAAYILFNLIYWSIFS,0,,,,,,,,,,1:P24046-1:|2:P24046-2:|3:P24046-3:,,,,,,,,,,5.0
P43681,,Neuronal acetylcholine receptor subunit alpha-4,CHRNA4,Homo sapiens,627,False,NACRA4,MELGGPGAPRLLPPLLLLLGTGLLRASSHVETRAHAEERLLKKLFSGYNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTTNVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSWTYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHHRSPRTHTMPTWVRRVFLDIVPRLLLMKRPSVVKDNCRRLIESMHKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPLDVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHMSSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAVEGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI,0,,,,,,"Epilepsy, nocturnal frontal lobe, 1:An autosomal dominant focal epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements.","Epilepsy, nocturnal frontal lobe, 1",Q6UY14-3(ADAMTSL4)|P05067(APP)|P83916(CBX1)|Q6UXH1-1(CRELD2)|Q6UXH1-3(CRELD2)|P20042(EIF2S2)|Q9NZR2(LRP1B)|Q92673(SORL1)|P17787(CHRNB2),,1:P43681-1:|2:P43681-2:,,,,,,,,,,5.0
P11230,,Acetylcholine receptor subunit beta,CHRNB1,Homo sapiens,501,False,ACHRB|CHRNB,MTPGALLMLLGALGAPLAPGVRGSEAEGRLREKLFSGYDSSVRPAREVGDRVRVSVGLILAQLISLNEKDEEMSTKVYLDLEWTDYRLSWDPAEHDGIDSLRITAESVWLPDVVLLNNNDGNFDVALDISVVVSSDGSVRWQPPGIYRSSCSIQVTYFPFDWQNCTMVFSSYSYDSSEVSLQTGLGPDGQGHQEIHIHEGTFIENGQWEIIHKPSRLIQPPGDPRGGREGQRQEVIFYLIIRRKPLFYLVNVIAPCILITLLAIFVFYLPPDAGEKMGLSIFALLTLTVFLLLLADKVPETSLSVPIIIKYLMFTMVLVTFSVILSVVVLNLHHRSPHTHQMPLWVRQIFIHKLPLYLRLKRPKPERDLMPEPPHCSSPGSGWGRGTDEYFIRKPPSDFLFPKPNRFQPELSAPDLRRFIDGPNRAVALLPELREVVSSISYIARQLQEQEDHDALKEDWQFVAMVVDRLFLWTFIIFTSVGTLVIFLDATYHLPPPDPFP,0,,,,,,"Myasthenic syndrome, congenital, 2A, slow-channel:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.|Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2C is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current. CMS2C is clinically characterized by early-onset muscle weakness with variable severity.","Myasthenic syndrome, congenital, 2A, slow-channel|Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency",Q9NWX5(ASB6),,1:P11230-1:|2:P11230-2:,,,,,,,,,,5.0
O60391,,"Glutamate receptor ionotropic, NMDA 3B",GRIN3B,Homo sapiens,1043,False,,MEFVRALWLGLALALGPGSAGGHPQPCGVLARLGGSVRLGALLPRAPLARARARAALARAALAPRLPHNLSLELVVAAPPARDPASLTRGLCQALVPPGVAALLAFPEARPELLQLHFLAAATETPVLSLLRREARAPLGAPNPFHLQLHWASPLETLLDVLVAVLQAHAWEDVGLALCRTQDPGGLVALWTSRAGRPPQLVLDLSRRDTGDAGLRARLAPMAAPVGGEAPVPAAVLLGCDIARARRVLEAVPPGPHWLLGTPLPPKALPTAGLPPGLLALGEVARPPLEAAIHDIVQLVARALGSAAQVQPKRALLPAPVNCGDLQPAGPESPGRFLARFLANTSFQGRTGPVWVTGSSQVHMSRHFKVWSLRRDPRGAPAWATVGSWRDGQLDLEPGGASARPPPPQGAQVWPKLRVVTLLEHPFVFARDPDEDGQCPAGQLCLDPGTNDSATLDALFAALANGSAPRALRKCCYGYCIDLLERLAEDTPFDFELYLVGDGKYGALRDGRWTGLVGDLLAGRAHMAVTSFSINSARSQVVDFTSPFFSTSLGIMVRARDTASPIGAFMWPLHWSTWLGVFAALHLTALFLTVYEWRSPYGLTPRGRNRSTVFSYSSALNLCYAILFRRTVSSKTPKCPTGRLLMNLWAIFCLLVLSSYTANLAAVMVGDKTFEELSGIHDPKLHHPAQGFRFGTVWESSAEAYIKKSFPDMHAHMRRHSAPTTPRGVAMLTSDPPKLNAFIMDKSLLDYEVSIDADCKLLTVGKPFAIEGYGIGLPQNSPLTSNLSEFISRYKSSGFIDLLHDKWYKMVPCGKRVFAVTETLQMSIYHFAGLFVLLCLGLGSALLSSLGEHAFFRLALPRIRKGSRLQYWLHTSQKIHRALNTEPPEGSKEETAEAEPSGPEVEQQQQQQDQPTAPEGWKRARRAVDKERRVRFLLEPAVVVAPEADAEAEAAPREGPVWLCSYGRPPAARPTGAPQPGELQELERRIEVARERLRQALVRRGQLLAQLGDSARHRPRRLLQARAAPAEAPPHSGRPGSQE,0,,,,,,,,,,,,,,,,,,,,5.0
P34903,,Gamma-aminobutyric acid receptor subunit alpha-3,GABRA3,Homo sapiens,492,False,,MIITQTSHCYMTSLGILFLINILPGTTGQGESRRQEPGDFVKQDIGGLSPKHAPDIPDDSTDNITIFTRILDRLLDGYDNRLRPGLGDAVTEVKTDIYVTSFGPVSDTDMEYTIDVFFRQTWHDERLKFDGPMKILPLNNLLASKIWTPDTFFHNGKKSVAHNMTTPNKLLRLVDNGTLLYTMRLTIHAECPMHLEDFPMDVHACPLKFGSYAYTTAEVVYSWTLGKNKSVEVAQDGSRLNQYDLLGHVVGTEIIRSSTGEYVVMTTHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRSWAWEGKKVPEALEMKKKTPAAPAKKTSTTFNIVGTTYPINLAKDTEFSTISKGAAPSASSTPTIIASPKATYVQDSPTETKTYNSVSKVDKISRIIFPVLFAIFNLVYWATYVNRESAIKGMIRKQ,0,,,,,,"Epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic features:A neurologic disorder characterized by variable combinations of epileptic seizure, and a varying degree of intellectual disability and developmental delay. Some patients have dysmorphic facial features or mild skeletal anomalies. In general, males are more severely affected than females, although there is evidence for incomplete penetrance in both sexes.","Epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic features",,,,,,,,,,,,,5.0
P48169,,Gamma-aminobutyric acid receptor subunit alpha-4,GABRA4,Homo sapiens,554,False,,MVSAKKVPAIALSAGVSFALLRFLCLAVCLNESPGQNQKEEKLCTENFTRILDSLLDGYDNRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLNNMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFPMDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSITGEYIVMTVYFHLRRKMGYFMIQTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMTTLSISARHSLPKVSYATAMDWFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQEVPAAPVQREKHPEAPLQNTNANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQESSKGTPRSYLASSPNPFSRANAAETISAARALPSASPTSIRTGYMPRKASVGSASTRHVFGSRLQRIKTTVNTIGATGKLSATPPPSAPPPSGSGTSKIDKYARILFPVTFGAFNMVYWVVYLSKDTMEKSESLM,0,,,,,,,,,,,,,,,,,,,,5.0
P07510,,Acetylcholine receptor subunit gamma,CHRNG,Homo sapiens,517,False,ACHRG,MHGGQGPLLLLLLLAVCLGAQGRNQEERLLADLMQNYDPNLRPAERDSDVVNVSLKLTLTNLISLNEREEALTTNVWIEMQWCDYRLRWDPRDYEGLWVLRVPSTMVWRPDIVLENNVDGVFEVALYCNVLVSPDGCIYWLPPAIFRSACSISVTYFPFDWQNCSLIFQSQTYSTNEIDLQLSQEDGQTIEWIFIDPEAFTENGEWAIQHRPAKMLLDPAAPAQEAGHQKVVFYLLIQRKPLFYVINIIAPCVLISSVAILIHFLPAKAGGQKCTVAINVLLAQTVFLFLVAKKVPETSQAVPLISKYLTFLLVVTILIVVNAVVVLNVSLRSPHTHSMARGVRKVFLRLLPQLLRMHVRPLAPAAVQDTQSRLQNGSSGWSITTGEEVALCLPRSELLFQQWQRQGLVAAALEKLEKGPELGLSQFCGSLKQAAPAIQACVEACNLIACARHQQSHFDNGNEEWFLVGRVLDRVCFLAMLSLFICGTAGIFLMAHYNRVPALPFPGDPRPYLPSPD,0,,,,,,"Multiple pterygium syndrome, lethal type:Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.|Multiple pterygium syndrome, Escobar variant:Non-lethal form of arthrogryposis multiplex congenita. It is an autosomal recessive condition characterized by excessive webbing (pterygia), congenital contractures (arthrogryposis), and scoliosis. Variable other features include intrauterine death, congenital respiratory distress, short stature, faciocranial dysmorphism, ptosis, low-set ears, arachnodactyly and cryptorchism in males. Congenital contractures are common and may be caused by reduced fetal movements at sensitive times of development. Possible causes of decreased fetal mobility include space constraints such as oligohydramnion, drugs, metabolic conditions or neuromuscular disorders including myasthenia gravis.","Multiple pterygium syndrome, lethal type|Multiple pterygium syndrome, Escobar variant",Q15323(KRT31)|P60409(KRTAP10-7)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|Q7Z3S9(NOTCH2NLA)|Q6UY14-3(ADAMTSL4)|A8MQ03(CYSRT1)|Q15323(KRT31)|O76011(KRT34)|Q07627(KRTAP1-1)|Q8IUG1(KRTAP1-3)|P60409(KRTAP10-7)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|P60328(KRTAP12-3)|P26371(KRTAP5-9)|Q9BYQ3(KRTAP9-3)|Q99750(MDFI)|P50222(MEOX2)|Q7Z3S9(NOTCH2NLA)|P0DPK4(NOTCH2NLC)|O43765(SGTA)|Q13596(SNX1)|O43597(SPRY2),,1:P07510-1:|2:P07510-2:,,,,,,,,,,5.0
Q8TCU5,,"Glutamate receptor ionotropic, NMDA 3A",GRIN3A,Homo sapiens,1115,False,KIAA1973,MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTTAPRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAEALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSFLQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQLSLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITANLPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQNVEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCMEVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTRLGSWQGGKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAGQLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIVGDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTRDTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSALNICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGIHDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNDPEKLDAFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFMDMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLLPRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLSHDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELSELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES,0,,,,,,,,,,,,,,,,,,,,5.0
P17787,,Neuronal acetylcholine receptor subunit beta-2,CHRNB2,Homo sapiens,502,False,,MARRCGPVALLLGFGLLRLCSGVWGTDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTTNVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAVVSYDGSIFWLPPAIYKSACKIEVKHFPFDQQNCTMKFRSWTYDRTEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDSTYVDITYDFIIRRKPLFYTINLIIPCVLITSLAILVFYLPSDCGEKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHHRSPTTHTMAPWVKVVFLEKLPALLFMQQPRHHCARQRLRLRRRQREREGAGALFFREAPGADSCTCFVNRASVQGLAGAFGAEPAPVAGPGRSGEPCGCGLREAVDGVRFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTIGMFLQPLFQNYTTTTFLHSDHSAPSSK,0,,,,,,"Epilepsy, nocturnal frontal lobe, 3:An autosomal dominant focal epilepsy characterized by nocturnal seizures with hyperkinetic automatisms and poorly organized stereotyped movements.","Epilepsy, nocturnal frontal lobe, 3",P43681-1(CHRNA4)|P30532(CHRNA5),,,,,,,,,,,,5.0
P36544,,Neuronal acetylcholine receptor subunit alpha-7,CHRNA7,Homo sapiens,502,False,NACHRA7,MRCSPGGVWLALAASLLHVSLQGEFQRKLYKELVKNYNPLERPVANDSQPLTVYFSLSLLQIMDVDEKNQVLTTNIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADERFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSWSYGGWSLDLQMQEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTLYYGLNLLIPCVLISALALLVFLLPADSGEKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIAQYFASTMIIVGLSVVVTVIVLQYHHHDPDGGKMPKWTRVILLNWCAWFLRMKRPGEDKVRPACQHKQRRCSLASVEMSAVAPPPASNGNLLYIGFRGLDGVHCVPTPDSGVVCGRMACSPTHDEHLLHGGQPPEGDPDLAKILEEVRYIANRFRCQDESEAVCSEWKFAACVVDRLCLMAFSVFTIICTIGILMSAPNFVEAVSKDFA,0,,,,,,,,P05067(APP)|P05067(APP)|Q9NSI6-4(BRWD1)|Q494W8(CHRFAM7A)|Q9UBU7(DBF4)|Q8N5J2-3(MINDY1)|Q09028(RBBP4)|P55000(SLURP1)|Q13573(SNW1),,1:P36544-1:|2:P36544-2:|3:P36544-3:,,,,,,,,,,5.0
P78334,,Gamma-aminobutyric acid receptor subunit epsilon,GABRE,Homo sapiens,506,False,,MLSKVLPVLLGILLILQSRVEGPQTESKNEASSRDVVYGPQPQPLENQLLSEETKSTETETGSRVGKLPEASRILNTILSNYDHKLRPGIGEKPTVVTVEISVNSLGPLSILDMEYTIDIIFSQTWYDERLCYNDTFESLVLNGNVVSQLWIPDTFFRNSKRTHEHEITMPNQMVRIYKDGKVLYTIRMTIDAGCSLHMLRFPMDSHSCPLSFSSFSYPENEMIYKWENFKLEINEKNSWKLFQFDFTGVSNKTEIITTPVGDFMVMTIFFNVSRRFGYVAFQNYVPSSVTTMLSWVSFWIKTESAPARTSLGITSVLTMTTLGTFSRKNFPRVSYITALDFYIAICFVFCFCALLEFAVLNFLIYNQTKAHASPKLRHPRINSRAHARTRARSRACARQHQEAFVCQIVTTEGSDGEERPSCSAQQPPSPGSPEGPRSLCSKLACCEWCKRFKKYFCMVPDCEGSTWQQGRLCIHVYRLDNYSRVVFPVTFFFFNVLYWLVCLNL,0,,,,,,,,,,1:P78334-1:|2:P78334-2:,,,,,,,,,,5.0
P47869,,Gamma-aminobutyric acid receptor subunit alpha-2,GABRA2,Homo sapiens,451,False,,MKTKLNIYNMQFLLFVFLVWDPARLVLANIQEDEAKNNITIFTRILDRLLDGYDNRLRPGLGDSITEVFTNIYVTSFGPVSDTDMEYTIDVFFRQKWKDERLKFKGPMNILRLNNLMASKIWTPDTFFHNGKKSVAHNMTMPNKLLRIQDDGTLLYTMRLTVQAECPMHLEDFPMDAHSCPLKFGSYAYTTSEVTYIWTYNASDSVQVAPDGSRLNQYDLLGQSIGKETIKSSTGEYTVMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKSVVNDKKKEKASVMIQNNAYAVAVANYAPNLSKDPVLSTISKSATTPEPNKKPENKPAEAKKTFNSVSKIDRMSRIVFPVLFGTFNLVYWATYLNREPVLGVSP,0,,,,,,"Developmental and epileptic encephalopathy 78:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE78 is an autosomal dominant form characterized by onset of refractory seizures in the first days or months of life. Clinical features include severe developmental delay, hypotonia, microcephaly, cortical visual impairment and profound intellectual disability. Some patients manifest a less severe phenotype characterized by pharmacoresponsive epilepsy, autism spectrum disorder and moderate intellectual disability.",Developmental and epileptic encephalopathy 78,P00533(EGFR),,1:P47869-1:|2:P47869-2:,,,,,,,,,,5.0
P31644,,Gamma-aminobutyric acid receptor subunit alpha-5,GABRA5,Homo sapiens,462,False,,MDNGMFSGFIMIKNLLLFCISMNLSSHFGFSQMPTSSVKDETNDNITIFTRILDGLLDGYDNRLRPGLGERITQVRTDIYVTSFGPVSDTEMEYTIDVFFRQSWKDERLRFKGPMQRLPLNNLLASKIWTPDTFFHNGKKSIAHNMTTPNKLLRLEDDGTLLYTMRLTISAECPMQLEDFPMDAHACPLKFGSYAYPNSEVVYVWTNGSTKSVVVAEDGSRLNQYHLMGQTVGTENISTSTGEYTIMTAHFHLKRKIGYFVIQTYLPCIMTVILSQVSFWLNRESVPARTVFGVTTVLTMTTLSISARNSLPKVAYATAMDWFIAVCYAFVFSALIEFATVNYFTKRGWAWDGKKALEAAKIKKKREVILNKSTNAFTTGKMSHPPNIPKEQTPAGTSNTTSVSVKPSEEKTSESKKTYNSISKIDKMSRIVFPVLFGTFNLVYWATYLNREPVIKGAASPK,0,,,,,,"Developmental and epileptic encephalopathy 79:A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE79 is an autosomal dominant form characterized by onset of refractory seizures in the first months of life. Brain imaging may show hypomyelination, cerebral atrophy and thinning of the corpus callosum.",Developmental and epileptic encephalopathy 79,,,,,,,,,,,,,5.0
Q04844,,Acetylcholine receptor subunit epsilon,CHRNE,Homo sapiens,493,False,ACHRE,MARAPLGVLLLLGLLGRGVGKNEELRLYHHLFNNYDPGSRPVREPEDTVTISLKVTLTNLISLNEKEETLTTSVWIGIDWQDYRLNYSKDDFGGIETLRVPSELVWLPEIVLENNIDGQFGVAYDANVLVYEGGSVTWLPPAIYRSVCAVEVTYFPFDWQNCSLIFRSQTYNAEEVEFTFAVDNDGKTINKIDIDTEAYTENGEWAIDFCPGVIRRHHGGATDGPGETDVIYSLIIRRKPLFYVINIIVPCVLISGLVLLAYFLPAQAGGQKCTVSINVLLAQTVFLFLIAQKIPETSLSVPLLGRFLIFVMVVATLIVMNCVIVLNVSQRTPTTHAMSPRLRHVLLELLPRLLGSPPPPEAPRAASPPRRASSVGLLLRAEELILKKPRSELVFEGQRHRQGTWTAAFCQSLGAAAPEVRCCVDAVNFVAESTRDQEATGEEVSDWVRMGNALDNICFWAALVLFSVGSSLIFLGAYFNRVPDLPYAPCIQP,0,,,,,,":|Myasthenic syndrome, congenital, 4A, slow-channel:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS4A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.|Myasthenic syndrome, congenital, 4B, fast-channel:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS4B is a fast-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in brief opening and activity of the channel, with a rapid decay in endplate current, failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.|Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS4C is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current.","Myasthenic syndrome, congenital, 4A, slow-channel|Myasthenic syndrome, congenital, 4B, fast-channel|Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency",,,,,,,,,,,,,5.0
P02708,,Acetylcholine receptor subunit alpha,CHRNA1,Homo sapiens,457,False,ACHRA|CHNRA,MEPWPLLLLFSLCSAGLVLGSEHETRLVAKLFKDYSSVVRPVEDHRQVVEVTVGLQLIQLINVDEVNQIVTTNVRLKQQWVDYNLKWNPDDYGGVKKIHIPSEKIWRPDLVLYNNADGDFAIVKFTKVLLQYTGHITWTPPAIFKSYCEIIVTHFPFDEQNCSMKLGTWTYDGSVVAINPESDQPDLSNFMESGEWVIKESRGWKHSVTYSCCPDTPYLDITYHFVMQRLPLYFIVNVIIPCLLFSFLTGLVFYLPTDSGEKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIGKYMLFTMVFVIASIIITVIVINTHHRSPSTHVMPNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTEDIDISDISGKPGPPPMGFHSPLIKHPEVKSAIEGIKYIAETMKSDQESNNAAAEWKYVAMVMDHILLGVFMLVCIIGTLAVFAGRLIELNQQG,0,,,,,,"Multiple pterygium syndrome, lethal type:Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.|:|Myasthenic syndrome, congenital, 1A, slow-channel:A common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS1A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.|Myasthenic syndrome, congenital, 1B, fast-channel:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS1B is a fast-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in brief opening and activity of the channel, with a rapid decay in endplate current, failure to achieve threshold depolarization of the endplate and consequent failure to fire an action potential.","Multiple pterygium syndrome, lethal type|Myasthenic syndrome, congenital, 1A, slow-channel|Myasthenic syndrome, congenital, 1B, fast-channel",,,1:P02708-2:|2:P02708-1:,,,,,,,,,,5.0
Q9GZV3,,High affinity choline transporter 1,SLC5A7,Homo sapiens,580,False,CHT1,MAFHVEGLIAIIVFYLLILLVGIWAAWRTKNSGSAEERSEAIIVGGRDIGLLVGGFTMTATWVGGGYINGTAEAVYVPGYGLAWAQAPIGYSLSLILGGLFFAKPMRSKGYVTMLDPFQQIYGKRMGGLLFIPALMGEMFWAAAIFSALGATISVIIDVDMHISVIISALIATLYTLVGGLYSVAYTDVVQLFCIFVGLWISVPFALSHPAVADIGFTAVHAKYQKPWLGTVDSSEVYSWLDSFLLLMLGGIPWQAYFQRVLSSSSATYAQVLSFLAAFGCLVMAIPAILIGAIGASTDWNQTAYGLPDPKTTEEADMILPIVLQYLCPVYISFFGLGAVSAAVMSSADSSILSASSMFARNIYQLSFRQNASDKEIVWVMRITVFVFGASATAMALLTKTVYGLWYLSSDLVYIVIFPQLLCVLFVKGTNTYGAVAGYVSGLFLRITGGEPYLYLQPLIFYPGYYPDDNGIYNQKFPFKTLAMVTSFLTNICISYLAKYLFESGTLPPKLDVFDAVVARHSEENMDKTILVKNENIKLDELALVKPRQSMTLSSTFTNKEAFLDVDSSPEGSGTEDNLQ,0,,,,,,"Neuronopathy, distal hereditary motor, autosomal dominant 7:A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.|Myasthenic syndrome, congenital, 20, presynaptic:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS20 is an autosomal recessive, pre-synaptic form characterized by severe hypotonia and episodic apnea soon after birth, generalized limb fatigability and weakness, delayed walking, ptosis, poor sucking and swallowing.","Neuronopathy, distal hereditary motor, autosomal dominant 7|Myasthenic syndrome, congenital, 20, presynaptic",,,,,,,,,,,,,5.0
Q8NDX2,,Vesicular glutamate transporter 3,SLC17A8,Homo sapiens,589,False,VGLUT3,MPFKAFDTFKEKILKPGKEGVKNAVGDSLGILQRKIDGTTEEEDNIELNEEGRPVQTSRPSPPLCDCHCCGLPKRYIIAIMSGLGFCISFGIRCNLGVAIVEMVNNSTVYVDGKPEIQTAQFNWDPETVGLIHGSFFWGYIMTQIPGGFISNKFAANRVFGAAIFLTSTLNMFIPSAARVHYGCVMCVRILQGLVEGVTYPACHGMWSKWAPPLERSRLATTSFCGSYAGAVVAMPLAGVLVQYIGWSSVFYIYGMFGIIWYMFWLLQAYECPAAHPTISNEEKTYIETSIGEGANVVSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFAISKVGLLSAVPHMVMTIVVPIGGQLADYLRSRQILTTTAVRKIMNCGGFGMEATLLLVVGFSHTKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPLIVGAMTRHKTREEWQNVFLIAALVHYSGVIFYGVFASGEKQEWADPENLSEEKCGIIDQDELAEEIELNHESFASPKKKMSYGATSQNCEVQKKEWKGQRGATLDEEELTSYQNEERNFSTIS,0,,,,,,"Deafness, autosomal dominant, 25:A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA25 expression is variable in terms of onset and rate of progression, with an age-dependent penetrance resembling an early-onset presbycusis, or senile deafness, a progressive bilateral loss of hearing that occurs in the aged.","Deafness, autosomal dominant, 25",P78329(CYP4F2)|A0PK00(TMEM120B)|Q96EC8(YIPF6),,1:Q8NDX2-1:|2:Q8NDX2-2:,,,,,,,,,,5.0
O00341,,Excitatory amino acid transporter 5,SLC1A7,Homo sapiens,560,False,EAAT5,MVPHAILARGRDVCRRNGLLILSVLSVIVGCLLGFFLRTRRLSPQEISYFQFPGELLMRMLKMMILPLVVSSLMSGLASLDAKTSSRLGVLTVAYYLWTTFMAVIVGIFMVSIIHPGSAAQKETTEQSGKPIMSSADALLDLIRNMFPANLVEATFKQYRTKTTPVVKSPKVAPEEAPPRRILIYGVQEENGSHVQNFALDLTPPPEVVYKSEPGTSDGMNVLGIVFFSATMGIMLGRMGDSGAPLVSFCQCLNESVMKIVAVAVWYFPFGIVFLIAGKILEMDDPRAVGKKLGFYSVTVVCGLVLHGLFILPLLYFFITKKNPIVFIRGILQALLIALATSSSSATLPITFKCLLENNHIDRRIARFVLPVGATINMDGTALYEAVAAIFIAQVNNYELDFGQIITISITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWALDRFRTMINVLGDALAAGIMAHICRKDFARDTGTEKLLPCETKPVSLQEIVAAQQNGCVKSVAEASELTLGPTCPHHVPVQVEQDEELPAASLNHCTIQISELETNV,0,,,,,,,,,,1:O00341-1:|2:O00341-2:,,,,,,,,,,5.0
Q9P2U8,,Vesicular glutamate transporter 2,SLC17A6,Homo sapiens,582,False,DNPI|VGLUT2,MESVKQRILAPGKEGLKNFAGKSLGQIYRVLEKKQDTGETIELTEDGKPLEVPERKAPLCDCTCFGLPRRYIIAIMSGLGFCISFGIRCNLGVAIVDMVNNSTIHRGGKVIKEKAKFNWDPETVGMIHGSFFWGYIITQIPGGYIASRLAANRVFGAAILLTSTLNMLIPSAARVHYGCVIFVRILQGLVEGVTYPACHGIWSKWAPPLERSRLATTSFCGSYAGAVIAMPLAGILVQYTGWSSVFYVYGSFGMVWYMFWLLVSYESPAKHPTITDEERRYIEESIGESANLLGAMEKFKTPWRKFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGFEISKVGMLSAVPHLVMTIIVPIGGQIADFLRSKQILSTTTVRKIMNCGGFGMEATLLLVVGYSHTRGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYASILMGISNGVGTLSGMVCPIIVGAMTKNKSREEWQYVFLIAALVHYGGVIFYAIFASGEKQPWADPEETSEEKCGFIHEDELDEETGDITQNYINYGTTKSYGATTQANGGWPSGWEKKEEFVQGEVQDSHSYKDRVDYS,0,,,,,,,,,,,,,,,,,,,,5.0
Q99884,,Sodium-dependent proline transporter,SLC6A7,Homo sapiens,636,False,PROT,MKKLQGAHLRKPVTPDLLMTPSDQGDVDLDVDFAAHRGNWTGKLDFLLSCIGYCVGLGNVWRFPYRAYTNGGGAFLVPYFLMLAICGIPLFFLELSLGQFSSLGPLAVWKISPLFKGAGAAMLLIVGLVAIYYNMIIAYVLFYLFASLTSDLPWEHCGNWWNTELCLEHRVSKDGNGALPLNLTCTVSPSEEYWSRYVLHIQGSQGIGSPGEIRWNLCLCLLLAWVIVFLCILKGVKSSGKVVYFTATFPYLILLMLLVRGVTLPGAWKGIQFYLTPQFHHLLSSKVWIEAALQIFYSLGVGFGGLLTFASYNTFHQNIYRDTFIVTLGNAITSILAGFAIFSVLGYMSQELGVPVDQVAKAGPGLAFVVYPQAMTMLPLSPFWSFLFFFMLLTLGLDSQFAFLETIVTAVTDEFPYYLRPKKAVFSGLICVAMYLMGLILTTDGGMYWLVLLDDYSASFGLMVVVITTCLAVTRVYGIQRFCRDIHMMLGFKPGLYFRACWLFLSPATLLALMVYSIVKYQPSEYGSYRFPPWAELLGILMGLLSCLMIPAGMLVAVLREEGSLWERLQQASRPAMDWGPSLEENRTGMYVATLAGSQSPKPLMVHMRKYGGITSFENTAIEVDREIAEEEESMM,0,,,,,,,,,,,,,,,,,,,,5.0
Q99726,,Probable proton-coupled zinc antiporter SLC30A3,SLC30A3,Homo sapiens,388,False,ZNT3,MEPSPAAGGLETTRLVSPRDRGGAGGSLRLKSLFTEPSEPLPEESKPVEMPFHHCHRDPLPPPGLTPERLHARRQLYAACAVCFVFMAGEVVGGYLAHSLAIMTDAAHLLADVGSMMGSLFSLWLSTRPATRTMTFGWHRSETLGALASVVSLWMVTGILLYLAFVRLLHSDYHIEGGAMLLTASIAVCANLLMAFVLHQAGPPHSHGSRGAEYAPLEEGPEEPLPLGNTSVRAAFVHVLGDLLQSFGVLAASILIYFKPQYKAADPISTFLFSICALGSTAPTLRDVLRILMEGTPRNVGFEPVRDTLLSVPGVRATHELHLWALTLTYHVASAHLAIDSTADPEAVLAEASSRLYSRFGFSSCTLQVEQYQPEMAQCLRCQEPPQA,0,,,,,,,,P25942(CD40)|Q99675(CGRRF1)|Q9GZR5(ELOVL4)|Q96P31-6(FCRL3)|P48165(GJA8)|Q8NBJ4(GOLM1)|Q8TDT2(GPR152)|O15529(GPR42)|Q8TED1(GPX8)|Q7Z5P4(HSD17B13)|Q58DX5(NAALADL2)|Q9NX40(OCIAD1)|Q86VR2(RETREG3)|Q6ZMZ0(RNF19B)|O95197-3(RTN3)|Q9NY72(SCN3B)|O95470(SGPL1)|Q3KNW5(SLC10A6)|Q6XR72(SLC30A10)|Q9BRI3(SLC30A2)|O14863(SLC30A4)|Q8IWU4(SLC30A8)|O95436-2(SLC34A2)|Q9NQQ7-3(SLC35C2)|Q9NUH8(TMEM14B)|Q8TC26(TMEM163)|Q9NWH2(TMEM242),,,,,,,,,,,,5.0
P31645,,Sodium-dependent serotonin transporter,SLC6A4,Homo sapiens,630,False,HTT|SERT,METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTRHSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIMAWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPETPTEIPCGDIRLNAV,0,,,,,,,,,,1:P31645-1:|2:P31645-2:,,,,,,,,,,5.0
Q12959,,Disks large homolog 1,DLG1,Homo sapiens,904,False,,MPVRKQDTQRALHLLEEYRSKLSQTEDRQLRSSIERVINIFQSNLFQALIDIQEFYEVTLLDNPKCIDRSKPSEPIQPVNTWEISSLPSSTVTSETLPSSLSPSVEKYRYQDEDTPPQEHISPQITNEVIGPELVHVSEKNLSEIENVHGFVSHSHISPIKPTEAVLPSPPTVPVIPVLPVPAENTVILPTIPQANPPPVLVNTDSLETPTYVNGTDADYEYEEITLERGNSGLGFSIAGGTDNPHIGDDSSIFITKIITGGAAAQDGRLRVNDCILRVNEVDVRDVTHSKAVEALKEAGSIVRLYVKRRKPVSEKIMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGKLQIGDKLLAVNNVCLEEVTHEEAVTALKNTSDFVYLKVAKPTSMYMNDGYAPPDITNSSSQPVDNHVSPSSFLGQTPASPARYSPVSKAVLGDDEITREPRKVVLHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDRIISVNSVDLRAASHEQAAAALKNAGQAVTIVAQYRPEEYSRFEAKIHDLREQMMNSSISSGSGSLRTSQKRSLYVRALFDYDKTKDSGLPSQGLNFKFGDILHVINASDDEWWQARQVTPDGESDEVGVIPSKRRVEKKERARLKTVKFNSKTRDKGEIPDDMGSKGLKHVTSNASDSESSYRGQEEYVLSYEPVNQQEVNYTRPVIILGPMKDRINDDLISEFPDKFGSCVPHTTRPKRDYEVDGRDYHFVTSREQMEKDIQEHKFIEAGQYNNHLYGTSVQSVREVAEKGKHCILDVSGNAIKRLQIAQLYPISIFIKPKSMENIMEMNKRLTEEQARKTFERAMKLEQEFTEHFTAIVQGDTLEDIYNQVKQIIEEQSGSYIWVPAKEKL,0,,,,,,,,P78536(ADAM17)|Q96PE1(ADGRA2)|Q9NQ90(ANO2)|A1A5B4(ANO9)|P25054(APC)|Q5VV41(ARHGEF16)|Q9Y297(BTRC)|Q86XJ0(CALHM3)|P15813(CD1D)|Q9UQB3(CTNND2)|Q9NS75(CYSLTR2)|O60447(EVI5)|P0C2L3(FAM163B)|Q14CM0(FRMPD4)|Q13224(GRIN2B)|Q14957(GRIN2C)|P33402(GUCY1A2)|Q9P2D3(HEATR5B)|P22459(KCNA4)|O60333-3(KIF1B)|P36507(MAP2K2)|P53778(MAPK12)|Q7Z628(NET1)|Q99569(PKP4)|P85299(PRR5)|Q15311(RALBP1)|O15427(SLC16A3)|Q9C0D5(TANC1)|Q9ULK5(VANGL2)|O57125(E6)|P03126(E6)|P06427(E6)|P06463(E6)|P17386(E6)|P21735(E6)|P24835(E6)|P27228(E6)|P36799(E6)|P50804(E6)|P54667(E6)|Q9ICL1(se6)|P09708(US32)|Q96PE1(ADGRA2)|Q8IWK6-3(ADGRA3)|Q9NQT8(KIF13B)|P31016(Dlg4),,1:Q12959-1:|2:Q12959-2:|3:Q12959-3:|4:Q12959-4:|5:Q12959-5:|6:Q12959-6:|7:Q12959-7:|8:Q12959-8:|9:Q12959-9:,,,,,,,,,,5.0
P78352,,Disks large homolog 4,DLG4,Homo sapiens,724,False,PSD95,MDCLCIVTTKKYRYQDEDTPPLEHSPAHLPNQANSPPVIVNTDTLEAPGYELQVNGTEGEMEYEEITLERGNSGLGFSIAGGTDNPHIGDDPSIFITKIIPGGAAAQDGRLRVNDSILFVNEVDVREVTHSAAVEALKEAGSIVRLYVMRRKPPAEKVMEIKLIKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIEGGAAHKDGRLQIGDKILAVNSVGLEDVMHEDAVAALKNTYDVVYLKVAKPSNAYLSDSYAPPDITTSYSQHLDNEISHSSYLGTDYPTAMTPTSPRRYSPVAKDLLGEEDIPREPRRIVIHRGSTGLGFNIVGGEDGEGIFISFILAGGPADLSGELRKGDQILSVNGVDLRNASHEQAAIALKNAGQTVTIIAQYKPEEYSRFEAKIHDLREQLMNSSLGSGTASLRSNPKRGFYIRALFDYDKTKDCGFLSQALSFRFGDVLHVIDASDEEWWQARRVHSDSETDDIGFIPSKRRVERREWSRLKAKDWGSSSGSQGREDSVLSYETVTQMEVHYARPIIILGPTKDRANDDLLSEFPDKFGSCVPHTTRPKREYEIDGRDYHFVSSREKMEKDIQAHKFIEAGQYNSHLYGTSVQSVREVAEQGKHCILDVSANAVRRLQAAHLHPIAIFIRPRSLENVLEINKRITEEQARKAFDRATKLEQEFTECFSAIVEGDSFEEIYHKVKRVIEDLSGPYIWVPARERL,0,,,,,,"Intellectual developmental disorder, autosomal dominant 62:An autosomal dominant form of intellectual disability, a disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRD62 is characterized by mild to moderately impaired intellectual development.","Intellectual developmental disorder, autosomal dominant 62",Q9P021(CRIPT)|O14490(DLGAP1)|Q15303(ERBB4)|Q12879(GRIN2A)|Q13224(GRIN2B)|Q14957(GRIN2C)|Q09470(KCNA1)|P22459(KCNA4)|O60333-3(KIF1B)|Q07954(LRP1)|Q00987(MDM2)|Q15311(RALBP1)|O43166(SIPA1L1)|P97836-5(Dlgap1)|Q8VDU0(Gpsm2)|P10499(Kcna1)|P63142(Kcna2)|P15384(Kcna3)|P15385(Kcna4)|Q8R4I7(Neto1)|O60260-5(PRKN),,1:P78352-1:|2:P78352-2:|3:P78352-3:,,,,,,,,,,5.0
Q96A49,,Synapse-associated protein 1,SYAP1,Homo sapiens,352,False,,MFRGLSSWLGLQQPVAGGGQPNGDAPPEQPSETVAESAEEELQQAGDQELLHQAKDFGNYLFNFASAATKKITESVAETAQTIKKSVEEGKIDGIIDKTIIGDFQKEQKKFVEEQHTKKSEAAVPPWVDTNDEETIQQQILALSADKRNFLRDPPAGVQFNFDFDQMYPVALVMLQEDELLSKMRFALVPKLVKEEVFWRNYFYRVSLIKQSAQLTALAAQQQAAGKEEKSNGREQDLPLAEAVRPKTPPVVIKSQLKTQEDEEEISTSPGVSEFVSDAFDACNLNQEDLRKEMEQLVLDKKQEETAVLEEDSADWEKELQQELQEYEVVTESEKRDENWDKEIEKMLQEEN,0,,,,,,,,Q15848(ADIPOQ)|P30301(MIP)|Q99608(NDN)|Q13526(PIN1)|Q9NUX5(POT1)|P10827(THRA)|O14798(TNFRSF10C)|O95159(ZFPL1),,,,,,,,,,,,5.0
Q12756,,Kinesin-like protein KIF1A,KIF1A,Homo sapiens,1690,False,ATSV|C2orf20,MAGASVKVAVRVRPFNSREMSRDSKCIIQMSGSTTTIVNPKQPKETPKSFSFDYSYWSHTSPEDINYASQKQVYRDIGEEMLQHAFEGYNVCIFAYGQTGAGKSYTMMGKQEKDQQGIIPQLCEDLFSRINDTTNDNMSYSVEVSYMEIYCERVRDLLNPKNKGNLRVREHPLLGPYVEDLSKLAVTSYNDIQDLMDSGNKARTVAATNMNETSSRSHAVFNIIFTQKRHDAETNITTEKVSKISLVDLAGSERADSTGAKGTRLKEGANINKSLTTLGKVISALAEMDSGPNKNKKKKKTDFIPYRDSVLTWLLRENLGGNSRTAMVAALSPADINYDETLSTLRYADRAKQIRCNAVINEDPNNKLIRELKDEVTRLRDLLYAQGLGDITDMTNALVGMSPSSSLSALSSRAASVSSLHERILFAPGSEEAIERLKETEKIIAELNETWEEKLRRTEAIRMEREALLAEMGVAMREDGGTLGVFSPKKTPHLVNLNEDPLMSECLLYYIKDGITRVGREDGERRQDIVLSGHFIKEEHCVFRSDSRGGSEAVVTLEPCEGADTYVNGKKVTEPSILRSGNRIIMGKSHVFRFNHPEQARQERERTPCAETPAEPVDWAFAQRELLEKQGIDMKQEMEQRLQELEDQYRREREEATYLLEQQRLDYESKLEALQKQMDSRYYPEVNEEEEEPEDEVQWTERECELALWAFRKWKWYQFTSLRDLLWGNAIFLKEANAISVELKKKVQFQFVLLTDTLYSPLPPDLLPPEAAKDRETRPFPRTIVAVEVQDQKNGATHYWTLEKLRQRLDLMREMYDRAAEVPSSVIEDCDNVVTGGDPFYDRFPWFRLVGRAFVYLSNLLYPVPLVHRVAIVSEKGEVKGFLRVAVQAISADEEAPDYGSGVRQSGTAKISFDDQHFEKFQSESCPVVGMSRSGTSQEELRIVEGQGQGADVGPSADEVNNNTCSAVPPEGLLLDSSEKAALDGPLDAALDHLRLGNTFTFRVTVLQASSISAEYADIFCQFNFIHRHDEAFSTEPLKNTGRGPPLGFYHVQNIAVEVTKSFIEYIKSQPIVFEVFGHYQQHPFPPLCKDVLSPLRPSRRHFPRVMPLSKPVPATKLSTLTRPCPGPCHCKYDLLVYFEICELEANGDYIPAVVDHRGGMPCMGTFLLHQGIQRRITVTLLHETGSHIRWKEVRELVVGRIRNTPETDESLIDPNILSLNILSSGYIHPAQDDRTFYQFEAAWDSSMHNSLLLNRVTPYREKIYMTLSAYIEMENCTQPAVVTKDFCMVFYSRDAKLPASRSIRNLFGSGSLRASESNRVTGVYELSLCHVADAGSPGMQRRRRRVLDTSVAYVRGEENLAGWRPRSDSLILDHQWELEKLSLLQEVEKTRHYLLLREKLETAQRPVPEALSPAFSEDSESHGSSSASSPLSAEGRPSPLEAPNERQRELAVKCLRLLTHTFNREYTHSHVCVSASESKLSEMSVTLLRDPSMSPLGVATLTPSSTCPSLVEGRYGATDLRTPQPCSRPASPEPELLPEADSKKLPSPARATETDKEPQRLLVPDIQEIRVSPIVSKKGYLHFLEPHTSGWARRFVVVRRPYAYMYNSDKDTVERFVLNLATAQVEYSEDQQAMLKTPNTFAVCTEHRGILLQAASDKDMHDWLYAFNPLLAGTIRSKLSRRRSAQMRV,0,,,,,,"Spastic paraplegia 30A, autosomal dominant:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG30A patients have a pure form of the disorder, limited to spastic paraplegia, whereas others may have a complicated form that includes additional features such as cognitive dysfunction, learning disabilities, peripheral sensorimotor neuropathy, urinary sphincter problems, and/or cerebellar atrophy. SPG30A is characterized by onset in the first or second decades of unsteady spastic gait and hyperreflexia of the lower limbs. Inheritance is autosomal dominant.|Spastic paraplegia 30B, autosomal recessive:A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG30B patients have a pure form of the disorder, limited to spastic paraplegia, whereas others may have a complicated form that includes additional features such as cognitive dysfunction, learning disabilities, peripheral sensorimotor neuropathy, urinary sphincter problems, and/or cerebellar atrophy.|Neuropathy, hereditary sensory, 2C:A neurodegenerative disorder characterized by onset in the first decade of progressive distal sensory loss leading to ulceration and amputation of the fingers and toes. Affected individuals also develop distal muscle weakness, primarily affecting the lower limbs.|NESCAV syndrome:An autosomal dominant neurodegenerative disorder with variable manifestations. Main features are delayed psychomotor development, progressive spasticity, intellectual disability, speech delay, and learning disabilities. Some patients never achieve ambulation. Additional variable features are cortical visual impairment, often associated with optic atrophy, axonal peripheral neuropathy, seizures, dysautonomia, ataxia, and dystonia. Brain imaging often shows progressive cerebellar atrophy and thin corpus callosum. Disease onset is in infancy or early childhood.|:","Spastic paraplegia 30A, autosomal dominant|Spastic paraplegia 30B, autosomal recessive|Neuropathy, hereditary sensory, 2C|NESCAV syndrome",P07339(CTSD)|P28799(GRN)|Q12756(KIF1A)|O60333-2(KIF1B)|Q7Z699(SPRED1)|P02766(TTR)|O76024(WFS1),,1:Q12756-1:|2:Q12756-2:|3:Q12756-3:,,,,,,,,,,5.0
Q9H7V2,,Synapse differentiation-inducing gene protein 1,SYNDIG1,Homo sapiens,258,False,C20orf39|TMEM90B,MDGIIEQKSMLVHSKISDAGKRNGLINTRNLMAESRDGLVSVYPAPQYQSHRVGASTVPASLDSSRSEPMQQLLDPNTLQQSVESRYRPNIILYSEGVLRSWGDGVAADCCETTFIEDRSPTKDSLEYPDGKFIDLSADDIKIHTLSYDVEEEEEFQELESDYSSDTESEDNFLMMPPRDHLGLSVFSMLCCFWPLGIAAFYLSHETNKAVAKGDLHQASTSSRRALFLAVLSITIGTGVYVGVAVALIAYLSKNNHL,0,,,,,,,,Q13520(AQP6)|Q9GZR5(ELOVL4)|Q969F0(FATE1)|O15552(FFAR2)|O15529(GPR42)|Q9NZD1(GPRC5D)|O95214(LEPROTL1)|P21145(MAL)|Q6ZSS7(MFSD6)|Q7RTY0(SLC16A13)|Q9NQQ7-3(SLC35C2)|Q8IVJ1(SLC41A1)|Q96MV1(TLCD4)|Q9BTV4(TMEM43)|Q9H1C4(UNC93B1),,,,,,,,,,,,5.0
Q99946,,Proline-rich transmembrane protein 1,PRRT1,Homo sapiens,306,False,C6orf31|NG5,MSSEKSGLPDSVPHTSPPPYNAPQPPAEPPAPPPQAAPSSHHHHHHHYHQSGTATLPRLGAGGLASSAATAQRGPSSSATLPRPPHHAPPGPAAGAPPPGCATLPRMPPDPYLQETRFEGPLPPPPPAAAAPPPPAPAQTAQAPGFVVPTHAGTVGTLPLGGYVAPGYPLQLQPCTAYVPVYPVGTPYAGGTPGGTGVTSTLPPPPQGPGLALLEPRRPPHDYMPIAVLTTICCFWPTGIIAIFKAVQVRTALARGDMVSAEIASREARNFSFISLAVGIAAMVLCTILTVVIIIAAQHHENYWDP,0,,,,,,,,P21145(MAL)|Q99946-2(PRRT1),,1:Q99946-1:|2:Q99946-2:,,,,,,,,,,5.0
Q2Y0W8,,Electroneutral sodium bicarbonate exchanger 1,SLC4A8,Homo sapiens,1093,False,KIAA0739|NBC|NBC3|NDCBE1,MPAAGSNEPDGVLSYQRPDEEAVVDQGGTSTILNIHYEKEELEGHRTLYVGVRMPLGRQSHRHHRTHGQKHRRRGRGKGASQGEEGLEALAHDTPSQRVQFILGTEEDEEHVPHELFTELDEICMKEGEDAEWKETARWLKFEEDVEDGGERWSKPYVATLSLHSLFELRSCLINGTVLLDMHANSIEEISDLILDQQELSSDLNDSMRVKVREALLKKHHHQNEKKRNNLIPIVRSFAEVGKKQSDPHLMDKHGQTVSPQSVPTTNLEVKNGVNCEHSPVDLSKVDLHFMKKIPTGAEASNVLVGEVDILDRPIVAFVRLSPAVLLSGLTEVPIPTRFLFILLGPVGKGQQYHEIGRSMATIMTDEIFHDVAYKAKERDDLLAGIDEFLDQVTVLPPGEWDPSIRIEPPKNVPSQEKRKMPGVPNGNVCHIEQEPHGGHSGPELQRTGRLFGGLVLDIKRKAPWYWSDYRDALSLQCLASFLFLYCACMSPVITFGGLLGEATEGRISAIESLFGASMTGIAYSLFAGQALTILGSTGPVLVFEKILFKFCKDYALSYLSLRACIGLWTAFLCIVLVATDASSLVCYITRFTEEAFASLICIIFIYEAIEKLIHLAETYPIHMHSQLDHLSLYYCRCTLPENPNNHTLQYWKDHNIVTAEVHWANLTVSECQEMHGEFMGSACGHHGPYTPDVLFWSCILFFTTFILSSTLKTFKTSRYFPTRVRSMVSDFAVFLTIFTMVIIDFLIGVPSPKLQVPSVFKPTRDDRGWIINPIGPNPWWTVIAAIIPALLCTILIFMDQQITAVIINRKEHKLKKGCGYHLDLLMVAIMLGVCSIMGLPWFVAATVLSITHVNSLKLESECSAPGEQPKFLGIREQRVTGLMIFVLMGCSVFMTAILKFIPMPVLYGVFLYMGVSSLQGIQFFDRLKLFGMPAKHQPDFIYLRHVPLRKVHLFTLIQLTCLVLLWVIKASPAAIVFPMMVLALVFVRKVMDLCFSKRELSWLDDLMPESKKKKLDDAKKKAKEEEEAEKMLEIGGDKFPLESRKLLSSPGKNISCRCDPSEINISDEMPKTTVWKALSMNSGNAKEKSLFN,0,,,,,,,,,,1:Q2Y0W8-1:|2:Q2Y0W8-2:|3:Q2Y0W8-3:|4:Q2Y0W8-4:|5:Q2Y0W8-5:|6:Q2Y0W8-6:|7:Q2Y0W8-7:|8:Q2Y0W8-8:,,,,,,,,,,5.0
P30531,,Sodium- and chloride-dependent GABA transporter 1,SLC6A1,Homo sapiens,599,False,GABATR|GABT1|GAT1,MATNGSKVADGQISTEVSEAPVANDKPKTLVVKVQKKAADLPDRDTWKGRFDFLMSCVGYAIGLGNVWRFPYLCGKNGGGAFLIPYFLTLIFAGVPLFLLECSLGQYTSIGGLGVWKLAPMFKGVGLAAAVLSFWLNIYYIVIISWAIYYLYNSFTTTLPWKQCDNPWNTDRCFSNYSMVNTTNMTSAVVEFWERNMHQMTDGLDKPGQIRWPLAITLAIAWILVYFCIWKGVGWTGKVVYFSATYPYIMLIILFFRGVTLPGAKEGILFYITPNFRKLSDSEVWLDAATQIFFSYGLGLGSLIALGSYNSFHNNVYRDSIIVCCINSCTSMFAGFVIFSIVGFMAHVTKRSIADVAASGPGLAFLAYPEAVTQLPISPLWAILFFSMLLMLGIDSQFCTVEGFITALVDEYPRLLRNRRELFIAAVCIISYLIGLSNITQGGIYVFKLFDYYSASGMSLLFLVFFECVSISWFYGVNRFYDNIQEMVGSRPCIWWKLCWSFFTPIIVAGVFIFSAVQMTPLTMGNYVFPKWGQGVGWLMALSSMVLIPGYMAYMFLTLKGSLKQRIQVMVQPSEDIVRPENGPEQPQAGSSTSKEAYI,0,,,,,,"Myoclonic-atonic epilepsy:A form of epilepsy characterized by myoclonic-atonic and absence seizures, appearing in early childhood. Patients have delayed development before the onset of seizures and show varying degrees of intellectual disability following seizure onset.",Myoclonic-atonic epilepsy,O75031(HSF2BP),,,,,,,,,,,,5.0
Q15700,,Disks large homolog 2,DLG2,Homo sapiens,870,False,,MFFACYCALRTNVKKYRYQDEDAPHDHSLPRLTHEVRGPELVHVSEKNLSQIENVHGYVLQSHISPLKASPAPIIVNTDTLDTIPYVNGTEIEYEFEEITLERGNSGLGFSIAGGTDNPHIGDDPGIFITKIIPGGAAAEDGRLRVNDCILRVNEVDVSEVSHSKAVEALKEAGSIVRLYVRRRRPILETVVEIKLFKGPKGLGFSIAGGVGNQHIPGDNSIYVTKIIDGGAAQKDGRLQVGDRLLMVNNYSLEEVTHEEAVAILKNTSEVVYLKVGKPTTIYMTDPYGPPDITHSYSPPMENHLLSGNNGTLEYKTSLPPISPGRYSPIPKHMLVDDDYTRPPEPVYSTVNKLCDKPASPRHYSPVECDKSFLLSAPYSHYHLGLLPDSEMTSHSQHSTATRQPSMTLQRAVSLEGEPRKVVLHKGSTGLGFNIVGGEDGEGIFVSFILAGGPADLSGELQRGDQILSVNGIDLRGASHEQAAAALKGAGQTVTIIAQYQPEDYARFEAKIHDLREQMMNHSMSSGSGSLRTNQKRSLYVRAMFDYDKSKDSGLPSQGLSFKYGDILHVINASDDEWWQARRVMLEGDSEEMGVIPSKRRVERKERARLKTVKFNAKPGVIDSKGSFNDKRKKSFIFSRKFPFYKNKEQSEQETSDPERGQEDLILSYEPVTRQEINYTRPVIILGPMKDRINDDLISEFPDKFGSCVPHTTRPKRDYEVDGRDYHFVISREQMEKDIQEHKFIEAGQYNDNLYGTSVQSVRFVAERGKHCILDVSGNAIKRLQVAQLYPIAIFIKPRSLEPLMEMNKRLTEEQAKKTYDRAIKLEQEFGEYFTAIVQGDTLEDIYNQCKLVIEEQSGPFIWIPSKEKL,0,,,,,,,,P28039(AOAH)|Q6IS01(DLGAP1)|Q9P1A6-3(DLGAP2)|O95886(DLGAP3)|O60469(DSCAM)|Q7L5A8(FA2H)|P24390(KDELR1)|Q9HB19(PLEKHA2)|Q8WUA2(PPIL4)|P10153(RNASE2)|Q9H7B2(RPF2)|P62241(RPS8)|Q9UIV8(SERPINB13)|P04004(VTN)|P35561(Kcnj2),,1:Q15700-1:|2:Q15700-2:|3:Q15700-3:|4:Q15700-4:|5:Q15700-5:,,,,,,,,,,5.0
Q92796,,Disks large homolog 3,DLG3,Homo sapiens,817,False,KIAA1232,MHKHQHCCKCPECYEVTRLAALRRLEPPGYGDWQVPDPYGPGGGNGASAGYGGYSSQTLPSQAGATPTPRTKAKLIPTGRDVGPVPPKPVPGKSTPKLNGSGPSWWPECTCTNRDWYEQVNGSDGMFKYEEIVLERGNSGLGFSIAGGIDNPHVPDDPGIFITKIIPGGAAAMDGRLGVNDCVLRVNEVDVSEVVHSRAVEALKEAGPVVRLVVRRRQPPPETIMEVNLLKGPKGLGFSIAGGIGNQHIPGDNSIYITKIIEGGAAQKDGRLQIGDRLLAVNNTNLQDVRHEEAVASLKNTSDMVYLKVAKPGSLHLNDMYAPPDYASTFTALADNHISHNSSLGYLGAVESKVSYPAPPQVPPTRYSPIPRHMLAEEDFTREPRKIILHKGSTGLGFNIVGGEDGEGIFVSFILAGGPADLSGELRRGDRILSVNGVNLRNATHEQAAAALKRAGQSVTIVAQYRPEEYSRFESKIHDLREQMMNSSMSSGSGSLRTSEKRSLYVRALFDYDRTRDSCLPSQGLSFSYGDILHVINASDDEWWQARLVTPHGESEQIGVIPSKKRVEKKERARLKTVKFHARTGMIESNRDFPGLSDDYYGAKNLKGQEDAILSYEPVTRQEIHYARPVIILGPMKDRVNDDLISEFPHKFGSCVPHTTRPRRDNEVDGQDYHFVVSREQMEKDIQDNKFIEAGQFNDNLYGTSIQSVRAVAERGKHCILDVSGNAIKRLQQAQLYPIAIFIKPKSIEALMEMNRRQTYEQANKIYDKAMKLEQEFGEYFTAIVQGDSLEEIYNKIKQIIEDQSGHYIWVPSPEKL,0,,,,,,"Intellectual developmental disorder, X-linked 90:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. Intellectual deficiency is the only primary symptom of non-syndromic X-linked intellectual disability, while syndromic forms presents with associated physical, neurological and/or psychiatric manifestations.","Intellectual developmental disorder, X-linked 90",Q6UWP2-2(DHRS11)|Q6IS01(DLGAP1)|Q9P1A6-3(DLGAP2)|Q15056-2(EIF4H)|P24390(KDELR1)|Q969R2-2(OSBP2)|Q9HB19(PLEKHA2)|P62136(PPP1CA)|P62241(RPS8)|P04004(VTN),,1:Q92796-1:|2:Q92796-2:|3:Q92796-3:,,,,,,,,,,5.0
Q5M8T2,,Solute carrier family 35 member D3,SLC35D3,Homo sapiens,416,False,FRCL1,MRQLCRGRVLGISVAIAHGVFSGSLNILLKFLISRYQFSFLTLVQCLTSSTAALSLELLRRLGLIAVPPFGLSLARSFAGVAVLSTLQSSLTLWSLRGLSLPMYVVFKRCLPLVTMLIGVLVLKNGAPSPGVLAAVLITTCGAALAGAGDLTGDPIGYVTGVLAVLVHAAYLVLIQKASADTEHGPLTAQYVIAVSATPLLVICSFASTDSIHAWTFPGWKDPAMVCIFVACILIGCAMNFTTLHCTYINSAVTTSFVGVVKSIATITVGMVAFSDVEPTSLFIAGVVVNTLGSIIYCVAKFMETRKQSNYEDLEAQPRGEEAQLSGDQLPFVMEELPGEGGNGRSEGGEAAGGPAQESRQEVRGSPRGVPLVAGSSEEGSRRSLKDAYLEVWRLVRGTRYMKKDYLIENEELPSP,0,,,,,,,,Q9NPB8(GPCPD1),,,,,,,,,,,,5.0
Q9BTN0,,Leucine-rich repeat and fibronectin type-III domain-containing protein 3,LRFN3,Homo sapiens,628,False,SALM4,MAILPLLLCLLPLAPASSPPQSATPSPCPRRCRCQTQSLPLSVLCPGAGLLFVPPSLDRRAAELRLADNFIASVRRRDLANMTGLLHLSLSRNTIRHVAAGAFADLRALRALHLDGNRLTSLGEGQLRGLVNLRHLILSNNQLAALAAGALDDCAETLEDLDLSYNNLEQLPWEALGRLGNVNTLGLDHNLLASVPAGAFSRLHKLARLDMTSNRLTTIPPDPLFSRLPLLARPRGSPASALVLAFGGNPLHCNCELVWLRRLAREDDLEACASPPALGGRYFWAVGEEEFVCEPPVVTHRSPPLAVPAGRPAALRCRAVGDPEPRVRWVSPQGRLLGNSSRARAFPNGTLELLVTEPGDGGIFTCIAANAAGEATAAVELTVGPPPPPQLANSTSCDPPRDGDPDALTPPSAASASAKVADTGPPTDRGVQVTEHGATAALVQWPDQRPIPGIRMYQIQYNSSADDILVYRMIPAESRSFLLTDLASGRTYDLCVLAVYEDSATGLTATRPVGCARFSTEPALRPCGAPHAPFLGGTMIIALGGVIVASVLVFIFVLLMRYKVHGGQPPGKAKIPAPVSSVCSQTNGALGPTPTPAPPAPEPAALRAHTVVQLDCEPWGPGHEPVGP,0,,,,,,,,,,,,,,,,,,,,5.0
O43424,,"Glutamate receptor ionotropic, delta-2",GRID2,Homo sapiens,1007,False,GLURD2,MEVFPFLLVLSVWWSRTWDSANADSIIHIGAIFDESAKKDDEVFRTAVGDLNQNEEILQTEKITFSVTFVDGNNPFQAVQEACELMNQGILALVSSIGCTSAGSLQSLADAMHIPHLFIQRSTAGTPRSGCGLTRSNRNDDYTLSVRPPVYLHDVILRVVTEYAWQKFIIFYDSEYDIRGIQEFLDKVSQQGMDVALQKVENNINKMITTLFDTMRIEELNRYRDTLRRAILVMNPATAKSFITEVVETNLVAFDCHWIIINEEINDVDVQELVRRSIGRLTIIRQTFPVPQNISQRCFRGNHRISSTLCDPKDPFAQNMEISNLYIYDTVLLLANAFHKKLEDRKWHSMASLSCIRKNSKPWQGGRSMLETIKKGGVSGLTGELEFGENGGNPNVHFEILGTNYGEELGRGVRKLGCWNPVTGLNGSLTDKKLENNMRGVVLRVVTVLEEPFVMVSENVLGKPKKYQGFSIDVLDALSNYLGFNYEIYVAPDHKYGSPQEDGTWNGLVGELVFKRADIGISALTITPDRENVVDFTTRYMDYSVGVLLRRAEKTVDMFACLAPFDLSLWACIAGTVLLVGLLVYLLNWLNPPRLQMGSMTSTTLYNSMWFVYGSFVQQGGEVPYTTLATRMMMGAWWLFALIVISSYTANLAAFLTITRIESSIQSLQDLSKQTEIPYGTVLDSAVYEHVRMKGLNPFERDSMYSQMWRMINRSNGSENNVLESQAGIQKVKYGNYAFVWDAAVLEYVAINDPDCSFYTIGNTVADRGYGIALQHGSPYRDVFSQRILELQQNGDMDILKHKWWPKNGQCDLYSSVDTKQKGGALDIKSFAGVFCILAAGIVLSCFIAMLETWWNKRKGSRVPSKEDDKEIDLEHLHRRVNSLCTDDDSPHKQFSTSSIDLTPLDIDTLPTRQALEQISDFRNTHITTTTFIPEQIQTLSRTLSAKAASGFTFGNVPEHRTGPFRHRAPNGGFFRSPIKTMSSIPYQPTPTLGLNLGNDPDRGTSI,0,,,,,,"Spinocerebellar ataxia, autosomal recessive, 18:A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR18 features include progressive cerebellar atrophy, delayed psychomotor development, severely impaired gait, ocular movement abnormalities, and intellectual disability.","Spinocerebellar ataxia, autosomal recessive, 18",,,1:O43424-1:|2:O43424-2:,,,,,,,,,,5.0
Q13702,,43 kDa receptor-associated protein of the synapse,RAPSN,Homo sapiens,412,False,RNF205,MGQDQTKQQIEKGLQLYQSNQTEKALQVWTKVLEKSSDLMGRFRVLGCLVTAHSEMGRYKEMLKFAVVQIDTARELEDADFLLESYLNLARSNEKLCEFHKTISYCKTCLGLPGTRAGAQLGGQVSLSMGNAFLGLSVFQKALESFEKALRYAHNNDDAMLECRVCCSLGSFYAQVKDYEKALFFPCKAAELVNNYGKGWSLKYRAMSQYHMAVAYRLLGRLGSAMECCEESMKIALQHGDRPLQALCLLCFADIHRSRGDLETAFPRYDSAMSIMTEIGNRLGQVQALLGVAKCWVARKALDKALDAIERAQDLAEEVGNKLSQLKLHCLSESIYRSKGLQRELRAHVVRFHECVEETELYCGLCGESIGEKNSRLQALPCSHIFHLRCLQNNGTRSCPNCRRSSMKPGFV,0,,,,,,"Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency:A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS11 is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current.|Fetal akinesia deformation sequence 2:A clinically and genetically heterogeneous group of disorders with congenital malformations related to impaired fetal movement. Clinical features include fetal akinesia, intrauterine growth retardation, polyhydramnios, arthrogryposis, pulmonary hypoplasia, craniofacial abnormalities, and cryptorchidism. FADS2 inheritance is autosomal recessive.","Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency|Fetal akinesia deformation sequence 2",P54253(ATXN1)|P42858(HTT)|Q96CV9(OPTN)|P50454(SERPINH1)|P37840(SNCA)|P37173(TGFBR2),,1:Q13702-1:|2:Q13702-2:,,,,,,,,,,5.0
Q01959,,Sodium-dependent dopamine transporter,SLC6A3,Homo sapiens,620,False,DAT1,MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDRETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELALGQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQLTACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSVDFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGIDSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAAGTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSIVTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKDRELVDRGEVRQFTLRHWLKV,0,,,,,,"Parkinsonism-dystonia 1, infantile-onset:An autosomal recessive neurodegenerative disorder characterized by infantile onset of parkinsonism and dystonia. Other neurologic features include global developmental delay, bradykinesia and pyramidal tract signs.","Parkinsonism-dystonia 1, infantile-onset",P14416(DRD2)|O15354(GPR37)|Q99578(RIT2)|P37840(SNCA)|Q5T9L3(WLS)|Q9EP80(Pick1)|Q5BJQ5(Rit2),,,,,,,,,,,,5.0
Q13002,,"Glutamate receptor ionotropic, kainate 2",GRIK2,Homo sapiens,908,False,GLUR6,MKIIFPILSNPVFRRTVKLLLCLLWIGYSQGTTHVLRFGGIFEYVESGPMGAEELAFRFAVNTINRNRTLLPNTTLTYDTQKINLYDSFEASKKACDQLSLGVAAIFGPSHSSSANAVQSICNALGVPHIQTRWKHQVSDNKDSFYVSLYPDFSSLSRAILDLVQFFKWKTVTVVYDDSTGLIRLQELIKAPSRYNLRLKIRQLPADTKDAKPLLKEMKRGKEFHVIFDCSHEMAAGILKQALAMGMMTEYYHYIFTTLDLFALDVEPYRYSGVNMTGFRILNTENTQVSSIIEKWSMERLQAPPKPDSGLLDGFMTTDAALMYDAVHVVSVAVQQFPQMTVSSLQCNRHKPWRFGTRFMSLIKEAHWEGLTGRITFNKTNGLRTDFDLDVISLKEEGLEKIGTWDPASGLNMTESQKGKPANITDSLSNRSLIVTTILEEPYVLFKKSDKPLYGNDRFEGYCIDLLRELSTILGFTYEIRLVEDGKYGAQDDANGQWNGMVRELIDHKADLAVAPLAITYVREKVIDFSKPFMTLGISILYRKPNGTNPGVFSFLNPLSPDIWMYILLAYLGVSCVLFVIARFSPYEWYNPHPCNPDSDVVENNFTLLNSFWFGVGALMQQGSELMPKALSTRIVGGIWWFFTLIIISSYTANLAAFLTVERMESPIDSADDLAKQTKIEYGAVEDGATMTFFKKSKISTYDKMWAFMSSRRQSVLVKSNEEGIQRVLTSDYAFLMESTTIEFVTQRNCNLTQIGGLIDSKGYGVGTPMGSPYRDKITIAILQLQEEGKLHMMKEKWWRGNGCPEEESKEASALGVQNIGGIFIVLAAGLVLSVFVAVGEFLYKSKKNAQLEKRSFCSAMVEELRMSLKCQRRLKHKPQAPVIVKTEEVINMHTFNDRRLPGKETMA,0,,,,,,"Intellectual developmental disorder, autosomal recessive 6:A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRT6 patients display mild to severe intellectual disability and psychomotor development delay in early childhood. Patients do not have neurologic problems, congenital malformations, or facial dysmorphism. Body height, weight, and head circumference are normal.|Neurodevelopmental disorder with impaired language and ataxia and with or without seizures:An autosomal dominant disorder characterized by axial hypotonia and global developmental delay. Affected individuals show impaired intellectual development, delayed walking, poor speech, and behavioral abnormalities. Some patients have a more severe phenotype with early-onset seizures resembling epileptic encephalopathy, inability to walk or speak, and hypomyelination on brain imaging.","Intellectual developmental disorder, autosomal recessive 6|Neurodevelopmental disorder with impaired language and ataxia and with or without seizures",,,1:Q13002-1:|2:Q13002-2:|3:Q13002-3:|4:Q13002-4:|5:Q13002-5:|6:Q13002-6:|7:Q13002-7:,,,,,,,,,,5.0
Q8TC26,,Transmembrane protein 163,TMEM163,Homo sapiens,289,False,,MEPAAGIQRRSSQGPTVPPPPRGHAPPAAAPGPAPLSSPVREPPQLEEERQVRISESGQFSDGLEDRGLLESSTRLKPHEAQNYRKKALWVSWFSIIVTLALAVAAFTVSVMRYSASAFGFAFDAILDVLSSAIVLWRYSNAAAVHSAHREYIACVILGVIFLLSSICIVVKAIHDLSTRLLPEVDDFLFSVSILSGILCSILAVLKFMLGKVLTSRALITDGFNSLVGGVMGFSILLSAEVFKHDSAVWYLDGSIGVLIGLTIFAYGVKLLIDMVPRVRQTRHYEMFE,0,,,,,,"Leukodystrophy, hypomyelinating, 25:A form of hypomyelinating leukodystrophy, a group of heterogeneous disorders characterized by persistent deficit of myelin observed on brain imaging. HLD25 is an autosomal dominant form with onset in early infancy and characterized by nystagmus, hypotonia, and delayed global development. Most patients show gradual clinical improvement over time with resolution of the nystagmus in early childhood. Many achieve developmental milestones and may have normal cognition, although some affected individuals may have persistent neurologic deficits. Brain imaging shows hypomyelination that may also improve with time.","Leukodystrophy, hypomyelinating, 25",Q9Y6M5(SLC30A1)|Q9BRI3(SLC30A2)|Q99726(SLC30A3)|O14863(SLC30A4),,1:Q8TC26-1:|2:Q8TC26-2:|3:Q8TC26-3:,,,,,,,,,,5.0
Q8WXE9,,Stonin-2,STON2,Homo sapiens,905,False,STN2|STNB,MTTLDHVIATHQSEWVSFNEEPPFPAHSQGGTEEHLPGLSSSPDQSESSSGENHVVDGGSQDHSHSEQDDSSEKMGLISEAASPPGSPEQPPPDLASAISNWVQFEDDTPWASTSPPHQETAETALPLTMPCWTCPSFDSLGRCPLTSESSWTTHSEDTSSPSFGCSYTDLQLINAEEQTSGQASGADSTDNSSSLQEDEEVEMEAISWQASSPAMNGHPAPPVTSARFPSWVTFDDNEVSCPLPPVTSPLKPNTPPSASVIPDVPYNSMGSFKKRDRPKSTLMNFSKVQKLDISSLNRTPSVTEASPWRATNPFLNETLQDVQPSPINPFSAFFEEQERRSQNSSISSTTGKSQRDSLIVIYQDAISFDDSSKTQSHSDAVEKLKQLQIDDPDHFGSATLPDDDPVAWIELDAHPPGSARSQPRDGWPMMLRIPEKKNIMSSRHWGPIFVKLTDTGYLQLYYEQGLEKPFREFKLEICHEISEPRLQNYDENGRIHSLRIDRVTYKEKKKYQPKPAVAHTAEREQVIKLGTTNYDDFLSFIHAVQDRLMDLPVLSMDLSTVGLNYLEEEITVDVRDEFSGIVSKGDNQILQHHVLTRIHILSFLSGLAECRLGLNDILVKGNEIVLRQDIMPTTTTKWIKLHECRFHGCVDEDVFHNSRVILFNPLDACRFELMRFRTVFAEKTLPFTLRTATSVNGAEVEVQSWLRMSTGFSANRDPLTQVPCENVMIRYPVPSEWVKNFRRESVLGEKSLKAKVNRGASFGSTSVSGSEPVMRVTLGTAKYEHAFNSIVWRINRLPDKNSASGHPHCFFCHLELGSDREVPSRFANHVNVEFSMPTTSASKASVRSISVEDKTDVRKWVNYSAHYSYQVALGSIWLMLPTPFVHPTTLPLLFLLAMLTMFAW,0,,,,,,,,P42566(EPS15)|Q9UBC2(EPS15L1)|Q15843(NEDD8)|P21707(Syt1),,1:Q8WXE9-1:|2:Q8WXE9-3:,,,,,,,,,,5.0
P54219,,Chromaffin granule amine transporter,SLC18A1,Homo sapiens,525,False,VAT1|VMAT1,MLRTILDAPQRLLKEGRASRQLVLVVVFVALLLDNMLFTVVVPIVPTFLYDMEFKEVNSSLHLGHAGSSPHALASPAFSTIFSFFNNNTVAVEESVPSGIAWMNDTASTIPPPATEAISAHKNNCLQGTGFLEEEITRVGVLFASKAVMQLLVNPFVGPLTNRIGYHIPMFAGFVIMFLSTVMFAFSGTYTLLFVARTLQGIGSSFSSVAGLGMLASVYTDDHERGRAMGTALGGLALGLLVGAPFGSVMYEFVGKSAPFLILAFLALLDGALQLCILQPSKVSPESAKGTPLFMLLKDPYILVAAGSICFANMGVAILEPTLPIWMMQTMCSPKWQLGLAFLPASVSYLIGTNLFGVLANKMGRWLCSLIGMLVVGTSLLCVPLAHNIFGLIGPNAGLGLAIGMVDSSMMPIMGHLVDLRHTSVYGSVYAIADVAFCMGFAIGPSTGGAIVKAIGFPWLMVITGVINIVYAPLCYYLRSPPAKEEKLAILSQDCPMETRMYATQKPTKEFPLGEDSDEEPDHEE,0,,,,,,,,Q6RW13-2(AGTRAP)|Q86W74-2(ANKRD46)|Q9BQE5(APOL2)|Q6PL45-2(BRICD5)|O14523(C2CD2L)|P13236(CCL4)|Q8NHW4(CCL4L2)|O95406(CNIH1)|P29400-2(COL4A5)|O14569(CYB561D2)|Q92520(FAM3C)|Q14802-3(FXYD3)|Q8WWP7(GIMAP1)|P29033(GJB2)|Q8TDV0(GPR151)|O43561-2(LAT)|Q13021(MALL)|Q6ZSS7(MFSD6)|O43451(MGAM)|P30301(MIP)|P11836(MS4A1)|Q5J8X5(MS4A13)|Q99519(NEU1)|Q8IXM6(NRM)|Q6UX06(OLFM4)|Q9P0S3(ORMDL1)|Q9Y5Y5(PEX16)|P60201-2(PLP1)|Q04941(PLP2)|Q01453(PMP22)|P54315(PNLIPRP1)|Q59EV6(PPGB)|Q9NS64(RPRM)|Q9BRI3(SLC30A2)|Q8IWU4(SLC30A8)|Q969S0(SLC35B4)|Q2M3R5(SLC35G1)|Q9NVC3(SLC38A7)|Q9NP94(SLC39A2)|Q9NRQ5(SMCO4)|B2RUZ4(SMIM1)|P32856-2(STX2)|Q9UNK0(STX8)|P02786(TFRC)|A0PK00(TMEM120B)|Q5BJH2-2(TMEM128)|Q9Y6G1(TMEM14A)|Q9NUH8(TMEM14B)|Q969S6(TMEM203)|A2RU14(TMEM218)|Q8WW34-2(TMEM239)|Q69YG0(TMEM42)|Q9H2L4(TMEM60)|Q6PI78(TMEM65)|Q8N2M4(TMEM86A)|O95183(VAMP5)|Q9BSR8(YIPF4)|Q96EC8(YIPF6),,1:P54219-1:|2:P54219-2:|3:P54219-3:,,,,,,,,,,5.0
Q9H598,,Vesicular inhibitory amino acid transporter,SLC32A1,Homo sapiens,525,False,VGAT|VIAAT,MATLLRSKLSNVATSVSNKSQAKMSGMFARMGFQAATDEEAVGFAHCDDLDFEHRQGLQMDILKAEGEPCGDEGAEAPVEGDIHYQRGSGAPLPPSGSKDQVGGGGEFGGHDKPKITAWEAGWNVTNAIQGMFVLGLPYAILHGGYLGLFLIIFAAVVCCYTGKILIACLYEENEDGEVVRVRDSYVAIANACCAPRFPTLGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFPGLPVSQKSWSIIATAVLLPCAFLKNLKAVSKFSLLCTLAHFVINILVIAYCLSRARDWAWEKVKFYIDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVLKGLFALVAYLTWADETKEVITDNLPGSIRAVVNIFLVAKALLSYPLPFFAAVEVLEKSLFQEGSRAFFPACYSGDGRLKSWGLTLRCALVVFTLLMAIYVPHFALLMGLTGSLTGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAIFVIGGICSVSGFVHSLEGLIEAYRTNAED,0,,,,,,"Generalized epilepsy with febrile seizures plus 12:An autosomal dominant neurologic disorder with variable expressivity and incomplete penetrance. Affected individuals have variable types of seizures, most often febrile seizures, sometimes combined with non-febrile focal or generalized seizures. Rarely, afebrile tonic-clonic seizures have been observed.|Developmental and epileptic encephalopathy 114:A form of epileptic encephalopathy, a heterogeneous group of early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE114 is an autosomal dominant form characterized by moderate-to-severe intellectual disability, onset of epilepsy within the first 18 months of life, and a choreiform, dystonic or dyskinetic movement disorder.",Generalized epilepsy with febrile seizures plus 12|Developmental and epileptic encephalopathy 114,,,,,,,,,,,,,5.0
Q6ZW31,,Rho GTPase-activating protein SYDE1,SYDE1,Homo sapiens,735,False,,MAEPLLRKTFSRLRGREKLPRKKSDAKERGHPAQRPEPSPPEPEPQAPEGSQAGAEGPSSPEASRSPARGAYLQSLEPSSRRWVLGGAKPAEDTSLGPGVPGTGEPAGEIWYNPIPEEDPRPPAPEPPGPQPGSAESEGLAPQGAAPASPPTKASRTKSPGPARRLSIKMKKLPELRRRLSLRGPRAGRERERAAPAGSVISRYHLDSSVGGPGPAAGPGGTRSPRAGYLSDGDSPERPAGPPSPTSFRPYEVGPAARAPPAALWGRLSLHLYGLGGLRPAPGATPRDLCCLLQVDGEARARTGPLRGGPDFLRLDHTFHLELEAARLLRALVLAWDPGVRRHRPCAQGTVLLPTVFRGCQAQQLAVRLEPQGLLYAKLTLSEQQEAPATAEPRVFGLPLPLLVERERPPGQVPLIIQKCVGQIERRGLRVVGLYRLCGSAAVKKELRDAFERDSAAVCLSEDLYPDINVITGILKDYLRELPTPLITQPLYKVVLEAMARDPPNRVPPTTEGTRGLLSCLPDVERATLTLLLDHLRLVSSFHAYNRMTPQNLAVCFGPVLLPARQAPTRPRARSSGPGLASAVDFKHHIEVLHYLLQSWPDPRLPRQSPDVAPYLRPKRQPPLHLPLADPEVVTRPRGRGGPESPPSNRYAGDWSVCGRDFLPCGRDFLSGPDYDHVTGSDSEDEDEEVGEPRVTGDFEDDFDAPFNPHLNLKDFDALILDLERELSKQINVCL,0,,,,,,,,,,1:Q6ZW31-1:|2:Q6ZW31-2:,,,,,,,,,,5.0
Q05397,,Focal adhesion kinase 1,PTK2,Homo sapiens,1052,False,FAK|FAK1,MAAAYLDPNLNHTPNSSTKTHLGTGMERSPGAMERVLKVFHYFESNSEPTTWASIIRHGDATDVRGIIQKIVDSHKVKHVACYGFRLSHLRSEEVHWLHVDMGVSSVREKYELAHPPEEWKYELRIRYLPKGFLNQFTEDKPTLNFFYQQVKSDYMLEIADQVDQEIALKLGCLEIRRSYWEMRGNALEKKSNYEVLEKDVGLKRFFPKSLLDSVKAKTLRKLIQQTFRQFANLNREESILKFFEILSPVYRFDKECFKCALGSSWIISVELAIGPEEGISYLTDKGCNPTHLADFTQVQTIQYSNSEDKDRKGMLQLKIAGAPEPLTVTAPSLTIAENMADLIDGYCRLVNGTSQSFIIRPQKEGERALPSIPKLANSEKQGMRTHAVSVSETDDYAEIIDEEDTYTMPSTRDYEIQRERIELGRCIGEGQFGDVHQGIYMSPENPALAVAIKTCKNCTSDSVREKFLQEALTMRQFDHPHIVKLIGVITENPVWIIMELCTLGELRSFLQVRKYSLDLASLILYAYQLSTALAYLESKRFVHRDIAARNVLVSSNDCVKLGDFGLSRYMEDSTYYKASKGKLPIKWMAPESINFRRFTSASDVWMFGVCMWEILMHGVKPFQGVKNNDVIGRIENGERLPMPPNCPPTLYSLMTKCWAYDPSRRPRFTELKAQLSTILEEEKAQQEERMRMESRRQATVSWDSGGSDEAPPKPSRPGYPSPRSSEGFYPSPQHMVQTNHYQVSGYPGSHGITAMAGSIYPGQASLLDQTDSWNHRPQEIAMWQPNVEDSTVLDLRGIGQVLPTHLMEERLIRQQQEMEEDQRWLEKEERFLKPDVRLSRGSIDREDGSLQGPIGNQHIYQPVGKPDPAAPPKKPPRPGAPGHLGSLASLSSPADSYNEGVKLQPQEISPPPTANLDRSNDKVYENVTGLVKAVIEMSSKIQPAPPEEYVPMVKEVGLALRTLLATVDETIPLLPASTHREIEMAQKLLNSDLGELINKMKLAQQYVMTSLQQEYKKQMLTAAHALAVDAKNLLDVIDQARLKMLGQTRPH,0,,,,,,:,,P56945(BCAR1)|P46108(CRK)|P00533(EGFR)|P29317(EPHA2)|P06241(FYN)|P62993(GRB2)|Q14451(GRB7)|P08631-2(HCK)|P16144(ITGB4)|O60711(LPXN)|Q92569(PIK3R3)|P25105(PTAFR)|Q9H3S7(PTPN23)|P29350-3(PTPN6)|Q9Y3E5(PTRH2)|P49023(PXN)|Q9NP31(SH2D2A)|P12931(SRC)|Q96SB4(SRPK1)|P42224(STAT1)|O43294(TGFB1I1)|Q68CZ2(TNS3)|P04637(TP53)|Q824H6(CCA_00170)|P05480(Src)|Q62219(Tgfb1i1),,1:Q05397-1:|2:Q05397-2:|3:Q05397-3:|4:Q05397-4:|5:Q05397-5:|6:Q05397-6:|7:Q05397-7:,,,,,,,,,,5.0
Q9HBH9,,MAP kinase-interacting serine/threonine-protein kinase 2,MKNK2,Homo sapiens,465,False,GPRK7|MNK2,MVQKKPAELQGFHRSFKGQNPFELAFSLDQPDHGDSDFGLQCSARPDMPASQPIDIPDAKKRGKKKKRGRATDSFSGRFEDVYQLQEDVLGEGAHARVQTCINLITSQEYAVKIIEKQPGHIRSRVFREVEMLYQCQGHRNVLELIEFFEEEDRFYLVFEKMRGGSILSHIHKRRHFNELEASVVVQDVASALDFLHNKGIAHRDLKPENILCEHPNQVSPVKICDFDLGSGIKLNGDCSPISTPELLTPCGSAEYMAPEVVEAFSEEASIYDKRCDLWSLGVILYILLSGYPPFVGRCGSDCGWDRGEACPACQNMLFESIQEGKYEFPDKDWAHISCAAKDLISKLLVRDAKQRLSAAQVLQHPWVQGCAPENTLPTPMVLQRNSCAKDLTSFAAEAIAMNRQLAQHDEDLAEEEAAGQGQPVLVRATSRCLQLSPPSQSKLAQRRQRASLSSAPVVLVGDHA,0,,,,,,,,Q16539(MAPK14)|P46379-2(BAG6)|O14901(KLF11)|Q14696(MESD)|P25786(PSMA1),,1:Q9HBH9-1:|2:Q9HBH9-2:|3:Q9HBH9-3:|4:Q9HBH9-4:|5:Q9HBH9-5:,,,,,,,,,,5.0
P50750,,Cyclin-dependent kinase 9,CDK9,Homo sapiens,372,False,CDC2L4|TAK,MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFPITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVKFTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNPATTNQTEFERVF,0,,,,,,:,,Q13535(ATR)|Q8WXE1(ATRIP)|O60885-1(BRD4)|O60563(CCNT1)|O60583(CCNT2)|O60583-1(CCNT2)|O60583-2(CCNT2)|Q16543(CDC37)|Q9HAW4(CLSPN)|Q9NR30(DDX21)|Q13451(FKBP5)|O94992(HEXIM1)|P07900(HSP90AA1)|P08238(HSP90AB1)|Q6NYC1(JMJD6)|Q4G0J3(LARP7)|P53041(PPP5C)|P40763(STAT3)|P04608(tat)|P28799(GRN)|P28799-2(GRN)|Q6XYB7-2(LBX2),,1:P50750-1:|2:P50750-2:,,,,,,,,,,5.0
Q00535,,Cyclin-dependent kinase 5,CDK5,Homo sapiens,292,False,CDKN5|PSSALRE,MQKYEKLEKIGEGTYGTVFKAKNRETHEIVALKRVRLDDDDEGVPSSALREICLLKELKHKNIVRLHDVLHSDKKLTLVFEFCDQDLKKYFDSCNGDLDPEIVKSFLFQLLKGLGFCHSRNVLHRDLKPQNLLINRNGELKLADFGLARAFGIPVRCYSAEVVTLWYRPPDVLFGAKLYSTSIDMWSAGCIFAELANAGRPLFPGNDVDDQLKRIFRLLGTPTEEQWPSMTKLPDYKPYPMYPATTSLVNVVPKLNATGRDLLQNLLKCNPVQRISAEEALQHPYFSDFCPP,0,,,,,,"Lissencephaly 7, with cerebellar hypoplasia:A form of lissencephaly, a disorder of cortical development characterized by agyria or pachygyria and disorganization of the clear neuronal lamination of normal six-layered cortex. LIS7 patients manifest lack of psychomotor development, facial dysmorphism, arthrogryposis, and early-onset intractable seizures resulting in death in infancy.","Lissencephaly 7, with cerebellar hypoplasia",P61158(ACTR3)|P05067(APP)|P23560-2(BDNF)|Q8TDN4(CABLES1)|P14635(CCNB1)|P24863(CCNC)|P30279(CCND2)|P30281(CCND3)|Q14094(CCNI)|Q15078(CDK5R1)|P38936(CDKN1A)|P46527(CDKN1B)|Q9UJC3(HOOK1)|Q6FHY5(MEOX2)|Q9Y6R0(NUMBL)|P37231-2(PPARG)|P62937(PPIA)|O60260-5(PRKN)|Q5MJ70(SPDYA)|A6NLX3(SPDYE4)|P20226(TBP)|P09936(UCHL1),,1:Q00535-1:|2:Q00535-2:,,,,,,,,,,5.0
P17948,,Vascular endothelial growth factor receptor 1,FLT1,Homo sapiens,1338,False,FLT|FRT|VEGFR1,MVSYWDTGVLLCALLSCLLLTGSSSGSKLKDPELSLKGTQHIMQAGQTLHLQCRGEAAHKWSLPEMVSKESERLSITKSACGRNGKQFCSTLTLNTAQANHTGFYSCKYLAVPTSKKKETESAIYIFISDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVQISTPRPVKLLRGHTLVLNCTATTPLNTRVQMTWSYPDEKNKRASVRRRIDQSNSHANIFYSVLTIDKMQNKDKGLYTCRVRSGPSFKSVNTSVHIYDKAFITVKHRKQQVLETVAGKRSYRLSMKVKAFPSPEVVWLKDGLPATEKSARYLTRGYSLIIKDVTEEDAGNYTILLSIKQSNVFKNLTATLIVNVKPQIYEKAVSSFPDPALYPLGSRQILTCTAYGIPQPTIKWFWHPCNHNHSEARCDFCSNNEESFILDADSNMGNRIESITQRMAIIEGKNKMASTLVVADSRISGIYICIASNKVGTVGRNISFYITDVPNGFHVNLEKMPTEGEDLKLSCTVNKFLYRDVTWILLRTVNNRTMHYSISKQKMAITKEHSITLNLTIMNVSLQDSGTYACRARNVYTGEEILQKKEITIRDQEAPYLLRNLSDHTVAISSSTTLDCHANGVPEPQITWFKNNHKIQQEPGIILGPGSSTLFIERVTEEDEGVYHCKATNQKGSVESSAYLTVQGTSDKSNLELITLTCTCVAATLFWLLLTLFIRKMKRSSSEIKTDYLSIIMDPDEVPLDEQCERLPYDASKWEFARERLKLGKSLGRGAFGKVVQASAFGIKKSPTCRTVAVKMLKEGATASEYKALMTELKILTHIGHHLNVVNLLGACTKQGGPLMVIVEYCKYGNLSNYLKSKRDLFFLNKDAALHMEPKKEKMEPGLEQGKKPRLDSVTSSESFASSGFQEDKSLSDVEEEEDSDGFYKEPITMEDLISYSFQVARGMEFLSSRKCIHRDLAARNILLSENNVVKICDFGLARDIYKNPDYVRKGDTRLPLKWMAPESIFDKIYSTKSDVWSYGVLLWEIFSLGGSPYPGVQMDEDFCSRLREGMRMRAPEYSTPEIYQIMLDCWHRDPKERPRFAELVEKLGDLLQANVQQDGKDYIPINAILTGNSGFTYSTPAFSEDFFKESISAPKFNSGSSDDVRYVNAFKFMSLERIKTFEELLPNATSMFDDYQGDSSTLLASPMLKRFTWTDSKPKASLKIDLRVTSKSKESGLSDVSRPSFCHSSCGHVSEGKRRFTYDHAELERKIACCSPPPDYNSVVLYSTPPI,0,,,,,,:|:,,P22681(CBL)|P46109(CRKL)|P49763(PGF)|P27986(PIK3R1)|Q12913(PTPRJ)|P15692(VEGFA)|P15692-4(VEGFA)|P98160(HSPG2)|P98160(HSPG2),,1:P17948-1:|2:P17948-2:|3:P17948-3:|4:P17948-4:|5:P17948-5:|6:P17948-6:|7:P17948-7:|8:P17948-8:,,,,,,,,,,5.0
Q14289,,Protein-tyrosine kinase 2-beta,PTK2B,Homo sapiens,1009,False,FAK2|PYK2|RAFTK,MSGVSEPLSRVKLGTLRRPEGPAEPMVVVPVDVEKEDVRILKVCFYSNSFNPGKNFKLVKCTVQTEIREIITSILLSGRIGPNIRLAECYGLRLKHMKSDEIHWLHPQMTVGEVQDKYECLHVEAEWRYDLQIRYLPEDFMESLKEDRTTLLYFYQQLRNDYMQRYASKVSEGMALQLGCLELRRFFKDMPHNALDKKSNFELLEKEVGLDLFFPKQMQENLKPKQFRKMIQQTFQQYASLREEECVMKFFNTLAGFANIDQETYRCELIQGWNITVDLVIGPKGIRQLTSQDAKPTCLAEFKQIRSIRCLPLEEGQAVLQLGIEGAPQALSIKTSSLAEAENMADLIDGYCRLQGEHQGSLIIHPRKDGEKRNSLPQIPMLNLEARRSHLSESCSIESDIYAEIPDETLRRPGGPQYGIAREDVVLNRILGEGFFGEVYEGVYTNHKGEKINVAVKTCKKDCTLDNKEKFMSEAVIMKNLDHPHIVKLIGIIEEEPTWIIMELYPYGELGHYLERNKNSLKVLTLVLYSLQICKAMAYLESINCVHRDIAVRNILVASPECVKLGDFGLSRYIEDEDYYKASVTRLPIKWMSPESINFRRFTTASDVWMFAVCMWEILSFGKQPFFWLENKDVIGVLEKGDRLPKPDLCPPVLYTLMTRCWDYDPSDRPRFTELVCSLSDVYQMEKDIAMEQERNARYRTPKILEPTAFQEPPPKPSRPKYRPPPQTNLLAPKLQFQVPEGLCASSPTLTSPMEYPSPVNSLHTPPLHRHNVFKRHSMREEDFIQPSSREEAQQLWEAEKVKMRQILDKQQKQMVEDYQWLRQEEKSLDPMVYMNDKSPLTPEKEVGYLEFTGPPQKPPRLGAQSIQPTANLDRTDDLVYLNVMELVRAVLELKNELCQLPPEGYVVVVKNVGLTLRKLIGSVDDLLPSLPSSSRTEIEGTQKLLNKDLAELINKMRLAQQNAVTSLSEECKRQMLTASHTLAVDAKNLLDAVDQAKVLANLAHPPAE,0,,,,,,:,,P05067(APP)|P06241(FYN)|O15259(NPHP1)|O75161(NPHP4)|Q7L0Q8(RHOU)|P12931(SRC)|P40763(STAT3)|P62258(YWHAE),,1:Q14289-1:|2:Q14289-2:,,,,,,,,,,5.0
Q8WU20,,Fibroblast growth factor receptor substrate 2,FRS2,Homo sapiens,508,False,,MGSCCSCPDKDTVPDNHRNKFKVINVDDDGNELGSGIMELTDTELILYTRKRDSVKWHYLCLRRYGYDSNLFSFESGRRCQTGQGIFAFKCARAEELFNMLQEIMQNNSINVVEEPVVERNNHQTELEVPRTPRTPTTPGFAAQNLPNGYPRYPSFGDASSHPSSRHPSVGSARLPSVGEESTHPLLVAEEQVHTYVNTTGVQEERKNRTSVHVPLEARVSNAESSTPKEEPSSIEDRDPQILLEPEGVKFVLGPTPVQKQLMEKEKLEQLGRDQVSGSGANNTEWDTGYDSDERRDAPSVNKLVYENINGLSIPSASGVRRGRLTSTSTSDTQNINNSAQRRTALLNYENLPSLPPVWEARKLSRDEDDNLGPKTPSLNGYHNNLDPMHNYVNTENVTVPASAHKIEYSRRRDCTPTVFNFDIRRPSLEHRQLNYIQVDLEGGSDSDNPQTPKTPTTPLPQTPTRRTELYAVIDIERTAAMSNLQKALPRDDGTSRKTRHNSTDLPM,0,,,,,,,,P11362(FGFR1)|Q06124(PTPN11),,,,,,,,,,,,5.0
P28482,,Mitogen-activated protein kinase 1,MAPK1,Homo sapiens,360,False,ERK2|PRKM1|PRKM2,MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS,0,,,,,,"Noonan syndrome 13:A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. NS13 inheritance is autosomal dominant. There is considerable variability in severity.",Noonan syndrome 13,P05067(APP)|P53004(BLVRA)|P15882(CHN1)|Q7L5N1(COPS6)|P28562(DUSP1)|Q13115(DUSP4)|Q16690(DUSP5)|Q16828(DUSP6)|Q16829(DUSP7)|Q99956(DUSP9)|Q9BRK4(LZTS2)|Q02750(MAP2K1)|P28482(MAPK1)|Q16539-3(MAPK14)|Q99750(MDFI)|Q9BUB5(MKNK1)|P35548(MSX2)|Q15121(PEA15)|Q9UPG8(PLAGL2)|P62487(POLR2G)|P35813(PPM1A)|Q6NYC8(PPP1R18)|P25786(PSMA1)|A2A3K4(PTPDC1)|P35236(PTPN7)|Q12913(PTPRJ)|Q15256(PTPRR)|Q15256-5(PTPRR)|O76064(RNF8)|Q15418(RPS6KA1)|Q15349(RPS6KA2)|P51812(RPS6KA3)|P29353-2(SHC1)|P61764(STXBP1)|Q08117-2(TLE5)|Q9Y296(TRAPPC4)|B2RXF5(ZBTB42)|A0A384NQ31()|Q9U1H0(cic)|Q05922(Dusp2)|P02687(MBP)|Q8VSP9(ospF)|P0A2M9(spvC)|Q69559(U24),,1:P28482-1:|2:P28482-2:,,,,,,,,,,5.0
Q9H2X6,,Homeodomain-interacting protein kinase 2,HIPK2,Homo sapiens,1198,False,,MAPVYEGMASHVQVFSPHTLQSSAFCSVKKLKIEPSSNWDMTGYGSHSKVYSQSKNIPLSQPATTTVSTSLPVPNPSLPYEQTIVFPGSTGHIVVTSASSTSVTGQVLGGPHNLMRRSTVSLLDTYQKCGLKRKSEEIENTSSVQIIEEHPPMIQNNASGATVATATTSTATSKNSGSNSEGDYQLVQHEVLCSMTNTYEVLEFLGRGTFGQVVKCWKRGTNEIVAIKILKNHPSYARQGQIEVSILARLSTESADDYNFVRAYECFQHKNHTCLVFEMLEQNLYDFLKQNKFSPLPLKYIRPVLQQVATALMKLKSLGLIHADLKPENIMLVDPSRQPYRVKVIDFGSASHVSKAVCSTYLQSRYYRAPEIILGLPFCEAIDMWSLGCVIAELFLGWPLYPGASEYDQIRYISQTQGLPAEYLLSAGTKTTRFFNRDTDSPYPLWRLKTPDDHEAETGIKSKEARKYIFNCLDDMAQVNMTTDLEGSDMLVEKADRREFIDLLKKMLTIDADKRITPIETLNHPFVTMTHLLDFPHSTHVKSCFQNMEICKRRVNMYDTVNQSKTPFITHVAPSTSTNLTMTFNNQLTTVHNQAPSSTSATISLANPEVSILNYPSTLYQPSAASMAAVAQRSMPLQTGTAQICARPDPFQQALIVCPPGFQGLQASPSKHAGYSVRMENAVPIVTQAPGAQPLQIQPGLLAQQAWPSGTQQILLPPAWQQLTGVATHTSVQHATVIPETMAGTQQLADWRNTHAHGSHYNPIMQQPALLTGHVTLPAAQPLNVGVAHVMRQQPTSTTSSRKSKQHQSSVRNVSTCEVSSSQAISSPQRSKRVKENTPPRCAMVHSSPACSTSVTCGWGDVASSTTRERQRQTIVIPDTPSPTVSVITISSDTDEEEEQKHAPTSTVSKQRKNVISCVTVHDSPYSDSSSNTSPYSVQQRAGHNNANAFDTKGSLENHCTGNPRTIIVPPLKTQASEVLVECDSLVPVNTSHHSSSYKSKSSSNVTSTSGHSSGSSSGAITYRQQRPGPHFQQQQPLNLSQAQQHITTDRTGSHRRQQAYITPTMAQAPYSFPHNSPSHGTVHPHLAAAAAAAHLPTQPHLYTYTAPAALGSTGTVAHLVASQGSARHTVQHTAYPASIVHQVPVSMGPRVLPSPTIHPSQYPAQFAHQTYISASPASTVYTGYPLSPAKVNQYPYI,0,,,,,,,,P61962(DCAF7)|Q09472(EP300)|P51608(MECP2)|Q01196(RUNX1)|Q9H3D4(TP63),,1:Q9H2X6-1:|2:Q9H2X6-2:|3:Q9H2X6-3:,,,,,,,,,,5.0
P07948,,Tyrosine-protein kinase Lyn,LYN,Homo sapiens,512,False,JTK8,MGCIKSKGKDSLSDDGVDLKTQPVRNTERTIYVRDPTSNKQQRPVPESQLLPGQRFQTKDPEEQGDIVVALYPYDGIHPDDLSFKKGEKMKVLEEHGEWWKAKSLLTKKEGFIPSNYVAKLNTLETEEWFFKDITRKDAERQLLAPGNSAGAFLIRESETLKGSFSLSVRDFDPVHGDVIKHYKIRSLDNGGYYISPRITFPCISDMIKHYQKQADGLCRRLEKACISPKPQKPWDKDAWEIPRESIKLVKRLGAGQFGEVWMGYYNNSTKVAVKTLKPGTMSVQAFLEEANLMKTLQHDKLVRLYAVVTREEPIYIITEYMAKGSLLDFLKSDEGGKVLLPKLIDFSAQIAEGMAYIERKNYIHRDLRAANVLVSESLMCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGCFTIKSDVWSFGILLYEIVTYGKIPYPGRTNADVMTALSQGYRMPRVENCPDELYDIMKMCWKEKAEERPTFDYLQSVLDDFYTATEGQYQQQP,0,,,,,,"Autoinflammatory disease, systemic, with vasculitis:An autosomal dominant disorder characterized by systemic autoinflammation manifesting in the first hours of life with diffuse purpuric skin lesions, fever, hepatosplenomegaly, and increased C-reactive protein. Additional clinical features include periorbital edema, conjunctivitis, urticaria, atopic dermatitis, abdominal pain, and arthralgia. Laboratory studies may show leukocytosis, thrombocytopenia, and autoantibodies.|:","Autoinflammatory disease, systemic, with vasculitis",P01023(A2M)|O43184(ADAM12)|Q13444(ADAM15)|P05067(APP)|P10275(AR)|Q8NDB2(BANK1)|Q96GW7(BCAN)|P20273(CD22)|P25063(CD24)|P16671(CD36)|P11049(CD37)|P46527(CDKN1B)|P50570-2(DNM2)|P00533(EGFR)|Q9BS26(ERP44)|Q13480(GAB1)|Q9HCN6(GP6)|Q9HCN6-1(GP6)|P08238(HSP90AB1)|P05556(ITGB1)|P10721(KIT)|Q96L34(MARK4)|P33993(MCM7)|P51608(MECP2)|P08581(MET)|Q9NWQ8(PAG1)|P27986-2(PIK3R1)|P07602(PSAP)|P63244(RACK1)|Q6UWF3(SCIMP)|P37840(SNCA)|Q7Z699(SPRED1)|P12931(SRC)|Q8R5G7(Arap3)|Q08857(Cd36)|O92972()|P22575()|P27958()|Q9WMX2()|P00533(EGFR)|P33993(MCM7),,1:P07948-1:|2:P07948-2:,,,,,,,,,,5.0
P35916,,Vascular endothelial growth factor receptor 3,FLT4,Homo sapiens,1363,False,VEGFR3,MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWAWPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARIEGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDGQEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSLELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNVSQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAAYPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNVPPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQDLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKVGQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHDAHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRSHDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEEKSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEIVILVGTGVIAVFFWVLLLLIFCNMRRPAHADIKTGYLSIIMDPGEVPLEEQCEYLSYDASQWEFPRERLHLGRVLGYGAFGKVVEASAFGIHKGSSCDTVAVKMLKEGATASEHRALMSELKILIHIGNHLNVVNLLGACTKPQGPLMVIVEFCKYGNLSNFLRAKRDAFSPCAEKSPEQRGRFRAMVELARLDRRRPGSSDRVLFARFSKTEGGARRASPDQEAEDLWLSPLTMEDLVCYSFQVARGMEFLASRKCIHRDLAARNILLSESDVVKICDFGLARDIYKDPDYVRKGSARLPLKWMAPESIFDKVYTTQSDVWSFGVLLWEIFSLGASPYPGVQINEEFCQRLRDGTRMRAPELATPAIRRIMLNCWSGDPKARPAFSELVEILGDLLQGRGLQEEEEVCMAPRSSQSSEEGSFSQVSTMALHIAQADAEDSPPSLQRHSLAARYYNWVSFPGCLARGAETRGSSRMKTFEEFPMTPTTYKGSVDNQTDSGMVLASEEFEQIESRHRQESGFSCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY,0,,,,,,"Lymphatic malformation 1:A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM1 is an autosomal dominant form with variable expression and severity. Onset is usually at birth or in early childhood but can occur later. Affected individuals manifest lymphedema, predominantly in the lower limbs, and hypoplasia of lymphatic vessels. Additional features are hemangioma and nail dysplasia or papillomatosis.|Hemangioma, capillary infantile:A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring.|:|Congenital heart defects, multiple types, 7:An autosomal dominant disorder with incomplete penetrance characterized by congenital developmental abnormalities involving structures of the heart. Common defects include tetralogy of Fallot, pulmonary stenosis or atresia, absent pulmonary valve, right aortic arch, double aortic arch, and major aortopulmonary collateral arteries.","Lymphatic malformation 1|Hemangioma, capillary infantile|Congenital heart defects, multiple types, 7",P08238(HSP90AB1)|P35968(KDR)|P49767(VEGFC),,1:P35916-2:|2:P35916-1:|3:P35916-3:,,,,,,,,,,5.0
Q9H422,,Homeodomain-interacting protein kinase 3,HIPK3,Homo sapiens,1215,False,DYRK6|FIST3|PKY,MASQVLVYPPYVYQTQSSAFCSVKKLKVEPSSCVFQERNYPRTYVNGRNFGNSHPPTKGSAFQTKIPFNRPRGHNFSLQTSAVVLKNTAGATKVIAAQAQQAHVQAPQIGAWRNRLHFLEGPQRCGLKRKSEELDNHSSAMQIVDELSILPAMLQTNMGNPVTVVTATTGSKQNCTTGEGDYQLVQHEVLCSMKNTYEVLDFLGRGTFGQVVKCWKRGTNEIVAIKILKNHPSYARQGQIEVSILARLSTENADEYNFVRAYECFQHRNHTCLVFEMLEQNLYDFLKQNKFSPLPLKVIRPILQQVATALKKLKSLGLIHADLKPENIMLVDPVRQPYRVKVIDFGSASHVSKTVCSTYLQSRYYRAPEIILGLPFCEAIDMWSLGCVIAELFLGWPLYPGALEYDQIRYISQTQGLPGEQLLNVGTKSTRFFCKETDMSHSGWRLKTLEEHEAETGMKSKEARKYIFNSLDDVAHVNTVMDLEGSDLLAEKADRREFVSLLKKMLLIDADLRITPAETLNHPFVNMKHLLDFPHSNHVKSCFHIMDICKSHLNSCDTNNHNKTSLLRPVASSSTATLTANFTKIGTLRSQALTTSAHSVVHHGIPLQAGTAQFGCGDAFQQTLIICPPAIQGIPATHGKPTSYSIRVDNTVPLVTQAPAVQPLQIRPGVLSQTWSGRTQQMLVPAWQQVTPLAPATTTLTSESVAGSHRLGDWGKMISCSNHYNSVMPQPLLTNQITLSAPQPVSVGIAHVVWPQPATTKKNKQCQNRGILVKLMEWEPGREEINAFSWSNSLQNTNIPHSAFISPKIINGKDVEEVSCIETQDNQNSEGEARNCCETSIRQDSDSSVSDKQRQTIIIADSPSPAVSVITISSDTDEEETSQRHSLRECKGSLDCEACQSTLNIDRMCSLSSPDSTLSTSSSGQSSPSPCKRPNSMSDEEQESSCDTVDGSPTSDSSGHDSPFAESTFVEDTHENTELVSSADTETKPAVCSVVVPPVELENGLNADEHMANTDSICQPLIKGRSAPGRLNQPSAVGTRQQKLTSAFQQQHLNFSQVQHFGSGHQEWNGNFGHRRQQAYIPTSVTSNPFTLSHGSPNHTAVHAHLAGNTHLGGQPTLLPYPSSATLSSAAPVAHLLASPCTSRPMLQHPTYNISHPSGIVHQVPVGLNPRLLPSPTIHQTQYKPIFPPHSYIAASPAYTGFPLSPTKLSQYPYM,0,,,,,,,,,,1:Q9H422-1:|2:Q9H422-2:,,,,,,,,,,5.0
P48730,,Casein kinase I isoform delta,CSNK1D,Homo sapiens,415,False,HCKID,MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGASRAADDAERERRDREERLRHSRNPATRGLPSTASGRLRGTQEVAPPTPLTPTSHTANTSPRPVSGMERERKVSMRLHRGAPVNISSSDLTGRQDTSRMSTSQIPGRVASSGLQSVVHR,0,,,,,,"Advanced sleep phase syndrome, familial, 2:An autosomal dominant disorder characterized by very early sleep onset and offset. Individuals are 'morning larks' with a 4 hours advance of the sleep, temperature and melatonin rhythms.","Advanced sleep phase syndrome, familial, 2",P05067(APP)|Q49A88-3(CCDC14)|Q6PGQ1(DRICH1)|Q92997(DVL3)|O60447(EVI5)|Q14C86(GAPVD1)|Q9H2S9(IKZF4)|Q96LR2(LURAP1)|Q9BRK4(LZTS2)|Q00987(MDM2)|Q9P286(PAK5)|O15055(PER2)|O75382(TRIM3)|Q9C026(TRIM9)|P62258(YWHAE)|Q96BR9(ZBTB8A)|Q5T7W0(ZNF618)|Q60838(Dvl2)|P05067(APP)|Q92624(APPBP2)|Q96GW7(BCAN)|Q8IU99(CALHM1)|Q03135(CAV1)|P45973(CBX5)|P06850(CRH)|Q01658(DR1)|Q9BS26(ERP44)|P35637(FUS)|P17302(GJA1)|Q9H8Y8(GORASP2)|P25098(GRK2)|Q00403(GTF2B)|Q9Y5Q9(GTF3C3)|P42858(HTT)|Q14114-3(LRP8)|Q5S007(LRRK2)|Q16539(MAPK14)|Q96L34(MARK4)|P35240-4(NF2)|Q6ZW49(PAXIP1)|O14494(PLPP1)|A0A6Q8PF08(PMP22)|P17612(PRKACA)|P07602(PSAP)|P54725(RAD23A)|P04271(S100B)|Q8WTV0(SCARB1)|P50454(SERPINH1)|Q8IUQ4-2(SIAH1)|P84022(SMAD3)|P37840(SNCA)|P00441(SOD1)|Q6NUL7(SPTLC1)|Q13148(TARDBP)|P37173(TGFBR2)|Q9NRS4(TMPRSS4)|Q9BVJ6(UTP14A)|Q9UBQ0-2(VPS29)|Q8IUH5(ZDHHC17),,1:P48730-1:|2:P48730-2:,,,,,,,,,,5.0
P11362,,Fibroblast growth factor receptor 1,FGFR1,Homo sapiens,822,False,BFGFR|CEK|FGFBR|FLG|FLT2|HBGFR,MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDDVQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSDALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPSSGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSINHTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKIGPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLEALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKSIPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR,0,,,,,,"Pfeiffer syndrome:A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).|Hypogonadotropic hypogonadism 2 with or without anosmia:A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).|Osteoglophonic dysplasia:Characterized by craniosynostosis, prominent supraorbital ridge, and depressed nasal bridge, as well as by rhizomelic dwarfism and nonossifying bone lesions. Inheritance is autosomal dominant.|Hartsfield syndrome:A syndrome characterized by the triad of holoprosencephaly, ectrodactyly, and cleft/lip palate. Profound intellectual disability is also present. Multiple other congenital anomalies usually occur.|Trigonocephaly 1:A keel-shaped deformation of the forehead, caused by premature fusion of the metopic sutures. It results in a triangular shape of the head.|:|Encephalocraniocutaneous lipomatosis:A sporadically occurring, neurocutaneous disorder characterized by ocular anomalies, skin lesions, and central nervous system anomalies. Clinical features include a well-demarcated hairless fatty nevus on the scalp, benign ocular tumors, intracranial and intraspinal lipomas, and congenital abnormalities of the meninges. Seizures, spasticity, and intellectual disability can be present.|Jackson-Weiss syndrome:An autosomal dominant craniosynostosis syndrome characterized by craniofacial abnormalities and abnormality of the feet: broad great toes with medial deviation and tarsal-metatarsal coalescence.",Pfeiffer syndrome|Hypogonadotropic hypogonadism 2 with or without anosmia|Osteoglophonic dysplasia|Hartsfield syndrome|Trigonocephaly 1|Encephalocraniocutaneous lipomatosis|Jackson-Weiss syndrome,P23352(ANOS1)|P12830(CDH1)|P35222(CTNNB1)|P05230(FGF1)|P09038(FGF2)|Q9GZV9(FGF23)|P11362(FGFR1)|P21802(FGFR2)|P22455(FGFR4)|Q8WU20(FRS2)|P08238(HSP90AB1)|P08908(HTR1A)|P46934(NEDD4)|Q8IVI9(NOSTRIN)|P27986(PIK3R1)|P19174(PLCG1)|O88900(Grb14)|O35082(Kl)|P10686(Plcg1)|Q02363(ID2)|Q9BRX2(PELO)|P09038(FGF2)|O35082(Kl)|P09038(FGF2),,1:P11362-1:|2:P11362-8:|3:P11362-17:|4:P11362-2:|5:P11362-9:|6:P11362-3:|7:P11362-10:|8:P11362-4:|9:P11362-11:|10:P11362-5:|11:P11362-12:|12:P11362-6:|13:P11362-13:|14:P11362-7:|15:P11362-14:|16:P11362-15:|17:P11362-16:|18:P11362-18:|19:P11362-19:|20:P11362-20:|21:P11362-21:,,,,,,,,,,5.0
P49674,,Casein kinase I isoform epsilon,CSNK1E,Homo sapiens,416,False,,MELRVGNKYRLGRKIGSGSFGDIYLGANIASGEEVAIKLECVKTKHPQLHIESKFYKMMQGGVGIPSIKWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFSTYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLKFGAARNPEDVDRERREHEREERMGQLRGSATRALPPGPPTGATANRLRSAAEPVASTPASRIQPAGNTSPRAISRVDRERKVSMRLHRGAPANVSSSDLTGRQEVSRIPASQTSVPFDHLGK,0,,,,,,,,P25054(APC)|O15169(AXIN1)|O14640(DVL1)|O14641(DVL2)|Q92997(DVL3)|Q9BQ89(FAM110A)|Q1W6H9(FAM110C)|Q86UY5(FAM83A)|P08238(HSP90AB1)|P23508(MCC)|Q00987(MDM2)|Q16625(OCLN)|O15055(PER2)|O75382(TRIM3)|P62258(YWHAE)|Q04917(YWHAH)|Q5T7W0(ZNF618)|O70239(Axin1)|Q60838(Dvl2),,,,,,,,,,,,5.0
Q9NVE7,,4'-phosphopantetheine phosphatase,PANK4,Homo sapiens,773,False,,MAECGASGSGSSGDSLDKSITLPPDEIFRNLENAKRFAIDIGGSLTKLAYYSTVQHKVAKVRSFDHSGKDTEREHEPPYEISVQEEITARLHFIKFENTYIEACLDFIKDHLVNTETKVIQATGGGAYKFKDLIEEKLRLKVDKEDVMTCLIKGCNFVLKNIPHEAFVYQKDSDPEFRFQTNHPHIFPYLLVNIGSGVSIVKVETEDRFEWVGGSSIGGGTFWGLGALLTKTKKFDELLHLASRGQHSNVDMLVRDVYGGAHQTLGLSGNLIASSFGKSATADQEFSKEDMAKSLLHMISNDIGQLACLHARLHSLDRVYFGGFFIRGHPVTMRTITYSINFFSKGEVQALFLRHEGYLGAIGAFLKGAEQDNPNQYSWGENYAGSSGLMSASPELGPAQRARSGTFDLLEMDRLERPLVDLPLLLDPPSYVPDTVDLTDDALARKYWLTCFEEALDGVVKRAVASQPDSVDAAERAEKFRQKYWNKLQTLRQQPFAYGTLTVRSLLDTREHCLNEFNFPDPYSKVKQRENGVALRCFPGVVRSLDALGWEERQLALVKGLLAGNVFDWGAKAVSAVLESDPYFGFEEAKRKLQERPWLVDSYSEWLQRLKGPPHKCALIFADNSGIDIILGVFPFVRELLLRGTEVILACNSGPALNDVTHSESLIVAERIAGMDPVVHSALQEERLLLVQTGSSSPCLDLSRLDKGLAALVRERGADLVVIEGMGRAVHTNYHAALRCESLKLAVIKNAWLAERLGGRLFSVIFKYEVPAE,0,,,,,,"Cataract 49:A form of cataract, an opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT49 is an autosomal dominant form characterized by congenital cataract located in the posterior region of the lens. Visual impairment has onset in early childhood.",Cataract 49,,,,,,,,,,,,,5.0
P29350,,Tyrosine-protein phosphatase non-receptor type 6,PTPN6,Homo sapiens,595,False,HCP|PTP1C,MVRWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK,0,,,,,,,,Q14790(CASP8)|P20273(CD22)|Q9BZW8(CD244)|P20138(CD33)|P11049(CD37)|P19235(EPOR)|P31994(FCGR2B)|Q13643(FHL3)|P62993(GRB2)|P08069(IGF1R)|P35968(KDR)|P43626(KIR2DL1)|P43628(KIR2DL3)|Q6GTX8(LAIR1)|P06239(LCK)|Q8NHL6(LILRB1)|Q8N423(LILRB2)|O75022(LILRB3)|Q8NHJ6(LILRB4)|O94916-1(NFAT5)|P16284(PECAM1)|Q9UKJ1(PILRA)|Q05209(PTPN12)|P08922(ROS1)|Q8N1K5(THEMIS)|O35274(Ppp1r9b)|B7UM99(tir)|Q7DB77(tir)|Q05397(PTK2),,1:P29350-1:|2:P29350-3:|3:P29350-2:|4:P29350-4:,,,,,,,,,,5.0
P52333,,Tyrosine-protein kinase JAK3,JAK3,Homo sapiens,1124,False,,MAPPSEETPLIPQRSCSLLSTEAGALHVLLPARGPGPPQRLSFSFGDHLAEDLCVQAAKASGILPVYHSLFALATEDLSCWFPPSHIFSVEDASTQVLLYRIRFYFPNWFGLEKCHRFGLRKDLASAILDLPVLEHLFAQHRSDLVSGRLPVGLSLKEQGECLSLAVLDLARMAREQAQRPGELLKTVSYKACLPPSLRDLIQGLSFVTRRRIRRTVRRALRRVAACQADRHSLMAKYIMDLERLDPAGAAETFHVGLPGALGGHDGLGLLRVAGDGGIAWTQGEQEVLQPFCDFPEIVDISIKQAPRVGPAGEHRLVTVTRTDNQILEAEFPGLPEALSFVALVDGYFRLTTDSQHFFCKEVAPPRLLEEVAEQCHGPITLDFAINKLKTGGSRPGSYVLRRSPQDFDSFLLTVCVQNPLGPDYKGCLIRRSPTGTFLLVGLSRPHSSLRELLATCWDGGLHVDGVAVTLTSCCIPRPKEKSNLIVVQRGHSPPTSSLVQPQSQYQLSQMTFHKIPADSLEWHENLGHGSFTKIYRGCRHEVVDGEARKTEVLLKVMDAKHKNCMESFLEAASLMSQVSYRHLVLLHGVCMAGDSTMVQEFVHLGAIDMYLRKRGHLVPASWKLQVVKQLAYALNYLEDKGLPHGNVSARKVLLAREGADGSPPFIKLSDPGVSPAVLSLEMLTDRIPWVAPECLREAQTLSLEADKWGFGATVWEVFSGVTMPISALDPAKKLQFYEDRQQLPAPKWTELALLIQQCMAYEPVQRPSFRAVIRDLNSLISSDYELLSDPTPGALAPRDGLWNGAQLYACQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRQSLRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS,0,,,,,,"Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative:A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.",Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative,Q07666(KHDRBS1)|Q9UNF1(MAGED2)|P55209(NAP1L1),,2:P52333-1:|1:P52333-2:|3:P52333-4:,,,,,,,,,,5.0
Q16566,,Calcium/calmodulin-dependent protein kinase type IV,CAMK4,Homo sapiens,473,False,CAMK|CAMK-GR|CAMKIV,MLKVTVPSCSASSCSSVTASAAPGTASLVPDYWIDGSNRDALSDFFEVESELGRGATSIVYRCKQKGTQKPYALKVLKKTVDKKIVRTEIGVLLRLSHPNIIKLKEIFETPTEISLVLELVTGGELFDRIVEKGYYSERDAADAVKQILEAVAYLHENGIVHRDLKPENLLYATPAPDAPLKIADFGLSKIVEHQVLMKTVCGTPGYCAPEILRGCAYGPEVDMWSVGIITYILLCGFEPFYDERGDQFMFRRILNCEYYFISPWWDEVSLNAKDLVRKLIVLDPKKRLTTFQALQHPWVTGKAANFVHMDTAQKKLQEFNARRKLKAAVKAVVASSRLGSASSSHGSIQESHKASRDPSPIQDGNEDMKAIPEGEKIQGDGAQAAVKGAQAELMKVQALEKVKGADINAEEAPKMVPKAVEDGIKVADLELEEGLAEEKLKTVEEAAAPREGQGSSAVGFEVPQQDVILPEY,0,,,,,,,,,,,,,,,,,,,,5.0
Q8WXH5,,Suppressor of cytokine signaling 4,SOCS4,Homo sapiens,440,False,SOCS7,MAENNENISKNVDVRPKTSRSRSADRKDGYVWSGKKLSWSKKSESYSDAETVNGIEKTEVSLRNQERKHSCSSIELDLDHSCGHRFLGRSLKQKLQDAVGQCFPIKNCSSRHSSGLPSKRKIHISELMLDKCPFPPRSDLAFRWHFIKRHTAPINSKSDEWVSTDLSQTELRDGQLKRRNMEENINCFSHTNVQPCVITTDNALCREGPMTGSVMNLVSNNSIEDSDMDSDDEILTLCTSSRKRNKPKWDLDDEILQLETPPKYHTQIDYVHCLVPDLLQINNNPCYWGVMDKYAAEALLEGKPEGTFLLRDSAQEDYLFSVSFRRYSRSLHARIEQWNHNFSFDAHDPCVFHSPDITGLLEHYKDPSACMFFEPLLSTPLIRTFPFSLQHICRTVICNCTTYDGIDALPIPSSMKLYLKEYHYKSKVRVLRIDAPEQQC,0,,,,,,,,J3KQ12(BSCL2)|G5E9A7(DMWD)|O43559(FRS3)|P41250(GARS1)|P62993(GRB2)|O43464(HTRA2)|P42858(HTT)|Q8WXH2(JPH3)|Q9BZ23-2(PANK2)|Q92569(PIK3R3)|Q9BXM7(PINK1)|Q96R05(RBP7)|Q7Z699(SPRED1)|O15269-2(SPTLC1)|Q8WW24(TEKT4),,,,,,,,,,,,5.0
P22607,,Fibroblast growth factor receptor 3,FGFR3,Homo sapiens,806,False,JTK4,MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT,0,,,,,,"Achondroplasia:A frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. ACH is an autosomal dominant disease.|Crouzon syndrome with acanthosis nigricans:Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.|Thanatophoric dysplasia 1:A neonatal lethal skeletal dysplasia. Affected individuals manifest severe shortening of the limbs with macrocephaly, narrow thorax, short ribs, and curved femurs.|Thanatophoric dysplasia 2:A neonatal lethal skeletal dysplasia causing severe shortening of the limbs, narrow thorax and short ribs. Patients with thanatophoric dysplasia type 2 have straight femurs and cloverleaf skull.|Hypochondroplasia:Autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.|Bladder cancer:A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.|Cervical cancer:A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.|Camptodactyly, tall stature, and hearing loss syndrome:An autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or intellectual disability, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.|Multiple myeloma:A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.|Lacrimo-auriculo-dento-digital syndrome 2:A form of lacrimo-auriculo-dento-digital syndrome, an autosomal dominant disease characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.|Keratinocytic non-epidermolytic nevus:Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.|Muenke syndrome:A condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, intellectual disability and respiratory insufficiency.|Keratosis, seborrheic:A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.|Testicular germ cell tumor:A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.|Achondroplasia, severe, with developmental delay and acanthosis nigricans:A severe form of achondroplasia associated with developmental delay and acanthosis nigricans. Patients manifest short-limb dwarfism, with a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. Acanthosis nigricans is a skin condition characterized by brown-pigmented, velvety verrucosities in body folds and creases.","Achondroplasia|Crouzon syndrome with acanthosis nigricans|Thanatophoric dysplasia 1|Thanatophoric dysplasia 2|Hypochondroplasia|Bladder cancer|Cervical cancer|Camptodactyly, tall stature, and hearing loss syndrome|Multiple myeloma|Lacrimo-auriculo-dento-digital syndrome 2|Keratinocytic non-epidermolytic nevus|Muenke syndrome|Keratosis, seborrheic|Testicular germ cell tumor|Achondroplasia, severe, with developmental delay and acanthosis nigricans",Q6H8Q1-8(ABLIM2)|Q8NC06-3(ACBD4)|Q6UY14-3(ADAMTSL4)|Q8N302-2(AGGF1)|Q9UKV8(AGO2)|P55008(AIF1)|Q99996-3(AKAP9)|Q9NQ31(AKIP1)|P53677-2(AP3M2)|Q9NXL2-1(ARHGEF38)|Q9Y2Y0(ARL2BP)|Q66PJ3-4(ARL6IP4)|Q6XD76(ASCL4)|Q96FT7-4(ASIC4)|Q9UII2(ATP5IF1)|Q9ULK2-2(ATXN7L1)|Q9H7T9(AUNIP)|Q8TBE0(BAHD1)|Q9UQB8-6(BAIAP2)|Q16520(BATF)|P54687-4(BCAT1)|Q00994(BEX3)|Q5H9J7(BEX5)|Q9H2G9(BLZF1)|Q5PSV4(BRMS1L)|Q9ULD4-2(BRPF3)|Q9NSI6-4(BRWD1)|Q6P5X5(C22orf39)|Q3SXR2(C3orf36)|Q96LL4(C8orf48)|P20807-4(CAPN3)|O00257-3(CBX4)|Q96HB5(CCDC120)|Q6ZP82-1(CCDC141)|Q5M9N0-2(CCDC158)|Q16543(CDC37)|Q96GN5-2(CDCA7L)|P24941(CDK2)|O14519(CDK2AP1)|P38936(CDKN1A)|O95674(CDS2)|Q9H3R5(CENPH)|Q9Y4F5-3(CEP170B)|Q86XR8(CEP57)|Q494V2-2(CFAP100)|Q8WUX9(CHMP7)|Q9H2A9(CHST8)|Q9Y3D0(CIAO2B)|Q3SX64(CIMAP1D)|Q96BR5(COA7)|P02458-1(COL2A1)|P21964-2(COMT)|Q86WV2(COX4I1)|Q03060-25(CREM)|Q8TB03(CXorf38)|O60759(CYTIP)|Q9UJU6(DBNL)|Q6ZN54-2(DEF8)|Q8NDP9(DKFZp547K2416)|O60479(DLX3)|Q96EY1-3(DNAJA3)|Q9H147(DNTTIP1)|Q92782-2(DPF1)|Q7Z7J5(DPPA2)|Q14117(DPYS)|Q9BPU6(DPYSL5)|Q9BVC3(DSCC1)|Q9Y6W6(DUSP10)|O14641(DVL2)|A0AVK6(E2F8)|Q658K8(EEF1DP3)|Q6UXG2-3(ELAPOR1)|O00472(ELL2)|O43768-8(ENSA)|Q6NXG1(ESRP1)|Q15910-2(EZH2)|Q96GL9(FAM163A)|A1KXE4-2(FAM168B)|Q8NB25(FAM184A)|Q86UY5(FAM83A)|Q8IZU1(FAM9A)|Q8TC84(FANK1)|Q9UBX5(FBLN5)|Q9Y3I1(FBXO7)|O94868-3(FCHSD2)|P05230(FGF1)|P22607(FGFR3)|P15407(FOSL1)|P15408(FOSL2)|P55318(FOXA3)|Q06547-2(GABPB1)|Q06547-3(GABPB1)|P15976-2(GATA1)|P23769-2(GATA2)|P23771(GATA3)|Q49A26-4(GLYR1)|Q7Z5G4(GOLGA7)|Q9NWQ4-1(GPATCH2L)|P52655(GTF2A1)|Q15486(GUSBP1)|Q96CS2(HAUS1)|Q9BT25(HAUS8)|Q99075(HBEGF)|A8K0U2(hCG_2001421)|Q5T447-2(HECTD3)|Q8IV36(HID1)|Q4VB01(HOXB1)|P09629(HOXB7)|O43248(HOXC11)|Q53T59(HS1BP3)|Q53GQ0(HSD17B12)|P14060(HSD3B1)|P08238(HSP90AB1)|Q96EW2-2(HSPBAP1)|P10809(HSPD1)|Q8NDH6-2(ICA1L)|P41134(ID1)|Q8IY31-2(IFT20)|P22692(IGFBP4)|Q9NZH6(IL37)|Q9NXX0(ILF3)|Q86VI3(IQGAP3)|Q8NA54(IQUB)|Q86U28(ISCA2)|Q13352(ITGB3BP)|P05412(JUN)|P17275(JUNB)|Q8N5Z5(KCTD17)|Q7Z7F0-4(KHDC4)|Q9BVG8-5(KIFC3)|Q2M2Z5(KIZ)|Q6P597(KLC3)|P57682(KLF3)|Q9Y2M5(KLHL20)|Q9UH77(KLHL3)|P08727(KRT19)|Q14525(KRT33B)|Q3LI72(KRTAP19-5)|Q3SYF9(KRTAP19-7)|Q8IUC2(KRTAP8-1)|Q6IAA8(LAMTOR1)|O43504(LAMTOR5)|Q14847-2(LASP1)|Q9H2C1(LHX5)|Q68G74(LHX8)|Q8N0U6(LINC00518)|Q1L5Z9(LONRF2)|Q96JB6(LOXL4)|Q96LR2(LURAP1)|P0DP58-2(LYNX1)|P27338(MAOB)|Q9GZQ8(MAP1LC3B)|Q15759(MAPK11)|Q9NS73-5(MBIP)|P33993-2(MCM7)|Q96EZ8(MCRS1)|Q9HAF1(MEAF6)|Q8TAC0(MGC27345)|Q53S70(MGC4677)|Q5JXC2(MIIP)|A0A0A0MR05(MLST8)|Q00013(MPP1)|Q8TCY5(MRAP)|Q6IN84-2(MRM1)|O60783(MRPS14)|Q96H12(MSANTD3)|P01106(MYC)|Q9NPC6(MYOZ2)|P41271-2(NBL1)|P14598(NCF1)|Q9GZM8(NDEL1)|Q8NC67-2(NETO2)|Q16621(NFE2)|Q8N5V2(NGEF)|Q99743(NPAS2)|Q14995(NR1D2)|F1D8P7(NR1H2)|Q6PHZ7(NR2C2)|Q9BZ95-3(NSD3)|Q96MF7(NSMCE2)|Q4KMX9(OBSCN)|A5D8V7(ODAD3)|Q5BJF6-2(ODF2)|O43482(OIP5)|Q6GQQ9-2(OTUD7B)|Q8IVL6-2(P3H3)|Q9H8K7(PAAT)|Q8N3R9(PALS1)|Q495U3(PANX2)|Q9NR21-5(PARP11)|Q9BR81(PCDHGC3)|Q5VU43-8(PDE4DIP)|Q13956(PDE6H)|O15534(PER1)|O15212(PFDN6)|Q9BUL5(PHF23)|P14618(PKM)|Q9UPR0(PLCL2)|Q6ZR37(PLEKHG7)|Q5SXH7-1(PLEKHS1)|Q96T60(PNKP)|P19388(POLR2E)|Q07869(PPARA)|Q9UNP9(PPIE)|O60927(PPP1R11)|O60237-2(PPP1R12B)|Q96I34(PPP1R16A)|Q6ZMI0-5(PPP1R21)|O43741(PRKAB2)|O60260-5(PRKN)|Q86UA1(PRPF39)|P62333(PSMC6)|Q06323(PSME1)|P06454-2(PTMA)|Q8WUD1-2(RAB2B)|Q9UNT1-2(RABL2B)|Q15311(RALBP1)|Q9HD47-3(RANGRF)|Q9NS23-4(RASSF1)|Q9NWB1-5(RBFOX1)|Q9BWF3(RBM4)|Q8TBY0(RBM46)|Q9P2K3-2(RCOR3)|Q04206(RELA)|P47804-3(RGR)|Q15382(RHEB)|Q8IXN7(RIMKLA)|Q8WVD3(RNF138)|Q9H0X6(RNF208)|P62899(RPL31)|P62244(RPS15A)|P62701(RPS4X)|Q66K80(RUSC1-AS1)|Q9BY12-3(SCAPER)|Q86SQ7-2(SDCCAG8)|Q9NTN9-3(SEMA4G)|Q13435(SF3B2)|O60902-3(SHOX2)|Q9NSD5-3(SLC6A13)|Q9UHI5(SLC7A8)|Q12824(SMARCB1)|Q13573(SNW1)|O14544(SOCS6)|Q02086-2(SP2)|Q7Z6I5(SPATA12)|Q86W54-2(SPATA24)|Q496A3(SPATS1)|Q7Z698(SPRED2)|Q9C004(SPRY4)|Q5W111-2(SPRYD7)|Q99469(STAC)|Q92783-2(STAM)|O75886(STAM2)|Q13586(STIM1)|Q8N4C7(STX19)|Q15814(TBCC)|O15273(TCAP)|Q86WV5(TEN1)|Q96A09(TENT5B)|P54274-2(TERF1)|Q6N021(TET2)|Q9BXU0(TEX12)|Q5T0J7-2(TEX35)|Q8WTV1(THAP3)|Q5T1C6(THEM4)|O60830(TIMM17B)|Q9BZW5-2(TM6SF1)|Q96B77(TMEM186)|Q8N0U2(TMEM61)|Q53NU3(tmp_locus_54)|Q9H8H3(TMT1A)|Q8IUR5-4(TMTC1)|Q71RG4-4(TMUB2)|P50616(TOB1)|Q9H496(TOR1AIP2)|P36406(TRIM23)|Q9UPQ4-2(TRIM35)|Q86WT6-2(TRIM69)|Q9Y3Q8(TSC22D4)|Q99598(TSNAX)|O60636(TSPAN2)|Q6PF05(TTC23L)|Q9UGJ1-2(TUBGCP4)|P49459(UBE2A)|Q13404(UBE2V1)|P11441(UBL4A)|Q9HA47-2(UCK1)|P22415(USF1)|Q495M9(USH1G)|Q9H270(VPS11)|Q8NEZ2(VPS37A)|Q9P1Q0-4(VPS54)|Q9NX94(WBP1L)|Q8TBZ3-3(WDR20)|O00755(WNT7A)|P19544-6(WT1)|O43829(ZBTB14)|Q53FD0-2(ZC2HC1C)|Q9NP64(ZCCHC17)|Q8WUU4(ZNF296)|Q96JL9-2(ZNF333)|Q9C0F3(ZNF436)|Q9P0T4(ZNF581)|Q3KNS6-3(ZNF829)|B7Z3E8()|Q7L8T7()|Q7Z637()|Q86V28(),,1:P22607-1:|2:P22607-2:|3:P22607-3:|4:P22607-4:,,,,,,,,,,5.0
Q06124,,Tyrosine-protein phosphatase non-receptor type 11,PTPN11,Homo sapiens,593,False,PTP2C|SHPTP2,MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR,0,,,,,,"LEOPARD syndrome 1:A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.|Noonan syndrome 1:A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints.|Leukemia, juvenile myelomonocytic:An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.|Metachondromatosis:A skeletal disorder with radiologic features of both multiple exostoses and Ollier disease, characterized by the presence of exostoses, commonly of the bones of the hands and feet, and enchondromas of the metaphyses of long bones and iliac crest.","LEOPARD syndrome 1|Noonan syndrome 1|Leukemia, juvenile myelomonocytic|Metachondromatosis",P10275(AR)|P32239(CCKBR)|Q9BZW8(CD244)|P20138(CD33)|Q08345(DDR1)|P00533(EGFR)|P29317(EPHA2)|P04626(ERBB2)|Q8WU20(FRS2)|Q13480(GAB1)|Q9UQC2(GAB2)|P62993(GRB2)|P08069(IGF1R)|P06213(INSR)|P35568(IRS1)|P43628(KIR2DL3)|P10721(KIT)|P08581(MET)|O95297(MPZL1)|Q15116(PDCD1)|P09619(PDGFRB)|P16284(PECAM1)|P49023(PXN)|P49247(RPIA)|Q13049(TRIM32)|P68105(EEF1A1)|Q71V39(EEF1A2)|P35570(Irs1)|P97710(Sirpa)|Q6P1J9(CDC73)|Q13480(GAB1)|O75496(GMNN)|Q9UKI8(TLK1),,1:Q06124-2:|2:Q06124-1:|3:Q06124-3:,,,,,,,,,,5.0
P08631,,Tyrosine-protein kinase HCK,HCK,Homo sapiens,526,False,,MGGRSSCEDPGCPRDEERAPRMGCMKSKFLQVGGNTFSKTETSASPHCPVYVPDPTSTIKPGPNSHNSNTPGIREAGSEDIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYQQQP,0,,,,,,":|:|Autoinflammation with pulmonary and cutaneous vasculitis:An autosomal dominant disorder characterized by cutaneous vasculitis and chronic pulmonary inflammation that evolves to fibrosis. AIPCV manifests soon after birth with petechial skin lesions, followed by progressive pulmonary involvement causing restrictive lung disease and respiratory insufficiency.",Autoinflammation with pulmonary and cutaneous vasculitis,O14672(ADAM10)|O43184(ADAM12)|Q13444(ADAM15)|P09917(ALOX5)|Q9ULH1(ASAP1)|P00533(EGFR)|Q92556(ELMO1)|P21860(ERBB3)|Q9HD26(GOPC)|P08238(HSP90AB1)|Q07666(KHDRBS1)|P10721(KIT)|Q6A162(KRT40)|P60411(KRTAP10-9)|Q5JR59(MTUS2)|P59046(NLRP12)|Q7Z3S9(NOTCH2NLA)|Q13177(PAK2)|Q8WUM4(PDCD6IP)|Q07889(SOS1)|P42768(WAS)|O43516(WIPF1)|P03406(nef)|Q90VU7(nef)|P12504(vif)|O92972()|P27958()|O95994(AGR2)|Q9NP55(BPIFA1)|P22681(CBL)|A6NC98(CCDC88B)|P78358(CTAG1B)|Q8WUJ1(CYB5D2)|A8MQ03(CYSRT1)|Q5TD97(FHL5)|O43559(FRS3)|Q9HD26-2(GOPC)|O75031(HSF2BP)|Q0VD86(INCA1)|Q5T749(KPRP)|Q15323(KRT31)|O76011(KRT34)|Q92764(KRT35)|O76013-2(KRT36)|Q6A162(KRT40)|Q07627(KRTAP1-1)|Q8IUG1(KRTAP1-3)|P60409(KRTAP10-7)|P60410(KRTAP10-8)|P60411(KRTAP10-9)|Q9BYR8(KRTAP3-1)|P21741(MDK)|Q9UJV3-2(MID2)|Q13064(MKRN3)|Q5JR59-3(MTUS2)|P0DPK4(NOTCH2NLC)|Q8TAK6(OLIG1)|Q92569(PIK3R3)|Q58EX7(PLEKHG4)|Q8ND90(PNMA1)|Q05397(PTK2)|Q93062-3(RBPMS)|O14492-2(SH2B2)|Q8WW24(TEKT4)|Q96N21(TEPSIN)|Q96NM4-3(TOX2)|P14373(TRIM27)|Q15654(TRIP6)|O76024(WFS1)|Q8NAM6(ZSCAN4),,1:P08631-1:|2:P08631-2:|3:P08631-3:|4:P08631-4:,,,,,,,,,,5.0
Q9Y6W6,,Dual specificity protein phosphatase 10,DUSP10,Homo sapiens,482,False,MKP5,MPPSPLDDRVVVALSRPVRPQDLNLCLDSSYLGSANPGSNSHPPVIATTVVSLKAANLTYMPSSSGSARSLNCGCSSASCCTVATYDKDNQAQTQAIAAGTTTTAIGTSTTCPANQMVNNNENTGSLSPSSGVGSPVSGTPKQLASIKIIYPNDLAKKMTKCSKSHLPSQGPVIIDCRPFMEYNKSHIQGAVHINCADKISRRRLQQGKITVLDLISCREGKDSFKRIFSKEIIVYDENTNEPSRVMPSQPLHIVLESLKREGKEPLVLKGGLSSFKQNHENLCDNSLQLQECREVGGGASAASSLLPQPIPTTPDIENAELTPILPFLFLGNEQDAQDLDTMQRLNIGYVINVTTHLPLYHYEKGLFNYKRLPATDSNKQNLRQYFEEAFEFIEEAHQCGKGLLIHCQAGVSRSATIVIAYLMKHTRMTMTDAYKFVKGKRPIISPNLNFMGQLLEFEEDLNNGVTPRILTPKLMGVETVV,0,,,,,,,,Q86V38(ATN1)|Q9Y5Z0(BACE2)|P02489(CRYAA)|Q14204(DYNC1H1)|P22607(FGFR3)|Q53EP0-3(FNDC3B)|Q14957(GRIN2C)|P06396(GSN)|P49639(HOXA1)|P01112(HRAS)|Q9BYR7(KRTAP3-2)|P45983-4(MAPK8)|P45984(MAPK9)|Q9UMX0(UBQLN1),,1:Q9Y6W6-1:|2:Q9Y6W6-2:,,,,,,,,,,5.0
P78368,,Casein kinase I isoform gamma-2,CSNK1G2,Homo sapiens,415,False,CK1G2,MDFDKKGGKGETEEGRRMSKAGGGRSSHGIRSSGTSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLSATEGVPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLITRMEYVHTKSLIYRDVKPENFLVGRPGTKRQHAIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRSGFVFDYEYDWAGKPLPTPIGTVHTDLPSQPQLRDKTQPHSKNQALNSTNGELNADDPTAGHSNAPITAPAEVEVADETKCCCFFKRRKRKSLQRHK,0,,,,,,,,Q92624(APPBP2)|Q9Y5P4(CERT1)|Q9Y5P4-2(CERT1)|Q9HCP0(CSNK1G1)|P60409(KRTAP10-7),,,,,,,,,,,,5.0
O95278,,Laforin,EPM2A,Homo sapiens,331,False,,MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLRPAGTAAGDGALALQEPGLWLGEVELAAEEAAQDGAEPGRVDTFWYKFLKREPGGELSWEGNGPHHDRCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSRILPNIWLGSCPRQVEHVTIKLKHELGITAVMNFQTEWDIVQNSSGCNRYPEPMTPDTMIKLYREEGLAYIWMPTPDMSTEGRVQMLPQAVCLLHALLEKGHIVYVHCNAGVGRSTAAVCGWLQYVMGWNLRKVQYFLMAKRPAVYIDEEALARAQEDFFQKFGKVRSSVCSL,0,,,,,,"Myoclonic epilepsy of lafora 1:A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. MELF1 is an autosomal recessive, severe form characterized by onset of progressive neurodegeneration between 8 and 18 years of age. Initial features can include headache, myoclonic jerks, generalized seizures, and often visual hallucination. Typically, as seizures increase in frequency, cognitive function declines towards dementia, and affected individuals die usually within 10 years after onset. At the cellular level, MELF1 is characterized by accumulation of starch-like polyglucosans called Lafora bodies (LBs) that are most abundant in organs with the highest glucose metabolism: brain, heart, liver and skeletal muscle.",Myoclonic epilepsy of lafora 1,Q6VVB1(NHLRC1)|Q9UQK1(PPP1R3C)|P06307(CCK)|P13473-2(LAMP2)|Q9Y371(SH3GLB1),,1:O95278-1:|2:O95278-2:|4:O95278-4:|5:O95278-5:|6:O95278-6:|7:O95278-7:|8:O95278-8:|9:B3EWF7-1:,,,,,,,,,,5.0
Q96T60,,Bifunctional polynucleotide phosphatase/kinase,PNKP,Homo sapiens,521,False,,MGEVEAPGRLWLESPPGGAPPIFLPSDGQALVLGRGPLTQVTDRKCSRTQVELVADPETRTVAVKQLGVNPSTTGTQELKPGLEGSLGVGDTLYLVNGLHPLTLRWEETRTPESQPDTPPGTPLVSQDEKRDAELPKKRMRKSNPGWENLEKLLVFTAAGVKPQGKVAGFDLDGTLITTRSGKVFPTGPSDWRILYPEIPRKLRELEAEGYKLVIFTNQMSIGRGKLPAEEFKAKVEAVVEKLGVPFQVLVATHAGLYRKPVTGMWDHLQEQANDGTPISIGDSIFVGDAAGRPANWAPGRKKKDFSCADRLFALNLGLPFATPEEFFLKWPAAGFELPAFDPRTVSRSGPLCLPESRALLSASPEVVVAVGFPGAGKSTFLKKHLVSAGYVHVNRDTLGSWQRCVTTCETALKQGKRVAIDNTNPDAASRARYVQCARAAGVPCRCFLFTATLEQARHNNRFREMTDSSHIPVSDMVMYGYRKQFEAPTLAEGFSAILEIPFRLWVEPRLGRLYCQFSEG,0,,,,,,"Microcephaly, seizures, and developmental delay:An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.|Ataxia-oculomotor apraxia 4:An autosomal recessive disease characterized by cerebellar ataxia, oculomotor apraxia, areflexia and peripheral neuropathy.","Microcephaly, seizures, and developmental delay|Ataxia-oculomotor apraxia 4",Q9UGQ2(CACFD1)|Q13554-3(CAMK2B)|Q9BWT7(CARD10)|Q49A88-3(CCDC14)|Q86WV7(CCDC43)|P28329-3(CHAT)|Q8N5K1(CISD2)|Q8N137(CNTROB)|Q9UMD9(COL17A1)|Q92997(DVL3)|Q8N9I5(FADS6)|P22607(FGFR3)|O43524(FOXO3)|O95995(GAS8)|Q13422(IKZF1)|Q13422-7(IKZF1)|Q63ZY3(KANK2)|Q53G59(KLHL12)|P23508(MCC)|Q6FHY5(MEOX2)|Q99735(MGST2)|Q8NCY6(MSANTD4)|Q9NRD5(PICK1)|Q96PV4(PNMA5)|O43586(PSTPIP1)|Q9NS64(RPRM)|Q8WV19(SFT2D1)|O60749(SNX2)|Q02446(SP4)|O43759-2(SYNGR1)|O43761(SYNGR3)|P08247(SYP)|Q15633(TARBP2)|Q86TI0(TBC1D1)|Q9NVV9(THAP1)|Q8WW34-2(TMEM239)|Q15025(TNIP1)|O94972(TRIM37)|Q9UMX0(UBQLN1)|P18887(XRCC1)|Q13426(XRCC4)|O43829(ZBTB14)|Q9UID6(ZNF639),,1:Q96T60-1:|2:Q96T60-2:,,,,,,,,,,5.0
Q15750,,TGF-beta-activated kinase 1 and MAP3K7-binding protein 1,TAB1,Homo sapiens,504,False,MAP3K7IP1,MAAQRRSLLQSEQQPSWTDDLPLCHLSGVGSASNRSYSADGKGTESHPPEDSWLKFRSENNCFLYGVFNGYDGNRVTNFVAQRLSAELLLGQLNAEHAEADVRRVLLQAFDVVERSFLESIDDALAEKASLQSQLPEGVPQHQLPPQYQKILERLKTLEREISGGAMAVVAVLLNNKLYVANVGTNRALLCKSTVDGLQVTQLNVDHTTENEDELFRLSQLGLDAGKIKQVGIICGQESTRRIGDYKVKYGYTDIDLLSAAKSKPIIAEPEIHGAQPLDGVTGFLVLMSEGLYKALEAAHGPGQANQEIAAMIDTEFAKQTSLDAVAQAVVDRVKRIHSDTFASGGERARFCPRHEDMTLLVRNFGYPLGEMSQPTPSPAPAAGGRVYPVSVPYSSAQSTSKTSVTLSLVMPSQGQMVNGAHSASTLDEATPTLTNQSPTLTLQSTNTHTQSSSSSSDGGLFRSRPAHSLPPGEDGRVEPYVDFAEFYRLWSVDHGEQSVVTAP,0,,,,,,,,P00533(EGFR)|P47929(LGALS7B)|O43318(MAP3K7)|O43318-2(MAP3K7)|O15294(OGT)|Q9NYJ8(TAB2)|P98170(XIAP)|P62258(YWHAE)|P0DTD1(rep),,1:Q15750-1:|2:Q15750-2:,,,,,,,,,,5.0
Q99956,,Dual specificity protein phosphatase 9,DUSP9,Homo sapiens,384,False,MKP4,MEGLGRSCLWLRRELSPPRPRLLLLDCRSRELYESARIGGALSVALPALLLRRLRRGSLSVRALLPGPPLQPPPPAPVLLYDQGGGRRRRGEAEAEAEEWEAESVLGTLLQKLREEGYLAYYLQGGFSRFQAECPHLCETSLAGRAGSSMAPVPGPVPVVGLGSLCLGSDCSDAESEADRDSMSCGLDSEGATPPPVGLRASFPVQILPNLYLGSARDSANLESLAKLGIRYILNVTPNLPNFFEKNGDFHYKQIPISDHWSQNLSRFFPEAIEFIDEALSQNCGVLVHCLAGVSRSVTVTVAYLMQKLHLSLNDAYDLVKRKKSNISPNFNFMGQLLDFERSLRLEERHSQEQGSGGQASAASNPPSFFTTPTSDGAFELAPT,0,,,,,,,,P28482(MAPK1)|Q16539(MAPK14)|P47811(Mapk14),,,,,,,,,,,,5.0
P27361,,Mitogen-activated protein kinase 3,MAPK3,Homo sapiens,379,False,ERK1|PRKM3,MAAAAAQGGGGGEPRRTEGVGPGVPGEVEMVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRASTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFAMELDDLPKERLKELIFQETARFQPGVLEAP,0,,,,,,,,Q9HCU0(CD248)|P53355(DAPK1)|P49366(DHPS)|P28562(DUSP1)|Q16828(DUSP6)|P19419(ELK1)|Q49AJ0-4(FAM135B)|Q96NJ5(KLHL32)|Q02750(MAP2K1)|Q16539(MAPK14)|P27361(MAPK3)|Q96HT8(MRFAP1L1)|Q6GQQ9-2(OTUD7B)|Q9ULW8(PADI3)|Q15121(PEA15)|P14618-1(PKM)|Q8N490(PNKD)|P23467(PTPRB)|Q12913(PTPRJ)|Q14160(SCRIB)|P13051-2(UNG)|Q08509(Eps8)|Q60793(Klf4)|Q9EPI6(Nsmf)|Q62132(Ptprr),,1:P27361-1:|2:P27361-2:|3:P27361-3:,,,,,,,,,,5.0
P24941,,Cyclin-dependent kinase 2,CDK2,Homo sapiens,298,False,CDKN2,MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL,0,,,,,,,,P20248(CCNA2)|O95067(CCNB2)|P24385(CCND1)|P30279(CCND2)|P24864(CCNE1)|O96020(CCNE2)|P51946(CCNH)|P50613(CDK7)|P38936(CDKN1A)|P46527(CDKN1B)|Q16667(CDKN3)|P61024(CKS1B)|Q09472(EP300)|Q969H0-4(FBXW7)|P22607(FGFR3)|Q14957(GRIN2C)|P06396(GSN)|P01112(HRAS)|Q9Y6K9(IKBKG)|O95835(LATS1)|Q8TD08(MAPK15)|P06400(RB1)|Q9BY12(SCAPER)|Q9UQR0(SCML2)|Q9UQR0-1(SCML2)|Q9UBI4(STOML1)|Q96PU4(UHRF2)|P30274(CCNA2)|P51943(Ccna2)|P03129(E7)|Q08619(Ifi205b),,1:P24941-1:|2:P24941-2:,,,,,,,,,,5.0
P30291,,Wee1-like protein kinase,WEE1,Homo sapiens,646,False,,MSFLSRQQPPPPRRAGAACTLRQKLIFSPCSDCEEEEEEEEEEGSGHSTGEDSAFQEPDSPLPPARSPTEPGPERRRSPGPAPGSPGELEEDLLLPGACPGADEAGGGAEGDSWEEEGFGSSSPVKSPAAPYFLGSSFSPVRCGGPGDASPRGCGARRAGEGRRSPRPDHPGTPPHKTFRKLRLFDTPHTPKSLLSKARGIDSSSVKLRGSSLFMDTEKSGKREFDVRQTPQVNINPFTPDSLLLHSSGQCRRRKRTYWNDSCGEDMEASDYELEDETRPAKRITITESNMKSRYTTEFHELEKIGSGEFGSVFKCVKRLDGCIYAIKRSKKPLAGSVDEQNALREVYAHAVLGQHSHVVRYFSAWAEDDHMLIQNEYCNGGSLADAISENYRIMSYFKEAELKDLLLQVGRGLRYIHSMSLVHMDIKPSNIFISRTSIPNAASEEGDEDDWASNKVMFKIGDLGHVTRISSPQVEEGDSRFLANEVLQENYTHLPKADIFALALTVVCAAGAEPLPRNGDQWHEIRQGRLPRIPQVLSQEFTELLKVMIHPDPERRPSAMALVKHSVLLSASRKSAEQLRIELNAEKFKNSLLQKELKKAQMAKAAAEERALFTDRMATRSTTQSNRTSRLIGKKMNRSVSLTIY,0,,,,,,,,Q9Y297(BTRC)|Q9UKB1(FBXW11)|P53350(PLK1)|P31947(SFN)|P62258(YWHAE)|P63104(YWHAZ),,1:P30291-1:|2:P30291-2:,,,,,,,,,,5.0
P27986,,Phosphatidylinositol 3-kinase regulatory subunit alpha,PIK3R1,Homo sapiens,724,False,GRB1,MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR,0,,,,,,"Agammaglobulinemia 7, autosomal recessive:A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.|SHORT syndrome:A rare, multisystem disease characterized by short stature, anomalies of the anterior chamber of the eye, characteristic facial features such as triangular facies, lack of facial fat, and hypoplastic nasal alae with overhanging columella, partial lipodystrophy, hernias, hyperextensibility, and delayed dentition. The clinical phenotype can include insulin resistance, nephrocalcinosis, and hearing deficits. Developmental milestones and cognition are normal.|Immunodeficiency 36 with lymphoproliferation:A primary immunodeficiency characterized by impaired B-cell function, hypogammaglobulinemia and recurrent infections.","Agammaglobulinemia 7, autosomal recessive|SHORT syndrome|Immunodeficiency 36 with lymphoproliferation",Q8IZP0(ABI1)|P42684(ABL2)|P10275(AR)|P30530(AXL)|P22681(CBL)|P10747(CD28)|Q13111(CHAF1A)|Q8IY22(CMIP)|P16410(CTLA4)|Q9Y2H0(DLGAP4)|P00533(EGFR)|P41970(ELK3)|P04626(ERBB2)|P21860(ERBB3)|P48023(FASLG)|P11362(FGFR1)|P17948(FLT1)|P36888(FLT3)|Q13480(GAB1)|Q13322(GRB10)|P62993(GRB2)|P42858(HTT)|Q9Y6W8(ICOS)|P08069(IGF1R)|P06213(INSR)|P35568(IRS1)|Q9Y4H2(IRS2)|P10721(KIT)|Q86VI4-3(LAPTM4B)|O43561(LAT)|P29376(LTK)|Q92918(MAP4K1)|P45983(MAPK8)|P08581(MET)|Q8WX92(NELFB)|P04629(NTRK1)|P09619(PDGFRB)|P42336(PIK3CA)|P42338(PIK3CB)|O00329(PIK3CD)|O00459(PIK3R2)|Q13905(RAPGEF1)|P26373(RPL13)|P19793(RXRA)|Q9UPX8(SHANK2)|Q9H0K1(SIK2)|Q96EB6(SIRT1)|Q07889(SOS1)|P12931(SRC)|P30874(SSTR2)|P58753(TIRAP)|O15455(TLR3)|Q15661(TPSAB1)|Q9ULW0(TPX2)|Q9UKW4(VAV3)|P35570(Irs1)|P03496(NS)|Q6PFX7(Nyap1)|Q8BM65-4(Nyap2)|Q99152(VP3)|P0DOJ9()|P01023(A2M)|Q9NY61(AATF)|O95704(APBB3)|P05067(APP)|P51451(BLK)|Q9UQM7(CAMK2A)|P29466-3(CASP1)|P55210(CASP7)|P06493(CDK1)|P20674(COX5A)|P09172(DBH)|P50570-2(DNM2)|P01100(FOS)|Q8TB36(GDAP1)|P14136(GFAP)|P62993(GRB2)|P42858(HTT)|P35568(IRS1)|P05556(ITGB1)|P05412(JUN)|P07948(LYN)|Q13387-4(MAPK8IP2)|P41227(NAA10)|P01111(NRAS)|Q9Y6R0(NUMBL)|P42336(PIK3CA)|P42338(PIK3CB)|O00329(PIK3CD)|P17612(PRKACA)|P49810(PSEN2)|P63000(RAC1)|P51812(RPS6KA3)|P23443-4(RPS6KB1)|P34741(SDC2)|Q9NP31(SH2D2A)|P84022(SMAD3)|P12931(SRC)|Q9UNE7(STUB1)|Q15583-2(TGIF1)|O60784-2(TOM1)|O14656-2(TOR1A)|P02766(TTR)|P42681(TXK)|P60604(UBE2G2)|Q9UBQ0-2(VPS29)|O76024(WFS1)|Q8IUH5(ZDHHC17),,1:P27986-1:|2:P27986-2:|3:P27986-3:|4:P27986-4:|5:P27986-5:,,,,,,,,,,5.0
Q9NRF2,,SH2B adapter protein 1,SH2B1,Homo sapiens,756,False,KIAA1299|SH2B,MNGAPSPEDGASPSSPPLPPPPPPSWREFCESHARAAALDFARRFRLYLASHPQYAGPGAEAAFSRRFAELFLQHFEAEVARASGSLSPPILAPLSPGAEISPHDLSLESCRVGGPLAVLGPSRSSEDLAGPLPSSVSSSSTTSSKPKLKKRFSLRSVGRSVRGSVRGILQWRGTVDPPSSAGPLETSSGPPVLGGNSNSNSSGGAGTVGRGLVSDGTSPGERWTHRFERLRLSRGGGALKDGAGMVQREELLSFMGAEEAAPDPAGVGRGGGVAGPPSGGGGQPQWQKCRLLLRSEGEGGGGSRLEFFVPPKASRPRLSIPCSSITDVRTTTALEMPDRENTFVVKVEGPSEYIMETVDAQHVKAWVSDIQECLSPGPCPATSPRPMTLPLAPGTSFLTRENTDSLELSCLNHSESLPSQDLLLGPSESNDRLSQGAYGGLSDRPSASISPSSASIAASHFDSMELLPPELPPRIPIEEGPPTGTVHPLSAPYPPLDTPETATGSFLFQGEPEGGEGDQPLSGYPWFHGMLSRLKAAQLVLTGGTGSHGVFLVRQSETRRGEYVLTFNFQGKAKHLRLSLNEEGQCRVQHLWFQSIFDMLEHFRVHPIPLESGGSSDVVLVSYVPSSQRQQEPTTSHDPPQPPEPPSWTDPPQPGAEEASRAPEVAAAAAAAAKERQEKEKAGGGGVPEELVPVVELVPVVELEEAIAPGSEAQGAGSGGDAGVPPMVQLQQSPLGGDGEEGGHPRAINNQYSFV,0,,,,,,,,P00533(EGFR)|P06213(INSR)|P42227(Stat3)|P62993(GRB2),,1:Q9NRF2-1:|2:Q9NRF2-2:|3:Q9NRF2-3:,,,,,,,,,,5.0
Q13115,,Dual specificity protein phosphatase 4,DUSP4,Homo sapiens,394,False,MKP2|VH2,MVTMEELREMDCSVLKRLMNRDENGGGAGGSGSHGTLGLPSGGKCLLLDCRPFLAHSAGYILGSVNVRCNTIVRRRAKGSVSLEQILPAEEEVRARLRSGLYSAVIVYDERSPRAESLREDSTVSLVVQALRRNAERTDICLLKGGYERFSSEYPEFCSKTKALAAIPPPVPPSATEPLDLGCSSCGTPLHDQGGPVEILPFLYLGSAYHAARRDMLDALGITALLNVSSDCPNHFEGHYQYKCIPVEDNHKADISSWFMEAIEYIDAVKDCRGRVLVHCQAGISRSATICLAYLMMKKRVRLEEAFEFVKQRRSIISPNFSFMGQLLQFESQVLATSCAAEAASPSGPLRERGKTPATPTSQFVFSFPVSVGVHSAPSSLPYLHSPITTSPSC,0,,,,,,,,Q9H8Y8(GORASP2)|Q96S90(LYSMD1)|Q8IV50-2(LYSMD2)|Q9BRK4(LZTS2)|P28482(MAPK1)|P45984(MAPK9)|Q86UR1-2(NOXA1)|Q9H8W4(PLEKHF2)|Q96N21(TEPSIN)|Q13077(TRAF1)|Q9BUY5(ZNF426)|Q8N720(ZNF655),,1:Q13115-1:|2:Q13115-2:,,,,,,,,,,5.0
Q9BY84,,Dual specificity protein phosphatase 16,DUSP16,Homo sapiens,665,False,KIAA1700|MKP7,MAHEMIGTQIVTERLVALLESGTEKVLLIDSRPFVEYNTSHILEAININCSKLMKRRLQQDKVLITELIQHSAKHKVDIDCSQKVVVYDQSSQDVASLSSDCFLTVLLGKLEKSFNSVHLLAGGFAEFSRCFPGLCEGKSTLVPTCISQPCLPVANIGPTRILPNLYLGCQRDVLNKELMQQNGIGYVLNASNTCPKPDFIPESHFLRVPVNDSFCEKILPWLDKSVDFIEKAKASNGCVLVHCLAGISRSATIAIAYIMKRMDMSLDEAYRFVKEKRPTISPNFNFLGQLLDYEKKIKNQTGASGPKSKLKLLHLEKPNEPVPAVSEGGQKSETPLSPPCADSATSEAAGQRPVHPASVPSVPSVQPSLLEDSPLVQALSGLHLSADRLEDSNKLKRSFSLDIKSVSYSASMAASLHGFSSSEDALEYYKPSTTLDGTNKLCQFSPVQELSEQTPETSPDKEEASIPKKLQTARPSDSQSKRLHSVRTSSSGTAQRSLLSPLHRSGSVEDNYHTSFLFGLSTSQQHLTKSAGLGLKGWHSDILAPQTSTPSLTSSWYFATESSHFYSASAIYGGSASYSAYSCSQLPTCGDQVYSVRRRQKPSDRADSRRSWHEESPFEKQFKRRSCQMEFGESIMSENRSREELGKVGSQSSFSGSMEIIEVS,0,,,,,,,,Q16539(MAPK14)|P45983-4(MAPK8)|P45984(MAPK9)|O76024(WFS1),,1:Q9BY84-1:|2:Q9BY84-2:,,,,,,,,,,5.0
P31749,,RAC-alpha serine/threonine-protein kinase,AKT1,Homo sapiens,480,False,PKB|RAC,MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA,0,,,,,,"Breast cancer:A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.|Colorectal cancer:A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.|:|Proteus syndrome:A highly variable, severe disorder of asymmetric and disproportionate overgrowth of body parts, connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations. Many features of Proteus syndrome overlap with other overgrowth syndromes.|Cowden syndrome 6:A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid.",Breast cancer|Colorectal cancer|Proteus syndrome|Cowden syndrome 6,Q6UY14-3(ADAMTSL4)|P31749(AKT1)|P31751(AKT2)|Q86V81(ALYREF)|Q8IXJ9(ASXL1)|P54253(ATXN1)|O95999(BCL10)|Q9H0C5(BTBD1)|Q9UQM7(CAMK2A)|P20248(CCNA2)|Q16543(CDC37)|Q8TAP6(CEP76)|Q92793(CREBBP)|Q15438(CYTH1)|Q96D03(DDIT4L)|P26358(DNMT1)|Q1W6H9(FAM110C)|Q12778(FOXO1)|O43524(FOXO3)|P06241(FYN)|P22466(GAL)|P49841(GSK3B)|Q96LI6-3(HSFY2)|P08238(HSP90AB1)|P42858(HTT)|Q5S007(LRRK2)|Q99683(MAP3K5)|P10636(MAPT)|Q00987(MDM2)|Q14696(MESD)|P42345(MTOR)|Q9BZQ8(NIBAN1)|P04150(NR3C1)|O15530(PDPK1)|Q96S96(PEBP4)|P19174(PLCG1)|O60437(PPL)|P62136(PPP1CA)|P67775(PPP2CA)|P30153(PPP2R1A)|P17612(PRKACA)|Q05513(PRKCZ)|Q8WUY3(PRUNE2)|P23443(RPS6KB1)|Q15047(SETDB1)|Q96EB6(SIRT1)|Q13043(STK4)|Q9UNE7-1(STUB1)|P56279(TCL1A)|Q9NYB0(TERF2IP)|Q5T1C6(THEM4)|Q92547(TOPBP1)|P53804(TTC3)|P10599(TXN)|P08670(VIM)|Q6GPH4(XAF1)|P17028(ZNF24)|P29067(Arrb2)|Q83730(m005R)|P03165(X)|Q15118-1(PDK1),,1:P31749-1:|2:P31749-2:,,,,,,,,,,5.0
P06493,,Cyclin-dependent kinase 1,CDK1,Homo sapiens,297,False,CDC2|CDC28A|CDKN1|P34CDC2,MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRHPNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHGDSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPGSLASHVKNLDENGLDLLSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM,0,,,,,,,,Q86V81(ALYREF)|P05067(APP)|O15392(BIRC5)|P14635(CCNB1)|P30307(CDC25C)|Q99741(CDC6)|P38936(CDKN1A)|P46527(CDKN1B)|P61024(CKS1B)|O75618-1(DEDD)|P36957(DLST)|P00533(EGFR)|P19525(EIF2AK2)|Q12778(FOXO1)|O95835(LATS1)|P27986-2(PIK3R1)|Q99640(PKMYT1)|O43508(TNFSF12)|P0CG48(UBC)|P21796(VDAC1)|P03070(),,1:P06493-1:|2:P06493-2:,,,,,,,,,,5.0
O95147,,Dual specificity protein phosphatase 14,DUSP14,Homo sapiens,198,False,MKP6,MSSRGHSTLPRTLMAPRMISEGDIGGIAQITSSLFLGRGSVASNRHLLQARGITCIVNATIEIPNFNWPQFEYVKVPLADMPHAPIGLYFDTVADKIHSVSRKHGATLVHCAAGVSRSATLCIAYLMKFHNVCLLEAYNWVKARRPVIRPNVGFWRQLIDYERQLFGKSTVKMVQTPYGIVPDVYEKESRHLMPYWGI,0,,,,,,,,Q8NA61(CBY2),,,,,,,,,,,,5.0
O43318,,Mitogen-activated protein kinase kinase kinase 7,MAP3K7,Homo sapiens,606,False,TAK1,MSTASAASSSSSSSAGEMIEAPSQVLNFEEIDYKEIEVEEVVGRGAFGVVCKAKWRAKDVAIKQIESESERKAFIVELRQLSRVNHPNIVKLYGACLNPVCLVMEYAEGGSLYNVLHGAEPLPYYTAAHAMSWCLQCSQGVAYLHSMQPKALIHRDLKPPNLLLVAGGTVLKICDFGTACDIQTHMTNNKGSAAWMAPEVFEGSNYSEKCDVFSWGIILWEVITRRKPFDEIGGPAFRIMWAVHNGTRPPLIKNLPKPIESLMTRCWSKDPSQRPSMEEIVKIMTHLMRYFPGADEPLQYPCQYSDEGQSNSATSTGSFMDIASTNTSNKSDTNMEQVPATNDTIKRLESKLLKNQAKQQSESGRLSLGASRGSSVESLPPTSEGKRMSADMSEIEARIAATTAYSKPKRGHRKTASFGNILDVPEIVISGNGQPRRRSIQDLTVTGTEPGQVSSRSSSPSVRMITTSGPTSEKPTRSHPWTPDDSTDTNGSDNSIPMAYLTLDHQLQPLAPCPNSKESMAVFEQHCKMAQEYMKVQTEIALLLQRKQELVAELDQDEKDQQNTSRLVQEHKKLLDENKSLSTYYQQCKKQLEVIRSQQQKRQGTS,0,,,,,,"Frontometaphyseal dysplasia 2:A form of frontometaphyseal dysplasia, a progressive sclerosing skeletal dysplasia affecting the long bones and skull. Characteristic features include supraorbital hyperostosis, cranial hyperostosis, undermodeling of the small bones, flared metaphyses, and digital anomalies. Extra-skeletal manifestations include hearing loss, cardiac malformations, and stenosis, particularly of the upper airway and urinary tract. FMD2 inheritance is autosomal dominant.|Cardiospondylocarpofacial syndrome:A syndrome characterized by growth retardation, dysmorphic facial features, brachydactyly with carpal-tarsal fusion and extensive posterior cervical vertebral synostosis, cardiac septal defects with valve dysplasia, and deafness with inner ear malformations. CSCF transmission pattern is consistent with autosomal dominant inheritance.",Frontometaphyseal dysplasia 2|Cardiospondylocarpofacial syndrome,Q16543(CDC37)|O14920(IKBKB)|O14733(MAP2K7)|Q9UQF2(MAPK8IP1)|O00743(PPP6C)|P40763(STAT3)|Q15750(TAB1)|Q9NYJ8(TAB2)|Q8N5C8(TAB3)|Q9UKE5(TNIK)|Q9Y4K3(TRAF6)|P0CG48(UBC)|B5Z6S0(cagA)|P0DTC9(N)|Q16543(CDC37)|P07900(HSP90AA1)|Q15750(TAB1)|Q9NYJ8(TAB2),,1B:O43318-1:|1A:O43318-2:|1C:O43318-3:|1D:O43318-4:,,,,,,,,,,5.0
P35968,,Vascular endothelial growth factor receptor 2,KDR,Homo sapiens,1356,False,FLK1|VEGFR2,MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLDWLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQDYRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWDSKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPPEIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVPPQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPYPCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGERVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPTPVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLTVLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNRNLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWLLLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLKRRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVSCMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDSGMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYSSEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV,0,,,,,,"Hemangioma, capillary infantile:A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring.|:","Hemangioma, capillary infantile",P35916(FLT4)|O60565(GREM1)|P98160(HSPG2)|P98160(HSPG2)|P98160(HSPG2)|P17301(ITGA2)|P35968(KDR)|P09382(LGALS1)|P08581(MET)|P16333(NCK1)|O14786(NRP1)|O75340(PDCD6)|P09619(PDGFRB)|P29350(PTPN6)|Q12913(PTPRJ)|P12931(SRC)|P15692(VEGFA)|P15692-4(VEGFA)|P49767(VEGFC)|Q9MYV3-3(VEGFA),,1:P35968-1:|2:P35968-2:|3:P35968-3:,,,,,,,,,,5.0
Q02763,,Angiopoietin-1 receptor,TEK,Homo sapiens,1124,False,TIE2|VMCM|VMCM1,MDSLASLVLCGVSLLLSGTVEGAMDLILINSLPLVSDAETSLTCIASGWRPHEPITIGRDFEALMNQHQDPLEVTQDVTREWAKKVVWKREKASKINGAYFCEGRVRGEAIRIRTMKMRQQASFLPATLTMTVDKGDNVNISFKKVLIKEEDAVIYKNGSFIHSVPRHEVPDILEVHLPHAQPQDAGVYSARYIGGNLFTSAFTRLIVRRCEAQKWGPECNHLCTACMNNGVCHEDTGECICPPGFMGRTCEKACELHTFGRTCKERCSGQEGCKSYVFCLPDPYGCSCATGWKGLQCNEACHPGFYGPDCKLRCSCNNGEMCDRFQGCLCSPGWQGLQCEREGIQRMTPKIVDLPDHIEVNSGKFNPICKASGWPLPTNEEMTLVKPDGTVLHPKDFNHTDHFSVAIFTIHRILPPDSGVWVCSVNTVAGMVEKPFNISVKVLPKPLNAPNVIDTGHNFAVINISSEPYFGDGPIKSKKLLYKPVNHYEAWQHIQVTNEIVTLNYLEPRTEYELCVQLVRRGEGGEGHPGPVRRFTTASIGLPPPRGLNLLPKSQTTLNLTWQPIFPSSEDDFYVEVERRSVQKSDQQNIKVPGNLTSVLLNNLHPREQYVVRARVNTKAQGEWSEDLTAWTLSDILPPQPENIKISNITHSSAVISWTILDGYSISSITIRYKVQGKNEDQHVDVKIKNATITQYQLKGLEPETAYQVDIFAENNIGSSNPAFSHELVTLPESQAPADLGGGKMLLIAILGSAGMTCLTVLLAFLIILQLKRANVQRRMAQAFQNVREEPAVQFNSGTLALNRKVKNNPDPTIYPVLDWNDIKFQDVIGEGNFGQVLKARIKKDGLRMDAAIKRMKEYASKDDHRDFAGELEVLCKLGHHPNIINLLGACEHRGYLYLAIEYAPHGNLLDFLRKSRVLETDPAFAIANSTASTLSSQQLLHFAADVARGMDYLSQKQFIHRDLAARNILVGENYVAKIADFGLSRGQEVYVKKTMGRLPVRWMAIESLNYSVYTTNSDVWSYGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRLEKPLNCDDEVYDLMRQCWREKPYERPSFAQILVSLNRMLEERKTYVNTTLYEKFTYAGIDCSAEEAA,0,,,,,,"Dominantly inherited venous malformations:An error of vascular morphogenesis characterized by dilated, serpiginous channels.|:|:|Glaucoma 3, primary congenital, E:An autosomal dominant form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor.","Dominantly inherited venous malformations|Glaucoma 3, primary congenital, E",Q15389(ANGPT1)|O15123(ANGPT2)|O15123-1(ANGPT2)|Q16678(CYP1B1)|Q05209(PTPN12)|P23467(PTPRB)|P08575(PTPRC)|Q12913(PTPRJ)|Q15262(PTPRK)|Q16827(PTPRO),,1:Q02763-1:|2:Q02763-2:|3:Q02763-3:,,,,,,,,,,5.0
P04629,,High affinity nerve growth factor receptor,NTRK1,Homo sapiens,796,False,MTC|TRK|TRKA,MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTRDGALDSLHHLPGAENLTELYIENQQHLQHLELRDLRGLGELRNLTIVKSGLRFVAPDAFHFTPRLSRLNLSFNALESLSWKTVQGLSLQELVLSGNPLHCSCALRWLQRWEEEGLGGVPEQKLQCHGQGPLAHMPNASCGVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSFPASVQLHTAVEMHHWCIPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHVNNGNYTLLAANPFGQASASIMAAFMDNPFEFNPEDPIPVSFSPVDTNSTSGDPVEKKDETPFGVSVAVGLAVFACLFLSTLLLVLNKCGRRNKFGINRPAVLAPEDGLAMSLHFMTLGGSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG,0,,,,,,"Congenital insensitivity to pain with anhidrosis:Characterized by a congenital insensitivity to pain, anhidrosis (absence of sweating), absence of reaction to noxious stimuli, self-mutilating behavior, and intellectual disability. This rare autosomal recessive disorder is also known as congenital sensory neuropathy with anhidrosis or hereditary sensory and autonomic neuropathy type IV or familial dysautonomia type II.|:",Congenital insensitivity to pain with anhidrosis,P05067-4(APP)|P22681(CBL)|P08238(HSP90AB1)|P01138(NGF)|P01138(NGF)|P04629(NTRK1)|Q16288(NTRK3)|P27986(PIK3R1)|P19174(PLCG1)|P18031(PTPN1)|Q99523(SORT1)|Q13501(SQSTM1)|O75385(ULK1)|Q8K4V6(Pirb),,TrkA-II:P04629-1:|TrkA-I:P04629-2:|3:P04629-3:|TrkA-III:P04629-4:,,,,,,,,,,5.0
Q9NRW4,,Dual specificity protein phosphatase 22,DUSP22,Homo sapiens,184,False,JSP1|LMWDSP2|MKPX,MGNGMNKILPGLYIGNFKDARDAEQLSKNKVTHILSVHDSARPMLEGVKYLCIPAADSPSQNLTRHFKESIKFIHECRLRGESCLVHCLAGVSRSVTLVIAYIMTVTDFGWEDALHTVRAGRSCANPNVGFQRQLQEFEKHEVHQYRQWLKEEYGESPLQDAEEAKNILAAPGILKFWAFLRRL,0,,,,,,,,,,1:Q9NRW4-1:|2:Q9NRW4-2:,,,,,,,,,,5.0
O14544,,Suppressor of cytokine signaling 6,SOCS6,Homo sapiens,535,False,CIS4|SOCS4,MKKISLKTLRKSFNLNKSKEETDFMVVQQPSLASDFGKDDSLFGSCYGKDMASCDINGEDEKGGKNRSKSESLMGTLKRRLSAKQKSKGKAGTPSGSSADEDTFSSSSAPIVFKDVRAQRPIRSTSLRSHHYSPAPWPLRPTNSEETCIKMEVRVKALVHSSSPSPALNGVRKDFHDLQSETTCQEQANSLKSSASHNGDLHLHLDEHVPVVIGLMPQDYIQYTVPLDEGMYPLEGSRSYCLDSSSPMEVSAVPPQVGGRAFPEDESQVDQDLVVAPEIFVDQSVNGLLIGTTGVMLQSPRAGHDDVPPLSPLLPPMQNNQIQRNFSGLTGTEAHVAESMRCHLNFDPNSAPGVARVYDSVQSSGPMVVTSLTEELKKLAKQGWYWGPITRWEAEGKLANVPDGSFLVRDSSDDRYLLSLSFRSHGKTLHTRIEHSNGRFSFYEQPDVEGHTSIVDLIEHSIRDSENGAFCYSRSRLPGSATYPVRLTNPVSRFMQVRSLQYLCRFVIRQYTRIDLIQKLPLPNKMKDYLQEKHY,0,,,,,,,,Q9NX04(AIRIM)|P10275(AR)|O95376(ARIH2)|O75460-2(ERN1)|P22607(FGFR3)|Q0VDC6(FKBP1A)|Q13480(GAB1)|P06396(GSN)|P54652(HSPA2)|P10721(KIT)|P08581(MET)|O60260-5(PRKN)|P49591(SARS1)|Q13148(TARDBP)|P42681(TXK)|Q9UMX0(UBQLN1)|P46937(YAP1),,,,,,,,,,,,5.0
Q16828,,Dual specificity protein phosphatase 6,DUSP6,Homo sapiens,381,False,MKP3|PYST1,MIDTLRPVPFASEMAISKTVAWLNEQLELGNERLLLMDCRPQELYESSHIESAINVAIPGIMLRRLQKGNLPVRALFTRGEDRDRFTRRCGTDTVVLYDESSSDWNENTGGESVLGLLLKKLKDEGCRAFYLEGGFSKFQAEFSLHCETNLDGSCSSSSPPLPVLGLGGLRISSDSSSDIESDLDRDPNSATDSDGSPLSNSQPSFPVEILPFLYLGCAKDSTNLDVLEEFGIKYILNVTPNLPNLFENAGEFKYKQIPISDHWSQNLSQFFPEAISFIDEARGKNCGVLVHCLAGISRSVTVTVAYLMQKLNLSMNDAYDIVKMKKSNISPNFNFMGQLLDFERTLGLSSPCDNRVPAQQLYFTTPSNQNVYQVDSLQST,0,,,,,,"Hypogonadotropic hypogonadism 19 with or without anosmia:A disorder characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. In some cases, it is associated with non-reproductive phenotypes, such as anosmia, cleft palate, and sensorineural hearing loss. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In the presence of anosmia, idiopathic hypogonadotropic hypogonadism is referred to as Kallmann syndrome, whereas in the presence of a normal sense of smell, it has been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH).",Hypogonadotropic hypogonadism 19 with or without anosmia,P05067(APP)|P28482(MAPK1)|P27361(MAPK3)|Q99623(PHB2)|P42681(TXK),,1:Q16828-1:|2:Q16828-2:,,,,,,,,,,5.0
P50613,,Cyclin-dependent kinase 7,CDK7,Homo sapiens,346,False,CAK|CAK1|CDKN7|MO15|STK1,MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF,0,,,,,,,,P24941(CDK2)|P11802(CDK4)|P08238(HSP90AB1)|Q96SB4(SRPK1)|P78362(SRPK2)|O00267(SUPT5H),,,,,,,,,,,,5.0
P42679,,Megakaryocyte-associated tyrosine-protein kinase,MATK,Homo sapiens,507,False,CTK|HYL,MAGRGSLVSWRAFHGCDSAEELPRVSPRFLRAWHPPPVSARMPTRRWAPGTQCITKCEHTRPKPGELAFRKGDVVTILEACENKSWYRVKHHTSGQEGLLAAGALREREALSADPKLSLMPWFHGKISGQEAVQQLQPPEDGLFLVRESARHPGDYVLCVSFGRDVIHYRVLHRDGHLTIDEAVFFCNLMDMVEHYSKDKGAICTKLVRPKRKHGTKSAEEELARAGWLLNLQHLTLGAQIGEGEFGAVLQGEYLGQKVAVKNIKCDVTAQAFLDETAVMTKMQHENLVRLLGVILHQGLYIVMEHVSKGNLVNFLRTRGRALVNTAQLLQFSLHVAEGMEYLESKKLVHRDLAARNILVSEDLVAKVSDFGLAKAERKGLDSSRLPVKWTAPEALKHGKFTSKSDVWSFGVLLWEVFSYGRAPYPKMSLKEVSEAVEKGYRMEPPEGCPGPVHVLMSSCWEAEPARRPPFRKLAEKLARELRSAGAPASVSGQDADGSTSPRSQEP,0,,,,,,,,P10275(AR)|Q9Y5Z0(BACE2)|P04626(ERBB2)|P08238(HSP90AB1)|Q92876(KLK6)|Q5S007(LRRK2)|P62258(YWHAE),,1:P42679-1:|2:P42679-2:|3:P42679-3:,,,,,,,,,,5.0
P19525,,"Interferon-induced, double-stranded RNA-activated protein kinase",EIF2AK2,Homo sapiens,551,False,PKR|PRKR,MAGDLSAGFFMEELNTYRQKQGVVLKYQELPNSGPPHDRRFTFQVIIDGREFPEGEGRSKKEAKNAAAKLAVEILNKEKKAVSPLLLTTTNSSEGLSMGNYIGLINRIAQKKRLTVNYEQCASGVHGPEGFHYKCKMGQKEYSIGTGSTKQEAKQLAAKLAYLQILSEETSVKSDYLSSGSFATTCESQSNSLVTSTLASESSSEGDFSADTSEINSNSDSLNSSSLLMNGLRNNQRKAKRSLAPRFDLPDMKETKYTVDKRFGMDFKEIELIGSGGFGQVFKAKHRIDGKTYVIKRVKYNNEKAEREVKALAKLDHVNIVHYNGCWDGFDYDPETSDDSLESSDYDPENSKNSSRSKTKCLFIQMEFCDKGTLEQWIEKRRGEKLDKVLALELFEQITKGVDYIHSKKLIHRDLKPSNIFLVDTKQVKIGDFGLVTSLKNDGKRTRSKGTLRYMSPEQISSQDYGKEVDLYALGLILAELLHVCDTAFETSKFFTDLRDGIISDIFDKKEKTLLQKLLSKKPEDRPNTSEILRTLTVWKKSPEKNERHTC,0,,,,,,"Leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome:An autosomal dominant disorder characterized by global developmental delay apparent in early childhood, cognitive impairment, ataxia, poor or absent speech with dysarthria, hypotonia, hypertonia, extrapyramidal signs, tremor, and abnormal involuntary movements. Affected individuals also exhibit neurological regression in the setting of febrile illness or infection. Many patients have seizures. Brain imaging shows diffuse white matter abnormalities with poor myelination.|Dystonia 33:A form of dystonia, a disorder defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT33 is a slowly progressive form characterized by onset of focal or generalized dystonia in the first decades of life. Disease manifestations are variable. Some patients show ambulation difficulties, dysarthria, or dysphagia. Some affected individuals may manifest motor delay, lower limb spasticity, and mild developmental delay with intellectual disability. DYT33 penetrance is incomplete. Inheritance can be autosomal dominant or recessive.","Leukoencephalopathy, developmental delay, and episodic neurologic regression syndrome|Dystonia 33",P78563-4(ADARB1)|P06493(CDK1)|Q7L2E3(DHX30)|Q96C10(DHX58)|Q08211(DHX9)|Q9UPY3(DICER1)|Q6P2E9(EDC4)|P19525(EIF2AK2)|P05198(EIF2S1)|P56537(EIF6)|Q8IY81(FTSJ3)|Q9HCE1(MOV10)|Q96P20(NLRP3)|P06748(NPM1)|O75569(PRKRA)|O75569-1(PRKRA)|Q9NUL3(STAU2)|Q15633(TARBP2)|Q9H0E2(TOLLIP)|Q9UL40(ZNF346)|Q27968(DNAJC3)|P0DTC9(N)|P20639(OPG041)|P04487(US11)|Q2HR71(vIRF-2)|O92972()|P27958()|P27958(),,1:P19525-1:|2:P19525-2:,,,,,,,,,,5.0
